0001144204-15-029365.txt : 20150511 0001144204-15-029365.hdr.sgml : 20150511 20150511170126 ACCESSION NUMBER: 0001144204-15-029365 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20150331 FILED AS OF DATE: 20150511 DATE AS OF CHANGE: 20150511 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Synthetic Biologics, Inc. CENTRAL INDEX KEY: 0000894158 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133808303 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-12584 FILM NUMBER: 15851617 BUSINESS ADDRESS: STREET 1: 617 DETROIT STREET, SUITE 100 CITY: ANN ARBOR STATE: MI ZIP: 48104 BUSINESS PHONE: (734) 332-7800 MAIL ADDRESS: STREET 1: 155 GIBBS STREET STREET 2: SUITE 412 CITY: ROCKVILLE STATE: MD ZIP: 20850 FORMER COMPANY: FORMER CONFORMED NAME: ADEONA PHARMACEUTICALS, INC. DATE OF NAME CHANGE: 20081027 FORMER COMPANY: FORMER CONFORMED NAME: PIPEX PHARMACEUTICALS, INC. DATE OF NAME CHANGE: 20061214 FORMER COMPANY: FORMER CONFORMED NAME: SHEFFIELD PHARMACEUTICALS INC DATE OF NAME CHANGE: 19970730 10-Q 1 v409108_10q.htm FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q

(Mark One)

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

	For the quarterly period ended March 31, 2015

¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ACT OF 1934

	For the transition period from ____________ to ____________

Commission File Number: 1-12584

SYNTHETIC BIOLOGICS, INC.

(Name of small business issuer in its charter)

Nevada	13-3808303
(State or other jurisdiction of incorporation or organization)	(IRS Employer Identification Number)

155 Gibbs Street, Suite 412
Rockville, MD	20850
(Address of principal executive offices)	(Zip Code)

617 Detroit Street, Suite 100
Ann Arbor, MI	48104
(Mailing Address)	(Zip Code)

Registrant’s telephone number, including area code:

(734) 332-7800

Securities registered pursuant to Section 12(b) of the Act:

Common Stock, $0.001 par value per share

Securities registered pursuant to Section 12(g) of the Act:

None.

(Title of Class)

Indicate by check mark whether the issuer: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated file, a non-accelerated file, or a smaller reporting company. See the definitions of “large accelerated filer, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer	¨	Accelerated filer	x
Non-Accelerated filer	¨	Smaller reporting company	¨
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

As of May 8, 2015 the registrant had 73,179,307 shares of common stock outstanding.

SYNTHETIC BIOLOGICS, INC.

FORM 10-Q

TABLE OF CONTENTS

		Page
	PART I. FINANCIAL INFORMATION	1
Item 1.	Financial Statements (Unaudited)	1
	Consolidated Balance Sheets as of March 31, 2015 and December 31, 2014	1
	Consolidated Statements of Operations for the three months ended March 31, 2015 and 2014	2
	Consolidated Statements of Cash Flows for the three months ended March 31, 2015 and 2014	3
	Notes to Consolidated Financial Statements	4
Item 2.	Management’s Discussion and Analysis of Financial Information and Results of Operations	10
Item 3.	Quantitative and Qualitative Disclosures About Market Risks	21
Item 4.	Controls and Procedures	21

	PART II. OTHER INFORMATION	22
Item 1.	Legal Proceedings	22
Item 1A.	Risk Factors	22
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	23
Item 3.	Defaults Upon Senior Securities	23
Item 4.	Mine Safety Disclosures	23
Item 5.	Other Information	23
Item 6.	Exhibits	24
SIGNATURES		25

PART I.-FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

Synthetic Biologics, Inc. and Subsidiaries

Consolidated Balance Sheets

(In thousands except share and per share amounts)

Assets	March 31, 2015			December 31, 2014
	(Unaudited)			(Audited)
Current Assets
Cash and cash equivalents	$	12,049		$	17,525
Prepaid expenses and other current assets		1,574			1,548
Total Current Assets		13,623			19,073

Property and equipment, net		75			65

Deposits and other assets		18			6

Total Assets	$	13,716		$	19,144

Liabilities and Stockholders' Equity (Deficit)
Current Liabilities:
Accounts payable	$	1,559		$	996
Accrued expenses		2,646			1,298
Warrant liabilities		10,908			6,756
Accrued employee benefits		228			538
Total Current Liabilities		15,341			9,588
Total Liabilities		15,341			9,588

Commitments and Contingencies

Stockholders' Equity (Deficit):
Preferred stock, $0.001 par value; 10,000,000 shares authorized,
none issued and outstanding		-			-
Common stock, $0.001 par value; 100,000,000 shares authorized,
72,725,987 issued and 72,807,469 outstanding and
72,594,626 issued and 72,513,144 outstanding		73			72
Additional paid-in capital		111,702			110,526
Accumulated deficit		(113,400	)		(101,042	)
Total Synthetic Biologics, Inc. and Subsidiaries Equity (Deficit)		(1,625	)		9,556
Non-controlling interest		-			-
Total Stockholders' Equity (Deficit)		(1,625	)		9,556

Total Liabilities and Stockholders' Equity	$	13,716		$	19,144

See accompanying notes to unaudited consolidated financial statements.

Synthetic Biologics, Inc. and Subsidiaries

Consolidated Statements of Operations

(In thousands except share and per share amounts)

(Unaudited)

	For the three months ended March 31,
	2015			2014
Operating Costs and Expenses:
General and administrative	$	1,713		$	1,122
Research and development		6,494			2,717
Total Operating Costs and Expenses		8,207			3,839

Loss from Operations		(8,207	)		(3,839	)

Other Income (Expense):
Change in fair value of warrant liability		(4,152	)		-
Interest income		1			1
Total Other Income (Expense)		(4,151	)		1

Net Loss		(12,358	)		(3,838	)

Net Loss Attributable to Non-controlling Interest		-			-

Net Loss Attributable to Synthetic Biologics, Inc.
and Subsidiaries	$	(12,358	)	$	(3,838	)

Net Loss Per Share - Basic and Dilutive	$	(0.17	)	$	(0.07	)

Net Loss Per Share Attributable to Synthetic Biologics, Inc. and Subsidiaries	$	(0.17	)	$	(0.07	)

Weighted average number of shares outstanding
during the period - Basic and Dilutive		72,673,959			58,324,260

See accompanying notes to unaudited consolidated financial statements.

Synthetic Biologics, Inc. and Subsidiaries

Consolidated Statements of Cash Flows

(In thousands)

(Unaudited)

	For the three months ended March 31,
	2015			2014
Cash Flows From Operating Activities:
Net Loss	$	(12,358	)	$	(3,838	)
Adjustments to reconcile net loss to net cash
used in operating activities:
Stock-based compensation		827			362
Stock issued for milestone payments		350			-
Change in fair value of warrant liabilities		4,152			-
Depreciation		8			3
Changes in operating assets and liabilities:
Prepaid expenses and other current assets		(26	)		259
Deposits and other assets		(12	)		(2	)
Accounts payable		563			631
Accrued liabilities		1,348			-
Accrued employee benefits		(310	)		(885	)
Net Cash Used In Operating Activities		(5,458	)		(3,470	)

Cash Flows From Investing Activities:
Purchases of property and equipment		(18	)		(4	)
Net Cash Used In Investing Activities		(18	)		(4	)

Cash Flows From Financing Activities:
Proceeds from issuance of common stock for stock option exercises		-			4
Net Cash Provided By Financing Activities		-			4

Net decrease in cash		(5,476	)		(3,470	)

Cash at beginning of period		17,525			14,625

Cash at end of period	$	12,049		$	11,155

Supplemental disclosures of cash flow information:
Cash paid for interest	$	-		$	-
Cash paid for taxes	$	-		$	-

See accompanying notes to unaudited consolidated financial statements.

Synthetic Biologics, Inc. and Subsidiaries

Notes to Consolidated Financial Statements

(Unaudited)

1. Organization and Nature of Operations and Basis of Presentation

Description of Business

Synthetic Biologics, Inc. (the “Company” or “Synthetic Biologics”) is a microbiome-focused, clinical-stage company developing therapeutics to protect the microbiome while targeting pathogen-specific diseases. The Company is developing an oral biologic to protect the gut microbiome (gastrointestinal (GI) microflora) from intravenous (IV) antibiotics for the prevention of C. difficile infection and an oral statin treatment to reduce the impact of methane producing organisms on irritable bowel syndrome with constipation (IBS-C). In addition, the Company is developing a monoclonal antibody combination for the treatment of Pertussis in collaboration with Intrexon Corporation (NYSE: XON), and a Phase 2 oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS.

Therapeutic Area	Product Candidate	Status

C. difficile infection prevention	SYN-004 (oral enzyme)	Initiated Phase 2a SYN-004 clinical trial during 1^st quarter 2015; Phase 2b proof-of- concept SYN-004 clinical trial is expected to initiate during 2^nd half 2015

Irritable bowel syndrome with constipation (IBS-C)	SYN-010 (oral compound)	Intend to initiate Phase 2 clinical trials during 2^nd quarter of 2015; Collaboration with Cedars-Sinai Medical Center

Pertussis	SYN-005 (monoclonal antibodies)	Positive preclinical research findings reported at ECCMID in April 2015; Seeking non-dilutive funding to support clinical development of SYN-005; Collaborations with Intrexon and The University of Texas at Austin

Relapsing-remitting MS	Trimesta (oral estriol)	The lead principal investigator presented additional Phase 2 clinical outcome data, including more detailed results on improvements in cognitive and disability measures at the ACTRIMS-ECTRIMS Joint Meeting in September 2014; Partnership discussions ongoing pending data from University of California, Los Angeles (UCLA); MRI data review underway by UCLA

Cognitive dysfunction in MS	Trimesta (oral estriol)	Patient enrollment underway in Phase 2 clinical trial

Basis of Presentation

The accompanying consolidated financial statements have been prepared pursuant to the rules and regulations of Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all of the information and notes required by U.S. Generally Accepted Accounting Principles (“GAAP”) for complete financial statements. The accompanying consolidated financial statements include all adjustments, comprised of normal recurring adjustments, considered necessary by management to fairly state our results of operations, financial position and cash flows. The operating results for the interim periods are not necessarily indicative of results that may be expected for any other interim period or for the full year. These consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2014 (“2014 Form 10-K”) as filed with the SEC. The interim results for the three months ended March 31, 2015, are not necessarily indicative of results for the full year.

The consolidated financial statements are prepared in conformity with U.S. GAAP, which requires the use of estimates, judgments and assumptions that affect the amounts of assets and liabilities at the reporting date and the amounts of revenue and expenses in the periods presented. We believe that the accounting estimates employed are appropriate and the resulting balances are reasonable; however, due to the inherent uncertainties in making estimates actual results could differ from the original estimates, requiring adjustments to these balances in future periods.

2. Management’s Plan

The Company has incurred an accumulated deficit of $113.4 million through March 31, 2015. With the exception of the quarter ended June 30, 2010, the Company has incurred negative cash flow from operations since it started the business. The Company has spent, and expects to continue to spend, substantial amounts in connection with implementing its business strategy, including the planned product development efforts, clinical trials, and research and discovery efforts.

The actual amount of funds the Company will need to operate is subject to many factors, some of which are beyond the Company’s control. These factors include the following:

	·	the progress of research activities;
	·	the number and scope of research programs;
	·	the progress of preclinical and clinical development activities;
	·	the progress of the development efforts of parties with whom the Company has entered into research and development agreements;
	·	the costs associated with additional clinical trials of product candidates;
	·	the ability to maintain current research and development licensing arrangements and to establish new research and development and licensing arrangements;
	·	the ability to achieve milestones under licensing arrangements;
	·	the costs involved in prosecuting and enforcing patent claims and other intellectual property rights; and
	·	the costs and timing of regulatory approvals.

The Company has based its estimate on assumptions that may prove to be wrong. The Company may need to obtain additional funds sooner or in greater amounts than it currently anticipates. Potential sources of financing include strategic relationships, public or private sales of the Company’s shares or debt and other sources.

The Company may seek to access the public or private equity markets when conditions are favorable due to long-term capital requirements. The Company does not have any committed sources of financing at this time, and it is uncertain whether additional funding will be available when needed on terms that will be acceptable to it, or at all. If the Company raises funds by selling additional shares of common stock or other securities convertible into common stock, the ownership interest of the existing stockholders will be diluted. If the Company is not able to obtain financing when needed, it may be unable to carry out the business plan. As a result, the Company may have to significantly limit its operations and its business, financial condition and results of operations would be materially harmed.

3. Fair Value of Financial Instruments

The fair value accounting standards define fair value as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is determined based upon assumptions that market participants would use in pricing an asset or liability. Fair value measurements are rated on a three-tier hierarchy as follows:

Level 1 inputs: Quoted prices (unadjusted) for identical assets or liabilities in active markets;

Level 2 inputs: Inputs, other than quoted prices included in Level 1 that are observable either directly or indirectly; and

Level 3 inputs: Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions.

If the inputs used to measure fair value fall in different levels of the fair value hierarchy, the hierarchy level is based upon the lowest level of input that is significant to the fair value measurement.

Cash and cash equivalents include money market accounts of $8.5 million and $13.6 million as of March 31, 2015 and December 31, 2014, respectively, that are measured using Level 1 inputs.

4. Selected Balance Sheet Information

Prepaid expenses and other current assets (in thousands):

	March 31, 2015		December 31, 2014
Intrexon prepaid research and development expenses	$	1,060	$	1,067
Prepaid insurance		140		228
Prepaid expenses		374		253
Total	$	1,574	$	1,548

The anticipated Intrexon research and development expenses for the next twelve months are classified as a current asset. The Company may terminate the arrangement at any time and receive a cash refund of the remaining balance minus any amounts owed to Intrexon.

Property and equipment (in thousands):

	March 31, 2015			December 31, 2014
Computer and office equipment	$	111		$	93
Software		11			11
		122			104
Less accumulated depreciation		(47	)		(39	)
Total	$	75		$	65

Accrued expenses (in thousands):

	March 31, 2015		December 31, 2014
Accrued manufacturing costs	$	74	$	247
Accrued vendor payments		225		176
Accrued milestone payments		1,000		350
Accrued clinical consulting services		1,347		525
Total	$	2,646	$	1,298

5. Stock-Based Compensation

Stock Incentive Plan

During 2001, the Company’s Board of Directors and stockholders adopted the 2001 Stock Incentive Plan (the “2001 Stock Plan”). The total number of shares of stock with respect to which stock options and stock appreciation rights may be granted to any one employee of the Company or a subsidiary during any one-year period under the 2001 Stock Plan shall not exceed 250,000. All awards pursuant to the 2001 Stock Plan shall terminate upon the termination of the grantee’s employment for any reason. Awards include options, restricted shares, stock appreciation rights, performance shares and cash-based awards (the “Awards”). The 2001 Stock Plan contains certain anti-dilution provisions in the event of a stock split, stock dividend or other capital adjustment, as defined in the plan. The 2001 Stock Plan provides for a Committee of the Board to grant Awards and to determine the exercise price, vesting term, expiration date and all other terms and conditions of the Awards, including acceleration of the vesting of an Award at any time. As of March 31, 2015, there were 682,449 options issued and outstanding under the 2001 Stock Plan.

On March 20, 2007, the Company’s Board of Directors approved the 2007 Stock Incentive Plan (the “2007 Stock Plan”) for the issuance of up to 2,500,000 shares of common stock to be granted through incentive stock options, nonqualified stock options, stock appreciation rights, dividend equivalent rights, restricted stock, restricted stock units and other stock-based awards to officers, other employees, directors and consultants of the Company and its subsidiaries. This plan was approved by stockholders on November 2, 2007. The exercise price of stock options under the 2007 Stock Plan is determined by the compensation committee of the Board of Directors, and may be equal to or greater than the fair market value of the Company’s common stock on the date the option is granted. The total number of shares of stock with respect to which stock options and stock appreciation rights may be granted to any one employee of the Company or a subsidiary during any one-year period under the 2007 plan shall not exceed 250,000. Options become exercisable over various periods from the date of grant, and generally expire ten years after the grant date. As of March 31, 2015, there are 428,657 options issued and outstanding under the 2007 Stock Plan.

On November 2, 2010, the Board of Directors and stockholders adopted the 2010 Stock Incentive Plan (“2010 Stock Plan”) for the issuance of up to 3,000,000 shares of common stock to be granted through incentive stock options, nonqualified stock options, stock appreciation rights, dividend equivalent rights, restricted stock, restricted stock units and other stock-based awards to officers, other employees, directors and consultants of the Company and its subsidiaries. On October 22, 2013, the stockholders approved and adopted an amendment to the Company’s 2010 Incentive Stock Plan to increase the number of shares of the Company’s common stock reserved for issuance under the Plan from 3,000,000 to 6,000,000. The exercise price of stock options under the 2010 Stock Plan is determined by the compensation committee of the Board of Directors, and may be equal to or greater than the fair market value of the Company’s common stock on the date the option is granted. Options become exercisable over various periods from the date of grant, and generally expire ten years after the grant date. As of March 31, 2015, there are 5,420,000 options issued and outstanding under the 2010 Stock Plan.

In the event of an employee’s termination, the Company will cease to recognize compensation expense for that employee. There is no deferred compensation recorded upon initial grant date, instead, the fair value of the stock-based payment is recognized ratably over the stated vesting period.

The Company has applied fair value accounting for all share based payment awards since inception. The fair value of each option or warrant granted is estimated on the date of grant using the Black-Scholes option pricing model. The Black-Scholes assumptions used in the three months ended March 31, 2015 and 2014 are as follows:

	Three Months Ended March 31,
	2015			2014
Expected dividends		0	%		0	%
Expected volatility		131	%		126	%
Risk free interest rate		2.03	%		1.57	%
Expected life of option		10 years			5 years
Expected forfeitures		0	%		0	%

The Company records stock-based compensation based upon the stated vested provisions in the related agreements. The vesting provisions for these agreements have various terms as follows:

	·	immediate vesting,
	·	half vesting immediately and the remainder over three years,
	·	quarterly over three years,
	·	annually over three years,
	·	one-third immediate vesting and remaining annually over two years,
	·	one half immediate vesting with remaining vesting over nine months,
	·	one quarter immediate vesting with the remaining over three years,
	·	one quarter immediate vesting with the remaining over 33 months; and
	·	monthly over three years.

During the three months ended March 31, 2015, the Company granted 550,000 options to employees having an approximate fair value of $817,000 based upon the Black-Scholes option pricing model. During the same period in 2014, the Company granted 587,500 options to employees and consultants having an approximate fair value of $1.4 million based upon the Black-Scholes option pricing model.

A summary of stock option activities as of March 31, 2015, and for the year ended December 31, 2014, is as follows:

						Weighted
						Average
				Weighted		Remaining	Aggregate
				Average Exercise		Contractual	Intrinsic
	Options			Price		Life	Value

Balance - December 31, 2013		3,909,580		$	1.78	5.59 years	$	785,000
Granted		2,382,500		$	2.36
Exercised		(6,583	)	$	0.58
Forfeited		(304,391	)	$	1.93

Balance - December 31, 2014		5,981,106		$	2.01	5.80 years	$	685,000
Granted		550,000		$	1.54
Exercised		-		$	-
Forfeited		-		$	-

Balance - March 31, 2015 - outstanding		6,531,106		$	1.97	5.79 years	$	2,628,000

Balance - March 31, 2015 - exercisable		4,168,043		$	1.89	4.98 years	$	1,939,000
Grant date fair value of options granted - March 31, 2015				$	817,000

Weighted average grant date fair value - March 31, 2015				$	1.49
Grant date fair value of options granted - December 31, 2014				$	4,974,000

Weighted average grant date fair value - December 31, 2014				$	2.09

Stock-based compensation expense included in general and administrative expenses and research and development expenses relating to stock options issued to employees and consultants for the three months ended March 31, 2015 and 2014 were $826,000 and $362,000, respectively

As of March 31, 2015, total unrecognized stock-based compensation expense related to stock options was $4.0 million, which is expected to be expensed through February 2017.

6. Stock Purchase Warrants

On October 10, 2014, the Company raised net proceeds of $19.1 million through the sale of 14,059,616 units at a price of $1.47 per unit to certain institutional investors in a registered direct offering. Each unit consisted of one share of the Company’s common stock and a warrant to purchase 0.5 shares of common stock. The warrants, exercisable for an aggregate of 7,029,808 shares of common stock, have an exercise price of $1.75 per share and a life of five years. The warrants vested immediately and expire October 10, 2019.

The warrants issued in conjunction with the registered direct offering in October 2014 include a provision, that if the Company were to enter into a certain transaction, as defined in the agreement, the warrants would be purchased from the holder at a premium. Accordingly, the Company recorded the warrants as a liability at their estimated fair value on the issuance date and changes in estimated fair value will be recorded as non-cash income or expense in the Company’s statement of operations at each subsequent period. At March 31, 2015, the fair value of the warrant liability was $10.9 million, which represented non-cash expense of $4.2 million for the three months ended March 31, 2015. In accordance with authoritative accounting guidance, the warrant was valued on the date of grant and in subsequent periods using the Black-Scholes valuation model. The assumptions used by the Company are summarized in the following table:

	March 31, 2015			December 31, 2014			Issuance Date
Closing stock price	$	2.19		$	1.46		$	1.75
Expected dividends		0	%		0	%		0	%
Expected volatility		90	%		90	%		95	%
Risk free interest rate		1.26	%		1.59	%		1.39	%
Expected life of warrant		4.55 years			4.79 years			5 years

The following table summarizes the estimated fair value of the warrant liability (in thousands):

Balance at December 31, 2014	$	6,756
Change in fair value of warrant liability		4,152
Balance at March 31, 2015	$	10,908

As of March 31, 2015, all of the warrants remained outstanding.

On October 25, 2012, the Company entered into a Common Stock Purchase Agreement with certain accredited investors. As part of this agreement, the Company issued warrants to purchase 635,855 shares of common stock to the placement agent, or its permitted assigns. The warrants have an exercise price of $1.60 and a life of five years. The warrants vested immediately and expire October 25, 2017. Since these warrants were granted as part of an equity raise, the Company has treated them as a direct offering cost. The result of the transaction has no affect to equity. Warrants outstanding as of March 31, 2015 were 316,522.

A summary of warrant activity for the Company for the three months ended March 31, 2015 and for the year ended December 31, 2014 is as follows:

				Weighted Average
	Number of Warrants			Exercise Price
Balance at December 31, 2013		1,632,501		$	1.99
Granted		7,029,808		$	1.75
Exercised		(232,619	)	$	1.47
Forfeited		(454,896	)	$	1.88
Balance at December 31, 2014		7,974,794		$	1.80
Granted		-		$	-
Exercised		-		$	-
Forfeited		-		$	-
Balance at March 31, 2015		7,974,794		$	1.80

A summary of all outstanding and exercisable warrants as of March 31, 2015 is as follows:

						Weighted Average
Exercise		Warrants		Warrants		Remaining	Aggregate
Price		Outstanding		Exercisable		Contractual Life	Intrinsic Value
$	1.60		316,522		316,522	2.57 years	$	187,000
$	1.75		7,029.808		7,029,808	4.53 years	$	3,903,000
$	2.22		517,257		517,257	1.66 years	$	-
$	3.30		61,207		61,207	0.16 years	$	-
$	3.75		50,000		50,000	0.88 years	$	-
$	1.80		7,974,794		7,974,794	4.21 years	$	3,280,000

7. Stockholders’ Equity (Deficit)

During the three months ended March 31, 2015, the Company issued 212,843 shares of common stock to Prev ABR LLC, with a fair value of $350,000, that was recorded as research and development expense, in consideration for achieving the first two milestones as set forth in the Asset Purchase Agreement dated November 28, 2012. In lieu of receiving any cash payment for achieving the first two milestones, Prev ABR LLC exercised its option to receive the milestone payments in shares of the Company’s common stock. The number of shares of common stock issued upon achievement of each milestone was based upon the average of the opening and closing prices of the Company’s stock on the date each milestone was achieved as specified in the Asset Purchase Agreement.

8. Net Loss per Share

Net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding. Diluted loss per share is computed by dividing net loss by the weighted average number of common shares outstanding including the effect of common share equivalents. All common equivalent shares were anti-dilutive at March 31, 2014 and 2015, as such there is no separate computation for diluted loss per share. The number of options and warrants for the purchase of common stock, that were excluded from the computations of net loss per common share for the three months ended March 31, 2015 were 6,531,106 and 7,974,794, respectively, and for the three months ended March 31, 2014 were 4,490,497 and 963,168, respectively.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL INFORMATION AND RESULTS OF OPERATIONS

The following discussion should be read in conjunction with the attached unaudited consolidated financial statements and notes thereto, and with our audited consolidated financial statements and notes thereto for the fiscal year ended December 31, 2014, found in our Annual Report on Form 10-K. In addition to historical information, the following discussion contains forward-looking statements that involve risks, uncertainties and assumptions. Where possible, we have tried to identify these forward looking statements by using words such as “anticipate,” “believe,” “intends,” or similar expressions. Our actual results could differ materially from those anticipated by the forward-looking statements due to important factors and risks including, but not limited to, those set forth under “Risk Factors” in this 10-Q and as applicable in Part I, Item 1A of our Annual Report on Form 10-K.

Overview

We are a microbiome-focused, clinical-stage company developing therapeutics to protect the microbiome while targeting pathogen-specific diseases. We are developing an oral biologic to protect the gut microbiome (gastrointestinal (GI) microflora) from intravenous (IV) antibiotics for the prevention of C. difficile infection and an oral statin treatment to reduce the impact of methane producing organisms on irritable bowel syndrome with constipation (IBS-C). In addition, we are developing a monoclonal antibody combination for the treatment of Pertussis in collaboration with Intrexon Corporation (NYSE: XON), and a Phase 2 oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS.

Product Pipeline:

Summary of Pathogen-Specific Therapy Programs:

C. difficile infections (CDI): We are in clinical development of a novel second-generation oral enzyme candidate, SYN-004, for co-administration with commonly used IV beta-lactam antibiotics, intended to protect the microbiome and prevent the development of and severe effects from CDI. CDIs are a leading type of hospital acquired infection (HAI) and are frequently associated with IV antibiotic treatment. Designed to be given orally and co-administered with certain IV beta-lactam antibiotics (e.g., penicillins and cephalosporins), SYN-004 is intended to protect the gut while the IV antibiotics fight the primary infection. SYN-004 is believed to not only have a similar profile to its first-generation predecessor, which demonstrated protection of the microbiome (gut flora) during treatment with certain penicillins, but also has the potential to protect the gut from a broader spectrum of IV beta-lactam antibiotics. Beta-lactam antibiotics are a mainstay in hospital infection management and include the commonly used penicillin and cephalosporin classes of antibiotics. SYN-004’s target market is significant and represented by annual U.S. hospitals purchases of approximately 118 million doses of IV beta-lactam antibiotics which are administered to approximately 14 million patients.* Currently there are no approved treatments designed to protect the gut microbiome from the damaging effects of IV antibiotics. This worldwide market could represent a multi-billion dollar opportunity for us. In November 2014, the U.S. Patent and Trademark Office (USPTO) issued Patent No. 8,894,994 that has claims to compositions of matter and pharmaceutical compositions of beta-lactamases, including SYN-004, and carries a patent term to at least 2031. We also have an extensive patent estate on other aspects of this program which includes patent applications that could carry a term to at least 2035. In the fourth quarter of 2014, we initiated our randomized, double-blind placebo-controlled Phase 1a clinical trial, reported positive topline safety and tolerability results from the Phase 1a clinical trial, and initiated the Phase 1b clinical trial evaluating multiple ascending doses of SYN-004. In February 2015, we reported positive topline results from the Phase 1b clinical trial of escalating doses of oral SYN-004, with no safety or tolerability issues reported at dose levels and dose regimens both meeting and exceeding those expected to be studied in upcoming clinical trials. In March 2015, we reported positive pharmacokinetics data from both Phase 1 clinical trials, with supportive evidence that SYN-004 should have no effect on the IV antibiotic in the bloodstream, allowing the antibiotic to fight the primary infection. We also initiated a Phase 2a clinical trial to evaluate the GI antibiotic-degrading effects and the safety of SYN-004 in March 2015. The initiation of a Phase 2b proof-of-concept clinical trial is expected in the second half of 2015, with Phase 2b topline data anticipated during the second half of 2015.

This information is an estimate derived from the use of information under license from the following IMS Health Incorporated information service: CDM Hospital database for full year 2012. IMS expressly reserves all rights, including rights of copying, distribution and republication.

IBS-C: In December 2013, through our majority-owned subsidiary, Synthetic Biomics, Inc., we entered into a worldwide exclusive license agreement with Cedars-Sinai Medical Center (CSMC) for the right to develop products for therapeutic and prophylactic treatments of acute and chronic diseases, including the development of SYN-010 to target IBS-C. An investigational team led by Mark Pimentel, M.D., at CSMC discovered that SYN-010 may reduce the production of methane gas by certain gastrointestinal (GI) microorganisms. Methane produced by these organisms is perceived as an underlying cause of pain, bloating, and constipation associated with IBS-C, and may contribute to the pathology of other diseases. SYN-010 is a modified release formulation of a statin being designed to reduce the impact of methane producing organisms on IBS-C. A 505(b)(2) regulatory pathway is anticipated for the development of SYN-010. We licensed an extensive intellectual property portfolio from CSMC including granted use patents and pending patent applications for SYN-010. Additional worldwide patent filings having composition of matter claims, which were recently filed by CSMC and licensed to us, could extend patent protection of SYN-010 to 2035. Based on guidance from the members on our IBS clinical advisory board, we plan to file an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to support the initiation of Phase 2 clinical trials in the second quarter of 2015, with Phase 2 topline data anticipated during the second half of 2015.

Pertussis: In December 2012, in collaboration with Intrexon Corporation (NYSE: XON) (Intrexon), we initiated development of a monoclonal antibody (mAb) therapy for the treatment of Pertussis infections, more commonly known as whooping cough. Combining two mAbs, SYN-005 is designed to target and neutralize pertussis toxin as a prophylaxis for high-risk newborns and in order to reduce the mortality rate in infected infants. To further the development of this potential therapy for Pertussis, we entered into an agreement with The University of Texas at Austin (UT) to license the rights to certain research and pending patents related to pertussis antibodies. We have patents pending on compositions and uses of SYN-005 and we have an issued U.S. patent on other pertussis mAbs from UT. According to the World Health Organization, each year, B. pertussis infection is estimated to cause up to 300,000 deaths worldwide, primarily among unvaccinated infants. Positive preclinical research findings for SYN-005 were reported in April 2014, and again in September 2014, for our proprietary mAb combination therapy for treating Pertussis, in non-human primate studies. In September 2014 we received a U.S. Orphan Drug designation for SYN-005 for the treatment of Pertussis. We intend to seek non-dilutive funding to support preclinical and clinical development of SYN-005 for prophylaxis and treatment of Pertussis, including the anticipated filing of an IND application and the anticipated initiation of a Phase 1 clinical trial.

Acinetobacter infections: In September 2012, in collaboration with Intrexon, we initiated efforts to develop a mAb therapy for the treatment of Acinetobacter infections. Many strains of Acinetobacter are multidrug-resistant and pose an increasing global threat to hospitalized patients, wounded military personnel and those affected by natural disasters. A treatment for Acinetobacter infections represents a billion dollar market opportunity. This program is in the discovery stage and the generation of a panel of antibodies to treat this infection is ongoing.

Summary of Multiple Sclerosis Program:

Relapsing-Remitting MS: Patient follow-up is complete in the University of California, Los Angeles (UCLA) led Phase 2, investigator-initiated, randomized (n = 158), double-blinded, placebo-controlled trial which evaluated our drug candidate, Trimesta, in women with relapsing-remitting MS at 16 sites across the U.S. In April 2014, the lead principal investigator presented positive Phase 2 topline efficacy and safety results. In September 2014, the lead principal investigator presented additional Phase 2 clinical outcome data, including more detailed results on improvements in cognitive and disability measures, at the 2014 Joint Americas and European Committees for Treatment and Research in Multiple Sclerosis Meeting (ACTRIMS-ECTRIMS) in Boston. The data as reported by the lead principal investigator for the UCLA-led Phase 2 study supported the potential of Trimesta to have a novel dual mechanism of action for both the anti-inflammatory effects that improve relapse rate, and a neuroprotective effect that improves standard measures of disability and cognition. Further analyses of the magnetic resonance imaging (MRI) data are ongoing, with topline data expected from the lead principal investigator during the first half of 2015. This investigator-initiated Phase 2 clinical trial was supported by grants exceeding $8 million, awarded primarily by the National Multiple Sclerosis Society (NMSS) in partnership with the NMSS’s Southern California chapter, and the National Institutes of Health. Annual worldwide sales of MS therapies are forecasted to be approximately $17.8 billion in 2019. We have licensed issued method of treatment patents in the U.S. for MS therapy with estriol and estriol combination therapies (including estriol with Copaxone^®) from UCLA, and numerous new provisional patent applications have been filed based on the Phase 2 clinical results. We are engaging with the neurology community and potential strategic partners, as we determine next steps for Trimesta.

Cognitive Dysfunction in MS: Trimesta is also being developed for the treatment of cognitive dysfunction in female MS patients. This 12-month, UCLA-led, randomized, double-blind, placebo-controlled investigator-initiated Phase 2 clinical trial is being conducted at four sites in the United States. The primary endpoint is the effect on cognitive function as assessed by Paced Auditory Serial Addition Test (PASAT). Patient enrollment is ongoing. The majority of the costs of this trial are being funded by grants from foundations and charitable organizations through direct funding to the lead principal investigator and we have pledged approximately $500,000 to UCLA to partially fund this trial, payable over three years. An estimated 50 - 65% of MS patients are expected to develop disabilities due to cognitive dysfunction and there is currently no approved treatment for this indication.

Since our inception in January 2001, our efforts and resources have been focused primarily on acquiring and developing our product candidates, our clinical trials, raising capital, manufacturing and recruiting personnel. To date, we have financed our operations primarily through public and private sales of our common stock, and we expect to continue to seek to obtain the required capital in a similar manner. We have incurred an accumulated deficit of $113.4 million through March 31, 2015. We cannot provide any assurance that we will be able to achieve profitability on a sustained basis, if at all, obtain the required funding, obtain the required regulatory approvals, or complete additional corporate partnering or acquisition transactions.

Pipeline Programs and Therapeutic Areas

Pathogen-Specific Therapy Programs

We are developing pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome. Infectious disease outbreaks are increasing while intervention options are declining due to widespread multidrug-resistant bacteria, increasing numbers of immuno-compromised patients (e.g., the elderly and cancer patients), and the isolation of new pathogens. We are developing an oral biologic to protect the GI microflora from the effects of certain IV beta-lactam antibiotics for the prevention of CDI, an oral treatment to reduce the impact of methane producing organisms on IBS-C and a monoclonal antibody combination for the treatment of Pertussis.

Microbiome-Focused Therapies:

Our C. difficile and IBS-C programs are focused on protecting the microbiome, or our gut flora, which is home to billions of bacteria and composed of a natural balance of both “good” beneficial bacteria and “bad” pathogenic bacteria. When that natural balance of all of these bacteria is disrupted, a person’s health can be compromised.

C. difficile:

According to the Agency for Healthcare Research and Quality, aggregate costs associated with CDI related stays in the hospital were $8.2 billion in the U.S. during 2009. CDI is a rising global HAI problem in which the toxins produced by C. difficile bacteria result in antibiotic-associated diarrhea (AAD), and in the most serious cases, pseudomembranous colitis (erosion of the lower GI tract) that can lead to death. The Centers for Disease Control and Prevention (CDC) identified C. difficile as an “urgent public health threat,” particularly given its resistance to many drugs used to treat other infections. CDI is a major, unintended risk associated with the prophylactic or therapeutic use of IV antibiotics, which may alter the natural balance of microflora that normally protect the GI tract, leading to C. difficile overgrowth and infection. Other risk factors for CDI include hospitalization, prolonged length of stay, underlying illness, immune-compromising conditions including the administration of chemotherapy, and advanced age.

CDI is a widespread and often drug resistant infectious disease. It is estimated that 1.1 million patients are infected with C. difficile annually in the U.S.*, and it has been reported that 30,000 patients die with a C. difficile infection each year. CDI has surpassed methicillin-resistant staphylococcus aureus (MRSA) as the most frequent hospital acquired infection. Controlling the spread of CDI has proven challenging, as the C. difficile spores are easily transferred to patients via normal contact with healthcare personnel and with inanimate objects. There is currently no vaccine or approved product for the prevention of CDI.

*	This information is an estimated derived from the use of information under license from the following IMS Health Incorporated information service: CDM Hospital database for full year 2012. IMS expressly reserves all rights, including rights of copying, distribution and republication.

C. difficile: Acquisition of Clinical-Stage Program

In November 2012, we acquired a series of oral beta-lactamase enzymes (P1A, P2A and P3A) and related assets targeting the prevention of CDI, the leading HAI that generally occurs secondary to treatment with IV antibiotics. The acquired assets include a pre-IND package for P3A (now known as SYN-004), Phase 1 and Phase 2 clinical data for P1A, manufacturing processes and data, and a portfolio of issued and pending U.S. and international patents intended to support an IND and Biologics License Application (BLA) with the FDA. Utilizing this portfolio of assets, we developed a proprietary, second generation oral beta-lactamase enzyme product candidate, SYN-004.

When co-administered with certain IV beta-lactam antibiotics, it is expected that SYN-004 can degrade the antibiotic that is excreted in the GI tract, thus preserving the natural balance of the patient’s microflora, and preventing opportunistic infections including CDI. Beta-lactam antibiotics are a mainstay in hospital infection management and include the commonly used penicillin and cephalosporin classes of antibiotics. SYN-004’s target market is significant and represented by annual U.S. hospitals purchases of approximately 118 million doses of IV beta-lactam antibiotics which are administered to approximately 14 million patients.* Currently there are no approved treatments designed to protect the microbiome from the damaging effects of IV antibiotics. The worldwide market for SYN-004 could represent a multi-billion dollar opportunity for us.

*	This information is an estimated derived from the use of information under license from the following IMS Health Incorporated information service: CDM Hospital database for full year 2012. IMS expressly reserves all rights, including rights of copying, distribution and republication.

C. difficile: Oral Enzyme Background

Beta-lactamase enzymes have the ability to degrade beta-lactam antibiotics that may be excreted into the GI tract. P1A (the first generation candidate) showed acceptable safety and tolerability in a Phase 1 study. In addition, two Phase 2 clinical studies demonstrated that P1A had the ability to preserve GI microflora in hospitalized patients treated with IV ampicillin or the combination of piperacillin and tazobactam.

C. difficile: Preclinical and Clinical Development

Compared to the first generation oral enzyme candidate, P1A, we believe that the second generation candidate, SYN-004, will have activity against a broader spectrum of beta-lactam antibiotics, including both penicillins and certain cephalosporins. Due to the structural similarities between P1A and SYN-004, and based on previous discussions with the FDA, certain preclinical data collected on P1A was used in support of an IND for our new product candidate, SYN-004.

In June 2014, we formed a Clinical Advisory Board (CAB) to support development of SYN-004. The CAB is comprised of industry leaders Mark Wilcox, M.D., (Chairman), Curtis Donskey, M.D., Ciarán Kelly, M.D. and Tom Louie, M.D., all of whom are providing expertise and guidance on each aspect of the C. difficile clinical program.

In August 2014, we announced an agreement with Evonik Corporation for Good Manufacturing Practices (GMP) manufacturing of our proprietary oral beta-lactamase enzyme, SYN-004. Evonik formulated and encapsulated enterically coated SYN-004 for oral delivery for use in our Phase 1a, 1b and planned Phase 2a clinical trials, using material generated by our API manufacturer FUJIFILM Diosynth Biotechnologies UK Limited. In January 2015, we entered into an agreement with Halo Pharmaceutical (Whippany, NJ) to formulate and encapsulate enterically coated SYN-004 for oral delivery for use in our planned Phase 2b and other future clinical trials, using material generated by our Active Pharmaceutical Ingredient (API) manufacturer FUJIFILM Diosynth Biotechnologies UK Limited.

In December 2014, we initiated Phase 1a and 1b clinical trials of SYN-004, and also reported positive topline safety and tolerability results from the Phase 1a study. In February 2015, we reported positive topline results from the Phase 1b clinical trial of escalating doses of oral SYN-004, with no safety or tolerability issues reported at dose levels and dose regimens both meeting and exceeding those expected to be studied in upcoming clinical trials.

In March 2015, we reported positive pharmacokinetic data from both Phase 1 clinical trials, with supportive evidence that SYN-004 should have no effect on the IV antibiotic in the bloodstream, allowing the antibiotic to fight the primary infection. We also initiated a Phase 2a clinical trial to evaluate the GI antibiotic-degrading effects and the safety of SYN-004. The initiation of a Phase 2b proof-of-concept clinical trial is expected in the second half of 2015, with Phase 2b topline data anticipated during the second half of 2015.

In March 2015, we also announced that late-breaking preclinical results supporting the development of SYN-004 were accepted for poster presentation at Digestive Disease Week^® (DDW) 2015 in Washington DC in May 2015. The late-breaking abstract title is “SYN-004, a Clinical Stage Oral Beta-Lactamase Therapy, Protects the Intestinal Microflora from Antibiotic-Mediated Damage in Humanized Pigs.”

In April 2015, we announced that clinical data supporting the development of SYN-004 were selected for poster presentation at the 115^th General Meeting of the American Society of Microbiology (ASM2015) in New Orleans, LA in May-June 2015. The abstract title is “Clinical Evaluation of SYN-004, an Oral Beta-Lactamase Therapy for the Prevention of Antibiotic-Induced Disruption of Intestinal Microflora.” A second poster featured data that support expanding the development of therapeutics designed to protect the microbiome from all beta-lactam antibiotics for the prevention of C. difficile infection, beyond penicillins and cephalosporins was also selected. The abstract title is “Development of Therapeutic Agents that Protect the Colonic Microflora from All Beta-Lactam Antibiotics for the Prevention of Clostridium difficile Infection.”

C. difficile: Intellectual Property

In November 2014, the USPTO issued U.S. Patent 8,894,994 that has claims to compositions of matter and pharmaceutical compositions of beta-lactamases, including SYN-004, and carries a patent term to at least 2031. In addition to this newly granted patent, we have numerous related granted and pending U.S. and international patent applications that are central to our intellectual property estate. Further, we continue to grow our intellectual property estate with new filings, many of which would expire in at least 2035, if granted.

IBS-C:

Irritable Bowel Syndrome (IBS) is a functional GI disorder characterized by gas, abdominal pain, bloating and diarrhea or constipation, or alternating episodes of both. According to reports published by The International Foundation for Functional Gastrointestinal Disorders (IFFGD), IBS affects an estimated 10 to 15 percent of the population, or as many as 40 million Americans. The illness affects both men and women; two-thirds of diagnosed sufferers are women. The onset of IBS can begin anytime from adolescence to adulthood. Four bowel patterns may be seen with IBS, including: IBS-C (constipation predominant), IBS-D (diarrhea predominant), IBS-M (mixed diarrhea and constipation) and IBS-A (alternating diarrhea and constipation). The development of SYN-010 is an oral treatment intended to reduce the impact of methane producing organisms on IBS-C.

It has been reported that up to one-third of all IBS patients have IBS-C. Current FDA-approved therapies for the treatment of IBS-C include AMITIZA^{^®}(lubiprostone) and LINZESS^® (linaclotide). Prescription and over-the-counter laxatives are also used by IBS-C patients for symptomatic relief. According to GlobalData, sales of approved drugs to treat IBS-C in seven major markets are projected to reach $1.3 billion by 2018.

IBS-C: Acquisition of Clinical-Stage Program

In December 2013, we entered into a worldwide exclusive license agreement with CSMC for the right to develop products for therapeutic and prophylactic treatments for acute and chronic diseases. We licensed from CSMC a portfolio of intellectual property comprised of several U.S. and international patents and pending patent applications for various fields of use, including IBS-C, obesity and diabetes. An investigational team led by Mark Pimentel, M.D. at CSMC has discovered that these products may reduce the production of methane gas by certain GI microorganisms. Methane produced by these microorganisms is perceived as the underlying cause of pain, bloating, and constipation associated with IBS-C, and may contribute to the pathology of other diseases. Initially we will focus on the development of SYN-010, an oral treatment being designed to reduce the impact of methane producing organisms on IBS-C.

IBS: Gas Producing Organisms Background

In the 1990’s, research showed that IBS patients (over a given time) produced five times more gas than did people without IBS. Since the only source of those gases was bacterial, the initial presumption was that IBS patients had excessive bacteria in the colon. Subsequent studies showed that IBS patients had excessive quantities of gas in the small bowel; these data were the catalyst for studying small bowel bacteria in IBS. Normally the small intestine contains a very small quantity of bacteria. In published studies, indirect measures of small bowel bacteria suggest that 84% of IBS sufferers have excessive quantities of bacteria typically found in the colon. The CSMC investigational team led by Dr. Pimentel is researching a recent theory that defines IBS as a bacterial disease. Gut microflora that should normally be confined to the large intestine inappropriately colonize the small intestine. This process is referred to as small intestine bacterial overgrowth (SIBO), which results in gas, bloating, abdominal pain and altered stool habits characterized by IBS.

IBS-C: Methane Producing Organisms Background

Further research by the CSMC investigational team led by Dr. Pimentel is focused on the IBS-C patient population. Extensive studies conducted by Dr. Pimentel and collaborators have shown that overproduction of methane gas is directly associated with bloating, pain and constipation in IBS-C patients. CSMC investigators have discovered that inhibiting intestinal methane production may reverse constipation associated with IBS-C, and can be beneficial in other major diseases such as obesity and type 2 diabetes.

IBS-C: Preclinical and Clinical Development

Efforts led by Dr. Pimentel included formulating and testing non-antibiotic FDA-approved oral drug candidates for ultimate product registration via potential expedited pathways. Such candidates are intended for the reduction or elimination of methane gas production within the intestines, with the goal of having little or no unintended impact on a patient’s normal GI microflora.

In April 2014, we formed a CAB to support development of SYN-010, and also announced that gastroenterologist and lead investigator for the IBS-C program, Dr. Mark Pimentel, is the Chair of the CAB. In October 2014, we announced the expansion of the IBS-C CAB to include William Chey, M.D., Gail M. Comer, M.D., Anthony J. Lembo, M.D., and, Philip Schoenfeld, M.D., MSEd, MSc.

In September 2014, we announced that our candidate, SYN-010, is a modified release formulation of a statin being designed to reduce the impact of methane producing organisms on IBS-C. A 505(b)(2) regulatory pathway is anticipated for the development of SYN-010.

Based on guidance from the members on our IBS CAB, we plan to file an IND application with the U.S. FDA to support the initiation of Phase 2 clinical trials in the second quarter of 2015, with Phase 2 topline data anticipated during the second half of 2015.

In February 2015, we announced that preclinical results supporting the development of SYN-010 (based on research performed at Cedars-Sinai Medical Center under the direction of Dr. Mark Pimentel), our candidate therapy to reduce the impact of methane producing organisms on IBS-C, were accepted for poster presentation at DDW 2015 in Washington DC in May 2015. The abstract title is “Lovastatin improves stool form in Methanobrevibacter smithii colonized rats with constipation.”

IBS-C: Intellectual Property

An extensive intellectual property portfolio including granted use patents and pending patent applications for SYN-010 has been licensed to us by CSMC. Additional worldwide patent filings, including composition of matter claims, among other claims, recently filed by CSMC and licensed to us could extend patent protection of SYN-010 to 2035.

Monoclonal Antibodies:

Monoclonal Antibodies for Infectious Diseases

Acting as the body’s army, antibodies are proteins, generally found in the bloodstream, that provide immunity in detecting and destroying pathogens, such as viruses and bacteria and their associated toxins. MAbs can also be designed and produced as therapeutic agents, utilizing protein engineering and recombinant production technologies. The mAbs being developed under our collaboration with Intrexon are intended to supplement a patient’s own immune system by providing the means to specifically and rapidly neutralize and/or clear specific pathogens and toxins of interest in a process known as “passive immunity”. Many pathogens that cause infectious diseases are innately resistant to, or over time have developed increased resistance to, antibiotics and other drugs.

Intrexon Collaboration: Monoclonal Antibodies for Infectious Diseases

In August 2012, we entered into a worldwide exclusive channel collaboration (“Second ECC”) with Intrexon through which we intend to develop a series of mAb therapies for the treatment of certain infectious diseases not adequately addressed by existing therapies. Utilizing Intrexon’s comprehensive suite of proprietary technologies, including the mAbLogix^TM platform for rapid discovery of fully human mAbs and the LEAP^® cell processing station, our initial efforts have targeted three infectious disease indications.** To date, we have initiated development of mAb therapies for the treatment of Pertussis and Acinetobacter infections.

**mAbLogix^TMand LEAP^{^®} are trademarks of Intrexon Corporation.

Pertussis:

Bordetella pertussis (B. pertussis) is a gram-negative bacterium that infects the upper respiratory tract, causing uncontrollable and violent coughing. Antibiotic treatment does not have a major effect on the course of Pertussis, because while it can eliminate the B. pertussis bacteria from the respiratory tract, it does not neutralize the pertussis toxin. Infants with Pertussis often require hospitalization in pediatric intensive care units, frequently requiring mechanical ventilation. Pertussis in adults generally leads to a chronic cough referred to as the “cough of 100 days.” The incidence of Pertussis is increasing due to the declining effectiveness of the acellular vaccine introduced in the 1990s, exposure of unvaccinated and under-vaccinated individuals including infants who are not yet fully vaccinated, exposure of individuals whose immunity has diminished over time, as well as asymptomatic carriers.

According to the World Health Organization there are 50 million cases of whooping cough and B. pertussis infection that are estimated to cause up to 300,000 deaths each year worldwide, primarily among unvaccinated infants. Recent news reports throughout the U.S. indicate that the pertussis vaccine introduced in the 1990s does not provide long-term protection and, as a result, whooping cough cases have increased to a 60-year high.

Pertussis: Intrexon Collaboration and The University of Texas at Austin Agreement

In December 2012, we initiated mAb development for the treatment of Pertussis focusing on toxin neutralization pursuant to our August 2012 collaboration with Intrexon. Unlike antibiotics, we are developing a therapy comprising a combination of two mAbs, SYN-005, to target and neutralize the pertussis toxin as a prophylaxis for high-risk newborns and in order to reduce the mortality rate in infected infants.

To further the development of this potential therapy for pertussis, we have entered into an agreement with The University of Texas at Austin to license the rights to certain research and pending patents related to pertussis antibodies. These research efforts are being conducted at the Cockrell School of Engineering in the laboratory of Associate Professor, Jennifer A. Maynard, Ph.D., the Laurence E. McMakin, Jr. Centennial Faculty Fellow in the McKetta Department of Chemical Engineering. Dr. Maynard brings to the project her expertise in defining the key neutralizing epitopes of pertussis toxin to optimize the potential efficacy of antibody therapeutics.

Pertussis: Preclinical and Clinical Development

Working with our collaborator, Intrexon, and our academic collaborator, The University of Texas at Austin, we established a combination of two humanized antibodies designed to neutralize pertussis toxin, a major cause of pertussis-mediated infant morbidity and mortality. Benchtop studies demonstrated high affinity binding to the toxin, as well as potent neutralization of the toxin. In addition, the antibodies were highly efficacious in a murine model of pertussis in which they completely mitigated elevations of the white blood cell count that is characteristic of the illness.

In April 2014, and again in September 2014, we received positive preclinical research findings for SYN-005, our proprietary mAb combination therapy for treating Pertussis (whooping cough), in three non-human primate studies (n = 19). In the latter two Pertussis studies in particular, SYN-005 rapidly blunted the rise in white blood cell count that is characteristic of the disease and accelerated its return to baseline.

In addition, during September 2014 we received U.S. Orphan Drug designation from the FDA for SYN-005 for the treatment of Pertussis.

We intend to seek non-dilutive funding to support additional preclinical and clinical development of SYN-005 for the prophylaxis and treatment of Pertussis, including the anticipated filing of an IND application, and the anticipated initiation of a Phase 1 clinical trial.

In April 2015, preclinical efficacy data that support advancing SYN-005 toward the clinic were presented in two poster presentations at the European Congress of Clinical Microbiology and Infectious Diseases meeting (ECCMID) 2015 in Copenhagen, Denmark. The data suggest that SYN-005 has therapeutic potential to diminish morbidity, long-term complications and mortality from Pertussis in critically ill infants. In addition, the data support a prophylactic approach for use in newborns that has the potential to save thousands of lives annually, particularly in the developing world where the unmet need is greatest.

Pertussis: Intellectual Property

We have patents pending on compositions and uses of SYN-005 and we have an issued U.S. patent and patents pending on other pertussis mAbs from UT.

Acinetobacter Infections:

Acinetobacter baumanii is a difficult to treat pathogen due to its rapid and well-established development of resistance to most antibiotics, making it a multidrug-resistant pathogen. In addition, as a biofilm-forming pathogen, Acinetobacter baumanii has the ability to survive up to twice as long as non-biofilm-forming pathogens. In the U.S., Acinetobacter baumanii has been reported to be the cause of up to 2.6% of hospital acquired infections, 1.3% of bloodstream infections and 7.0% of ICU respiratory tract infections, and more than half of the Acinetobacter baumanii isolates are multidrug-resistant. According to published articles, mortality rates associated with Acinetobacter infections as high as 43.0% are reported in hospitals and ICU settings. While Acinetobacter baumanii is a well-documented pathogen in the hospital setting, this pathogen also poses an increasing danger to wounded servicemen and women in military treatment centers and to those treated in trauma centers following natural disasters.

A treatment for Acinetobacter infections represents a billion dollar market opportunity.

Acinetobacter: Intrexon Collaboration

In September 2012, we initiated a mAb discovery and development program for Acinetobacter infections pursuant to our August 2012 collaboration with Intrexon. This program is in the discovery stage and the generation of a panel of antibodies is ongoing.

Multiple Sclerosis Program

Relapsing-Remitting MS:

MS is a progressive neurological disease in which the body loses the ability to transmit messages along the central nervous system, leading to pain, loss of muscle control, paralysis, cognitive impairment and in some cases death. According to the NMSS, more than 2.3 million people worldwide (approximately 400,000 patients in the U.S. of which approximately 65% are women) have been diagnosed with MS. The diagnosis is typically made in young adults, ages 20 to 50. According to the NMSS, approximately 85% of MS patients are initially diagnosed with the relapsing-remitting form, and 10 – 15% with other progressive forms.

There are nine FDA-approved therapies for the treatment of relapsing-remitting MS: Betaseron^®, Rebif^®, Avonex^®, Copaxone^®, Tysabri^®, Gilenya^®, Extavia^®, Aubagio^® and Tecfidera^®. Many of these therapies provide only a modest benefit for patients with relapsing-remitting MS. All of these drugs except Gilenya^®, Aubagio^® and Tecfidera^® require frequent (daily, weekly & monthly) injections (or infusions) on an ongoing basis and can be associated with unpleasant side effects (such as flu-like symptoms) and high rates of non-compliance among users. Despite the availability of therapies for the treatment of relapsing-remitting MS, the disease is highly underserved and exacts a heavy personal and economic toll. Annual worldwide sales of MS therapies have been forecasted to reach approximately $17.8 billion in 2019.

Relapsing-Remitting MS: Background

Research has shown that pregnant women with MS tend to experience a spontaneous reduction of disease symptoms during pregnancy, particularly in the third trimester. The PRIMS (Pregnancy In MS) study published in 1998, a landmark observational clinical study published in the New England Journal of Medicine followed 254 women with MS during 269 pregnancies and for up to one year after delivery. The PRIMS study demonstrated that relapse rates were significantly reduced by 71% (p < 0.001) through the third trimester of pregnancy compared to pre-pregnancy-rates, and that relapse rates increased by 120% (p < 0.001) during the first three months after birth (post-partum) and then return to pre-pregnancy rates. It has been hypothesized that the female hormone, estriol, produced by the placenta during pregnancy, plays a role in “fetal immune privilege”, a process that prevents a mother’s immune system from attacking and rejecting the fetus. The maternal levels of estriol increase linearly through the third trimester of pregnancy until birth, whereupon it abruptly returns to low circulating levels. The anti-autoimmune effects of estriol are thought to be responsible for the therapeutic effects experienced by MS patients during pregnancy.

Rhonda Voskuhl, M.D., Director, UCLA MS program, UCLA Department of Neurology, has published that plasma levels of estriol achieved during pregnancy have immunomodulatory effects. Dr. Voskuhl further postulated and tested in a pilot clinical study that oral doses of estriol may have a therapeutic benefit when administered to non-pregnant female MS patients.

Estriol has been approved and marketed for over 40 years throughout Europe and Asia for the oral treatment of post-menopausal symptoms. It has never been approved by the U.S. FDA for any indication.

Relapsing-Remitting MS: Clinical Development

Trimesta (oral estriol) is being developed as an adjunctive once-daily treatment for relapsing-remitting MS in women. An investigator-initiated, 10-patient, 22-month, single-agent, crossover clinical trial to study the therapeutic effects of 8 mg of oral Trimesta taken daily in non-pregnant female relapsing-remitting MS patients was completed in the U.S. The total volume and number of gadolinium-enhancing lesions were measured by brain MRI (an established neuroimaging measure of disease activity in MS). Over the next three months of treatment with Trimesta, the median total enhancing lesion volumes decreased by 79% (p = 0.02) and the number of lesions decreased by 82% (p = 0.09). They remained decreased during the next 3 months of treatment, with lesion volumes decreased by 82% (p = 0.01), and numbers decreased by 82% (p = 0.02). Following a six-month drug holiday during which the patients were not on any drug therapies, median lesion volumes and numbers returned to near baseline pretreatment levels. Trimesta therapy was reinitiated during a four-month retreatment phase of this clinical trial. The relapsing-remitting MS patients again demonstrated a decrease in enhancing lesion volumes of 88% (p = 0.008) and a decrease in the number of lesions by 48% (p = 0.04) compared with original baseline scores. The study was published by the lead principal investigator in Ann Neurol. 2002 Oct;52(4):421-8.

Patient follow-up is complete in the UCLA-led Phase 2, investigator-initiated, randomized (n = 158), double-blinded, placebo-controlled trial which evaluated our drug candidate, Trimesta, in women with relapsing-remitting MS at 16 sites across the U.S. Positive Phase 2 topline efficacy and safety results were presented in April 2014 by lead principal investigator, Dr. Rhonda Voskuhl of UCLA at the 66^th American Academy of Neurology Annual Meeting. Dr. Voskuhl presented additional Phase 2 clinical outcome data, including more detailed results on improvements in cognitive and disability measures, at the 2014 Joint ACTRIMS-ECTRIMS in Boston in September 2014. The data as reported by Dr. Voskuhl for the UCLA-led Phase 2 study demonstrated the potential of Trimesta to have a novel dual mechanism of action for both the anti-inflammatory effects that improve relapse rate, and a neuroprotective effect that improves standard measures of disability and cognition.

Specifically, Dr. Voskuhl reported the following results:

	(i)	Annualized relapse rate: A 47% reduction in annualized relapse rate in the Trimesta+Copaxone^{^®} arm as compared to the placebo+Copaxone^{^®}arm (active control arm) at 12 months of therapy (p = 0.02), meeting the primary endpoint of the trial. These improvements in annualized relapse rate were sustained during the 24 months of therapy. When compared to the placebo+Copaxone^{^®}arm at 24 months, the Trimesta+Copaxone^{^®} arm demonstrated a 32% lower relapse rate (p = 0.11).

	(ii)	Cognitive disability: Patients in the Trimesta+Copaxone^{^®} arm who had Paced Auditory Serial Addition Test (PASAT) scores lower than 55 before treatment (PASAT scale maximum of 60) experienced an approximately 12%, or 6 point, improvement in cognitive scores within 12 months of treatment (p < 0.05). This improvement from baseline was sustained throughout the 24 month study. In addition, a significantly larger proportion of patients in the Trimesta+Copaxone^{^®} arm demonstrated sustained improvement in cognition during the entire 24 month period, as approximately 33% of the patients showed sustained improvement of at least 3 points during this time period, compared to only about 21% in the placebo+ Copaxone^{^®} arm (p < 0.05).

	(iii)	Physical disability: Expanded Disability Status Scale (EDSS) scores in the Trimesta+Copaxone^{^®} arm significantly improved during 24 month follow-up by at least 0.5 point (p = 0.03) compared to the placebo+Copaxone^{^®} arm which experienced no change in EDSS scores. The between group difference showed a positive trend (p = 0.25). The 25 foot walk test showed a significant difference, while the patients in the Trimesta+Copaxone^{^®} arm were stable during the study, those in the active control arm did worse. The between group difference (p = 0.02).

In addition, adjunctive oral Trimesta plus injectable standard of care Copaxone^{^®} demonstrated a strong safety profile and was well tolerated by women in the study. Further analyses of the MRI data are ongoing by UCLA, with topline data expected from the lead principal investigator during the second quarter of 2015. We are engaging with the neurology community and potential strategic partners, as we determine next steps for Trimesta.

This investigator-initiated Phase 2 clinical trial was supported by grants exceeding $8 million, awarded primarily by the NMSS in partnership with the NMSS’s Southern California chapter, and the National Institutes of Health.

Relapsing-Remitting MS: Intellectual Property

In March 2014, we announced that the USPTO issued U.S. Patent No. 8,658,627 entitled, Pregnancy Hormone Combination for Treatment of Autoimmune Diseases, to the Regents of the University of California. The patent includes claims to the use of our drug candidate, Trimesta, in conjunction with a gestagen for the treatment of MS and other autoimmune diseases. The patent also includes a claim for the administration of Trimesta, a gestagen and a third standard of care MS agent, such as glatiramer acetate injection (Copaxone^{^®}), interferon beta-1a (Avonex^{^®}, Rebif^{^®}), interferon beta-1b (Betaseron^®, Extavia^®) or sphingosine-1-phosphate receptor modulator (Gilenya^®).

In April 2013, we announced that the USPTO issued U.S. Patent No. 8,372,826 entitled, Estriol Therapy for Multiple Sclerosis and Other Autoimmune Diseases, to the Regents of the University of California which includes claims to the use of our drug candidate, Trimesta, in combination with glatiramer acetate injection (Copaxone^®). According to Teva Pharmaceutical Industries Ltd.’s Form 20-F for the year ended December 31, 2014, filed with the SEC on February 9, 2015, Copaxone^® continued to be the leading MS therapy in the U.S, and globally, with approximately $4.2 billion in global net revenues. Currently marketed exclusively by Teva Pharmaceutical Industries Ltd., U.S. Orange Book patents on Copaxone^® expired in May 2014 and, subject to further judicial review, in September 2015.

Through our wholly owned subsidiary, we hold the exclusive worldwide license to issued U.S. Patents 8,895,539, 8,658,627, 8,372,826 and 6,936,599, as well as pending patents for MS and other autoimmune diseases covering the uses of our drug candidate, Trimesta. Numerous new provisional patent applications have been filed based on the Phase 2 clinical results.

Cognitive Dysfunction in MS:

According to the NMSS and the Multiple Sclerosis Society of Canada publication, Hold that Thought! Cognition and MS, it is fairly common for people with MS to complain of cognitive difficulties, such as remembering things, finding the right words and the ability to concentrate. Among MS patients, 50 – 65% have some degree of cognitive dysfunction.

The major areas of cognition that may be affected include complex attention and executive functions. Complex attention involves multitasking, the speed with which information can be processed, learning and memory, and perceptual skills; executive functions include problem solving, organizational skills, the ability to plan, and word finding. Just as the nature, frequency, and severity of MS-related physical problems can widely vary, not all people with MS will have cognitive dysfunction, and no two people will experience exactly the same type or severity.

Cognitive Dysfunction in MS: Background

In the investigator-initiated, 10-patient, 22-month, single-agent, crossover clinical trial conducted by Dr. Rhonda Voskuhl, a statistically significant 14% improvement from baseline in the PASAT cognitive testing scores (p = 0.04) was observed in relapsing-remitting MS patients after six months of Trimesta therapy. PASAT is a routine cognitive test performed in patients with a wide variety of neuropsychological disorders such as MS. The PASAT scores are expressed as a mean percent change from baseline.

Cognitive Dysfunction in MS: Clinical Development

Our Trimesta drug candidate is also being developed for the treatment of cognitive dysfunction in female MS patients. This randomized, double-blind, placebo-controlled Phase 2 clinical trial to evaluate Trimesta’s potential neuroprotective and therapeutic effect on cognitive dysfunction in female MS patients is currently enrolling relapsing-remitting or secondary-progressive female MS patients at four clinical sites in the United States, including UCLA. Up to 64 patients between the ages of 18 and 50 will be randomized 1:1 into the treatment and placebo groups. Investigators will administer either oral Trimesta or a matching placebo, in addition to an FDA-approved MS treatment, including Copaxone^®, Avonex^®, Betaseron^®, Extavia^®, Rebif^®, Gilenya^®, Aubagio^® and Tecfidera^®. Each patient will be dosed and monitored for one year after being enrolled. The primary endpoint in this clinical trial being run under an investigator-initiated IND application is expected to be improvement in PASAT cognitive testing scores versus matching placebo. We and a private foundation pledged to equally support this new clinical trial, and we will also provide Trimesta drug supply. The trial also received contributions from several other supporters. Patient recruitment and enrollment into this trial is ongoing.

Critical Accounting Policies

The consolidated financial statements are prepared in conformity with U.S. GAAP, which require the use of estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses in the periods presented. We believe that the accounting estimates employed are appropriate and resulting balances are reasonable; however, due to inherent uncertainties in making estimates, actual results could differ from the original estimates, requiring adjustments to these balances in future periods. The critical accounting estimates that affect the consolidated financial statements and the judgments and assumptions used are consistent with those described in the Management’s Discussion and Analysis of Financial Condition and Results of Operations section in our 2014 Form 10-K.

Results of Operations

Three Months Ended March 31, 2015 and 2014

General and Administrative Expenses

General and administrative expenses increased to $1.7 million for the three months ended March 31, 2015, from $1.1 million for the three months ended March 31, 2014. This increase of 53% is primarily the result of increased employee costs, audit fees related to the additional procedures required under the accelerated filer status and stock compensation expense for the three months ended March 31, 2015. The charge relating to non-cash stock-based compensation expense was $582,000 for the three months ended March 31, 2015, compared to $255,000 for the three months ended March 31, 2014.

Research and Development Expenses

Research and development expenses increased by 139% to $6.5 million for the three months ended March 31, 2015, from $2.7 million for the three months ended March 31, 2014. This increase is primarily the result of increased program costs associated with expanded clinical development programs, manufacturing and research activities within our pathogen-specific microbiome-focused pipeline, including our C. difficile, IBS-C and Pertussis programs. Research and development expenses also include a $1.0 million expense for achieving the third milestone as set forth in the Asset Purchase Agreement with Prev ABR LLC, dated November 28, 2012. Prev ABR LLC exercised its option to receive the milestone payment in shares of our common stock that were issued in April 2015. The charge relating to non-cash stock-based compensation expense was $246,000 for the three months ended March 31, 2015, compared to $107,000 for the three months ended March 31, 2014.

Other Income (Expense)

Other expense was $4.2 million for the three months ended March 31, 2015, compared to other income of $1,000 for the three months ended March 31, 2014. Other expense for the three months ended March 31, 2015 is primarily due to non-cash expense of $4.2 million from the change in fair value of warrants. The increase in the fair value of the warrants was due to the increase in our stock price from the previous period. There was no non-cash expense relating to fair value of warrants for the three months ended March 31, 2014.

Net Loss

Our net loss was $12.4 million, or $0.17 per common share for the three months ended March 31, 2015, compared to a net loss of $3.8 million, or $0.07 per common share for the three months ended March 31, 2014.

Liquidity and Capital Resources

We have financed our operations since inception primarily through proceeds from equity financings, corporate partnering license fees, laboratory revenues and miscellaneous equipment sales.

Our cash totaled $12.0 million as of March 31, 2015, a decrease of $5.5 million from December 31, 2014. During the three months ended March 31, 2015, the primary use of cash was for working capital requirements and operating activities which resulted in a net loss of $12.4 million for the three months ended March 31, 2015.

Our continued operations will primarily depend on our ability to raise additional capital from various sources including equity and debt financings, as well as, license fees from potential corporate partners, joint ventures and grant funding. Such additional funds may not become available on acceptable terms and there can be no assurance that any additional funding that we do obtain will be sufficient to meet our needs in the long term. We will continue to fund operations from cash on hand and through the similar sources of capital previously described. We can give no assurance that any additional capital that we are able to obtain will be sufficient to meet our needs.

Current and Future Financing Needs

We have incurred an accumulated deficit of $113.4 million through March 31, 2015. With the exception of the quarter ended June 30, 2010, we have incurred negative cash flow from operations since we started our business. We have spent, and expect to continue to spend, substantial amounts in connection with implementing our business strategy, including our planned product development efforts, our clinical trials, and our research and discovery efforts.

However, the actual amount of funds we will need to operate is subject to many factors, some of which are beyond our control. These factors include the following:

	·	the progress of our research activities;
	·	the number and scope of our research programs;
	·	the progress of our preclinical and clinical development activities;
	·	the progress of the development efforts of parties with whom we have entered into research and development agreements;
	·	our ability to maintain current research and development licensing arrangements and to establish new research and development and licensing arrangements;
	·	our ability to achieve our milestones under licensing arrangements;
	·	the costs involved in prosecuting and enforcing patent claims and other intellectual property rights; and
	·	the costs and timing of regulatory approvals.

We have based our estimate on assumptions that may prove to be wrong. We may need to obtain additional funds sooner or in greater amounts than we currently anticipate. Potential sources of financing include strategic relationships, public or private sales of our shares or debt and other sources. We may seek to access the public or private equity markets when conditions are favorable due to our long-term capital requirements. We do not have any committed sources of financing at this time, and it is uncertain whether additional funding will be available when we need it on terms that will be acceptable to us, or at all. If we raise funds by selling additional shares of common stock or other securities convertible into common stock, the ownership interest of our existing stockholders will be diluted. If we are not able to obtain financing when needed, we may be unable to carry out our business plan. As a result, we may have to significantly limit our operations and our business, financial condition and results of operations would be materially harmed.

Several factors will affect our ability to raise additional funding, including, but not limited to, market volatility of our common stock, continued market listing of our common stock and economic conditions affecting the public markets. If our common stock is delisted from the NYSE MKT, the liquidity of our common stock could be impaired, and prices for the shares of our common stock could be lower than might otherwise prevail. These factors could be negatively impacted by the matters discussed under this heading and under the caption “Risk Factors”, included herein; also see “Risk Factors” in our 2014 Annual Report on Form 10-K.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

As of March 31, 2015, our cash and cash equivalents consisted primarily of money market securities. Due to the short-term duration of our investment portfolio and the low risk profile of our investments, we would not expect our operating results or cash flows to be affected to any significant degree by the effect of a sudden change in market interest rates or credit conditions on our securities portfolio.

ITEM 4. CONTROLS AND PROCEDURES

(a) Evaluation of disclosure controls and procedures

Pursuant to Rule 13a-15(b) under the Securities Exchange Act of 1934 (“Exchange Act”), the Company carried out an evaluation, with the participation of the Company’s management, including the Company’s Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), of the effectiveness of the Company’s disclosure controls and procedures (as defined under Rule 13a-15(e) under the Exchange Act) as of the end of the period covered by this report. Based upon that evaluation, the Company’s CEO and CFO concluded that the Company’s disclosure controls and procedures are effective as of March 31, 2015 to ensure that information required to be disclosed by the Company in the reports that the Company files or submits under the Exchange Act, is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to the Company’s management, including the Company’s CEO and CFO, as appropriate, to allow timely decisions regarding required disclosure.

(b) Changes in Internal Control over Financial Reporting

There has been no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that occurred during our fiscal quarter ended March 31, 2015, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II-OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

None.

ITEM 1A. RISK FACTORS

The following information updates, and should be read in conjunction with, the information disclosed in Part 1, Item 1A, “Risk Factors,” of our Annual Report on Form 10-K for the fiscal year ended December 31, 2014, which was filed with the Securities and Exchange Commission on March 16, 2015. There have been no material changes from the risk factors disclosed in our Form 10-K for the year ended December 31, 2014, other than as set forth below.

RISKS RELATING TO OUR BUSINESS

We will need to raise additional capital to operate our business.

With the exception of the three months ended June 30, 2010, we have experienced significant losses since inception and have a significant accumulated deficit. We expect to incur additional operating losses in the future and therefore expect our cumulative losses to increase. With the exception of the quarter ended June 30, 2010, and limited laboratory revenues from Adeona Clinical Laboratory, which we sold in March 2012, we have generated very minimal revenues. We do not expect to derive revenue from any source in the near future until we or our potential partners successfully commercialize our products. As of March 31, 2015, our accumulated deficit totaled approximately $113.4 million on a consolidated basis. Until such time as we receive approval from the FDA and other regulatory authorities for our product candidates, we will not be permitted to sell our products and therefore will not have product revenues from the sale of products. For the foreseeable future we will have to fund all of our operations and capital expenditures from equity and debt offerings, cash on hand, licensing fees and grants. If our current cash, cash equivalents and short-term investments are not sufficient to sustain our operations, we will need to seek additional sources of funding, such as additional financing or grant funding, and additional financing may not be available on favorable terms, if at all. If we do not succeed in raising additional funds on acceptable terms, we may be unable to complete planned preclinical and clinical trials or obtain approval of our product candidates from the FDA and other regulatory authorities. In addition, we could be forced to delay, discontinue or curtail product development, forego sales and marketing efforts, and forego licensing in attractive business opportunities. Any additional sources of financing will likely involve the issuance of our equity or debt securities, which will have a dilutive effect on our stockholders.

RISKS RELATING TO OUR STOCK

We cannot assure you that the common stock will be liquid or that it will remain listed on the NYSE MKT.

We cannot assure you that we will be able to maintain the continued listing standards of the NYSE MKT. The NYSE MKT requires companies to meet certain continued listing criteria including a minimum stockholders’ equity of $6.0 million if an issuer has sustained losses from continuing operations and/or net losses in its five most recent fiscal years, as outlined in the NYSE MKT Exchange Company Guide. At March 31, 2015, we had a stockholders’ deficit of $1.6 million. The NYSE MKT Exchange Company Guide also states that the NYSE normally will not consider removing from listing securities of an issuer with total value of market capitalization of at least $50.0 million and 1,100,000 shares publicly held, a market value of publicly held shares of at least $15.0 million and 400 round lot shareholders. Although the total value of our market capitalization exceeds $50.0 million and we have 1,100,000 shares publicly held, a market value of publicly held shares of at least $15.0 million and 400 round lot shareholders, there can be no assurance that the NYSE MKT will continue to list our common stock due to our lack of minimum stockholders’ equity. In addition, in the future we may not be able to maintain such minimum stockholders’ equity and/or issue additional equity securities in exchange for cash or other assets, if available, to maintain certain minimum stockholders’ equity required by the NYSE MKT. If we are delisted from the NYSE MKT then our common stock will trade, if at all, only on the over-the-counter market, such as the OTC Bulletin Board securities market, and then only if one or more registered broker-dealer market makers comply with quotation requirements. In addition, delisting of our common stock could depress our stock price, substantially limit liquidity of our common stock and materially adversely affect our ability to raise capital on terms acceptable to us, or at all. Delisting from the NYSE MKT could also have other negative results, including the potential loss of confidence by suppliers and employees, the loss of institutional investor interest and fewer business development opportunities.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

On January 22, 2015 we issued 212,843 shares of our common stock to Prev ABR, LLC in connection with an asset purchase agreement that we executed on November 8, 2012 (the “Asset Purchase Agreement”) with Prev ABR, LLC upon the attainment of certain milestones in connection with the Asset Purchase Agreement. At the time of issuance, the shares of common stock had not been registered under the Securities Act of 1933, as amended, and therefore could not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. For these issuances, we relied on the exemption from federal registration under Section 4(a)(2) of the Securities Act, based on our belief that the offer and issuance of such shares of common stock did not involve a public offering as the purchaser of the common stock and its beneficial owners are “accredited investors” as defined under Section 501 promulgated under the Securities Act and no general solicitation had been involved in the offering. On April 20, 2015, a registration statement registering the shares of common stock was declared effective by the Securities and Exchange Commission.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

None.

ITEM 6. EXHIBITS

10.1		Employment Agreement with Steven A. Shallcross dated April 28, 2015 (Incorporated by reference to Exhibit 10.1 of the Registrant’s Current Report on Form 8-K filed May 4, 2015.)

10.2		Severance Agreement with C. Evan Ballantyne dated effective April 29, 2015 (Incorporated by reference to Exhibit 10.2 of the Registrant’s Current Report on Form 8-K filed May 4, 2015.)

31.1

Certification of Principal Executive Officer pursuant to Rule 13a-14(a)/15d-14(a) *

31.2

Certification of Principal Financial Officer pursuant to Rule 13a-14(a)/15d-14(a) *

32.1

Certification of Principal Executive Officer pursuant to Section 1350 of the Sarbanes-Oxley Act of 2002 *

32.2

Certification of Principal Financial Officer pursuant to Section 1350 of the Sarbanes-Oxley Act of 2002 *

101.INS		XBRL Instance Document *

101.SCH		XBRL Taxonomy Extension Schema *

101.CAL		XBRL Taxonomy Extension Calculation Linkbase *

101.DEF		XBRL Taxonomy Extension Definition Linkbase *

101.LAB		XBRL Taxonomy Extension Label Linkbase *

101.PRE		XBRL Taxonomy Extension Presentation Linkbase *

*Filed herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned.

	SYNTHETIC BIOLOGICS, INC.

	By:	/s/ Jeffrey Riley
		Jeffrey Riley
		President and Chief Executive Officer
		(Principal Executive Officer)
		Date: May 11, 2015

	By:	/s/ C. Evan Ballantyne
		C. Evan Ballantyne
		Chief Financial Officer
		(Principal Financial Officer)
		Date: May 11, 2015

EX-31.1 2 v409108_ex31-1.htm EXHIBIT 31.1

EXHIBIT 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO RULE 13a-14 OR RULE 15d-14 OF THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Jeffrey Riley, certify that:

I have reviewed this quarterly report on Form 10-Q of Synthetic Biologics, Inc.;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 11, 2015	By:	/s/ Jeffrey Riley
		Name: Jeffrey Riley
		Title: President and Chief Executive Officer
		(Principal Executive Officer)

EX-31.2 3 v409108_ex31-2.htm EXHIBIT 31.2

EXHIBIT 31.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

PURSUANT TO RULE 13a-14 OR RULE 15d-14 OF THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, C. Evan Ballantyne, certify that:

I have reviewed this quarterly report on Form 10-Q of Synthetic Biologics, Inc.;

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 11, 2015	By:	/s/ C. Evan Ballantyne
		Name: C. Evan Ballantyne
		Title: Chief Financial Officer
		(Principal Financial Officer)

EX-32.1 4 v409108_ex32-1.htm EXHIBIT 32.1

EXHIBIT 32.1

CERTIFICATION PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to 18 U.S.C. § 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Synthetic Biologics, Inc. (the “Registrant”) hereby certifies, to such officer’s knowledge, that:

(1)

the accompanying Quarterly Report on Form 10-Q of the Registrant for the quarter ended March 31, 2015 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(2)

the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.

Date: May 11, 2015

	By:	/s/ Jeffrey Riley
		Name: Jeffrey Riley
		Title: President and Chief Executive Officer
		(Principal Executive Officer)

EX-32.2 5 v409108_ex32-2.htm EXHIBIT 32.2

EXHIBIT 32.2

CERTIFICATION PRINCIPAL FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

(1)

(2)

the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.

Date: May 11, 2015

	By:	/s/ C. Evan Ballantyne
		Name: C. Evan Ballantyne
		Title: Chief Financial Officer
		(Principal Financial Officer)

GRAPHIC 6 image_002.jpg GRAPHIC begin 644 image_002.jpg M_]C_X``02D9)1@`!`0```0`!``#_VP!#``$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_ MVP!#`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_P``1"`$D`F<#`2(``A$!`Q$!_\0` M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4% M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$! M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$" M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#]N?\`@OW^ MWU^U9^P[??LC+^S)\1]/\`)\4[3]H,^.EOO`?@3QK_;#^!)?@V_G=_X?Z?\%4O^CC-`_\`#%_`[_YW M]?J[_P`'5G_'[^P/_P!>?[6?_HW]F>OY1/`W@CQ'\2/%_A[P'X.M-+O?%'BK M4!I>AVFM>*/"/@G2KB^,$]R([[Q9X\UWPQX.T&$PV\I^W>(?$&E6'F!(/M7G MS012?U#X:\-<+XW@G+LPS3(\HQ5?FS-XC&8W#QG/V5#,,5&+J5)35H4J2:NU MI%:WL?@G&V?9[AN*,;@L!FF98:E".`A1PV$Q4Z<'.K@Z-1J%-0:4ISJVLGK9 M/1MV_5[_`(?Y_P#!5(_\W&:!_P"&+^!P_GX`I3_P7S_X*I#K^T7H'/\`U0OX M'?\`S`5\]:A_P2[_`&R?#=YKUGX^\&_#;X=2:!\&_B-\=95UKX^?!#QE=ZEX M!^&?@:X^(FKW6G:'\%_'?Q6\31/KGA>V:Y$:KK6A:/X.UV>:SA/BNRCO;:> M7\^@DAG%KY$_VO)!L?(E-\K&%;G:;(QK=@K:D73[H%*6^^X<+$CLOV."X=\/ M,R=19=DG#&.]E&C*H$AJ=>,5B%6="U2G6<*CJK#UW"-)5)?N:EU>+1\YB,Z MXTPCIK%9CQ%A_:R<*?ML56A.52,HPQ=6+]I.$$YQBISG&,$Y-)_L3_P_ MT_X*I?\`1QF@?^&+^!W_`,[^C_A_I_P52_Z.,T#_`,,7\#O_`)W]?CH"IC>9 M49X8XY97FCC,L*PVYB%Q,9HPT7D6_GVWGS!S%"+NS,CJ+VT,TTD,L+RQS6MQ M#)`@EGCEMY8I(8F)42RI(BM'$2"/-8"/C.[!4GN?!7!D7:7"^0Q:M?FP5.-K MI-7YJT$M&GJU:ZORW2?-_K/Q/K_PN9WIO_ME?3WIPM_N^_-2JQLKMRIU$DW" M7+^PO_#_`$_X*I?]'&:!_P"&+^!W_P`[^C_A_I_P52_Z.,T#_P`,7\#O_G?U M^/`CD:X^QK;3O>Y9?L26\CWI98UF919HC7+.(724HL1;RY(WQMD0LD2M.D,E MO#+<1W#M';26\+W$=U*A`:*VDA5TN)060>5"SN3)$`I,L89?ZF<%+5\,\/I< MJG?ZK0MR.,IJ=_K-N1PC*:DFXN,924G%-@N)^)VU%9YG;E)M12QE:[<7",DE M[!-N,JE.+5KJ4X)I.23_`&('_!?/_@JD>/\`AHS0/_#%_`[_`.=_2_\`#_/_ M`(*I?]'%Z!_X8OX'?3_HG_/X5^>_@']F3XE^-M1^")UJ;P3\&?!'[0Q^(A^% MWQG^/7BRV^&GP5U:'X6IK$/C.?4/'D]OJ<.D1V&MZ'=>$[%+RP\_5_%E]I.E M6,$L-X+M/GP!GC%PJ2M;-*84N#$_V=IE19&MA/M$!NQ$P=K57,^TLWDJ@)'/ M#A;@&I4J4J?#_#=2=%3]M&&%I24)1JUJ#BZJKNC[2G7P^(IUJ'/*O3=*=Z2Y M6RY<1<60ITZLLZSN-*IR.$I8O$7G&I"E5ISC%8?F5*=.O0G"O)1H.-:FU4]^ M-_V*_P"'^G_!5+_HXS0/_#%_`[_YW]'_``_T_P""J7_1QF@?^&+^!W_SOZ_. MCPA^S/\`'CQ]\$/BC^TEX.^&.KZ]\#/@KJNDZ'\4/B);ZGX6MM.\+:KK'JPA7=/V]%NA:I19[V(L) M+-('>\0HL=]L5Q"\D:E&`9=K`]"-I!'4$$9!!'( M()%:+@O@N3<8\,9`Y12;BL'3@_(4U@H'(_+C_`#_GO5K@G@RZOPMD:5U=K`0;2NKM+VFM ME=_(%Q3Q*VE_;V!DUZ7_P`$L/C-I?[/W[(7[<7Q8UOXN_&3X+Z/X3_:!_X) M[ZGJGB7X#^'-$\4?$+7-+T[Q[\5=0U3P%;Z5XC\:^`]#DT+QS86T_AOQ'/JN MJZEIUGH][=3ZAX7\46'GZ'>=AKNG?L1?''3OV,?B5XS_`&>OA5\'_"W_``4* M_;Q_:BM_BK\3=0\4^-="\3?!_P""W@C]H;P3J/AGP;X>/AWQMX=^%W@R[\6: M7XGMO`_B_P`=ZAX6U*S\.>%;WQ#/X<309S;>)=&^*Q.'X2P.99CA,3X=8"K@ ML%BGA(8W!8;#SG6Q%'*99MB,/&CBJE*%6NL/&52G#"3K.,8+#8A0QN(P\#Z> MA6XAQ6!P->AQKBXXO%8>EB:F$KXW$0C0IU\94P5*7M:<)2M[=4HU)5HTH14Y MRB^6FV_!/^'^?_!5+.W_`(:+T#(+`C_A1?P.R"N[<#_Q;_@KL?=G[NQLXVG' M0:S_`,%QO^"O_AS3_#6K^(_B_=>'-(\::5-KO@O5O$'[-'PHT/2O&6A6VH7> MD7.N>$=2U3X96EEXGT6VU?3]0TFXU;0I[_3X-4L+[3I;E+RSN88OJW3?V+_@ M!>_$S]G?0/VD/V4/@_\`LU_M$>*/BG^U]HW@3]D3PC\9O%5OX3_:/^''PZ^$ M,VO_`+,=YX_U?7_C/XVU#PQ=^+OCC!/X#TOQ?8>+_A_9?&N33B]EI4^CZAI6 MFZ?N_%[]G"U^.'A#X+_!7Q%^SU\.O`?[0^G?\$A/VA-;^"W[.G@SQU>:IIWA M/]ISPM^UI:7FL>&_AK/X@^)'C"^/C>QT:3XDZ@WPGU_Q[XPUGP.R^)?!FJ_; MKCP'?RZ?P3Q_A[[?#TJ?`^5.G*53ZSB)T\OE2A3C-THUL++#UYPQ>%A-PK8C M,*,YX"CAU7A*M'%T9072Z'%T`1U/'6F+_P7V_X*GMOV_M'^'6,;%)`OP.^!A,;@`E)`/`!*,`02K8(!&0, MBOKZ]_8<^&/AK4/BAI/P>_94^"_[4/[27@;X(_\`!.>[N?V?/$_Q>OH_!-MX M9^*OPQO;_P#:<^/.C:AX2^-?@#3_`!E-?>.4T'1;OQ_IWCW5?`WPXLM?M_'$ MM@WA6]E.L_%__!16>/Q'^R]_P30\>>&?@?\`!OPIX!U+]EK1?"\_Q6^&B^(+ MB]D^)_@[QC\4]/\`&7P5N]2U/XF>+K>\L?"EF-'\8:H=8\-7OB>3Q-KNISR> M-9M.DM/#>F^A@H\!YCF.!P6#X(R=TL9B:V%>*JPP$?93AEN,S*E/ZK&K]8J4 MJT,+"%.HDHU_:3EAI5?9R2X\35XLP>#Q&)Q'%69>UH8>EB5AJ6(QK@@4%C@`FM/P]_P78_X*V^+M?T;PIX2^.$7BOQ7XDU.ST3PWX6\, M?LZ?!_Q!XE\1ZUJ5W#8:=HWA_0-(^&UYJ^MZOJ-_<6]C8:9I=G=7U[>3PVMM M!+/+'&WXKZD,6%Z5!R+2Y(QD#*PLVYL$?ZL*95R0`\:GDX4_W*_MGZ-=^._B MO;^'OBUJ7Q6\)^#1_P`%/_\`@G)KWP:U#XT?%+POK7ASXO:#K[^'/`'Q0\+_ M`+#,O@:Z\#?%7X#VG@73]>F\>_%+6KO4?&%_J-UI^MS:;XCT'^U;A]$^0XGP M7!_#V)RVA'@GA[$QQU/'U*E2I25%T5A:;]BZ=*G[:K7]I7<(U5&G)TZ3G53I MPA.O2^CR+&\0YS1Q]1\4YUAZF#EA5"FL6Y1K*O4HJI*52<8JE&G2G5:E)J,J ML(4M7-I_@AJ__!=O_@K3X>UC6/#WB'XZVF@>(?#VJZCH7B'P_KO[/7P:T?7? M#^NZ/>SZ;K&AZ[H^I?#FVU+1]9TC4K6YT[5-*U*VMK_3M0MKBRO+>&Y@EB34 M\2?\%O\`_@L+X,;0%\9_%J^\'-XL\*Z-X[\)KXM_9E^%7AEO%7@7Q&+@^'/' M'AA=<^&-@?$/@SQ"+2Z.@^*]'%[H&LBUN3INH77D2[/KSP)^QW^R[XJNK+7? M%/P+^'7CWX`^*?B[_P`%%H?V\_VO/&/QL\80_$3]C_4?AW\5_B=HOP,TKPQ, MWQ4TNP\,:C:Z-9^!?$]G+X[\"_%/6_CM<>+HWEN?LCS7$U/Q#\&=`^,O@/X4 M>(_#WP,^'W[6/[5GPX_X)"_\$OH_@+^S=X_\9:[8>'?$MKXKU[XH:7\>_'5S MX2$_$;X4^)/B%JOPRT&W\,6[:/'XZT^'0&\91>)=5M+B:*R#>2\P\//:TH1 MX(ROD::J2J8?"4FJDJ.&C3YY.O4H99!8ZI75?^UJM*=#+(87,IVHXNFST'A^ M+5&3?%F9)OEG"*Q&*G+V<<0HXA*,(.6*J+#2C4PZP2J0K5U4H7;HU5'XK'_! M?+_@JF3@?M%:"2>N/^%?\`3KSTX/H:Z37_`/@M_P#\%AO"<'AF MZ\6?%F_\*VGC;PY9^,O!5UXG_9D^%?AZU\9^#M2N+BTT[Q?X0N=9^&%E#XH\ M*ZA=V=W:6'B30GO]%O+JTNK:VOI9K:9$_1OX4_L"_L1OX@_:F^(GP\_9X\*_ MM#?#SX;_`+2_BOP1J7PXM?\`A?/[1'B#3=&T/]BCX:SX-UKQE\8;F^TGQ-\.]$N?#/A[Q,WB+P_P#:HOG'P]^S;\.O MB'\+/A#X@\+_``1$?M'?M/Z1_P2N_92\?\`P-_96^)?Q"^*%YX)\6>)_'7[ M5?Q7\-?M"ZYH?A>X^,?@GQ%+9_!CX:VIOM$^%VA^//#^A:'-J=SJ+^'[[7K> MU>*89GX=U:CC3X$P,84IPI5G7PN!IR=?$9?AL90HJ4\53IX.,*N)5/%XW,7# M`TZ-*K7A47NP'+"<7THI5N+L9[6I3=6DJ&,Q=:'LZ6*KX>LY6H\]2`/VBM>E:ZT3Q;XE\,6^HZ18V?A?Q5X_AUGXA^&[>*UL M4L_1S5\`Y/BL73Q7!.5?5L)E4,9+$4\)";JYE6HX/%T,JHS4/J-253!8ZEB? MK$,;.5H5E'"3A#VCY)K8^IAWAJV.E!T\%2E7I5,PFDW MB(05>A*DJ4\+&.L).O%SC%?FV/\`@OG_`,%4CR/VC/#Y&,@CX&?`T@CU!_X0 M#D>XXH_X?Y?\%4^O_#1>@8X.?^%%_`[')`'/_"`8Y)`'/)('4C/Z$?"#]D#] MB_XA:M^TCXDNOV,O%NK7.B_MH^//A/XN_9XTSPSX@TSXG?L[?LR:#\//#\/P MF\37.F?$7]MC]GV\^`.I_$M3J_Q)U/\`:&\3?'G4_%'Q(M?BE%\7? M@?K_`,4Y/A=J-IHNB>/K+X8:=:W%GX:N?^%AZY9+>*VC!EDF81(I<@5T?C;_@M__P`%?_AQXO\`$O@#Q]\: M[+PEXV\&ZS>^'?%?AC6?@/\``F+5M`UW393!J&DZG##X%GCAO;.96AN(5F)= M=T_Q?K?CW4[:WO\`1/YH?%'BKQ)X\\4>)_'?C/4)M:\8^.?$6N>-/%FLSLTD MNK>)O%>J76OZ_J4DDLLTCM?:MJ%W=;GFF=A*"\LK$NWL9%E/!^=U9.'!O#V& MHTCQ'Q7B:D:6'SG/:]6=^2E1Q5>M4DXQE-\M.G1E.=HQFY^AG_#_/_@JE_P!'%Z!QZ_`OX'?_`#OZ3_A_I_P52_Z.,T#_`,,7\#O_ M`)W]?`OCC]E3XL_"A?CII_QH/@KX+>._V?C\/#XE^$OQ0\8Z=H/Q0\>0?$K7 MIM$T>^^"7AZQ&J:;\8=(TB.+_A)/$VO>$/$,F@67A![;7-+U/5TG51\XB*7S MDM?LMP;J1!)':"WE:ZDC,4DP>.W$8GE0012SEUA&VWBDF<(D;LN>&X5X"Q<' M/#<)+:9#;(LMRKP MNK6\;K&ZR3J5W1(RRPD%PH_?VXZW$`DZ%P9P4[6X9X?=W%)+"46[SG&E&-EB M&U*52<*<8R49.:44\7Q1Q,KMY[G22=FWC*Z2=G*WO8>-W9-ZSNHYQ&9O M(DM98Y_(4R*TX@=%E,"^3.6G"&)4@G=G"02LA_J9P5:+_P!6>'[2BI1:PM!J M46VE)6Q+O%N,DI:*\7KHQKB?B=JZSS.VE-TVUC*WQI)N'\#XDI1;CNE)76J/ MV#_X?Z?\%4O^CC-`_P##%_`[_P"=_1_P_P!/^"J7_1QF@?\`AB_@=_\`._K\ M=P%(R`,'D<"FNR1J78<`9.%R?H`!DGT`Y)X&3Q5/@K@Q)M\+9$DDVW]1C9)) MMM_O-DDV_)-]"?\`6KB7_H?YQK;_`)CY]6DO^7:W;2WZKN?L5_P_T_X*I?\` M1QF@?^&+^!W_`,[^C_A_I_P52_Z.,T#_`,,7\#O_`)W]?&/Q]_8)_:^_9?T` M^*?CI\$KWP=H$7BC3?!6HZCI/CSX2?$P>'?%VM:#!XHT/PWXRLOA+\0/'FH^ M`]8U[P]=6VKZ!9^-K/P_+KEI<0MI(O))%C/R(`2'(B=ECM([^1UC9HX["9?, MAOWD`*+931$3PWC,+:6V(N8Y6MR)3RX7A?@#'47B,%D7#&,H*4H.MA:.&Q%- M2BXQE'GI8F2YHRG!-6=G*.]TSHKY_P`7X6JJ&)S7B'#UY*+5&OB,32JM3Y^5 MJ$\-=J7LY\K6_)*VL6C]BO\`A_E_P52(S_PT7H&.G_)"_@:/Y^`*/^'^7_!5 M+_HXO0#GT^!?P./\O`%?EU\'OA9XG^./Q6^&?P>\%/I4'B?XL?$;P?\`"[PQ M?^(+F^L/#%MXI\;:S8Z'I']N:MINF:QM/)XD\'20ZX\.FLS6E*IPOP%3Q5/`R MX>X>6,JW]G0_L^3DG&@<_\` M5"_@=_/_`(0#\O6D_P"'^?\`P52SC_AHO0,YQ_R0OX'=?_#?U^7GAWX:W'B' MX<_%;XCMX[^%_AV+X2S^!+:_\`>+_&EOX=^*WCMO'NOW>A)/\*?!%U9M<^-H M/!ALWUGXBS_:M+A\)>'I(]0GENY)DC7SI8IVD2W6UNGNG@2[6W2UG:Y>U=@J M7:6Z1FX:TD8A8[D1F&0L@21F9!JTJT:7#?#\_85_J]1_45:-1T:6(2 MNZMIKV%>G-RI.I"S;YTG&^;XDXK@HRJ9SG<(S2E3;QU5\T&YPO*/L'*G+GHU MER5%&24)*24J=3E_8G_A_G_P52_Z.,\/_P#AC/@;_P#,!2?\/]/^"J7_`$<9 MH'_AB_@=_P#._K\U=>^!_C/P[\!OA?\`M&7][X9D^'WQ>\=_$OX=^$[2QU._ MN/%46N_"BR\*7OB2ZUK3&T>#2;/1KV/QEI:Z'>6GB#4[N]>VOS0X'H/R%%#A'@?%4W4H<-9#4A&K6H2<HJ=6#4IIWC)QVNG&<'=\R8 MI\3<4T^55<[SFFY0C4BGF$IPK]!-1_X);?MR>'?&'PR\'^./@[I_@,_%3XK?#3 MX,Z9XBU3XG?"WQ?X=\'^./BZVFMX!MOBG'\'_%_Q0\4_#2PU^RU2UU2QN/%7 MA2SNM2LF1-$L=3U&6&QFY\;PYX>Y=R?7LCX9PLJL*TZ-.OAZ4*M>-"/-66'I M>U]I6E36LE3C)QZIW2EO0S[C#%1JRPN:Y_B8T.3VTJ.+JRC2]HXQI^UFJ3C3 MYW)*"FTYMI1O>Y]$?\/\_P#@JE_T<9X?_#X%_`X_R\`4?\/]/^"J7_1QF@?^ M&+^!W_SOZ_)/Q1X;U+PAXJ\0^#]62&76/#?B#6?#-X=/,]S:WE_H&LW_`(?O M+G26E@M[J^TVZU/3KN/3KL6D!O`A46\%RLMK#AA7,EQ"+:X,UHLSW4`MIC/; M);M&D\EQ`$\V".&26..225%1)'6-F#L%KK7!W!$H>TCPWP[*G[*-?G6&H*_AMM1YFVN;W7[WNF/^LW%/,X?VWG?/&4H2BL96;C."YIP;6'MS1BG M)I._*G*SBFU^Q'_#_3_@JE_T<9H'_AB_@=_\[^C_`(?Z?\%4O^CC-`_\,7\# MO_G?U^.F1L641N8GN#:),(V,+7(A^T_9Q,`8O.:V_P!(2,N&>#]\@:,AC[?X M4_9M^.OCCX,?$?\`:)\+?#'7-2^!WPEFT^U^('Q+FO/#VC^'M'O-2U70=$BL M=-37=9TO5O&.HV>I^*O"]OKNF^!M-\2W_A>/Q)H-[XFMM(L-7L+JXFOPAP-A M8QGBN&^'L-"=6E0A+$82E1C.M7J2I4*4)5:L%.I6JPG3HPBY2JU(3A3YY1DH MU2XBXLK.U'.<^JOV4JUJ6*KS?L8QE.5:T:#?LHPA*4JGP*,9-R23/T<_X?Z? M\%4O^CC-`_\`#%_`[_YW]'_#_3_@JE_T<9H'_AB_@=_\[^OQWP/0?D*,#T'Y M"M?]2>#?^B6R+_PAC_\`+#+_`%JXE_Z'^%O@=X,L?&6L^!O`VJ?$SQBNJ>/?AE\-M(\-^`M$U70]$U7Q/JWBC MXL>-/`GA6VL;'5/$FBVTL1UIKXK>M=1VDEE9:A-;K2]2M;VQN]`36K%[J^M?/K\/^'6&Q"PE?)N%J6+; MH+ZK.A1^L_[2VL/>A&O[6$:UGR5)Q5-*TI.,91E+KIYUQI6H_6*.9<0U:#]I M:M'%5E1DZ*O5C"LZ/LY3AU@I7O=6NFE]M_\`#_/_`(*I?]'%Z!_X8OX'?_._ MH_X?Z?\`!5+_`*.,T#_PQ?P._P#G?U^.2.KV\EV@:6TC,?F7:HS6T9F\KR4E MN`##'),9X%AC=U>5IX$C4M-&K.)"QQRO&Z1S!C"\D9C6<+)Y+F`N%$WES8AD M\O=Y^ M^7_6GB;E4GGN=13@ZFN-JZ04U3&-"T"WB6/4]2\0^(KVTT[0](A@NFM_+O-3OK^RM[=+ MEH$WW,;2O'&2X]P^//[)W[0O[,<'@:]^./PW'@_1_B;8ZYJ'P^\3:1XV^&?Q M,\&^+X/#.IC1_$<.B^./A)XT\>^#[C5-`U)XK;6=#?7(]6=U M:$W#6/$/%LZ5:O#-\_E1PS@L16CBJ[I8=U.7V:KS5#EI.ISPY/::5R,A(XU+NY`!)"JK$X!.!TKI7!'!S=EPKD; M;V2P$6]TO^?G=I>K7)=0^)7PL\7Z%X-\8?&^]TBS^''_ M``M.U^$OC+XD>*_AGI?B"/6]/OK&Z\7>%M/GU&":.STJSU#5I[;39_B/QCX5 MU;P-XT\5>!-<2V?7O"/BOQ#X-U$Z<]S[L["ZU#3;K M5=-G&G3FR@GGBDA\RWAF2\+8N2C*HOJM"C6A[*-54)2= M6.(]FW&NU2:A*5I/6R]]]=?.>-<*D\3F'$>'C*2A&57$XB#E-P=11Y'A^=2= M.,YI-:QBW?HOUF_X?Z?\%4O^CC-`_P##%_`[_P"=_1_P_P!/^"J7_1QF@?\` MAB_@=_\`._K\=@K-)-"L$QFMX9;BYA$$GG6T$'E^?-<1;?,@C@,L2SO*J+"\ ML<;L_=?:W@2Y2U$@^0W+6TL5R(`QE^S2Q3[/*E1V[ MUP5P8[6X6R&7-*G&/+@J<^:56'/2BO9UJEY58-3II:U(^]!21RKBGB9WMGN= M:*4G_MM96C"2A.3OAU90DU&3VC)I2LVC]BO^'^G_``52_P"CC-`_\,7\#O\` MYW]077_!?;_@JI';7$J?M&:!NB@FD&?@7\#<%DC9EW!OA\V5#`$XP>.N,@_# MOPP_8L_:@^-/PVUOXM_"OX2R^-/`OA^Q\8:G?W&G^._A58^++K3/A_;P77C7 M4?#?PNUOQWI7Q6\:V'AJ*YB34[WP5X(\0VT5V)M/CEDU"VN;6'Y2O&5["\9/ MNFRN2",8(:%B"/4$<@UA1X3X$Q%2O2P_#W#E6KA9QIXFG2PM*I4PU6<9RIPK MT_:*=*?[6?_H[]F>OY$[J+S[>6'8LAEC=%C?9M=V1@B$R$1KN?:`\K)%& M<22R1QJSK_79_P`'5G_'[^P/_P!>?[6?_H[]F>OY&F&1TSU!![@@@@]L$'!S MQC/!Z5_7?A(^7@7)Y:^[B,SDK;WCFN(DK:QZQ75;6NKW7\W^(:YN*\VCH^:E M@8V>SYLLP\6GH]&I-7L[73L[6?[H^&_VZO@1X)_;"UWX]^$_BI=:);V'_!)B MR_9S\"^,[7X?_$'^T+?]IO1/V=_"/@30_#-MH][X)?5(([#XAZ2MK;>,-8TB M#X;[8#J;>)7T>2:[;W?X8_\`!27]E\:KI_B_Q[\3[B7]H7QA_P`$U/V/?@SX MM_:/\7Z/^UKH.J:-^T)\)OBGX[U[XW^#_&OQ._9ILO#?[3EQXB\>^"+SX:VL M_P`5/A;>^(_#WBRX\'V/AWQAXCUG1$O=$OOYM"#C&WTQG:<<[B!V`W88`#[W M/6C#8(*YR M'PT*T:="VA"M4@Y+V:E*G/FPW%F8X6I[2E1PBBL;6QBH MM59Q4Z]3#5*C4(N$?:1]@U1JWYZ2F[2=K/\`HIUW_@I=\';BV73-&^/6L?#2 MQ^('_!5VT^.G[0*_LN>`/BU\,;7Q-^S++\!?A7X4\5>-_#R^/M!U6_'AWQE\ M4_`U_P",?%OP_P!>UN?Q_P"*M6C3Q?KGP]M?-TBQL?M3PE^UM\!/CM\1M4UG MX&?M'3+XK^"?_!*?_@HQIGQ$^/&G>&?VOO&NM?"RVU#XN?!KQY\(_&$WB']J MS3KSX_?%N7X>:?/J_BFWMO[:\1ZAH>N:7JEGX1TW0M.F\(Z7R2`2<"I$>:+>8GEA:6-X93#*T1EADP'AE*.#+"XSYD3[D?H MRD5P8GPYRJI&,L+B<;A<1!8B,)NCEM7#/?B9<3_&)M>^+U[^QM^Q%\%H_ MVV/&'A/]KOX=6?QK^*'P(\5?$#Q!\;]7UKQ!^S7'X;_;#\*VWCC1O%OPSTB/ M6]5T:`?$(_!\Z1\4K:7PY;Z#)JGFGPW_`&U_V,_%/Q5\$?$#XH_'C0O@[_PI M+_@JUX^_;`AT[P'^S=\<;[P?\7/AGXW\"_#7PLWB+X?>'-)T;7=5\`7,GC'P M7?>)/%VB_$O4-+\4V7A_Q!JVJZ+I'BKQ2;7P'>?SI_/SD'GK\V,YR&SSR6#, M"3UW-G.:"#D97."#G/<+M!'0@@9`]`2!P:N/AUE--5W1Q>:4ZV(P^'PTZ_M< MNE.%.A3Q=)J@JF%J0C3JT\=BH+#^SI4L)3J0AA4HT:481+C/,IQHQJ87+ZD, M/5J58TO88I*I.I4PD^>;6)^*>B7'ACPEXH\.:]X>^''@'Q9X8^$7ASPYA/B!X%TSQ0;+3?#6G>`]#U3 M4H/@C]I[]H_P)\3_`-D']F3X>_"W]J'7/#GAKX9_LW_`#X4>//V$V^%_Q$TO M1H_CC\/=:\2W'Q*^.X\8QZ0GP2NAXVUF_NO'J^,++Q/J?Q4UJXUJT\,^(M%L MM.?7?[)_+':2,')YRA@^"LNP6-PV.I8C$JIA<15Q%*C.CE%7"J53$8G%U%4H?487G.KBZT*6)IRA MC:--N$,7"#:ER8CB;&XC!XC!3H8?V>)H4J$ZBJ9C"ORT:-&A3Y:_UV4HP4,/ M2<\.XSP=2<74J86N_`W5OB5\7O$'P'T7XZ\('QHMKJ,=XWX+_\`!1'X,?#CXC?\$P_!WC?XOZYX MP_9W_9E_9T\5>$_BM9:9X*^*C^#/!O[2M]@ZUX.EOO$_@+2M9U6?X?7FD_$!-5TVY_`O#=A[XR."#D$8Q@YYZ= M1G-*`5SM4`';G!QNVXVC@#.W'&[..V!653@')Z[Q4JV)S.K]>J8S$8F-7%8: M:EBL70Q>%GBJ:JX*H\-5IT,6Z=)0E5BUAL+:5+V'H89TJ=E'#T*F$JJA5C)M5:`]2M=!U;PM!J/AKQ-XB MO-7L-03PYKVEZ)K>C-?K=O=S6&K:/INH0SS2_:K.&5F6OF3#`[E&UN.00",? MKQU')V]L4Y00#GN<]^%.EZ9?^ M+O$$&LZDUUX@UW3/"_A7PYX=\,Z1>^(?%7B_Q?XGUB:WTS0/"_A?0-.OM7UG M49WEG6WMQ;Z?9:AJ5S9V%SY$PR"/\]:^O?V'?VD/"W[,'QMU+Q;\1/".O^-_ MA3\2/A)\5_@#\7_#G@_4=-TKQU+\-/C'X9?PYX@U/P'J&L1OHUOXNT25+'5M M+75V@L+]+.YT:XU#1X=5EU6U]O-*F.HY;CZN6T8XC,*>$JSP=&4>=5,1>E&$ M8T^>DJTXQE6JPH3JT88B5*%"5:FZRD>1@(86IC<+#&UGA$\12^L5DVN2DG4 M%.I.C"4ZD*'M!TV;7=3\/26OBJ.V\!^'/&W@;4?[2TV]>UL_&7@_0(O M$.G/!K/A2X\0:3>6MY+YQX;_`&5OVE/&/AG4O'?A#]FOXX^*?!]G#XM?6O&' MA[X/>.]9\.V<7PZO$TOQXNJZY8^';C3[1O`U[)_9WBR&^N(I-"NA=:=J,<$\ M5W;+^C'['_[5/_!/7]D+Q3XLU#2?"7[3_P`7CJEU\#/%OAGQ[\5O@3^S1XAU MWPOXI^%/Q'\5>*O$>A>'/A+K'QTU_P"'WAZX\5^%KOPOIOASX]/XC\3?$[X: MZ^OB34?!/A'2;;4[F>^]M\/?\%9O@KH?QZ_9D^)5KX=_:&M?!'PC_;B_X*&? MM._$/PUING>"+:^\6>#?VLK_`,1O\+=)L-&3XLPZ%K7C'PSI?B&^T_QK;^)- M0TO1]'.I:W9^%?$?BR.\>74?D99[QA#$8VAAN'\3C:%+"TI8?,\;DV-RS%8^ ML\'BJM=2P&$Q]6AA*DL1##Y?0:Q;BDX5L2Y4:M:D?2PRSA>I3PU2>;T,/4J5 M:OML%@\=2QD,-%8K"4Z3ABZT(.+-#\ M->%K;6M3N-/UW7WT?3_'?A_PW>>*/#LT&A7*7-O]J>$_^"B_[.UE\!K?1M;T MC]I[3?C+9_\`!)WXB?\`!,>/P1X6M/AO)^S9L:=XN7PE\<+Z[O/B-I/C2 MZUO6M1U/P_)XRTQO`(FT07&JZOIFI>+;W2;#3M;]#US_`(*B?LR^./$WC%_$ MOA_]K+P+X8@_:#_8A_:>^'^O?!VR^%NF_$+Q1XI_93_9N\(_!/Q!$_B6VJ_ M$^QTWP[\/-?\0^%W\3>$_$OAS6/&FKZ<]R-8OO!\%]!#I5[S5*C05.=#"4?[.K5\+@Z2=>$*U2TGC(KK&4Z5>I43H5*E.:DIT*5.LYXI2;C.I&-.FHSC.=/ MF_+CXO\`[#WQN^&_BK]H^P\/_"#XF?%+X1?LQ?%_XN?#'QC\>/#/P;\6_P#" MKHKKX/\`B74-!\0>)=7U6UM/$&@>%5%I:6VNZO87WB34#X);RRNM.U#S MGX;_`/!3/]GCPEXN^$7C#7/`WQAU>[_X=@:3_P`$Z_C?IFL_#SX*_%+POX;U M;P)8>!U\)?%/X:>#OB%X\70/C9X;\?[U+\8/&'@WQG\.O$VL^"/B'X/\4>`?&GAJ\_L[Q%X/\:Z#JGA M?Q3H5]Y$-TMKJ^@:U:V>IZ=/+9W-K>P1W=M$TUG=6MU&&@N(G;G:^K/VU?V@ MM/\`VE_CK<_$?1-1\0:IX>T_P!\-_A_X;N?$_P`+OAC\&=5CT;P)X6M-(BL( MOAK$=7\1>"/"NAZ5?"_T_PKI5CXG\27=CX6M]'LKW57:VCMK?Y3K[O+:^*Q M.7X+$8[#PPF-K8:E4Q6%@ZKA0K3C=TXNO&%;S<:D5*#]UW:;/D\;3P]'%XFC MA*SQ.'I5IQHUWR?O:5_(/"7A_Q#>O?^"/`/Q' MUJ34K6[\8:7>16@\/"VDT^VU&=K^*Y@MK.\Z3QO_`,$]?VCO!/C+P[X1\%?# M"/\`:#M/B'\.],^*?P^\=_LL:=K'QO\`A_\`$GX9:IXCM_!,/BCP]J7AKPY! MK]MIMGXQO;;PKK6D>-/"_A77-"U^[L(M;T.P_M72;J^Z+]B'X^?!_P"!FJ_M M/:7\;H/BM_PA?[1'[''Q;_9BAUCX.>%_!GC'Q=X7USXE>,OAKKMMXEDT#QW\ M0OAEH=[I.F:5X-U43(GBA;Z74+G3((K-K:6\O;#ZPO/^"B'P7\(?"'Q3^SM\ M&/#7Q]T'X9>&OV#?BM^RC\'?&7BB?P19?$SQ)\3OCI\?O!_QP^*WQ"^)T/A+ MQ=!IG@+P+X@ETG6-`L/#?@W7OB5JVC:;*EM_8_FLTQW%5'.'2RK+Y M8W!WP5&FJV62^J4Z>*H4%B,4LVH8BGC9UL/F$I*KE]"$4\+"=2=6/+357W-/V5?V@_AW\/M)^) MWQ'_`&^.?A-XN\+^"=:G\1V4E[H,EAXBUK0K31KR36 M[$37>C[+MGU&U$EU8B:V8S/^FVG_`+>W[+VH_`\:7KGAW]H/3/CYJ/\`P2GU M[_@F3(L&C?#6[^!%H]QK.K:GX9^+^I>)3X[C^)LT&H+)I?\`PE6DV/@-7$6 MC>(9=&B^(<\6DQWOU7_P6I\=_"/QY\,;G4?A=\9OAA%_"LGA77/@ MG^S!I6NZGXJ378/A_:ZWY=O/Y[XLXAI9SDF48G(G@5FF,J4:^(K4,X4+8:GB MHUJF$Y?K,:L*E6GAW2Q%?EI)5IQDE"G*I'KAP]E4\LS',*>9^WJ8'"8>O0P\ M9Y5%PGB/9WA55N52*?Q/\#H/VY_V??V7?!_C/PC^T MO^S-^S_X&\36OQ+^.W[/'PG^-%Y\%[GX^>+(-)T%O#OC?XI_LXM\0/@[X^U' MX1W?B&R\+7.C>$M3/Q4^">K^/->T19/`=KKFM:AI-[K/Y^ZU^RQ^T?IFC>!O M%'B7]F_XX6/A_P",WB'0M(^&_B/Q!$/'UII?Q2\6>.&5_#.F^$M5UCP]$GC M'Q'XQ\^.7P_9V$]_JGB42)-IBWQ`=?K+XE_M"?LF_M#?!3]G*V^->E?M(^%? MVA/V8?V;O^&;O#T'PN\-_";Q5\$OBSX6^'-SXKUSX%7OBS5O&?COPQXP^'-W M::SXNO\`3/BK)HW@[XBG6=#$]_X?AT_55T\V7VIXS_X*G?LYW_Q)^+WQ9\-> M&?VJ=8U_]J?]I#]@_P"-7QD\%?$8?#C4/!'P-T#]D#XC^!?BEKNA_`74],^( M]Q?_`!*U?Q!?^$+GP9X'N?%V@_!NRT+P+>6VC:A%;7*RFLZ&)XCR_%8RMAN% ME/&9CF.,686R?^S*!^KYG+'YGAE"57VN!I4XXC$ M?]AW]LFTFLDN/V//VFH)U\/ZWXJL!-^S]\4(9(_#7AU[& MQ\0:Y:^=X3B:#2=(:_TVWU+4E$5FBZA81FX?[=:K-W_P%7]N_P"!_P`,OB9\ M3?@;$OBDOP.^)7@KPWX@^+7B35_V8M!^-'P)\7^!/!?B779_"GBOQ7:_%CX M4?$7X876G>#O$NB>)?[`\5S645SX?%2/3 M+CXA^'EN=8MK_P`,WMY#X$T72M9OK70?&-ZVHRV+]W'^VA^SS\"_V)?C+XX^+?AO]CG]M7X;^$_@MX#UOX:7WP2L]9^/_P`4?B=X;BC_`&A;.?QF MOBSP-?Z%I&H:3XF?2-*\'^+9_&]M:^"I8W\/6GAWRZE4HJ=2,8U+J$_:1IU*BC4I*$YUZE=#A97[6-CH/A>TT"2#1?(T_3M#\/PK:6EA:)Q/_``S?$O`'QC\0>%O#_[0)^.7QU_ M8Y^`W[(FN_"?Q6O@6']E#X9Z=$G\"0:IX^^'VKZ9X\U3QOJ\TL'PXM]1\"^ M$[[X<>$8_!6N^-O'VJ3>(=2DU>,7OLWB#_@II^QLOQ4\2?&#P7X#_:J37_BK M_P`%#OV2OVY/B7I'BS0/@Q_9/AK2O@8FMMXV^&W@!]&^)S:AX@U2YO-8O]3\ M'^)/%#>'K;Q+#K=OI&L:-\/_`/A&O[?\6]M+-N**&'IT(\(2H\DJE"E0IX7, M%1H5*"BX4:T5B^1?5Z=&%"EC!S"JZ%;"4J-*G9V7A?3XOAU>?!KQ=HFO?M`Z;X$U^R\;^&[#PSIFI^$HO$WBZT M\.^()M/\226?A(R(LPLKO58KB`6F;W[2_P"R5X[_`&6/#?[.^I?$DZ[HOBWX MZ_#+Q)\0=6^&WBOP'K7@+Q=\+;SPY\2O%'P^G\*>(['7KZ6^U*[N5\.PZ[;W M\FD^'3%:ZFMD-+GAB@U2\_0+X2_\%/\`X;^#=3\&S^.=%^/WB?[+^TE_P4$^ M(7B/Q1IL_A:?X@>%_A;^VI\-K7P5X\$:M'J.O:IHVHR MZ'X4`OI[?3O&%\]_=7\/QQ^V7^T3\(OC9X,_8_\`AY\'W^..H:/^S!\!M3^" MNH^)OCS;>#[?Q1XL9/B%KWB/1-9TR+P;XR\966G:-_8.HV5K:^%;F_D/@6U@ ML?!NGZQXML=$3Q5JFN!QO%$LWP='%Y*LMP5>MF%3,L9A<%BHTLPK0PE:.%J5 MJ]67LX0I8B>'H-5:/UBM6IU,1'$1PDN0RQ^%R199B*M'-:F88JC3PRPN%Q%? M#R>!C.I0^L>RHTJ?/*?LXUI>TA65"G%TZ?L)5XQD_AG!V8[YQ^.ZOT)_8S^( M/P,TOX`_M]_!#XS?&G0?@=??M'_##X'>&/AWXF\5?#OXP_$7PYH&/J,SP$)P\*%2M0JX' M&X7,:$XQQ,:E"4/K.!H*I&I3J*46TXN+E?PLOQCP.(C7]C2Q"5*O3G1KRJPI MU*>)PU7"UHRE1<:MY4<15C%0G3?-)-5(-*2_H>O?V]OV5[;P/XT^#WA/XRW[ M6?PP^%'_``2+_9]^$/Q2^*?P/^)7BS1_C5%^QM^UEXS^+WQ9^+.N_"+2+6;4 M+/X9>&-!\8+=6GPG\?>*?"/C#QQX1\/KX-T.23Q'?VEG;]'X[_;Y_9J\4^._ MCCKW@[]LGX@?"_X\?%[]E;X9^"O#G[7EKHW[6'Q&^'_P'\?>'?VEM=^+/Q6^ M%WP8U+QKX";]L?P_\/?BSX1U,VEK;ZEX9UC1/`-[ M7T$>,LS]G*$\-@9SE*@^>,,32450^N0CR*&(C6C55'%1I4Z\*ZK4_8J4)*?/ M4J_T-?#K]OG]G?PO\-_A[!XB_:I\3Z[X%\#_``N_;6\%?M'?L=#X&?$BSLOV M]/BU\;?$GQ1/ACX[Z]K$'AN\^$.FCXB3>-/!WCW53\4_%%AXP^%3>!+CPAX7 MT2^L=:/V[/;_`(*+_LGVWPE_9P^(/B.;7?B'^TA\7/&'[`_A/_@I!X)N?`>M M:F=9^$?[!?B+Q/,^M6GB/Q3HVG>"/'FN_'.71?A;XGUWPCHGB;6]/O\`3/#L MWA[Q-+ILNVVA_GU^;KM(.G;':X>'^2\ZK3K9A*J\54KR?UC!X/GI5*.+@L+5GA,&ZE6FJ^,EB_K%:6 M)Q<*N$RJ$*WLL#0C2F7%V9NG[.%/"J*PD,/"-66)JNG7A5PTEBJ?UFIB'2?L M<+&@Z<)1I2^L8RA_'OP%XF'@_P%_P`% M!1\/_B-X?\`?MQ>,O'?AOQ#\:/AQI^G?!?PAXFU7]JF'Q?J,.B^)_&MO;W47 MPT\!:1>_`?X77?AI+RVUC2_#FN-:P>(>#_VG[O7O^"5GCC]K#XM:UXT\5?M; M^`'^.7_!-7X;?%?QK<:IXBUCQWX8_:TO/`/QI\2>(=2\F,;L#CGIQQGG''-2&28Q+ M;F24P([RQVYE8V\1("WE+)(AV22*@=T)1B5XKGPOA[E>`HT*.#KXF$J M6-RZM4KU50G4K9=@JE>6(RU_5OJ\H4\QIU84\7"=2="HZ49*-*?OO6MQEF.* MJUZF(A!*KALRI4X4E90Q&/IT:=+$U/:J4*DL&Z+E2E",:JC4<8S<5'E:@"JJ M@``*``.`````!V`'`IDP+(5"EB>,`;C@\%MH^9]@)^`EU_P4FMO$WPPM/!7A#]DGQ1 M^U1^S3\>/CK^T9HWA;]H*_\`B1\;(O@E\%?#?A'0;C6_`WB]+C5O"?A[X?:U M*/'/Q@\.?MA^(]#^+/P-NO`6G^$O!?A%[+]D^]TNT\7Z- M\,(K'4=(TC]F[X^Z3I_P'M-$\1VS:+#X>N+34H-+_G(VD$X7&?=>@&`.G0`` M`<@#@#@&CYL`8.!@`;AP`-H`Q@``8``'RC@8XQ\!+PYX>E@:>"5.O%1P^"HU M*$8>>(KRP>)KXGVM2IB)5'*6(=94L3%SA1E1H8>%*C16'I(^KI<:9Y#$/$R ME1G*53$58TYSJ'=<^'VH:9+X:ETOQ7I;C6]9^,6FCP19_#K3O#5TGBG6HH^\\ M.?\`!1K]G_P-X`DN?`GQSU;PS\4?#O[$G_!6#X=^!-1TSX>_%:'4-#^/'[0G M[9FF_&O]FM-*U*3P#+I>G:AXA\.:9:^+]/\`%LMQ%H'@/5M,L;/QEK'A;Q+% M8:>W\Z.#TV#&`,9_A'1>O3I@=`!CL,&#UP,\GKR690K-]2H"M_>`P20!74^! MLJFHTY5\=[&-=U?9M93",X2Q5?&3HUG3P"ECE4K8FK&57'JO5>'<<-*'+_`.&_CW4->^-O MQ#_9%^*%]XB_:ZT_Q'?>*_">E^$_$&OZ7X6BTL3:MXQUVQ\*_$R)8M)$:_X MCDL[Z*QZ#X8_MU?L^>&/VE?CU\6OBS_P4G^)OQSN_$$FBZM\"O%G_"&?MS?" MKP)X/\$77[3&J^-?%/P;\5VGPJT'P/\`';6=4T_XF45U"F\1A\12I477RRI/!THK M#4\/76!GAWB,+"EA9R5"A1A'2GQ?F-.I"K[/!2G1J1KQ)4XQJ2J37+*K5Y_U8_P""@O[27[/OQH^'<'A+X)>*X]9DL_V_ M/V^?CC::1;>"?&GA&PM_A+\<_$G@75_AAXCLSXD\+>'],A'B.WT?59G\,Q3_ M`/"3Z-)!*^N:%I*RH@_*JHMK>@'0#[O&/<#/';'3M4M?5Y5E=#)\#2P&'J5J MM.G*I/GKSI3FYU72:LM+*/5.].^B>:VNHHUW/):S(BY`W.R,%&20!EB!DD#U. M*_HS^,'_``50^".I?M\:'J/PEL/!'AW]E_Q;^TS^PI\8OVC_`-HZS\-_'J]^ M)/QATC]EOPM\/$TA=5\`>-#+=>%O#OPPUO3O%.FVGA_X<_"/2-6\:77A_1/$ M=L;^74+J^\5_SK$'G`SD8[>_7/'?CK]/5N">HYSG)VL>,8//?(Z]>ASQ7%G' M#V`SJK0JXSVSEAL+F&&HP5O8J680I1=>5.-2G&M4P\J,9T5B(UJ=.I:?LIN% M)T^C`9UCLLHUJ.#5*,,15PM6M)RDJE3ZK452%.ZA+EISLH55"TYPT52%W?\` MH7\$?\%#_@?X_P#%7P4\5_M%?M*?$B?QS\,?CY_P46U?PSXYLK#XZ^'M3\%? M"7XR_#W1]+_9U\.WWC;X0>$;;XJ>%?@[JVK)KNCS^&/@5>6'Q6^'%A/IIM;# MP7ID_"[XI:EH'BC5/&"6.MW.@:'XC\"?MGV'C#X#D\ M$[NH`P`<=1MPN.F`!@8KYROX;Y)B*U2K]:S&C&=&I1IT*4,IIX?#4IXNCF$H M8:C'!15)_6J$:E!^_&C4ES1IKWHR]JCQIFE*FH2P^"JR]K1KU*M6&,J5:U6A MAJN#A*I46*C%KZO5E2DJ=.@IP?))\MV?OEXZ_;S_`&;=6_X)R^%OV?\`P!XD M\`Z+KMI^Q+\._@)XN^`WCCPC^UQ>>(I?C9X8\2:?=>*OB=X+T;PQK<'[#NF> M(]?U^&3XNZ5\=M0-I\98-]WX;UEM5M[V'18/C_\`8Z\2_LW:'^R[^VMX$^+O M[5O@_P"$/CO]H[X?>!?AMX$\+>(O@[^TIXZ&B/X"^,?@_P"*-WXJUS6?A7$ M?&OA"TT/Q-::)>:/9V=EJAUNTU6Q%YK.F6%C+"R?F;AO0\CD;A@_7U'Z].>! M2_..0"",8(;&-HP,=^`!WSP,$5ZE+A+!T<%C,!0QF9488_.,/G=?$-996JRQ M6$QKQ])U5.D_:SJ8B4_K%9)H4U3JT:]"I.'L\0E"3A7E[.,E.FIKFDHQO&38F?8GF(8G9$9XRP\,?L#O%'AC2-F.A!_/T_*FX? M(..1T)VDCIWZ]A^5?+YCPEE&:XK%XO&PJ5:^*E@FY35%PHT\%0E0C1HT:RKX M5QQ$9*6*KRPL<76]G1I/$NA1IT8^[@>(LSP.&I8/#RIT\-0^LRC'GE&=6KBY MPJ2K.4(\\9TG'EI)5(QBG-\LI3(+#XYZUKTW[+6H?##X6_#_P`/V/[/.D:'KNAZ MA8/XKUS]H7PO>_%GX?\`B8Z;::'#X,$1+=Z55\.?\%#OV.[;QO^PKX^^+'Q MLOOB9XE^#.H:[X4UO2OAU\-OVD](_9\^#_A6T_9>G^%WPO\`BY_PI#XDV]IJ M7PZ^,7A#QS+X=3Q)HO[&7B[4_!FJ:?H>N_$OPXLGQ.MO"$L_\T>&Z[1G`&00 M.!NZCO\`>;\"0,9)HPV0<8(&%((!7Z'J`.HVXQ@'D@&O"?AKDW-7;Q^$IQC)PI^TG",(WBU*=3U/\`7;,DH*&$RR,J M$8PHOZK7E33AC_[4I3E!XA*:HXE_NHM0A&2W/@W2/A[X(^%?Q,^//@SP?\`M;^-7T'09?B?XJGU+7?%UY^U--8^'O@C7(?$7VS4;4ZGJ=O>'X?^'IM8&BV5_/<_X*&?$G]GOQ%X7_9^ M^#O[)'QY\'>._P!F#]G#3/$_@_X0?"W3/A]^T+X9^(NFS>.+Z+QE\3OCC\7? M%_QC^$7PT\,>*?&_Q<\="6^U#0/`,C:)X*MCIFC:#HHL(-5UO4/S"`;N!W/. M,$_A_7@^QI0O^R!D@GGG().3QC/+8QTW-_>-?18/AK#X"60*ACL=]6X>H8RE MA,'+ZA+#U)8RG7ISQ-2V'=>EBH4\15P]-T:[C#"3J4Z/L)5L1+$>7B<]Q&)C MF[J4L/[?.*U"IB<1[3%NK"E0C2MAJ,Z?LZ9+)9W$<41(`DD>"540DL@`9B%)+HH!RS*/F%^FG=G(]NA`(QGU] MCU'/]?HM5JFTTTTUT<90G%VZKFA&\6TI*\6TI-KP&FTTE%O:TFXIIJ49*\4V MFXSFD[?%9]#^B+XP?\%2_@E<_MS>$[SX.V/@?0/V;O&7Q_\`^">'Q)_:>_:0 ML_#'QYNOB=\6M!_9%LOAW>Z5INH^"?%Q9_#/AWX3Z[:^+HHM*^&GPHTS5O'L MND:5J$5QJR7NK_\`"55_"_\`P46^!GQ%\7?"WQ5^T7^TG\3;KQ-\,?VM?^"@ M'BCP/XZL].^.>AZOX%^`/Q@^$VF^'O@!HJ>-?ACX1LOB9X.^$>O>)[>\TG4/ M!_P9U&P^,W@6V?3IM)TKPH8K2ZM/YY,<8VGGU(..GJ>V!CIT'2FE223MZDGJ M!U()ZY(W%5)YY*J3]T8^&_U!R5X:CAZ4\90=##+"+$JG@I8RK#FQ#J5'7Q4< M7[/V]/$RPU:G2]E3GA:=+#PI4:$(TX?7+C3-_:U:E2GA:D*M7VSHU/;RI1:^ MK2IPC"A4PTHTZ-3#*K27M).-2K5E*51S:?\`4M=?\%&/V.[C]I#XD^-8/VI$ M\+_#7Q[^S[^R/X.^)OC/X:>!OVY?"7[0?C3XD?!'PC\7M-UK4OA)\6=6\,:] MXE\1SZ+?W'@VP\0^$?VR=+\7?#SXT:!J7A@>./&$_%$C_,/BG]OC]FBZ M_P""<_AS]GWX>:_X"\/:M:_L6:7\!/%_P*^(/@[]K?4/$-]\9K3Q;+J^O?%S MP?H?@[5X?V'[+Q9KWBYK7XP:7\&=0DU.QDM?#1_`?:202I M)'`RP.!R,`XR."1QC@D=":7#9/R\'@@D'(Y&#ZC!(YR>>O4'FP_AOD>%J8.< M<1F=6."Q67XFE1J2RSV3>70<*,9)8>,I3E'V&(C M.C@N?$4,=1E65+%.K%YA*E*NX2J8FI&$'[*5Z<:?+*51N73V?[!_\$Y?C_\` MLH_LY^#O&7B'XY?$CX63V7CWP+\;_"7CKX8^'_V8OBJG[;30^-?`LW@OP[X; M^`'[9OA'3;;PM\._#FOPP:1J6I0ZQ\2?"MEI,M[XNTC4/"\MWK&D^*I_QJ=9 M$TF5)6C:4::_FM#&(H6E^RDR-%&J1K%&7+%(TCCC5"JQ1QQA$&D58YX!)Y+' M!.>>I/)/)Y]SCTJO?_\`'E>`#_ESNN@_Z8L:^MP&38?+\?F>8TZU>I7S>="I MB(U'05*DL-3KPHTZ<,/2IQE**K5'*O4_>S3C&48QA%R\#&9E5Q>"P&!=&C1H M9?3K0H\CG.K)UZE.K5E.5R4FYNW^L#^S%_P`FW_L__P#9 M$/A+_P"H!X?HH_9B_P"3;_V?_P#LB'PE_P#4`\/T5_"F+_WO%_\`89C/_4O% MG]88;_=Z'_7BA_ZCX<_(G_@KG_P3\;_@H]^T+^QK\%!\7?\`A3*>%/@S^V5\ M43XE'P__`.%BOJ']E>./V*_"?]B?V.?&O@86BSKXU-]_:7]IW1C:P2#["ZSM M+'^=A_X-5E4%F_;TFP.N/V7$SSP,`?M"$DDX&`,\U_1CXV&?V_/V91D_\F@? MMT$$=01\9O\`@GH!UX.,]#QD"M?]KWXH^-?AQ\/O"&C?#?5-*\-?$'XT?&/X M5_`?PCXSU_3+;6]'\!7GQ+\2)8:QXZFT6[GMK+6]7\->%++Q'?\`@OP_JDAT MCQ)\0(_"?A_5XI-)U"_CF^NRKC3BW)L%EF59+F_U/"*@ZD*,L)@:T(U*V)QU M:M5G4Q&&KU7SEQ-;VT$NG6,_P`-_AQ\-K&7 M3YIXOM[Q:GIVIWEI>W<]O;7]MIPL["#\[_B?^UM\2/%'Q/\`AKHFD-X2^'_P M$U#]JCXG>`+[QA%XQUJ+XRZ[X6_8CT7XB_$+]HCQA/X9L?#TF@V/PBO_`(E? M!G4/V>-:TVYUK[?>Z?KFDZ]J6IQ6OQ"L/"NF^G@_$7Q"QN(G2H<1\\:493=6 M>6992C*,88F7NTZF7*I.=\/*+C"C.W-2DYN+3EAX_$L5))+ZS3;ZKEFG%-1O^-Z_P#!J[`!^RY&<8SD''[0AY&"".""#QQ7VI MK7Q/_;3\4>$'\2>"_B(/!=[X6_9__8T\#>$=(\2>._'VMZWX;_:H_;^UK1M` M\3WOQ!EM6T31?BIK7P8M/B1X7U#P3I/COPW<^'/#6E#PMKUIX9;4[G48[#ZS M^"_QB^-./&T7B/XKZB?%'[07QI^*_B[PCH?A']G6'X2_` M/Q-#H5YJ>C^+OB1D>$O%_CKQ7K6J:UJGASP9K M?IXSC3Q%PE&=;_6FA4E"_/3679;!45%*4I5IU,N5.,8QE3O[.%1RE-QA=1*O%?Q M`_;`\#?L=?LH+;)HWA/6-_&CXRZE^P_\`M#_%KXK?#Z_^%WCCP=\+?C_K.@6/A_6-8\&Z MUKGAOP?X+\1:CX/\>Z;::M97OC+X0:SXD@LX[^P\.^*8=1\8>#KB.UO]5LXK M]AI%GAB../$J@\)[3B&G&.+KX;#4Y/"9)3E[?$UX8?E<)X2$G"G.<'.24E3A M4IN?+)RC#HI<+<$595E#*$U1I5*TW]9S27[NG"51O2K%*4J<7.G'F;J1:E%* M+4G_`#__`/$*RA75CW_ M`.,7$.#\PP?^,@5PD?M:_&G_A9]]X-M_AW\.7^%FC?'[X M9_LOP^+M4\;^*-0^)=YXT^)G[''PO_:*\/>,=1T!/"]MH4_A_0_%WCS2_`WB M*W7Q2NM^(=!U.^\6V4VBZGX230_'?RA^S-^V-^TUX9T#X4^%;[X. M/'G@[X5?M#_%[Q'HZ?';QK<-H_[2/Q(\8>#;/1O`UPGA?Q+X#^$5AX%TGX:^ M,/&0T#7M5\'_``RGAM;+PCX/T706E\4^,-+(<;^)DZ%:K_K!03A"C5A36&R+ MF=*K3=6I*I4>"IT:%+C]L'PS^SAXBB\ M;:-%X:M?#\=[XS_M*&[U^#P_J-OJOPLM-3O/"EI>>(?%K:7XLT[3\._M(_&Z M?XL?$#X%?"[P_P"#=9^)VI_%W]H+5%U?XQ_$/Q;_`,*YT+P?\"OA_P#LLC6] M*\)Z=H7A74O$>GPZ_P"+_CYX9L-`\-6S)I/A?28O&_CR^U#7]1M[3PAKLPXX M\29T*E9<2X;DI.?/;#9,I48TJM"E6GB'++DH4X2Q$'S1G5]V,WRM1UT_U8X) M4W3EDV\3#6/'6NS?%*TE_;VU'X=>%?#\'AV MSL/!P\'7UK\+/$WQ+\/ZIJNL7>JK#XX\-1:K;:59Z%?VUIJ-_P#6GP#UG6_B M5\6/VD?BG<:QJT_P_P!-\:VO[/7PMT3^TKS_`(1B[A^`UQK5A\7OB!::"UP= M/L?%FK_'KQ/\2OA3XBOX[&&YU#0_@=X.D%S/:>2D?-B?$+Q'P<*D\1Q!&')1 MA57^QY+53]HZ'LX-4L'6:E.&(C4BK7Y(RE?:)M0X1X,Q$^6EDO-:HZ;V9`PO_`!>/_@GP@P,``A"5Z=\]17V9L'J?T_PJ<3XF<=4Z67N&?SC* MMEU.O6O@,LGSU)XO,8.34L&DFX4:<;)17+"*Y4TW+2AP/PG4GBO^$>G:GB5" M-\9F'NKZMA9M17UC1<\Y26K=Y-W3T7\@_P#Q"IK_`-'YS'Z_LO(?_?A/\_2@ M_P#!JFIZ?MYS#_NUU.G'_5P@)X'4O'I^RY'ZY_Z.#_`,_G7]?&P>I_3_"C M8/4_I_A2?B;QVW=Y_P#^8O*4ON6#2_#SWU#_`%"X3LU_9*2:LTL?FD5:Z>BC MC(I:I/1+UU=_Y!_^(5-/^C\YO_$74Y^O_&0G/XYH_P"(5).O_#>4W_B+J?7_ M`*.$K^OC8/4_I_A1L'J?T_PH7B;QVML_:_[I>4_KA'_6FV@_]1.%;M_V5J_^ MIAFO_P`V:?*W??4_D'_XA4UQC_AO.4?7]EU./Q/[0?3W/3`/:O(I_P#@VI$' MQXT?X(_\-K3,VJ_"'Q+\53XE;]F^-&MQX>\:^%?!XT/^Q1\=6$@N_P#A)3J' M]I?VI&819"W%A,+@SP?VIN@".>>%8\XQP#[5\?W8W_MZ^$"QY/[('Q%!/?\` MY+/\+B/R_EQT`KIPWB9QY4EB$^(*DG#!XS$)RP.6Z3@J$^?7"2DXR^LO?B!O\`Q97E,ONYL'*WJK/S.C_4/A/_`*%$$NJ6-S)1 M?K%8KEE_V]&6MFK-)K^0;_B%37.?^&\Y<\_\VN)W^O[0I_+T_.D7_@U0B0DI M^WC(I8Y8C]EN,%O3)'[0@Y&3@G)Y/K7]?6P>I_3_``HV#U/Z?X54?%+C^-N7 MB.<;.Z4)_U!X1U_P"$:E:7Q+ZWF-I>J^LV M?HU9=%W_`)!S_P`&J:'K^WE-W_YM>3O]?VA*/^(5)/\`H_.;CI_QBZGL!_S< M)[?7WK^OC8/4_I_A1L'J?T_PJ%XF\=WO_;]WO[V5Y3*[O>[Y\')-WUNTWYE+ M@/A16ME*22LDL?FEDK624?KG*DEHE:RZ+O\`R#?\0J:]_P!O.4]>O[+J]_\` MNX4].HXZT#_@U20$D?MXR`G&2/V7(P20`,G'[0?8``$Y(`&"._\`7SL'J?T_ MPHV#U/Z?X4WXG<>-R?\`K!+WOB2RS*E&6J>L(X2,&]%KR7LN6_+[K/\`4/A. MS7]CTU=).V,S"+M&<:BUCB8O2<(25FM8K=73_D'_`.(5->W[>I_3_"A>)_'D=L M_P#LN#;RK)VW%N[3]W+$R; M\ELMHJ*T/Y!O^(5)/^C\I?\`Q%Q/_HA#C\*7_B%33_H_.;_Q%U.#ZC_C(3CI MCZ<5_7QL'J?T_P`*-@]3^G^%)>)O'D?AX@E'ORY;E<;KLU'"I-7ULTU?6U]0 M?`/"4K)Y1%J+;BGCLSY5S.[M'ZWRJ[Z6LMDDM#^*/6_^#:X:-\?/AI\#1^VG M-P71AX4-LUAJ0UK[1I7LG_$*I_U?I+_XBXA_]^$%?T4^->?V]OV;'/++^R#^ MW*5X&%(^-/\`P3Q0$#&,[21R#Z]>:^S]@]3^G^%=N*\2^.J5++G#/YQ=;+J5 M>HW@,LGSU)8O,J;F[X2R;A0IQ:C:-H1M%.[EA0X'X3J2Q2_L>G:GB?9J^+S# M1+#X634?]ITCS3DUJ]9-MZV7\@__`!"J?]7Z2_\`B+B?_1"T?\0JG_5^DO\` MXBXG_P!$+7]?&P>I_3_"C8/4_I_A7)_Q%#C[_HHI_P#AMRK_`.9#H_U#X3_Z M$]+_`,*\P_\`FD_D'_XA5/\`J_27_P`1<3_Z(6C_`(A5/^K])?\`Q%Q/_HA: M_KXV#U/Z?X4;!ZG]/\*/^(HQ?\0JH('_&>DOH?^,7$()!Q MD?\`&0@X/49SQW-?T6_MP$GX,>"<_P#1X/\`P3QSP!D_\/`_V91DXQSA1_\` M6K[)5!M')[]_<^U=$O$SCM8'"5X\05$ZU?'P^EL(\"\*O$UX2R>ERQI8248K%YARQE-8SG:_VA/WO9PO=M7BK)=?Y" M?^(53_J_27_Q%Q/_`*(6C_B%4_ZOTE_\1<3_`.B%K^OC8/4_I_A1L'J?T_PK MG_XBAQ]_T44__#;E7_S(;_ZA\)_]">E_X5YA_P#-)_(/_P`0JG_5^DO_`(BX MG_T0M'_$*I_U?I+_`.(N)_\`1"U_7QL'J?T_PHV#U/Z?X4?\10X^_P"BBG_X M;I_3_"C_`(BAQ]_T44__``VY5_\`,@?ZA\)_ M]">E_P"%>8?_`#2?R#_\0JG_`%?I+_XBXG_T0M>/?%;_`(-K1\,-9^">D']M M636Q\8OC)IWPD^T']G*/2_\`A'CJ'@+XA>-QKPB/QSU#^UC$?`@TS^RS)IHD M_M0W?]HH;,6MU_:SL'J?T_PKXW_:S0#QC^Q-UX_;(\.-^*_`?]H(CM7;E_B9 MQU6Q=.G5X@G.FX8J4H_V=E:O[+`YA75FL*G=2H0DM5[T8WTNGRXW@;A6GAJL MZ>44XS3H\LEB\?=I_3_"C8/4_I_A5?\10X^_Z**?_`(;8?\`S2?R#_\`$*I_U?I+_P"(N)_]$+1_Q"J?]7Z2_P#B+B?_`$0M M?U\;!ZG]/\*-@]3^G^%'_$4./O\`HHI_^&W*O_F0/]0^$_\`H3TO_"O,/_FD M_D&/_!JK@$_\-YS''I^RXF?R_P"&A>?T]:\@^&?_``;6I\1?&G[0G@\?MK3: M0?@/\7]$^%7]H_\`#-Z7X\4#6?V?_@7\P_8`_88_P`YZ_K77A_$KCRIALSJRX@FY8;#X"=.7U#+%R2K9K#"S<8+ M"A_ M%K\?O^#:=?@9\"OC/\:C^VO-XG_X5'\*_'_Q+'AL?LW1Z-_;Y\#^%M4\2C1C MJQ^.VI_V:-3.F_8OMPT^]-H9Q.+2Y,?D2>M_\0JG)_XSSE'_`':ZA!'8@_\` M#0@R/1N-WH*_H]_X*`J!^PG^V81_T:W\>NN#_P`TP\3^U?7*H"">G0<8'`'` M_#)KJEXG<=+"4I_ZP5/:RQ=:#FLORO6$<+0G&#C]4MRJ4IRT2?,[MOX5@N!> M%7BJE/\`LBER1P]&=GB\PLI2K5XMI?6-VHQ3;ELDK*UW_(3_`,0JG_5^DO\` MXBXG_P!$+1_Q"J?]7Z2_^(N)_P#1"U_7QL'J?T_PHV#U/Z?X5S_\10X^_P"B MBG_X;&/!7B_Q*?V MZ9K\>'O"WB+7?L(_9D2T-[_9&C7VH_9/M0_:`F-M]H^S>6)_)F\HL&,,H!0_ MV1;!ZG]/\*\T^,Z@?"#XJXSS\-O'8[/NG&C5E% MKFQ#5U)1:NFKI735T^0_95FEN/V8_P!G.XF9&DG^`WP>FD9$*(TDOP\\.N[( MA)*(6)VJ22H."3C-%1_LF_\`)K7[-G_9`?@T/R^''AH_U-%?"XEWQ.)?5XG$ MMZ6UEB<0W9:V5V[*[LM.A];ATEA\.E_T#X??5_[O06KZO35V5W=V5['FOC49 M_;\_9F'K^Q]^W2/S^,__``3SJ;]L/XH?`WP7X1\*>`/CS\,?^%P>!?C%XRT' MPGXF\*7'AWPMXI\.^%_"5OKFB?VM\8_B)I7BO4+&TM/AI\+?$FH>"K[Q)XFT M^+5-:\*ZEK7AO6=-TXRP->647C4X_;]_9E([?L?_`+=)_P#,S_\`!/.L#]H' M]B;P9^TY\2/$7B+XQ>*/B%>^!+CX%W7P7\)>"/AW\4/C%\'9-'M?'NL^)+[X MY:CXKU7X4_$+P;%\1]%^)VEV7P=T=/`_C'3M9\.:0/AC-=26M^?$]W%I_32E MAX5\NJ8NK4HT*>"C4W?Q`T7PU<-8V4+:?:? M$'Q#/J?B#08M2N;<_$3QHFK0:,^O^,+34;*'X]U3XY?L&ZOX/^*7[1OPW_9M M^&'C:Y\4>&OVT7^*-_K?A/PS\-OB1XYE^"G@?Q8WQ(T)[76O#L^I^,M-^+.E M:)?VFJ7T-U)%;:1KL6L>,+#^V;K5M)M?H"S_`&//'M]X=UV'QW\7-*\4^._% MOQ'_`."?WQ,\7>,(O`MWID.L^(OV,_&7P6\:>,)VTQ/$%S]E/Q9U'X4:I)I4 M4=Y-'X)F\3H]Q%XBATJ4W_CGQ1_8YEC\$7?@/XD_M'_#'PEX?U[6/^"B&C_" M^_UCPQ)X>UF?3?VQO!/Q=^(NHZ+J\VN_$)].\3^)O@[I.I^/_%NJW6@6VCV^ MO_#OP1J.M7&B^'(M+UK48O5PLLJBI*.;9A/%UOJU*K"%7&15:A"-:=>4E0<: MU:$YTZ+HPJ.JJ,X5<14C.\XQYL1'%Q2_V7!TZ=-\].G*C12@ZGL(M^UK5%1A M4A[.\I1A#VCE2A3=.48S>;X%M?@OXP\2?"SQ'X3_`&DM*^.,'B;]LSP]XT^* MFEZ+??#+P=INO?%6'X'PP?`5+:RLM'GGNOAY\-?AS\)O"FL?#SPQX#G5_BG? MZ98?%"/X@:]H.FZ_I^N>A>.?CC_P3"_X1@_%RYL/@I\3XO@!XXTSQ%IE_P"" M_!6B^-_$O@[7OV@/C3%/_C-9W_BZ]\>^'KC4/"_BOQG MX7U35=-U77/%>APPBQHW[('BCXJ>)O"WQS\=_'?X>^/[K5/$'P3U;1M>^%'P M_N_"_@KQ/\#?AA\+OVA?#7@U=&N)_B-X\N)_%'C"]_:>\7>,KOQS8>(+SPO! MI,?AK0O#WATV]I=^(]6YZU_8'^*=[\-].\+^,_COX!U/Q+\*/@#X+_9]_9\U MSPQ\&=7\+:+IFA^`OB%\,/B3:^+OC'H8^*.JR>-=4\1:G\$/A7INH:'X)U/X M=:#X;TVR\>S^&@S^.K6#PK-3$9?*K'VN98M^SDY1I4Y5X MRIQ=&!?@1X=^$]IX@^$WP*T^UU#2])\0S M?$G1]!^&'A?]J_X8Z%)\/;+PZ_BC2=4\!_\`"Y_&7Q&T#P6^EZEKWA;2X-:^ M,KG0]/U:ZO+#Z,\8ZM^RU\%_@58>'/$UI\./"G[/WB?0Y?`VD>%;#0[;4/!O MB[P]XQT;5=0OO#FA^%?#NG:BWBJQU_P]-XBU[6K;2=,U-+K0AXD\3:N3IMOJ M^HQ_+FD?LX?$+Q%XG/[4WPA^/'P;U'QY\1OB)9?&_P`,>)6\!Z[X^^"7B'P1 M\2?V/?V+]"LC\+OBMJ_@7Q=K7Q(T?XB_%Z?7?%GQ[U'P9\6&L?" MGCG19=$NO#_@3X]_#WQ)X$T6#Q3XUB^)&F^'/AUXQT#PMG_:N)DH55+$.5>O4>&Q+Y)3ERSYJE.LI0O]84N:K4A&ZI M>SO'HI?6E3K2C@J.L%3I>SPT(^TP_O1A#W/=JTO9N,71Y:<:--M7JM\IWEI\ M1OV(Y/%6@:'I^O\`P/N/$GC?_A%_VD]"GTV;PY?V.L2:/\+(]+\#?&$>)[`7 M'AV.['P6^&Y7P9XCN]7@O=1^&O@*^O/#[W?AOPM?3V/D&O>*_P#@F#=^#/A; M\6=?T_\`9YO/"?PUUA?A_P#!S7KSP3IMSJ7AK5O#UG;_`!(B\)^`]`_L&3Q4 M\&CZ)I=K\5+?3]'T:YTRQ\+V4'Q,A6+0(HM?KRS1_P!CSQ#\#K;]G6?4/CA\ M+O#/A/X7?!3X/_LL>*+R;X8_$F2X_:/UA?AIJG[/OP_\#_&'PA'\.]"\6^'],UOP7?_$#PK!#JO@+PY\1=%TOQ#KWC=-+X;?LH?%[P%JV@ M:I\/?VEOA/J'QK^#%]\1-+T[P!XI\)_$_P")7PL^%'P9^//A7X210_#K2/"? MB3]H?4OC5X4CA\5?`/1/B%X"OM5^)1\.Z=HNN_$'X8>$/!VE>#+KP_=^&->3 M!N\H9ICITE&JZ=5UZT8."^L4US349*C&K*GA*4FX5(4_K,855*<8TS-SQ44H MSP.&A.4:3J4_8TY3U="2C&GS+VTJ<93G&":E)TFZ:C"$ZD>\^(-[_P`$X-'D M^(EM_P`(?^RWXJ\;?M"_#B?XL>(M#@T[P)+!\;?#T^GZ]\5/"?B'Q1XPT[2] M6T"UT?QYJ_A#5?&?A/QEK=XEOXK\1Z%J?C+P_-KVN:'=WD-W5[S_`()X?$.# M2/AG\4?!7[/FK^)-_#76/#&B>-HX?%-_\&]/US6Y--U!-$NM,\2>. MS\%-.CO;O1='=_%WB3X3Z9_;9\.W/@\^:?+/!_[*=Q\(/AG\4/A_\./VG_A' M;_`R?X):+\'_`-H'5?'O@RTU3Q-X5\9_"W]G^V^#M]K?_"::#\4/"_@GX:Z5 M=^'+;P+XI\7>!/$GA;4CX.AT_6U\/W-A9>-;&[\*\EX-^`V@R?%CX(_M10_M ME_#;XH_!'X2?$/X7Z1X;.A:AXY\8:38>*+GX`G]D#2/A=X;U/PS\<]8^!?A; M1]?^(_Q&C^(<.JGX12>/(O$/C?4/#VM>)SH[R:O<]4/91E*<,USB,:,DZ=7G MS'VSK4$ZF#H6A%4J%>5>GAZ=*F\3STX3A7H\RI4U*'.LH0B\'EW//F'?VF/^"?WC?X1^`/BY=:G\-O` MWA+XZR?#;Q?H">/O"^G>%-8_M;X*77@GQ1X$U_Q#I-]8366EVOP"UZ3X?W-O MXYNWE^'GP^UP^$FB\5VZ7NB2W>WX%^.?[/OP!\5?L]_L.?#WQC;^.O'DGC&^ M^#>MV=SXHTFY\=Z'J&B?`7XG_M!^(_'_`,07L-'T[3O$?B_Q(?!5C=?$6UT* MSTN]TKQ#\7_#/B?5],T:Q\0Z'::A\Y:Q_P`$TO'.M^"_@CX=U?XI_#;Q/=_" M7X(:O^RUJUGX@\#_`!ST;P9X[^!\%QX>C\(W?B/PU\,OVE?AUJ-YXQLM*T2] MLO'^CZIXCU7X>>.T\026]KH/A2/2+!I_?/#_`.Q_\1O#GQH\!>)+;XL^$I_@ MC\,/VH_C1^U-X8\!/\,M8C^)%QXH^.WPJ^/'@OQ7X8USXE'Q]-H5UX;T'QA\ M>_%/B3PE)8?#BTU%?#46A^#=1OG7PU'K.MX5_P"R%[>G#-,77I+ZY4HTIU6Z M.(E2>)HX&K%SHRJ-TJ"PTY0E[%2^LS4'&6'DZFD?K\:E%PPF&C:="E/$4Z+N MJ%5QJ8AN"G35/GFY)2O6Y.7WZS_P"'D_X)[_3^0K[.?[K? M0_GV_6O,QJ;P^5J2:;R>@I)/5-XO-E))Z:IMI.ZU5[G=A%[^.2=O]M:3WM_L MN#2?GW/E']IO]I.X^`#?";1M*$Z1XJ\6_&OXB2_#7P1'XR^(FG?"3X?IXEB M\*:_XMMM*\0_$;4]$\2Q:;KWBB'P]/H/@#PU8^']7U?QAXHNH-.MX;2QAU+5 M-/XW_AL"%?B_)\`+[X=^(--^,$7Q&TG2)/!UUXBT[S8_@CJ7PSN?B;)^T@VH M6=I<1/\`#ZSETCQ#\)I$MH+B";X\Z'<_#J+7FTV[M/%3>G_M*?![QO\`&WP' M>_#[POXN^%WA_P`.^+=/UKPW\2-"^+WP+A^/GA/Q=X1URP6SFM(O"ES\0_AY MI]GKNFRH+K2;[Q!)XP\*EI+B+7?`NO(;5K7`\$_LL:!X%^(WP]\?Z9XKUO69 M?A[^RG:?LJ6,_B^SM]>\;Z[H&FZ]X:UNR\6^*?'S2VM]JVLS-X;636;1M+AM M]5U;4KS6C/;3YMFUP[RF.'3Q;D\3&&+DHPE5LZ[<)8*562Y53P[K2]C6I04Y MOV%.I"K3A4K4W%=YC[::H$8.+]I.4(QJQJ3/\`[-/[??AW]H_3?V=Y[#X?>(O!OB+XV6GQ!3Q1X1US7K"\U;X2:WX' M\">"_BAIFE:R]A:?8_$MIX_^'7Q&\$>//!^M:?)917W@KQ=X:UYK:-]2^Q67 M6?&']L>Z^&'C[QYI.E_"C6/&7PY^!\/PNF_:$^(EOXPT70I?A_%\5M2\G2O^ M$3\&WUCP^(?Q0BGUGP=%H_@;5-.D\$S_`!"\8_;/!UEYYX/_ M`."<'@+PQXS^`/B/4O%\GB?1/A7^RBG[+OQ/^'^K^#=+E\%?'NUT_P"'FC?# M'0O'OB73)]1NQH>MVW@]?%/AS7]/5]?3Q9X9UCPQX>U?4#9_#[P^SZ_BG]@G M2)M8\3>'?A?XRT#X1_L\?%+3OA7I/QH^!N@_"RRN4US3_A+J!?B/%J_@[2K8^`#\-/%]SJ?B^_Z*O]B2Q$ MIT'55*=&I.-&HL5*-"H\744J/MURUZ]2&%C!X><*4Z$Y5$JTX5*;YN6,LWAA MHQJJ#J1G&/M(5*$)SH+#T[590JIP4)8ER]NE45:,%^Z4E)O?#6_P#!7P8^*/BOXU>!_@Y\9-6\<^'KB/Q5XD^`J>,;WQ?+XP\&):V\ M_P`/_#'BOP[\./B'XU^&.OMXD\3-K'@_PA>7OCO2OAMK6HZ5H-_Z=^S#^TA; M?M+:5\4/$.G>#-?\&:/X%^)O_"%>'9/$-Y$]]XX$:Q\-OAI\5_`WQ)BTA+> MVN_"]AXX\%_$W0=:T_PQKB_$+HUI/%!XBMM(UMM0T'2O`H/^"?&E>()9O`O MQ6^)=Y\0/V;?#NH?'_5/AA\'--\/:W\./%OANX_:33QKI_CJT\7?&?P=\0;; M7?%6D^$O"'Q,^(WPZ^%$7@_P]\+=7\.^!_%UU!XWUKXD^*-/TSQ5:^\?LZ_L MK^$_V;_$7QUU_P`,>,/B?XI3XV>.O#/B^:S^)/Q:^,WQ6F\-6OACX9^#?A]: MZ7;ZI\7?B3\0[S4-4NY_#>HZOJGB]&TO7]7TF_\`"_@K5YM1\-_#3P+!I7/C M?[$5'$O!NI]87L?J[DL2XI4ZLVG)SJ)?6JN'G'ZS&=+V,9T_W2YIOEUH/-)5 M*#Q$81HN,_K/).E=U)TUM%0;^K1J)^PE3JJK*Z=5)+7ZED_U+->TCQ)X?\+:3K.K^&-?L=,T/'O[.GQ3; MXI>-OBC\!?COIOP$_#'B?PC^R]X'\+:=XAT"^\9:/8>$OV7[+P]I.G>"?B M796WC+PIJOQ7^'_Q8T+0O^$4^,'AG_A(?!-UXO\`!VN>)]`FUR+^VY[Q/64, MHE3C&=5TY6PKA*A]<=3VDX4XXYXM582P[4<0ZTJ$,-.*<(P]Y04[^5.>90E4 M<8*;C[>RK.@H2C%U*U+V"I5/:*+7LZ,Y5H\R;E-+E2@_:/`?[5/A/XG_`!4^ M&W@KX?VE]K7A'XD_![XW?$V+Q;J]CXH\%^(?#>N_!'XL?"_X2^(_AYXA^&GC M+PKH7BWP[XEL/$?C_6=.\5:7XJB\.>)O!6O>#+OP[K7AAM0N[E]+NZW^V5^S MKX;\5^._!FN>.=3TS4_AOHGC'7?%.KW/@#XEGP(!\._#<_C'Q[X<\.?$^/P< M_P`-O'/Q!\&^$[34/$7B?X7>!_%OB+XEZ%I6E:S=:IX2M%T75A9>7_LT?L26 M7[.FL?#36K/QSIFKQ_#SP7^U)X3CT#P[\.-.^'_A>1OVGOVC_#'[1-Z_AW0M M-\0:M;>$M`\!7GAYO!?AWPW"VJM=:)<6=W>:M'=Z>R7OD>L?\$R?!U]XU_:` M\0Z?JGP?M--^-MC^T%J>G^)=2_9QT?6OVA_A_P".?VC?!7BSPIXWOM*^/9\> MV,FI^!;6Z\>>,]7TOPE_P@&F^,H;#6O^$&/Q4/@6UB\/L1I9+4Q+A+%8J&$C M&E&E7I4N:$J MGN4:4:3<(P<6E-N<8Q;T2C>3OJG[_)^W_P#LPK\/_&'Q2M_$GQ+U?P9\/]0T MZT\8W/AS]G/]I+Q-KFAZ3K/AS4/%VA_$&?P5X=^$>J>-KGX,Z_X9TK4=;\/_ M`!VLO#UU\%]>L;.:32/'EX0BMW;?M<_`!=&N->D\=3V]A:^-='^'4\-SX/\` M'MKK$7C37OA-IGQVTW0W\-7'A>/Q*)'^#^K6?Q!N[X:/_9>F>'EOKG4[VSFT MG5X+'P;XU?L7>,_B1>>*]1\%_&3PYX4?QKI7[,GASQ;H'C[X0ZE\2_!?B_PM M^S;KGQ;\50^%_%FC:'\7/A9KFJ>&OB!XI^(N@:AXIT6R\5Z3;7VA^#;_`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`(*L>#P2/^$%\-\''_)=#!)'Y3+_`,$\_&[2RF'Q1X:CAWMY*'P= MX1EVQ;CL'F2:*78XZEOF]:_./$'*?%O&9EE%;@GB?(#O\`Y24?\/6? M!W_0B^&__#Y>#O\`Y25A_P##O'QY_P!#5X9_\(OP=_\`*6C_`(=X^//^AJ\, M_P#A%^#O_E+7P7^KWTB?^B\X4_\`#-D?_P`YS'ZIQG_T,\K_`/!6#_\`E1N? M\/6?!W_0B^&__#Y>#O\`Y24?\/6?!W_0B^&__#Y>#O\`Y25A_P##O'QY_P!# M5X9_\(OP=_\`*6C_`(=X^//^AJ\,_P#A%^#O_E+1_J]](G_HO.%/_#-D?_SG M#ZIQG_T,\K_\%8/_`.5&Y_P]9\'?]"+X;_\`#Y>#O_E)1_P]9\'?]"+X;_\` M#Y>#O_E)6'_P[Q\>?]#5X9_\(OP=_P#*6C_AWCX\_P"AK\,_^$7X._\`E+1_ MJ]](G_HO.%/_``S9'_\`.$[;0/"7AZ71_C-^S=\56O;GXQ^$M2AGM?@-^T5\+/CG?:(D$&FVDB77B2S M^'-QX=L[YI7BTZ\U:'4+B"Y@M9+:3VG_`(>L>#1P/`GAL#GC_A>7@['))[Z* M>V/8=!D#)^X#_@GEX[.X MCQ7X:QOD"Y\%^#N%#LJ@'^Q>0%`P>_7O6\N'?I&K#8=2X^X4=&-;&1I6R;(T MO:+^SUB7_P`B;E]ZJXM6;]VR;;1E'"<8JM67]J99*JH4.=^QP<5R?[5&A:]) MWO&G4E+5V<[;IN6[_P`/6?!W_0B^&_\`P^7@[_Y24?\`#UGP=_T(OAO_`,/E MX._^4E8?_#O'QY_T-7AG_P`(OP=_\I:/^'>/CS_H:O#/_A%^#O\`Y2UA_J]] M(G_HO.%/_#-D?_SG-?JG&?\`T,\K_P#!6#_^5&Y_P]9\'?\`0B^&_P#P^7@[ M_P"4E'_#UGP=_P!"+X;_`/#Y>#O_`)25A_\`#O'QY_T-7AG_`,(OP=_\I:/^ M'>/CS_H:O#/_`(1?@[_Y2T?ZO?2)_P"B\X4_\,V1_P#SG#ZIQG_T,\K_`/!6 M#_\`E1N?\/6?!W_0B^&__#Y>#O\`Y24?\/6?!W_0B^&__#Y>#O\`Y25A_P## MO'QY_P!#5X9_\(OP=_\`*6C_`(=X^//^AJ\,_P#A%^#O_E+1_J]](G_HO.%/ M_#-D?_SG#ZIQG_T,\K_\%8/_`.5&Y_P]9\'?]"+X;_\`#Y>#O_E)7BWQ>_X* M`>%OB?K/P,U>#0/".D#X/?&O3/BU.H-0%[/'=Q+#ILT'V<23QSP^F_\.\?'G_0U>&?_``B_!W_REKPKXU_L M6!M=040F".Y%K/=PS]6#X=^DA+$TUAN/>$U7<<0J;>2Y&XJ^$ MQO/S+^Q]8^R592U2L]7:YAB<+QU+!WUKX=1:_"U/R>!?#1PH7/_``O+P:"1[JNB;01@`X]AT`I__#UGP=_T(OAO M_P`/EX._^4E80_X)Y>.3C9XM\-D`8`;P7X.)QVW'^Q`,XP20H'3@#@+_`,.\ M?'G_`$-7AG_PB_!W_P`I:Y%P]](BUX\><*J+47&^39'>SA3;O_PC+5R=1O2Z M;:>J9LL+QHU=YGEB;; M#O\`Y24?\/6?!W_0B^&__#Y>#O\`Y25A_P##O'QY_P!#5X9_\(OP=_\`*6C_ M`(=X^//^AJ\,_P#A%^#O_E+3_P!7OI$_]%YPI_X9LC_^#O_E)6 M'_P[Q\>?]#5X9_\`"+\'?_*6C_AWCX\_Z&KPS_X1?@[_`.4M'^KWTB?^B\X4 M_P##-D?_`,YP^J<9_P#0SRO_`,%8/_Y4;9_X*L>#2"#X%\-XZ\_'+P=CCG_H M"8_/^6:\9^%W_!0+PK\._'/[1WB^7P_X1U2+X[?&;0?BK96%O\8_"=G+X^(4OK>.SB6RUZSTY[4W%A-=7'I?_``[R M\=CKXL\-+[_\(7X.P`>.?^)+@=NOO[@^'_"C]CCXE^-_B%^U+X9O/&OAN>Q^ M#OQW\+?#GP]&/`/@2'[+I&J_LI?LQ?%^\A:6#PU!=7K-XK^*?B:?[3J%S>7" M),EG%*FGVUC!#M3X=^D=*CC%2X^X5BEAZ'M5_8N2N,HO')T[I9.HOEJQIN,9 MS5YM.#52S,*F%XRYZ,7F>6J3JS5*2HX245-X.;]Y*FDU\5KM7E:+:NC]@?!_ MQLL?%GP%3XZ0Z=;P:?)X%UWQN-+3Q%8WMG]FT.VU:XE@7Q+%:P6#6UP-,<#5 MOL:V\".97B=(B&\<_9A_;(T;]I?Q)XE\/:3X>TS1&\-Z%9ZY+<:;\0]$\:&= M+J_%@()K73-/LY;`!V#1W$KR13E6B2-64N?5?!GPRO\`PW^S[;_!Z:9)M4A^ M'^M^$&U&+3;2.P^U:G9ZI;17'V)((K$VR-?1N]NEK]F95='AVED/BO[+?[,? MB#X#>)O$^MZYJNGZO#KWAZRT:WBTKP_HVER126NHK?.\SZ5IUDSQE%"()YG4 M,242.0EF_1,1@>.99KP=6AG.7T\GPF"G#C7#RPF#5?-,;+#4Z4,1@)5J7M\+ M"->55JG@?9JU2$FFH(^CE3S3ZSEO[^C]6A!QS2$HTXU*]3V4;5:$81;BE53E MR0G&/+*TD[(H?&7]NSP_$?C3/\`!R\\+Z9J-[;7?A&U?4+GXEZ!X?O)#XKM MM+N8FA\.WNE76H2M;KJD:Q1QW&Z^>("%HA(]>Z_M)?'JP_9W^'EIX^U/2K;5 MK:X\1Z9X<-KJ'BFP\(P12ZC::C=BXDU748+NVWQ)IDJ"U\EI968L'5(Y,_.G MQF_9'\3_`!.^-TGQ1T_6M*T_3Y[_`,%W+V=WX+H4ZM64GE M%3V=&"PM.4$X.ORQJ*;A4=I*K&3E:S6[?XR_MT_MEZ3^U/\`LY>+/A'X:T'P M?X>UV^U;PCXCL+^]^,/A'5(9&\(>)=.\0RV"V2V&GQ23W\5B]K;FZO;>U%P\ M2W$T<;,3\6?`;]M?XP?LS:=H3^"/B_X7B$RV<$UY\%/BUXCLKWPM:PAI4F3 MPU;7VLZ3XE\%*Q6X:P;POJ5MH[R,;W4]#U<1I;K]D?ML_L8_%KX;?L]^)-=\ M+WH\3ZW>:[X/\-VVA>$O!^APZ]J-KXA\0VEAJ$%I<:+HT6HVD(M#(U_=6MW; MO'8?:!*_D-.&_);X0_\`!/3QW\2_%TVJ^-],U'7O$$]Y%'+HULDB:=I"P[(( M=.DNPK11VVGVH6VC2T*.L<"[FWM(U?@>8\*^,6(XPP=;%<0U,3GV$P=&I#,^ M'<#A,!AOJDIUXTJ&.KXBE@,FQ5*$J:Q-2EBE7K)2ER89)+F^-K8#B6IFE&5; M'.6-C0_\*L\52R)X4^(&@PG2[H; M5"V^G^)K/PGKEU*Q@TW2M0*-*W[RPD,N5(8$*]?SF_$+_@G M@OP?_8E_:O\`%6HRPZ!/IW[+OQQO(=*T0&T#M!\,O$ MS_(S%B.?Z*M/MEL[>.V1Y'2*.-%:5BSG`(.6/4\?A^I_JKA^CGM#AO`4^)'C.=*/+%N.)Q%N9)V<[7YI*,8R;5DEHKU%%%>F>H%%%%`!7F M?QH_Y(_\5/\`LF_CO_U%-7KTRO,_C1_R1_XJ?]DW\=_^HIJ]73_BTO\`K]1_ M]/43*M_`K_\`7BO_`.F*QQ7[)O\`R:U^S9_V0+X-_P#JN/#-%'[)O_)K7[-G M_9`O@W_ZKCPS15XC_>,1_P!A&(_]2*X4/X%#_L'H?^F*!YMXT('[?O[,A/3_ M`(8__;G/X'XS_P#!/,C@<]Z^Q_,7U/\`WRW^%?GC^T+XR\6^!_VW_P!EC5?! MOPC\;?&;4[C]E?\`;>L9_#/@/7OA?H&L6-C+\7/V`)Y=:GN?BO\`$'XZL)KZVDAT][:.ZFA]/_`.&AOCM_T85^TA_X M%K5*."G#V"3P<-*F,P=&:MB<IUZ]*<7\I*UG?5(Y*>(A3JXJ#A5NL0E>- M*O.+_P!FPCO%TJ=16UM[S3OLFM3Z[D<$#&20<_=;^ZP]/?'XU^$/CCP7\E:WJ'AS]KC5?BQX._:8_:V\0ZEJYN?B+=_LQ^%?@M?\`[)W[7W@G]DW6 M/A+9F];X3Z5XVU#0/%_P]\-:GJWPETVT\?P_$O5?'>E_'K4X?$.O?#&+7_TB M/[0WQV[?L%?M(9[9^)7[&//Y?M1#^OTJ'_A?_P`88#D47#$PDI.&)ES M1DL3*7+*=).=.E>4DI0GSXV&'Q]-4JD\91CS)R]E@Z\E.TL/-1DZD(MI/#1: M2C=.4K-MQ MZIX[T#X?^(M,LQZE^S-\$?C$'_X)[GXH^-?VO+@K^R#XO^,W[2$?C'XV?'&- M-3_:O`_8B'ACPW\5(Y?$UNMC%IRVWQB&G_`Z,:1X!UDVWQ'/B+P3KKZIXU;4 M_K\_'[XXGG_A@?\`:/!.,E?B7^QJI(4D@$K^U,"5!).TY7.#C(&#_A?_`,<@ MN<8_X:D(()Y(/!XR#@5TU<7BJE)4X8;+L.E"I!NEB\ MM4G[18B/-[2I5FVX?6:LH)5&HRDG&W)'V>-/"X>DYRGB,=B.:4'!5,%B+TE' M:,53JT[Q=H*7/!MJ$4[IOF_*;P-$/VN/@S^RKX!\$_#6_\`VF+(Z[^Q1^P7 MJ'Q5TWQ1??%_QYK7P[\2:%XYT'PS^TKX;^$WA72O%_@WQG\._&.E?`9]1TG6 M_A+^SSXH^&?CTZ=X:MM6^%5II?QUO;'Q)K=#XO6O[8.B_`CX0Z9\.]>_:J\? M>,-&T+XZ^-_A7\3-.^'O[>/A'Q/=>)M'^(%O/\-O@W\1?A)?_&N+Q2ZZ1X92 MZU#P]\4?^"A&M_$W0O&WA/P_9:!??#+XD>,/%U]8:I^M(_:`^.7_`$8/^T=T MV_\`)2_V-/NYR5/_`!E*,@G.0<[LD'(.*#^T!\N,?M38&>IX.X@%LX&-5F>-595JF"RZM4>)KXBI*6,R^+JSKNMS<[@JG,HJO M*,6E!NFN5WYN>,/!8?V?LXXO,(Q5*G2IQ^JXAJC&G3I4TJ2<_=+9A)C3XTU;]E+]JG0OA^=37RVAGMY? MBYK'PW@T6&1E1O%=QX=E@,M^L<4WPO\`#*+]I[X/?$B#]LWQ9\`;K7=._:'T M3XX:C\3/`OPRM?'NO_M#2:5<>&=6^,G[)VB_%_X?7'@+3+#PSXC^"'@#X6VG M[*<6DZ5K.M&/XD_&1I;](/MNIW4/V[K7Q>^*7B6RBTSQ+_P3K^/'B+3;?6?# M_B*WT_7?''[$FKV-OX@$Z]IOBOPMKUO:7_[3D\$&M>&O%.C:1XF\/ZI$BWV MC>(M*TW6].N+;4[&UNHM@_M`?''``_8%_:-X).#\2?V,`,DEB>/VH@AAEAHX?`U%.G6P]?VV-P+YZ%;$RQ,H1_P!OI(K>V=;&0]G5A7HNEA\3&4*T,,L/SRI3PKA6Y$YJG3G.--PJ34[ MN5U^7>H_`7]JKX3_``2_:B^''C?X7Z!XMU']IK]COQYXS\7:I^S]'X_^(]AX MB_:R\%WTE[\3/%/B;3I_`OA^YT_X@?M+V?Q?B7PEX?T2'7K3^R_@&GAW2[F> M2UT?3]0]`_:2L!XX\%_\%`_CI\+?A?XZ^%?@+Q/^P7XP^$]IJGC3X8>)/@=X MF^.?[2*/XN/P7U;1/AG\0M"\)?$:WUSX5:AJ5EX1\-^._&/@C0#XBUGXCZ+I MW@W4?$>C>%/MNF?H$?C_`/'-E56_8'_:-*IMV@_$K]C1@-N-N?\`C*4$D8'+ M$DGELGFLG6OB_P#%/Q-:0:=XE_X)V?';Q!IUMJ_A[Q#;Z?KGC;]B35["#7_" M'B#3/%GA+78;/4?VG;N"+6?"WBG1-&\2>&]4BC2]T+7])TW5]+GM=0L;6XB[ M5F&.]HJLL/@>95(3G.CFF&@I*,\$]<(L;4P]2HJ>7X:C"K/GE3A'G@E4C3<. M:678)T'2C4Q2CR2A3C/`57*+E#&P:]K&DZT:% MBB%9?]9N8OM5@I8G+%!EB$+$E`3G;C.3R9?,7U/_`'RW^%?'R?M"?'1%VK^P M5^TA@$G'_"ROV,."3D_\W0\89:G\T\9=/N>S]WDD4_&8(_;O_9Q7!W'] MDG]N#`[G_B\G_!/AN,]?EYXZ@''/%?9?F+ZG_OEO\*_)?Q?\=?C%)^VG^SYK M$G[%GQ]M]5L/V8/VQK&U\+R_$#]D=M6U73]2^*W["DE]K]AJ$/[2DOAZ&P\/ M76FZ=8:S9ZKJFGZO/)XDTFXT&RU:WM=<;2_JG_AH;X[?]&%?M(?^'*_8P_\` MHHJ[\;@L1[+*;+#J^44&^;'Y='7Z_G"=KXJ-U9)W5UOK8Y<-BZ*J8Y15:5L8 MKOZOC-W@\&VO]WZ77?SUT/K_`,Q?4_\`?+?X4>8OJ?\`OEO\*^0/^&AOCM_T M85^TA_X^%_P##CEO_ M`,V'5]8OJ?^^6_P`*^0/^&AOCM_T85^TA M_P"'*_8P_P#HHJ/^&AOCM_T85^TA_P"'*_8P_P#HHJ/J6)[X7_PXY;_\V!]< MI_R5?_"?&?\`S.?7KNI1P,Y*L!\K#D@^HQ7Q_=';^WIX0SD?\8@_$7L<\?&C MX7`\8SU_QZ4X_M#?'4@@_L$_M'XPEE* M^K5M[-'/B<937U>\*UGC,*KK#8QZOZU;;#^7IW:TO^L'F+ZG_OEO\*/,7U/_ M`'RW^%?('_#0WQV_Z,*_:0_\.5^QA_\`114?\-#?';_HPK]I#_PY7[&'_P!% M%7)]2Q/?"_\`AQRW_P";#H^N4_Y*O_A/C/\`YG/K_P`Q?4_]\M_A1YB^I_[Y M;_"OD#_AH;X[?]&%?M(?^'*_8P_^BBH_X:&^.W_1A7[2'_AROV,/_HHJ/J6) M[X7_`,..6_\`S8'URG_)5_\`"?&?_,Y]?^8OJ?\`OEO\*/,7U/\`WRW^%?(' M_#0WQV_Z,*_:0_\`#E?L8?\`T45'_#0WQV_Z,*_:0_\`#E?L8?\`T45'U+$] M\+_X<^%_\` M#CEO_P`V!]8OJ?^^6_P`*^0/^&AOCM_T8 M5^TA_P"'*_8P_P#HHJ/^&AOCM_T85^TA_P"'*_8P_P#HHJ/J6)[X7_PXY;_\ MV!]I_XO3_P3P;@=?N\XZXS MQQ7V?YB^I_[Y;_"OR4\8?'3XPR?ML?L]:S)^Q;\?;?5;#]EK]LJQM?"LGC[] MD=]6U;3]3^+?[!DM]X@L-1A_:4E\.P:?X?VP/^">!Z'I_P\$_9F/\`(@XZXK[+5U"CG]#Z_2OR9_;"^.?QCU;X M3^$K75/V*_V@?#5M!^U/^PEJD=_J/CW]D>_@O-1T?]N7]G/5M-T*.#0_VE=1 MOHM3\47]E;^'='NKBWBT.UU74K2X\1:GHFA0W^KV?U*G[0OQUP"/V!_VCAR> M1\3/V,3CD@@?\918([]BX M_"TEI'J[MG/'&4OKF)M&LW['!7_V;&=5CVK/ZOKI>^NCTWL?87F+ZG_OEO\` M"CS%]3_WRW^%?('_``T-\=O^C"OVD/\`PY7[&'_T45'_``T-\=O^C"OVD/\` MPY7[&'_T45H^*OV0Y=0_8L^/VA2Z5^UCX>U/3;74?B#^R//+XDO8_@K\=+4:! MI,FE_M)7]O;:M);W<^I0/KDFEZ/+:Z9>0/JUOJ$FG6U[Z&5X+$?7J*_V9WIX MR.F8979G!VMBV[I3;V>VIQYAC*:P=9\E;1T'_NV,_P"@O!?]0_\`7WV_ M5^#Y<%@0#&F."?X4[`$CH>M6?,7U/_?+?X5\?+^T+\=`,+^P7^T>PP,,/B5^ MQB=X`'S9/[463GKVX(X&:=_PT-\=O^C"OVD/_#E?L8?_`$45>;#!8AQ37U97 MO)J6898OJ?^^6_PKY`_P"&AOCM_P!&%?M(?^'*_8P_^BBH_P"&AOCM_P!&%?M( M?^'*_8P_^BBJOJ6)[X7_`,..6_\`S8+ZY3_DJ_\`A/C/_F<^O_,7U/\`WRW^ M%'F+ZG_OEO\`"OD#_AH;X[?]&%?M(?\`AROV,/\`Z**C_AH;X[?]&%?M(?\` MAROV,/\`Z**CZEB>^%_\..6__-@?7*?\E7_PGQG_`,SGUW*ZF-N3V/W6[$'T MKX\_9B=5^-/_``4,SG)_;!\$D<$\?\.__P!A?'0<=>AYJ<_M#?'7'/[!7[2` MSQG_`(65^QAD9!&1G]J(OCI\8K'XN_MU76G_`+%OQ_URYU;] MJ?P;?:QIMCX__9'M[KPGJ47[#?[%^F+H.L2ZE^TG:6=WJ-QIFG:=XE@N/#]U MJ^D?V-XATJ*XOX->CUC1M)[\)@\2L'G$4L.U+"Y:I26/R]J-LZI5-9+%K6':6^EVD^FNA^M/F+ZG_`+Y; M_"CS%]3_`-\M_A7R!_PT-\=O^C"OVD/_``Y7[&'_`-%%1_PT-\=O^C"OVD/_ M``Y7[&'_`-%%7!]2Q/?"_P#AQRW_`.;"_KE/^2K_`.$^,_\`F<^O_,7U/_?+ M?X4>8OJ?^^6_PKY`_P"&AOCM_P!&%?M(?^'*_8P_^BBH_P"&AOCM_P!&%?M( M?^'*_8P_^BBH^I8GOA?_``XY;_\`-@?7*?\`)5_\)\9_\SGU=J=I;ZG9W6GW M*N]M=V[V\Z`.`\4H9)8VP,E'0E'4$%E8@,K89>2\)_#GP9X,0KX?T2QL-SO( M[QVN)69SDDN5+$D\DL6)R>>1CY^_X:&^.W_1A7[2'_AROV,/_HHJ/^&AOCM_ MT85^TA_X^%_P##CEO_`,V!]]?E#^ MV]\=?C/K'[&7[66DZI^Q1\?O"NFZE^S=\;;&_P#$VL_$/]D6YTGP]9W/PX\1 MQ76MZE;:%^TAK&N7-CI4#R7]S;:-I.J:KK^M66G6]KV6^AS1QE-8VK[E:[PE#_F&QFWUC$I?\P]MUWOY6LW]@>8OJ?^ M^6_PH\Q?4_\`?+?X5\@?\-#?';_HPK]I#_PY7[&'_P!%%1_PT-\=O^C"OVD/ M_#E?L8?_`$45X_86_:)TZ"X^'WC6":_NOB1^QLUI8QR^&=41[R[%M^T] M-=?9;929K@VEO=72PHY@M;B0")M*6!Q+K45_LNM:@O\`D89<]ZU'I'%2?W1; M_-16Q=-T:ZY*S_<5]%A\4F_W%=Z.5",5MU:7F?07[)O_`":U^S9[_`+X-_\` MJN/#5%)^R;D?LM_LV!E9#_PH#X-':^W>N/ASXS5T[-:/?J=.':>'P[77#X?Y?[/0=GYJ]GYGG'C7+? MM^_LR`+?$J^&O'OP:^&GP^TWX;:6W MBCQEXZ\:?%WX?>)O'%AI#Z3>WVD:5I$"R^&KG2HM9OM5L?#VDQ2KK/BW5]#\ M/VNK:WIGW$2!C/KC^=?,.N?LK>`O$'Q3N/B]<^(O&EOXAF^)OPT^*K6%K?\` MAX:`-?\`A1X`\7?#C0-/%M<^&KF_70KW1?&6IWFO0#5!J4VLVVGW.FZKI5I% M+]G'ZG M.*J^TC?VKBX^S3ASZ2Z\O.E;52<7TL_)=1_;0M-=\3Z#H?@;P9X\L+6V_:.O M/V>?$>I>+O`E@^E>,/&^@>%?BSK'BCX>?#/6HOB=X=@_X2;3-0^'VGB7XAZA M;:Q\++1[V3PM+J-SXE;73X(XS1O^"D/A+2_V8_A-^T]\8/@A\8/A/X.^(OAM M_%6N?;;KX;>(=/\``GAVST+2?$.I^*+C68_'6D7?B[0GT_4+^_\`#/A_PEX? MU#XS^+-'\-^)-5T[X.QPZ/>1Q_0]M^RAX`MF\+&+Q'XV<>$?VFO&?[6&F!K_ M`,-N)_B!X[7XBC5-!O57PNAD\"6S?$O79-,L+4VGB-)++26N_%=Z(=0&H_$O MQ?\`^"=7[/%SX+^"WP;\>?M"?M`V.CW^@_&#]D[X0I]@^!&O:M)\./C'X/@\ M8ZC\%=)UC5?V:_%4?ANP\&^$?@>;_P`+?$^-]`^+%W;>'39?$+XO^.[Y]'LC MZE&/#]6="E[+%P3JIUI>SJU*TJ$TC*K4=2BHJ%.*I_NXUK^ M=/\`MJDY5?:X9Q5%JTYPC259XB"BY6]]1]CH[27O2O92Y4_,?@I\./B+8>$;V/X7:CXATGX+Z!\7?#O@OQ1XCO?$QO MYO&VMZ;_`,);<1ZMH^C6?@'_`(EFF^$+W7]'\=:KI6E:WSOP=_X*3?"?Q18_ MLZ>%O'\WV'XG?%WX>?LX7OC6]\.Q:3;^`/`GQ8_:*^'/A[QKX,^'=U8ZWXOG M^(HNO%-SXATRVT.;2?#OB[1_#\/B?P-:>.O%6B7GB?2KC4/66_8G\&7/Q4U' MXF7OQ2^,MYI>L?%/6_CM/\&KG4_AV?A?;_%_6/AJOPDA\>6RI\-H_B6DV@^# M,1:+X5E^)$_P^A\1LGC+4?".I^+X;?6XN8^&G_!/CX6?";QA\//&/@#XA?$O M2X/!/A7X1^&M;\,WFD_`CQ)I?Q-U#X*?#S0?A-X-\8^,?$7B3X)ZQ\2?#?BN M3P3X.\':/KQ^#7CWX4>&]7;PIIDDGAN&6YULZM,I\-NC/]UBE7G"-2/L83A! MU%A<-2DG*K&4I+V\:M:7+!P%K+X9>,_AYI>M>(]1>37M,T5?!^B^%/%&N:OJ>A6=GJGQ M#\27UE8Z?\/-&\3ZL)?#]SM7W[;WPJM_&[^$]+\-_$SQ3H/_``E5A\-[?XK^ M%_#.GZE\*=0^+^M^"+;XA>'/A+IOB*?7K+5;WQ/XB\.W^E6NF^(XO#Q^%L7C M/6-,^&NI_$/3_B+%=-L;?Q?X/N/"OCWPS9 MB_?P9XK\.ZC?75^^#IW[$OPXTSXDVWC'2_B'\4;/P#9_$C1/C';_`+.=OJG@ M0_!!/C!X=\+Z3X5\/?$#8W@-_BY]JTR'P]I/B"T\&CXMCX8'QOIL'C9_`LGB M97U$\U)9-]7INM&LL3##I3A".(C"I6C*HZCO&$H^UM&G&@TUA[3JSQ/*H4.? M:H\T56:I2H^Q=2IR3E*FYP@W1C2:5TG&-Z\JJJ7JR<:4*+?-4M'X>_;Y_9_\ M71Q2>%KWQ/KWVSP?^R?XUTI;+0TC_MS3OVS/%&G^%O@]8:-/?7]G97NMV&-<^(FGB[3_`(03PQXP\):YJLSVFOV)?QF^_P""EWPN\;:=;I\$7&J:]<_% M+]EC2M!F\71:;<:!\0_@W\:%9 M_$&R\&^);>^U+P3XFU#P-J_@W7M/EU3=T;]B3]G3X)?$3X&>(X/%OQ<75M!^ M,GQU\8^!-'OGM=<\"WU]\0?!-MKH\!>.KO1OAX^G^'OAC\$_!OP=\*0?!&?Q M%KWA:?0KWX=>#=+U7Q?XW\5WXM?$G*_"O]D;]FC27TOX.?#_`.-WCOQ/X8ET MW]G7]H?X6>#M*T[X(2>'?"'PI^#GQ^\&_&'X3P^"_BEX*^!.C^(/B!\/=;\3 M_#;PQX6GG^)_Q0^*?C>_^'UH9=`\2:/JNI-XUEZZ5/AU2C4]GFM>E"-*JW*@ MXWNZJJMJ--1;HOV3R#4]>`H16EK6;T2C9:RT5X-_>_\E[:;>O-+[_-KMV2]=^K M/B_QFO\`QG;^SB<#(_9(_;@YQW/QF_X)\$D>YRW/OCI7V7L/J/U_PKXV\9_\ MGV_LY?\`9I/[;_\`ZN7_`()\5]F.Q5&90"0I(!(`)';)P/ID@$\$@DO\`;7UM_P`PN#\AFP^H_7_"C8?4?K_A M7RSXD_;.^`/A+6OBCHVO>*]?M(?@MI-_K'Q1\60?"GXQZI\,?!<&C0:'>>(] M/U;XO:3X!OOA9)XD\*Z7XCTOQ#XP$6'B^[\6>#O"::IXM\5:+H_AK0M?U72 M-7Q7^UM\"/!'C73/AYXK^(6FZ'XLU;XP>"_@!9VEUHOBV;2C\:?B'X%E^)/@ M[X;3>*;709O"EIXFUSP6^DZU;VE]K=HL`\3^"M,U%[#6?'O@O3M=YOJ>)O:. M$Q4_=E*\,.YI*--U6FXT]'[-*:CNXRC)+EES+=XG#Q5Y8NC%*<8-RKPBE*4X MTXIMV2O.<8_XI);M)_2.P^H_7_"C8?4?K_A7`>$_BGX(\;:9XKUGP[K]I=Z7 MX(\6^,O`WBF^NK?4-'M=&\3_``_U"?2O&.GW,^MVFFQR0Z%?VMS#>-['XH6VB>%_AOX;\/>-O$VM>/O"7Q` M^%UG/X"\8W>H:?X&^(WA`?$SPIX0N/B-\-?B#J>DZGI7PZ^(WP\@\4^"/B#J MUE/I/@O7M=U-19M,<-5FYJ%&K-TYTZ=3EI.7).JH2A&5J6C<:D';6RG%O247 M)RKTX)2E645)2E&]1)RC!5')Q5]4O95.UW%K=-+ZSV'U'Z_X4;#ZC]?\*^5O M%?[:G[/'@KX>?"SXH:YXUU6Z$_&;P-'\4/A[)X2^&?Q;\?:]JWPP&A^'O$F MI?$S4O!7@;P)XB\<^$OAQX8T;Q=X3N?''CSQGX9\.^%/`,OBCP[8^-M6T#4- M:TVTN?1]=^-F@Z=J/@'1_#>D:U\2=5^)/AO7/''A>V\`3^%KRUO?`/AN;P;: MZUXWCUWQ)XI\+^&[O0;6Z^(G@B&TCTO6=2US7%\0VUSX?T75+.UU6YTT^K5> M6,W1K1A-U%",I146XQJ M*4E&;2C)I-OEO*%W:RYX7MSQO[`Z$(YXX5CW[`^U?(%TN?V]/"&./^,0/B*! MD^OQH^%I_I_AQ7V')_JY/]QO_037Q]<_\GZ>$/\`LT'XB?\`JY_A=71@(I5, M8K+7*\PZ1O\`PJ"TM%?D_NT(Q#=J'O2_WS"]?^PKR/K_`&'U'Z_X4;#ZC]?\ M*EHKBY%_2C_\K.C7^:7_`($_\B+8?4?K_A1L/J/U_P`*EKYI^,G[6_P/^!'B M`>%_B%XD\01:U!X#OAA\6_BH/`7@6YN=5L;3X@_%BZ^$_@3QO9?! M[X=W=[H/B**U^('Q3N?"'@ZZB\*^,;BVUN:'PCXC?3+A0G4ERTJ=2K.S?)2@ MIRLK7=E!:*ZNVTM4M6XQE$ZD::YJE7DC=+FG/E5W>RNUN[.RL_DDVOI'8?4? MK_A1L/J/U_PK'T_Q'HNJZ98:SINL:/J.D:IIT&L:;JNGZG97FF:AI-U:0W]M MJMA?6]Q):W>FW%A(OB;IUG'8W;Z?+X.\+^(/"WAC5M0;5U3^STFCUCQCH<-O9"9[JZ@GENX M8S;0R2"8T^9R2A4;A&4Y?NVN6,(.B;#ZC]?\`"C8?4?K_`(5Y_P"+OBAX3\$^(_AGX5UZ M]E@UCXN>,K[P'X*AM[.XO(;OQ'I_PW^(GQ9NH-0N+8/%H]FO@GX6^,M0BU'4 M3!9W%W86^EPS-?7]I#)W`O82747%J3&)#(!.F8Q"2)3)\YV>401)NP4(^;&# M0Z=E!M22J1YH/D?+*/,X\RDJ$HJ/,G&\I1UT*C.,G)*LKPERSBZB4HRLI0 MP1BIQAMC;>AQ;!SW!Z=.G(R,>WOWI.*4N5J2=KJ\4DUW3=.S2O9M;/0%-2UC M4;UMI*^JZ:=;:V[:[$>P^H_7_"C8?4?K_A4M%'(OZ4?_`)65=_S2_P#`O^`? M%GC0$?MY_LW=,_\`#(/[/EQO=7./!Q.!XM\+$GH!K^DDG\/ME3_P#"6^&,`_\`"2>'L$`@ M_P!LZ;@@C((/VKD$$$$=0:3Q.#6^)H_*K0?Y2#VD?^?J_P#!M/\`^6'RI^W" M0WP9\$G8,C]L#_@GB,GG@?\`!0/]F0`?FN[..#CJ>:^QTC.T=!UX^I.>@[]: M^(OVV-=T.[^#G@R*SUO2+N6/]KG_`()\W4D-KJ5E<2I;6?[?G[,]U>7+113N MZ6UI`LDUS.P$4$*-+*Z(K,/L%/%?AKA!XC\/ELD;1K.G$D@G(`%UDD8.1U&# MGI7;5Q.#CEV`4\1057ZUFSFE4H[.KEG*[.6K%KV." M5U5A:Z6/TOS[K9KIV-[8?4?K_A1L/J/U_P`*RAXAT0]-:TH_M?3R0!?6))(`'VNWR2>`!^^ZD\"G[;#?\_8?^!4?\Q\R_ MY^?^58?_`"9?V'U'Z_X5\,_P_`?]H$GT[<>GK7UW M_:=I_P`_-M_W^B_^.5\>_M77<,WC#]B@QRQ.%_;)\,ARCHP02?`C]H)06(8A M03P"<9;"C)(KTLIJ4'CZ*56FG[/&\O-.C!"7-2<;P=XN@Z34N:S:EJI*2. MV35VHSN[R:BIIR=YS5U'>U]$[6TWT)MA]1^O^%&P^H_7_"H$O8)"%BGMY689 M18YHW9QC<<*CL?E&23S\H+<`$T/>0QOY;S0HV,A7D568`E254L&(!&"=I&01 MU%/GHO55(R7.Z=X"E4GLI_8`_87)`ZG!;DC/7GDU]=R7L!5T$]N7#^7M$R$^:'V^40& MW"3>#'L*YW_)C<,5\B_LSMY/QG_X*$L^$$O[8'@EXV?Y%DC_`.&`?V&4,B%B M`\8D5HRZEE$BLA.]2!Z.#JT%@,\7M*;7U?+DI<]%Q%=11DIJ'-"G%\\9 M6<4G=7VSJ/W\/^\O^]K:J::7^RS:NT[).SM?>TK;.WV+L/J/U_PHV'U'Z_X4 MU9E==RM&R@`DJP8<@G[P.!\O.2<`%/`) M!YXKSG.DK7G%7BYIMTDG",7)SCUE!):SA&<;R@K^\C36R:E)WVM*][ZJVU]- M=+W6JN2;#ZC]?\*-A]1^O^%-:=58J7C!!/RLP#8^A8'/0CCD8QP0:1KA%`8L M@4@G5&T4E>4I/[,8KXG/DY7NA7> MOO3=MVI:*V]W>R:6K3M9-/84JV0``0<)?".N_#J&&S\36$^K:+?:=K_Q$\,>'M:L[NRL=3TB]?S] M)U6\6"2UU.TGM[DP3I+F,JWS_P#L^?\`!5SX(_$E],\._%^S;X"^,+]8EM=0 M\0ZBNI_"O7'FB1[>;3?B*;?38=#^U*RRK;^.-,\-P*TL5G8ZMK$S)-+\WC.+ M^&A'8BOKD+GD8'3.>YP,D=>/;VKX^_;XO M(+W]@W]L.XMI[>YM[O\`94^.]S;3VTJ30W$$OPL\32Q36\J$I+#)&RNDB$JZ MD,IP:^PXSG(Q"O=733O^0FP^H_7_"C8?4?K_A4M%TJX2DH7:4;RQ..BDWTV;^5 MDG*48RRA-4UC*DOAA5T<-A6[22;7TVV.,DCG.1]#_GO MS7X@?$3X+_%'PIXE_;B^)TO@/5OAWX0T?1_$W[2/ASX__&#Q!\)[3Q1K/Q3^ M!'Q,\*?&KX7^'M-\;_#GXO\`BS7?$W[,*Z=X$U73SI/QZ^%WPR\;_!#P#=2_ M#GPYK?C3P?XIU33/!?8^._VVOC;X-U3QC'I?Q<_99\"O$]CK?[56I_%WXO>,?AI<:)\$6L/CMXGM_AQJ-AJ?A@_"KPRD=O\<'\0_' MVS\0^'-7M?#UCIL.ES6XOVKOVH;J?Q%J5_\`\,WZ]X8\9>)?^"DOPU^$?A+6 MM!\5>!TT#Q3^QU\6/BAX*^&6N?%KXG:Y\3-6\,:QX2\9:?\`#R?3_B+IUKX/ M\&1Z5><8X24:U&BW&O5Y.>#JPQ,%"%7#1E MSRH4I5).2M3IU*E"O3IXE5<)1X,5B\)B8\DGB%[*JHWI4U/E=6G5HJ4O98B3 MY8UI03LU*,HPFK12F_&/$_['OQH^,'PI\4?$K5?AUXGN_B[\0_V,?VEOC#X, MTR[^(]AHVI_"_P#;;^./C&/XL_!OP;IK7?C31=,M?'OP"L;CPW\,/AQ\6=1L MK+2/!NG>"#_L]:U^S!\3OAUX#^%>E^"I_B+_P`+"@OOAYXQ\2Z+X?O_ M``7>?#:U\#VNI2:Y\5_#'B/5M?\`%OBCRV_"G]I/XV_%7XT_LG:7+\<_`&@Z M9K%C^U9X3^-_@+5/@:WA.7Q)\0_A9XH^!C2?#NS;1_VG_B;X1@\"+B6U\5^(K%?$]IJ0TSP9XY\%_VX_C+IGPJ_9Y@T+7_`(!Z M3H6@?LZ_\$M]!?$&C^!?'WC?XZ:KXNL[OPK* M\UWX,\4^.;7XS^)?'.NAM.\?:\;RUU+Q=J_J.GFWOSI4\!4?L9.G1B\52^KT M%4QE)4N=PC*Z<8>TI\CP\Z;HSK3;A*_F1>75::H2>)BW*+J5E+#SEB*DJ&"G M.I:I.5*7OR;IU(R>(A-U8TH/VJ0Z;]BKXC>#O@/^S)X.O_V6_%OQLFM/V/I/ M"OC[P/X<^,OP]T'Q'\./VXM>\&_"G2+O]H3Q]XU\:_%KPS'XBU_2(?#&H^&= M-^.7PZ\4_$GXJ?"./0/,^$'AK5=.\42W%KWJ?L,_$_Q/XO\`$OBWXM>'=7^( MOCNY_:X_9IN[OXDVGQ*?1(?%O[/>@_L5_LX?"+]HJ\T[2=/\<:.^B>`_B%\3 M_#?Q3TOXF?#672-'U;XK6FGZ8WB;P?XL\,:?X,N$\N^)W[?W[07BO0OVQ_#W M@3Q]X0\,:-X2_9N_:$^-7PB^+D?PO\)^']2\/:7\!?BQX8^'?B"Y'A>P_:Y^ M*/CO4K/58=6\4Z3;>-_C'\./V:Y-$\0^#+CQ)H7P_P#B%H%/B#X0L-OB(^(/%&M?$KQ9I"?\)0W M2SVG2IRE'+(57&OB)PY,1*MR-.I4;ARKDA.GBYKV=.-2K6JX:C)TI*C"2UA5 MRRM*HHT\3.-)4X3(?V<_BIX M?OOC;\8?!FG^&8M(_9KF^%FF_##Q5X`UCQ5\6/@QH7A2;P,O@6Q3Q%XBT"OT M/_;2^"GQ4^(K_"G5?A1I5]J^I:I=_$#]GGXPOI_BS3_"USH_[,_[2/A[3]"^ M*?C_`$J74-4T59O%'P\\2^"/A;XYTR'1;F7Q0=+T/Q%IOA6SO=5U*&WF^/S^ MWI^U!KO@3Q?\3O#-S^SW#X:^"/[-LGQ[\>^9X-\?Z_:?'.V$?M`?M#?">^U M3X/Z[!\3-$M?`'P]^-'@CX(6WQ)^&WB76++XH/X;L_%WAX,?B)HTLVJ2_>O[ M4-U=S_$#]B;P-=7;+X:^(?[7MM:>*[7>R+JMM\,_V8;@!_/J/,*5?+G76!7LXX]P4%&M"=$B:U;V\%"E*K M6=*G"M&-^:,W2E4Y9PG%],88%TL4Z2Q+]M]1=YN5-WGB*-.DJ$N>M&E&FW., MVXI)\\;-24CX:\#_`+*'[0GB1?AE'\:O"DVMR0?%KQ5\*/B++XC\;>$M=TS7 M/V:OA=^PS\<_V:?AKXV\4:9IWB&]AUK1?C9\7_&6L_%Q_"T%IK?CC0HOC)I, M7C?P[HUQX4U>'PSY!:_L,?$O5_V;=-L--_9DU7X5_%?X3_\`!-+7?AS\%O"< M'Q!^%.BW?A?]N/PMJ_BK6?#7CCPO=?#SXLZIX%M_%NN?$2WTWXC^!/BOX@U6 MUGT*V\57B?LQ?MZ M?$:V\6^)?VWOC)^S9:^&?%?@']H[3]`\&_$:>P\,+?\`@G]H/6?AUI12TT'X M7?'V_P!!^%5QH]NVA>(O$FB>'=1U.6'[/T;XPZGI'[4GACXH:A?_`!0^-&D_ MM"Z'O_9_^'7@/]H*Z\,>*_AUK&C?LIQ?%75_V<_C'^QIXG^('@?X#:?XC\4S M>"?&/Q!\,_'W6]7N/%GAOXB>/=$^&_Q&UKX>?#32?#?B75?0Q$\PH1E[^!NZ M6+J1P^'HUZ47[*5JT5">+I4G[2FII.K4ARTY55'F?NK@P[R^O*"Y,4TZN&E4 MJUZN%K2YY+VF%W`,`N?O$YP M%7)Z#&3BK*.&Z;LX!^9&3@]/O`?CCIWK\D_$/Q#T[XL_M">+]/\`VB/B7\8? MV,='^&O[/'PH^+/PP^%^L?'[PM\%]:TS6_$7CGXU:1\2/BQXXUWX.?%3Q5\* M?C3%X0/@?X<:0WP\\5^,/C!\&O!5CJ-C?_$#P->S_%&VL3]4?LK7]W:^-_VS M?`">>GAOX;_M:ZG;>$K6=ED;3[;XM?L_?L\?M)>-+)92WFO')\5OC?\`$#5H MHRI@LK75;738)62Q\J'Y>I@9T*7-*;+J5Z,9)Q4N;#4^>HYTF_:TE.TO9^TA%S3 M51+VAEBT5\ MHHK5E3'>6-Z>6%P9^M5^/FL?\)U+K'CG^SOB#\&OCU\/O!WC'3?'5Y/>:UK?C MWPW=>*OA?#X5\0?:[O6?!)\.:!=Z1=6R^#M->V_8$*`<@?J:"H(P1D?CWK:. M;XV"C&E*%.*A3@W!3YY.GA\5AHU:DISG.I6C2QE>,)RFN2*H4XIPH4[9RRS" MRYKPYTYSJ*,KUW5==?3K6XCZOX<^!_VCK+Q#>_& MCQ[\!=*T[Q3\.OV8_`O[._A3X3>$/BGX.UVX^)'BJU\86?B+QSXZT?Q-K3>' MO#FA>`]!GTO0+CX7S>++C0_'6J6Y\67/B+PIX0U)="L-2_3C8OI_/U)]?(E*E@TJ]55>6-&5.%)2^KQK4Z,,/.@H0G2PT M*<75EB)PO)TY05DE'+,/"%"$9XANA!4U.=6-2I4495Y1=2=6$^9IXFK*24(J M;:YFTC\=?A+\'?VM?A%\/_V2O%.D_`;0_$GQ$^$O[$E]^QEXT^&^O?%SPAHL M-AXLT>W^#\O@[XJ6_BC3CX@T:^^$^N:K\.-?@\<6MC)<_$O2-'U/PI?:+X%\ M2W\6LZ/8_76B^+[SX?^&=;U+0-4NM0T\ZCHFB7OD_; M]*M+J/ZFV+Z?J1_(TX#`QZ<5%?,<37@Z(A!))M59<[FU&2NAE^'H2YHN=23IJ$O:M7GQ#@A^& M5Y<7.E7>O??E-VJ23CD\_IC\./2MZ.(G0]HHPI5(5H*G5IUE4<9PC5IUX6E2 MJ4JD'"M2IS3C--6G5IR4 MZ56I!J4'R\RG%J<(L_#C_AW)XP\#_"/XC>&=%^'7PH^*_CBP^&'[$OP/\'^. MO$_@_P"%GB3Q+K_PF^"W@WX9^#/CH/AYH/QLT;QY\-?!7C;6-,\+:YJW@+2O MB'HNL>`=4\6Z;X&'CZ'6-$T.UGT_V3]AW]DWXT_`G6/@S/X_TG3;#3/`GP@_ M;(\"W"V^O>"-0GTA?BS^VAIOQ@^$>@1:?\/O!_PZ\#6UK:?":SM+>XL/A_\` M#[P5X!\*75BGA;POX4\-Z#::1I%O^L>U<`8Z=.3_`#SFC8OH,\\]^1@_IQ75 M6S?'UZ->C5=&2Q,IRK5.6:G+FI2C:*YW&G#GE*U."C&,).,6U:*Y:6582E.G M.G[6G[*,(TX1E'EC[-)1;ER1G.:LFYSE)N2Y]).Y^(_B/]B7XPZG\;)_%<7P M0^&5YXBM/V@OVL?B9KG[4$_C/0H_B'\3?AE\@_#_P`)Z]X$BU[3]?\`%B>$:OQ4_8?^+?@O MX#7?PT_9[^!OPSN;GXH?\$W_`(F_LF>,])M/&?A[X=V7A;XP^,?#6E&X^('B M6_ET;49/'J>*;Z;Q)%K7B.*XU#Q-JWB_3_#LFOS'1O$NN>-O"?[A;%ZXY^I^ MGK0R*WWAG\^WTJEFV*4J5Z>'G2I4U35&?UE4JMN6ZJQCB.>W-!2C[.<%%W4( M14I\U_V=07M7&=:,ZL_:.:E!3A+7^&Y4YQ5TVGSQG=-)\W+#E_G]^#VE>!]4 M_P""H_BKQ;XI\*>!?$WQ+M_C=^T'H?A*/0+KP/=_'SX6:!?Z M`8QQ[]#^'\NM-:&-E*LI*G.5+-M.3DY7=@\\\CCM4@``P.@^O]:SQ^-6.GAY M^R=)T,)1PMN=2C^[44W",:=.,(RDG)W3J3E)RJRE/4O!X1X2%:+J*JJN(G7C M[C3ASWNG.52I.;2?*OAA&*4:<(P226BBBN`[#\5O^"E_P,\7?M`_'_\`97\& M>"M'O@G^UE\0KS5[B-Y[B+1O"/Q9_87%_;Z7:>1/;WFJZA<:E96"6 MVH;-.DL;C4#=B8*L$WY]W?PV\7V5S/:RWNL&2"5XF,?P<\+-&61BC%&!`*%@ M2N.@(&%QM'[L^.$23]O']G!'571_V0/VYU=6`*LI^-7_``3Q!!!XP02"/>OJ MU_!OAEV+-HFF,3U+6D.2 MI4CB_9P]G7C2C&G'"8))-2IU&Y-N3;326F[>G\N(^'_BGG==:TX.#M;X.>&0 M..F-DB$>O!Y[Y!(IA^'OBIL[9M77G@CX.>'LXR>#BY/'?MTZ>G]1W_"%^&/^ M@%I?_@)#_P#$4?\`"%^&/^@%I?\`X"0__$5\&_HV>%CU>7X]OSKY?_\`.`G_ M`%,R-_\`+G%)]']:IRM_VZZ"3]'^B/Y<_P#A7OBO!!N-6'&,-\&M"<8^GVA@ M/<`J3W/0A%^'_B9,^;<:@Q/"A_@OHZ#/7/[J]W'H002!SD'C!_J-_P"$+\,? M]`+2_P#P$A_^(II\$>%V()T+3#CM]EAQ]?\`59S]&`_7,R^C7X7VM'`X^.J_ MYB,`K;_]2!]P_P!2\C_DQ?\`X.H+_P!PG\NI\`>)#_RVNQWY^#&G$>V/].R# M[TG_``@'B7/-U=9SG!^#&G'!//`:]./PK^HO_A"/"W_0!TO_`,!(O_B*/^$( M\+?]`'2__`6+_P"(J%]&GPP6OU3-;NU^7$Y6UW>E3(H67:S;[I+4B7!62NW* ML6M=?WU%:?*B?RG>)M+O/`FD0Z[KUY>6VGW?B;P)X,26#X(6<\G]M?$WQYX7 M^&7A6W:.#48S]FO?%7B_1;*ZF(865O/)>%=D+))T1^'_`(BP=[$XZEO@M;'! MR3@LVI<_-GG)5B2!D'%?N=^VMX8\/VGP:\&M!H^G1F7]KO\`X)YP2%+2`%XI M?^"@?[,BRHW[O)5PBAEZ,HP<9.?L$>"_"[*/^)#I>WD8-G%ZGJ"GKFM_^)9/ M"Z."PF(CA,V_VBMCH23Q.4/7"_V=24K/)W9SC/FE9ZRU:,WP;DTJ]6DOKC5. MGAYWE6HGKQT&!@#^I;_A!/"G_0`TK_P#@_\`C5)_P@?A/_H7])_\`K?_`.-5+^C5 MX86]W"9NGW^M93MVNLGN"X'R;;GQZ71QQ%%2?JU1V_R1_+3_`,('J\?,C:4R MGA<_!"\SD_P-OR3]"-7.,>O'6OZDV\`^ M$6^]X>T@XZ9LK?\`^-5'_P`*[\&?]"WH_P#X!0?_`!NI_P"):?#3_H'S?_PJ MRK_YSC_U(R7_`)^YE_X4T?\`Y4?RW-X!U8@[9-%4^@^!E^>_J=7';_/-,L+. M+P?XR^%<&N7FCP/XT^*?A'P1HBK\#M807NN7CW_B.*RGN(=7*6$4FE>%]7E^ MWSA[:WDMXS-&Y=4/]2G_``KOP9_T+>C_`/@%!_\`&Z^0OVJO!/A2T\6_L71P M^'])1+G]L?PRLRK90`2+%\"/V@W57P@W("2=ARK';N!P*[LL^C3X;?VAA)PI MYS2G0J_6X5*>+RV,XRP-.MF$7&5++*%127_P49LCKGP"L+.RF MTR6:/XD>&;@I=>'YO%L"K#IGB4N7TJRO+293'E3'>^=H MVE?LZV]G?7>G_:#XY\6R$6V@S^$H5262R\M(M)O;RZG4JO\`R\B9A<-\X",& M4?7%O\//!&?E\+:$IV`Y73;5."J$CY(A@8)&!P5RI&"14C_#3P+(Q9_">@.Q M.2SZ;:NV?9FA)';`&`,#`%?HD."\G?&,N.Y1Q#SV>32X?G)UH/"_4(PEAVE2 MC2A+VEH74TXM)ZNWN+Z=Y9AXYG+-(NH\3]7>$46W[+V2G)IN*E\5[WM'9K6] MS\2_V&/#M]I7[5-IJ5Y/H@MVTSXC;C#\/-6\-741DBD`?^V[W5;JVS]R.6+R M-UY&RNHC4#/:?\%+M$O=:^+'@FYTZ?09(X_ADT3OJ'@/5O&$GFKXG\0-^[O] M*U>P2R5%=5%HT;2.=TWF@,%'[`M\-?`SJ$?PMHCH`H"O80.N$!"?*\;+\H)" MG&5!8`C<;7E7#_J[@/[*K M91S5XX:O6^L5)1G+G]K[95^52=1R5/G5KH>$#+N\.VUW%?S1LB-LM!GW& MB^$/BRFJ7FCHUQXJ\.F!M/\`"VI^#XEVZ+<[RUKJ^I:C)>3<9^TQ2(B1J86C M#$NWZ*CX9^!%<2#PGH`<-O##3+16#X(WAEA!#\G#`Y!.0<\TDWPQ\!W`/G>$ M]`D)7:&DTVU=E7.2JEHB0I/)`^]@9S@8^@?!.4RXGR/BV4\7'-<@R?$9)@Z= M.K%8&6#K+D4J]!^_4K\KE+GC*$(S;:I]8P>%6#I1YOW M3HWB[S7,[S]U6DXR]=7?\4-'T353_P`%!S?>?H!L_P#AH'6KE0OP\\3+JS6_ M]H:BR*OBIM>;2F?#+G4AIYM)(`VRU564I[7_`,%.-'U"]UCX)G3KG28%CTSX MCK+_`&UX,\2>+2[&\\#G-LVBZMI7]G@<^*O"CB3^WHW=KFY\0ZUJD-V MK1C;%!!'#+"1)(SNC;5_64?#?P>$$8T'31&%VB,6T>P+M";`NW`3:`-@&S&< M+RV6I\-/!:9V^'M,0,`K".VCCW*#D*Q15R`><'(R!Q7HU.`LFJYOPGG4JF.> M,X*P%;+LE4JZ=&IAZV'IT'+'0@Z:JU5["E[SC5C9U&XN7+;K>5T)U\LQ$G/V MF4P5/#)2ERRBJ2HWJKF2E+E5]8S][KU/Q5_;`TS7)_VRM0FM;KP[':?VU$V MCBU'X?\`C+6]4(_LOPVC_9==T[7;+2(M[PR+!(+"9+*X96OHY1$[#[G_`."C M=K?W7P"TF.QETZ"8?$OPS(QU?0-<\169C72O$I:)[#P]>Z??&1V*^74%9?#FFRJ3DK+"LBD\\E71E.=S`Y'()!R":Y(^&V10H\+?/+F@ MZU/V<_8>_P"Y9:JSA9^1_)K\5ISX9^'OB?6?%$7@37]'BL([6XT0_"WX@P?V MO+?7<%A96(O;_P`8VMMI[RWUY;&/4'N8I+(HUS:L+R*W!_.73OC)\4O$%]%X M"^&/P_\`"WB30=)C%A+JVOZ9K]ZKS[I7OOL]W;^(].MXM)MGE6RLFNX3)/!! M]K2ZEBFC!_MK_:)_9+^%OQ\^$GB#X6ZUI--5A^'&H?LV_'*/7?A5X:TJZU7P"+>^^'7B-)WM5\5ZAK1$3*93=75Y MX)?19[ET'VLW_F-G^R;1;N:_L8+NXMWM99XHI)+>0`/"Y7#(VTL-P8'(!..G MN?@O]L3X2>!_AS^P'^V+9>&=$LK$1_LK?'E!+'"AE(/PM\2@XB>J%%%%`!7F?QH_Y(_P#%3_LF_CO_`-135Z], MKS/XT?\`)'_BI_V3?QW_`.HIJ]73_BTO^OU'_P!/43*M_`K_`/7BO_Z8K'%? MLF_\FM?LV?\`9`O@W_ZKCPS11^R;_P`FM?LV?]D"^#?_`*KCPS15XC_>,1_V M$8C_`-2*X4/X%#_L'H?^F*!\X?M"?%OXI:*FF6=].':TTV]FW/$(@L1W.'*(_=:Q^VS^ MQAXATK5-"\0?%7P5KNAZYIUYH^MZ-K/AOQ'JFDZQI&H6\MI?Z7JNG7WA:>SU M#3KZUGFMKRQNX9K:Y@FEAFB>.1U-[QF3_P`-_?LR#)P?V0/VY\CL'QM*A!)8G&N"C">"KSBXV6L:NL MDI*S2MQQIXF=3%*G4PRIRKI.%7#5:LG?#85-2E#%THSNM/>IWL^5W2U^!5_: MF_8`6\\%Z@OBGX2K?_#>SGT[X=WR_#Z^6\\`Z?=6$>E75CX*N1X,$_A6SN=+ MAATV>UT)["":PBCLY$:W18Q>N/VNOV$KNS;3[KQS\,[JP=_%$CV-QX)U:>S: M3QO+?S^-)&MI?"#0M)XOFU75)O%#E"WB"74K^35C=O>7!D^ZPZG&&')P/<^E M&Y?4<=?SQT^M$L1@9-.<,WE)-V7IZ72P%9/96NEC5T2M?HET2M\"VO[4O\`P3_LM'\*>'K+Q/\` M".TT#P'J]OX@\#Z':_#V]M]'\&:]:"^%KK?A33(O!:67AW5[8:GJ(M]2TB"S MO81J%Z(YE^U3^9PF@?&3_@G;X<^)FI?%;3_'O@23Q+<:-X(T+P_%=^#[R73? MAUIW@'P]KOA71H?AI!'X$ANO!:W6@^(KW2=732[Q8KS3H[73XH[6RADMYOTV MR/4?G1D>H_,4UB\%:I%1S?\`>)QJK^UJ+YU*<:DHS_X3FVI3C&4[M.;^)N[O M$L+7?)S3R[]W+FIIX"K:$E%P347C>72+:245;1JSC&WP-9?M3_L`Z=>>(M1T M_P`5?":QU'Q>VKOXMU"S^'U_:WOBE_$,>GQ:^_B.Z@\&)/K;:[%I.E1ZP=3D MNCJ::9IZ7IG6RMA'3G_:7_X)Y77A:]\#7.N?!FX\$ZEIVA:1J/@Z?X:W$OA: M_P!)\+Q6<'AK2[WP])X);2+K3O#L&G:?#H5E/9R6VD16-G'I\5NEM"J?H('4 MD@$9'!__`%]*`ZG)!!QUI?6L"W?ES>Z<7=9O25G#X;?[`VN2UH:W@DE%QL/Z MMB(V7/ERO>R^H54VGJW_`+XKWO>3^U>[O>[^&I_VP?V&KF"\M;GX@?#BXMM1 MT"U\*ZA;S^#=9F@OO"]D;LV7AN\AD$M'=:!9F_OC:Z-.KZ=;F]NS#;(;B;? MSOQ$_:E_8G^)D?@PZY\<-.LK[X?_`!%$_$_PKJ^CV7B>UU33/$?A.YF'EQ3 MW'A2[B_LWQ)H&H:_X*\46Y@\[4?!_B?Q!IEI7EMJ5G^@^]?7]#_A070= M6`^N:E8C+HRC-4LT4HM\LGFF&;C*<90=N;+)6(BG:49+6./6THP:ZW2ZGYZ:U^T=_P3J\2R>'9O$FJ_!/Q!-X0N[G M4/"DNM_"^359/#&H7FHQZQ>7_AU[[P/+]4^(-CXV^&%EX]US3H='UKQO:>!]4MO%^L:3;BR%OI>J>) M8?!Z:UJ&G0#3=.$-C=WLUM$+"R"1*+6#R_NW>AZ,#U_3@_D>#2AU/1A_G_\` M55+%8%P4.7-W!1E",5F]-PY)RYIQY7@91M.=/FJ)14:E2'/*#E!.*^KXF,G+ MVF7*=TW)8"K&5XI).ZQJE[JDE'7W5*T7%.S^%/$/[77["GBV[\.W_BGQW\,_ M$NH>$-7B\0>$K[Q#X)U?6KSPMKL#1M%K?ARZU'PC<3Z'K$1BC,.IZ9):WL31 MQLDP*+C"^''[4G[%'PQM_%L6A_''3]0N_'/Q"\:?$WQ-J^MV/B2[U?5/$OC7 M5WOI$N+NV\(V4;Z;X;T>'1O!/A2V:W:?2_!7A?PUHUQ=7\VG/?W7Z$;E]?YT M;E]?T/?\*GV^7.#I>RS1P:5Z;S/#RA:-3VB7(\L:455]]J*C>?O/WO>'['%N M2E[;`\Z::DL'B+W<>1\UL>G+FIW@N9NRM;16/R7\7?MG?LPW'[:7[/WBR'XO M>'G\/Z5^R_\`MC:!J.H+IWB40P:QXA^*?["^H:182Q'01<&2]M/#6N7,3Q6T MD*C3I1+)'(T22?4W_#>?[)'_`$6OP[_X*O%O_P`SE5_&-S6 MR=\LEM9Z^:[&&&6/G4QO[_!JV+LK83$K183!I7MF"N_/3;9MN3^._P#AO/\` M9(_Z+7X=_P#!5XM_^9RC_AO/]DC_`*+7X=_\%7BW_P"9ROL2BN'FRK_H%S+_ M`,..%_\`G4=7)C_^@C"?^$N*_P#GB?'?_#>?[)'_`$6OP[_X*O%O_P`SE'_# M>?[)'_1:_#O_`(*O%O\`\SE?8E%'-E7_`$"YE_X<<+_\Z@Y,?_T$83_PEQ7_ M`,\3X[_X;S_9(_Z+7X=_\%7BW_YG*/\`AO/]DC_HM?AW_P`%7BW_`.9ROL2B MCFRK_H%S+_PXX7_YU!R8_P#Z",)_X2XK_P">)\=_\-Y_LD?]%K\.CW_LKQ;Q M[\^',<>_%?+UY^VA^R^W[:?A?Q2GQ>T`Z#;_`+*WC_0YK]=.\2^1'JEU\8/A MM>VUH4.A"Y:6:UM;F9"D#1A8)-SK\N[]8I"1&Y!P0C$$=0<'FOD"Z=S^WEX0 M4NQ7_AD/XBMM+$KN/QF^%P+8)QN(`!/7`QG%=6#>5REBH_5+?\`YG*/^&\_V2/^BU^'?_!5XM_^9ROL2BN7FRK_`*!+?_F+?\`YG*/^&\_V2/^BU^' M?_!5XM_^9ROL2BCFRK_H%S+_`,..%_\`G4')C_\`H(PG_A+BO_GB?'?_``WG M^R1_T6OP[_X*O%O_`,SE'_#>?[)'_1:_#O\`X*O%O_S.5]B44*VDA`T^5998 MY&B63ZI_X;S_`&2/^BU^'?\`P5>+?_F`&#G(P"0/3)]:^T*[\;+*_8Y5?"YAKE-%KEQ^&6CQV;V3OEDKM6> MJM>^W0Y<-]?J3QG[_!KEQ;BK83$K187![VS!7?GIYW=Y/X[_`.&\_P!DC_HM M?AW_`,%7BW_YG*/^&\_V2/\`HM?AW_P5>+?_`)G*^Q**X.;*O^@7,O\`PXX7 M_P"=1U)\=_\-Y_LD?\`1:_#O_@J\6__`#.4?\-Y_LD? M]%K\._\`@J\6_P#S.5]B44+?_F+?\`YG*^Q**.;*_^ M@;,O_#CA?_G4'L\?_P!!&$_\)<5_\\3\D_VP_P!L[]F#Q/\`"7PC8:#\7-`U M&\L_VJ/V$-?G@AT_Q*CQ:/X6_;F_9S\2Z]>9N-!MXVBTW1-)U#4)51FGDBMI M$MXIIBL;?5`_;R_9(`'_`!>OP[TS_P`@KQ:,@\@_\BYW';MT[9JM^W`S'X+^ M"*3Q&#?[G`V_V3$JRY]LPU MN[OR6GFOCW_AO/\`9(_Z+7X=_P#!5XM_^9RC_AO/]DC_`*+7X=_\%7BW_P"9 MROL2BN7FRK_H%S+_`,..%_\`G4=')C_^@C"?^$N*_P#GB?'?_#>?[)'_`$6O MP[_X*O%O_P`SE'_#>?[)'_1:_#O_`(*O%O\`\SE?8E%'-E7_`$"YE_X<<+_\ MZ@Y,?_T$83_PEQ7_`,\3X[_X;S_9(_Z+7X=_\%7BW_YG*/\`AO/]DC_HM?AW M_P`%7BW_`.9ROL2BCFRK_H%S+_PXX7_YU!R8_P#Z",)_X2XK_P">)\=_\-Y_ MLD?]%K\._P#@J\6__,Y7RO\`M+_MF_LQ>(?%?[(5QI/Q=T&\A\.?M9^&]=UF M2/3?$JK8Z4GP6^.FFM=R^?H<+-&;W4;*U`@6:0R7,>46/?(GZV5\-/&RUS#"M M/ERW-)M-+*X[J+COIS7UL"[Y@_Z_%4_;R_9 M'"+CXU^'#\JC(TOQ:1T&,'_A&\D8P03USVQR[_AO/]DC_HM?AW_P5>+?_F MOVM;N[?9*GCTW_M&$WE_S"XG^:?_`%,%_7W+X[_X;S_9(_Z+7X=_\%7BW_YG M*/\`AO/]DC_HM?AW_P`%7BW_`.9ROL2BKYLJ_P"@7,O_``XX7_YU"Y,?_P!! M&$_\)<5_\\3X[_X;S_9(_P"BU^'?_!5XM_\`F+ M?_F+?_F+?\`YG*^Q**X.;*O^@7,O_#CA?\`YU&G)C_^@C"?^$N*_P#GB?'? M_#>?[)'_`$6OP[_X*O%O_P`SE'_#>?[)'_1:_#O_`(*O%O\`\SE?8E%'-E7_ M`$"YE_X<<+_\Z@Y,?_T$83_PEQ7_`,\3X[_X;R_9(_Z+5X<_\%7BW_YG*/\` MAO+]DC_HM7AW_P`%7BW_`.9ROL+*?V,_P!K/PUH M/Q?T"_UK7_V;?C;HVD6$.F^*$FO=3U+X;^([.PM(FN-`A@$ES=S0P*TLL<:; M]\DB(K,/J)OV\?V2%8C_`(75X=!!P?[)'_1:_#O\`X*O%O_S.4?\`#>?[)'_1:_#O_@J\6_\` MS.5]B45S\V5?]`N9?^''"_\`SJ.GDQ__`$$83_PEQ7_SQ/CO_AO/]DC_`*+7 MX=_\%7BW_P"9RC_AO/\`9(_Z+7X=_P#!5XM_^9ROL2BCFRK_`*!?[)'_`$6OP[_X*O%O_P`SE>?_`!9_;F_9 M1U'X5_$RQL_C-X=GNKSX>>-[6V@&F^*D::>?POJL<,*O+X>1%:21E4%F`&3U MZ']!*\T^,[,OP@^*A4E2/AQXZ(()!!'A75B"".000"#V(!ZU=.>6*K2<<-F- M_;4;7S##6O[:CORY7%V]))^9G6ACO8UKXC"6]A7_`.83$/\`Y<5NDLPE%_-- M'$?LF,K?LM?LV%#N0_`'X,LK%64E6^''AHJ2K`%&J*X\1_O&)\\3B6N]GB<19-]6EN]+O6RO8ZZ'^[X?O\`5\/> MRLK^PH7LM;*^RN[*RN[7/-_&?_)_W[,G_9H'[='_`*NC_@GG79?MC_$_Q5\% M_P!E[XV?%/P1=VUAXM\$>![_`%O0;V[\.WOB^*UU"*>VBBG'A/3734O$]Q&L MS-:>'M-)U'6;H0Z=8I)=7,*-QOC/_D_[]F3_`+-`_;H_]71_P3SKZ2^)'P]\ M)?%?P/XC^'?CS2GUOPAXKL5TW7M*CU+5='>]LA<07/E)J>AWVFZM9L)H(I!- M87]K."FT2A68'?FIPGETZT%4I0H8>56FTFITXXK&2G!J7NM2BI1:EIKKH<_) M4J4L?3HS]G5G*<*53_GW4EA,,H3_`.W9-2^1^5GA7_@H?XC\&_#7Q#K/C:2U M^+%WJW[3>L_`3X&^)?$'@;Q;^RYJ?B:U\._!W3OBEX^N?CI\.O%NA^+?B+\& M=2^'.M:9\1O!,(U/X8:9X@\9_P!F>!]:L?AU9^#_`!)'\1=1Z.Q_;_UEM2^( M?C\:78Z?X(U/X/\`[&?B?X;_``Z^,7B'0O@Y?>%O&/QUNOVA3XIT;Q1KL7AS MQAXLU/Q'<#X?:!I5KX8\)>&/B+J=_J%C!<^$]!_L#4=9\21_27Q?^"/[*4FN M:YK7Q2U>S\`>*_B/X^\'?$"7Q%I?Q[\=_`[Q7>?$_0?!EO\``[PYXL\$>(/" M'Q&\$Z_X5\7:S\/]2TWX0ZW?^!;_`$J_\=^$KC2O`WBQ_$&F+ING5C:A\`/V M2/B+.]])K%WK'B#2/$OP^^&*^.?#7[2WQ8LOB;H_Q!^!.D?$G1?"OA:+XI>& M?BU9?$72_BOH?AGXH?$_0_'B)XFM_'_C31/&'B;2_B1-XDTN\>%/1A5R=THU MG@,6JM9R59PHN<%!UL,Z3IJ,:4+QA1K0J3IRBW&K*I:*O"/!.GF/-44,?12I MKFI1E4I1DINC6HWE&;E4DW7K4)1C4;@E&.K;E,\?;_@I/'J7@2/XI^%?@'XS MU_X>^&OV:/AE^U?\8M:F\9>#-)O_`(./! MW_"G?$_B&UT/3#INA^*_#FEZO)%XJT+Q)#X6\+^.MSQ9^VOJFHZK\5O!=CH= M[\-]9^%O[1'[-?PJ9&\3>#[CXMZCHWQ*_:Y^'OP*F\4^)/@UXP\)F\\+?"7X MK6&L:EJ'PT^(VCS^+]/\>_#:ZUG5_#?B/P-\1=(M]/TWYX^('PL_8%^%'Q=N M#\5/%,OAWX+^"_V9?@_X6T/11\3/BC:?"_2M.^$O[4GQ=\.ZQX7^)FM>'?BO M+U\3?%/XN>&_#NL_"OXI^&?&OAK3+KP/JY\32DW-_I<'TV/`O[&VNZ_\ M4/B?XNO=1DM=-\=>`O$,?Q,^*O[2GBSQ'\.[F?3-1^%'[:GAO6_@9=^)/C=X MBT#X;_#-O%^D>`O&'B#POX5L/AQX9\7/\/=.BU3PQK_PQT/PQ=W6V)I951EA MZL,OS-T:F%IUE-4,3+FG4?M)4N6I5C2DXIF-1U%4 MQ>%YG4=-*,L.I>Y>E[135%3Y925.:ISD^>4W>HERP6.?^"B"Z5IWQ!\3^,_@ M5XOT#P-X6\#_`+8GC7P;KNG^,?"'B35?B#%^Q3\19/A]\3;*3P[:BQ_X1"/Q M)+-9:UX`OM6U>X^TV%IXC'C&T\('2=*E\3>@?L^?MT>$/BWX=M];\:V?@_P5 M%XK^+E_\(OA)K/P[^(5]\>OAU\8K[3;#P>+KQ/X`^)GA7P#H7AK5/"Z^)?%W M_"''5Q(VGVOB/0/$6D:I>:;JVAZSI>F^2_&?X7_LT>./"GQE^!V@:UIOPFUG MX:_`;6?BJGQD\8:[J&I?"CPYX,_;K^+WQ.\6^,M1EUB[^)VA2W<'BWQQ\`_$ MNIZYJT.M^$]9^'&CZSX^.+7PG_`&IXIU:ZT/0])@.H:EK''C(99##.K'"UZ&*G4I>QI5)8 MI3>'J4G5HO#JK*=)UL3#6<(R( M?CEX`\"2_$/1]0\0ZA\%?"F@_#J_U'6YKGPWX2UW3H/'WBK6OB-I^F?"[X?^ M>^G>(-(CM]<^('COX4WT]_X%]#M? M@Y^S%XP^&_[5'Q"^%FM:YX?O+#P_H`^&/@[XM_#7XM^$_&GQ2T_6AX(\,-JO MA6X\7>*DU_7_``?H>L7]A>>(M!TS5-/D^'EQ^RA\0;#P%\3;)K;PKKGQN^,\ MWQR\":+\0/'MSH/C/QC\:?A=X`L?V?3K6A>&Y/'&H+X@N]*^'/@71](NO"_A ML:IX;N+2.V\5:KHK^(=6N=5FW4LH:E4CD^/=*,JT'4E5Q;ITIRJXUX?GA[9N M7)0HX:=O>GS4<9&K&+E!0'3S!UHPEF.%3DX6-FJE&5/G3//"&B7?B/7-4T/Q'IGB32O#&H6FIV'A#Q#HL6C^)GT&RU% M[O39O1-=_:J_:&M?%GQC\.>,_`OA?X=^&/AK^T/^PC\+-(\3_#OQO8>,_%=S MJ'[1/Q/_`&7]#\4>#?$.D^-/`$6@ZAH5W#\6?$VEZGXQT>+PYKUCX1VQ^&M) MLO&!TWQ=9=[K_P`'_P!A&S\._%A/$>O_``XTO1(M#\6>%/BMJ5_\?-8T'_A# MK3XP_'/Q9\8=8_MCQ#'\1K#4/AUK^L_'N]\6:_X3\0V.I^'_`!%X=\1Z:^A^ M"-3T>#PU9:?I_1:U\$OV5H/'&F?VSK;WOCWQQHGPB\5:-X7U;]HGX@W>L_$] M/V5O%G@_XI_"[XC+X+UCXI?8_B-XR\%:[\.?!E[K'Q5U+3-7\4^)?#NF)X>^ M(GBW7O".H:KIDU2Q614TH+*,4H9J$G)3JU$K0GH\'%+E22K>60 M_P#!11M/TSQ]XL\9?`GQ?X:\#^'OA]^U?\0/`NLV?C#PAX@U3X@VW['GQ*L_ MAK\3+&?0;=+,>"H]>O-6TG7/`M]J^LWYO=#A\1R>)[7PE<:-IZ^(/H;]D?\` M:0U7]I[P-XH\=3^$_"FA:%H_CW6?!?AGQ)\/OBE9_&3X>?$K3=$TS0[F\\<^ M`/B)I?A'PCHGB7PH=9U74?"T5]I-K=PIK_ACQ%I=Y-:ZGI=[8V_SSXH^!O[/ M?QZ^$/AOX;_#W7O#_P`*?BG\1/@G\0_'WPT\+>+?%[^)_'?A?P5^TUXZ\+?& M+XKWFN^!M`^*SZIK&F>)O'>A66G:KXS\%>+_`+;\/]22XF^"7Q)\(:C8:3J] MO]*?LK?`WX@_`_PSXTT[XA?$V?XA7_B_QY<^+M+TR+5_B?KGAOX=Z2_AOPQX M?7PIX2U3XR?$?XL?$*YL=2O_``_?^-=9;4?&*:2/$WBG5QHGA[1[<32ZACF$ MQQ=2NZD*-&I.+G1BJDZ$O@=/$5.9PE4A/V<;-7_`()\<_C7V:[K&C2.<(BEF."<*HR2<9.`.2>PY/%? M&7C+C]NS]G$?]6D?MO\`_JY?^"?%?8U[;6UY9W=I>6T%Y9W5M/;7=I=11W%M M=6T\313V]Q!,DD4\$T3O'-#*CQRQLR.C*Q!XL<[4:VDEBBU#3-2M;G3]1LG=;JQOK:XL[N*&Y@FB3\/M!_9 MGT7X_#35]-\-_#3Q%\8/!>G6]YK&E6L.F6OQ!6:YL;R'QJH=EUZ[ M_:?DT[Q?H_@CQY\8OA-;^'/"W_!8;XL6S?#?X:^"]/E\8_$;X4_M=^#H?V:$ M\11:O\+M9L=;.M>'=?\`$?B"PL],M-/UKXUV;7VI:YJ7B_2;KQ%_:?6LIC4G M-T>%]4A_8Y^ M(7CWXE^,-)CT/Q!\/=%^,.G?M#67QHT7P;K_`,)_V;?B+<^&O#%MXR^%WP6L M-=71_@QX_P!6^$?AOXF^*]>.H_#S1)+7QWX(W_`GQ2_:+D^(7[(^C^/OBY\4 MO']OX[\'IH>L:#\+?!GC[P=<6\6J^/\`XR:9IOQF\6:W\1?V2/"7A3XI:(?A MS9>`(?'^I:AJ'[.VH>";OP2WQ;^&W@S7H/C)X1\/WJEDU6,546-P56,^9TXT MO;SFZ<,-#$RFXV3BG"4TE4J0LZ4N97E"#%FBQ[CD9R*\SLOC=\&=1 M\2ZEX,T_XM?#.^\8:-J.KZ1JWA2S\>>%+KQ+I>J^']._MC7],U'08-6DU6QU M#0M)_P")IK%E=6D5SIFF_P"GWD4-I^^K^>CQ-\6OVB_@;^P[\#_"_P`%_$?[ M5E_\8?"'PK^/6I:W-XDTSQ5,N@_'[X/Z-\/[/1_@GJ/AS3/V1?B]XK^(FI)K MNI:AJ7@OP%K>L?#KX7^,?!5K\3=;USXH>(+31-)\0^#/W/\`'7[+W@;XB:[? M^)-\8>"OA/#X M&\26R7IU&[\+>//B%:V6K:==ZGH%YX:C$9;'!-2Q&)4Z-6MBJ5&I0HWJ?[-- M1525"=5OV=5>]"]52UM))14IW0Q]3%DHMIOE]]T;Q!H?BC0=+\2>&M7TWQ#X=\0:18:YH&OZ'?6NK:)KF MB:O9Q7^DZSH^K6$UQ8:II.J6-Q!>Z=J-C<3VE[9S0W-O-)!+&[?*US_R?IX0 M_P"S0?B)_P"KG^%U?2_@[PG9>!O!?A;P7IL]Y=Z=X/\`"^A>%M/N]2FBGU*Z ML/#NDVNDV=QJ$]M;65M-?36]HDEW+!:6L$D[R-%;0(1&OS1<_P#)^GA#_LT' MXB?^KG^%U<^"_C8Y+6*RW,5!]904*/+)KHVM;79TUFW'#N2LWBL&VNS:Q3DN MNST_5GV)1117&=0UG"*S$,0JEB%5G8]3A54%F8XP%`))P`"3BJD6H6LQ(AD\ MT!WC+Q#S(Q)&"7C,B;E5T`RRL5(&#SD5\O\`[;>F?$#6/V6_C9IOPRMO%FH^ M*KOP64.C^`KB\M?'FN^%8M6T^;XA^'O`5QIEU8ZM;^//$GP]3Q1H?@NXT>]L MM:B\2WVF/HE[::J+6=?R]\66_A+1-:\9^/\`_@FO\.-<^!?A;3_V<]?\-_$S MQ-\+/V=-9^$?AC5/BMXG^.G[.9^!Q3X<^+_A]X8T/X@_$[X<^`[;]H*Z\43- MX/UF^\#^&?$T'ASXAS6@\4>'K2#MPF#CB8.;KJBW5G37/&'L::I*DY3Q-1U( MU(0JJM^Y5"E5JSG1G!1?-)PXL1BY4)N,:7M>6$9N,9256HY.:<*4%!INGRQE M.4Y)*,XI:N[_`'GGNK>VB>:>18H8T>225R%CBCCC>6221V(6.-(T=W=B$55) M)Z9@T[5-.UBPLM4TF^M-3TS4K2VU#3=2T^XAO;#4;"\A2YL[ZPO+9Y;:[L[N MVDBN+6ZMY)()X)8YHG:-U8_B7XA^(G[1'AS]LO1O@GH_B#]H7Q-\--'U'Q;\ M,O&E[\2_M/B'2_&_@-OV+_'_`,2].\?06OA/]E'PY\--&\.ZC\;;;PMX:TOX MF7O[1$?C7J-O!XIT#Q3\//AI_P`*:@3Q!/*WA[X._'/Q9X+G/C;3?!7@ MSQ=KMG\&O$^I^!O"_B+Q#K5Q<>`(=.N_B-X-Z'E-1/!P^M8=3QM6G&G*?[NG M"$Z5:IS5;RE*#?LX67OV]K"+;GS*/.LTC_M4IX>LJ>$HU*DVHMRJ2C6A3BJ- MU&,XRC*6[BU[.4VHQ:;_`&"DE2)&D0?L7:3\59[']B?X5O\`%O\`:8TGPKX, M^"/[1.N_M`:)XKT.*SO'^-WP@\>_L=^'=!^#7BS7_&GPRAU*T\%:7;>+OB9) MIFG^&M0L[_QM8'7CI_CK7?#NFZTDU/*7"G.53&8?FBYN*A&K*-6G#ZQS3IRO M!NT\/["*G3ASU*T))\D9#AF;J2Y*>$KR:]R?/.E#V=22HSAS12JN2=&HZCY* MC:4;-1DXJ7[3Z=K>DZSIFG:UH^HV6KZ/K%A::II.JZ7=0:AINJ:9?P17-CJ. MFWUI)-:WUA>6T\-S:7MK++;7-O+'-!+)&ZL7:3K.DZ]9C4-%U*PU:P,]Y:K? M:;>6U_9M=:=>W.FZC;+^.?@7XI:;\%_^"<=K\%_@GX.^`UGIGP<^)V@>+?!OPQC M_:=OOBHVG?"9]`\*:AX?NKOXE^&_'?A]/%OPV@_9Y\&>!?`7BGPKX2\*:AXF M2]\E:EH]S%\:OVK+N.SU;3;O2;UM/U3]JSXU:KI% M\;*^AM[E;;5=)O;+5;"X:%8[_3[ZUO[9YK:YAF?#$9;+#T:N(GB\//EKTJ-+ M#4TIU)QF\0ZE>53GMR0A3HI3E5DKRNX0C-:22/L*BBBO/.T^+O&X*?MZ_LVAN"?V0?VYL=_\` MFM7_``3Q;D]N`0:#86]U8Z-<+J[ MH5CU---LW@O(KV2UE^:7_:?_`&KU8A_'GC=&R=RO\3OAK&002"-C:#N7!!!4 MA2K`KCBOS;Q!\6,)P7F63Y1B.&.)_HTK(^6Q6?4LKQ>,PW]G9EBFZ\*KJX:%&=*]7"82:A>HXR4HI6D MK=4[]OZ1OM$7]]?^^E_^*H^T1?WU_P"^E_\`BJ_FV_X:A_:N_P"A^\:_^'1^ M&G_RAH_X:A_:N_Z'[QK_`.'1^&G_`,H:^"_XF%RW_HA../\`P1E/_P`M,/\` M6^E_T)LZ_P#!6%_^3/Z2?M$7]]?^^E_^*H^T1?WU_P"^E_\`BJ_FV_X:A_:N M_P"A^\:_^'1^&G_RAH_X:A_:N_Z'[QK_`.'1^&G_`,H:/^)A![?] M)!/V9C^'!'7WK['2XBVCYU[_`,2^I]Q7\Q_C/X^_'KQ9HMMI?C[Q;KVI:#:> M+?A]XFLH-:^*GPQ@M(_&O@SX@>%_%_PRO[>5M,MB-6TGXDZ'X2U30X?,;[;K MEEINF^3>"^-C<]4W[47[5V>?'OC4-@;@/B=\-$`/H`=$QJXRJG5PV3Q<_K:RZKIRXJLGR*"C+6/+.ZL]UE'BVBZ]:K M'*,XE"I3P\%;#TH-.B\9%MJK-.TU4A.#2LXR5];I?TD?:(O[Z_\`?2__`!5' MVB+^^O\`WTO_`,57\VW_``U#^U=_T/WC7_PZ/PT_^4-'_#4/[5W_`$/WC7_P MZ/PT_P#E#6'_`!,+EO\`T0G''_@C*?\`Y::_ZWTO^A-G7_@K"_\`R9_23]HB M_OK_`-]+_P#%4?:(O[Z_]]+_`/%5_-M_PU#^U=_T/WC7_P`.C\-/_E#1_P`- M0_M7?]#]XU_\.C\-/_E#1_Q,+EO_`$0G''_@C*?_`):'^M]+_H39U_X*PO\` M\F?TD_:(O[Z_]]+_`/%4?:(O[Z_]]+_\57\VW_#4/[5W_0_>-?\`PZ/PT_\` ME#1_PU#^U=_T/WC7_P`.C\-/_E#1_P`3"Y;_`-$)QQ_X(RG_`.6A_K?2_P"A M-G7_`(*PO_R9_23]HB_OK_WTO_Q5?''[6,B/XQ_8GVD-_P`9D>'!P0>6^`W[ M06,X)QTK\??^&H?VKO\`H?O&O_AT?AI_\H:Y+Q3\?/CUXBN_!=UXN\6Z_?WW MA7QE:^)_`ZL/#NM>)K>/3R+M)[.XO M9FLV-LMS:].#^D9EF&Q$:\N`>.ZL84\4G3I8?*'4FJN!Q]"T$Z\$Y?O[I.45 M[KN]->?%\5TZN'G3CE&<0E.5%*4Z.'<5;$X25VHS4GI!I).]VC^FZ%ECVLY` M#(H&2!R%3(.2,$8JQ]HB_OK_`-]+_P#%5_-N?VHOVK.J^/?&H!Y_Y*C\-#P< M$<_V&03[C((YSR*3_AJ']J[_`*'[QK_X='X:?_*&N2/TA,N2L^`N.HR3O*,L M/DZ:E-*K)6CB*JLI5FE:C_7&E-*?]C9U:2JK.,Y\R?NO M?NK'])/VB+^^O_?2_P#Q5'VB+^^O_?2__%5_-M_PU#^U=_T/WC7_`,.C\-/_ M`)0T?\-0_M7?]#]XU_\`#H_#3_Y0U7_$PN6_]$)QQ_X(RG_Y:'^M]+_H39U_ MX*PO_P`F?TD_:(O[Z_\`?2__`!5'VB+^^O\`WTO_`,57\VW_``U#^U=_T/WC M7_PZ/PT_^4-'_#4/[5W_`$/WC7_PZ/PT_P#E#1_Q,+EO_1"<_LR.L?QI_P""AN\A M?^,PO!/4XY/_``3_`/V&#CG`SQTSGKQQ7X]?\-1?M6#KX^\:D?\`94/AIV'7 M_D!`]<=/TKD_#GQ\^/6@ZS\0-4\,>+-?L->\:>+K#Q/\2KG3OBM\-)+S5_&M MK\/?`?@W3]0UZ+^S;A;/5D^&WA+X>Z;%;""Q\W0M/T/4C:,^HOJ>J=%+Z1F7 MTL/CJ2\/^/)1Q5/!4IU%ASS*&)BW+ZW%Q]^C%2_B1IM2XFNO#%\XGU'3+::1(9/$'AV;7/#;S`PPZS-*C"OYY?VB_C/\4? MB+\'/%OAGXX>+/%NI_#R1=.U"_@G^(W@*_F35].U&"[\.SV-AIND1WFI7T6L M):?9=-C+QWLI$=S$\&[;^7-Q^T1X6T[5M%\.Z=X3\8>(_&?A@::+7Q1X0U&' M2-0TS6+>)&MGL-3MKG^U['6-.CEBMY[O3;E)H[EI6683_:7KP<3X^9K/.J%3 M*N$\UK9$\+AH8O+LTIX?!9E1JQJXAU,9@\;"NL)RRIT%'ZOC;^UJ--2C2;D< M-3C+$RQ5/ZKE.(^J.G'VE'%TUA<3SJ5ISH2=5QG'EMR4^2\Y*RE[R9_:)_P4 M`=6_83_;+`SS^RW\>N<'_HF'B<<]QSZ@&OKJ,@@CZ'\"./Y&OY-[/]N;]J?Q M+^R#^U%\//B_:6GBOP#J7[+WQTT^U\0>/;EX/BWI"2_##Q+':)_:OABRN[#Q M9%N,0>+Q9:6&M7#>=<7?CEY#%:-_5_87,=W!'<1;_+ECB9=ZE&^X,Y5@I4^N M5'/8=!_2>0YU3XAX)QV*MALWP,\#B8VR_!23C&WI.4ZD: M>)I+ZOB(P=3#RE33D?4X'%+&5YUXTJU*,L'A[PQ%)TJD)+%8A-B>J%%%%`!7F?QH_Y(_\`%3_LF_CO_P!135Z],KS/XT?\D?\` MBI_V3?QW_P"HIJ]73_BTO^OU'_T]1,JW\"O_`->*_P#Z8K'%?LF_\FM?LV?] MD"^#?_JN/#-%'[)O_)K7[-G_`&0+X-_^JX\,T5>(_P!XQ'_81B/_`%(KA0_@ M4/\`L'H?^F*!YOXS_P"3_OV9/^S0/VZ/_5T?\$\Z^QI/NGZK_P"A#-?''C7( M_;\_9E*@DC]D#]N7L3U^,_\`P3T/3/1L''/TK[$+.1C8>?;_`.O3KV]GA-$_ M]B@FFTD_W^.TUTL[]+HC#J\L3U_VA)JZ33^K81V>J=]MOO1^>O[77[(6M?M& M>,O$FO6ND?#+5K6Y_8?_`&MOV<_#;^/8[F>[TGXE_'JZ^%K>%=:A6+POKR:; MX4@T_P`&:Y9>*M;T^:3Q#:I>6%MIWA_6XKJ^:T\S\3_L6_$KPGXU7X@_`_PY M\$--;PEJ?['GBGP-\-+S5M;^'/@_Q)X@^`_A/XV?#;X@6/B/6?!WPO\`%:^! M%N_`7Q,\-VW@KQ5I'@WQG<7W_"$:1X7US0="T*WLKV#]4PK#LY^N/_K?YS2D M$]48_4#_`!KIH9OC\+3HT:4Z'L*%)4(4I1YXRH^RJT)0G"=115H2I4W&+?)[K7)RRDI M?B\/V!_V@M3\&>/8M;O/@A+XO\4^$OV@[F'2K?Q#XSE\&W/Q!^)O_!07Q3^V M9X5TB\OM2^'LNK:?X0E\/:GIWACQ#X@_L35M8\-^(9[R33O"OB:PT^*ZO+_Q M6^!'QUTCXN_#+Q[;?!OX,^/O$'Q!_;DT3XY:=\/-2\4^,KGX8>#8O"?_``2O MUGX'ZA!XI^)%M\"=>O?"JZ'\3?`E_%\/?&(^$U_%K"7/@:-](\,>)?$CZ-X< M_9(`C_EF?R_P84?/G(5QR#@8QQ]2?K]>F*Z5GV.=6=6K]7J.K2J4:D/9RI4_ M9U(5::A&-#$0=-0C5]UTZD)>XKS,I9/AE",:7M:4H3A4BXSI-N491DW)SC)2 MYG'F:E%QO9J*:5OP[N_^";7QTTWPAH-IH'BWX=G5O!OPZ_8EM=&\,:-XP\7? M#_PUJ7B[]GCXM_ME_$;QCX&L?$,?PT\>7G@'X;>#K?\`:8\&CX!>($\%>-M9 MTW6/A;HLNM>"/#BZ;IU]7VEX>_9CDTC]B+6_V:[_`.'7AO6KSQ%X4^(=AJ_P MUU7XY_$";PIJ.I?$7QIXF\9ZWHH^/FE_"C0/'6A6D]_XFN[C3/%7A[X0Z:_A M2=K.ST+PD-)T/2;,_>6&QC:WUP,_J<<]^*7+YSM;ICHO2LL5G>8XOV'MZ\9> MPQ%/%1<;TY>UIRE..M*<$N64Y.%16JQYI)U7S-E4LIPM#VGL82BJM">':;HR M48U%%2DN=2O?D3Y'[BU2BDVC\H?AK^R]^U'X-\1_"WQMXXT?]F[XS>(U\&^/ M/ACX\M/'6M7MK%\+_"OB+]H;4/BWI/B7X>ZMX/\`V;/#?A[XO>,M1\,7NBZ3 M\4H[WX:?LYGXD>-/A]X(\4ZAKL6H6]_JC^.6'_!.3XPVGB#X6W/B#_A$/&?A MZU\#_#?P9X^TS3?CUXX^%3^$+GX8_M*_%;XZZ5XJ\*&Q_9[^(-W\2)M2_P"% MA^']6&AW&K_!:ZT/QC\-K!E\4ZG%KUCK?A']P,-S\K<^R\?2@;AT1N>O"\]/ M\*4<[S""JQA]4BJW\11H*FI_Q5#X,4W3=&-:?O4U&55OFJ.I)MD2R?#34%+V MLHTU:$93I3Y=:4I>\US2C*5&FXPJ.<*2C&%*-.$8Q/RR3]CGXF^!]%^%GB'P M-X)^`/C;QS\/?VM?VO/V@]>\`>-_$?B'P/\`#[Q_:?M&>/?CYJ?A+Q1>^.M& M^$GQ"U?3/BWX`\'?%31+.&_U3X8^)K>."?Q[X.L=:M+&_P!+\5RD:1X&^'.G^"/C+XIL/&6N7EMXC\/Z7_PO'7?"?P@^'WP M+\2?`O6+'PCX8^$/B+XSZEH?PE^+?A#XX?#?QQ8>`)IO#WC+PGXLT'2K+P5/ M^O95CU5_IASA3E[C@X)U(TX*4N=M/F ME%*52JY_E)^R]^QU\(QM9XC%2IRK2Y^:5-.'@X4XN,92YVFZ3L^6$59P4$URPCK).3>KDSXV\9_\`)]O[.7_9I/[;_P#Z MN7_@GQ7V:1D$=,U\:>-48?MY_LW1X;:_[)'[;Y'!+'/QB_X)\,,`S3RFBK/3_F-S=-6DE=>ET_,SPL)1J8V]FW MC+Z2B[7PN#:OJM=-A&B)'#[3C`.W)`[`<]`<''J!2&%B`/,(Q]W"\+SQ@9[+ M\HYX'Y4[>_\`Y[\4F]_[A_+_P"RHWO_`'#^7_V5#A3=[QB[WOKH^:+B[I22 M:Y6U9K1;6LFG9]D[[WY'>_>[_P"`((CW?..%V@KA1T4D.20#R.V>U2J,`#K@ M`9Z9P,=.?YU'O?\`N'\O_LJ-[_W#^7_V5-**=THIV2T:6BV7Q-)>B^;%9Z^Z ME=INW(KM*W1KHOUW'2?ZN3_<;_T$U\?7/_)^GA#_`+-!^(G_`*N?X75]?,S% M6!0@$$$XZ`C'8YKY"O%=/V\_"#;&Q_PR%\1E&1P2OQH^%O`)QDA2K,`>-RDX MW+GLP*DWH\NQL%;7WI0H)7LFDKO5MI+P3LF\9A;)M:_P"\[:[^ M5[GV'146]_[A_+_[*C>_]P_E_P#95R77=?>O\SHL^WXQ_P#DAY7/H.G;/3/7 MVY_GZT@4C^+/7MR"?0YS_CWIN]_[A_+_`.RHWO\`W#^7_P!E0K)MWWM>\DUI MV3=D^[25^MQ]XIZ>:E>WEMY#MA_O'_`#^-(8^X(!]=HSSC/((.3@$\ M]0/2DWO_`'#^7_V5&]_[A_+_`.RI*,5=I13;O>ZWUU^)VW>UMQM-[J_JXO\` M4!'C^(D9SCG!.<<$=SWS^7'_P#U[-'++;5^LE?[^9/\`X&@[9QC/ M'.1CJ3G)///)YSU_$TX#'N?6H][_`-P_E_\`94;W_N'\O_LJ$DK;:*R]Z]E> M_5O[W=]+VT#E?;\8_P#R1+146]_[A_+_`.RHWO\`W#^7_P!E3NNZ^]?YA9]O MQC_\D?$?Q.TRSU[]N7]G73-1A66RNOV._P!NF"XA).)8W^-'_!/-#N(P1]_) M`X..O<=K)^QS\"99))9?!VFO)([.[-&Y+.Q+,?F+'EB21G`[>_.>-D8?M\_L MUQX;#?L@_MR[>"6.?C/_`,$\&X`R90DY8QRNN23L\+@TD MWILE;EZ>5]?E7_AC7X"_]"7IG_?IJ/\`AC7X"_\`0EZ9_P!^FKZJWO\`W#^7 M_P!E1O?^X?R_^RKS[+N__!D__EIU_]P_E_P#94;W_`+A_+_[*BR[O_P`&3_\`EH_]P_E_]E1O?^X? MRS_[-19=W_X,G_\`+0Y?[D?NA_F?E3^V-^RK\$M$^#_A.>R\&:;')>?M6_L! M:5,2A):SU7]OG]FBPO8P?^FUG)<6YR"")V(VL%8?5A_8W^`QY/@W36]S$?4G M''IG'X=`#CF?]^FKZJWO_`'#^7_V5&]_[ MA_+_`.RHLN[_`/!D_P#Y:'+_`'(_=#_,^5?^&-?@+_T)>F?]^FH_X8U^`O\` MT)>F?]^FKZJWO_F?]^FKY1_:>_90^".D^*OV.K>U\&Z8L>K?M@>%K.]PC*9;./X M'_'ZZ>WS@X$LL,+$C!'ECD#(/ZL;W_N'\O\`[*OCG]K`2R>,OV)PJ-D?MD>' M"<*20@^`W[01D;`)P%4$DGA1R>`:]#+(Q>.HIM_!B^7]Y4TFLNS-TWI5;TJ> MS>S6B;329QX]6PE5VC&SH:^XK?[7@NJ=UV^=NNNQ'^QS\!G`'_"%::`%4C]W MQT4XP.F,\`=,8.>M2?\`#&OP%_Z$O3/^_35]21*R!2%;)C4$$="%4$=L=/4F MIM[_`-P_E_\`95YT7S*[E)MMM.52K?EN_9I\U52TI>SCJK^[9W:;?;)BMKYGRK_PQK\!?^A+TS_OTU'_``QK\!?^A+TS_OTU?56] M_P"X?R_^RHWO_.PC(/IW^OY9Q7RO^SU^RG\$M9^,'[>MM=>#-,\ MG0_VL?`^DV"A&(CLU_8(_8AO2A'=FO+V\G+9/^O*#"JJC]4'+LI&P],].N.< M<$\GMQ7Q[^S+O3XT_P#!0L>6W/[8'@EL[3C/_#`'["X."2!PP8<9Y!`Y5@._ M"J#P>;W<^98;+G3M4KQTC0] M8M]3UF"QM;:"1[C4]0LK>2RL8Y&M[7SI@US=6\2;G^!_V&2ZTQ- M'TV.X?S-6U)5?7M37S!(\[3/N\B2=RTTH@?RQ*TB[I%!!_H]8,X*LA(/!!5? MK_.FQQB+`CBV@#`"J`,?@1ZUXE?AW)L7FT,\QN7T,;F=&A1PN'KXR7UB.%I4 M93J1GA:56K4I4:JK3E753V+JJKRRC-627//!8:==8F>'I3KJG&BIS4)I0@K1 M4:U?(_[?PDD_85 M_;,01N2?V6OCV0%0LQV_"[Q0QPJDD\`GIVKZW!9>`I8$`]#C..<$D?E^/-?3 M3?\`L5'56^O8AV6B7^Q89:67)%6224>5*VD8W]Z8W6-JK5_['AHI73LEB,39 M?%I%:\JT2Z(FHJ+>_P#_]P_E_P#9477=?>O\PL^WXQ_^2):\S^-'_)'_`(J?]DW\=_\` MJ*:O7H^]_P"X?R_^RKS3XSL[?"#XJ#8PS\-O'>,*2<_\(IJ^.A/T'')(`Y(! MTI?Q:6J_C4>J?_+ZCVN_P,JZ?L*^G_+BOUC_`,^*W]XX[]DW_DUK]FS_`+(% M\&__`%7'AFBC]DW_`)-:_9M_[(%\&^V/^:<>&O\`.**K$?[QB/\`L)Q'_J17 M_KH_)"H?P*'_`%XH?^F*!\W_`+0?PB^''QH_;@_98\,?$[PO:^+-"L/V5OVX M==L]/N[S4[*.#5K;XM_L`Z=!>"32KZPG=X[+4[Z!4DE>';<,YC,BQNGJ/_#` MW[(G_1%M%_\`!]XR_P#FCJIXV./V_/V9B.W['W[=)ZXZ?&?_`()YGKV^M:FA M_M)^)?%WQ0\7>'?!7P8UGQ#\(OAOX]G^%OC_`.,\WCCP?X>CL/&NF:78ZCXM MN_#7@K7+FSOO%'@#X=W.IVWAWQ[XK?7-&U>S\367B#3O"O@_Q?:Z#$ M[3P/JDULWPK^,MKXC\7Z!\4=>?PK\+/%7PA\&7GP[M_&/QU\'?%+Q5&_ASX9 M>,O@KH/C[PK\0M9CFT_P?K.M7D,EN,6Z_P""B'[)ECX<\-^*=0^(/BK2=,\5 M:9X_U_3X]6^"7Q^TK5],\*_"GQA%X"^*/C?QEX9U'X76?B7P!X!^&OBF:'3_ M`(@>/O'>D>&O!G@N!UU7Q'KVFZ,PU(O_`(6FY*,EHV=]4XI..4)0;CET>>*G#F]A%2IN<8,OAY8 M^+/$'B7P_HVMP6OPCD\0Z)X;G^(/BW3["Z^/?CB\^'?P93P[JNM?#+P)XC\8 MZ?X_\8V<_AG2-2L?!%I'#K]CK&EWT<$FBW\ZDWF\(*;ECY0?*^:$ZLDE/X7= M2V^*E3C\#M*S:L[:.UW[KOZK_PP-^R)_T1;1?_ M``?>,O\`YHZ/^&!OV1/^B+:+_P"#[QE_\T=>A_"G]I7X-_&KQ!XE\+?#KQ7> M:UK/A>TBU.Z2_P#"/CGPOIGB'0)]0O-)A\8?#?7_`!?X;T#0?BUX`DU73[O2 MQ\0_A;J/C#P/_:"169U];BZM(I_"OBC^W[\$/AU\5_"/PI6^U77=1F\?>//" M'Q-UJQ\-?$I/#OP^L/AU^S3\8?VC_%=QHOB73OAYK/@_XJ^.?#NF_"_1M"\4 M_"'P-XFNOB'X7@\=:=K6LZ;:W%E;^'=>4)9O4G*E%YA[:$/:3HMUO:0@DVY2 MC>Z6CM?5M62O>,;E2RN$(U)4L`HU)JG3DHT7&"?& M6NZ_#?\`AKX6^/?%>J?V+I]])X5\(>'IO%7BN/1?#U_I6I7WF?@/]MKPYXQ_ M:+^+/P7OO"^L>$_#/PY^(OA3X(>&_''B7P]\<-'U'XD_&?Q#X!_X65<^'/#N MF:[\"=&^&Y%RO-^TYH^[I>$[M6;C#CE,73BZ>"O5J.G! M1ITI>\J4ZLN:R7*HQBKM]91T=TGV'_#`W[(G_1%M%_\`!]XR_P#FCH_X8&_9 M$_Z(MHO_`(/O&7_S1U'XJ_;O_98\%R6D7B#XG7$7VAOB%)=36'@#XHZ_;Z!H MGPE^)^J?!KXI>-/&%WX>\$:M;>!_AM\.?B1H]_X=\<_$_P`93:!\._"J?8M< MUKQ19^'-4TO5[W*^,?[>_P``O@QIOQGN=2'Q1\;:C\"/#FIZYX^T_P"&7P7^ M,'CO2;+4=)L-&U*^\$Q_$?P]X&O/A1'\0=/TWQ#HNM:]X+O?'MIX@\(^%[YO M&7B^QT'PE8ZEK=FX2SBJZ<:<%=)^( M/BRS\+:#XA\1^,M,\$CPYKVGV#[_`/;\_9-TP>#3+\68KNW\=>%M!\(-0TU-;\7+'=:SX<^*_["VFZ+?/./$/VM7L+'Q/KUO'%%<1V[ MKJ,K30R.D+1_5O\`PP-^R)_T1;1?_!]XR_\`FCJAXRR/V[/V<0PP1^R1^V_D M'D@_\+E_X)\9!/L:^SZVQF-QGLK\]R,+@\ M)*ICN;"X=M8Q[T:;_P"83!K^7LK>BMHM#X__`.&!OV1/^B+:+_X/O&7_`,T= M'_#`W[(G_1%M%_\`!]XR_P#FCKZ_R/4?G2Y'K_G_`"17%]=QG_07B?\`P=4_ M^2.SZC@O^@3#?^":?^1\?_\`#`W[(G_1%M%_\'WC+_YHZ/\`A@;]D3_HBVB_ M^#[QE_\`-'7V!1D=<\>M+Z[C/^@O$?\`@^I_\D'U'!?]`F&_\$T_\CX__P"& M!OV1/^B+:+_X/O&7_P`T='_#`W[(G_1%M%_\'WC+_P":.OL#(]111]=QG_07 MB?\`P=4_^2#ZC@O^@3#?^":?^1\>O^P/^R($<_\`"E=%X5CSKOC+'`)Y_P"* MD%?+=U^Q9^R]_P`-J>%O"H^$>D+H%S^RSX\U^?3EUOQ<(I-6M/BU\-["VNRY M\0F4-%:7EU$L:R"(^/:_?5-'[/#O^;>Z3^2,,1@L':@OJF&M])_\'5/_`)(/J."_ MZ!,-_P"":?\`D?'_`/PP-^R)_P!$6T7_`,'WC+_YHZ/^&!OV1/\`HBVB_P#@ M^\9?_-'7V!11]=QG_07B?_!U3_Y(/J."_P"@3#?^":?^1^1_B_\`8Q_9AM_V MT_V?O"D'PETB+P]JW[+7[97B'4=,36O%JQW>L^&_B[^P?INB7TDX\0?;%>PL M?%&O01Q17$=O(NHS--#(Z0M']8?\,#?LB?\`1%M%_P#!]XR_^:.LWQK_`,GZ M?LV_]F@_MS?^KK_X)X5]I5W8[&XM4K. M/"8/"2GCG+"X=OZ[+5T:;_YA<$OY>R2\DK'Q_P#\,#?LB?\`1%M%_P#!]XR_ M^:.C_A@;]D3_`*(MHO\`X/O&7_S1U]@45P?7L7_T%XC_`,'S_P#DCL^HX+_H M$PW_`()I_P"1\?\`_#`W[(G_`$1;1?\`P?>,O_FCH_X8&_9$_P"B+:+_`.#[ MQE_\T=?8%%'U[%_]!>(_\'S_`/D@^HX+_H$PW_@FG_D?'_\`PP-^R)_T1;1? M_!]XR_\`FCH_X8&_9$_Z(MHO_@^\9?\`S1U]@44?7L7_`-!>(_\`!\__`)(/ MJ."_Z!,-_P"":?\`D?DA^V#^Q?\`LP^&/A-X1U+0/A+I&FWUS^U5^PCH,\\. MM>+)#)I'BO\`;E_9W\+^(+(QW'B":)5U'0M5O["258UN(5N/.MIH;B*&:/ZM M7]@?]D3:/^+*Z+_X/O&7K[^),_4FJ7[;Y_XLQX)_[/!_X)X'_P`Z"?LS_P"- M?9J?='X^W<^M=CQN+_LG+9?6Z_-+%9OS/V\[NU3*TKOFN[7=K[7=MV8+!8-X MS%/ZIAF_8X&_[FGT6/7;MH?(/_#`W[(G_1%M%_\`!]XR_P#FCH_X8&_9$_Z( MMHO_`(/O&7_S1U]@9`ZG%)D>H_,5Q_7L7_T%XC_P?/\`^2-_J."_Z!,-_P"" M:?\`D?('_#`W[(G_`$1;1?\`P?>,O_FCH_X8&_9$_P"B+:+_`.#[QE_\T=?8 M&0>AS11]>QG_`$%XC_P?4_\`D@^HX+_H$PW_`()I_P"1\?\`_#`W[(G_`$1; M1?\`P?>,O_FCH_X8&_9$_P"B+:+_`.#[QE_\T=?8%%'U[&?]!>(_\'S_`/D@ M^HX+_H$PW_@FG_D?'_\`PP-^R)_T1;1?_!]XR_\`FCKY4_::_8L_9?\`#WBK M]D.VT?X2:19P>)/VL/#^A:W&FM>+'^W:4WP5^.FJ?9'>37WDB4:AIMA=!X'B ME\RVC!,O_FCKZTMNO\` MVS3_`-`CJY7FPQN,Y?\`>\3I*HE^_J;1K58Q7Q;*,8I=DDNAVSP6#YG?"8;= M[T:?\T_(^/\`_A@;]D3_`*(MHO\`X/O&7_S1T?\`#`W[(G_1%M%_\'WC+_YH MZ^P**KZ[C/\`H+Q'_@^I_P#)$_4<%_T"8;_P33_R/C__`(8&_9$_Z(MHO_@^ M\9?_`#1T?\,#?LB?]$6T7_P?>,O_`)HZ^P**?UW&?]!>)_\`!U3_`.2#ZE@O M^@3#?^":?^1\>O\`L$?LB(I8?!;1,C&,Z[XRQU`_Z&.OE;]GC]BO]E_7OBY^ MW5IVK?"72KRR\)?M4^$/#_AVW?6_%J)IFCW'[#W[&7B:6RC,7B!'G5M<\1:S M?++=M/<1F^>WCE2TB@@B_6>7_5M^'\Q7QW^S%Q\:/^"AN?\`H\+P5_ZP!^PO M7H8/&XSZCG;^M8BZPF66?MIW5\^PL79WNKQE*+M:Z;6S9G4P."W[FGHWA9)VTT;22=MUH]"Q_PP-^R)_T1;1?_!]XR_\`FCH_X8&_9$_Z(MHO M_@^\9?\`S1U]?Y'J/S%>%>+OVE?@AX#^*^B_!/QM\1-`\'_$3Q+X9T_Q7XPIX?_`+336[A/(FL[&ZB= MFC\BOFU7"PC4Q.8SH0G4IT8SKXQ482JU7)4J49UJM*#J5'&2IPY^:;344VFB MI83`02(U2?\`'F]'YJ;3]4VGT;*^HX-:/"8:_6U&FU?UY=?4^/\`_A@;]D3_ M`*(MHO\`X/O&7_S1T?\`#`W[(G_1%M%_\'WC+_YHZ^P**?UW&?\`07B?_!U3 M_P"2#ZC@O^@3#?\`@FG_`)'Y._MP?L3?LM>$_P!C']K/Q/H'PAT:PUSP_P#L MW?&S6='OEUKQ;,;/4]-^''B.\L+M89_$$MO,UM=0PSI'<12P.\86:*2,LC?4 M/_#!/[(TA+/\%]%+$G).O>,LG/))_P"*DY))ZGFI?^"@7_)B7[9G_9K?QZ_] M5?XGKZY3H?K_`$%=$\;C/J5'_:\3_OV(?\>I9/ZEAU=+FLFUHVM6M+V.>.#P MGUNM'ZKA^7ZIAWR^QIV_WG$/:W?7UUW/D+_A@;]D3_HBVB_^#[QE_P#-'1_P MP-^R)_T1;1?_``?>,O\`YHZ^P**Y_KN,_P"@O$_^#JG_`,D='U'!?]`F&_\` M!-/_`"/C_P#X8&_9$_Z(MHO_`(/O&7_S1T?\,#?LB?\`1%M%_P#!]XR_^:.O ML"BCZ[C/^@O$_P#@ZI_\D'U'!?\`0)AO_!-/_(^/_P#A@;]D3_HBVB_^#[QE M_P#-'7GWQ:_84_9-TWX6?$K4++X-Z/!=V7@#QG=VLRZ]XRW17%MX:U2>"0#_ M`(2/!*2QHP#`KD#(R!C]`:\S^-'_`"1_XJ?]DW\=_P#J*:O5TL;C/:TO]KQ/ M\:C_`,OJG_/ZC_>,ZV!P7L*_^R8;^!7_`.7-/_GQ6\CB?V3%`_9:_9LP``/@ M#\&E`'``7X<>&L`#H`,G&**7]DW_`)-:_9L_[(%\&_\`U7'AFBL,1_O&)?5X MG$MONWB,0VWW;>K?5G3A],/ATM$L/ATEV2P]!)+R25D>:^-AN_;[_9G7.,_L M??MU#)Z#/QF_X)Z#)^E<-XF_9_G\#>*O'^BWG[1GA3P3^S9^TI\1-#M'C\>:Q\3/C%I!T+Q'\/OA#\9]5^(&D:9H/A_P"*>KVMSK][X&O/A-X^ M^(ESXEU[QL:F?%LWB0Z;'*(_"$=E) M&=>?4-NE1PO";UH=Z25UTIR4\#3]JJ-.K@X1JSE&$U%4ZF:UZOA3X5M?A-X/\`!/P4\9:'\#?@]\5= M!^)]YX@^Q^-OC;IGA?QO\==>\1^%O!U]XC\6:3\6?V>O"NG+X:TSQ!\+/!OA M#5](O_"_C[O/AC^QUXX\:_`2^\-_%!M+^"/B#Q#^RM^U!^RA;^#M+\+^'[J[ M\/>"?C3\0+B]\#_$CQQ!X8^*/C;PIJ/Q>M_"FF:5K/Q4TGPSX]\1^&O%OQ%U M_P`3:QIWC?38[P6*:7[$/@SX]^"O$'P+OOB+X@_:.\1_\+4_8Z?Q9\>!\;_% M'CGQ;IWAOX]^&?%'PNL?"ND:?IWBUWTCX3^(_P#A$O%?CO2=6\*^$['PU-XX MM/"MMXJ\=VGBKQKI.I^,-1X&Y^#OQQ\:_%_2M4\0^//VP-&\.^._V[?CS\,/ M'5EX;^+7Q=\$^$],_8\3]GGXN>.?!H\/Z=H&HZ?IO@#POJWQP\'?#S3_``_\ M>?"1\/?%NROO%4G@#P7\7]"\*:WIG@VW]BK7Q:A7RN69Y8Z6%<\92Q=*C7Y: ME7_:[X:C3IU52BE++G.#ITY"Y)*GB91.2%*BZD,7'"8IO$7PU6G*M&,: M5.$*2]K4]H^62E[>4.5)N].I9MPL?33?LDZUI/Q(T_XH>#_BOINF>(;']J]? MVBKBTU_X;3>(M#O/"VM?LT>%?V8?&WPS%K8?$#PSJ-OJ^J^&?#EQXH\*_$.# M57A\+>)[NQCU?X?^-=&TZ\TO6_,OA;^Q9X`TWQ#^S-XK\._'G3/%6A_LU:9X MI^'WQ5T31-,T"?1OC/XH^$OB?QA>_#6W\;75GXNU5O!VL_LO_$KQM\1M<30( MI-7FM?%_B"Z@UM='N-)BA7YFG\9?M=>$?A%J'A_Q#H?[7'B+X@_$3]C[X`^" MOA?JGACP?\2O$.KZ5\8?A7\:/CQ#\9/$7C[6/#UC%IOPM\?ZY\)_%'P;\2Z] MXJ\=3>$]5^,&GZ)=:5X)D\<^+-%3PL_2>"O@KK.A_M.?"/XH>./!/[0VF64' MQQ_X*6^'=%U+P3=?M"67ANUUGXG_`+37@OXA_!74_B!X1^%FJ1>'7^%_Q`\/ M:%XUU6[\;_%'PY+\)/$%MI'@NP\<:U5*$'\252[O)P9S*MAY3PE&AEM54Z?+*<:OMJ<:4H5: M56-DX*FGS/GD[W]RZTYT?3/[!W['_P`-?V==.T_Q7\,?%'P`^(WPVUKX9^'= M`^"'Q'^&7P=TGP[\0O$?P=U"33]>\,7OQ"^.FC_$[QIX>^-T>LZ+;^%K[3O% M/@;P5\*_#OB:6WD\67VB:S>:GI]SIKO`O[+SZM\5/!_Q1$?M'>&_&O[/GA' M]I3XS_M%^$OAOHG@/0/$-U=?$SXK>`_CM$/C!X;UWXS6'CB]L]>\):!XZ^+ MOCO7?#^A6'@31==$:O%KO@?Q9KOC&V@T./PC^?/PE\0?M%WNH_!KP?K>L?M MCS_M"^$?AM_P2LGTC01=?%P_"OPUJ^KZ)X0N_P!M&3]I"'3@?A_8:AJGPWTS MQ?\`$SI_P"TKMOKC5%BN_V=(8_C_/J%[%'#X+_:ZT34_@UX9T[Q#\=O@CX+ MM;SX@ZI\+I/"WP2_:>^(=JOQCU?]M+X]Z_XMA^+7AGX&^-O"/A/3_#GB?X6: MC\%)_#UW^U]H.L_`*Y\.:YXKUSP]J7AN[M/$.IR:5<#BXU<55>=X?ZSC8M3F MW2Q#K86-#&5?:2ASRJQKM8N5.A6HJ'+*OF$8I*"3=#%T(4J5&&7UJ=*@[1A2 M@?#CQ MKK/QK\4^*M(UCXF_#R+XH>,OA1\*O`F@7?[/_P"R];_"[Q/\+OC)\+=3^&'Q ML^&7[-OA#X9'2_BEX3^(>M_V=XUU/XD7>JZ%XEN/%VL,OT%\3?V:$T+3?%_C MJU_:&T+X?^,;[]I3X+_';P#\1?BUX6TKQ%X2T/Q_HGP7^&?[*>F>%OB)H<'C MOX:#XA1?%.VL;ZTCB\.^+OA9K%QXU^(6C6'AJ47^F6,&N4/^"A%S\1+/3/A+ MJ?P[?XZ>(+_1?%&O:M#\)?@K8?M%:+#\7-+/@U=_"W1+:[/[/%_P"* M-,_9\T+0];\6:O\`#S1M2^+GAW4-"^-=Y\8]1TJVFLS?\6&GC<75H5J^/I4* M.*K5E6Y*%"])5Y>QJ7E6JQBJ;I>Y**_V/O&_B7PU^T[\*[/X]V^A_ M`K]H;3?C)J=AX/M_A5IE[XY\"?$?XV:=,OB77)?B3<^-5LO%G@32/%=UJOCC M0?`?_"`>&O$4.M:S"_"OP?_:'(/@9XR^!/Q3\?>+/&W[,+S^$_@W;WTGA MSP[^S;X(TS4_%_A'Q7J%W^U#X9UCXC^$KA[?W/XC>$?C%X)^.]UX-\$WG[8] MQXA\.?$']F6/]DV_LO&_[0WQ`_9\N_@HWBSP9=?M0S?M'^/M;U_Q5\/O%'BI M[*3XQV?BB3]J?7]6^(,'PVC^&F_&K6?VFOA=X%_:` MUKXL?"+6_!7B+Q'\*9[7X/:S\6++X!^,/V=]:\'0?"K5OCU8^,/$VE_$[PSX MX\5:QX0\&^'_`(UZ-XV\,>)[#P[CQ5XVL-)U_3_$C[3]@*VC^'?QM\"K\6]4 MO+WX[?LY^+_@[XN\27?@RTF*^-?B/\6?CY\9_B#\4[31=/\`$&FV(L]:\;_M M`^)9-&^'4#V]OX4TBPLM)3Q7JL3/=#YS^'#?M`KXQU[2M,C_`&J?&6EV_P"V M1\!?$7B#XM^/M-_:<\$0:]X5UOQA\5YOB+X#M?@[\9L^&_!_A'X4>'+7P3:> M,O'/[/"P_LI?%*QUOPS?^%]%T#6=&\2:=%]0_P#!.ZX^(,/A+XDZ)X\'QP\2 M+HWB?3#8_&#XYVG[17@[7OB[J]]H=J_BW6]/^#'[3LESXT^#3Z1J$5EINN>& M/A;?7_[,VIZA)#XB^":83#JM#-*4I4U2O1HTL,YQH8 M;%X&6%I<_LXU5"$H0J4Z,[UER2E*/(IVZ*$\)5K*FL'4C[6552G* MQ'4'L:\O&I^PRM7=_P"R*"YK1O?ZYFRYN62<+WUY9)POHTXW3[L)9SQ_-L\8 M^9:[/"X/F7NM/J_A:?9IV:_%[P]XL^/_`,,OBM\0?"_A+XP>-?C1KU]^VE9_ MLA>!-(_:*\4Z;$-7_8C\#?M.:I\0=8L_AYX!\.^(?$_BWP_XBM/% M2Z9IJ:IH]OK^D:O_`,(I+JGAZ26S\5Z-;NOVO?CEX+TKQ+8?#3PKX&\5WVC0 M?\%3/C%XIO/BYX^\?ZC)_8?[&?[4_A_P/IW@SPH]G9ZK>:;:^/=/\<2:5H,% MW-_8/PCTRVTXZ3I/BO3?#\7A'6?U7_X57\-_[6;7QX"$#77\'M) M_M1_B0G@E?AJGCYK[[,;A_&2_#N./P(/$CNVK_\`"(1IX=^UG24%I65)\#_@ M[)_:!/PJ\`%M6TOXGZ)JA_X1+0,ZCHOQM\1V7B_XR:1>DV/^DZ;\5_%>FZ=X ME^(UG*6@\::]8VFJ^(4U"^MXIUZ7F&#G)2Q>74L5+_9VI2I4Z=ITG"G-M866 M%A*+PTL3%1=)7G53E4FU%PY7@:Z<%2Q^^*/C'6OV;KCX7CX=M\0/B#X=T M#PK^TKH'QR\06-EXRT)=,\.>+/&OBGX=Q?LZ^/K%I/#1\'Z9\2]1U[P/;P0? M#DW>LG3>\T#]KC]H?4/$7P#T[XC?!C1_@3X?^*6C-X=U;Q%X_P!!^(&OZ7J/ MQHO?&WQ%\!Z)X)AO?"ZB3X,1ZK#X6\#_`!$\$0_&_3M)A^*=I\3],^#VE>(_ M"WQ4T6XM]1^V_$WP!^"'C;2_$.A>,OA!\-O%>B>+="\&>&/%.D^)/!/AK6]- M\1>'/AQJFI:U\/-"UJRU'3KFWU+2/`FL:OJNK^#K"[CEM_#6J:G?W^CQV=W= MW$TF%I'[+'[-6@:[X$\4Z#\`/@UH?BCX6Z&/#/PS\3:3\-/!MAXA^'OA]6UR M1-'\%ZS:Z/'?^&M/CG\3^)KB.UTB>UB2Y\1Z_,RMTXN8 M_#NAZEJOAV'PY$O&>FQ>+=5\,?=?C+]G#XDS^//$'C3X=_$.?PBNO>--?UM MH8_$7C>:*/0O&WA;X6>"]/_`=DL2Z'IGQ+UOP1J5P MD5E-XC>#TS6_V,/V1/$NG)HWB+]E[]GW7M&C\2^,_&4>DZS\'OA_J>EQ>*_B M-]B/Q`\11V%]H$]JFL>.6TW39/%M^L0N/$$VFZ=<:H]S/86DL/TPHP`/0`?D M,5G6QV&YO:8#"K#59U,14K>UHTIT)1JU)3HTXX=_NG&C&24;ZZ6;=H\NM+!X MAMQQ>)=:FJ=*--0E.-6G.$5"I45=I5'*M;FG*]^9NR2;///A?X:U;P9\,?`G MA#7M0?5]<\*^!O"7AO6=9DO=4U)]8U70?#NFZ5J6J'4=;EN-:U#[?>VD]T;[ M6)Y=6NS*;C49'NI)';Y_N?\`D_3PA_V:#\1/_5S_``NK[!D_UV*P<=D MM(K$Q6B\D?8E%%%<9U'S!^V9\4O$WP8_9F^+WQ(\'7>D:3XB\-^&[1K'Q+X@ ML8M4\/\`@B'6->TKP]J?Q%U_3;FXM+74-#^&NEZM=^/=7L;RZM;.ZT[P]&_$V@6>L_#*U MU?X:^'=)BTOX@:;KWZU:GIMCK%C>Z7JMC:ZII>IV=SI^I:;?V\%YI^H6%[#) M;7EE?65TDEM=V=W;2R6]U;7$4D%S!(\,T%OAOX.T+1/$\OA^X-UX?;7]/TS2+:VU<:#<8FT.. M_2XCT>0N^FI:M))O[L%B<)AX_P"TX-8I>UJ.=&4:3ABE*%.-%5:B7MZ5/#2C M.I#V,Z4IRFXRJ4XW./%,4WA/4]2B\->'+'2G^&VAR:UJ6FZ?XATGQC=? M$9-%9_B)-&WAN\\ M&2"3QG+IC>(&,W@[4+WPC,YO]\GA:ZE\.LQT$M`U7X?V>C^#Y-.F\):7:^$;ZQGT.WLO#$VCZ1 M+X?MX[%8M&ETS3Y--%J]G`T>KQ66S6#C++Y,?K#6$KX>5E=M1F_$7X,:/\!]`^*FBOX>U7Q'X_P!`^(&OZ9J/ MQJO?&/Q&\$:1X(@OO"ZK)\'(]2A\*^!?B'X)@^-VGZ-#\5+'XH:=\(](\2>% M?BKH-S9ZCR'[,7[1G[5WCSP[^Q'X3\8S_!7Q9XF^/GP(^)/Q\^(OQ"ATKQ5X M6ET[P/\`"WQ)^S)X>;3-#\+Z+=2Z3J/Q!\62?&_7(S?I=^&O"&B2V.GZQ:Z5 M?PZ7<>'M>^ZM(_99_9M\/Z_X"\5:#^S_`/!O1/%7PMT,>&/AKXHTCX;>#-.\ M0?#[P\AUQX]'\&ZQ;:1'?^&]/CD\3^)9HK72)K6&.?Q%KUPJ";6-1>YZ3P=\ M!_@M\.]4?7/A_P#"3X<^"-8DN/'UVVI>%/!GA[0+[[1\5=7\+:_\39ENM+L+ M:9'^(6N^!O!6L^-&C=#XFU3PEX;OM8^V7&C6$D!+&9>Z,Z=/+(1E+GE^\IJ: MC)_68Q5-SQE23C^]HUFJCE^]P])*/LTU*_JF,=3FJ8V;CR1A>+<9.#C1E-2C M3BX)^UIR2<4GR3DVTVK?E7\#?VYOBKJ'P+^#OCK2O"'@[5?A[\//A7_P3ZTO MXS1^/OB#XQ\1_&_QMXB_:V\&_!VZ.L>#/$&H03IJG_"%6GQ0T"]L]<\<_P!N MZ_\`M`>/+;QEX.67X>ZEHZ^*]?\`OS]B;Q'XE\6?`6'6_%^NZMXDU_\`X7!^ MT[HLNK:W?76HW[Z5X7_:>^,?AKPY8&ZO))9S9:-X>TK3-&TJ`OY=II5A96<" MI;V\2+W47[+O[-T&O_#GQ5#\`?@Y%XF^#_ASP[X.^%'B%/AOX-&M_#;PEX/A MGM_"/AGP-JG]C_;?"^A>%(KJ[3PSI>C3V=IH`O+L:1%9BZN!)ZMX6$^&/!. ME?V'X0\/:-X7T47^LZJND:!IMGI.F+J?B/7-3\3>(=16QL(8+87VN^(]:U?7 MM7N_+^T:CK&IW^H7F MW>2I3GB)3;3AI&$.64:<&KPU#%0JQE6Q,JE.G2J4U3;FU+VDJ3A4;DH^]"G1 M5/E]]+FG+F3E9='1117EGH'XV_\`!17]IC6?V6/VI?V.OB#H/ANQ\57/B7X/ M?M<_#*XL+RVU:_-I:>)OB1^Q)JDFJ6FGZ)/;ZAJ%S8W'AJV5K."7S#837D\: M2RVZ1/Q/_#T/Q]@$^&_A\C9A4ANA((!P0>]?87QS\#:%\0OV MT/V=?#^O:?8WR+^R1^W/?Z9->V-K>RZ3JP^+W_!/_3XM6TUKI)/L>H166IZA M:1WD!BN4M[VYA618YI5;DI_^">]I)-+(GQ)\80J[LPC36=0$:!B6VHBWH2-5 MSMVQJJ9!8#YLG\V\1>$?$/.\SR?%\,&LKAPUEM%9?3IJM"6)AC>(G7KV M609G*$IN=-23Q,D[)QC'6*^4Q."SW&XK&UEO_P!%.\9?^#G4?_DVC_AWI;_]%.\9?^#G4?\`Y-K\_P#^(<>, MO_1WZ_\`X2/_`.A`Q_L;BK_HJ<3]]#_YA/F[_AZ)X^_Z%KP!_P"$#\;O_C=' M_#T3Q]_T+7@#\?`7QN'ZB)OY&OI'_AWI;_\`13O&7_@YU'_Y-H_X=Z6__13O M&7_@YU'_`.3:/^(<>,O_`$>"O_X2/_Z$`_L;BK_HJ<3]]#_YA/F__AZ)X]_Z M%KX?_P#A!_&__P"1Z/\`AZ)X^[>&?A_GM_Q0?QOZ_P#@/7TA_P`.]+?_`**= MXR_\'.H__)M'_#O2W_Z*=XR_\'.H#_V]H_XAQXR_]'?K_P#A(_\`Z$`_L;BK M_HJ<3]]#_P"83X=^+/[>WBGXO>%=+$ZWI'A72K32OB;\$OBC;W6E?#[XR27 M,NL?`KXT>`/C?H.FRK?V&\C@D3T]?\` M@J/X^89'ACP'_P"&_P#C@WZB$@U;_:>_8NG\`_#'P_K6C_%GQ]I]]J7[1?[& M7@EKJP\1:Q:3G2/B1^V;\`?A]XELI9;>^61['5_"WB77='U*S+^1J6GWUS8W ML?AMXU+" M8:4O&;$U:,JV-C1O@U92H_V?"O+3@^UZE1JIY*UK+181RGBCV]6G'B3$1G&& M'<]C2?\/1OB#_T*?@3_`,('XV?_`!%?2O\`P[TM_P#HIWC+_P`'.H__ M`";1_P`.]+?_`**=XR_\'.H__)M8+PX\9?\`H\&(_P#"2W_OH&_]C<5?]%/5 M?^*&&F_O>"3MV70^:C_P5)^(*@_\4GX'/&1M\`?&PCO_`+'7CIUZ>HIH_P"" MIOQ$[>$O!0_[D#XV_P`B%'YD?TKZ7_X=Z6__`$4[QE_X.=1_^3:/^'>EO_T4 M[QE_X.=1_P#DVJ_XAWXSI67C%B;+I]5?_P!!X?V-Q3_T4U5?X:>&B_O6";MY M'S1_P],^(W_0I>"L>O\`P@7QJ'\G8_H*3_AZ;\1O^A.\%?\`A#_&,_F'E3'Z M^^._TQ_P[TMO^BG>,C_W&=1_^3:=J?^:G>,/QUC43_.\/Z8I_\`$.O& MA_\`-X\0O7#4U_Z+OB;JGPHU/5O#NB6$WPC^* M6G_%?1(M,\!?%-HM4UC3O!_C7P9%I>J_;))G&F2V7CB_NI3:&"Z-U9VBK*86 ME5ONS_AWG:_]%.\7_P#@VU#_`.2Z^<_V@/V*[WP;K_[,%CI/Q<\?62^._P!I M[PWX,UM;+Q#J]K'J'AZ?X2?&CQ!>:=J"P7Z+>V+ZCX>TB[>PN5EM9IK*"62- MI((A75@_#CQNEB8*AXSXBG6Y,0X3^KX=\G+A,;.;=N%')I4X54[)NS=EH<^* MR?B2&'J.MQ+5G37LU.$:>'2DI5\/!>ZL"U)JS,?PUB_!_,7>1]17-_Q#OQGE[T/&.O&+46H^PHKE?)34HM5.%(S34XU%)- M:232=EIN\EXI=G/BGDE9J47AZ4O>4IQOS+`M--1C+?JUI9'RX?\`@JK\2E4D M?#_PP?8>!?BJ,\X_Z"F>G^S^G-1_\/5OB6?^:>^&?J?`GQ5/\]47^9^GI]3? M\.\[7_HIOC3_`,'>H_\`R93A_P`$];8<#XG>-/\`P=ZC_P#)E'_$.O&G_H\F M(_\`!.%_^A8?]B\3V_Y*R3\G0BX_*+P%H_+T/EC_`(>K?$L=?AWX;..FWP+\ M4"#^#:TI'TP3ZBF'_@J[\3QT^&WAXCU_X0;XFCGTP=:!].<8.>.0H_P#R91_P[UM_^BG^-/\`P=:C_P#)E'_$.?&?KXQ8B7_<.C'_ M`--\,1O\[VZ6UO+R7B>W_)5='_S"T_\`Y@/E-O\`@JY\4"O'PST%FY(5?`_Q M)!XSR"=>4\=3Q],\9\Q\!_\`!0GQ[\/?%?QN\7:9\/K6]O?CG\3M'^*?B"VU M#P-X[%MHVK:1\%?A!\$8-,T9[?689WTR71/@WH^M2F^>>Y&K:QJ<:R_9([1% M^^6_X)ZVH!+?$_QDP]#K.I\D\#I>9')']>*^>/@K^Q7/XN^)W[8NAWOQ8\?7 M-A\-/VC?!W@GPY!>>(M9G@TS2+W]C;]DSXA7UEID,M^Z6-A-XH\>>(M6>TM_ M+ADU/4M1U)HA=:AN?$B^IQQ7YG_MH?&W7/VD_BS\.OBWXMT&+P M\ND^%_\`A5VH>'I/#NMZ+I6K:4VK:UXE2[AN-?O=32YO(7U2[:]M=\1MX+.S MOX"QAD6OW<_X=XVG_13?&'_@YU3_`.3J_([_`(*(_P#!/SXL'XB>%+7PEJ7B M/4_AM%\,DA\0^,]7U2>XCMM;USQ;KL&H>&?#MK->S7ESJMUHVFZ1<:J]G;;( M+*YL6NYXO]%''BK+):]+,^/,9Q7A:];#4*F2T<,L3+%RJ57R3J4O[( MRV/LZ$H^UE4J8I4Z4U2J3IU.5/[' MQMXAT6"TA8(+3P=XF72AX@\&M'$3!8)I^I:CX4M8F6<>%+]HT:3^DC]DC]L[ MP;^U9X7EU?3_``?XO^'NO6/D0ZCH7BRP(T^\GFB9FN/"GB.*"V@\1Z;&\;(T MT^G:)JD3-%]KT6U66)Y/PM_99_X)8WUP+*]C\-)H]L8X?.UW68/,U"53@$V\ M;*8H`68_<#N&)VD*I-?OQ\"/V4_!?P3@@GT[S;K5A&GG7>&D(7G@; M5``XP!7Z7X;<(<8\,X:%/.N)\;C,M]FZ6&R7,O8YMC,->*4;9MR1K83V=1-O M#TYUZ%.FHTZOKE.A^O]!7R-_P`%`O\`DQ+]LS_LUOX]?^JO\3U],1_V$8C_`-2*X4/X%#_L'H?^F*!YMXU(3]OS]F5CT'['W[<[''/' M_"YO^">;8^H&#?B[XT^#&IP?LJ_MP7]QXF\#:#\,/$.J:A80_%O]@*UET* MYL_BKX!^(6A0Z?'H5:.#E5S"EA9?4Z?[N>'Q=:7^\8[>6'H58*VGVDW>_ M0X?;XBG4Q,:6`JXF/M]:D,1AJ27^SX1+W:M12;>K^&RM;6Y];I+;1DE(RA.< M[5/.0@Z8`QA%`]`H`[TADM>/W70$?<((!*L1T/!95..@*KC[HQ\D_P##-_QU M_P"C\_VA?_#7_L;?_0QT?\,W_'7_`*/S_:%_\-?^QM_]#'6?U'!WO_;-'T^I MYI;[OJGZC^MXVUO[)Q'_`(68&_W^T_0^LV-L6W"%`3@D^7R2``#]SKM51GT& M.E(6A)W%`3GC*L-ORE"5(4D$J2I(QE25.03GY-_X9O\`CK_T?G^T+_X:_P#8 MV_\`H8Z/^&;_`(Z_]'Y_M"_^&O\`V-O_`*&.D\!@9)_\*^&3?VEE^8G^'-$L M/$7B=-+3Q+KUEH]E:ZSXB30[::RT1-=U2"W2]UA=&L;FXLM)&HS7`TVTN+BV MLQ#!-)&VL/LZ8$<:@`@_<*;<8("A4Q@%0P'`W@/]X9KY/_X9O^.O_1^?[0O_ M`(:_]C;_`.ACH_X9O^.O_1^?[0O_`(:_]C;_`.ACIO`X)_%G&'G963G@J@*>. M*^3_`/AF_P".O_1^?[0O_AK_`-C;_P"ACH_X9O\`CK_T?G^T+_X:_P#8V_\` MH8Z/J."U_P"%?#ZVO?`9B[V]<%):];)7NVU=W&L9CEJLJQ*[6QV#C;TY:\?Q MN_.VA]8*8!MS$O[LYCX<[2!MR/D&/E^7!R-I*]"07.T$@VO&"F`-NPX&.1CY M<\=N?ER<=37R;_PS?\=?^C\_VA?_``U_[&W_`-#'1_PS?\=?^C\_VA?_``U_ M[&W_`-#'1]1P-N7^UL+RO1Q67YCRM/=``'K+$I#!.0"OW6X4\D*=N M0"<$],X`.0!CY+_X9O\`CK_T?G^T+_X:_P#8V_\`H8Z/^&;OCK_T?G^T+_X: M_P#8V_\`H8Z2P."3NLXPZ?E@I6W MBJ?X=_LG#5=(L-*^*_["]GJ&@:?I\'[.T'AZ:P\1RZSI][JM[JFD:AK5M-X8 MT:WT'4M&L+KQ%:ZY]5?\,W?'7_H_/]H7_P`-?^QM_P#0QUZ&,PF%='*^;-L/ M"V544K8/,I.26.S:TG_LLK771V>[:5TEC2Q%:%3%^PR_$5D\7[]\1A*?))83 M!72J:9]>?:HO]O\`[X-'VJ+_`&_^^#7R'_PS?\=?^C\_VA?_ M``U_[&W_`-#'1_PS?\=?^C\_VA?_``U_[&W_`-#'7#]3PG_0YH?^$.9?_,9M M]=RP M>9)QARX=2<4\*DVHMM))RNM.SSK8G$RITY2RZO"<<9A>2G[?"3]IIBG\:K)0 MUM'5/?FV3/U=^U1?[?\`WP:/M47^W_WP:^0_^&;_`(Z_]'Y_M"_^&O\`V-O_ M`*&.C_AF_P".O_1^?[0O_AK_`-C;_P"ACKE^IX3_`*'-#_PAS+_YC-/KF-_Z M%%?_`,+,%_\`+3Z\^U1?[?\`WP:/M47^W_WP:^0_^&;_`(Z_]'Y_M"_^&O\` MV-O_`*&.C_AF_P".O_1^?[0O_AK_`-C;_P"ACH^IX3_H$_Z'-#_`,(+@G@$'`((P2 M#C^$@U]C>?;_`-UO^^#7Y,^+_@7\98OVT_V?=(D_;4^/%SJUY^RW^V1J=KXK MF^'G[)ZZKI&G:1\7?V#[34/#]AIT'[.T/AV?3_$DVL:??:K>ZKH^H:U:S^%] M$@T#4]%L;GQ%::]]6_\`#-WQU_Z/S_:%_P##7_L;?_0QUW8S"89T+]AEV(K7Q;Y[XC"4^27U7!- MI$_Z'-#_PAS+_ M`.8P^N8W_H45_P#PLP7_`,M/KGS[?^ZW_?!H\^W_`+K?]\&OD;_AF_XZ_P#1 M^?[0O_AK_P!C;_Z&.C_AF[XZ_P#1^?[0O_AK_P!C;_Z&.CZGA/\`HO3H MW`SOX.5`&:^QQ/!CYE;/?Y#_`)Z5^3G[8?P(^,>E?";PC=:G^VG\>?$]M-^U M3^PCIL>FZK\/?V3;*UM[[6?VY?V=]'TS7DET']G/2;Z34?"NI7MKXHT:VFNY M-(N]:T;3K;Q%INN>'9=5T+4_JE?V;_CJ0/\`C//]H7'./^+7_L:@XR3SC]F/ M&1TR,`X!QG)/4\+AY9;@+YKAH4UB&E+1\MDTE;6+>I MBL5C(XS$I9;7J_N,%=_6<%3MIC[67MG?=]M=-=SZ[\^W_NM_WP://M_[K?\` M?!KY&_X9O^.O_1^?[0O_`(:_]C;_`.ACH_X9O^.O_1^?[0O_`(:_]C;_`.AC MKE^IX3_H*?V18KW]M+XZ:[/JO[5_A_3=,NM1^''[)L+>&[ M]O@I\=+H:_ID.E_LZ:=#=:I':VMUI<,>L+J6E16FJWMQ_9CZE%IM[8=^683" M+&TFLWH3_=8V\?J>91O%Y;FBG[WU16M!SE?O%63;2?+C<7C'AJBEE5>$7*A> M?UK!3Y?]KP6O*JR;]%KV/U>C:.,`O\P**!@$G(5,G'!QD'&?RJ3S[?\`NM_W MP:^08_V=?CK+@?\`#>?[0PPH(7_A5_[&VU5*@A1G]F1FPN[`R2<#KZR_\,W_ M`!U_Z/S_`&A?_#7_`+&W_P!#'7FT\'A7!.6<8=2;DY*."S.RDYRK%-VG]9P=.]Y3;7(ZUU9Z>>Y]<^?;_`-UO^^#1 MY]O_`'6_[X-?(W_#-_QU_P"C\_VA?_#7_L;?_0QT?\,W_'7_`*/S_:%_\-?^ MQM_]#'5_4\)_T.:'_A#F7_S&9_7,;_T**_\`X68+_P"6GUSY]O\`W6_[X-'G MV_\`=;_O@U\C?\,W_'7_`*/S_:%_\-?^QM_]#'1_PS?\=?\`H_/]H7_PU_[& MW_T,='U/"?\`0YH?^$.9?_,8?7,;_P!"BO\`^%F"_P#EI]<-+`X(52#C.2I` MXY/7V''O7Q_^S,\:?&?_`(*%^8"0W[8/@E@`,X_XU_\`[#&,XX]>F1^8S,W[ M.'QU0;O^&]/VAQCKM^&'[&P//'!_X9C!'7J".,U\L_L]_`7XR:G\6OVZ+2R_ M;1^.NBW.A_M4^$-,U;4[/X=?LG7-WXNOY?V'OV--7CU_68=2_9UO;"PU*VTS M5=-\*PVWANST31VT/PQHL]SIMQXAEUS7=9[\)A,.L'G"CFV&=-X7+?:2>#S% M2BEG=)II/#)N]548^[!M*4F_=YG$GBL3:A)Y;B%/VN(2I+$8-II81V;J>W2C MS-R5K-KEULI)GZP^?;_W6_[X-8NL:-H6O)#%JMA#>Q02++''<0+*JR+N`8+( MK*&`9@&&&VO(FX))(K?,'_#-_P`=?^C\_P!H7_PU_P"QM_\`0QT?\,W_`!U_ MZ/S_`&A?_#7_`+&W_P!#'7!]3P?_`$.*#]<#F3_/!A].3]A3]LQ5W9_X9:^/9^92.!\,/$^> MOUKZY\](_E;=GKP">H'7W_,>AK\HOVWO@%\9]$_8S_:QUC4_VUOCKXHTW2_V M;_C9?:AX9U?X;?LF6NE>(;&V^''B.:[T/4[K0/V==%UZUL-5MTDL;NZT36-* MU>VAG>?3=1L[V."XC^H3^SE\=Y"2?V]?VAR,G`;X8?L;'D\DY_X9C/7@=NG. M>*Z)X3"_4Z*6;X:WU[$7D\'F7-;ZEA]H_55L]/A=T^EKF<<3B/K%:?\`9V(5 M7ZK07L/;X1IKZU72?M?;$_Z'-#_`,($_Z'-#_PAS+_`.8P^N8W_H45_P#PLP7_`,M/KS[5%_M_]\&O-OC+.DGP MA^*JKNS_`,*V\>'E2.!X4U;_`!'0&O#/^&;_`(Z_]'Y_M"_^&O\`V-O_`*&. MN`^+'[/'QPLOA;\2[J?]NG]H"^@@^'OC:2:QG^&7['L=O>1)X8U1Y+6XDM?V M:;:Z2&95*2&VN;>;:2(YHV(=:IX3"*I2:S>C-JK1:@L'F$7+]]1TYI82,5ZR MDEIOJB*F+QCI55+*J\(NC73E];PPKZ\L:MWT5EKK?H?0?[)O_)K7[-O? M_BP7P;Y'3_DG'AJBD_9-W?\`#+7[-FYBQ_X4#\&@6(4$G_A7'AHEB%"J"Q.2 M%50#T`&`"N3$?[QB?+%8E)]TL3B+/YK6VZN=]#_=\/T_V?#Z=O\`9Z&GRV/. M/&?_`"?]^S)_V:!^W1_ZNC_@GG7V37QMXS_Y/^_9D_[-`_;H_P#5T?\`!/.O MLFKK?!@_^P.G_P"I&.(H?%B?^OZ_]1\*%%1K*C.8QDLI8-\IPI7:=I;&-Q5E M8#.2I#=",J\BIC.3G)X&>%&2?H.![9R<*&(YSH!V90Q5=[!/-/L/%WPS^*GPIO_%'P^UZ9 M[;1_B-X%LOBQX,\$W7Q`^'5_=JEK#X]\"Q>)?!ZW-S8VTNN)/J-@EQ]+$$\C MKE>OH&!;N.2/RXZ]*_"[4O\`@FI\06_8L^#'A"\UGX@>+_C?X6^'_P"SYX-^ M)G@_5?&OPE\4VD?PN\!G2-9^(GP!^$.G?%KX;>._V>;?P_<>,+#1_%L-C\2O M`/B32_BG=?#SP)X*^(WCJW\/Z-X6\4>"^O"4<)752.*Q4L+.=:E1H2]YP@N2 MI.=:JHQD^2\%3E;>52FE;WK<>)JXFDXNA15:,8U)U$W:6CIJ,8*S4G9R:3MM M+75'[?:EK%AH^GZAJVJW=O8:9I5C3R.0$MX+:*6 M=Y&X$<T@O\` M3-2M)N!+:WUG<07-O(!^\BE1A]X"OQ]^%/\`P3LTF6&QLOBK\*M'\3Z%I/[) MOBSX6_#V#X\P_!/XCZO\._&GC[XP_'/Q5>:*WA?X4^`O!WP:\/:9X6\#_$/1 M/"?AZS^%WP^TKPMX$\"-??"[P=J.H:#%J=WKGFVH_LB?M":1^SM?_#;X:?LN M>`?"M[\6O^"?B?LG>)O!&E^/OAEX2\-_"WXE^$O$_P`4];\0>-=2;P]:7&E> M*O#OQANOB=XC\8^';OPQ;-KM]XTFM(OBCIG@O_A*_$7BOPAU?4<#),Z!,K.Z\9:OX*33O$4-YHWACP]XLN-;NO"OB&W\&76G^)-1\2Z79Z?I7CB:PC M\)ZMXDT^?PK?W/B+PMINKW7B'PUI.I>%]9UW3;#3/%OARZU+\@_&O[&7C;6? M'?[9DL7P`N=1^'OQQMY]6UO5TU[]FNY^./C[Q?%\:?`'BWPU:?"_XB^*/"EY M!XN^#4'A?1/$7B3QA\"?VW]*\;^"K368?#OP(\'27/[/%WJGARSP=3_8F^+W MB+X;^)M'^)7P/\+WNF:Q^SY^R%X!M?AO\`G^!'ABSLM1^!W[1?[4GQ)A\/Q? M#3XMZ7KW[.VM6OAWP?\`$;X7R^/_`(?^(=-?X,:[KNH>-HOAE):IX<\&O!,, M#@_W;EF4>24::49^UHU8.<%&*C*\W-*"EC,7=J.#J+E MN#[4^O'O@ M!H'C+PI\$O@_X6^(6B_#_P`->./#?PN\"Z#XN\-_"C3Y])^&/A[Q'HWAS3=. MU;0_AYI=PSRZ;X)TF[MY-/\`#.GL<6>D6UK;H?+1`OL#':"QR0H)(`))P,\` M9)\K5W9K9J[U6[%HJ'ST/0N1ZJA8`C)(;"L4*J,D/M."H`+'%2( MP=0PS@^O!&#@@CL01@CJ#P0#Q4)MMKEDK=7:S]-;_@4?&?C/_D^W]G+_`+-) M_;?_`/5R_P#!/BOLZOC'QG_R?;^SE_V:3^V__P"KE_X)\5]B7L\EM9W=S%;7 M%Y+;VT\\=I:"$W5U)#$TB6UL+B6"W-Q.RB*$3SPPF1U$DT2;G7OQG\+*[;_V M30M=I*_UW-NK:2]6TENVDFUPX1VECWKIC&]$V],)A'HEJWIHEJW9+5HM45^6 M/P\_X**ZCK/P3\&_M'_$OPA\)O!7P:U/XE>'_`OQ7USPE\<=6\<:]^S+!XK\ M.SK:6O[0WAG7O@O\.KOP!\0?!'Q2O_!'PR^+W@2[G8_#P>,X_%NI:W)HV@ZD M)+.G?\%#/%MA\2/#/@#XD?`&^^'4/C;]FKP_\<-`U/5/&TUQJNC_`!`^(5U^ MT;XA^%GP$\?>'9/`>G-X2\6^)_A1^SAXO\0ZUK@U+5-.\/?$:TU#X6P6.L7C M^&-;\56LIS!N7+AU)0=>,IJM14'+#K2C4HSG1HJ57V=>E4BIP MFF/^T<&MZSB_=NI4JL7%3#=*U_XB?'%?@!HW@KX7W7C5='TFT\:_']O#*Z79>*?'$/A? M6M1TCPCX3MM>O=<\0>)+;P)J.M77A_0+U]!\'ZKK=[INC7/C>G?MI_'7Q3XH MO_@WX)^`'@#4_P!H[P1>_&B/XI^!=<^/.J:'\+]&T[X0VWP5U/3;CP1\5++X M%:_X@\6ZK\4=`_:&^%FM>%=,USX7^";/1/-\:Z?XJU?3KSPQID7B?.CEV,KQ MG.G1BH4IU56E5K4:/LJ=&?LZF(J*K*,HX>%9QHNK9I5)PO:,E,53,<)2G&$J MJYYJ#A&"=1RE4INM"FG!22J.A&=?E=OW4).]URGZ945^7OPR_P""ATOQ6^*O MPG\-:-X;^&W@WX7_`!B\$_!CQQX$\5_%?XE^-/!7Q)\=Z?\`&?X16'Q9T33/ MAUX+L_@=X@^%GB[Q-9PZHOAZ;PTOQYTW7KV]T/Q'DK#I]K_:GM7Q:^/GQ M`\*^'?VF6\-ZW\-M$\6_"."2_P#ASIWB[PWJOB(>,+;2?@MX:^)GB'3[O1-, M^(7@S4M:OK/4-:F$E_X?U"PMM%T$6[ZCIU[+OU%RIEV,HUXX:O1]C7E"$W3J M3A[BEB(X62G.+E34J6(K1:9;Q:W>6%_JD=E$E_>Z7IUQI%A=7JPXNKBRTRZU36[C3[2:7+V]G M/J^I3VT9\J6^NF7S6^3[G_D_3PA_V:#\1/\`U<_PNI8'^)B_^Q7C_P#TW0-< M1M0_[#,+_P"[1]B4445QG0>/?$KX[?"_X1>*?A1X/^(7B^Q\+Z[\;_&)^'OP MPM+[3].?&?QR_93\31?LP)XOTZWFUA?`^K?LQ_`JZ_9DOO MB+8:7+"VN/$]_IER=9-A/ZU#"9;4PU*I4QZHXB4*L9T:E2BDL1/$Q^KSL MUSK#1PD*WME)J2Q$L.HOV4Y2CYE;$9A3Q$H0PL*E#GC*%2+DI.@L-)5H-7M[ M;ZRZ!O MV;+O]J+QI\6H_P!E'4X/AYXB\#_#CP7=?L?M\%XY-;^'_AY=1^$4NJ>.OB]8 MW'CW4?`W@0>)/"6GW6K6'Q`U*]N/B!J'BB?3?+HOV%?CW=>&_A5H7B[X1>"O M'GQ,L?V?OV0?AW\._P!H7Q!XZT:^\4?L5^-O@7=WEQ\3M<\,W]_Y_C$W.K(^ MG^)O"VL?".YU34/BOXP@;P/\8+WPWX`TS1O$ZQ]0P4DG_:U.BI).?M(T5[)S M51OWI5%3DL,H.==QD^:/LU0]I*I%$?7\7",F\OJU$N=QE3=6I*4:;@HR<(P5 M2+Q#E:C>+=XU?:^S4-?VF^(7Q0\+?#'2M&UOQ9?266F:[XZ^''PYT^XM=.OM M5,GBKXL>.=`^'/@>REATZ.>6V@U/Q9XIT.SN-0F5;'3K6YDU&_GM[*"6=.^2 M?*J6>$ONV,%;`61OF1#N;(9D*,HR2X(9,HRL?QVT_P#9$^(UIJ'B*VA_9O\` MAG8?$8_M>?#7XN^+_P!JJ/Q7X.F\>?'+X;:9^WGX)_:)L=.N[I-(M_B!J$/@ M'X/Z4VB:EX<^(.J:98^"O$'@O0/`'P?T_P`<>"I;#Q!I?B,/_!/_`.--U\.O M&_A&/X*>!/!OC^3]EWXW?!;XS?%_2?'.AIX@_;K^+/Q&\ZW\7[O3/&?PR\8_%"_\`!'PM:\\+W'B'Q'J.U/+<%.=. MF\TP].4JCC.K.K0J484Y5%OJ$\26>HM&?"5U^R;\-?!4WB+X>>#OVA_A3\6 M_@3\/[?4_C]HGBFX^+$\GPFU[QW=>$M=\7>+?`6DZEXM\1W2:U]:?L,_`GXQ M_!Y?$MY\8(;9]:USX+?L=^$KO5D\2IXFO=7\9?"3X%V'@SXF7&H7[SW-]=RQ M^,([Q(=7OYYI==B8:BDTP=I7RJ8+!4Z%6NLQHUJKI1EA\/3J0C4YIRP$Y1JT M;.3G1I5ZT)I-1C4IS<9SA9O2GBL7/$0HRPKIPNO;55=TERTJ_-[&;LY1G4]B MUS0B^5M-)IJ:=XI^"/[8'PJL;:UOK+35BUWQ5\0?V+/%.G M7-]J&I,+.QT\P^`[W3S/*=HU'4-,CD,5O)/<0VO^'HO@/_HG]_\`^'$^'W_R M77R'%?BCP'PSBLLRK/N(<-EF8TLDP=2IA:V%S2K.,*V+SBK2DY8+*L?2M.FU M)?O8NS2LVGR_/2SK*LLQ6.PV-QL*-=8I5'#V.)J>Y4PF$E"7-2P]2+4DGM)[ M-/70_4VBORR_X>B^`_\`HG]__P"'$^'W_P`F4?\`#T7P'_T3^_\`_#B?#[_Y M,KY?_B./A5_T6."_$,__P#H;'_K5P__`-#*'_A-C?\`YD/U-HK\LO\`AZ+X M#_Z)_?\`_AQ/A]_\F4?\/1?`?_1/[_\`\.)\/O\`Y,H_XCCX5?\`18X+_P`( M,_\`_H;#_6KA_P#Z&4/_``FQO_S(?J;17Y9?\/1?`?\`T3^__P##B?#[_P"3 M*/\`AZ+X#_Z)_?\`_AQ/A]_\F4?\1Q\*O^BQP7_A!G__`-#8?ZUOLU/NC\?YFOQ%^/O[=G@_X MQ>!M!$:9X3.BW&D?&O]FCXJRW>H^/O!-Q;R6'P'_:2^$_QRU?28X[2],RWW MB#2/AYJ&AZ7,VZWM]5U"REO?*LEN)4]N7_@J)X#`_P"2?7XY/!^(OP^)P"<$ MXO,9(P<#.,X[5TR\=/"=9?@I@?9O\`Y)N_O?5Z MCU2TLU=.ZQ7%&0K$UYO,:?+.C@U%JABY)N$<6Y*\<-)7C[:">NC;70_4ZBOR MR_X>B^`_^B?W_P#X<3X??_)E'_#T7P'_`-$_O_\`PXGP^_\`DRN;_B./A5_T M6."_\(,__P#H;-O]:N'_`/H90_\`";&__,A^IM%?EE_P]%\!_P#1/[__`,.) M\/O_`),H_P"'HO@/_HG]_P#^'$^'W_R91_Q''PJ_Z+'!?^$&?_\`T-A_K5P_ M_P!#*'_A-C?_`)D/U-HK\LO^'HO@/_HG]_\`^'$^'W_R91_P]%\!_P#1/[\_ M7XB?#_'XXO,X^G-"\'KC07\&6_ARYNFF\2>&_$"W2^(I=_:3^`GP<73(;35/A#^U)\,O$FHZG=>)O#T/\`;D/B?X<>)_!L M5AIVD-.=4AOHKSXN:7=QPW$"&]M=*O$MG6:[L=_UV`\2N!:&`R?B6MQ)@H9% MG>,Q.3Y5F7LL?.EC`EBHREC:E/#<]3#TZ7/.,O:.G[YIC M,UR^IEM/%4\3&>'QN(PV&PM10J)5J\L5AVJ<5*G&49+V-1/GC!)Q:NNOZD6W M7_MFG_H$=7*^7_VCOVD]"_9MTOPEJ>M:#/KB^*[_`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`-A+N&B)!5LXP5.1P1GGV_SWKX^_9A_Y+1_P4-_[ M/"\%?^L`?L+U^5GP+_X+"Z_X0>T\+_M-6_ASQ]I"$01?%'X77?AFS\5Q0H@' MVGQ3\/5U*WT?79&_8?\`B'X,^*GC M7]N;XA?#_P`06OBCP=XO_:O\':KX>UZSCN8;;5+.V_81_8FT:\EBAO;:TNHI M;+6M*U;1M1M9[>&YTW6=)U32+Z"VU/3;^TM_M^">.^&.,\HSFMD>94ZU=8/* MW7R^O&>$S'#N.=X*K4]I@\1&%24*:E%2J476I\STFTG;KPF:X#,EAI82NIRY MJLITI1=.M3OA6VITYI25DTFUS13?Q:H^_:***]\]0****`"BBB@#Y#_X*!?\ MF)?MF?\`9K?QZ_\`57^)Z^N4Z'Z_T%?(W_!0+_DQ+]LS_LUOX]?^JO\`$]?7 M*=#]?Z"NB7^YT?\`L-K_`/J'ASEC_OM;_L$P_P#ZD8@?1117.=04444`%>9_ M&C_DC_Q4_P"R;^.__44U>O3*\S^-'_)'_BI_V3?QW_ZBFKU=/^+2_P"OU'_T M]1,JW\"O_P!>*_\`Z8K'%?LF_P#)K7[-G_9`O@W_`.JX\,T4?LF_\FM?LV?] MD"^#?_JN/#-%7B/]XQ'_`&$8C_U(KA0_@4/^P>A_Z8H'F_C/_D_[]F3_`+-` M_;H_]71_P3SK[(;H><<'GTXZU\;^,R!^W]^S)DX_XQ`_;G//''_"Z/\`@GGS M7V,60]64CCN/7COZT8EI4L(FTF\%"UY*/_+_`!RTNU]Y%!I3Q.J_WA=NF'PM M^I^4'BW]H+5O@I\3_P!KKX]>*-0T@_#KX7?M>_LY_L]?%B_U2#5I]0$_LX: MM^RG\(O%GA>_\*K9:C96.GZCHG[3?[59\7>*=>U/3]=TU_AO<>,M/N[6UN;# M3==\->#Z]^U9^T_\8?AO:^$]1M_A]\*_C'\*/BY^Q+X9^--GIT/CB33O#OQN M^)/_``4+^'G@KPIX75;7QQ9:Q_P@&K?!+PFWQ`\9>!;[4)M8\:>%?C)X(L%\ M6:%I5[?QZG^NH^"/P^_X3#XJ^+;S3H]8A^-&F^!K'X@^#];M-*UKP1K5]X"M M-5TK3O$<_A^^TZ9)_$&K:!=Z'X;U^[O;J[M+W1/`W@BWMM/L;G1Y[N_[)O`W M@N:XU>ZD\+^&9+K7]?T'Q7KUS+X?TDW.M^*O"\6B0>&?$^K7!M?.U+Q'X&X?#^MWKW&I:)%X?T6/3;BV32M/%MZU#-\KP\*(O*4)U4X MUHU8SAHHP48V48RKQ3Y9P5/\I+W]LK]HA5C^'E[\1_V6_AA\0?"&G_MI:WXT M^+GQ.\$>/A$/&MG^R9\3O!7@JPT[PGX'A^.GAW7/`CZ]X;\E>*KW]I'4+W]J;X9?!#X@:OXNT;QI#X]T+2]"M?A4?C9J=Q=>& M+OX&>(V\0>%_@?\`$?5;SQAX:%S,O@W].]=^$GPK\4V=MIWBCX=_#_Q)IUGX ML/CVST_7?!WAO5K&T\=&:YG/C6UM-0TZY@MO%S37EW,_B6!(]9::YN)?MHDG ME9[ES\/O`]UXUT[XCWGA3PE>_$#2M(E\/:7XZN_#&B3^-=,\/S23RW&AZ=XK MDLVUVSTBYFO+V:XTRUOH;&66\N7^SJ9I=_/+,LEE&:AE=+G<)\MI4+J3BDTY MRE&+E%.,J<'4C*4VX^SA3 M;E=5+SE4NWK^'^I?ML?&3Q[\'M/U/QEXC^`?CC3OBO\`!*^^+EMX:^$4GQ9\ M#>(/@]K?PS_:=_9\^$]SX>\>>,/"O[0`\2ZS_P`)K-\3==DABT./X2R^%?$_ MPX\4>"M5B^)FA76OM:^WZW^VG^TAX'LO&GQ+\3)\$->^&H\5?\%&/!'@3P=I M7ASQ]X<\8Z5JO[%^K?&V^\'>(_&WCV^^(GB;1-:TOQ=HOP8U+0?&.@:%\.M$ MN--O=3T[Q/H>OP1?:O"5M^@OPH_9C^#/P=\!VWP_\+^$/#]_I[:/X8T7Q'KG MB+PYX6OO%'CV#P86_P"$5NOB!JEEH.F1>++_`,/JQ31;K4[.0Z2H!TY;5R[/ MO_$3X%_#/XG_``^\8?#7Q'H-A;^'?&FA_$+1=2G\/6]MX>US3V^*>G:SIWCO M6M`UG3[>.[T7Q%XEA\0ZU-K.LVI%UJ]SJ5Y-JYOUOM02\[ZF:\.NI.G')Z53 M#RQDIJLW"E+ZI*M4DX1P]/$*%*I5INA><9RFW149N\JCGST<#F,*?VE7WY0=67-R."CHFDVE;YE_82^.OQ?\`VAO!GQ%\=_$C MQ=\)/%GAJQ^)4'A+X8:U\*O"-IX*N-2\/:9X'\):AXHU/QKH>D_M+_M.V.E: MLGC_`%SQ+XH?\`"/\`AG3O%+Z9<:7XMT/4Z^=_#G[9WQO\5_#[ MX+^*8OBW^RAX?\0_M3_$/P3X9$>&+_P=XQU*?\`9(TOQ#H7QO\`%5W8?M`- M%^T3IMY\4O&#:M\*(OV>;.STJS_9ZTV']H:ZU#0V.I+;1>%E^_?@;^SIX?\` M@G/XYUS_`(3GQO\`$WQ[\2;[0+OQK\1OB%;_``ZTWQ#K-MX1T>30?".D)X?^ M$?P_^%7PUTC2_#6ESWD%DNA>`M+U"^EO;B\US4-6O/*GC[FZ^"WPAN[+QMIU MQ\,/AK<:=\3=035?B7IL_@/PK<:?\1M3B:.2+4O'EI-IDD/B[48I(89([[7U MO[M)(HV292IW>9/&90\7C91P].>'Q-6'L*<88:$:%*%'$4O8\M24J;Y:M6%1 MSBJ4:LJ%YQC[6\.F&&QKH8:,\7.->C%*I/VM>7M)*I3G=>^K1<82ARU'4M&H MUS2Y?>_*/7?^"C?Q'\(_!CXY^.O$FL?`JW\0_#']DS]KCXG^"/$)M]?TCP'\ M6_BK^S-\=OB1\$-#U_PI8:E\0I+J\^&_Q'N?#_P\UH>!='\4Z[KVD:G\1='\ M.:=\3/$*:AH7B#6,_P"(W[8_QU\??%[]K#X,>%/%OPCT?X;_``F^&7[5%KXG MTFSTN2U^,VD6?P^^%)M/!_BCP]XZ3]I'3O$QUW5OB%JUU=:C:_\`#,6GV'AC M1O#\K6GC*\L]5\#^.?%7Z[:W$OA9XETWPWHWB/X<_#[7M(\':?=Z5X3TO6? M!GAK5-.\,:5?:(_AF^TSPY8WVFW%KH6GWWAJ27P]>66EQ6MK=:%++I,\,M@[ M6Y^>])_8H^&6F_%B3XG:EXN\?^*M,A\;_$?XG^'OA/XH_P"%?:G\./"WQ(^+ MWAWQ/X3^(WBRQOXOA_:?%KQ&OB#P[XZ\=:+!X/\`B)\5/&_P\\.Z5XJGTOPO MX/T73O#W@NT\,>C1S+(83J3>5TX5N3F@G["O14U5A-^S@ZD%3=3DUB^>%)S? ML8^R4H5.*>7YK[2DHYC*I2CRJK%5\13JN*H2IN\VY*34I<\>7E;4??O-Q!/$OCKX$?#W_@G-^U?\-?%WPYT'Q;X4O9HOB?\` M&3Q9X9E^%/B9O%7CGQYJ7C#5[Y?@?XH\+:]\0[*Y\$Q?$#PM\6;_`$9_`?A* MZT^ZU#5?VSC&U`N2V"XR>N`[`9X'0<9Q@]1P:\;\??`_X?\`Q&M-$LM9L([& MTTCQ9$O%<\>A6VE:9+K_P#PHOQK#\2/A;X9UZ\&F37\_@[PIX\MK;Q38:!8 MW.G0QZA'3E)MSBI*G*;]ZK92;LDCXV\9_P#)]O[.7_9I/[;_`/ZN M7_@GQ7U_JMK/?:9J%E:W]UI5S>65S:V^J6*6$E]IL\\+Q1:A9)JMAJNEO>6< MC+I:>9XXQ>6%Y;^9;R?('C,_\9W?LXCN?V2?VW\#N?^+R_P#!/CH. M_KQVYZRROWX?\BJA]J'_0;FW>3\MUVTL]8PGQ8Z M]M<8UKL_]DP:[K3H[/N?`EU^PG9>)/!W[36D?$SXQ^+_`(@^.?VJ_AMX0^$W MQ!^),GA3X<>#[ZS\'?#^S\9V_@V/2?"_@WPKH_AJYUK3[CXA^+[W4?$6O6NK MZOJB7NDZ+]IL_#?ACPUHVD]Q\;_V//!7QVN/CM=^(_%?BS1KWXW_``@^#?PL MBU+PW-IUCJ?PVUCX!_$3XQ?%3X7_`!5\#WLUA=&/QUX7\<_%S^WK2+6DU;P[ M-<^"O#T%YI%S87FO6.I?8>]/[R_]]#_&C25-TH.E--3CS3O.\JLUS/VFO MO5Z[=[W<]U96^(=<_83^#5WX`\/>'O"^F:5\/?BCX2TKX(VNA?M'>$/!?P_M M/C2VJ_L_'P:_PZU/Q#X@O?"E_!XMTV%/`VB:3K7A3Q';7V@:IX6:]\-00:9; MFQNK'ES^P=<65[:^,_"'[1_Q9\&_&S5)OBX/B;\;-,T#X2ZCXE^)%E\:W^'( M\4VESX8UWX?:EX%\.2>$-/\`@_\`"K0OA%?Z-X>6Y\%Z!X$TW3_$!\=S:OXI MO-<_0;7\Q_C5T\TQE*,HQQL[5'4=1.I"49JM-5:M.49.2 MEAYU4JCPTN;#\\82=%RA!Q)X+"3:?L:4;0A3CR7A)_$`>$6^)NI>&/#_B'PAX8$1JVI^,-&MXM1\2W'@.>]\ M!77UV=#T>74=-UN?2].EUK2K#4M-T[5GL[=]0L+'6Y],NM:L[*\9&GMK75;K M1M)N-0@AD6*\FTRPDG61K6$IJ;T_O+_WT/\`&C>G]Y?^^A_C7/5Q4Z\E.M7] MI->V;E*<.:4L15E7KU)R3YZE6M5G*=:I4G.=64I2J2G*4I2VI4J=+GY(QC[2 M4)22\U]Y&(:M0U7^^87JO^HKS/L6BF[T_O+_W MT/\`&C>G]Y?^^A_C7'SP_GA_X''_`.2.BZ[K[U_F9^JWD&GV%]J%S((K:PLK MF]N92DTHCM[2&2XF>(_ADN@>'[[X;_`+:?Q!^(OA>T\1ZY\)OA]^V- M\=?$3'2_"'@"S\<^#[#QQ\2?@O\`$'6SXEBT#QM\)_AS##9^*M=_=ERCJR[P M,J1N5@&&?[K`A@?0J0PZJ0<$>:Z#\'/A'X6BD@\+?#3X=^&;:;4[#6Y[;P_X M)\+Z+!/K6E:OJ'B#2]8FBTW3+:.75=,U_5M4US3-2=&O;#6-2U#4K6>*]OKN M:;MP>.R_#JJL7AJ>+E)0=&,ZD?9TY0E?GE%-OB?9*C MBY8:$5-5.3FYY\\7'W9PFN2W>S>]I1N[_E]H'Q\_:5\E?#;Q=I5A\6?%O[*'[1G@3X16_B7P3J%S\?XM?^'^K> M)?#5U;ZWX=TJ.Z\?W/PY:7XA0W>I>-TU?0==\#>#?`#]I_XL^&+C0?$NE?$' MX52>&O$&F_\`!*CP[X@^"'BW5?BCXP^)6N6O[3WP[^$/PZU*Z^$WBKQ?\9]1 MUSPC;^%YO%.J>/K;4_&OA[XQ:]\6=5\+>)-+\8^+/#VH1ZO\0(OW'OOAI\.- M2?29+_P-X,O9/#_B;5?&>@R7?A'P_=OHGC#76U%]<\5Z0USI\ITWQ+K3ZQK# M:OK]EY&KZFVK:DUY>2M>W!DJV_PE^&%KK?AOQ):_#WX>VWB+P;;R6G@[7[;P M3X:@UOPE9S:#:^%;BT\-:M'IJW^A6UQX7LK+PU/#I=Q9Q2>'K.UT8J+"WBB7 MTXYSE:HU*+RNA[.K2C3LEA8VBISK2;DKU'.4YZ54XUJ<5",)-0A"/FRRO%JM M3K?7ZDY0J*HN:K7Y>:+HI:1JJT?94G%P:<)3G*E_$;X"?'GXQ>%/`&@Z/XTTCQ+^S1=_"GXG_``Q^'5K;?M&> M*9_B5KUMXR\/>$Y_B1<6OQMOM*\%_!6X\&>*_`7B/0]+AU"PN[S5O#/.-^T1 M\1OAS\0?B/XK\5>*/"?[2/B'P%^VIX_TAQ\(M0^*G@CPEJO_``KO_@CEXO\` MC%-X-\$?#[3_`(Q_$?2=(U^_\4^%9M"U?P5XSU'XO>&;?Q%K.L^/=.\*:7\2 MX_#VL^$/VIT[X:?#K1-0\9ZSHO@?P3H^L?$65)OB!JNE>$]`L=2\=31V\MFD MOC.]M+**Z\52)9SW%JC:[-?%8+B>$9CD*56\/?"WX9^$;31+#PGX!\#^%['P MS#?#VA6GAZ\@T"Z\*Q76AV^EV%K%I%Q'X8OKSPY'<:,,JI.=4\&?"+1I;;6/A7XIT_QT-.^!GB@:A\'?'/@3XJ>+_%NN>"O@5\. M_P#@I/\`$%OB5-X*C\`^&O$&EZQ+^T3\.?$7C_X;^*/&NM_#[X/^+O%/PM3P MIXU_9'X=>*+'QQX(\(^-M*U.UUK2?&/A7PUXITO5["RU33+#4]/\0Z+9ZO:: MC8Z9K:IK&F65_;WD=W:Z=JZ+JME#,EMJ`6YC=$X9_P!G?X`2Z%J'A5_@E\'G M\*:OXFC\;:QX8?X7>!CH&K^-8E"1^,=4T=M".G7WBE(QY:Z_-:MJJ(65+I05 M">U*R\DE02@]37GXW%8"NU+"X.A@DJM:2C"5-_NJG+RPG*5:I4E.,H)N M:DHM72@N9L]'#4:]!)5:_MU[.,6Y_$JD6_?B^?12B^5Q<6[^]SO1$E%-WI_> M7_OH?XT;T_O+_P!]#_&N#GA_/#_P./\`\D=5UW7WK_,_,;]KOX/>'OCC^UC^ MS3X+\0Z1I^K/I?[,7[:OC3PR-2@%Q#I?B[2OB=^POX;L=92!W^SSRV^A^+_$ M=LL-U%-$XU`2*J3P02Q_/TG_``3M^(TCN89_A\L88A=W@OPVQ*Y)4Y_LZ/)" MD*3@EB"Q.37W5XT_Y/T_9MQU_P"&0?VYOKG_`(77_P`$\#_+GZ<]*^S]T?JG MYK7G9]PKPIFL\KQF8Y#DF.QM3)<)"MB\5@Z56O55+&9W"FIR6,HJU.G.,(KD MORI7;O&WEPP>`Q=7&5<1@L-5JK%\KJUJ;J2E&&$PD8I7K4XQC'6RC&UV[ZGX MA_\`#NKXE_\`/S\//_")\-__`"%1_P`.ZOB7_P`_/P\_\(GPW_\`(5?MYF/U M3\UHS'ZI^:UX/^HG!'_1+\.?^&ZG_P#/(T_LG*O^A=@?_"=?_-1^(?\`P[J^ M)?\`S\_#S_PB?#?_`,A4?\.ZOB7_`,_/P\_\(GPW_P#(5?MYF/U3\UHS'ZI^ M:T?ZB<$?]$OPY_X;J?\`\\@_LG*O^A=@?_"=?_-1^(?_``[J^)?_`#\_#S_P MB?#?_P`A4?\`#NKXEC_EY^'G_A$^&O\`Y"K]O,Q^J?FM&8_5/S6C_43@C_HE M^'/_``W4_P#YY!_9.5?]"[`_^$Z_^:C^=OX^_L9_%?X7>`M%\2Z?>?#>&]U/ MXW_LN?#M6F\!>&+B.;3OC-^U'\&O@WK]N8I=,D17E\.>/=86WNODEL;DQ7L$ ML<]O$X]H_P"'=GQ*;)%Q\/0`=HSX*\-YPN`"[$GG.3]W_MOD?\*8 M\%>W[8'_``3P]L?\;!/V9NOX8X/(&.U?92-%M'S)WXRH/4]CS77/@#@5Y?@J M\>$^&X3JU\RISY?^$3X;_P#D M*C_AW5\2_P#GY^'G_A$^&_\`Y"K]O,Q^J?FM&8_5/S6N3_43@C_HE^'/_#=3 M_P#GD=/]DY5_T+L#_P"$Z_\`FH_$/_AW5\2_^?GX>?\`A$^&_P#Y"H_X=U?$ MO_GY^'G_`(1/AO\`^0J_;S,?JGYK1F/U3\UH_P!1."/^B7X<_P##=3_^>0?V M3E7_`$+L#_X3K_YJ/Q#_`.'=7Q+_`.?GX>?^$3X;_P#D*C_AW7\2QS]I^'O' MIX)\-Y_](O\`&OV\S'ZI^:T9C]4_-:?^HG!'_1+\./R_LZGKY:9E?7;37736 MP?V3E/\`T+L#\J%G\FL5=/S6JW6J1\%_LA?L]^)/V>KWXBR^)%T6Y_X2^U\' M160\,^'],THK_8$OBN2Y^W'3HK;S@W]M0_9C,66/]_M(\PAOE/\`:D^"WQ%T M?]K/X`_&'PX_A5=%^)G[7?P;T+4=/U'PGX>NO$5YX=\-_"_Q-XJU6T@UF^LY M[G3]0FU+X66HL-4CN8KJRA:&*&XAA+!?VAW)_>7CIR./UKXV_:S*GQC^Q/@@ MG_ALCPX.,$Y/P&_:"QT_'%>]E_#'#=98#*JV4996RS!5,1C,)ETZ:4=3TJ/1=.T)F\8:MXBU*"7^R%>%8XK>/6XTOHE@(N)8[A M]LHE!?ZUM\#K@`QIUP`?E3U_&K>Y/[R?F*R63Y-]=JYK'`8&&:8G#K!XO,73 MC+%XO"T[TE3JS=>,/9U*<$G[*E2YJM%TJM5ZSE M"+G%4V[W4+:2BK7>ME)N1^9G[+W[+/CS]G[XB7WC?4]/\.ZU!=>"M5\++:^& M=%T#0+]+C4=8\-:F+B6[B@M#)9JFA2I+:^8`\T]L[(XM$:/"_:0_9!\?_'/X MFZ[X]TVQ\+:3;:OHVDZ8MEXBT#P_K>HI)INFBP=Y;^6"[9H'RWDQB5BD3%%\ MM&9#^J&Y/[R_F/\`&DW1_P!Y/S6N5\,<+O`PRIY)E#RFGB98R.6.AS86.+E4 ME5GB81>,_M&A45'`^WE6G3ITX MSG&4:OU:K5IJ*E2<:JC-K3EJOY6/V6?^"75YJLEG>6GA223+1O)XA\068**R&-A/:V4XQ&5QYB,Z ML58*P`PN/V^_X)Z_!]OA1XY_;BT!]:NM0DT7]IWP#I+Q[ECM=Z?L&_L3WF8X M(ML:B$WK6D0V+BVAB("ERJ_I#I^D:9HUHEKIEM:V<$2+&D5M%'$NT'@87DX! M/X?R'+LWIY1@,)A M)4\'@$\1^[J8ZO&IG&"I5%B<7.4J]>_(ZCDY0TWIQ4>9[4,#A,%+#.A3C&HY MUXRJOE=2HI82SYYM6"NV_LFBF[T_O+_WT/\:-Z?WE_P"^A_C7 M7SP_GA_X''_Y([[KNOO7^8ZBF[T_O+_WT/\`&C>G]Y?^^A_C1SP_GA_X''_Y M(+KNOO7^8ZBF[T_O+_WT/\:-Z?WE_P"^A_C1SP_GA_X''_Y(+KNOO7^9\B_\ M%`O^3$OVS/\`LUOX]?\`JK_$]?7*=#]?Z"OD7_@H"RG]A/\`;,`92?\`AEOX M]="/^B7^)_>OKA'3!&Y'Z\U MOQ.:+7UVMJO]TP_5?]!&(\R6BF[T_O+_`-]#_&C>G]Y?^^A_C7-SP_GA_P"! MQ_\`DCINNZ^]?YCJ*;O3^\O_`'T/\:-Z?WE_[Z'^-'/#^>'_`(''_P"2"Z[K M[U_F.KS/XT?\D?\`BI_V3?QW_P"HIJ]>E;T_O+_WT/\`&O-/C0RGX0?%3#*? M^+;^.^A!_P"94U>M*4HNK12E%MUJ-DI1;?[ZCLE)M_),SK->QKZK^!7ZK_GQ M6\SB_P!DW_DUK]FS_L@7P;_]5QX9HH_9-_Y-:_9L_P"R!?!O_P!5QX:_P-%: M8C3$8A/1_6,1H]'_`+QB.CLPH?P*'_8/A_\`TQ0/*OC[X'_:-7]H+X'?&WX" M>`/@[\1D\#?!S]HWX4>+=`^+7QL\8_!-+=OB]XV_9@\6>'M:T/5?"'P"^/DF MMK9Q_!#7[/5+"]TG0?L[:CID]M>7H>X@BA_X33_@HA_T:M^QC_XGQ\;/_I;U M?;;,$5F8X55+$^@`R3^`%,$@)P59?7<,8ST[\CD#(R`3@D'BM%BDH4X5,+AJ MWLH>SC.JL5S\OM*M1)NAC<-#1UI+X&^7EN[)WS^KRC*I*GB:])59J>VHW3JI-O'8JRM? M7#:7=E?_`&;3737J?%7_``FG_!1#_HU;]C'_`,3X^-G_`-+>I?\`A-?^"B/_ M`$:M^QC_`.)\?&S_`.EO5]KB4'=\K#:VT\=_4$$@C'.0?4?>#`(957J&'S*N M2/XF(4#KW8A1ZL0HR2`3ZS2O;ZA@;ZZ6Q]]+7T_M;S7WZ7UL_95KNV-Q>B3> MN'T3V=_JMM;=WZ'Q1_PFG_!1#_HU;]C'_P`3X^-G_P!+>H_X33_@HA_T:M^Q MC_XGQ\;/_I;U?:RSHTC1[9`456+,A5?FS@#/.[@DC'`P3U&22XCB0N^[:`3P MN?NC<>>@`&222``"20`30L32>V`P/3[.8+?;?-42Z=5)MX[%66[OAM/6V%=O MN/BG_A-/^"B'_1JW[&/_`(GQ\;/_`*6]1_PFG_!1#_HU;]C'_P`3X^-G_P!+ M>K[4-R@QE).20/DZD-MX!().<@C&5(PP!9`T@D!`)##.>"!GC/'!//'3MWQ@ MT+$TGM@,#M?;,-KM?]#9=4_/R*]C6V^NXNZ\\-Y?]0WFOO/B?_A-?^"B(Z?L MK?L8C_N_CXV?_2WJ/^$T_P""B'_1JW[&/_B?'QL_^EO5]J?:8\N/F.S(;&TX MQC(X8G//W<;N#QP:)I+?`8)?\` M;N8__/7^O347LJK=ECL4WVYL*_\`W7_X/D?%/_":?\%$/^C5OV,?_$^/C9_] M+>H_X33_`(*(?]&K?L8_^)\?&S_Z6]7VN)06*A7('\87Y#\H;(;.""#@'IN! M7.X8IQD7&<$\D'`R1@XR?;WH^LTKI?4,#=[*V8:Z7_Z&W;T'[&M_T&XO[\-_ M\S'YD:UH7_!1#5OCU\,_C6?VCZC'JW_"2R7$^IZ.-'B@U;U[_`(33_@HA M_P!&J_L8_P#B?'QL_P#I;M?:JW$;;P`^4.U@5*G(Y(`;!88P0PRK*0RD@@U) MO`SPW'7BJGCJ4E!2P.`_=4W332S"_)&M4?O6S9W<:E6<;[]-;-DJA42E)8W% MVD^:3YL._><8ZZX;2\5%V2MUW9\3?\)I_P`%$/\`HU;]C'_Q/CXV?_2WJ/\` MA-/^"B'_`$:M^QC_`.)\?&S_`.EO5]KO*J+N(<@#)VKDX'7CN1Z+DGHH)P*2 M2>.,9;..I(QP.Y//11U/3TS4+%T6F_J&!LKZ\N8].BOFJN_))M[)-Z#]G5O; MZ]BKV3M?#;/9_P"[;,^*?^$T_P""B'_1JW[&/_B?'QL_^EO4?\)I_P`%$/\` MHU;]C'_Q/CXV?_2WJ^V?,'HPZ'D8ZY]^V,$'D&D,JJ"QR`.IQTSP.GJ>`.YI M_6J*CS?4,#RVO>V8>7_4V;ZK2UT]&D[I/V-=?\QN+^_#?_,Q\3_\)I_P40_Z M-6_8Q_\`$^/C9_\`2WJ/^$T_X*(?]&K?L8_^)\?&S_Z6]7VLDZ.0`'!)(PRE M6&%W?,IPRC&1DJ,,-IP2`9"P'KWZ>U+ZU1O;ZC@;ZO59@MM7OFJ6BWU$Z59; MXW%Z>>&?Y85GQ+_PFO\`P41&2/V5OV,L@'&/V^/C9G/8#/\`P3>`YZVGBU_P`9^$_& M"ZR=9;_@GFES#<6LGAN2P.F?V'/!<17BW?\`:UO);_9+C].**UAC8T^?EP&` M7M*52C*\<>_SYK?\`"OH_W:L];7?E:98>I/EYL;BWR3A4BN;#JTH>TY6[ M875?O'=/1\L>SO\`$?\`PFG_``40_P"C5OV,?_$^/C9_]+>H_P"$T_X*(?\` M1JW[&/\`XGQ\;/\`Z6]7VY14?6:7_0!@?NQ__P`]BO95O^@W%_?AO_F4^(_^ M$T_X*(?]&K?L8_\`B?'QL_\`I;U'_":?\%$/^C5OV,?_`!/CXV?_`$MZOMRB MCZS2_P"@#`_=C_\`Y[![*M_T&XO[\-_\RGQ'_P`)I_P40_Z-6_8Q_P#$^/C9 M_P#2WJ/^$T_X*(?]&K?L8_\`B?'QL_\`I;U?;E%'UFE_T`8'[L?_`//8/95O M^@W%_?AO_F4^(_\`A-/^"B'_`$:M^QC_`.)\?&S_`.EO4?\`":?\%$/^C5OV M,?\`Q/CXV?\`TMZOMRBCZS2_Z`,#]V/_`/GL'LJW_0;B_OPW_P`RGQ'_`,)I M_P`%$/\`HU;]C'_Q/CXV?_2WJ/\`A-/^"B'_`$:M^QC_`.)\?&S_`.EO5]N4 M4?6:7_0!@?NQ_P#\]@]E6_Z#<7]^&_\`F4^(_P#A-/\`@HA_T:M^QC_XGQ\; M/_I;U'_":?\`!1#_`*-6_8Q_\3X^-G_TMZOMRBCZS2_Z`,#]V/\`_GL'LJW_ M`$&XO[\-_P#,I^8>MZ#_`,%$-7^/OPR^-I_9Q_8Z@'P]^#OQT^%(\-Q_MQ_& M:>/5!\9?&_[.GB\ZW)K+_P#!/:VEL)-`'P'-C#ID>CZC'JW_``DLEQ/JFC#1 MHH-7]@_X33_@HA_T:K^QC_XGQ\;/_I;M?;E%5+&0FJ:E@,!^[IJE%VQ]^15* ME1)_\*^K3JS2>]K7N]6E0JJ]L;BUS-REKAW>323>N%TT2T6G7=L^(_\`A-/^ M"B'_`$:M^QC_`.)\?&S_`.EO4?\`":?\%$/^C5OV,?\`Q/CXV?\`TMZOMRBI M^LTO^@#`_=C_`/Y[#]E6_P"@W%_?AO\`YE/B/_A-/^"B'_1JW[&/_B?'QL_^ MEO4?\)I_P40_Z-6_8Q_\3X^-G_TMZOMRBCZS2_Z`,#]V/_\`GL'LJW_0;B_O MPW_S*?$?_":?\%$/^C5OV,?_`!/CXV?_`$MZC_A-/^"B'_1JW[&/_B?'QL_^ MEO5]N44?6:7_`$`8'[L?_P#/8/95O^@W%_?AO_F4_,+XX>'_`/@HA\8_!FB^ M$3^SC^QQX?\`[&^,/[.OQ474(OVY?C1K'V@?`C]H/X8?'$Z*;27_`()Z:.(8 M_$O_``KI?#LNJ?:9IM&BU236(M+UF6PCT;4?8?\`A-/^"B`&!^RO^QGQZ_M\ M?&W!]1_RC?.1SC)&3[=:^W**T>.BZ5.B\!@'"G*K."Y^B6'FISJ+&8OGFH1D^:AM3=7D5OJUO=5:26]THWUNW\1_P#":?\`!1#_ M`*-6_8Q_\3X^-G_TMZC_`(33_@HA_P!&K?L8_P#B?'QL_P#I;U?;E%9_6:7_ M`$`8'[L?_P#/8?LJW_0;B_OPW_S*?$?_``FG_!1#_HU;]C'_`,3X^-G_`-+> MH_X33_@HA_T:M^QC_P")\?&S_P"EO5]N44?6:7_0!@?NQ_\`\]@]E6_Z#<7] M^&_^93XC_P"$T_X*(?\`1JW[&/\`XGQ\;/\`Z6]1_P`)I_P40_Z-6_8Q_P#$ M^/C9_P#2WJ^V/-4$@Y&#CM^G-'FKZ-_WR:S^NX;_`*!,M[?%C=UNO^1QNNJZ M#5&L]L;B_G]77YX57^5SXG_X33_@HA_T:M^QC_XGQ\;/_I;U>._%?P]_P4/^ M)FL_!/5F_9P_8XTC_A3_`,9-.^+*V\'[K M&M2PN6*<%-1;>,DOWE*M1E=/.+/W*]1:]6NVL5<)4K0E3J8S%RA)PZ^)AXS_X*'J-J_LK_L9[5^50W[?'QLR5'0D#_@F^ MP!]?F.#D#(YI?^$T_P""B'_1JW[&/_B?'QL_^EO5]L>8I[-^6/Y_Y].]+YB^ M_ICCKZ=>IJ%BZ#U6!P#4GHU_:#BVK)VE_:[5[K;FO=NR;T+=*M=MXW%;Z^]A MGK)MJ_\`LSMO97MHEKNW\3?\)I_P40_Z-6_8Q_\`$^/C9_\`2WJ/^$T_X*(? M]&K?L8_^)\?&S_Z6]7VR)`>Q_3^AHWCT/Z?XT?6Z&WU++_OQW_SX#V-;_H-Q M?WX9_EAFOQ/B;_A-/^"B'_1JW[&/_B?'QL_^EO4?\)I_P40_Z-6_8Q_\3X^- MG_TMZOM9YTC&Y@Y&0"57=MS@`M@\`D@9YQD$X7)$NX8!/&>.>O\`GWZ#O3^M M4KV^H8"]K_\`,?MWO_:UK+KKIU%[*MH_KN+U_P"P?\OJM_O2/B,^-/\`@H@> M/^&5OV,AGC(_;X^-@.#[_P##M[./7'->/_#+0?\`@HC\/O&O[1'BT_LX_L<: MJ?CM\8]$^*OV"3]N+XSZ?%X:&C_L_?`SX&?V)#>I_P`$]]3DUZ.X'P73Q,-5 MFL-`EAE\13Z'_9,D.BP:[KOZBC+'`!(K[7,R#.<\=?N_CSNP,>I('O1YJ;=W.W`.>,`'OG...^,_J*;Q5**3>`P M2NKKWWUW&?)8=[^:PC2^_P#S/S,_:`T3_@H?\;?@3\:/ M@T?V;?V./#W_``MGX5^/_AL-?MOVY?C-K,VB'QOX6U3PW_:\>D7'_!//0H-4 M;31J1O5TV76=)COV@6S?4]/68WL'KI\:_P#!1$G/_#*_[&>#\V#^WS\;>"W4 M8/\`P3?(!&.0I*CD*2*^UVD"@$JYW':`JY).TL.,]#C&>F2,X&2!9%8\9Q@$ M$XVD'I@@G/X5H\=#V2HO`X!4XU9U%=8]6J5*=.#LWFZ5^2DK)7ZWOHE"P]15 M)5/KN+YY4X4W[V'LHPJRFI**PUDW*HXMV=X\NBMS'Q/_`,)I_P`%$/\`HU;] MC'_Q/CXV?_2WJ/\`A-/^"B'_`$:M^QC_`.)\?&S_`.EO5]LEP/7\,?XTUY51 M2[!@HZG&<>_';U/0#DX`)&:Q5%NRP.`;[)XY_EG#*]E6W^NXO_RW_P#F4^*/ M^$T_X*(?]&K?L8_^)\?&S_Z6]1_PFG_!1#_HU;]C'_Q/CXV?_2WJ^V!(&S\K M#'7<-OH>02"#@@X(&U#Q-)7;P&!T5W_O[LN[2S9M+U71] MG8]E6U_VW%Z:?\PZU]7A4NG1O\K_`!-_PFG_``40_P"C5OV,?_$^/C9_]+>K MF?&FK_\`!1'Q3X0\5>%_^&7/V-[7_A)O#6O>'3=P?MY?&BXELQK>E7>FF[6W MF_X)SV<=P;?[3YHA:YA$FW;O7.X??_F*>><'('3G'XT@E4XX;)QQCD9&1GG` MX]^XI+&T(RBU@LOYHRA-)?79.\9PG!V>:U$TW&+LX233VMJIG0J2A*,L;BU& M<94W?ZNM)PE%K7"I_#)_.VM]'Y;\"O!>L_#CX*_"#X>^(GT^77_`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`ECMIK'0-*\1_''C7X:_MQ^+OV?O$?@OQC<_$OQMJ?CSX M-?&W0-7\-:)!\%O!6OZ?\8/$GPG^&/AKP9I&IZMXA^+/C?PWXD^#VN>*?^%Y MWNMRPZOI-I8Z[XE\-VN@^"M/\&Z+X5FTK['^)W[5U[\,_B;XC\`2?#^\\7O; MQ>&H_#2Z%J>E:5Z_J%K:6]I#X<^"]WI/AL:7;7TM]X MGUS3;35SI.AMJ7B/1>;T;]LN]F\0>*;35?A[&_AA/BVG@SP?XBTG7HI#!X`L M_P!ECP-^U!KOCWQSI]W;1WUI<6OASQ)J&G:=X>\+6OB'5-1UJ?0]'>UL],BU M;QA%Z5*GF5.%.K#`T*E+V="M3G6<9737)&%):\F[E4A#E<9*3ES.2:\ZJ$Y M34\34C->UA)TU)))U;2]JDN6+-;\.O##;ZWX(T#QS\,$^#UQ MJ/ARPTT>(M%L+RRAT/6K'XHZ;X_\2WN[I?AC]H'Q;\(OC'\/?BG9^/I;'Q!J MGC[0H/&WA[Q5X+T'XSZOX3\3^&]#OM$UWP#X0.J>-OA9X-K7X?:?OH*>!?%7C'4=<\76]E-X/L/%_ MPB\7_#+1_$/B+QMXO^#&F_$^OHW[>.C^)7\!V'A[X3^+M3U[XK>&OAG\0/AS MI;Z]X0LK?4OAO\8OA?\`M!?%?X?^)?$.K7.I"W\/:E>Z%^S3\0M.UOPY;PZY M+HNL7OA2.'4M5T[4]5U'01TLQJQBJ.6T8S5--3I4E)WPM2*J5HU'5;E*#ER5 MI/W>><5*$G"/*H?4U*4GCZ]1)N=2,ZE2,(QK1:A345&/+'2,X:#(K[PCI?PL\,WDOPU\&^--2^$>C?"_X=W4OPQ\,>-/VW=1U M.".SC\3>._%7A*/4M-\1_L\ZYJO@_P`->+M;M_!>N^-=8_X5IJ&C:@/',.C8 MNM6'[T2\TWXHS_%7PM?W$/V_2K^XL-3U&]G7PQJ?PNM-#^O[CXZ>(?'& MO?`GPW$+?0M._X79\&?&7Q_L?$7C_2-3U&&R\%>$Y?@W:6OAEO#6A^(]"N$ M\2^(+GXV:!-<:NOB&YTWPK:Z)J2S:3K\^IZ<(^-O/VT](2_T;3].^&?BO4I/ M'6O7FB_"Z1=:\+6T7B^+1/CKX=_9\\4:UJ[2ZF6\'Z7H'C+Q?X7\0-%>IJ6N M:GX%U@7VG:+-XQT[5_`M@X2QG.[9=AJE2'M%*E.+E.BU+$4Y2FN=/G4L-B)6 MG.?+*C*5HV7,5:.&M%2S#$TDY4WS*3C3K.]*T8M1:Y7*<(M)1O[7E;E=V\J^ M,'PB_:)G_:9\?^/_`(9Z=K9$?&#P5\,/V>?%>K0^.-'T:S$_#N_'C/6/%O MQL\/:;=:ZNH+XW^#-Q)J&C^&=+TS1[;4?$FH_%QK\RW^G^%YYM+\T\"_#K]N M?P+\-_"OA;PWJ>L^#W^'O[-7@/P;X,$6UM\/O$VG7&KZ'^S5;>'-7\+:MXX M\2_%>XT[3_BMH_Q[B;Q#IGBS4_AIXR\/ZKI6D>$=+N_%DWA#Q#\19-%^G-+_ M`&T])U;6M&\-P?#7Q+;:]XW\5^,O!WPPL[_6O#44'C'5?AY\6O$7P@\;7FHW M]KJ-]!X/T;1]2\.S>+[.34EN]=U[P3=;M)\/3^-K&^\#Q/T/]M+1_$F@^*?$ MFE>!9M)TWPK9>';&YG\>^.O`_@N'4?B'KUC<7UQ\--*GGU74H[W6_#SZ5K>F MZEJMF;S1-4U.UTUO"5UXDT.^U37_``]E>3YG0YHI7DYQ=JBE-1R8#GJ3688BG4K.M5475<.1SA[:MR)J\8PBHUFI- MN$7!J$*!\XZ-\,OVC/"_B/Q'XG\,>"?'EGI6N^/?B'?ZK>ZGK7P4NOC/>?# MGQ)\7/V4S<:+I'C*VUYY[#5=6^%O@WXGV\*/XAL_$,FE^';.]\1ZLWQFB\-^ M)[CI_B#X<_:?^('Q!L/#L/P_\>P?"?3Y/A3J=W=>-/B7\)];G\2:OX"^/7[' M'Q`T/Q$WAW3+RRF\+:YX9\,:5^T1#XF@T>]U=3\,7=S=3ZU_'_B?4],U274[.;Q7?W7@C M]I+P1J6C:/8Z;9/=:QI/BG1+N[L8K+3-8U?.4\%?`MQXL^+OB'2M2O_`-D3XLW)-?LK'PU?^&O%-A\2_##:UK^JVMGK>G> M!N6TGPK^V3::IX=NO^$J^(VJ:)H]S\.K^TL=3C^''AB=K74?VG=)/Q#\/>+] M,G^(7Q.U;Q'-X:_9SN_$ECINLW7CB=]5T.XL+WRY/B[H^C:Q8?2OQ/\`VD=& M^%VM?$VPU+PKKFKZ1\%/@G#\>?BGK>F7FAPOHW@W58OBS_PC=KH.EZIJ&GR> M(=:UB^^"_C*PN(KFZT'3=),V@7DVIW-I>ZD^C?/?C3]KSQE8_$C3O`6D>#]$ MT#6]#\=Z+\/_`(FZ+KXO?$K:=X@UCXU?L$Z%:3>%/$.A:MHT&I:7J/P8_;!F MUU9I](6XLO&L6F6US:3VGA_5]/\`$>'/!7@W14CU,:E)X<^(]WX@\4V?Q6\?S>/X_ M$NO:O\9]'NK#PKX]^&X_:*?3_$?@VU^+.IV6H>&;VZ^(4/AO6DN M_#W@>PO4^(LVBC5X/!U[X?M++X?P>*+3X:_9-0C\-V\GG6N_MS7%UXK\-Z)\ M//!FD>+[6'QQKVC^+K?2?%WA'Q%'J_@\?LY_$KXY>%=9\)^,=.\46OA6RUFZ MG^'SZ#J^G3#Q+8Q:C)':VM^_A[4%\?:5U^H?MW>#HM)L_$VB^`/&7B/POXHU M'5?#_P`/=2LKGPWIU]XT\5:%XJ\!^$-7T)]'UW6-,G\*(FJ^/2FFZOXEN+.R MO!X,\6_VDNAK>>`9/'&N(HYE4G1J/+:,54K<\8QI1IRJ M"OVJ_&>K0Z9K.C>-=5T-/B;H.M^(;;Q%XB^%1$ZCX.\(_M'?`/QQ M$Y_"FG:-K-O=67CCPG\-/#OC:\^),HM-+TC5?%">.["WG\6PO\`"![7Q[XB M_"G]KW4_@WJGP*\%_"_Q'%H&M_!']H_P-XGG'Q(^%\_A77&^)'PD_:13PIX7 MB$7U[!'H^NI\5=1^#BCQ8-9N9?[/U^2WO)],\'V_BLVGU7\3?VR;WPMXAE^ M'_A?P=X5\0>/XO$WP?TL6'_"Q=+U314M?%_[1?PG^`7Q$T_6;SPY9ZC?>&?$ M?AC4?BGI-WX']6U9M"^ M(VB>"?%?B#3M.TW0+/P[%\5?VO/B[^R1\%ELO#\_B[Q1?^(?M?CWX6W=KXOU M1-3T&"-7'TH49K`X1P35:E&46ZB?N25.< MUK**:4G"(2IX2=2KRXW$W@N6IOR+EJ34HJ7*TN646I1@WRI)NT7KY)J^G?MJ MN/%,'AS_`(6=9Z0;GXE/\$TU_P`2_!U_$^B>,QX7^`L7P[U/X^7&GZY<6>N_ M#@_$E/VB]4O-$$7^O11?#?6-'LW\*MJ>G?#O3_#W2ZO:_MOPYM-)T;XD M>(=8UCX]:KXF\<>+;SXE_#/3=(\%?"@?M/\`A_2XO"]WX*CM;*T\0Z'?_LK2 MZZ=&.FW1UG29]&?5[J/4/C9J*:S+]'_L\_M%Z=^T#I,6IVW@_P`0>")K[X=? M";XM:3IFO7V@ZC=77@'XTZ'JVL>"[Z[F\/ZAJ-E8ZVDGA[Q!INN:()[N/3[C M3XI[74]3M+^"9/I`#&<$\G/;K^5<=3%5:4W"K@,-"I"?-)-+FG*49WE-Q5M7 M-SDEI.I%3:C;E-XX2-:"G3QF)G3G%Q3C47)925^5.UFG%Q3U:BW%7OS/\F_A MU\*_VC?`.B^"]/3PSX[33=$\*?#;P/\`$?6+/Q1\.K_XO^(=#T;XG?'&Y\7Z M?X*^(&M^(KCQ`^ARQ:K\*]?T^.]\2Z"MI\/M2\52^#[/PW\4KNYTL^I_"'0O MVR;?Q?X'UWXIZSXJN["#QEX0T?Q3I+ZS\,)/#S_#*;]F+Q#/XCUO4M.\.1HU MQXRD_:`M/!EMXEO-!G>*'Q%;ZN?AY86/PKU77Y=8_1`H"X_[Y M!J*F/J34_P#9L)>HI1GS4[NTG)OEDXMQ=Y.-XI>ZHI6Y;RVIX&-*--1KXINF MDHWJ))6A&'O+:?P\WO7]]N6[LGT445Q'<%%%%`!1110`4444`%%%%`!1110` M4444`%%%%`!1110`4444`%%%%`!1110`4444`%(3@$]<`G'TI:*`/YROBG\5 M/VSO"?QC^.EOX@\2^/=`\&'XS_$9?A4VJ?%?4OATDWP_M_$NH0Z*;+3+BSGL M[G0DC0CP[?VPMVNM'%NS1W5N+6_FXK_AH3]I?M\1_$W_`(DO(?U_L_FOZ%?' M'P=\`?$6ZCNO%WAZTU::!&CADN85DV)O+`*2&(YPP'`R,CC`KA/^&4O@=W\# M:3_X#)_\;K$S#P2JYAF&.S!^(?'.&ECL7B,4\-AE*M.4Y0IXBLZ<5**?VF;U/#4WB1=/N#HT>O/96UK>+I3ZA]G2[\BZL]\ M3-$^HZ6'&I6OT5^SQ\?OCY\5_P!@[]F'_AI.Z^,=CJNAZW\(/#W[;GB?P#-X MOMOBVGAI?`OBU?%&K7M_$C)XUT71+OXZVWPTL?B?XA^&]Q`^C_"/4O%NN/J MUCX$CUO7K?\`7+_AE+X'?]"-I/K_`,>R]?7_`%=>H^"/AIX0^'MO-:^$])M] M(@G8&2.VC"*Q&[K@+G);/(/05^C^'O!+X"K8^I+B#/.)5CG0FO[>QF*Q<\+. MBI0:PE?$9CFGL5*$E-I4)1E4C%-Q6IZ>`R:6!HXND\QQN*>+C&*J8FT:E:O'EFHN,E":DX2:7*V?F-8?'WXA>'?BA\,OAQ\#+[QM<_"2?5O@QI7P MV\$?$3X2?M#>/O%7QJ^%/CWQOJFG?&SXOW7[1WQ1U674?"%K\#M!76/$7AG3 M/&Z7;W>@>"-&2\E\2>'OCQ\%9])H_"CXV_MSSZM\(-;^)/B3PEK7ASQ-X=_9 M!\5^-/"V@_LY^)?!]_;7/[3]EX]T3QQX6/B2\^)'B1M%M?@9J/A+P]XMEU&X MT1[^2XUW5M+\9+::)>:)#HO[![#TW>YXZGU///XU'+`LT;1.Z37-1O9/%?AK1/%.A_!"YTWQ4LT(U#4?C!HEM!JUU<:GX/L[+T'X??'O] MKSQ6WP%^(/BSQW;7NFR?$+X[>$[7PQ\.OAG\2;/PY\:KF/X3^`_%OP[\"_$# M5O'GP\^'*?#WQ-?>-;;XD^$=`\1V_AR+PSHBV6G:1J>N7?Q&L/$]@_[.^&O# M&@^#O#VA>$O"VDZ=X>\,>%]%TKPWX;\/Z-96^FZ/H/A_0[-&T72=.M$BM M+#3-+T^UM[*QLK:*.WMK6&*&&-$10-S9GJQ/3VZ>_OSD'@D]*VEF=!*LJ658 M2,'.6UW.,WF.)]VFDX*35 M-SYH6G=MUI2C%3M&/-7\,>$YO&NH?$30C MX[\"?LR_M*?$V_TWQ%#\'/#FOZ!\!=<^%0\*?#+QCX?\2>(O'^N^*=(TS7=- M&H:UIUCX6L_@Y>ZI!\;-13Q)=?M'\$8KJ'X-_"2.]BNX;R/X8>`8[J&_+F^A MN4\*:0D\-Z9`)#=QRJZW!FB,C!WL<8'X#)Q^OZ#.:?SGKQCI[^ MM^%?[1DADLIK:ZBL8]$.I'6IH[B%8M%.H/-(D0 M9A\2?L">._C;KGQR\1^'/BGXFUC4TT_X4Z_>76CZA\8=;\7=I?7-L\QB=O*FN M[&SG=00Q>VC(8#<&_/,VX->;\69%Q14SS.,''($_9Y/@J\J.6YDFJ_,LPITL M92=>[KJRK86JDJ,$JD%9//$Y<\1F.7Y@L5B*:P+GS86,W&AB%-35ZD8R7,X\ MZ:4TU>*?16_*C]JCXI?�/VMK[PYX8\;ZQI7AB+5OA@%T>U^.FI>$X5@O\` M2O#\FHK%X*M]/FM]EY++.98C.R:@7:9U!OF*?5?_``4-\8>.?!?PN\!:CX$\ M0WGAS4KKXDVUA>7-I\1KOX9M=:>?"?BJ[-I+K%G;73WT;W5I:2-I9C3[GVT3 M`V6R3Z:US]G_`.&WB7Q`?%7B'1(M9\1E["0ZQJ"":],FEB%;!C($4$VJ6\*P MDJ67R_O$$K6WXL^$GA;QYI]MI/C5;OQ1IUI=KJ%K9ZO(L\$&H);7%I'?1HD, M82XC@NKB-&7";)I$*&-MM>=/P\7U/CC!KB//.7C;%5<5*M&M5C5R*4U!0I9/ M.GFE.MAJ=.5.,E[*IA.;9QNY(P>3+V6;4ECL9S9K6=7VDJ]:2P>B2AAE[5NE M&]Y6IJFE>UM#Q7]C[Q!XI\3?LN^$=;\5ZQ?:QXDO$^(HN=5N?%]QXQO)/L7C MCQ996`'BNYAMY[XV]G;00Q,8A_9BPIIJM(+`2/\`SX:K^TQ^W5X4^-W[)?B3 MPIX[N]?^#6G_`!9:3]HK1(_CMJ_Q`\2:QX9OO!7B.S\+V_\`8FHG3K=_!<'C M"XLKOQ9=:;I^K:W)=P>&Y2FG>%K+Q6NH_P!0WA_X:Z+X4T2W\.>&KB_T30;/ M[9]ETG3Y(X;*`ZA=W%_>E8?LY!-U>W=SS`0*Y0G:H&!N+'&1NYKIJ\!TZE;@JNL]S=U."Z*HP=6M5JK/ M']7IT)5,W4\PI>VJ3E2A6525'%SISO*"]I9/2651G+*9RQ.)4LKA&+4:M3EQ M3C3C"^(_>Q=2\H^T?.JCU:W>OY2^/O`W[0OQ/O/V[?C9IVL>,/#?A#2/!WQ7 MM=&T[3_BW\<_$NJ?%&SUK_@G[\--(TKX7>$OV>;VSA^#'@[PKH7Q6\2S_%'3 M?BAX&O/$7Q'UCXB^&KCPE;6.E6FM^-;_`%GTF\_:P_:YUCXS?'WX?^$=-@TS M1M*^(W@CP1\.M7\4?`GXAW'_``@?F?M@?#3X`^(]3U_28KG1=#\9:-KGPN\: M:U\7M%.E?%W5M4U[P7IWA[XJSV_P?\,>*;7P3I?[&:9I=MI-A:Z=8H+>TLX8 MX((4Y6..-=JJN>@[D#`SSBM#;TY/``]CC_)R/?ZY_4UFD)*2K9;@ZMHQCAXN M.F'<)4I*?O)JM)NFT_:\WN5)0LHZ%3RZ7,I4L56IJ4YNJE*3=2$Z=2GR*3DI M4U'GY[TVFYQB[WU/R0TSXY?MGR>(](L+G5=!;1/AYXI\!^'/'DC?`?Q&MW\7 M[*]_;W^)W[+>O>(-/U./QE':>`TN/@7X6T?XOWL.A:?X@M+/7M1T+Q=9SZ1\ M-TN_#?B[R_P?^V%^V-JNG>.;[XBCP?\`"_0X/C#X)$Z_KND?!?XV_$?Q1^S M9HVI3?&-M5L?%?@J3P1X3TWQG!J^H^#?A+\/=-\2:)XE\90Z+K7Q(U?XJ:G> MWOPXO_!=E8_M\%/'S$X.>WIC_/;GI04);.X_3^GM^&/?-3''X=0Y7EF"%/&LVDZYX2C M73].O=3UW4/MKVW"?MY>+8[3X(?#;1?B3J/CWX8_&?Q_-J&B^$O%'P1^)G[0 MD/P^^#'CHZ!]MU[XJ>*/%OPRTOX?7OCWPM\+[>(ZIX/\,>/O!5LGQ+\32:1X M37PEI=AKGB76_#_Z?;.,;CCW&3QTYS_+'Y4NPXP&(Z\CKT`^G&/3'M6$<6EC M7B_J]&/^TSQ,8PO&3HJ-22BX2HTG5BH05)1E&FX2CR2<37ZI+ZJ\.JU5 MR^KPH*=:U9/EC1BY\LFDYOV+]Z4E)2J.:E&237XX:7XG\1W'[3%]?:AXQ_:+ MT3QS;?&3]H2;XU1B^^,!^$/AO]BFP^`_CVX^#GC#P=X?U2ROO@=:WA\6'X!Z MQX?USP5HES\2K_XCW7Q7TN4ZFFF_%32['P?X@>,;[Q/^RC\'_&'@CXN?%S6_ M%'PK\7?M.V7A7X8>)/#G[=/BGQ#^T;JVF^.9]6^&?PQO_B!\(?BS\*OB)I?Q M`UWPB_A'2?AWXN^*%_\`%K1KK1_%VO\`B,?#WQV_A36;C2?Z!C&3C+L<'/4C M^1'\J`F,?,QQU)).?S/\\CT%=,,U<%%+"QNG35W4HSBXQHXJE44H2P$6U4CB M/9Q49QE3252,_:PA4ASK+7*W-7?)>?-3Y*T6^:I1JPM*.-J*$T(MN2DIIN$ MHNFYQG%9R236UO--";>66W@DEA:2*8Q2/&'DB,T!,$IC=BADA)BD(WQDHRFB MK-%>2M;Z.8_#-QX/\36'C/13XD\) MZGH6J:5XD\.?$QJ/C5=?T+5+233]6T:;PEI.EZUJ'B.VU*QNIK.[T:VTG4' MO[6:>%K2:(R+6!\-OB%X,^*?AC3_`!AX#NM;N_#FI")])U+5?"OC#P@FJ6DM MG:WMO?:79^,="T"]U+1Y[6[A>TU6RM;C2II1`?@_\`#CX60>-M2BN?`/ASPYH3 M^+/#MEINB7NL?\(_;Q6[?Z!K-IXOM]/T_541X[VT$U[=I$P%OJ,+@NVEH.GJ MW[2-1."YI64)P<:LN6*;;LH1=OBC[O16SG?G24%).G*[6DTXRC*"3>EG*[L] MI)/UX#XI?$+]E_P5XK\3M\4?#4:^*/#'@CQ%\0_$.O7OP*\>^*%A\!>"_!.L M67B7Q)%XOT[X?:QI>K:3H7@SQ[K_`(7U"?3-8OF@3QEJ_@8C^T=?O-#N_3-) M\*?`;2M3TGQ%H6@_#"PU?6-5BCT+7-*TWPM:7^K:_P"'_"T_P]5-%U&SACGU M'6]'\#Z7/X(D339IK^Q$Z8OAR41Z381VOV- M_P!F;XW_`+.T@NO#K:\EBWQB?PNR>+9H/[9TJ'4H/#R>'G2?PRRVO]N+=JCZ M[IB0,)O+=;_8=TW5OB[)\23XITZ7P^_CN3Q?;_#MK'QWH6@:)#'J/[/_`(CL M/[#'@+XG^#-.&MP>,O@6GBR]N]=T37M!U;5]:TNYOO#;3>'=2E\7=4'@Y4(< MV,Q-"JJ4)RI6J2ISE"%2U"$')*,HSC3:OIRW3?.XLY*L\7&LE#"T*U%UY1;Y MHTY04JD&Z[NFY1<9U7)6O[1$?!.D7UAH'C3_A7WBV M:2_U?6O#NCW5AX(E;X=:]XJT.VUK7KW0]/.D^-/^$1L;WSO'NG:3K?->+_V= M]8\2^/\`7/$5GXWTO3/!_C'QQ\!?B+XM\,3>%KB^U]O$OP`\3Z-XKT"/PWXJ MB\2Z?IVE:3XBO/"?@VQUNUU/PEKMU;6&EZW_`&=>I<^(+*7PWX#X>_X)T>%; M#PW\-/!&O>+-)U;P5X/^"_PK^#OC+0=)\!1^'E^($7@;X#_M5_`WQ;XE,\/B M:^CT#5?'UG^TS#KTTDEKK]YI+>!AIEQJ.M/XAAU/P[5..'Y*;GF&*BU&/,HP MDI.]&/.FE.*YO:NI9:)KE';;DN9RTY8RE[/EDX-!?!VM:/X9N;;P_;:#H%IIU M[8>$_#U[;/%IEEI/A>^LK+4[/1[.&TL-"N[>&]BAL)HU.,=#_9RT*[O==T_P MG\.9M:UWQ1X M\'1V7CG7W\+^-_"MCJ7Q-@\2_&[Q1#\3O#?A/PK\8=.\.Z>TS?&V]\*W/A?Q MM;?$:W3P)X,\)>&+;58[*VN!+V*_L3-:ZQX1N-`\;^'?"?ASPWX;_9XT;5O# M&@>`;M+#Q7??L[?%+X*_$/PIJUQ977C2;0O#,]MIOPL\0^$-.?P5H7AV:33/ M'.D/XQE\;+\+?!=O2A2PBE%1S3$RY>;F_=RC&[3E)-PGSR4ZDII.:NY2&?'7C#7?$WB/Q=>:?X-UN_\`%?B#Q!\7_$_Q$TY-?U2VT;3Y-1G\ M/?$[7]6;P$M_"=2TV^MK.XTVYN]8$FI77:?$'1_V6/A[X)\43^/_``W$M$\ M&^!_"%C\2/$FD7WA7P_+'I/@[X8:.VB:'XD'A2QTRXU&ZT_PGHMA'X9\-/I^ MDW4L5HD'AC1(ICEZK\./`MM\0]4^)LUGX>T M_2-,\=+X.\?/X_\`V4_"_B;1;KQ'JFHS>(OAGX[^(7C;XEZ/XHTJQ3P__P`) M3X3EOVM?#%]JV@:/<;_QC_8DO_BKK?Q8NS\2-)T/2?B3JGQ"\466/`DE_P"* M-&\2_$#]DJ[_`&2I=(U3Q$/%EE%XA^&NDZ+>_P#"PX_"$>D:-J=[XPT[0HO^ M$GLM/TA%N=:OL77IU)YGBI4IJ-:=N:56$HU53=->\XNHZ-*$HJFDK."7+*$@ MBJLJ$HQP5&-2/[J"UE"452$;KX=6 M;_##3+)_B3IOAJQ\`PZ%^SMXPU:QU:VL_AGXK\,^&]"6;PW\.]2TG3;_`$+X M-2>--`B\/ZM-9:EH'PNDURPN;*R\(2W"'T33_AG^S?:Z3J>C:9X%^#BZ';Z/ MX_\`"&LZ?;:!X/EL(]`UAO#-A\4O"^K11VK1?V1J'_",>#+#Q[HU\6M)H_#W MABS\00&/2M)B@Z/QO\-!XN\4_!;Q);ZI'I$7PC\>:WXV.GIIWVAM%_!^E_$.R\:?&3Q18 MS^#M?T+P_.GQ*$^$8O"-KXJU?3_`(<:O87>@CX;:;I^I94_83C%RQ>(I3M) MR3E4JWE[2LX-ZQLO9\FRE)5)W^"#M;C6BY'/@9XKUE?$OBC1_AEXB\06K7OPO77M;LO"^KZK%+J\= MYI][\.Y;_4(KB=KF_AUO4[*;PC<2O<7*:UJ-N^G2?VM>I<\MK_AO]E_X6Z'= MZGXA\._"#P=HWPX\.:S\2;D7/AWPM:OX4\,Z#KWACQUKGC2*P6P>^M+"R\6_ M#_P/XDN]8M;;GQ9X+\'WJS-KFA:(UO\`-<'[#_Q!;Q%>^,=5^/&BWWBV;Q7\ M+/$.E>(K'X1P^'IO#L/PZB^(&AZR-.\/:)XWL_`VIWGCKP#X^N/`VJV_BGPG MX@\/V>F:?IUZ^BZIJVC^&[[0NO\`CW^Q]XK^/'C34=8O_C%IWAOP3=>&_'V@ MV?@ZQ^%^D7>IV5S\0_@#\2_@=K5]/XS@UO2-5UB"&;X@67C"#3=9MKZU,OAB MST*,6BSVNK:2^*? MAS\`;+P'XQ\4>#]!\+O)X`\'WWAOQ!XF\5:;=>"O!]OIT5EHEW97<5UX:UK5 M=`M;I(SH^G>";O6+6ZGLO"D&H^1ZO?\`PW^`<&J>(/%>I>"/A5;ZS>02:AXH M\17_`(=\)PZA<0^%[WPOK<]_K>KW5K]I`T#4?"7@K5KR\NIU;3;OPQX3O[F2 M&;0]$EM/&OCQ^RC>_M$:#X&\+^-/BAJ7A7P[X8\`?$GP]J^G?#/PKX=TJ74? M''Q%^'Z?"Y/'F@7GC6W\?KX6B\)>"/$'Q3TG0=&M[.^UD2?$".\7QE:R^'`N ML^:77[$GC'7]4U+4O%WQ9\'>(DU+0O&[7$%I\-_&7A.]E^(/Q&\6?LR^/_$/ MCBV\0>%/C5I6NZ!'HWCC]GN\\0>!-)\/7EC?^'9?%7AZ'4?$7B#_`(0*YF\: MVO83I*I/,,3"O&E.$W/EYHI2E5U3TMI7['WB/Q7XXTJ+P=$_$?BZ?Q M0G@_XG26/P_TK7KZP\0:AX=TKX^Q/\0]9L-`NX]!T^_L]"\/>/H?%?BB^T_0 MI_&=EX>\K63X];2;5_0/^$"^`.ZW^()\(_"G?X:O/$6J6WC9="$B/0;^7Q3 MKWB/Q3JB>(OL@BTZ]7QMJGBC7-;OFNXIH?%>H:_J=Y*NMWFISR_(WB_]@;Q+ MXU\`^-O!6O\`QIT2_O?'"76H:OXN?X0:;I^H7GBG6?V"?$7[#WB+5;K0M`\7 MZ+X9@TF^.IZ9\5]/\.:%INAV.CS1Z]X"M'_LS5].U[0?9M;_`&6GETSQO8>& M/$?A?0H-?_:#^&'Q\\-:'=>`XK_P3H$_PV\'?"#PO%X.U;PI9:_I*:YIU]J/ MPNN?&&G:KI]_X;N/#WBO6M%U>VLKRZ\)!]?F?U;EC[/'U9-I_&-C#X>\*VGQ/ MOM;EEM-3BU:"S^#.N:_X:^)EY9^&7L!XFU>U\+ZWX7UNQGGT?2+Z+4C;0W&C M/J-KJ&FSW?R9XB_8>U+Q++XE6;XB^%]'MM9U#QMXAL9_#_PN?3];AUSX@>`? M!G@/6-)UG56\;W":Q\-]#L_"5N_A#P7'9Z?>:99:'\+-*OO$VI1?"^&?Q-E^ M./V%/&/C6ZM+)_CAI6G>$+'6_CYXGM]!7X36%QJD/B'XZ6O[8&F7=VOBH>+; M77'M-#T?]J;3+./3KB>:QN?^%G M<^\K;QWX/N]+TG6H/$^A-I>NZC#HVC7LNI6MM'J6MSR301:%:K<2Q22:\;BV MN;5]#"#5HKNUN;26S2YMYHDF;QKX12\73G\3:"-1?5(-#2Q_M:Q^UMK5U%// M;Z0+?SO-.J3V]I=7,5@$-T]M;3W`B\F)W7\[]4_X)]:SJNE^)[%_B=X*TMO& MG@/XC?"C6=+\/_!^72?!OA_P/\1?A/\`L^?"6;5?A_X83X@W`\,_$CPMH_[/ M>C7GA;Q++J&HZ%8Q>)]6T:3PI+9Z;IT[=MXL_8O\1:MHNA^&O"OQ6\/>#]&3 MXW_$_P"-GC*.'X1:-J6I^,-<\<_M6>%?VF?#07Q`_B"TU[0K_P`'6_AV[\"W M>IZ?J1_X2JYU+2O&=Y:V$O@[0_#ISE2P'.HK&RC&4X\LI4)-ZN67"0ND>6SNVCZH\,?'/X4 M>-+.74_"WC73-;T.VLO%>H7GBBQAU&3P?86_@?Q"WA?Q5'J7C![)/#&FWVD: MRLD1>*/#D][8:;#K^C3:CJMG)J&EZ?%J M5FU]J5A#!;W,M[I]H)S<7EK%;7EI<27%O%+"D%U;RLXCFC9OAJ?]BC64N-`U M#3_B-X82Z\&^+?&/BKPSI]W\,9Y=`O%\0?M-Z)^TEHNF>*]-A\<1'4ET"^TJ M30DOM+ETEGUV'P[X\L+33)_#Q\-ZG/\`#O\`8=@^'_C7PKXWA\`_$A,'@%-'E6/PII_[2$&H^%O#U['XFO;GPWX,:?]H[7-/\$^'8WU&'P5X) MT5?!\L_B./6;_5$*E#`I3E3QE5M1;A3='>2&I1@Y)2DJ[DXQ:BVTFKMIN22O]F[TDDOOL'(R.AZ?X_C2TU00H!_F3U.<9 M/)QTR>3U/)IU<1W!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%% M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444 M4`%%%%`!1110`4444`%%%%`!1110`4444`%)@'J`?P%%%`"X'H*,#ICCTHHH M"PF!Z#\A2T44!8*3`]!^5%%`!M7(.!D<`X&0/0'M2D`]0#]:**`"BBB@!,`] M0/RI<#THHHM_G\^_J`F!Z#\A0%4=`!]`***`%I,`=`!^%%%%EV7W(!:***`L M%)@>@_*BB@!:***`LNR^Y?Y!1110`4444`%%%%`!1110`4444`%%%%`!1110 M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`! F1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`'_]D_ ` end EX-101.INS 7 syn-20150331.xml XBRL INSTANCE DOCUMENT 0000894158 2014-01-01 2014-03-31 0000894158 2014-01-01 2014-12-31 0000894158 2015-01-01 2015-03-31 0000894158 2015-03-31 0000894158 2015-05-08 0000894158 2014-12-31 0000894158 2013-12-31 0000894158 2014-03-31 0000894158 us-gaap:ComputerSoftwareIntangibleAssetMember 2015-03-31 0000894158 syn:ComputerAndOfficeEquipmentMember 2015-03-31 0000894158 us-gaap:ComputerSoftwareIntangibleAssetMember 2014-12-31 0000894158 syn:ComputerAndOfficeEquipmentMember 2014-12-31 0000894158 us-gaap:EmployeeStockOptionMember 2013-12-31 0000894158 us-gaap:EmployeeStockOptionMember 2014-01-01 2014-12-31 0000894158 us-gaap:EmployeeStockOptionMember 2015-01-01 2015-03-31 0000894158 us-gaap:EmployeeStockOptionMember 2014-12-31 0000894158 us-gaap:EmployeeStockOptionMember 2015-03-31 0000894158 us-gaap:EmployeeStockOptionMember 2013-01-01 2013-12-31 0000894158 syn:ExercisePrice14Member 2015-01-01 2015-03-31 0000894158 syn:ExercisePrice175Member 2015-01-01 2015-03-31 0000894158 syn:ExercisePrice222Member 2015-01-01 2015-03-31 0000894158 syn:ExercisePrice330Member 2015-01-01 2015-03-31 0000894158 syn:ExercisePrice375Member 2015-01-01 2015-03-31 0000894158 syn:ExercisePrice180Member 2015-01-01 2015-03-31 0000894158 syn:ExercisePrice14Member 2015-03-31 0000894158 syn:ExercisePrice175Member 2015-03-31 0000894158 syn:ExercisePrice222Member 2015-03-31 0000894158 syn:ExercisePrice330Member 2015-03-31 0000894158 syn:ExercisePrice375Member 2015-03-31 0000894158 syn:ExercisePrice180Member 2015-03-31 0000894158 syn:StockPlan2007Member 2007-03-20 0000894158 syn:StockPlan2001Member 2015-03-31 0000894158 syn:StockPlan2007Member 2015-03-31 0000894158 syn:StockPlan2010Member 2015-03-31 0000894158 syn:StockPlan2010Member 2010-11-02 0000894158 syn:StockPlan2001Member us-gaap:MaximumMember 2001-01-01 2001-12-31 0000894158 us-gaap:MaximumMember syn:StockPlan2007Member 2007-01-01 2007-12-31 0000894158 syn:EmployeesAndConsultantsMember 2014-01-01 2014-03-31 0000894158 syn:EmployeeMember 2015-01-01 2015-03-31 0000894158 syn:GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember 2014-01-01 2014-03-31 0000894158 syn:GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember 2015-01-01 2015-03-31 0000894158 syn:PrevAbrLlcMember 2015-01-01 2015-03-31 0000894158 syn:PrevAbrLlcMember 2015-03-31 0000894158 syn:StockWarrantsMember 2015-03-31 0000894158 syn:StockWarrantsMember 2014-10-10 0000894158 syn:StockWarrantsMember 2014-12-31 0000894158 syn:StockWarrantsMember 2014-01-01 2014-12-31 0000894158 syn:StockWarrantsMember 2015-01-01 2015-03-31 0000894158 syn:StockWarrantsMember 2014-10-01 2014-10-10 0000894158 syn:MoneyMarketAccountsMember 2015-03-31 0000894158 syn:MoneyMarketAccountsMember 2014-12-31 0000894158 syn:StockWarrantsMember 2014-10-01 2014-10-10 0000894158 syn:StockWarrantsMember 2014-10-10 0000894158 us-gaap:WarrantMember 2012-10-25 0000894158 us-gaap:WarrantMember 2012-10-01 2012-10-25 0000894158 syn:StockWarrantsMember 2015-01-01 2015-03-31 0000894158 syn:StockWarrantsMember 2015-03-31 0000894158 us-gaap:StockOptionMember 2014-01-01 2014-03-31 0000894158 us-gaap:WarrantMember 2014-01-01 2014-03-31 0000894158 us-gaap:StockOptionMember 2015-01-01 2015-03-31 0000894158 us-gaap:WarrantMember 2015-01-01 2015-03-31 0000894158 syn:StockPlan2010Member us-gaap:MinimumMember 2013-10-22 0000894158 syn:StockPlan2010Member us-gaap:MaximumMember 2013-10-22 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure 10-Q false 2015-03-31 2015 Q1 Synthetic Biologics, Inc. 0000894158 --12-31 Accelerated Filer SYN 73179307 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt"> <strong>4.</strong> <strong>Selected Balance Sheet Information</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 34.1pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><i> </i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Prepaid expenses and other current assets (in thousands):</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><i> </i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>March 31, 2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>December 31, 2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>Intrexon prepaid research and development expenses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>1,060</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>1,067</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>Prepaid insurance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>140</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>228</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>Prepaid expenses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>374</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>253</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>1,574</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>1,548</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The anticipated Intrexon research and development expenses for the next twelve months are classified as a current asset. The Company may terminate the arrangement at any time and receive a cash refund of the remaining balance minus any amounts owed to Intrexon.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Property and equipment (in thousands):</i>   </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>March 31, 2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>December 31, 2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Computer and office equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>111</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>93</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Software</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>11</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>11</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>122</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>104</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Less accumulated depreciation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(47)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(39)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>75</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>65</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Accrued expenses (in thousands):</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><i> </i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>March 31, 2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>December 31, 2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Accrued manufacturing costs</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>74</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>247</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Accrued vendor payments</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>225</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>176</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Accrued milestone payments</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>350</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Accrued clinical consulting services</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1,347</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>525</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>2,646</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>1,298</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt"> <strong>5.</strong> <strong>Stock-Based Compensation</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -37.4pt; MARGIN: 0pt 0px 0pt 37.4pt; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><i>Stock Incentive Plan</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 34.1pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">During 2001, the Company’s Board of Directors and stockholders adopted the 2001 Stock Incentive Plan (the “2001 Stock Plan”). The total number of shares of stock with respect to which stock options and stock appreciation rights may be granted to any one employee of the Company or a subsidiary during any one-year period under the 2001 Stock Plan shall not exceed <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 250,000</font>. All awards pursuant to the 2001 Stock Plan shall terminate upon the termination of the grantee’s employment for any reason. Awards include options, restricted shares, stock appreciation rights, performance shares and cash-based awards (the “Awards”). The 2001 Stock Plan contains certain anti-dilution provisions in the event of a stock split, stock dividend or other capital adjustment, as defined in the plan. The 2001 Stock Plan provides for a Committee of the Board to grant Awards and to determine the exercise price, vesting term, expiration date and all other terms and conditions of the Awards, including acceleration of the vesting of an Award at any time. As of March 31, 2015, there were <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 682,449</font> options issued and outstanding under the 2001 Stock Plan.</div>  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On March 20, 2007, the Company’s Board of Directors approved the 2007 Stock Incentive Plan (the “2007 Stock Plan”) for the issuance of up to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,500,000</font> shares of common stock to be granted through incentive stock options, nonqualified stock options, stock appreciation rights, dividend equivalent rights, restricted stock, restricted stock units and other stock-based awards to officers, other employees, directors and consultants of the Company and its subsidiaries. This plan was approved by stockholders on November 2, 2007. The exercise price of stock options under the 2007 Stock Plan is determined by the compensation committee of the Board of Directors, and may be equal to or greater than the fair market value of the Company’s common stock on the date the option is granted. The total number of shares of stock with respect to which stock options and stock appreciation rights may be granted to any one employee of the Company or a subsidiary during any one-year period under the 2007 plan shall not exceed <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 250,000</font>. Options become exercisable over various periods from the date of grant, and generally expire ten years after the grant date. As of March 31, 2015, there are <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 428,657</font> options issued and outstanding under the 2007 Stock Plan.</div>  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On November 2, 2010, the Board of Directors and stockholders adopted the 2010 Stock Incentive Plan (“2010 Stock Plan”) for the issuance of up to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3,000,000</font> shares of common stock to be granted through incentive stock options, nonqualified stock options, stock appreciation rights, dividend equivalent rights, restricted stock, restricted stock units and other stock-based awards to officers, other employees, directors and consultants of the Company and its subsidiaries. On October 22, 2013, the stockholders approved and adopted an amendment to the Company’s 2010 Incentive Stock Plan to increase the number of shares of the Company’s common stock reserved for issuance under the Plan from <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3,000,000</font> to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 6,000,000</font>. The exercise price of stock options under the 2010 Stock Plan is determined by the compensation committee of the Board of Directors, and may be equal to or greater than the fair market value of the Company’s common stock on the date the option is granted. Options become exercisable over various periods from the date of grant, and generally expire ten years after the grant date. As of March 31, 2015, there are <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 5,420,000</font> options issued and outstanding under the 2010 Stock Plan.</div> </div>  </div> </div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In the event of an employee’s termination, the Company will cease to recognize compensation expense for that employee. There is no deferred compensation recorded upon initial grant date, instead, the fair value of the stock-based payment is recognized ratably over the stated vesting period.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company has applied fair value accounting for all share based payment awards since inception. The fair value of each option or warrant granted is estimated on the date of grant using the Black-Scholes option pricing model. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The Black-Scholes assumptions used in the three months ended March 31, 2015 and 2014 are as follows:</div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0"> <tr> <td style="TEXT-ALIGN: center; WIDTH: 100%"> <div style="CLEAR:both;CLEAR: both"></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 37.4pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="26%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="32%" colspan="6"> <div>Three Months Ended March 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="26%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="26%"> <div>Expected dividends</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="14%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="14%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="26%"> <div>Expected volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"> <div>131</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"> <div>126</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="26%"> <div>Risk free interest rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"> <div>2.03</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"> <div>1.57</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="26%"> <div>Expected life of option</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"> <div>10 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"> <div>5 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="26%"> <div>Expected forfeitures</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 34.1pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company records stock-based compensation based upon the stated vested provisions in the related agreements. The vesting provisions for these agreements have various terms as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 37.4pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 6%"> <div> </div> </td> <td style="WIDTH: 4%"> <div><font style="FONT-FAMILY:Symbol">⋅</font></div> </td> <td style="WIDTH: 90%"> <div>immediate vesting,</div> </td> </tr> <tr style="VERTICAL-ALIGN: top"> <td> <div> </div> </td> <td> <div><font style="FONT-FAMILY:Symbol">⋅</font></div> </td> <td> <div>half vesting immediately and the remainder over three years,</div> </td> </tr> <tr style="VERTICAL-ALIGN: top"> <td> <div> </div> </td> <td> <div><font style="FONT-FAMILY:Symbol">⋅</font></div> </td> <td> <div>quarterly over three years,</div> </td> </tr> <tr style="VERTICAL-ALIGN: top"> <td> <div> </div> </td> <td> <div><font style="FONT-FAMILY:Symbol">⋅</font></div> </td> <td> <div>annually over three years,</div> </td> </tr> <tr style="VERTICAL-ALIGN: top"> <td> <div> </div> </td> <td> <div><font style="FONT-FAMILY:Symbol">⋅</font></div> </td> <td> <div>one-third immediate vesting and remaining annually over two years,</div> </td> </tr> <tr style="VERTICAL-ALIGN: top"> <td> <div> </div> </td> <td> <div><font style="FONT-FAMILY:Symbol">⋅</font></div> </td> <td> <div>one half immediate vesting with remaining vesting over nine months,</div> </td> </tr> <tr style="VERTICAL-ALIGN: top"> <td> <div> </div> </td> <td> <div><font style="FONT-FAMILY:Symbol">⋅</font></div> </td> <td> <div>one quarter immediate vesting with the remaining over three years,</div> </td> </tr> <tr style="VERTICAL-ALIGN: top"> <td> <div> </div> </td> <td> <div><font style="FONT-FAMILY:Symbol">⋅</font></div> </td> <td> <div>one quarter immediate vesting with the remaining over 33 months; and</div> </td> </tr> <tr style="VERTICAL-ALIGN: top"> <td> <div> </div> </td> <td> <div><font style="FONT-FAMILY:Symbol">⋅</font></div> </td> <td> <div>monthly over three years.</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -17.6pt; MARGIN: 0pt 0px 0pt 80.3pt; FONT: 10pt Times New Roman, Times, Serif">   </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">During the three months ended March 31, 2015, the Company granted <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 550,000</font> options to employees having an approximate fair value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">817,000</font> based upon the Black-Scholes option pricing model. During the same period in 2014, the Company granted <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 587,500</font> options to employees and consultants having an approximate fair value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.4</font> million based upon the Black-Scholes option pricing model.</div>  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>A summary of stock option activities as of March 31, 2015, and for the year ended December 31, 2014, is as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 37.4pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>Weighted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Weighted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>Remaining</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Aggregate</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Average Exercise</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>Contractual</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Intrinsic</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Options</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>Life</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Balance - December 31, 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,909,580</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.78</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>5.59 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>785,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,382,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.36</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(6,583)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.58</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(304,391)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.93</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Balance - December 31, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5,981,106</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.01</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>5.80 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>685,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>550,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.54</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Balance - March 31, 2015 - outstanding</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6,531,106</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.97</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>5.79 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,628,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Balance - March 31, 2015 - exercisable</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4,168,043</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.89</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>4.98 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,939,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Grant date fair value of options granted - March 31, 2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>817,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Weighted average grant date fair value - March 31, 2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.49</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Grant date fair value of options granted - December 31, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>4,974,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Weighted average grant date fair value - December 31, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>2.09</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Stock-based compensation expense included in general and administrative expenses and research and development expenses relating to stock options issued to employees and consultants for the three months ended March 31, 2015 and 2014 were $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">826,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">362,000</font>, respectively</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">As of March 31, 2015, total unrecognized stock-based compensation expense related to stock options was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4.0</font> million, which is expected to be expensed through February 2017.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" align="left"><b>7.</b> <b>Stockholders’ Equity (Deficit)</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" align="left"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">During the three months ended March 31, 2015, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 212,843</font> shares of common stock to Prev ABR LLC, with a fair value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">350,000</font>, <font style="WIDOWS: 1; TEXT-TRANSFORM: none; TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px 'Times New Roman', Times, serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"> that was<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></font> <font style="TEXT-ALIGN: justify; WIDOWS: 1; TEXT-TRANSFORM: none; TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal"> recorded as research and development expense,</font> in consideration for achieving the first two milestones as set forth in the Asset Purchase Agreement dated November 28, 2012. In lieu of receiving any cash payment for achieving the first two milestones, Prev ABR LLC exercised its option to receive the milestone payments in shares of the Company’s common stock. The number of shares of common stock issued upon achievement of each milestone was based upon the average of the opening and closing prices of <font style="WIDOWS: 1; TEXT-TRANSFORM: none; TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px 'Times New Roman', Times, serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"> the Company’s</font> stock on the date each milestone was achieved as specified in the Asset Purchase Agreement.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 12049000 17525000 1574000 1548000 13623000 19073000 75000 65000 18000 6000 13716000 19144000 1559000 996000 2646000 1298000 15341000 9588000 15341000 9588000 0 0 73000 72000 111702000 110526000 -113400000 -101042000 -1625000 9556000 0 0 -1625000 9556000 13716000 19144000 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 34.1pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><i>Prepaid expenses and other current assets (in thousands):</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><i> </i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>March 31, 2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>December 31, 2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>Intrexon prepaid research and development expenses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>1,060</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>1,067</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>Prepaid insurance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>140</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>228</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>Prepaid expenses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>374</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>253</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>1,574</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>1,548</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><i>Property and equipment (in thousands):</i>   </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>March 31, 2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>December 31, 2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Computer and office equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>111</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>93</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Software</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>11</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>11</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>122</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>104</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Less accumulated depreciation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(47)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(39)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>75</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>65</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><i>Accrued expenses (in thousands):</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><i> </i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>March 31, 2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>December 31, 2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Accrued manufacturing costs</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>74</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>247</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Accrued vendor payments</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>225</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>176</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Accrued milestone payments</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>350</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Accrued clinical consulting services</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1,347</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>525</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>2,646</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>1,298</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Black-Scholes assumptions used in the three months ended March 31, 2015 and 2014 are as follows:</div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0"> <tr> <td style="TEXT-ALIGN: center; WIDTH: 100%"> <div style="CLEAR:both;CLEAR: both"></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 37.4pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="26%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="32%" colspan="6"> <div>Three Months Ended March 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="26%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="26%"> <div>Expected dividends</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="14%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="14%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="26%"> <div>Expected volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"> <div>131</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"> <div>126</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="26%"> <div>Risk free interest rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"> <div>2.03</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"> <div>1.57</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="26%"> <div>Expected life of option</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"> <div>10 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"> <div>5 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="26%"> <div>Expected forfeitures</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>A summary of stock option activities as of March 31, 2015, and for the year ended December 31, 2014, is as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 37.4pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>Weighted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Weighted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>Remaining</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Aggregate</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Average Exercise</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>Contractual</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Intrinsic</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Options</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>Life</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Balance - December 31, 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,909,580</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.78</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>5.59 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>785,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,382,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.36</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(6,583)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.58</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(304,391)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.93</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Balance - December 31, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5,981,106</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.01</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>5.80 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>685,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>550,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.54</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Balance - March 31, 2015 - outstanding</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6,531,106</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.97</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>5.79 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,628,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Balance - March 31, 2015 - exercisable</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4,168,043</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.89</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>4.98 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,939,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Grant date fair value of options granted - March 31, 2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>817,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Weighted average grant date fair value - March 31, 2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.49</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Grant date fair value of options granted - December 31, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>4,974,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Weighted average grant date fair value - December 31, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>2.09</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 0.001 0.001 10000000 10000000 0 0 0 0 0.001 0.001 100000000 100000000 72725987 72594626 72807469 72513144 1060000 1067000 140000 228000 374000 253000 1574000 1548000 11000 111000 122000 11000 93000 104000 47000 39000 74000 247000 225000 176000 0 0 1.26 1.31 0.0157 0.0203 P5Y P10Y 0 0 3909580 2382500 550000 6583 0 304391 0 5981106 6531106 4168043 1.78 2.36 1.54 0.58 0 1.93 0 2.01 1.97 1.89 P5Y7M2D P5Y9M18D P5Y9M14D P4Y11M23D 785000 685000 2628000 1939000 4974000 817000 2.09 1.49 1632501 7029808 0 232619 0 454896 0 7974794 7974794 1.99 1.75 0 1.47 0 1.88 0 1.8 1.8 1122000 1713000 2717000 6494000 3839000 8207000 -3839000 -8207000 1000 1000 1000 -4151000 -3838000 -12358000 0 0 -3838000 -12358000 -0.07 -0.17 58324260 72673959 1.60 1.75 2.22 3.30 3.75 1.80 316522 7029.808 517257 61207 50000 7974794 7029808 517257 61207 50000 7974794 316522 P2Y6M25D P4Y6M11D P1Y7M28D P1M28D P10M17D P4Y2M16D 187000 3903000 0 0 0 3280000 2500000 682449 428657 5420000 3000000 250000 250000 587500 550000 1400000 817000 362000 826000 4000000 212843 350000 362000 827000 3000 8000 -259000 26000 2000 12000 631000 563000 0 1348000 -3470000 -5458000 4000 18000 -4000 -18000 4000 0 4000 0 -3470000 -5476000 14625000 11155000 0 0 0 0 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" align="justify"><b>1.</b> <b>Organization and Nature of Operations and Basis of Presentation</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -37.4pt; MARGIN: 0pt 0px 0pt 37.4pt; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b><i>Description of Business</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 34.1pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> Synthetic Biologics, Inc. (the “Company” or “Synthetic Biologics”) is a microbiome-focused, clinical-stage company developing therapeutics to protect the microbiome while targeting pathogen-specific diseases. The Company is developing an oral biologic to protect the gut microbiome (gastrointestinal (GI) microflora) from intravenous (IV) antibiotics for the prevention of <i>C. difficile</i> infection and an oral statin treatment to reduce the impact of methane producing organisms on irritable bowel syndrome with constipation (IBS-C). In addition, the Company is developing a monoclonal antibody combination for the treatment of Pertussis in collaboration with Intrexon Corporation (NYSE: XON), and a Phase 2 oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS. <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 37.4pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; WIDTH: 26%"> <div style="CLEAR:both;CLEAR: both"><b> Therapeutic Area</b></div> </td> <td style="TEXT-ALIGN: center; WIDTH: 1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; WIDTH: 26%"> <div style="CLEAR:both;CLEAR: both"><b> Product Candidate</b></div> </td> <td style="TEXT-ALIGN: center; WIDTH: 1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; WIDTH: 46%"> <div style="CLEAR:both;CLEAR: both"><b>Status</b></div> </td> </tr> <tr style="VERTICAL-ALIGN: top"> <td style="TEXT-ALIGN: center"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr> <td style="TEXT-INDENT: -11pt; PADDING-LEFT: 11pt; VERTICAL-ALIGN: top"> <div style="CLEAR:both;CLEAR: both"><i>C. difficile</i> infection prevention</div> </td> <td style="TEXT-ALIGN: center; VERTICAL-ALIGN: bottom"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="VERTICAL-ALIGN: top"> <div style="CLEAR:both;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="center">SYN-004</div> <div style="CLEAR:both;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="center">(oral enzyme)</div> </td> <td style="TEXT-ALIGN: center; VERTICAL-ALIGN: bottom"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="VERTICAL-ALIGN: top"> <div style="CLEAR:both;CLEAR: both"><font style="LINE-HEIGHT: 115%; FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> Initiated Phase 2a SYN-004 clinical trial during 1<sup style="font-style:normal">st</sup> quarter 2015; Phase 2b proof-of- concept SYN-004 clinical trial is expected to initiate during 2<sup style="font-style:normal">nd</sup>  half 2015</font></div> </td> </tr> <tr style="VERTICAL-ALIGN: top"> <td style="TEXT-ALIGN: center"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr> <td style="TEXT-INDENT: -11pt; PADDING-LEFT: 11pt; VERTICAL-ALIGN: top"> <div style="CLEAR:both;CLEAR: both">Irritable bowel syndrome with constipation (IBS-C)</div> </td> <td style="TEXT-ALIGN: center; VERTICAL-ALIGN: bottom"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="VERTICAL-ALIGN: top"> <div style="CLEAR:both;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="center">SYN-010</div> <div style="CLEAR:both;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="center">(oral compound)</div> </td> <td style="TEXT-ALIGN: center; VERTICAL-ALIGN: bottom"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="VERTICAL-ALIGN: top"> <div style="CLEAR:both;CLEAR: both">Intend to initiate Phase 2 clinical trials during 2<font style="FONT-SIZE: 10pt"><sup style="font-style:normal">nd</sup></font>  quarter of 2015; Collaboration with Cedars-Sinai Medical Center</div> </td> </tr> <tr style="VERTICAL-ALIGN: top"> <td style="TEXT-ALIGN: center"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr> <td style="TEXT-INDENT: -11pt; PADDING-LEFT: 11pt; VERTICAL-ALIGN: top"> <div style="CLEAR:both;CLEAR: both">Pertussis</div> </td> <td style="TEXT-ALIGN: center; VERTICAL-ALIGN: bottom"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="VERTICAL-ALIGN: top"> <div style="CLEAR:both;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="center">SYN-005</div> <div style="CLEAR:both;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="center">(monoclonal antibodies)</div> </td> <td style="TEXT-ALIGN: center; VERTICAL-ALIGN: bottom"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="VERTICAL-ALIGN: top"> <div style="CLEAR:both;CLEAR: both">Positive preclinical research findings reported at ECCMID in April 2015; Seeking non-dilutive funding to support clinical development of SYN-005; Collaborations with Intrexon and The University of Texas at Austin</div> </td> </tr> <tr style="VERTICAL-ALIGN: top"> <td style="TEXT-ALIGN: center"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr> <td style="TEXT-INDENT: -11pt; PADDING-LEFT: 11pt; VERTICAL-ALIGN: top"> <div style="CLEAR:both;CLEAR: both">Relapsing-remitting MS</div> </td> <td style="TEXT-ALIGN: center; VERTICAL-ALIGN: bottom"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="VERTICAL-ALIGN: top"> <div style="CLEAR:both;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="center">Trimesta</div> <div style="CLEAR:both;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="center">(oral estriol)</div> </td> <td style="TEXT-ALIGN: center; VERTICAL-ALIGN: bottom"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="VERTICAL-ALIGN: top"> <div style="CLEAR:both;CLEAR: both"><font style="LINE-HEIGHT: 115%; FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> The lead principal investigator presented additional Phase 2 clinical outcome data, including more detailed results on improvements in cognitive and disability measures at the ACTRIMS-ECTRIMS Joint Meeting in September 2014; Partnership discussions ongoing pending data from University of California, Los Angeles (UCLA); MRI data review underway by UCLA</font></div> </td> </tr> <tr style="VERTICAL-ALIGN: top"> <td style="TEXT-ALIGN: center"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr> <td style="TEXT-INDENT: -11pt; PADDING-LEFT: 11pt; VERTICAL-ALIGN: top"> <div style="CLEAR:both;CLEAR: both">Cognitive dysfunction in MS</div> </td> <td style="TEXT-ALIGN: center; VERTICAL-ALIGN: bottom"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="VERTICAL-ALIGN: top"> <div style="CLEAR:both;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="center">Trimesta</div> <div style="CLEAR:both;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="center">(oral estriol)</div> </td> <td style="TEXT-ALIGN: center; VERTICAL-ALIGN: bottom"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="VERTICAL-ALIGN: top"> <div style="CLEAR:both;CLEAR: both">Patient enrollment underway in Phase 2 clinical trial</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b><i>Basis of Presentation</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 34.1pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The accompanying consolidated financial statements have been prepared pursuant to the rules and regulations of Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all of the information and notes required by U.S. Generally Accepted Accounting Principles (“GAAP”) for complete financial statements. The accompanying consolidated financial statements include all adjustments, comprised of normal recurring adjustments, considered necessary by management to fairly state our results of operations, financial position and cash flows. The operating results for the interim periods are not necessarily indicative of results that may be expected for any other interim period or for the full year. These consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2014 (“2014 Form 10-K”) as filed with the SEC. The interim results for the three months ended March 31, 2015, are not necessarily indicative of results for the full year.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The consolidated financial statements are prepared in conformity with U.S. GAAP, which requires the use of estimates, judgments and assumptions that affect the amounts of assets and liabilities at the reporting date and the amounts of revenue and expenses in the periods presented. We believe that the accounting estimates employed are appropriate and the resulting balances are reasonable; however, due to the inherent uncertainties in making estimates actual results could differ from the original estimates, requiring adjustments to these balances in future periods.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 10908000 6756000 228000 538000 0 4152000 -885000 -310000 1000000 350000 1347000 525000 2.19 1.75 1.46 0 0 0 0.9 0.9 0.95 0.0159 0.0126 0.0139 P4Y9M14D P4Y6M18D P5Y -0.07 -0.17 0 -350000 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt"> <b>2.</b> <b>Management’s Plan</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company has incurred an accumulated deficit of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">113.4</font> million through March 31, 2015. With the exception of the quarter ended June 30, 2010, the Company has incurred negative cash flow from operations since it started the business. The Company has spent, and expects to continue to spend, substantial amounts in connection with implementing its business strategy, including the planned product development efforts, clinical trials, and research and discovery efforts.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 34.1pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The actual amount of funds the Company will need to operate is subject to many factors, some of which are beyond the Company’s control. These factors include the following:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 34.1pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: top"> <td style="WIDTH: 6%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="WIDTH: 4%"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY:Symbol">⋅</font></div> </td> <td style="TEXT-ALIGN: justify; WIDTH: 90%"> <div style="CLEAR:both;CLEAR: both">the progress of research activities;</div> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: top"> <td> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY:Symbol">⋅</font></div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both">the number and scope of research programs;</div> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: top"> <td> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY:Symbol">⋅</font></div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both">the progress of preclinical and clinical development activities;</div> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: top"> <td> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY:Symbol">⋅</font></div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both">the progress of the development efforts of parties with whom the Company has entered into research and development agreements;</div> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: top"> <td> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY:Symbol">⋅</font></div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both">the costs associated with additional clinical trials of product candidates;</div> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: top"> <td> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY:Symbol">⋅</font></div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both">the ability to maintain current research and development licensing arrangements and to establish new research and development and licensing arrangements;</div> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: top"> <td> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY:Symbol">⋅</font></div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both">the ability to achieve milestones under licensing arrangements;</div> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: top"> <td> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY:Symbol">⋅</font></div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both">the costs involved in prosecuting and enforcing patent claims and other intellectual property rights; and</div> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: top"> <td> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY:Symbol">⋅</font></div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both">the costs and timing of regulatory approvals.</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company has based its estimate on assumptions that may prove to be wrong. The Company may need to obtain additional funds sooner or in greater amounts than it currently anticipates. Potential sources of financing include strategic relationships, public or private sales of the Company’s shares or debt and other sources.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company may seek to access the public or private equity markets when conditions are favorable due to long-term capital requirements. The Company does not have any committed sources of financing at this time, and it is uncertain whether additional funding will be available when needed on terms that will be acceptable to it, or at all. If the Company raises funds by selling additional shares of common stock or other securities convertible into common stock, the ownership interest of the existing stockholders will be diluted. If the Company is not able to obtain financing when needed, it may be unable to carry out the business plan. As a result, the Company may have to significantly limit its operations and its business, financial condition and results of operations would be materially harmed.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt"> <b>3.</b> <b>Fair Value of Financial Instruments</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 34.1pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The fair value accounting standards define fair value as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is determined based upon assumptions that market participants would use in pricing an asset or liability. Fair value measurements are rated on a three-tier hierarchy as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -13.2pt; MARGIN: 0pt 0px 0pt 41.8pt; FONT: 10pt Times New Roman, Times, Serif">  </div> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 6%"> <div> </div> </td> <td style="WIDTH: 4%"> <div><font style="FONT-FAMILY:Symbol">·</font></div> </td> <td style="WIDTH: 90%"> <div>Level 1 inputs: Quoted prices (unadjusted) for identical assets or liabilities in active markets;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 0in; FONT: 10pt Times New Roman, Times, Serif">  </div> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 6%"> <div> </div> </td> <td style="WIDTH: 4%"> <div><font style="FONT-FAMILY:Symbol">·</font></div> </td> <td style="WIDTH: 90%"> <div>Level 2 inputs: Inputs, other than quoted prices included in Level 1 that are observable either directly or indirectly; and</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -13.2pt; MARGIN: 0in 0px 0in 0.2in; FONT: 10pt Times New Roman, Times, Serif">  </div> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 6%"> <div> </div> </td> <td style="WIDTH: 4%"> <div><font style="FONT-FAMILY:Symbol">·</font></div> </td> <td style="WIDTH: 90%"> <div>Level 3 inputs: Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions.</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 34.1pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">If the inputs used to measure fair value fall in different levels of the fair value hierarchy, the hierarchy level is based upon the lowest level of input that is significant to the fair value measurement.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 34.1pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Cash and cash equivalents include money market accounts of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">8.5</font> million and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">13.6</font> million as of March 31, 2015 and December 31, 2014, respectively, that are measured using Level 1 inputs.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 8500000 13600000 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt"> <strong>6.</strong> <strong>Stock Purchase Warrants</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 3.3pt 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On October 10, 2014, the Company raised net proceeds of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">19.1</font> million through the sale of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 14,059,616</font> units at a price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.47</font> per unit to certain institutional investors in a registered direct offering. Each unit consisted of one share of the Company’s common stock and a warrant to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 0.5</font> shares of common stock. The warrants, exercisable for an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 7,029,808</font> shares of common stock, have an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.75</font> per share and a life of five years. The warrants vested immediately and expire <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">October 10, 2019</font>.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 3.3pt 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 3.3pt 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The warrants issued in conjunction with the registered direct offering in October 2014 include a provision, that if the Company were to enter into a certain transaction, as defined in the agreement, the warrants would be purchased from the holder at a premium. Accordingly, the Company recorded the warrants as a liability at their estimated fair value on the issuance date and changes in estimated fair value will be recorded as non-cash income or expense in the Company’s statement of operations at each subsequent period. At March 31, 2015, the fair value of the warrant liability was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10.9</font> million, which represented non-cash expense of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4.2</font> million for the three months ended March 31, 2015. In accordance with authoritative accounting guidance, the warrant was valued on the date of grant and in subsequent periods using the Black-Scholes valuation model. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The assumptions used by the Company are summarized in the following table:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 3.3pt 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="45%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>March 31,<br/> 2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>December 31,<br/> 2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Issuance<br/> Date</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Closing stock price</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>2.19</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>1.46</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>1.75</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Expected dividends</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Expected volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>90</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>90</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>95</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Risk free interest rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1.26</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1.59</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1.39</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Expected life of warrant</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 6px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>4.55 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 6px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>4.79 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 6px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>5 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -6.6pt; MARGIN: 0pt 3.3pt 0pt 6.6pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -6.6pt; MARGIN: 0pt 3.3pt 0pt 6.6pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following table summarizes the estimated fair value of the warrant liability <i>(in thousands)</i>:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -6.6pt; MARGIN: 0pt 3.3pt 0pt 6.6pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Balance at December 31, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>6,756</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Change in fair value of warrant liability</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>4,152</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Balance at March 31, 2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>10,908</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -6.6pt; MARGIN: 0pt 3.3pt 0pt 6.6pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -6.6pt; MARGIN: 0pt 3.3pt 0pt 6.6pt; FONT: 10pt Times New Roman, Times, Serif" align="justify">As of March 31, 2015, all of the warrants remained outstanding.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -6.6pt; MARGIN: 0pt 3.3pt 0pt 6.6pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On October 25, 2012, the Company entered into a Common Stock Purchase Agreement with certain accredited investors. As part of this agreement, the Company issued warrants to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 635,855</font> shares of common stock to the placement agent, or its permitted assigns. The warrants have an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.60</font> and a life of five years. The warrants vested immediately and expire <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">October 25, 2017</font>. Since these warrants were granted as part of an equity raise, the Company has treated them as a direct offering cost. The result of the transaction has no affect to equity. Warrants outstanding as of March 31, 2015 were <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 316,522</font>.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 34.1pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>A summary of warrant activity for the Company for the three months ended March 31, 2015 and for the year ended December 31, 2014 is as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 37.4pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Weighted Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Number of Warrants</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Exercise Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Balance at December 31, 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,632,501</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1.99</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>7,029,808</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.75</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(232,619)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.47</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(454,896)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.88</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Balance at December 31, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>7,974,794</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1.80</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Balance at March 31, 2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>7,974,794</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1.80</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 34.1pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>A summary of all outstanding and exercisable warrants as of March 31, 2015 is as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 37.4pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="20%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>Weighted Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="20%" colspan="2"> <div>Exercise</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%" colspan="2"> <div>Warrants</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%" colspan="2"> <div>Warrants</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>Remaining</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%" colspan="2"> <div>Aggregate</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="20%" colspan="2"> <div>Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%" colspan="2"> <div>Outstanding</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%" colspan="2"> <div>Exercisable</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>Contractual Life</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%" colspan="2"> <div>Intrinsic Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="19%"> <div>1.60</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"> <div>316,522</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"> <div>316,522</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"> <div>2.57 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"> <div>187,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%"> <div>1.75</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>7,029.808</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>7,029,808</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>4.53 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>3,903,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%"> <div>2.22</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>517,257</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>517,257</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>1.66 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%"> <div>3.30</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>61,207</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>61,207</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>0.16 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%"> <div>3.75</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>50,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>50,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>0.88 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="19%"> <div>1.80</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"> <div>7,974,794</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"> <div>7,974,794</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>4.21 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"> <div>3,280,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 3.3pt 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The assumptions used by the Company are summarized in the following table:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 3.3pt 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="45%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>March 31,<br/> 2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>December 31,<br/> 2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Issuance<br/> Date</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Closing stock price</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>2.19</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>1.46</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>1.75</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Expected dividends</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Expected volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>90</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>90</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>95</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Risk free interest rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1.26</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1.59</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1.39</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Expected life of warrant</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 6px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>4.55 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 6px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>4.79 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 6px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>5 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -6.6pt; MARGIN: 0pt 3.3pt 0pt 6.6pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -6.6pt; MARGIN: 0pt 3.3pt 0pt 6.6pt; FONT: 10pt Times New Roman, Times, Serif" align="justify">The following table summarizes the estimated fair value of the warrant liability <i>(in thousands)</i>:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -6.6pt; MARGIN: 0pt 3.3pt 0pt 6.6pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Balance at December 31, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>6,756</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Change in fair value of warrant liability</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>4,152</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Balance at March 31, 2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>10,908</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 34.1pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">A summary of warrant activity for the Company for the three months ended March 31, 2015 and for the year ended December 31, 2014 is as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 37.4pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Weighted Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Number of Warrants</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Exercise Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Balance at December 31, 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,632,501</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1.99</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>7,029,808</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.75</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(232,619)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.47</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(454,896)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.88</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Balance at December 31, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>7,974,794</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1.80</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Balance at March 31, 2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>7,974,794</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1.80</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 34.1pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">A summary of all outstanding and exercisable warrants as of March 31, 2015 is as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 37.4pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="20%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>Weighted Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="20%" colspan="2"> <div>Exercise</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%" colspan="2"> <div>Warrants</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%" colspan="2"> <div>Warrants</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>Remaining</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%" colspan="2"> <div>Aggregate</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="20%" colspan="2"> <div>Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%" colspan="2"> <div>Outstanding</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%" colspan="2"> <div>Exercisable</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>Contractual Life</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%" colspan="2"> <div>Intrinsic Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="19%"> <div>1.60</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"> <div>316,522</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"> <div>316,522</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"> <div>2.57 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"> <div>187,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%"> <div>1.75</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>7,029.808</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>7,029,808</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>4.53 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>3,903,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%"> <div>2.22</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>517,257</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>517,257</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>1.66 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%"> <div>3.30</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>61,207</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>61,207</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>0.16 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%"> <div>3.75</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>50,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>50,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>0.88 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="19%"> <div>1.80</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"> <div>7,974,794</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"> <div>7,974,794</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>4.21 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"> <div>3,280,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 19100000 14059616 1.47 0.5 635855 7029808 1.60 1.75 10900000 4200000 2017-10-25 2019-10-10 316522 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt"> <b>8.</b> <b>Net Loss per Share</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b> </b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding. Diluted loss per share is computed by dividing net loss by the weighted average number of common shares outstanding including the effect of common share equivalents. All common equivalent shares were anti-dilutive at March 31, 2014 and 2015, as such there is no separate computation for diluted loss per share. The number of options and warrants for the purchase of common stock, that were excluded from the computations of net loss per common share for the three months ended March 31, 2015 were 6,531,106 and 7,974,794, respectively, and for the three months ended March 31, 2014 were 4,490,497 and 963,168, respectively.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 4490497 963168 6531106 7974794 3000000 6000000 EX-101.SCH 8 syn-20150331.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink 102 - Statement - Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 103 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 104 - Statement - Consolidated Statements of Operations link:presentationLink link:definitionLink link:calculationLink 105 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 106 - Disclosure - Organization and Nature of Operations and Basis of Presentation link:presentationLink link:definitionLink link:calculationLink 107 - Disclosure - Management Plans link:presentationLink link:definitionLink link:calculationLink 108 - Disclosure - Fair Value of Financial Instruments link:presentationLink link:definitionLink link:calculationLink 109 - Disclosure - Selected Balance Sheet Information link:presentationLink link:definitionLink link:calculationLink 110 - Disclosure - Stock-Based Compensation link:presentationLink link:definitionLink link:calculationLink 111 - Disclosure - Stock Purchase Warrants link:presentationLink link:definitionLink link:calculationLink 112 - Statement - Stockholders' Equity (Deficit) link:presentationLink link:definitionLink link:calculationLink 113 - Disclosure - Net Loss per Share link:presentationLink link:definitionLink link:calculationLink 114 - Disclosure - Selected Balance Sheet Information (Tables) link:presentationLink link:definitionLink link:calculationLink 115 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:definitionLink link:calculationLink 116 - Disclosure - Stock Purchase Warrants (Tables) link:presentationLink link:definitionLink link:calculationLink 117 - Disclosure - Management's Plan (Details Textual) link:presentationLink link:definitionLink link:calculationLink 118 - Disclosure - Fair Value of Financial Instruments (Details Textual) link:presentationLink link:definitionLink link:calculationLink 119 - Disclosure - Selected Balance Sheet Information (Details) link:presentationLink link:definitionLink link:calculationLink 120 - Disclosure - Selected Balance Sheet Information (Details 1) link:presentationLink link:definitionLink link:calculationLink 121 - Disclosure - Selected Balance Sheet Information (Details 2) link:presentationLink link:definitionLink link:calculationLink 122 - Disclosure - Stock-Based Compensation (Details) link:presentationLink link:definitionLink link:calculationLink 123 - Disclosure - Stock-Based Compensation (Details 1) link:presentationLink link:definitionLink link:calculationLink 124 - Disclosure - Stock-Based Compensation (Details Textual) link:presentationLink link:definitionLink link:calculationLink 125 - Disclosure - Stock Purchase Warrants (Details) link:presentationLink link:definitionLink link:calculationLink 126 - Disclosure - Stock Purchase Warrants (Details 1) link:presentationLink link:definitionLink link:calculationLink 127 - Disclosure - Stock Purchase Warrants (Details 2) link:presentationLink link:definitionLink link:calculationLink 128 - Disclosure - Stock Purchase Warrants (Details 3) link:presentationLink link:definitionLink link:calculationLink 129 - Disclosure - Stock Purchase Warrants (Details Textual) link:presentationLink link:definitionLink link:calculationLink 130 - Disclosure - Stockholders' Equity (Deficit) (Details Textual) link:presentationLink link:definitionLink link:calculationLink 131 - Disclosure - Net Loss per Share (Details Textual) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 9 syn-20150331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 10 syn-20150331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 11 syn-20150331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information [Abstract] Document Information [Table] Class of Stock [Axis] Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Entity Filer Category Trading Symbol Entity Common Stock, Shares Outstanding Document Type Amendment Flag Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Organization, Consolidation and Presentation of Financial Statements [Abstract] Supplemental Balance Sheet Disclosures [Text Block] Supplemental Balance Sheet Disclosures [Text Block] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Stockholders' Equity Note [Abstract] Stockholders Equity Note Disclosure [Text Block] Stockholders' Equity Note Disclosure [Text Block] Statement Of Financial Position [Abstract] Statement [Table] Scenario [Axis] Scenario, Unspecified [Domain] Statement [Line Items] Assets [Abstract] Assets Assets, Current [Abstract] Current Assets Cash and Cash Equivalents, at Carrying Value, Total Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Cash at beginning of period Cash at end of period Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Assets, Current Total Current Assets Property, Plant and Equipment, Net Property and equipment, net Total Deposits and Other Assets Noncurrent Deposits and other assets Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer and also includes aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet due to materiality considerations. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer). Assets Total Assets Liabilities and Stockholders Equity [Abstract] Liabilities and Stockholders' Equity (Deficit) Liabilities, Current [Abstract] Current Liabilities: Accounts Payable, Current Accounts payable Accrued Liabilities, Current Accrued expenses Total Warrant liabilities Warrant liabilities Beginning Balance Ending Balance It represents value of warrant liabilities. Liabilities, Total Total Liabilities Commitments and Contingencies Commitments and Contingencies Stockholders Equity Attributable To Parent [Abstract] Stockholders' Equity (Deficit): Preferred Stock, Value, Issued Preferred stock, $0.001 par value; 10,000,000 shares authorized, none issued and outstanding Common Stock, Value, Issued Common stock, $0.001 par value; 100,000,000 shares authorized, 72,725,987 issued and 72,807,469 outstanding and 72,594,626 issued and 72,513,144 outstanding Additional Paid In Capital, Common Stock Additional paid-in capital Retained Earnings (Accumulated Deficit) Accumulated deficit Accumulated deficit Stockholders' Equity Attributable To Parent Total Synthetic Biologics, Inc. and Subsidiaries Equity (Deficit) Stockholders Equity Attributable to Noncontrolling Interest Non-controlling interest Stockholders Equity, Including Portion Attributable to Noncontrolling Interest, Beginning Balance Total Stockholders' Equity (Deficit) Balance Balance Liabilities and Stockholders Equity Total Liabilities and Stockholders’ Equity Schedule Of Other Current Assets [Table Text Block] Schedule of Other Current Assets [Table Text Block] Property, Plant and Equipment [Table Text Block] Property, Plant and Equipment [Table Text Block] Accrued Expenses [Table Text Block] Tabular disclosure of accrued expenses. Share Based Compensation Arrangement By Share Based Payment Award Options and Warrants Vested and Expected To Vest Outstanding and Exercisable [Table Text Block] Share-based Compensation Arrangement by Share-based Payment Award Options and Warrants Vested and Expected to Vest Outstanding and Exercisable [Table Text Block] Tabular disclosure relates to share based compensation arrangement by share based payment award options and warrants vested and expected to vest outstanding and exercisable. Schedule Of Share-Based Compensation, Stock Options, Activity [Table Text Block] Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Balance Sheet Parenthetical [Abstract] Balance Sheet Parenthetical Preferred Stock, Par Or Stated Value Per Share Preferred stock, par value (in dollars per share) Preferred Stock, Shares Authorized Preferred stock, shares authorized Preferred Stock, Shares Issued Preferred stock, shares issued Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Common Stock, Par Or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares, issued Common Stock, Shares, Outstanding Common stock, shares outstanding Schedule Of Other Current Assets [Table] Other Current Assets [Line Items] Prepaid Expenses Research and Development Intrexon prepaid research and development expenses Sum of the amounts paid in advance for research and development expenses. Prepaid Insurance Prepaid insurance Prepaid Expense, Current Prepaid expenses Other Assets, Current Total Property, Plant and Equipment [Table] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Domain] Equipment [Member] Manufacturing equipment [Member] Computer and Office Equipment [Member] Computer and office equipment [Member] Computer Software, Intangible Asset [Member] Software [Member] Laboratory Equipment [Member] Property, Plant and Equipment [Line Items] Property, Plant and Equipment, Gross Property, Plant and Equipment, Gross Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Less accumulated depreciation Schedule Of Accrued Expenses [Table] Class of Stock [Domain] Accrued Expenses [Line Items] Accrued manufacturing costs Accrued manufacturing costs The manufacturing costs incurred in the production of goods for sale. Accrued Vendor Payments Accrued vendor payments Carrying value as of the balance sheet date of obligations and payables pertaining to vendor payments. Accrued Milestone Payable Accrued milestone payments The carrying value of accrued milestone payments payable as on balance sheet date. Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Range [Axis] Range [Domain] Minimum [Member] Maximum [Member] Liability Class [Axis] Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Expected dividends Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected volatility Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Risk free interest rate Risk free interest rate Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Expected Term Expected life of warrant Expected life of warrant Share Based Compensation Arrangement By Share Based Payment Award Options Expected Forfeiture Rate In Period Expected forfeitures The number of shares under options that were expected to be cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. Option Indexed to Issuers Equity, Type [Axis] Option Indexed to Issuers Equity, Type [Domain] Employee Stock Option [Member] Stock Option [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Number Options, Beginning Balance Options, Ending Balance Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Net Of Forfeitures Options, Granted Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercises In Period Options, Exercised Issuance of common stock for exercise of stock options (in shares) Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Forfeitures and Expirations In Period Options, Forfeited Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Number Options, Exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Weighted Average Exercise Price, Beginning Balance Weighted Average Exercise Price, Ending Balance Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-Based Compensation Arrangements By Share-Based Payment Award, Options, Grants In Period, Weighted Average Exercise Price Weighted Average Exercise Price, Granted Share-Based Compensation Arrangements By Share-Based Payment Award, Options, Exercises In Period, Weighted Average Exercise Price Weighted Average Exercise Price, Exercised Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Forfeitures and Expirations In Period, Weighted Average Exercise Price Weighted Average Exercise Price, Forfeited Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Weighted Average Exercise Price, Exercisable Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Weighted Average Remaining Contractual Life, Balance Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Weighted Average Remaining Contractual Life, Exercisable Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Intrinsic Value Aggregate Intrinsic Value, Beginning Balance Aggregate Intrinsic Value, Ending Balance Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Intrinsic Value Aggregate Intrinsic Value, Exercisable Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Fair Value Grant date fair value of options granted Fair value of stock (or other type of equity) granted during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP). Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted average grant date fair value Weighted Average Grant Date Fair Value, Granted Antidilutive Securities Excluded From Computation Of Earnings Per Share, By Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Beginning Balance Number of Warrants, Beginning Balance Number of Warrants, Ending Balance Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Number of Warrants, Granted Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period Number of Warrants, Exercised Share-based Compensation Arrangement by Share-based Payment Award, Other than Options, Exercises in Period Number of share warrants exercised during the period. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Number of Warrants, Forfeited Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value, Beginning Balance Weighted Average Exercise Price, Beginning Balance Weighted Average Exercise Price, Ending Balance Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted Average Exercise Price, Granted Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period Weighted Average Grant Date Fair Value Weighted Average Exercise Price, Exercised Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans are exercise in period. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Weighted Average Exercise Price, Forfeited Income Statement [Abstract] Operating Expenses [Abstract] Operating Costs and Expenses: General and Administrative Expense General and administrative Research and Development Expense Research and development Operating Expenses Total Operating Costs and Expenses Operating Income (Loss) Loss from Operations Nonoperating Income (Expense) [Abstract] Other Income (Expense): Fair Value Adjustment of Warrants Change in fair value of warrant liability Change in fair value of warrant liabilities Investment Income, Interest Interest income Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total Net Loss Net loss Net Loss Net Income (Loss) Attributable to Noncontrolling Interest, Total Net Loss Attributable to Non-controlling Interest Net Income (Loss) Attributable To Parent Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries Net loss Income (Loss) from Continuing Operations, Per Basic and Diluted Share Net Loss Per Share - Basic and Dilutive (in dollars per share) Continuing operations (in dollars per share) Earnings Per Share, Basic and Diluted Net Loss Per Share Attributable to Synthetic Biologics, Inc. and Subsidiaries (in dollars per share) Net loss per share - basic and dilutive (in dollars per share) Earnings Per Share, Basic and Diluted [Abstract] Net Income (Loss) Per Share - Basic and Dilutive Warrant [Member] Exercise Price 1 [Member] Exercise Price 1.14 [Member] Exercise Price 14 [Member] Exercise Price 1.60 [Member] Exercise Price 1.60 [Member] Exercise Price 1.75 [Member] Exercise Price 1.75 [Member] Exercise Price 220 [Member] Exercise Price 2.20 [Member] Exercise Price 2 22 [Member] Exercise Price 2.22 [Member] Exercise Price 3 30 [Member] Exercise Price 3.30 [Member] Exercise Price 3 75 [Member] Exercise Price 3.75 [Member] Exercise Price 199 [Member] Exercise Price 1.99 [Member] Warrants Exercise Price Exercise Price Exercise price of the warrants. Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number, Beginning Balance Warrants Outstanding Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Warrants Exercisable Number Warrants Exercisable The value as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the share warrants plan. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms Weighted Average Remaining Contractual Life Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding Aggregate Intrinsic value Plan Name [Axis] Plan Name [Domain] Stock Plan 2001 [Member] 2001 Stock Plan [Member] Stock Plan 2007 [Member] 2007 Stock Plan [Member] Stock Plan 2010 [Member] 2010 Stock Plan [Member] Related Party [Axis] Related Party [Domain] Employees And Directors [Member] Employees And Consultants [Member] Employee [Member] Consultant [Member] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Income Statement Location [Axis] Income Statement Location [Domain] General and Administrative Expenses and Research and Development Expense [Member] Legal Entity [Axis] Entity [Domain] Cdfour Biosciences Inc [Member] Epitope [Member] Equity Components [Axis] Equity Component [Domain] Stock Purchase Warrants Aggreements [Axis] Stock Purchase Warrants Aggreements [Domain] Common Stock Purchase Agreement With Single Investors [Member] Stock Purchase Agreement With Three Institutional Investors [Member] Common Stock Purchase Agreement With Institutional Investors [Member] Consulting Agreement For Financial Advisory Services [Member] Award Type [Axis] Equity Award [Domain] Stock Options and Stock Appreciation Rights Sars [Member] Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross Stock Options, Granted Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Fair Value Fair value of stock (or other type of equity) granted during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP). Allocated Share-based Compensation Expense Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options Stockholders Equity [Table] Subsidiary, Sale of Stock [Axis] Sale of Stock, Name of Transaction [Domain] IPO [Member] Private Placement [Member] Intrexon [Member] Prev Abr Llc [Member] Cedars-Sinai Medical Center [Member] NRM VII Holdings I, LLC [Member] Equity Offering Sales Agreement [Member] Stock Issued During Period, Shares, New Issues Issuance of common stock, net of issuance costs (in shares) Equity Issued in Business Combination, Fair Value Disclosure Disclosure Management Plan [Abstract] Management's Plan [Table] Cantor Fitzgerald And Co [Member] Management's Plan [Line Items] Fair Value Disclosures [Abstract] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Domain] Stock Purchase Warrants [Abstract] Earnings Per Share [Abstract] Statement Of Cash Flows [Abstract] Net Cash Provided By (Used In) Operating Activities [Abstract] Cash Flows From Operating Activities: Adjustments To Reconcile Net Income (Loss) To Cash Provided By (Used In) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Share-Based Compensation Stock-based compensation Stock issued for milestone payments Stock issued for milestone payments The value of stock granted for milestone payments during the period. Depreciation Depreciation Increase (Decrease) In Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) In Prepaid Expense and Other Assets Prepaid expenses and other current assets Increase Decrease In Deposits and Other Assets Deposits and other assets The aggregate net change during the reporting period in moneys given as security, collateral, or margin deposits. Also includes, net change in other operating assets not otherwise defined in the taxonomy. Increase (Decrease) In Accounts Payable Accounts payable Increase (Decrease) In Accrued Liabilities Accrued liabilities Net Cash Provided By (Used In) Operating Activities Net Cash Used In Operating Activities Net Cash Provided By (Used In) Investing Activities [Abstract] Cash Flows From Investing Activities: Payments To Acquire Property, Plant, and Equipment Purchases of property and equipment Net Cash Provided By (Used In) Investing Activities Net Cash Used In Investing Activities Net Cash Provided By (Used In) Financing Activities [Abstract] Cash Flows From Financing Activities: Proceeds From Issuance Of Common Stock For Stock Option And Warrants Exercises Proceeds from issuance of common stock for stock option exercises The cash inflow from the additional capital contribution to the entity for stock option and warrants exercises. Cash Period Increase Decrease Net decrease in cash Supplemental Cash Flow Information [Abstract] Supplemental disclosures of cash flow information: Interest Paid Cash paid for interest Income Taxes Paid Cash paid for taxes Organization, Consolidation and Presentation Of Financial Statements Disclosure [Text Block] Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Accrued Employee Benefits, Current Accrued employee benefits Liabilities, Current, Total Total Current Liabilities Nonoperating Income (Expense) Total Other Income (Expense) Increase (Decrease) in Employee Related Liabilities Accrued employee benefits Net Cash Provided By (Used In) Financing Activities Net Cash Provided By Financing Activities Stockholders Equity [Line Items] Accrued Clinical Consulting Services Accrued clinical consulting services The carrying value of accrued clinical consulting services payable as on balance sheet date. Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table] Fair Value by Liability Class [Domain] Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items] Stock Warrants [Member] Share Price Closing stock price Fair Value Assumptions, Expected Dividend Rate Expected dividends Fair Value Assumptions, Expected Volatility Rate Expected volatility Fair Value Assumptions, Risk Free Interest Rate Risk free interest rate Fair Value Assumptions, Expected Term Expected life of warrant Weighted Average Number Of Shares Outstanding, Basic and Diluted Weighted average common share - basic and dilutive (in shares) Weighted average number of shares outstanding during the period - Basic and Dilutive (in shares) Disclosure Management Plan [Text Block] The entire disclosure related to Management's Plan. Fair Value Disclosures [Text Block] Money Market Accounts [Member] Cash Equivalents, at Carrying Value Stock Purchase Warrants [Text Block] The entire disclosure related to Stock Purchase Warrants. Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block] Schedule Of Estimated Fair Value Of The Warrant Liability [Table Text Block] Tabular disclosure of estimated fair value of the warrant liability. Schedule Of Warrant Activity [Table Text Block] Schedule of Warrant Activity [Table Text Block] Tabular disclosure of warrant activity. Schedule Of Warrant Outstanding and Exercisable [Table Text Block] Schedule of Warrant Outstanding and Exercisable [Table Text Block] Tabular disclosure relates to warrant outstanding and exercisable. Exercise Price180 [Member] Exercise Price 1.80 [Member] Proceeds from Issuance of Common Stock Proceeds from issuance of common stock Sale of Stock, Number of Shares Issued in Transaction Sale of Stock, Price Per Share Issuance Of Warrants To Purchase Of Common Stock Issuance of Warrants to Purchase of Common Stock Warrants issued to purchase common stock. Share Based Compensation Arrangement By Share Based Payment Award Warrants Exercisable Number Share-based Compensation Arrangement by Share-based Payment Award, Warrants, Exercisable Number The number of exercisable share warrants that may be converted as of the balance sheet date. Warrants Exercisable Price Per Share Warrants exercisable price per share. Investment Warrants Expiration Date1 Investment Warrants Expiration Date Expiration date of warrants held. Class of Warrant or Right, Outstanding Earnings Per Share [Text Block] Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Equity Option [Member] Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Supplemental disclosure for non-cash items: Common Stock, Capital Shares Reserved for Future Issuance Document Information [Line Items] EX-101.PRE 12 syn-20150331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EXCEL 13 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0`!@`(````(0#*#;D0WP$``!85```3``@"6T-O;G1E;G1?5'EP97-= M+GAM;""B!`(HH``"```````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````#,F-%NVC`4AN\K[1TBWT[$ MV&R4381>=-ME5ZG=`[CV@40XMF6[';Q]3T)!$Z(@5*2=&R(2^_Q??/%)^:,6%?OS^&LP847*RAEEO8.*K2&QF]FGJ^GC.D`J M<+=+%:MS#M\Y3[J&5J72!W#X9.YCJS+^C0L>E%ZJ!7`Y'(ZY]BZ#RX/;BY\KO+TAB6`3*VXW"[NLBJD0;*-51E+^XLQ>RN`MH<2=_9I4-R%] M1@S&#R9T3]X/>-OW&X\F-@:*>Q7SG6H1@Z\L_^OC\LG[97E\R`%*/Y\W&HS7 MSRV>0)E"!&52#9!;6_;7LE6-VW(?R>\7)]Y?Q(5!NO?K!Y_)(8EPC(AP?"'" M\94(QY@(QS41C@D1CF]$.,20"@@5HPHJ2A54G"JH2%50L:J@HE5!Q:N"BE@% M%;-**F:55,PJJ9A54C&KI&)62<6LDHI9)16S2BIFE53,.J)BUM'_,FO&U@=X M__MQA'[,B=HAY;6%=.%/A;%]XI)2;8M?[J+*+ MBQJZE/PC8C0=3Q0+\>QRI9$P4P>J M/OH\^;*W-$UO>"_F?6*73HQ`GA,[RW;E0V8+J<_;J)I"RTF#%?.&PO7W)E M;',O=V]R:V)O;VLN>&UL+G)E;',@H@0!**```0`````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````"\6,MNVS`0O!?H/PB\U_0N$RY=J54)1G]Z0667,2O\# M3N9#%LXM@L,;83B\07"D:P5+Q23-#4%NKI:$$SL;7/LMA3RH,2<^-_-%&*&Y M61),&:$92`F=I^H&@2$61D,,X4B30Y`=OA9FAZ\1.V;1(8_I.&1+F1OXM$;[ M2_<*;A5I_26HOYSM6]2=>`U+=2<-YP[!D?8#:`?2C0/[AL2I@=SPHE99K&A6 MF1(ZNQ-?H;XQBTI.RF=C-T,Y+?7I"3F1-@'H`22-AB`<7M222G/,12JA]W[! M!T_I.P+#.P))FP)!4R!I4R!H"D9:^@P<G#+'B*SQ@/F;^^6?@XG)5".\OTX8K.?*CH]#WF$Q5QN5BY/^>W7T[ M]3UCJXHR==>6M%R'>9D5MI MN7TC][)1GRMH8:WZ/506^9X^Y_!#WV=1G3BF7(.(2O",@D3DB@HJ4T:F]:T& M(9(8,>(#&&1",091G-@?9C*UD%#=;T/4G#R6#%$&B#+8FTN;%40'^-U172HO;4IHS37:L@[$J?;VB M!AQRK0J8?H/NCL!=`)I5.=^)6'"7-OK M:1NTQJWC3U=)5TLRHR\"]BSBX)&+.@YUG*ZD/1SLT&B/18WS*,AJ*1>&S-C* M8J<-L&&C`QW;$@A;-CK0LR#*5FELVJCKVKWF!U6V(.Q>V-D[*W)_[T&6+0B[ M..YW<4_O&\D1)\:]AV`WH?YY?&\=UCK&S8?@(!#6.L;=AZ`/U./&;F6X^?&G M7=UP6I7AYC?O8]>&]Y?C1^/1@%J5M9K?\?5^$'91W&I^U]=UTSZ4"+LHQFL, M@CZM^WB;E`P``GPT``!@```!X M;"]W;W)KWU]L_GZ4A;6,VT$ MX]76)HYG6[3*>,ZJX];^]Y_'V=*VA$RK/"UX1;?V*Q7VU]UO7S87WCR)$Z72 M`H9*;.V3E/7:=45VHF4J'%[3"D8.O"E3"8_-T15U0].\G506KN]Y"[=,664C MP[J9PL$/!Y;1!YZ=2UI))&EHD4K0+TZL%E>V,IM"5Z;-T[F>9;RL@6+/"B9? M6U+;*K/USV/%FW1?P+Y?R#S-KMSMPXB^9%G#!3](!^A<%#K>\\I=N<"TV^0, M=J!LMQIZV-K?R#HAD>WN-JU!_S%Z$8/OECCQR_>&Y7^PBH+;$"<5@3WG3PKZ M,U>O8+([FOW81N"OQLKI(3T7\F]^^4'9\20AW"'L2&ULG;\^4)&!HT#C^*%B MRG@!`N#3*IE*#7`D?6G_7U@N3UL[6#AAY`4$X-:>"OG(%*5M96?D_@DA' MA21^1Q*`^F[;AE\L2!I84M2I2D&R!N+KQE#&;:OO[12V MJ$B^*9:6"S8A(#S/NS#:N,_@:-9!8H3`@;A!B(Y(K@@5"%!WDPC[-B4&$,&W MO;\J4I,,14M]O7@,\75$,D:$JQM$TPC6#37>UZ;`6WL^L&+AW6A;0V.$8"HI MAY/!"VUA8)F^L`)#Z@T7-H(0(V35QI!$)-!U)=HP\7O#-%&0T]-%*;`AJJ=% M-Q"R:$4MYJNY(6HX[$>DSSQ-U.(SHA38$&58$2,$12U]KU^UU9P,AX-E\$[> M1)\1I<"&*,.*&"$H:O:&*FW\?5GJWAI4A?OIK,!&.H=ZA&*$#-)Y\$(+TNHS M"RNPX!XV&96?P8U201JS70S6K0ARDB-N,/@JL8!3-X9 MU"495?M^?`@65NW8F[6PP_1&C60AB:E9EV54Z@]D87759/6G!`\^04PGB_A! M:`A/=`1D=`_0M:D".DAI==%]?(L0-4N/9M2G2:<1,68.817H",Q!79I1PR=* M&Q?SR`A:3(;E>O:F?1KBCGU&29^H<5S;(^,$QJJ-`HLA[57;,/.<0?WN/-01 MD>/I?]'OLYY4=]:H^4KU'-@^2,QQ\8_,XD\07N+_7FL^O.VP[X-0'M&PO=V]R:W-H965T"QA""%&2J4W5;=(F3=/^/#O@)%8!(]MIVF^_:RX!3-,L?8&` MCT]^/MX#JLRD?-JMW1__WJXF;F.TK3*:2$JMG1? MF'(_K3Y^6!R%?%1[QK0##I5:NGNMZ[GOJVS/2JH\4;,*6K9"EE3#H]SYJI:, MYDVGLO##()CZ)>65BPYS>8V'V&YYQNY%=BA9I=%$LH)JX%=[7JN36YE=8U=2 M^7BH;S)1UF"QX077+XVIZY39_.NN$I)N"ACW,YG0[.3=/+RR+WDFA1);[8&= MCZ"OQYSZJ0].JT7.800F=D>R[=*])?,UB5Q_M6@"^L/940U^.VHOCI\ES[_Q MBD':4"=3@8T0CT;Z-3>OH+/_JO=#4X$?TLG9EAX*_5,+]UHZL5)$!&0.QNF]`,W MEJZ3'906Y5\4D=8*3<+6!.ZM"8F]21@GL_>X1*T+W$\NTZM=?!Q7$],]U72U MD.+HP-P#!HNL3>"@R2,B:WQF7IPJ*!+!14^6D5)9.%_P25 MR5K-'6K@VFF(K5B_5D1DVFE\(.ZP(9C/B,5L_#["$ MJ(D;ML#F7F-;RQV$Z2R8=0J+:OH>*B,>4R6=+U*AYCP5MB'531B%4Y)VO2VJ MY#U41CRFZD>+5*@Y3X5M+=4DGLS2/FF+RGP1!QO%Y0H:\9BJ'RU2H>;2[+JD ML-A2F\VLP?^O`--IQ!B.5P!J2-!,,^*-@EV/FM-^B!8>]+>RNXZOZ34&[(N# M(;:B].PZ:!OA9G9DX@T6N,UG-MY!;:_DP^W:VD+"\8(@*'J##QL[ODG?V^8; M[?97\N$>;O.-*GA'4/0&7_L5..4WZWO;?&9G?G]^IM>XOOT,:NN+HBZBGJ!I M-V^ M4[GCE7(*MH6N`KF/+$1&DY"S<\]G'P9?+L"#\1;(?3IP9S9 MNK/TZA\```#__P,`4$L#!!0`!@`(````(0"B`@@[MP(``-<&```9````>&PO M=V]R:W-H965T&]9J1R)9333H5Q7O5,_6T/?0-40^'+LK*IH.*`Z\YOK9DF+4T,V7LA62 M'&K(^RE<$MISV\4%?<.I%$H4V@,ZWPF]S'GMKWU@VFUS#AD8VY%D18IOPTV6 M8'^WM?[\YNRD1L](5>+T2?+\*V\9F`UE,@4X"/%@H%]R\PJ"_8OH>UN`[Q+E MK"#'6O\0I\^,EY6&:L>0D,EKDS_?,47!4*#Q%K%AHJ(&`?"+&FXZ`PPA3_;_ MQ'-=I3A*O'@51"'`T8$I?<\-)4;TJ+1H_CA0>*9R)(LS203JS_N+]Y+X3I#- M[XYHLMM*<4+0,W"DZHCIP'`#Q'UB3L:0ZFN90HJ&Y-:P6"Y(0D%U'G?1*MSZ MCV`I/6/V#@,78L#,$%F/,)4`>8-&2'RN,8(2OFQ^+\D$324M9N?M7X!,-6>7 MB'@]0"8:P;NYQN6K#=)K-$$I7HXLB9+K@=]:NW<8UU3&ZVST8J(`:,8*WG;' M@*$)QR>O%K.3'69MRYFLXF2ZG;EM*VRB`[(>ZS`=]?]JF:"IGNM@>M[>01(K M9QG&,[69VX[M]K_0B;)DJNQMAPQXJBA:13-)#N,<"H-U,*L=3"3#,;+(#1AW M`1LF2Y:QNE:(BJ,9'B&(']ZZN;:'N6:G@#]LP%SI2,F^$5GR5J&:%1`:>"LP M0+K)Y!9:=+;_#T+#1+&/%7Q`&/10X`&X$$+W"W/CAD_2[B\```#__P,`4$L# M!!0`!@`(````(0!\2P,:10,```4*```9````>&PO=V]R:W-H965TO5>F\$"XHJY[]ZO.GQ8'Q9U$0(AU@J,72+:1LYKXOTH)46'BL(37, MY(Q76,(CW_FBX01G[:*J],,@F/@5IK6K&>;\(QPLSVE*$I;N*U)+3<))B27H M%P5MQ(FM2C]"5V'^O&_N4E8U0+&E)95O+:GK5.G\:5"Y=(#.E\+'7J._=@'IM4BH^!`A=WA)%^Z#VB>Q*Z_6K3Q^4O)0?3^ M.Z)@AZ^<9M]I32#8D":5@"UCSPKZE*DA6.P/5C^V"?C)G8SD>%_*7^SPC=!= M(2';8S"D?,VSMX2(%`(*-%XX5DPI*T$`_#H5594!`<&O[?U`,UDLW='$&T^# M$0*XLR5"/E)%Z3KI7DA6_=,@=*32).&1!.Y'$C3VHG`\G=W",CJR1!U+"$/7 M)?C:3AN=!$N\6G!V<*#B0+!HL*I?-`?"4UBTB2Y0E^($`5(D#XIEZ<)6@1`( MR.W+:C2)%OX+)"0]8M8:`[\]S-C$;(889"*2(6*$)AW&!U>=-8ARW]K[F3XY M4&#E0&5>65KK`5/N^44M9C/$A)V4%I&\@SA##+60PH^K56"H0".64_/5:XW1 MM:P<;>R!I#=@2($ZZ$M1-1%=W"JG`*I%@#,DS2Q)&M.39`\DO0%#$KR^+^EZ M+A78C$X8V='1&!2TQ8J\J5V)QGSHH=BTDACSR(O.I6'HGMRB6X%-W6AFAU!C MXKC5'9BB-M3H_````__\#`%!+`P04``8`"``` M`"$`"DHVF'0'```%)0``&0```'AL+W=O#J M*D^`F8M)^/)7X;^[NKL,?OSUZWXW^))7=5$>GH;1W7@XR`^K3W\]?GGGQ[?R^ISOAR["HKLE1;C;% M*A?EZFV?'QJ7I,IW60/77V^+8WW*ME]=DVZ?59_?CK^LROT14KP4NZ+YUB8= M#O:KQ6^OA[+*7G;@^VLTR5:GW.T+EGY?K*JR+C?-':0;N0OEGA]&#R/(]/RX M+L"!'?9!E6^>AI^BA4EFP]'S8SM`_Q;Y>XU^']3;\EU7Q?KWXI##:,,\V1EX M*!M^V2Q/-I-)W=<"DSG^4>9[G5 M#RR.=E#@Y_E2+@W&R`UL.T\B:[+GQZI\'T#QP]#5Q\PNI6@!"4\3Y(;S/&7? MFS&8*IODD\WR-(1XF(P:RNS+%K0.;5IP`2AO- MPB!YTIR"E`.N!&P638%!8`3#K)LQ=;RZ7V7#D#N\QB0$4BY M8OH0NA%A6U- MYN=A:XM[Z30/[6J9C-M_H2)UBLZXH$!2H"C0%!@$`I\P5=3GY>FS0=0G*>FE MTW0N4@H$!9("18&FP"`0V((=]W9;-NA253H-LD6!H$!2H"C0%!@$`EMP@%!; MR<6JM$%DMJ;CL.:63C-KJW(>SZ`L0T&*!*TVF0+0H$ M!9("18&FP"`0V(J@$O$T7>>KC:+S18[0I1L(%F,9$0QHADQ MF(1^;4-!FJC+9T3DVI#@D)B2LW[I1=BO"W-^(W=PA$M4L"#)B&)$,V(P"0W; MM@`9_G@=1JZ)"(W20]Z+L%$7UA'!-)(1Q8AFQ&`2^K)-`/)U9>':J$LK,G*B MSDW*B&!$,J(8T8P83$)_]O"_W9]K&<+Y8PO3B?PRA$5(EV$:H<[#M_>42*91 MC&A&#":A7]L5$+]7+$S72X1^V<)T(M>^S:/['K^H)?%^*9'V7AA*IZL*Q8AF MQ&`2^K7M`O)[85VZYB+T26X2EA'J0%H7*2."$'^4"*:1C"A&-",&D]"?;1!N]^?:BG#^R`W<,G(BMRYG M\W@R(?UYZA5=#0I&)".*$\"/MS81T17N-J.NXY:R3+HAC1C!A,0K\W]3MQ7[]#[_Z]J'.5,B(8D8PH M1C0C!I/0%ZPEN@ZOF$<;=;%.G0C[HT3$E$A&%".:$8-)Z,\V&&2?N<*?:TO@ MXKIS8TKWU=B)7`U.XOEL2G:BU"NZ$1",2$94D-?5-KG!UBS(8!(.@.TOR`!< MWFCM!]HPP>$`D&-CZ46=O901P8AD1#&B&3&8A/Y(PW-=8Q"[GN;CQL"+L#_: M"@FFD8PH1C0C!I/0WP\U/K'K8,+Y8QLM;7-2']8Y%HQ(3[Z_]2H6HQDQF(1^ M22/T<0,;]S1`,[):EE[4N4H9$8Q(1A0CFA>BKI^&Y8B-R#<^%.G4B[(\2 M$5,B&5&,:$8,)H$_NZ?0?>:ROS:*[C-TH_4B5W'3B?W`D4QQZB7=$`A&)".* M$>V)>ZO$OA%]*X.#PA'H:8FL^.,*3GI:HAG]C-*+.GLI(X(1R8AB1#-B,`G] MD1;HNITV<:W0QQ7L1=B?"^N(8!K)B&)$,V(P"?W97N3FDS*Q4:2"9W2G]:+. M3&;0-SNV$;10W3ST82)\*&*1%,(QE1C&A& M#":AOY[6YXHMR;4^<+E=[\>_D'0B[(\2D5`B&5&,:$8,)J&_GM;GB@W']3!! M:\`+EC8Z*3PC8J>]BT.]6"7;^"MQG?W,*N5>XS%O6C*8_L,Q4O9P.,G[:];>-PHAZ^IQW<@WI1E M&ULE%A=;ZLX$'U?:?\#XKT!0SX@ M2G)50-V]TEYIM=J]]YD2)T$-.`+:M/]^9QA([8&V21[R88Z'J(FW@9[5WZE,ETVT[J3@Z MGNO.G2+-2YLB+*MK8JC=+L]DHK+G0I8-!:GD,6V`?WW(3W4?KDU=/S MZ2Y3Q0E"/.;'O'EK@]I6D2V_[TM5I8]'T/TJIFG6QVY_#,(7>5:I6NV:"81S MB.A0<^B$#D3:K+8Y*,"T6Y7U[L4P\WW8VJS9!/W-YKK7O5GU0YS^J?/M7 M7DK(-M0)*_"HU!-"OV]Q""8[@]D/;07^KJRMW*7/Q^8?=?Y3YOM#`^6>@2(4 MMMR^);+.(*,09N+-,%*FCD``WJTBQ]:`C*2O[>W/)[.%ZPN`6X^R M;AYR#&E;V7/=J.(7@407BH)X71#X[()XTZLG^]UD^.PGP]G#9S\9 M2'P^V:$4M!E-TB;=K"IUMJ!-061]2K'IQ1("]JDDX9?D?I1;2"H&N<H(A9AXD(`^\7C#`1\5B4N8E)>@SV!TBXZ(`,Z#K&6Z&G MBV"DBZV!_",:T+EYYGWC$02#)$.(+Q:7,`9;*/;U;!$,+:HESA?!)2X)(`PU M.RJ*^4"B#1A4H.@Z%6R`Z8=KJ4\@3@*<06G**!%&H\0'$FW`H`2WURE]7DL$ M\^R$C`IAYFUCSL)`")>U5:PC_-`-9X%KQD@(TG?L@D)OUL3C.\A2:".4V6CX@P1&4^ M\T>:5$>,MG&B(W@;&UTKP'2OSW*+YOSY>N]`)&`JY@%DTRQYW$'>]X1$'S$) MXD:OM0'N2SZ0_KP=!-F#L5=Z`R,B$-P:C"0!\(H(N7FH2L M_9-N]@AC-)?;&9,EF8RY]>%S,6P][Z1836(3\-5J2$RXL1K,]8L>=+LD:RM3SWAJXH$]7T8O)SKW'OY=9N,Q MG/2TQR+.Y0(NM3Z:A[[$ZY5E1'[?^]V\ODP??DXK6&2UYS;;^ M!Y/^X^[3'YL+%Z_RQ)CR@*&66_^D5+,.`IF>6$7EE#>LAC5)5!%(:+H*)%[1N&M1C#P?.\2-DS3\\5JY4A$:RD"O3+4]'(CJU*Q]!5 M5+R>FTG*JP8H#D59J`]-ZGM5NOYZK+F@AQ+V_4YF-.VX]JRG0 M!4;H[9Y7P2H`IMTF*V`':+LG6+[UG\@Z(3,_V&VT0?\5["('UYX\\!G+Z;E4__#+%U8<3PHBS<$&=&.=?3PSF4(:(-8TFB-KRDN@@%^O M*K">P$;Z;M05F3IM_7@QG2_#F`#<.S"I7@JD]+WT+!6O?A@0::D,2=22P/_% MO(^B*9F%BSLXXI8#_EL.$H[D",R>M%W/5-'=1O"+!\4*JF5#L?3)&GC_WQ,P M`[%/"-[ZT$RP70F)>=N%F^`-K$];Q-X@X+='$!N1=`C,'FCHA8`QXX4@&(5@ MLE#9WCP8QHVYC4@ZA)L'6#->"()M(0L[S-X@YMKVA]6,S!]L M0-(!7!V+>W0@V-:QM,/L#0)UY+O)A$23&`HSQQ*>D)6-33JL*VEYCR0$VY*< MG>\-`O;?Y\@5TB%<(?@Y&]VT"+:%$+=K#62HA+AMVT%<*2M;"IZM,1SKOS]' M<)$CZ=J.IJ$-9-`XYL%"%](R)LM5'%YS;+42@?CC[=%H1XS;Q2W&,LCIN*3' MN`X1//%&9TNC'3E.Z^Y;C)%ST(XX&4UZR(V:N\Y98D[-X4E#W`YO,4NM8Q:% MJQMG#(G.I9TH/`S'.V..3DO+M0),U1"#L1+EM%W28VZLN>L,AC'GIHB=_MVW M&'/Z12%Q$HFC$G(,G#$#C?E"5TP<6<+*4GHI/^.`0L#C_FD_<;6C4/\"9I>& M'ME?5!R+6GHERV%I.%V"*\),/^9&\49__P]J'Y=TO````__\#`%!+`P04``8`"````"$`)'K1CE,%``!%&```&0```'AL M+W=O"7$25,`1T*;]]SOV.!@;)T`?VB8]GC,SGG-PW,WWSR)W/FA5 M9ZS6*3MDY6GK_O/WZ[>5Z]1-4AZ2G)5TZW[1VOV^^_FGS955;_69 MTL:!"&6]=<]-:9'4'KO0$OYR9%61-/"R.OGUI:+)02PJ1?G[-+?8M6I&/"%4GU]G[YEK+B M`B'V69XU7R*HZQ3I^L>I9%6RSZ'N3S)+TEML\:(7OLC2BM7LV'@0SL=$^S7' M?NQ#I-WFD$$%O.U.18];]XFLGVBU[OSNU&=V_;7*#K]G)85N MPS[Q'=@S]L:A/P[\+5CL]U:_BAWXLW(.])B\Y\U?[/H;S4[G!K9[#A7QPM:' MKQ=:I]!1"..%O M&0_I.NE[W;#B/P01&0J#A#((_)1!PFAHL8^)B+I>DB;9;2IV=6!8@*J^)'ST MR!H"W@I"^K;$>Q5":3S($X^R=6'*(?D:MN5C%ZV"C?\!K4PEYADQ\+W%D!;A M0S9M2I!&-R5[;V_,',R9>:]Y*L_X1I M6IV+*;0<;-)&;5RD13B'F8)/8;"QBAHFYK1OBBEA#8E50R*2(`OG)!\BZ#NZ0ZAYQ8&6H%9(2[7O>FNY ME73*'6@M&H].;6J)((@$*.)E$,;>*E`;H/,;EC7`CSZD\YN2(@A"37'V^^2& M?7&_'%85?PKW1ENU5_8?0;JNXG8(]1Y,LC-B\S-361(D?24.HOO:FF1IQ.)I ML5*MK!U!ECFWN-@(;:%%P:XJB^H]H,C-Q_B9JON()Y-<2Z!-[^AI"WU+:BOT M0C@:=[X47$LDG&1B`FTF8BI-@G"7YV09SM4I,@D:P6V8 MVSB1A3:3,T4F09K(8G56TEO`76FTT?%C;J\%JKDXYQ(T%\\O)0*==I*_A19_ MB]4\25H$]>7%#_;=$L<=_\2JH4>7!%DX)WE7:/.N7GT(DO**/#7U>F03":9%0";;2V)R<)DH\(_H2TGW\BP[<&AHFC M3>K>KB)HF-JPKW%RBFPV9LI)@G0Y*9`NITE>%MF\K"HFL@>M;\>L9KNLIW$P&'H"/C#6W%UP8[3\`=O\#``#__P,`4$L#!!0`!@`( M````(0"TB/^5!`4``/`2```9````>&PO=V]R:W-H965TRVSXI,VT(LT9"4./G[#C6R M30ZWB?/BR]'AT1P..4-I]?6U.5HOO.MKT:YM-G-MB[>5V-;M?FW_^%Y\6=A6 M/Y3MMCR*EJ_M-][;7S>__K(ZB^ZI/W`^6*#0]FO[,`RGI>/TU8$W93\3)][" ME9WHFG*`O]W>Z4\=+[?CH.;H>*X;.4U9MS8J++M[-,1N5U<\$]5SP]L!13I^ M+`>(OS_4I_ZBUE3WR#5E]_1\^E*)Y@02C_6Q'MY&4=MJJN6W?2NZ\O$(OE]9 M4%87[?&/(=_452=ZL1MF(.=@H*;GV(D=4-JLMC4XD--N=7RWMA_8LF"Q[6Q6 MXP3]4_-SK_RV^H,X_];5VS_JEL-L0YYD!AZ%>)+4;UL)P6#'&%V,&?BKL[9\ M5SX?A[_%^7=>[P\#I#L$1]+8N3]4-12TK:JYWX0S;](8I,4BGB3B`_13]>]3XL$ MDPC<]B(2S@(OG"\^$THTJ<#W1<6;>8N0A=''AAR:.(G) M83HCO3!D+J5LA@!\*K*Q/BC_"2<*=4YQX;EF38.$H&`I>D M+4%./*8]8"&426(@51GD6H;7<`/+I.<4*!1`,P+;ZGXCDJP;\7U]"A.D1*,/ MYL;NPC2"E%NP&05R"A2J:C0/(U54LP/5X7X[DJS;"=Q;OL?=DR`'_?@L"I4% M,1)2)"AN*)!3H%``+7@H'?<'+\DT>)H,Y-QB2RF042"G0*$`6K!S/5A9\WQH M3^]O?SF(!AV0%80<)6@*9`A@3B(_7(2D5.5T1*$`F@EYS%$*]_O!2S(-GMPY M08X2/`4R!)B+.V1&2E!.^84":*''GPE=DFGHY,X).(D15:J*-T-[*[*6[>W\<,>Z'N@APIDHFDNL!A-R0S./F$ MP"*2QS171#IQ9Z30%=?+ M]#@HGRZHD0"P#W*"/5$SPL@I)QFEU_8M`ZF!9`:23PBNK+GKQ0N7+-E"':1G M178_)2L?F,!>J9EPR<0E3&FH>((PD,Q`\@FY+JPYD2W4(;H%V?ONMX"=4K=` MSZH,2=->A4.>67G2B7/+568@N8$4*J*[D&WP?A?8-%47M%DE##G3B5N>MVGU M3">*ZD'IQF/R03/#D8Q[!$[:$1U19 M-*X7X'W#J=SS/\MN7[>]=>0[D'1G"HL" M```Q!@``&0```'AL+W=O,!,!R?[YSO MXL7UD^K0HS!6ZK[$-$DQ$CW7E>R;$O_X?GLT[TH\;.P^'KY_MUB MJ\V#;85P"!AZ6^+6N6%.B.6M4,PF>A`]_*FU4"A]Y7_ M!)O)V>Z[4("O!E6B9IO.?=/;3T(VK8-J%V#(^YI7S[?"PI/+>R2PL;QZWABK+(P].,/F-B! M->(+,XWL+>I$#5O3Y!+'T$.9FK1W,:GAMX6@6T'UI`N!::[=?^%-E M/.R7OP$``/__`P!02P,$%``&``@````A``*'<^WF!```\1(``!@```!X;"]W M;W)K,.6[COKW&^K7W]9G'G[TAT8ZQW( MT'1+]]#WQ[GG=<6!U7DWXT?60&3'VSKOX6N[][ICR_+M,*BN/.K[L5?G9>-B MAGD[)0??[^'>'\MA=LM7%E'1UWKZ\S3<5K/N-A'EQR3U\&:6ORZ+E'=_U,TCG(='QFE,O]2#3 M:K$M805"=J=ENZ7[G:C$(]&_)SIWVO],=^/FWMMS^438,U(8ZB0IL M.'\1T!];\0@&>Z/1ST,%_FR=+=OEIZK_BY]_9^7^T$.Y(UB16-A\^_[$N@(4 MA30S&HE,!:^``/QUZE*T!BB2OPV?YW+;'Y9N$,^BQ`\(P)T-Z_KG4J1TG>+4 M];S^#T%$IL(D5":!3YF$T+N3!#()?*HD]#$B4?PU%0^7-:CTE/?Y:M'RLP.M M!\2[8RX:FU?%U1?^&]@OR%A*P1`KM'04Q$=@-! MKQ`/:%VY@5PZ-U&Z`!K@X M00LZ7J"("1&>E%BL<_,PT>`+3Y6+Z\1BRS5,AG',J:I$LWD M95GRYYN,H*\:O)358_=(#/*B<:@FQFH9<4)3U6`F,>&DD[N:"+391H':OI(8 M8J1@?NJKF24S'1`GD6)N,KO+R\G8S`/5H)(98K!4E(YXZ>$H4&&3EN7E7U1R M;.*!LA=)R[3I(+1:,!/'+E`=%4VCQX^8W67D9.SD@:J$9&98=72#F0[XA-E= M7D[&9A[89BXQ(,SUN*053/;9Q=1O8LRBWN7M!,T9VD5-;MG"6F)TS[I8NCAU MZZ;F@EGQ);1AE MNH3=TVN)P=FU(P"6SHPJZS/)W>7U=.SUH4J,_2XQTKH(27P+D5D(/Z)JSYCD M[C)\.C;\T/95B4%R#X0$H:^J)F7#-!>(3WQMB28]R_:GG4CIV/ZU4X#44'?W M!P*O6.8Y+)-)+F[VD?U3X<:3?Y@&M-5RUL1KB;$;7DJGF[_2U11-^/!T2@)M M45+-(L5"S*5@-\32`6GTH5B6]4\LY_@G(+2-%JX8Q"KD&U`P/A6:@!O'0KQA MP'?GFK5[EK&JZIR"G\3M`07[N3[%FXTUF<.;)KBD]3P3-Q[BN7<-P(7#,=^S MGWF[+YO.J=@.4OHS85$M7EG@EYX?AU?;#>_AJF'X]P!72PS>8?T9@'><]Y\>7S.P<[T]KEMT!,5DO%N MAD,OP(AV!2]9MY[AW[\>;L88246ZDC2\HS/\0B6^G7_\,-UR\2AK2A4"AT[. M<*U4/_%]6=2T)=+C/>U@IN*B)0J&8NW+7E!2FJ"V\:,@2/V6L`Y;AXFXQ(-7 M%2OH/2\V+>V4-1&T(0KX9-_U-P=L>+%:L8>K%F&+4%I.O MZXX+LFI@W<]A3(J]MQDL$%SR2GE@YUO0XS7G?NZ#TWQ:,EB!3CL2M)KA MNW"RS+$_GYK\_&%T*]_<(UGS[6?!RF^LHY!L*),NP(KS1RW]6NJ?(-@_BGXP M!?@A4$DKLFG43[[]0MFZ5E#M!!:DUS4I7^ZI+""A8.-%B78J>`,`\(U:ICL# M$D*>S77+2E7/\"CUDBP8A2!'*RK5`].6&!4;J7C[UXK"G94UB78F<-V9A-'5 M)J.="5P/)M$X"9/T_RB^79;)TCU19#X5?(N@\P!<]D3W<3@!9YV>$23Y='H@ M+SKF3@>94%!+*.G3/!Y/_2^=1IL8N5!.YC%U:26JK`?ES)\JS$ M@8NO@=/B`5SH/GEA)8F!&X`O3\\Y./"?N3Q76CS`.72(Z<2%E9S&.3WGX*0N MSF7=KX,&6(/.65C)^YWU_KR#E[EXYSM+BP=8\:!X5N)VUK"(YS4.GCXBW^P= MY_&T>("7#/"LQ.)E418E^3AS)4M7DN1Q&J6O$@J;[0H"BQ05L7CLB>\:#AAV15%IDS59DUF5FB MV/##P-A]\B\PL`L(?M[W?>?^D_XE_KYS(C(C(S.K2MV6/9CQ8*:G6167$R=. MG,MW3D1]\[F:*,TDDT MR]+XVT?W%8L\CB;%;1R7\]FSG='HX-D\2M)'9IPMT_+;1\]W=QZ999K\81F? MZB=[V\\?'7]3),??E,E.4DGYE5:)N6].4]U?)#]S;/R^)MG;*K- M=\V;+"UO"S2=Q)/PVS=1/C2[VP.S,]K>#[^L9O*&-S^\3M+8G)?QO/C'L(.E MYGU\DQ1E'H'&M]$\#EM=WH.>N$S&YD62S;*;9%P,L(+Q,&QHASO%8O-HAB:3 M^*/Y^_@^;'>ZS'.T,6=),4:[W\91SM6:EU'9FMR.>9;,XMR7OWT;?N26DLWG66HNRVS\^X&YO(WR MN##OEJ7(%`8,NU4[<'6_:"UE>[3UJ[##"21C(M)Q-HOZA[N(\R2C]'0SJ9K6 M&,O]H./PE[RWYT]CW-TB*;)1-A](MH%J7C&%S!N2C,D^\O7YK' M3\/!SU-S=9LM"YQ!2,TRG<5%83+(4WZ7%+$I%O$XF29M07\9CRM!WPL'=0)T M4A28NO5M5-P:S&?&_)?X#\OD0S2#O+4:7N3Q(DHF)OZ(,U]@9]E):#-C*Z)1 MYPQ760FY74W%10Y-DN.L`V#TP:ER'!+^-%5B3@83W_JGE[5FTI?IU$ MU\DL*9.X^"J<".>$^JDPB^@^NIZU)!3?YTN<(<>0L/]OHERTQ*R>(VQ2#3%? MS++[.#;7<1I/L;BP89.''M7=#59GGR8SR!",`6F:0HR&K9\GZ%PK5!`:V8:.5, MASN#PYW]P?.C0W\^?'HT.ASL'3PW63VUD(*O]I_O#0YV#H(.^]N[@^V]/;]# MR,:3R01BEZ4X&CQ66TF*$[A(<%1:+<V+1SP;99NC2$9>3:;T10D:1E#F[<.HYV8.]LK$N'8VL<3427/&^/_ M_]M/__Q_?_J?_V;)#`=8J5@O8'6L!8YF3_L4;4LJ*W$T3[`3$RP[RG'R849% M)%N:NC5`2W)#JOMZJ&AOVMH3P;!+4_H_=T'-WFM7T]5\8$_!:L+LT"L7XAG. MRQ*"K^HJFYIWV)&(QV9#$QI_',>+4GT1`TLHE5$ MA#U>9_`EIGDV]Y@8MGE'5X/>:C:/S1.[G+9./[V-8#&@%,PT2JP:-]B=N\#B MM5S/&2^K[W)R499Y<+TN:;E-F)E1ICI:-!]A< MO?8."5?3RN*6>1$5"!(H$2^3V9*RL*'J<2LW]6CA6C"W./'D'12=C\+G'VYO\;EE8OPC2DL2? M7BOT$8:.^H<6CVGK.F(?B#W=9]%AH9A(.^=)(.0U<\P/9P;^#UQ0T8%AETU/ M8H=O!S\:BTPZ*=%ABV"%XMV+Q'HN;4O7.9_6:Q-230F63?J>+#E/G49J[%#8 M*=S5\_0#F$/6K]C5BR5T*1B/*&IJ%IU!1CA/B[BNB<).(7%G28IP;QUQ>3:. MXXG5RO0#)$0$I9"2RI$UE`1Q:2%M-'T(..)\C'BP4_<))0BG/B0`1,R+>X3X M;5)"\KGF23P&<(,H$V(]QAD+V\C`48D0Y29)4RZ-+)7CW=<4T7I_H\OE8C$3 MRP[#.`&X@4.V)&+`]?.,3W'&04R%_;0D32B2F)0LZG-1FZW*Z&.;;^_RFRA- M?I2C(/+]-BI!"BGQ'`ZJ:BIMH1#>7`$_L_/T^,,-X!XX;X9[QT'\OIS#[A#8 MX&FZ'TZNB3*-RQ8.]1\R_,N*X>:'J_AC:5[,X,,'<^5$Y+8M9_,HY;?3"'KM MWH[`#Y[)H`(Q?E4LHC&&@6HJXOQ#_.C8J'!YLU^CRY>AX-AG[<\6!)#J(90O MXV*<)WIPL=>Y?=;\B)X8`M;%KD:\Z!3R11# M`%TQSH;.!-*\R2+857K+(%,`5%I>?\*;9>FMPSRYB7!2,IY_V@-T?/+=^5-M M`1V21T_5[46#'.Y+"GS-/#G_]5-L<)E@#ED3-0@9"L%#$U&SV*V6["5?3O9. MAV#.E"B*@YH\F?\R\DY0O^/$0>=B;YVV&:*^W0"+RTV=TEY M"]E+L8F0&T[_Y/S%Y=;ITR%=A,CB)0.9K4=P#*QF!D-"(9#=S2;W%.=KB(6, MZ+:Y7@4(AA]=+@LJ=IH^AO[7D!II+S0A4LCCCZ#G-,L7[ILG;W][^>HK\P_O MWCX=8"YXQN:"GH;94>&%+,+SA67+ES=BPLFDQK1Y/(L6T`8W6WD,2$X.#'`> MK!Z\@3F,<^"<$-4WEQ15NHXW*7Q7Q`F3^V*Z3'6+0/*;RUI%>YH'!\R=V8=/ M)]BVT$S#2\`&E0^?3C&\X-1A"]JC$!2GKCK^4Q36^NA6Q];C!M(66Z-1*XQ_ M(IHF3G^$?QU$(;+0<[)[NY&Q(QFG-;&K">3-!CTV8>"=741,Y0F!)^X^I@Q)Q0-[)-L@^/R3K7%7"!]DO\2+J>3%AU?ALO'1.)OH]G4 M2V5BT9Y\GW^V6FT==N[$]BC\6$\(?0)D0R;=9Z2DI^]ODU.%S3,"*Z_(P%_D M]KDC`8O#?/37,"H#[^'>-*5L,L(6%6HJU"9 M91I'&#OS?0KCB.H&Y*/0%U%-!(\7E01+NH4A*]YW6-\WEV&KJYSQ2]DRG=9L MJ(UO\8_$S%`$`74'H!/>S`R,$;3B)BKA:(*M#!ZAVIQ7@Q:M(P.$'*<.UEY@ M:PPT6PK?YAE"TTE<1G`4)]B$`CZ#>E9SJ-W-];]@DW*;3?M#K6=M-N$9\`8(E3B@@R M.-C?Q3(G+H2-RF2O\B49Q0W-XQMF!97Q."LQTO`XMO;;5Q\!?!&E/V7"5_;' M/&%T^.I4HL$*,DGFIJ;%@UN&P-7&68X@-)`U[YT9`R(:@FB" M&@F[*%;K!^))4&%#^SP&M^V^*CX/9I^DZ1([^%ZL%2/0,VPIB@ZV_KY:`&F' M1IA@&U%*(YKNX9,M'-N38T.]5W<4J81UF8H*KJC%V=(=/"J1O="`R-B/1>[:P> M7)S%`?$=$&M/-8`@C`\(B7)$Z`4E@#&D^'?+R8TF;+DWJ,U9S@7^8GL(630E MNB!]H[D6V*"_EO"(ZO`2!S3?G$0]#6M1H'8&Q?-(7*:: M!,`JE%\G2R`2!X=0$<(KR>=RC:B6`2R/9E6_@=TGDN;I+$L`=JVB%Y-.EP)X M6TY9.*$NLWQ3J[,+U+&U$@\>FAPT-?TX]JI.JR'IG1KO<.'?EPF[>H);/6>< MV@:?7Q"2KOGYTQ__M3!D?S6]%_Y=009@Z1=4UX"AJ`19X@:Y!736+B#BD7V\ MO;T[W&.2<49+`]V4+6]N35,AX:@0EJ.(:2T%FZ(S/W`!C2JROUL"\]L=2;$M M_LD&G02E,9Q@6I_*K*D46ZM&-Q*@V!@N14F+*0$&![NVR+EJ6']H@,NL%:16 M4,Q`(&HH/KC]>N+8`J5D!4J@4-\,)`'PH-4]JO!@(&N\#U"F)J9X=%AIZ*8& M/2R;O8$[I$:C;`KN2@ME0#T34')@M]C^>0IN6T(M5)"4N)3X@P51)=;T' MDC)PX.%"V$ZM@WB%R:P^T`5P+QA0J3)V7+G#GL+H@R*H&V4L^`G&+J]_)\HW M@YJ!I$PQ5I:#E(*!!H92!4]==QW?9U;-VE%%_LA5.,[.T-L!+#L4"9["K\[N MP)I6PNZG?_E?H8D2[N79#?@@>;6:']@03=5_W=7'UA^0A>#9PODRRDMLPTT> MS8O.GO*EG0T6H=H5#E7]X<>AX-$J2OSQN!J_J]U&O&AX<1;N;E&&P\9N MPWAD:9IX8F$*B*S[6%FM4250B'- M2NT8+!`8N)MQ+GH$=2SHI\VJ*G][R9TE8Y0[B`UB-:SZQ!J_8!P8*YC(!,G> M%%%>[R#>S7#T:,G1'886[A5L]FU9?,UV73)N]Q*# MP+?BZ!`C&_2AK%^]$>1ABTXMX4N6EIY0DSGO@&YPRS.C^P_:Z!-E],SON181\&1+%5&1H6(%I4%,R1M(*UB",,*J6Z:&J-G%.J4EXA'J8V(D M\!V'Y@)AH^KG`G$2`BJNV8:G8(!U[9T>1OT4DR@2`@.*@!Y;+"%.8\X--^T# MQC0%JMEE%.^XB28KM-0832?Q-=S2:J_LS"NY2CX4`+?(*9A7JA/19*WI&0!C MI^=1_GO6_=_=(K:'#M7:7W45I]$')"&8$+/^(?)7-UM@VAPF4BJ"L4J)H\6K M;F[(),/J4H1X`AU0IX^EP)M'OY.%XNS"%$"D8C5!V`W\C=!+_5#2B+5@R^H* M90?9B5V!9$0?`#X)R;(@2@3FHQ,!JLD*S%*UE4!?&H-9"0PU6([O`1X@L:>> MA!/6/&)9BS5HP`R*6,N//5+^R"#U%%W$N)%"A,8Y10(N!&AIM$5(X''0P`,A`8:DD`?DT'B^(H`H`1"F2: M<$D$RIRG:P;-@?V%Z'G^%67=]VM\Y*$23CD1.IF<'Z__G8O=&?$Q^86)<)KF M8$BHQ\Y8(/IKUOGS))]5H-'(T.JX.(74NKY\;_ MV081'H=6[P*8$005T[K"UPN0Z48C4P&WDS<2X/C[S5076O]4=8$3&/A;,7Q_ M\4MYN"%D&OJ+RN;U(D@PG.RT8'0;07R=,8!PXIX'-H*A`."`I)^XE9+KHM(M5V8TBCPD_8 M`R3!RHC=]Y=1T3PTPG>8:$B_Q=Q%X@5,8"0A.C/"48=/MP7W,#=P5W+&`["+ MT(/B2;=O)CW\O_#,O*:':+9!T@)W5+XROUK"D$K^@3;T"?2+`)SQY.G#)_@J M!I@ES2Z<$0N\X#-'M\4AQ.T%W6JY6HZ6SKA3S7@N,T.YB^T0,_^'!A'6=M._ M-8Y<$0Y&&]DUR[U$;<:(-\&("7#C,348J86]U+\Z?24=;;QRHS0@N8K MZ&-@IRWE..(2ACC1TZUHK>42>2@I.GCA7]A$`1).#:P=]$UX]!IUK,U>GV&- M]BPE?PG6:%,>-XW1!2'J3>Z?RI4&U!WJ-=KV[161)H'W'SYU7@SW,P#2I%4U M=.XJPA:6*,B>!^-XX;K#HD.I>1Q^X):7I,42]F_=YA<>\") M2X*!B+VP.8)JFZ/DM#2M'Z%R=$FJS[QS8VST7]IK.BF#EEPZ\.JC9 M_TLR(RNWLGF09-NA_0!&2NZA3J/42:Z7*KMXL00OAE#9<->A6`0M>I$AVJ$H MO!1/%*"YG,D&.!!-<$&'N@=].8J^A!',:ES=OM>"U#"EK&JSE/<2VA?L<-6. M*U9$USH[]-346]7O](:01YN@A.ZP6\`1SJ[D^8&12Q$2QJ#^Y#TSF^Z48-UC M`9WD2-(G/-!_W&DQ,W&UF7*IV"4%JW1%`$?-<,0T1'P!&Z8SAY<+0SV-M[;F_H(?#I M?*^B_VP$/DIY_`YE_1+U[$A&%0]0;*22()C`[RL5=+A6!;D63@55;I]_'7&Y MX([AL8OF*QU@R=A#5-GF.M;-%A(TGXQC995N0T7)PQ[((*,0D#YD\-V*U/L`5$/BDM%B]FN^8!Q3K4UV)F5%LYO8@/%(IP!L"Z'`2; M>/)X8*S9D#DX%[/.[N$-:GC$VCQ3N"T/.MR&$>PF)0YHQ@%_RUI.7K+>84Y] M=*C6H7E2.&>#=4T1\W>7@(`/>\'E!K'8P,H'JE('P0G&')75@X8`ZZP!P0X` M02*[\BK1(\@/1Q;P8*ZPBD)@3?[8='*-R$O^`!WEB',$>]T5=%M+]>=G'P]5 M%/HMXSM;.G6-^^@(D.SN"U#&2@%<*<$M(P1`MG*G+@@2+H+CPCK=-5S$`[A( ML%X4*DUF*F5[D,,I-*T(A.IJ]EZM]A@#[NT<#0[V#S]+Z_DBV:7UFE*/IX&$ MJL]WO[9'/;H/A:6(^MVW&^B]W?!U(G#UO_6>AEJ;ZST8M'?C,A-])@H-3R3) MUC;47J4/J66,I65$BLIVU;W\IOH]X*&@,\T,_3]V,+J]128N=:=5I[XWBQP;[O)N*J?J]@R0VG3I/+8Q56?8$$F=P? M`QMMX3_KIP$\6IQMM2OPA%@/)$6F\(J9Q8=/;Z3B_.'3*Y:X MXT]&%H*`AQC=*W?GTGG9+0#MKWN[H#X*0HV(\SYL\CXI?@_/!)%A567![&?8 MK)H<,8&XH,K'L!E.'_&&%F7[W1]7HT)HID@N+J'3PR%]Z=,S`K?="PP:ARC( MJGGR#7EM1^52H81OZL(]E<7J0-1Q/,4:T@1C53?6N@[GYE%WP%OK3PTG8E`>FUO/QY(^[NVJ1,9V9<;IIT\+RE?BWV29+7*I^FT7+:_05\11L. M0=WP(BIRPUR8,R\5Q4>'1#2Z*::@^;']1BO8]LKI/W\5X4$]`7(P1P`-6]H, M\ED!;BN2J0KPK4)%WB4B4&^5B1P)5*C2ZG)#@3+]%'?M`I[GK+>G'FE]KNHS._!74G&81_K<(8? M7P#+;1'P&J8F;/AK%NR$'[K,_E:+B[MAT_WA_O-N6_2=(NYA![?X5A7PF9JL M]H//_=2T@[D5TE&/VA0H/-^WXKG._>%ASW)7C.\/G1RO8 MI_A0TY-31Z'"B4!OT1EXWC&QGJQ?.8YN>UM'[V22M'4GB M7^NC-QP7%SK`*695CB#\%A,2X]]\F90@4?W0]_IZ`:W$AI:'YA??J>*"!<,; M%B'4KTY;K;4^M>LKP/OCHQT)MN7CQ[L'.Q)YPT>H:X%"3I]TJDS-NBU3+Y3I M]0`=(YUKUUHQH=W'>\.1JV-R-R<94C@/&YV`EMNAZ'DI7'X67^=+*GT8KL.6 MG9:]->Y50_,;?7"UY<_V-%N1EN[ML3K??&`I_.(U$G\"-_%Z6*3BU4PW>V`7 M$>]6&]7G4HRJZ!DE(\8[E MJ:P1:O]D##F1T%55=;Z&2#8B1]+%,Q?BV-"3=#X%J8'GN/,<[[0?]8PWT#`* MW>Q(47=ZG:1"9L?IO<+G"AI;).F+;$9 MR,U!6A"7HPB@$A:OO+HK)5Q%I^I85\NH[@6X'887R@=X*1Z:V)*T*EB/!\^6 M%8%+[&_8(:IO'=`D5L*M!6H!LQ._(N MADA^9T=W<:6B`=/R`1LI1P-_Y:HD)E7SR!T@D3:Z$/$72$!*#7A0)PU@:UB33; M4N-1+<"1#K^*AZRQ-6AUBW6RK4,'0O?,PN_.[>O^X:?O^P(BD[Q$J[4L$DB0_14 MV.V5\R*@-8O4LH:41KW_-I&6=/`<&OXC"&9&S\X^.F`TY,V(XH/UHNP,7Z<3= M5=::->>*0#W`TTCH2%1^B"2;%[@C36L.]`^:WG5N3FQ-9643?'_B8'=_<`2! M[_8IZ`UQ"2B^P!,O5+Z`,/AP`%!7UFE`%4O]$KP55#;?I$5@\.T-RVX/XF"D M(13TLF+7O]!OL%Q'T< MB[`!B2]#_1WWG$==BMF`OISBL*@77BU0F-R9W.KOM:9+MLCU MEIK%'ER,N1\LL>_^E8,/\*QJ-Q#V5GX=@1=<'CXYEH0GUH$^#Y\Z@2GOY(=: MH@4X-=@E9[X^VK)FWWVN9`@+Q%EKJI4U"W?7?(@V>'6*N-FLK9VK4=&-JCO=T5)NP"3UV9DQ?OS>O7I_#T M^3H/WEBLT^1T[';_L$TR7%+LD0V ML;J"(M8`OYY(4P-^VY#OA#^(4H-QM;?#4'/BU6\>J0C\VCY4[4>-Y4$P;6WQ-7[ M<2Q"W0"1Z2J@\ELY)$.O4^OC*RX0EM"W)H%A:Y`DP^N7\N-"X@("SP+^K`Q" M+L[&1!(-T7"):#?)+21>@GO"=4BXWS&E?1&&3E[]>YKK=K1&.;W;\?S1%#Q> M*HZCN>1K(J'V?A7AB5.^E'L!B$5:K%#;78U7@Z]'-5D\.G_6O\S1QVPL/-@2 M"(INB<@U'1H(*&_1R2ND4M="H2+T*DTM)G#7_PM73L#M@S&U3S/4G^["R/^) MDT)6W4O`E',\,:5X+9^)$,NP4-)`/*O",81IP%W%`P;=JH?,LIVO%:I])"=BCT46M2ERVC*A/ MY9TZ-]U!B=29;H4\Y[2>M&RD`M>)-*%5H8UHB2T70L3+K78;05XUC##*S;/6 M7-N+'H-]I-FW1P?"DL/!\\.]P2%^`Q1ZMLXX:;GUIB/OZO&S0.QH>E50 M?8D6E@CW&1!.8_]>N=NI&_0'^BL_H$LP2WY1>/V4X@]W7-_L7R8WV29#3_V[ M#B?UO;0,I M;1!NKE_A%+3L&P.ZE M".5^@XW6GJVL9>^FG=&;E<@.CY#+4^7T(9`&>E^_PHREX1<=X=WHL\P#::^: MYRH>W\KOR^/1H+5"3'ZW./P?@A-77'TW-:^0?.-C2?C%]7IM^)RS6Z$RKZNW M;M93[8_M^G_.AKC##Q)<=R]6_QEB6S]3^C?Z2"E_$AK7%_%R"34(RG=Z?XNW MW?6'UZR\.\>KZ$7PBV3EL<<_6(3.!Z6ZIGZ#?.4]P0Z^Y\.TTY(WMGYX(S>L M_G%@>G^/_8T^CPKAV_SGV%=/%GJ)I_3]J3>MO8;U*/'SB'@'C'Z*'(.PRR9Z MW[*_E^W=2G\%YS]C4K/=.^V%?7FAQVBLF']ESX'Y#H\RM@HAJ,%Z'U"HMK_% M7ON20G^#M:_$U#*XT\N*MOU;L?I^R^K4P_4`!AVZYWY:$&CG1.$(E>UZ4?V&I859>UOV5.Q5(SE$M%6Z M5[4XZZOAJUI@M3SIZTA9@9@Z0-I8/-HXLOB3"DR^KEWPVA%Z&+&VGZ.DQ:"U M/7L9M[;G:H:N[ZZUJ'380KEH]:U*7@&<5)6J,.53,MT^(>59UG`\FYPUR-VK MY,-9FT3W+3W6;G>TLMVA&V^GL]EG+6.%W.TIQFVV4;2D]._L=DY8%0#C-0Q; MM:N6;0/17-%W]4:OZMB_Q9L6=89;6?'4H5B2G@,W$!?7\&S8:[T:7><^>6IQ M9']\KDZD^5\>AG/#&QHB/M#;Y>&7N(<[-".]J=GZ33"4'*&GO<89]GQE+[OA M%VGD#9Y&;-4,*>#!\\8%W.*3.[[^P5_+]>ZCO\53(??PU^#VV^ME01023FU_ M7D;\UY,)GH9"N1J+;X!I5$$F@Z+W2*;*ZPK\XZ7W7)=M59FJ<`(@*1E^/`4$ M]\5);J*PI^,*?^R(;P?)2T5R?=8YH6&/WADV#5T'^/5BIFO!5A%J07L!1>(' MV7OVZATMUS.GE>_@VRG\&SSRU/3":T0WI[B/+_!-"#=QR6TVF`+'%8I?H0$<7OMLNCQ]IK\PTE<'!9AB MY,I'^#B&VV#2@&.\BI/J^G6@"\XQ-D^TB8UTUX=]HY5^J"@_5]8;2D3/3&&S M^BC\8H1C1T[3>1;?7X-JM\T+6<7I%V+?6`5UMRM?.W!]EZUJW.OG=C7^A6S:[0U&'N75H*_L[^Q6PH4IGW[J[EB<`<5XTY%A9.[ MTU1-#N^XRZ.\O5[+N]K'<(L]]7U2_7*@KV+"#J=\ M+=5KP)K#]_SU#_AH=3XQ[&5/4B^KG#$U-8P+N#6K2Q+PN6^A>\8'WE*'0_;\ M5QGKL,^Y>.R2TZ\..KQF]S[;2SC'K2@$R!W?^T-!'6\#5%1#):^B[M)>>9&- M=AX8>6C="XX#1QS9D*NZ-#$D-QA$X)`Z'=]J+2G!%ZW708WOKJ-GVO!QW5N7L_&E5#TH6F=C5?1 MX`J?UJ)^LH-8N2UVLA92W"P+:'`O[V/DU*JH8&+8ZP3.+U8\5>[^JBE]4];+,H-AEF"F3 M[>H-9,CD0>)Z^&=%41[_NP````#__P,`4$L#!!0`!@`(````(0">;B#1D`T` M``"(```-````>&POT!UI.EWMI&JE;E41C!-V>'@!SR1;]7_O.3S/-08NY@))H^[8V)SSG>\\ M[KF7:[CZ_LFQI2^F'UB>NY+'YR-9,EW#VUCNPTK^^YUVMI"E(-3=C6Y[KKF2 MG\U`_O[Z][^["L)GV_ST:)JA!"+<8"4_AN'N4E$"X]%T].#;U;RA2S%)J^]#8#XTZ][+_SN#_$_;_[\ MYLWH/]]^]Z^?S,V_?_ZF^-G/W\I*JH;(!!]4RSP?58J%CV/)2F+!]=76?BUZZO@-^F+;L.1,<(S/-OSI1"\#/9%1US=,>-O MK'7;NOSWBR;:E-M+M0R)A:+?D.%4TTDE34*M;?S=[W1 M*5Y9F75)&>XK`S#AQ+)H0>I6Y/=&^\LQPRD MC^97Z2?/T5TDE@YJT;>9,9D)O&[$,R$@7D7'XJ%Y#M_:UH,;MSK!?@?=M.%; MNQ#)S4);O%W'1&>C8C%-&W@^"H``(L.R[:S;G(>F[VKP1DI> MWSWOH!MT88Z`5BOQ]VJ^_>#KS^-)U!/QG1!XMK5!%`_KJ`=-K%U?W&KKVT@O M0<:+HD2HIJWG'0B]O5FNQ2-=+Y>BA4XT^!,L].T,_P0+U>!_:V&<)J.`*@ID M)D\*+9PSCL[GR^5R,;Y8+!9+=3I6U8CD^R2B+7=C/IDXC11&4Q'!#!`LIXOE MQ02`C-1%I*I7!%,`,)_-%K/QC:8M MBH#*GV0*K.`,G*L$P4!>)0@&\NI<<`6>#^Y5@F`@KQ($`WDU6FP3F*NP,CIP MKA($`WF5(!C(J\*:SZ0"+P?W*D$PD%<)@KZ]FDRKL+'6HJ678F`YSQ/C8]95M;D.8D?K6PR/^&WH[^.^]%X9P MP>?Z:F/I#YZKV_!22<](_ZTX$RZ)P=6OE1P^6L9G4,:LN,30BGK`)4NV8&VOO%*W+=!^-2Z`1N:TWG'#H9DJ2<,A7_13T0N(^ MSC,B5T>>YCP!8B(-"/=4""?`C$7,@R*8 MU"=<78TO@W"7N^/FUHHG5H.$9L,5MPU$27K.`;5#VIU"JN5*D,L[-KU6//'& MR2YOHB3EM_:<*GZ3[@F:,<.T[4_8'OUSFW5DL,AY??6T)5M:8)\1[OG`'3/X M$JXD)"_C[BM^`^:7G30I/4G2=SO[^>/>N3=]+=I\%*F(CN(5B_S=3=0VYN^C MJSB.&2W3RK&8'WTO-(TPVAP57<$IPS,MP3-.!/'@::,?=O`<)1%XXN:CC7Y8 M!CRJ'W@95#\$%[=^D?&`V\"2H`87T*"NPB,2`2SVI`C`"4,@P&UK"0<0GD,@ M@$ETB@`"-$<`<"JBHDT>C$DU@QC(58+^KE1"C4FM9%1V:&59^07]%59J3/EM M13.IMQ#H.`,`H$X8CS0^`NKD%E9'@\T M`M-H&&@(IA"8,;C'G*">8$;(@3``GD&R@@0D,V+T2`.!,%2%)-$P&:I$4@Q# MU&*I$4PU`U,G?% M=*@222`,52&))Z8=ETB%+IO&BZAD_70,U\K*UT+!0^G\_]!93]O:E=1QV:P) M9*6GQ].G>.H(SH@F4V0NC>!TW`*/BZ?2H^=;O\$L$W\Q:,`!TY?Q%Z:A9=`C M7WU]=V<^P5PTO@SXM#TP,)I>)DO$_!C9==84:[_(T1^U:]L'W):RF3,'UP5D MJ98VHIR?-4Y^6F!!6,E:(+QD:CL;9*5$U%J.2T)-:3\>+J=CH$'+;;)H$%V& M@*#DQIHSM*]@?!\<`W45C/5\*<*9K;4)0Y4C&5SYV87R,LMQ!8NM#JSVFV3A M+"WSI7E[+&H'I>=5`&I1[L>BXZD%%OAUB=C8IL[#+3BTO2D,TA+^I`>7W$O: MG"Z3D`)-.[%!P[Z%%X5'%"5'I!?1H5R5M+1:-7%1>VUM?%)6N&OJMA#+>P@( MZH@LC^,?D16F*R2/<561+P38X>QETD))@`TY2I7EU"?3PQ6]JI%U^ADVXL5;E M1$>`^XLI?Y1>LHC"%/,:N,>7,-C*),"(:/MZPT6P'NL^)\>D56`X[F#`+":8 MP!#N&&];9[,A"Z3S%ZR3"FQ+[_<-MRV]C/=QD\W+H+>L@-7`?8T%[-4U#3T, MLB+'X"U$0_,:5[HB0?L*7M!< M)!=`5_600N&5<5J38LU)/:FYX"6YS`HF,HJC]0NS@H2*\-5[NNIQ=`I$E(_) M`B<[81E<3(-SCW7$++)AQX+]CP)Q3(KZB M58#[PHI6F15,7A;J1G,CA(YZM-B5KI3@KI:7$2DO!2[O<,R'MQ`454W/2>U# MQZ6OD)H=&5`[=G/EX+@`MWD2GN2%ME$#N.^C+2^XJ?/E)V7?<,72^^J3\M4W M5-T;T#9BF*&]A]4MSGZJ;-1A$[)0!3LJV@(;[KX-$!L??751`@EG`QQV[;Z, M-I!OF"_`?27#/$MZ]VG:-LK9K"RPWE%9:=(+3C!@DDUY[$X!_(T$&].O,D@* M5@@G_;4%25N\3!(VZ@6YYN=MEW(`43X5J(''!:C86F1;PN+'OE5O_",+I<*A MG<15&:"ZBZ8G3>Q.0DB76]@2VM=UL7:-0D51[:US/\$"TCLTL>"5#`ML('7O M!^[(!V#;]-><-/*KZVQSUKF*7=O!@6&YIOJRV]ZXX'&32F*9V4G&X"M6O.:L MGE05V[+,A$;QFN6+:W'ZQBMZ45?XP%W54T0W,*[&%9'57@HF M1:L'HH["P4Q.BRB^Y/J9T?%D+V6I=EI%"GF?&*(;),`M$<@-9MG;RV8W4)#P M:8?P=.;1'Z4SZ:V!Q30;!_&"_OW>LN&A(;B&CC>W,.#'&IYS$Q],?J97)2MK MSK![H+*`F*:R0$(\^9S@#4\(+@BVIK)`?2QK"M8267#OW<:RLI4J>.@?(POF MF4UQ95/3* M\@#ZP=0WEOL@`2_)(,X0A"O+3<1DN<#2@[<1;2(&SH[1L/&'T\,F8N#L6`Q; M5+%_XA'SWMWM,P^QM12';AX1'RSWL[EA(X>M$A,`R2/IH[D/?3V+/S:E)IS$ M?,1'"60RV!(1/]LY?>Y!TG]^A"<'I"3B7@V2.]C'\P#_VSXD-.)91`ANC.41 M%\/R=Q)ML#B,L+A$>W,PK$W%043AE_$/W7:-#];Y[R MQTI$O(N!$-A\`HC;F5M_;X5WVX4K.7_\U>K(5!%/RK1^M+UX8B5C) M^>L/^,@PR&*8BD&Y^1#`8ZC@7VGO6ROYO[33-T;&4R&BV5I>+HT4.`0,AE8,.W_,38!/RG_-A* M)F]B^-$T&V###_=3(Y0`G\[Q"95<_Q\``/__`P!02P,$%``&``@````A`/MB MI6V4!@``IQL``!,```!X;"]T:&5M92]T:&5M93$N>&UL[%E/;]LV%+\/V'<@ M=&]M)[8;!W6*V+&;K4T;Q&Z''FF9EEA3HD#227T;VN.``<.Z89UC1"SF67"72(6=L#/F-^-"0/ ME(<8E@HFVE[5_+S*UM4*WDP7,;5B;6%=W_S2=>F"\73-\!3!*&=:Z]=;5W9R M^@;`U#*NU^MU>[66\/7.=K?;=/`&9/'-)7S_2JM9 M=_$&%#(:3Y?0VJ']?DH]ATPXVRV%;P!\HYK"%RB(ACRZ-(L)C]6J6(OP?2[Z M`-!`AA6-D9HG9()]B.(NCD:"8LT`;Q)__/QY.1`R:"'1BR^?_/;LR8NO/OW]N\ M*1R5D1SBB!4-?A.KL$S(P5SX15Q/*O!T0!A'O3&1LFS-;0'Z%IQ^`T.]*G7[ M'IM'+E(H.BVC>1-S7D3N\&DWQ%%2AAW0."QB/Y!3"%&,]KDJ@^]Q-T/T._@! MQRO=?9<2Q]VG%X([-'!$6@2(GIF)$E]>)]R)W\&<33`Q509*NE.I(QK_7=EF M%.JVY?"N;+>];=C$RI)G]T2Q7H7[#Y;H'3R+]PEDQ?(6]:Y"OZO0WEM?H5?E M\L77Y44IABJM&Q+;:YO..UK9>$\H8P,U9^2F-+VWA`UHW(=!O-29#`P<7""P68,$5Q]1%0Y"G$#?7O,TD4"FI`.)$B[AO&B&2VEK//3^RIXV M&_H<8BN'Q&J/C^WPNA[.CALY&2-58,ZT&:-U3>"LS-:OI$1!M]=A5M-"G9E; MS8AFBJ+#+5=9F]B(K5"MQ:FNP;<#N+DXKLZBO8 M9=Y[$R]E$;SP$E`[F8XL+B8GB]%1VVLUUAH>\G'2]B9P5(;'*`&O2]U,8A;` M?9.OA`W[4Y/99/G"FZU,,3<):G#[8>V^I+!3!Q(AU0Z6H0T-,Y6&`(LU)RO_ M6@/,>E$*E%2CLTFQO@'!\*])`79T74LF$^*KHK,+(]IV]C4MI7RFB!B$XR,T M8C-Q@,'].E1!GS&5<.-A*H)^@>LY;6TSY1;G-.F*EV(&9\F_W4`BA;JI) M6@8,[F3\N>]I!HT"W>04\\VI9/G>:W/@G^Y\;#*#4FX=-@U-9O]2!=(.SB"QLD.VF#2 MI*QIT]9)6RW;K"^XT\WYGC"VENPL_CZGL?/FS&7GY.)%&CNUL&-K.[;2U.#9 MDRD*0Y/L(&,<8[Z4%3]F\=%]P8`U8Q1K;3M/]^USA0(*N4EP2;XW///??ZLKE[%35Z84ISV60X]`*,6$-E MSILRP[]_/=[<8J0-:7)2RX9E^(UI?+?]_&ESDNI95XP9!`R-SG!E3+OV?4TK M)HCV9,L:>%-()8B!I2I]W2I&\NZ0J/TH"!)?$-Y@Q[!6UW#(HN"4/4AZ%*PQ MCD2QFAC0KRO>ZIY-T&OH!%'/Q_:&2M$"Q8'7W+QUI!@)NGXJ&ZG(H8:\7\.8 MT)Z[6US0"TZ5U+(P'M#Y3NAESJF?^L"TW>0<,K"V(\6*#._"]3[!_G;3^?.' MLY,>/2-=R=,7Q?-OO&%@-I3)%N`@Y;.%/N5V"P[[%ZPD)V;S6^=L#TQ0,!1HO6EHF*FL0`+](<-L98`AY[?Y//#=5AA>) MMUP%BQ#@Z,"T>>26$B-ZU$:*OPX4GJD<270F68#Z\_OH6A+?">KR>R"&;#=* MGA#T#(34+;$=&*Z!N$_,R1A2_2A32-&2["Q+AJ'9(0D-U7G9QF&R\5_`4GK& MW%]BPBEBWR-L)4#>H!$2'VO\O^F]%`NV4FP1K+9[MP'<@[9H%O<2L4P'R$0) M.'2]$@N&0H\"Q^%JX'7B',:UC%6['VU,(L?3R+9.\8<-V'MA#\T5W,X4.$S2 M%2U9+L(PF!5N/T;$<1K$Z7L6$XV@YWIW+'BF+5C,M#G,R)W1QB1R,HU\G3OV MT$Q!.'?'89P[JW05K])XJA&FCF5QB#19A,D[A9/HAHJ[=(*IDNU976M$Y=$. MC`B,'W:'6;:+;/_.]N]AQG43P1]>P(QI2"OP2;DIY19& MMMU5/T@#TZ5[K.!CPJ#C`@_`A92F7]C;-WR>MO\```#__P,`4$L#!!0`!@`( M````(0#VYA3E^@(``$<(```9````>&PO=V]R:W-H965T@"&0BY)4)55W*^U*J]5>GATP8!4PLIVF_?L=>Q(" MM.HF+R5XCL^<.3/87=V^U)7SS*3BHEF[9.*[#FM2D?&F6+N_?SW2DM64S41+6L@D@M94PVO MLO!4*QG-[*:Z\@+?C[V:\L9%AJ6\A$/D.4_9O4CW-6LTDDA640WZ5F)V[Z\H:]Y*H42 MN9X`G8="W]:\\!8>,&U6&8<*C.V.9/G:O2/+[=SU-BOKSQ_.#JKWVU&E.'R1 M//O&&P9F0YM,`W9"/!GH8V:68+/W9O>#;<`/Z60LI_M*_Q2'KXP7I89N1U"0 MJ6N9O=XSE8*A0#,)(L.4B@H$P%^GYF8RP!#Z8I\'GNER[8;Q))KY(0&XLV-* M/W!#Z3KI7FE1_T40.5(A27`D@>>1A`17DX1'$GB>28)Y1*+X_U(\+,NZ=$\U MW:RD.#@P>2!<_0A_2( M21`#7U&'"8:([3N(,\0#?9U(\.UZD6;34&0PUH@0.WVVL&UO82``G.D+^-@= M`UZ[TU[E,"S#VA/$X,`92[>]A4%FH+D\LP%#_WJ9R2P<94;,PG9M-AT&M_U@ M,)UUT8$DF/O+)1GP6-(H:X*8R$H*@JC+BCWI1\DL[J(#3?$UF@QXK&F4-4%, M;#41W_>[M"@*PR@YC,[1@:C9-:(,>"SJ7*S-FB#F*"KL]0=%81A%13T?!Z+, MO=;[X#\>90,>B8K'HA"#`Q7$TU$8SG9#@6$2+.:=D:@*#VX\DFHF"[9E5:6< M5.S-H1R`_]TJWA<)62:!.5U'ZUNX1^RZUP7@'&]IP;Y36?!&.17+@=*?S&"B M)-X$^*)%:P^*G=!P@MN?)5S8#+Y+?P+@7`A]>C%W3?8B"?;KU\\Y/APO;U[*`CUSI86L$DR\`"->,9F*:I?@W[_N MK^88:4.KE!:RX@E^Y1K?K#Y_6AZD>M(YYP:!0Z43G!M3+WQ?LYR75'NRYA7, M9%*5U,"CVOFZ5IRFS:*R\,,@F/DE%15V#@MUB8?,,L'XG63[DE?&F2A>4`/\ M.A>U;MU*=HE=2=73OKYBLJS!8BL*85X;4XQ*MGC855+1;0%QOY`)9:UW\W!B M7PJFI):9\<#.=Z"G,<=^[(/3:ID*B,"F'2F>)?B6+#9S[*^637[^"'[0O?]( MY_+P58GT450K[YL#^*%0RC.Z+\Q/>?C&Q2XW M<-I3",C&M4A?[[AFD%"P\<*I=6*R``#X1J6PE0$)H2_-[T&D)D]P-/.FUT%$ M0(ZV7)M[82TQ8GMM9/G7BQ*`US%"X'W&MY/>HEBQ1;&'8-G6;@"\.[9PM.^I8AIWD@$)9*A/8K,U M.5L&+9%=!+H>0$0FG;^#=!I7.I9ZTQL8$(!-G^#]7%@QE%IO9S*?CW9VFCAN M3BT83F[.3`Z((/[+B:QX1!2/-ET[S9&(>-&X3$;SX:R#'G#-/L)EQ6.NT;YK MISERA5X0QH//EZMQ70T6$&\Z&^CC_H(!^?5'R*UX2!Y.QF?L-)"W[A4@\>CU MW+RE^5^E`SY[J?5ZQOLU:,5#/A)/NQ-SU>\T9VKPS*0C]4[42E4<$SL`R\:\BC M`>S"R;OKH5AIHW&PO=V]R:W-H965T/@-)44C54'6KM$G3M(]G!PQ8Q1C93M/^ M^UW;*042=+!K"L'1Y3SI8J;A@ M6,%0U)[L!<&E"6*M%_I^XC%,.V094O$1#EY5M"!WO-@STBE+(DB+%>B7#>WE M*QLK/D+'L'C<]U<%9SU0[&A+U8LA10XKTH>ZXP+O6LC[.5C@XI7;#$[H&2T$ ME[Q2+M!Y5NAISM?>M0=,FW5)(0-MNR-(E:';(,V7R-NLC3]_*#G(T;3!(=2>#]1A*NXB!._B_%LVD9E^ZP MPINUX`<'3AX(ESW6YSA(@5G;$X')Y^T!7W3,K0XRH8"64-*G3>0OUMX3U*$X M8K86`[=HP(131'X&\0;Q0-\@$GR[7*0.FHH,@ZF"K86L3*UT8OEH8B(`G!D+ M>-\=#<[08I1YY,>SG2W&'CBS\VABLC/0C'?^6'UT$-1QI"!(WJPU-=Q:S+6I M7N`G_E1@/EM>#LL3=7`%QNK>]T6#YZKFI\9B8JMJ,1#>/HO*;E)9HT>*XI&7AM]2SF6+WX1-1T>3%WRG9+VP<8 M$37)2=M*I^![W0E#<'^8M4UZ&Z1P6:`[SN9S:-YFWAL6H'GVN";?L:AI)YV6 M5$#INTNHG;#MUPX4[\WMW'$%;=-\-O"7)'`-?1?`%>?J=:`;_/#?W?P#``#_ M_P,`4$L#!!0`!@`(````(0#A>O8;00,``%0*```9````>&PO=V]R:W-H965T M6S`P:L M`D:VT[3_?F<[)3;ITF1?0C@_]_#X[GSGY>US4WM/A`O*VI6/@LCW2)NQG+;E MRO_U\^%FYGM"XC;'-6O)RG\APK]=?_RPW#/^*"I"I`<,K5CYE93=(@Q%5I$& MBX!UI(65@O$&2WCE92@Z3G"NG9HZC*-H$C:8MKYA6/!+.%A1T(S3L:8#BBVMJ7S1I+[79(LO9PP[4AM;Y"_W1&004:`)XK%BRE@-`N#7:Z@J#8@(?M;//1@D"N+E[V4Y(UOPQ('2@,B3Q@02>!Q(47TV2'$C@>22) M9V,TGKPO)33;TE&ZQQ*OEYSM/2@]$"XZK`H9+8!9A2>!(+\='HB+\KE33MH5 MT`)R^K1.HLDR?((\9`?,QF#@&/68V$6D;R".D!#T]2(A;M>+5$ZNR!BY"C8& M,M.Y4AM++8,C`")SO0#EM/)'5@22:#I08#"F\+0"R^`H`!I;P?G\*##DT?GR M;/!E@YGK[*'X&'B=X=19C4:]KZ,)#L#EFA38U82FPWP8S%AKNAD-8I4ZJ\G\ M;4V3:S0I\$#39%C'!F,T3!FF57GW'E]%[U&HREP#(X"N:N@O/5J\##O0^KUV!,5A`:U%%JK\Z3 M/F>.)`1=SH[*>4T:/1"%HI[9).0`LN)A6]RO_U_?-2T3#F??5$];"C(@6X5E M<54,&NL[,3#=\7Q;@5FNLG?H*\/$_&O5J#)#W(RGAO"2I*2NA9>QG1K0,;2% MWFHN#QNT@!X.0WM@3^%2H>UAOP`SO<,E^89Y25OAU:0`RBB80E/AYE9@7B3K M]-#8,@G37/^MX/9&8#I$`8`+QN3KB[IW]/?!]5\```#__P,`4$L#!!0`!@`( M````(0`!+CS<`PD``+4H```8````>&PO=V]R:W-H965T&UL MK)I=;^)*$H;O5]K_@+@?P%^0H)"CX&_IK+1:G3WGFH`3K`&,L#.9^?=;[>ZR MNZI\")/9FV'RN/K%55W=?FEX^.W[\3#Z5ESJLCJMQLYD-AX5IVVU*T^OJ_%_ M_TB^W(U'=;,Y[3:'ZE2LQC^*>OS;XS__\?!>7;[6^Z)H1J!PJE?C?=.S^?2X*4]CK;"\W*)1 MO;R4VR*JMF_'XM1HD4MQV#1P__6^/->H=MS>(G?<7+Z^G;]LJ^,9))[+0]G\ M:$7'H^-VF;^>JLOF^0!Y?W?\S1:UVS^$_+'<7JJZ>FDF(#?5-RISOI_>3T'I M\6%70@:J[*-+\;(:/SG+W//&T\>'MD!_EL5[;?U_5.^K]_12[GXO3P54&^9) MS%>7KOH'I#B`CE=AR]R,J MZBU4%&0F;J"4MM4!;@#^'1U+U1I0DC8CK3^Z"P)_?+4#ERDC?C(17,_)Z/%QM M;Q=>3;SC31Q_-E=W>^5]YF8PVF"NZO-&K5UG"6K8$;HZ78_\78M`;RB1)Z6R&D,6 M,/LU]/6W1R>8/TR_02]N3GON*KC-'>]X MK4G@=[T="A()$@N2")(*D@F2VX1D!;OT[5FI8)J5)I"5/7WW=([#+@B+$0D2 M"Y((D@J2"9+;A"0*#Y7;$U7!-%%-[.D3)!(D%B01)!4D$R2W"4OQ`)HH M)]#LR^W7=06K"K;L@87JP8-&/WZ4!DU6$\_:?02)-/')S,]G=.;C+@AG/A%" M:1=CM=#E9+F8%^^P&E7;4Q(J>MD;=@ ME4[PO7J5%(?T*ADBK>(&K$USHD)KI"S1+]=(^RI2(XU8'S$['#HFJN^`R"`? MKE@-R!**,4IM?\IGR[H)Y13'7%7.,`J5?=%OMC*MI3)<5VKY1W7^NVW<7I3& MMMD-9]"\Z\'0$2B2*)8HD2B5*),H)XCFK=O5^&`+5M%L"S;(GFV!(G5DH0;V M4;%$B42I1)E$.4$T/^7-K-G^(#_MY,C6T)D[>TK9,@N=+JJ?4H%B&95(E$J4 M29031%-6QNWVE+7-(RD;U$]6Z`@4211+E$B42I1)E!-$\U,NS,I/'X#\I/]T MM)4C:=ONKGW>A2;*,J6101]XT#X*^R&16FD?9?<6MZ%]%&KE1(L61YDMJS@? M]+NV9J0*QJW!CFUM8?S3E6-[.G/R8Q"L=&N@>!3J*#BO:!^%#DLVD<(IHJO" MF8DRPO?L?7,4:9T)J9C+3.BGVJD5H1NC0=13+)BK##'*\A0&^?WRBQ$M3-6H M>4ND2(HC>I$,T;!(3D1HA9@SO=Y3<'[$GQ$&Z7-RO;(0]4XQ0J2/L=7Y4VP0 M=HO+/@&S!YT2%=H?R=K]<(V,0+2_E:L0^ MMW!/CE%]!T0&^;"=7]F(,$I_4%NPST.)U$UQQ%7=#*.T[ISIYD27UG'`ESI! M_UB[S8^[TI0BZK>"4*)(HEBB1*)4HDRBG"":M[*&5O]\L+L8(VDWBD;T/'#! MMHI0G<7`DK,.TR*)8HD2B5*),HER@FC*RAK>GK(VDK`"\?F_!A_-D@DEBB2* M)4HD2B7*),H)HODQ!_JY;5,:4U#0^BBL:B*UTC[*WDO81IWU M4:B5$RU:'&4S;Y]\;4K)Y&M$-\8%,SRA:Z+LC=$@6`G7-D8=99ZYXJA"ZJ:( MKNIF)LKHNOPYE:/*P%-8><;;*Z8=)JF8L:;0/GWB/+/0-5'VX[8;B!,;8Q0> M\+$-/L'KO4J*R#HF1*15G`5[K.5XO54A[>,QNWI]NVRCJ2\UB+4/2R/$**M] M$+6_=M#G@08%,^U+9S-F;Q,1K23YJ)()JIO@<@,_,"AF:A`GVVZ$V5:2]OM0F:\EK>Y-%4R=HYF4/NQ1;^C_DV0_NG'L;B\%F%Q.-2C M;?6F?N\#1O+QH$KP\E3^^6\&V@Y'`:M(SA,$9>@;.=939X!?S),@9[,#`&KB@O M(:^L'2@)'.(.78&BP/'GT!4H"YP2#EV!PL#Y&ER9=G,(/QH[;UZ+?VTNK^6I M'AV*%VBR6?OQXZ)_=J;_:,S7`L]5`S\7:[\AV,//`POXN#Y3A^@O5=7@'^H- MNA\&PO M=V]R:W-H965T&ULK%?;CJ,X$'U?:?X!\3XAD)`+"ADE03T[ MTHXT&NW./!-P$M2`$78ZW7^_5;X0.S#I[.6EZ1R7CT\=EPNS^O1:ER^$>9^6G_X;76A[3,[$<(= M8*A9[)XX;R+/8]F)5"D;T8;4,'*@;95R^-D>/=:T),W%I*KT@O%XYE5I4;N2 M(6H?X:"'0Y&1A&;GBM1B89JMRAZAJ]+V^=Q\S&C5`,6^*`O^ M)DA=I\JB+\>:MNF^A+Q?_6F::6[QHT=?%5E+&3WP$=!Y4F@_YZ6W](!IOGV)T$HV`1^N$,XIT]8?RI0$[7R'*A/2(XU*5:['P&Q]E#*Z%S]E:G@)I)LD"5VX6"!70PJX67M M3\.5]P*[EZF8[4",';'3$;A52)L8@`=Z.]'@]?\@&EE0M%YNJX%K%L&-0AVA MIR0&8"F$S345#I>D=@^#8Q?<-]R;V2MO94P@:P_-V?60Q$0L-4#]N!H,CMT` M,C/DS&_DJ"!8T0A:V$&[+JBSRT0LA5#YCRO$8*%0\VX5,NOV5WJ\J#+;E*&1Y=:F' M)"9BK8UOS9M&,5E@8_U%O]7%C?-L&1+QC%^+UKWK0XD%V0*PC1H"\`B&L,P[0F3SM81(R/*K@^[Z-1@U M&:XN'QNM(?<=F:HMFWXIR"@PP0F;?X42"[+]PCYJ"$"_U&'\IR]NU9%-<0JR MNE8X[:Q0^]M%Z2I(?!.R]6+O-?2^8YCJU*8F!5W=V>$M"X_M%4HLR!:`+=40 M\!\,4\W9%-?U:[/";JX_.ZC)GEX3LO5B&]9ZH33?,4PU;5.3A,2U5S++:[2\ M^U6D/9(=*4OF9/2,5V2P;KWJ8'E_AV,-%WAQX^B-3&!D@@V@-S*%D>G@2`@C M0E!OS@Q&Q#[>C,`7Q$8D=8-O4=C0&D$$-[(!52!W2.UF&FWD%\KM`I#%8!*0 MPV`*D,%0`MMY!&_4`4'+"%X@@'O=PO!ETJ1'\C5MCT7-G)(<8%O&HSF4>2N_ M;>0/3AMQ:]]3#I\DXM\3?(,2N!*.\=)RH)3K'[A`]U6[_AL``/__`P!02P,$ M%``&``@````A`(X6]FSU!```7A,``!@```!X;"]W;W)KJ2J:L^Y)L1)T`*.@&QV M_WUGP)@98$FVZLVR>1D/CU_;8\SJZUL2&Z\BRR.9KDU[-#8-D8;R$*6GM?G/ MW\]?%J:1%T%Z"&*9BK7Y+G+SZ^;77U8WF;WD9R$*`S*D^=H\%\7%LZP\/(LD MR$?R(E*X&<&,O\N(YPI2F$5[S0B8_JR!;I:J2."H) M7%42>SJ:.-/YHLPRT-)5+>&J6CJ/-9RHAG#]-+=5>5!:Z@=%L%EE\F;`/(5> MYI<`9[WM0>+:RXI?N_N1N>`J)GG"+&L3%ACXEL.,>-W8SGQEO<(HABIFVQ/# M(W9U!`X9IO6)8`&OA@;3_P=HS(+0]>.VM=#TPFD1UA%U$Y\(C!`&MTWHPD3O MGZ*UB]AH;<(H$!<7G&!;Q3C59$23=AW%IPJC@M24:I@&@]>F`STD.,L6C@J" M)S9![I@'[720MHTJC!`6X..$&%P2UGFW2IGI,=UU%)\J[-DS_FQ<"HLEEA!5 M!QY>#9B(3N9'H/'+Y//+K*+"%S+:)CN*86&/)<-[!K"HR%(7:_*VM)(JI)0K0 MP511''/Z`2866H*)B].9CF!MW@&N"C0#5A(%UM(@L(KBP+,/@+$(MX#5,KE# MK*HWM5A)E%A+@\0JBA,W&S.?"5B46\0/6:R*.056$@76TB"PBN+`S1[(@;&2 MMX"G,*GN^*OJ/\55$L75TB"NBN*XS1[)<;&:MW`?\E?M`A1821182X/`*HH! M3YK]F@/C%M`"?FP*J[V#$BN)$FMID%A%<>)FZ^3$$$6)[\P$C&[57"513"T- M8JHHN#0U=])L71P3-PUB[!U,M<50-^FN4[XJ[^R.Y#.)`3BMO0FKZUUHB6WE7\IG$`;#T M$X#JF`35];-VJ2V$C"6^8.,LY'8UNW4UO$U48Y=N"!*GQ;)/:(?G%QS5.W95 M4GEXKC)7A_'JY)B(["1V(HYS(Y17/&C#Z7NSTG+U%6"[].#E"-#:N@TW8&KV MW''&\.&@//NWVSCX2:$\\W3N.'"GM+-U![Y"//7I6TC5GPD2]5&Y'ARHNK1/ M$\C?=V,[\?Q)3X/MU(.S1S?1=N;!BWZ//O?@);Q'7WA^>6BU=(_AZ\8E.(GO M07:*TMR(Q1$&95RNYZSZ/E+]*.2E//'O90'?-Z_WY>69(NB[RX9]G*]?$11)$61LOWP\?/Q M,/J45W51GE9!>#,)1OEI4VZ+T\LJ^.M/]>$^&-5-=MIFA_*4KX(O>1U\?/SQ MAX?WLGJM]WG>C*#A5*^"?=.W\X?-N7Q#!7/Q:%HOK1*@]%QL_SEY516V?,!?G\.9]G&ZFY_"/7' M8E.5=;EK;J!NK`V5/B_&BS$T/3YL"WA`81]5^6X5/(5+-8V"\>-#&Z"_B_R] M=OX_JO?E^T]5L?VU..6(-O:)=N"Y+%])])B]FJW8'?J]$VWV5OA^:/ M\OWGO'C9-]CN6WA$CBVW7Y*\WB"B4',3W9*F37F``?AW="PH-1"1[/,JB+!P ML6WVJV`ZO[F]FTQ#B(^>\[I1!:D,1INWNBF/_VBAT*C22F9&"?X:)>'BYBZ< M+*9W4/*-B7,S$7^O7GVL/6D#DV1-]OA0E>\C9!MLK<\9Y6ZXA&(;$6U&%Z.O MA0BQ(25/I&45X)C`^QK[^NEQH#Y8`Q M'.J\P@;]#UZ1%O+*&K2VH'I]&'VU5RU&T&35@%2 MJ]^(>V[B6HM$.BDISK$@B2"I(,HES'"L[@9_^'!9@TD8!PI!Z"U>>!8;&2S8 MR823"1>*.Z$N](*D@BB7,"<0ZAU201)!4$.429A]U M>:\4WJ&\VYI\<3$D/=QT0Q`9)]I^Z>B$NF@+D@JB7,*\67!OOGT*29B;;(@3 M;4$205)!E$N8?2&ZMQ_N\/:&>F"S+S:OZQ*Q0GT?,'R*#F/Z#BGAAK=Z,9-7 MBZE7+:Q4?T`3B_C$&9^86JE^HK*(3[SM)G*WJ64Y63;@'NX2G7^ZP:$\VJ18 MAQKAVF)1+%$B42J18HB;25W),9/N!3.P:^\%NKDQ^S4*<0R=PS#OHM5N;!P: MJ;[Y)A;QFN5=,U(KU4]4%B$5G17[)L,=QRZZCG]G?TC:RS^-X%^_/P;U-B64 MGIA(ET_')J]5IU:JGZ@L6I!Z;CGU,F?+OF.YZ7QN9FG$,DN@)!0HE4@QQ,V$ MRZZ9E%G1G.[;5R<7:?*";Q#*0A_6T+\J4-0I^'U8$XLPXDST&F)JI?J)RB*6 M7&%?;KCOU!LOWR+32=TM,JA]S#$G12/FC$'<&:_?I*&8J"P:2"[JFI=;;GJL M:[E&"%=_+`1*J"KH8V&E4HD40SS`U`X=,]NR==\VE6LKEVFLK@L&\>3R&D2, MC1#)91#?C[Y!M!N9RHG*(IY_P&.0FET8LN0SBSGCU M.PW%1&613*[(NPI\V_)6FEMND)M<$B42I1(IAEB`\4UA-A,=/?#(KX??7?3R66EG,IE$7:J+WE17_*X[]2/+TXN>ISS MDLLB)[D,8LZ8ML^[GENB]#G2U`ZZAKU1;%$B42I1(I MAGB`J:U>;J9NPLQ,@U@"15[1CR/3O?L\2"QB,0]%`HF)RD[D"?25UD?]_0K_ M2-H[(`:Y":012R"#\,=):I%`8J)J[<.=8""!J$]>OC.ZJ[*=,[S<MD87>(&2%D[7>!2&..JD^]`*E4DHQ MQ'R:7M5Y6VE^*BUR0B]1(E$JD6*(FSG0>>?3_])YIZ;-.MEC$0^^=Z&)>ZDN M^!*E$BF&N%=7]51\%_%+HD'ME5IKUE\^]`O^8UZ]Y'%^.-2C3?E&7S6F=WBQ MT&']R64=W2WI;,(K,7*/D;91B)$%1MI*Z8],)_B"TY9H,4+?=MJ7SO[([1*O M.0?6GR_Q+G&`P^!!>V'NH+4P=M#6"`N@G@ZL$,V6:S0$.8+^N8P'1U*,I(,C MZ)-89T@;/G<]M8GH1P2A&HQ4!$4#5JVG".T`?YHMG_3G-'\!6-2^P/)Y>+]< MZQ;HC>"Q9AD/CN"Y94G7?1DL/+[`CZ&1=10BP$.NX(:+``^-I!BAF]_`.ABA M"Z`<68<1_!D*#5XPP9^A$;Q!@C]#(WB1!'^&1M;A+=892J48(_'@"%XF8)VA M.7BG@'7:D7&W#?@,>\M^RZJ4XU:-#OL.!GK0EL-(?,O6/ICRC+>%C9-G@ M`V3[WST^..?XSC.A=]F[LFSL#P1LW'W"?OP7``#__P,`4$L#!!0`!@`(```` M(0`&PO=V]R:W-H965T&ULG%A= MCZLV$'VOU/^`>$^(34A(E.3JPFK;*[525?7CF1`G00LX`G:S^^\[]CA@FWS1 ME]V$.1X?GQD?'*^^?1:Y\\&J.N/EVB7CB>NP,N6[K#RLW;__>AV%KE,W2;E+ M?5F=>O=5'QAH',I3UVCTVS6GI>75Z9$52C_F)E1#9\ZI( M&OA:';SZ5+%D)P<5N4-0\BK9YK#N3S)-TDMN M^:67OLC2BM=\WXPAG8=$^VM>>`L/,FU6NPQ6(&1W*K9?N]_),J:AZVU64J!_ M,G:NM<].?>3G7ZIL]UM6,E`;ZB0JL.7\34!_[,0C&.SU1K_*"OQ1.3NV3][S MYD]^_I5EAV,#Y0Y@16)AR]W7"ZM34!32C&D@,J4\!P+PURDRT1J@2/(I_Y^S M77-$I+K M>TF:9+.J^-F!IH$IZU,B6I`L(?%E84BC7>JME<(219+O(HO,!8NHH3P?FWFP M\CY`T51!(H3`AF@AQ$3$%X0H!+!K*<*Z;8H^5/"Z]A=&8I#)B%KS15<@%J,^ M(EBT$(,C2*=SO,]-@-?N5)-B/FO32D$CA&`K"85C[8$Q,61Y?F(!AM;3)IYU MZ\&)$;*0-1P1Z@>AR2PV`'[H=W&#%[2USDOTU>.BB4&6,'-S^@@AFC#:`X/` MS"1POR(";`HS[]:%PB`DD,*$U*(5ZU%_1EO2!J7Y$$H";%&R:X40I.0'DW92 M23C6HUW,("1>3];F?UPD,<@D%G;I42N$S*164Q)T_;A<@JC:!%+NM@,=U%3-&&< M6H\_8(4VJXOEVZU$$(.L@EG7,=C<1GBFC39I#?)MTC?NT)HW4AC<=,2?6F+& M*HZT;^PZ<:09(!9:KR'6M-T_Z`0RX]I5)?1)-[%2ZV+?XLPP"L.N,TVY!KDY MZ=MYV".&&)1K%$Q[[SF51`'\Z;RC;E(;Y.H$71GJV1Z#M#4KS2[.+W'/Q!=U^Q;FNO1T0WYQ'I=9$1[D0U60UR;W+%OJW7:Z0P%R?HL=(M M?'2#%;4\_+Y6$FUYMS5MI#":=^M/#$GH__)N.8&-4R`P5O4A-4^;=X4C=F@9)NWPK3;WCYXQR;@ M]K:G@PQIY>-/]AIZM6Z:BZYCE'J(T?>B]L349Y!C4W1CHZNZ MU:G)+XXMWF+6+HA5`GL7F)0&^3C<=/1*9ONXPN`/N1XE3&`'D1)>@N`E0<&J M`XM9GM=.RM_%!0>!0WW[%"]?(KA\D3<57AN`NX]3(1;+@:_>"=C`.\Y;RY?Q+5`>V^V^0\``/__ M`P!02P,$%``&``@````A`!C7$'JM$```-U0``!D```!X;"]W;W)K&ULK)S;7[D46*.E:OUY?_OO7])?%Y<7A>/M\?_NX?]Y>7_ZY/5S^X^/?__;A M^_[UM\/#=GN\(`W/A^O+A^/Q975U=;A[V#[='D;[E^TSM7S9OS[='NF?KU^O M#B^OV]O[KM/3XU4X'L^NGFYWSY=:P^KU/3KV7[[L[K;Q_N[;T_;YJ)6\;A]O MCW3\AX?=RX&U/=V]1]W3[>MOWUY^N=L_O9"*S[O'W?'/3NGEQ=/=JOCZO'^] M_?Q(Y_U'$-W>L>[N'Z#^:7?WNC_LOQQ'I.Y*'RB>\_)J>46:/GZXW]$9*+-? MO&Z_7%]^"E:;Z>3RZN.'SD#_V6V_'YR_+PX/^^_9Z^Z^WCUOR=KD)^6!S_O] M;TJTN%>(.E]![[3SP#]?+^ZW7VZ_/1[_M?^>;W=?'X[D[BF=D3JQU?V?\?9P M1Q8E-:-PJC3=[1_I`.C_%T\[%1IDD=L_NM_ON_OCP_7E)!J%BVDPG9'\Q>?M MX9CNE,[+B[MOA^/^Z;]:*C"ZM);0:*%?UC(;3>?C2:"4G.@X,1WIUW0,IJ-Y M,%Y.YJ<[1J8C_9J.[QN0M';G2[]\I.-1%$[GB[<.=69ZTJ_I&=(D.G%N<].! M?L\Z1-+:'2+]FG[OM,G2=*3?,\\MH+C38:`"4'MX.0JB<1<$)\XQZ..'_N!! MW^>)@(-&_6&ZOK,G1TU@PR8,1XOI-)HMWHB;@`-'_6%&?<./:CIIXSA!$YX* M[RL]R;HY&]\>;S]^>-U_OZ"%D(QT>+E5RVJP4FIYMFH+]_/W1].7YJW2\DFI MN;ZD^*")>:`UY_>/X63^X>IW6B?NC,P-R@128LT2:E%0:F,?)#Y(?9#Y(/=! MX8/2!Y4/:A\T/FA]L''`%=FZ-SB%UE]A<*5&&9Q-=FG[#N\$6'HU9)7U_2M'.B=B&M=J-E M0GUU44&Y!A(#28"D0#(@.9`"2`FD`E(#:8"T0#8N$48E`YUA5"5]?1F2AQRK M+CVK&B$:T@I%8RFT[H7ZB`62`$F!9$!R(`60$D@%I`;2`&F!;%PB#$WK[QF& M5M*=H=D\-X;,^E5A#20&D@!)@61` MA=,1R9]Y15.*I'4-H1\G9OU+6"_$3HF!)$!2(!F0'$@!I`12`:F!-$!:(!N7 M"(-3+BD,?GK%5=+2JH8X,0LD!I(`28%D0'(@!9`22`6D!M(`:8%L7"),2&F3 M,*&*VI+ M1!6BVB)7_52J;ZP4JV\%DH97E066;"-59AX?=G>_W>QIJI/00%!/J#0S!9NN M3RA-XR%O5.5,<2[\`2AFJ9FN\L:!=S*)%6#-*2/KZ0Q1SJC7#%XP1V.G7LIIN*[`+BHR1'2QG='*PPDB9 MP8)1Y-FV9#5VL(J1':QF='*PQA]L[D5@RVJZP:375(USAM=,2>1.$HTF=#&W MQE]X1>-:;0,IK]GZ/&8T[QV9,%IV+O*JGY1;Y4B>%S.6LB/EC.Q(!:/!D4IN M/3E2Q5)VI)J1':EA-#A2RZT_&DDZ2]5)9SC+E%6NLS024RQ8>H9>JWTW?XKU M'7D-2XS4-.BJC2]C@Q5,52[O2"LVJ\H6`F M]3V&AY+^HFE[CK^4N)<1:"0GU](OL=0VI3^Y^HYLQ(2E="`&H]!;DE(6^%$L MFB41!LMM1QZL8,2#33W'ERQP<8E#] MU%L02NQ8,;+J:T96?3.D/EAZ:4PK.DI?D,?.\842]V:01DN;(JT#0#&B!%&* M*$.4(RH0E8@J1#6B!E&+:".0-*FJ`<\(;U,RNN&M$9G4"6ZJTG+#1=]U/+.$I7LR_O)GD$@@9MYQK5G(7F5C@R*[ M;"8&3QMY%/!6JY3FKBN?4.?^Z?_G1KH13)X=*C1?&&KDK M@Y%R4(PH090BRA#EB`I$):(*48VH0=0BV@@D3:V20IW#BSC2R+ND M>7G*VG045NX[\E4N0:D4488H1U0@*A%5B&I$#:(6T48@:665>)]A99VG"RMK MY-AOK;;T*;P=%"-*$*6(,D0YH@)1B:A"5"-J$+6(-@))DZI\WS7I3]^<"W7E M(*QMD$S3O()VS1WM0A\C2A"EB#)$.:("48FH0E0C:A"UB#8"20><5U^$6%\P MLO9;(XH1)8A21!FB'%&!J$14(:H1-8A:1!N!I$E5DN_&]!N+L:X)1.`:)`,7 MDI9>BE?>6#TDIJZ5UA<)HA11ABA'5"`J$56(:D0-HA;11B!I997WGV%E728( M*QMDC;4.`<6($D0IH@Q1CJA`5"*J$-6(&D0MHHU`PJ23\^J+3EPF9@9-W$>C ME%)*4"V*42I!E"+*#%K(9->[/Y);*9X7A=`ES_DOJ3OH[/P(8H,B M2J+Z+#R<>CEV8J7XC%+4E5DI5Y>W499;*=95"%W2.BK]?_\DF^AJP9UD!LGZ M9.9MKZVM%!]4;-#4WDA(6$K?#:3[6^%T[&VZI"QC*YV,$25:O8WAYEANI/K[ M54O/<`6KP=I5G=PY5L*"IM-`DX2NKOTAAJ%W;FLK9:VD=3EWE1(C-=-W)>;C M<+F`HHTUV7HW8^0>PH"5S'B\T>S?:"M83:=9QI(J%,Z()5U7B%C22`WA6,G? MO:#[HMV"8S=A8T8V*!*#S%;%+^$DG,'M4.R6,7(/8LMAY-])+81F&6(JX7>-=SKSFBAQ[P*FD0PQ?Y]G M;3J2E+62[BB6*Z-++U?SY3R:^QO_*6NRQLT8D1GZ*!^PDE;>+U?>):-@+0,1 M=E[&KP+&-Y)&7BC!:M5+62,99&,B,>HGE'CU9QO"C3F6LATS1J2R[SA@)C/B M2?4%ZQI8M%1"?49$F?S;V<6FI=DL1_8XPQ`6K5[*&LL@&QJ)T25OA:&QH&,V M=!`#QM(=3ZLO6-=`9*GLV376SZU=)@=W;:B11I<;<*8C3;S^(`9L^![UA0IWE11CP$5^#OY3-NRTR)7-(&]E\VUHI7H; M&K2PEX3$(+,K/+RRL28;OIE!$879"0NR%*<8_LHF%(OE/WHKEW_?AG.GQC.> MR>^=4I&E+(H1)8A21!FB'%&!J$14(:H1-8A:1!N!I*G/*PPB+`P8N=.)SF85&?RPJ0:T28$ MA^1:E>^TG#LH-HA*:Y9*$*6(,D0YH@)1B:BRR"ZX]!:QG&.UE>)#;1"UB#8" M22NK'/X,*^N47UA9([G5,_/3)DI_P?`:"K*#')TY5;JA*[" M2K%)2]156>3H"KR]D=I*L:[&JG<[>FMG:Z6XXT;HDAY3]83KL9_+.W15(ARI MD8J5_J(?!EZ^M58U(JJ&-&5R9ZC_Y!!S5)V26BL>K>C-T%;*\4'L1&ZI"-5Q>,Z\HUKABZ0 MA,1V/3[M3(B4%.C9RRE*Z1)\%LZI=&&8O8 M]38W:&&S\X*1SAJ'%)6LR,989="2DN[^5,.9EW'6V+%A=-)&+4N9#&1;":4FGR.8[4Q9MPI$:B;!IPI)'B?-O?THN[`^DV)SG\$D;6`:E!2[OM M.()]QXS[V5HB9V15%0:=VL$LL5O%B')UQYG>-F[-4G:\AA%%=-\1[-0:*7-4 MD^5X,N!-8\M.N9R6JN([8UKJ`E%XT]2,)[<>UY&6,EN/X2BD3]TX_WD7T-B( MBUEJQK'3)&6E^KFN:3"')")#13DCJZAX6U&)O2J#EF)YG7LSJ<:.#:.3)FN- MU.EMCPWKPHE*>\CGN+83E^6E06],5)8R2]S(J]UC;K>3*V%D@STUR(3Q+`C' MWN4FXTY63\[(ZBG>U%-BIXJ1F*)S+W&I6U,U^Z6>C#LYEU2#9LL^`2O>U%.R'CMXQ9WD7/66G1H[-@:=-E'+4B*` M_!W0C5`OEF&Z9?%7>%AI\3RLD:KE3WE82RTCOK22NU+*7/;Q(N M,(0W0KETL;]IXD_B]^T"TN8F^%@CY\U/_<4S_?6DI^WKU^UZ^_AXN+C;?U-? M,Z-+QL,AUJB:BEF^:^MG!*+9U)H&5&+=W&$[3,J:6+3+^% ME`WJ(E6#FDC1H!XR\J"-Z=0'SSP@1?3&R,"91[.5JDZQA:K1E:HUL85JRY6J M'+&%"KZ5*N>PA3[!]VG0C^3Z0<^3XP?ER85#'OP4K3Y12./`-^39(.X"::4LM0."34HO9K MON^7#QN/U""^&X>XWC M57_X4?_C:)[]_[P_TO<:N]<`'N@#G5OZFM98?9KGRWY_Y'^H`?I/?G[\GP`` M``#__P,`4$L#!!0`!@`(````(0"F<2N/.!,``%AE```9````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`-0>>!2PKM M$%_*BO^/^!HS)KXA(9L!)("R8#D0`H@)9`* M2`VD`=("Z7RB@DMUNPKN\97%2.L8.N)E(Y`$2`HD`Y(#*8"40"H@-9`&2`ND M\XD*F-FOJ(B9&GPQO9`=Y?O+<&-*A[.W3DCGY#28(45J2$I$*:(,48ZH0%0B MJA#5B!I$+:).(1UN4ZK[H_]X@IH=81A2A[P492E!":(4488H1U0@*A%5B&I$ M#:(64:>0CI^ISOWXF73]A=DSLE4^%96<,=*[.PEQUBGZL`:5BB\UGB')$ M!:(2486H1M0@:A%U"NE8F_K=C_4;N>K*?3^D#DFP-N:\P62TH`11BBA#E",J M$)6(*D0UH@91BZA32,?/%.HGQ,_5]7[\'-(I.0]3/,DG%STR?\?R"(G!B^1D92\%B[Y#.UD68K8.49"N@E,U+ M-V6(JV#'ZV6D0#@H*E;9L2^`3;KF+V M;?M%='_BN8D`)8A21!FB'%&!J$14(:H1-8A:1)U".GZF(O;C9\^>^[KW\/!X M]_O-CH8&U5HCB]Z4SIC=R;.KJ_VP6C2W3X'ZT[P(4.+0C.9I:L8=6J^"0^M4 MI'BL9(AR1`6B$E'ED'5512<>VQ5$\Q.CTUO1\X9SIT)2J(B\/@@/BC4BQ M4XE#\^50P*8.T9FT>002G'UF8L-O*3A&S46*6RJPI?)H2Y78&&])AS`LZ$?& M&SU[XP%G3H <>A*4V5$L)U(;2QC)@XV4T;H/830-SO(ROJ[:6D$0 MK9/D$;=5L**T53)R;<7!0EGQ]9^UI<-HRFI_.GLCC*X*]^:MV"*=B>L@`!N1 MXEM+&,FQ<>H0[D=\86]""`J`X.FPFCKZA+"ZLML/JT5!=H:G6,)*,21G1G":DK&49%^. MJ&`DYDM&VGPP058LU9O7P3)U]`G!11//B%^1CPH4!RBF'EC+)B;-_$@)2D( M*$6I#%&.J$!4(JH0U8@:1"VB3B$=TM,V&C%N-!A)9;9!E"!*$66(D4]B!SR/19TS.-1J;74"]KCTZKO*5;?#BD_K939U,OXA\B* MHB>UEHI%^WE:B3O%$M5>LO/$2EZ"*SA_;85`^_Y+$K.[R9;&J1\GA`1ST>D8HG4IIJ MC\U*['O\1O:ZA=OWTR+EYX".^CDB%4^D@-5^GK:R3G%E=6A%&3A,5E.9+>VA MG@CQ\I$@2A%EB')$!:(2486H1M0@:A%U"NF(AFNMS` MA)6A2$FTG2U9OU.4RA#EB`I$):(*48VH0=0BZA12T9Z%%$)(;36I0FJ1"BF@Q#Q*,J=B$O@4488H1U0@*A%5 M@OR0RB:HGWUJD9*0@JLM2G4*Z9":^O6$D-IR5X74(B]8&_,JOXY?@BA%E"'* M'5K1\/!*A2#9"I'BR)1HJQ+DV8ID"^>B#-XW8MY7E)U4K]B*%#O128N$=.!- M&7Y"X&W5K@)OD0H\H&0&*$64(<':($H=23.C2?]`\VI^O)>AY^R"A#M9R1 MOQY$BV`J*=BX?6H:72R#?"S9C#A4B8Z7R#&L#C8J=,3%-]>P(ET9A@ZXU#JI MA;W?Y6H^\0X/^WFL4TZI'J4H'9^T_KG[]K-7;.BI&3_R[\WH?:-#ZJ%J'`=+ MVT:D^*X31O+4,W5HX9Y53U1PW-C?8X9J.2.:+'\>OX*E[#/^^&(:S',E M"XA#%:/UT%DU(Y%J'%K(J57+R%M1E*+NG-,VG^85Z^!)F4-Z7,7!6KL1*>D$ M:\O+QM1)D;OFA8'?%O-5,#@RMB,IG#,Z/JK8M.W?";T0X+^*L%Y#CX!WE9C@ M>ZBY;7&G823A;U&Q8ZE>4?=(N'?]I35^CEM:AX+1$@1X(U)\DXE#"[G)U"'Z MT7?4=#*;AN^(9&Q)LC5WR!0XQT:+]9W66&,\NE@'/I9HN6+DCQ9KAHX)^4X: MEI)W(EI&HM@QZA5UWYB-KE]_'3_JFAOQ8,JRR'MI8>.D/)0XY+_5Y1`5Y7PW M&2M*O^2,1*I`Q9*E1+%RB-*2S=D*?8L=1(;IL=GQ^_7\MMNV_T MZ]>YVTKZTW`[V:HEC/R78"5M&`I7@DF M$S4-A4L]BXM[%2-_Q8YC>;9@]R,L)8J-0PO:(OY\\+4LM>@'WV)LJ5>V]?@P MV\]C_?O.I=[N8E4'NXTM9=O@_,A2/TA)!SLDN9[26Z=F6+I59FZ*&5CI02MW M6FJ=&^E?9YN+MWF0@R6;$7\J]L]!^XZ06_MQEI1;2R9TRK_O&;#3]OGEC M[K+[4M4'%@4+"*ST@Y3T@4/B9TK[EOZ816=QL`AG+"6*.:,WAME[S)=L2\Q7 MC&0YJ!F)5,/([XNA1;[MCJ5Z1=T7Y+WJBU^;!XV58'FQ2"5I'`?KYX;6E3[X M,HTG#BWDOE.'S"F[-^2@BYPMR>><%:GN'Q1'1HI5/&Z^9%?%?.60M^+4*-4P MDGML4;%CJ=Z\[J+3]O%SW,<[1,.%,V*#*'%HV7_O5#]WIXQD/LA847(P9RFI M_`M&HEBB8L5(NKIF).8;1N)]RT@4.T8C*6[VFOYT\VLI;JP$*6Y1D.+!8<]F M/DAQ\!.'EI(1J4-N7[N83\>6>F=),C!W:N;'L02WBLL9E[&!CZ4SXVV`*K:L MQUQ0%=2HV+#B49=:)^7N-U[$*UCZ.F5<#0E2.]ZE[UO=>S.Z3QWRAPJBQ"'Z M2#KW:>K00OHT8T7)Y9REO*'"2!1+5*P82<;7C,1\P[;$?,M(S'=*4C4<*@X%0R4\\A(I#FOBD#]4'**[,)NR6;18T9XO.!]A2]Y0<<@DU9&A MPNWQ4`G?P"[1`4#Y7W?\:,CGB@?]T.EU;2(;AQ^&&5C5/T!E?BD!I)UI8:2-DZ(?G*TM(W^P^8JZ9\Q^]=A@XYXY M7AY3G*`W+*+1QIYMG)2'$D8R1E*'O((F0ZG<(:_^+QA)$$M4K!SRS-.[Y,))+>WG!Z.+63"IEFBY8B3MUXRD_8:15WGZ*>_15Y^9JPH4KE#RZ.S=N&D5FZ56B]G M(U,/N%`Y-<^%&EUH&/E#!'SO6&IDB)@M8M@U$7T#JQLD//.<,&+LIE/UC-N' M2OYL%H`21I)X*2/)LHR12.4.+>6Q8^'0RMMUH&+%2,S7C,1\PTB\;QF)8L=H M)/O-IC(,\=_,?F,R*%,_-2WMCS'.Y8:2?UP-QWN!CGWWUAU<9=-AU]] M]TA";A`EB%)$&:(<48&H1%0AJA$UB%I$G4)ZMJ?I4.7[&_$SXD$N.T1SQ%#1 MQ=/@.'E#YT)!E!-$*:(,48ZH0%0BJA#5B!I$+:).(152.HDY):2]N`XI(R\E M$26(4D09HAQ1@:A$5"&J$36(6D2=0CI^X6[V>$HN<=O*2*=DD64 M(LH0Y8@*1"6B"E&-J$'4(NH4TB$UNQE_57LCI';SXU<%])WX9OQZ7UUAO^+> M?@WW\_;UZW:S?7K:G]WMOINOKZ=3V8\?!FR_6_]FL;XRXX;"'5Y93NAK]_L3 M3+ABOI"_KPS"*]/5E?D(QXBU*;5#'S<8N3*C=NA%^K$KU`XY/78EIBO];C'T M8$$>T-0ZHA.1#GTAVMB5*5WI5\'06C2C*_W*!U?F=*4//5Q9T)5^FH`KY!M] M:\V(!Z0RJK&D0(_)DZ%1.Q3DT1A'%&/ZXL*1EB.*,7TE'UZA%P.O4GI7>@OVC1O^GU0'_! M9$M?<$ZOX9R??=GM#OP/T\#P-U$^_D<`````__\#`%!+`P04``8`"````"$` M_MC6_)$"``!H!@``&0```'AL+W=O-> M)',UG-G97=*KJP?=D7MIG3)]2;,DI43VPE2J;TKZ_=OMV8(2YWE?\<[TLJ2/ MTM&K]=LWJ[VQ=ZZ5TA-@Z%U)6^^'@C$G6JFY2\P@>_A2&ZNYAZ5MF!NLY%78 MI#N6I^DETUSU-#(4]A0.4]=*R!LC=EKV/I)8V7$/^;M6#>Z)38M3Z#2W=[OA M3!@]`,56=J2)(?2.!]()E=)A?S=):!YBLD+"84_-UPS]>('=IWN!\$P!.!B+%.^^%VH MJ!1!V<3DXB\V80).5T=P4!_+&2,@A:?@N$N74UX<_'P6IOR56<&-4XT8R::> M9V-U)[+SJ>R_QQ+!4ZD8.>I1/-EQ\K6TC7PGN\X1879X:G.8Y3$Z7BB;'*OQ M9_R\V(2+AHT?X*`/O)&?N6U4[T@G:Z!,$SS9-EX5<>'-$,[;UG@XXN%G"S>Z MA'%.$P#7QOBG!;9A_(]8_P(``/__`P!02P,$%``&``@````A`-N\Y2Q_`@`` M\`4``!D```!X;"]W;W)K&ULE%3;;MLP#'T?L'\0 M]%[+ER1+C21%DZ);@0T8AEV>%9FVA5J6(2E-^_>CI"1-T@YK7RR+.CHD#TG- MKAY51Q[`6*G[.&DC$K6E#<)GJ`'D]J;11WN#4-LX,!7H5+JF-YFDZ8XK*G MD:$T;^'0=2T%W&BQ4="[2&*@XP[CMZT<[)Y-B;?0*6[N-\.%T&I`BK7LI'L* MI)0H4=XUO39\W6'>C]F(BSUWV+R@5U(8;77M$J1C,="7.5^R2X9,BUDE,0,O M.S%0S^EU5JY&E"UF09_?$K;VZ)_85F\_&UE]E3V@V%@F7X"UUO<>>E=Y$UYF M+V[?A@)\-Z2"FF\Z]T-OOX!L6H?5'F-"/J^R>KH!*U!0I$GRL6<2NL,`\$N4 M])V!@O#'L&YEY=HY+2;)^%-:9`@G:[#N5GI*2L3&.JW^1%"VHXHD^8X$UQU) MEK^;I-B1X/I,DD_'V7CR_U!83"NH=,,=7\R,WA+L/`S<#MSW<58BLY=G]$]Y M4!=_Y]I?"E<1;;&D#XLB36?L`>L@=IAEQ.`4'3#Y*6+U"N(9PC"^0Y"HVW&0 MK]=N'YP'GP>7G;I>1LPT%,EGM#HRG'A&2=[NV8.Q/XY2+M+GC()TRXB)G18\ M'QE./(_>X]F#SST79SE'3):&>DV3\>DQSF"0+1YG13(YG,>PXH3%WE%@&EA! MUUDB],9/3XZL!VL<[&56HLXX46?V%0Y\L+/#`0[TLZJ)$R33YA M(YHXLG'C]!`JN]8.1RW\MOBR`E8P31!<:^WV&_\H'-[JQ5\```#__P,`4$L# M!!0`!@`(````(0`59T-/@@(``/L%```9````>&PO=V]R:W-H965TR;$O_Z>3>: M860=ZRO6Z5Z4^$58?+7X_&F^T>;1MD(X!(3>EKAU;B@(L;P5BME$#Z*'-[4V MBCE8FH;8P0A6A2#5D2Q-+XABLL>14)CW,'1=2RYN-5\KT;L(,:)C#O*WK1SL MCJ;X>W"*F?!6R:1UT>PH%^;J* MZN566`Z&`B;)II[$=0<)P"]2TM\,,(0]A^=&5JXM\?@BF5ZF8PIRM!+6W4F/ MQ(BOK=/J3Q31+2I"LBT$GEL(S3X,&6\A\'R%9+,IG5[\/Q42RPHNW3+'%G.C M-PAN'B1N!^;O,2V`[.T9@\EOVP.^^)AK'Q1"06VAI4^++)_-R1/T@6\U-U$# M4_2J.58LWU!D>PF!_/9)@F\?3]('G21)]_A0QTV4S$*O?&'+@XVC!,"9PP3^ M[8X7EWAR6'F>GYP<-?'"A9,/-HY.!LS[3_9BZ-_!R9/QR<%1DH>FC2@=3]+T M6`'#Z"$[14K3R6E7XK#%:Z2$:<12=)U%7*_](&7`WN_&&;^A!7@-PW6ROX39 M#_MD_P)F;V"->&"FD;U%G:@!F2:7,&PF3F]<.#V$YJZT@ZD+?UOXR`KH8IJ` MN-;:[1;^^[#_;"_^`@``__\#`%!+`P04``8`"````"$`097W@GD"```@!@`` M&0```'AL+W=O0)CI>Y+FB8S2J`7NI)]4]*?/^XNKBBQCO<5[W0/)7T!2Z\W'S^L#]H\VA;` M$63H;4E;YX:",2M:4-PF>H`>=VIM%'>X-`VS@P%>A4.J8]ELMF2*RYY&AL*< MPZ'K6@JXU6*OH'>1Q$#''>9O6SG85S8ESJ%3W#SNAPNAU8`4.]E)]Q)(*5&B MN&]Z;?BN0]_/Z9R+5^ZP>$>OI##:ZMHE2,=BHN\]K]B*(=-F74ETX,M.#-0E MW:;%34[99AWJ\TO"P1[]$]OJPV5SZ$A]F[TW>A M`=\,J:#F^\Y]UX.;M=$' M@NU&M!VX'YZT0.+3N6`2'KOUX)+B.**,Q?H];;)\OF9/:%K\Q=Q$#'Y'3#HB M&(J.RJAVOK('>V5?%9_*30P)T'M_VS(< MY#$Z/@3;S,_:V_B\V(8'@HT;>$$'WL`#-XWL+>F@1LI9DF-!3;SB<>'T$"[; M3CN\FN&WQ9<8<)9G"8)KK=WK`H79^+9O_@```/__`P!02P,$%``&``@````A M`.>$"/,P"```#B,``!D```!X;"]W;W)K&ULK%I= MC^HV$'VOU/^`\GZ!A"1\:*%:\BVU4E7=ML]9R"[1`D%)]NZ]_[[CV":>&0IT MMR_+WJOZM=D513L`AF.SM'9M>UJ,1LUF5QSR9EB= MBB.T/%?U(6_A:_TR:DYUD6^[3H?]R!F/_=$A+X^69%C4]W!4S\_EI@BKS=NA M.+:2I"[V>0OWW^S*4Z/9#IM[Z`YY_?IV^K*I#B>@>"KW9?NC([4&A\TB>SE6 M=?ZTA[R_VVZ^T=S=%T9_*#=UU53/[1#H1O)&><[ST7P$3*N';0D9"-D'=?&\ MM![M1>;,K='JH1/HK[)X;XS_!\VN>D_J2Q`;1@G,0)/5?4J0K.M@*#S MB/6.NQ'XO1YLB^?\;=_^4;VG1?FR:V&X/FK8Z_"V# M;$4E25Q%`I^:9.C,/-OS!O"INMGCX=0>SR>7KS>2:G7BAWF;KQ[JZGT`%0UZ-*=\+1=*-G+TTZ/M^BTM&"6G,=[/L-9K66((^>7&,V`(2%#(H;$ M#$D8DC(D,Q&4+MRS.9(1%# M8H8D#$D9DID(RAV&]?[<17"7N[[CM40@48T$#`D9$C$D9DC"D)0AF8F@K'R< ME5S!AF(9;'?EYG5=R57_PDA/8*62ZY?@P,E*9&*4+T-"B;B@][D\;'^,1SXZ M!VG58D:4G&-,(K(ZIN<@39291$@2V$S,@1:2.+[8-F],:]$/RR"1"4PG(T4' MIQBHH+XP0H6(,=`;@NU/<+=(!?G=?F&/J7(QHTWNH4TI[11?-C-ID6K"21I; MX86"`05UQ8A@+)5$)D!OY$PVP4`%]?M#>.ZFAS52R%SJXI*"BAE%PBA21.$X M9&W.3`HD`3@`4X(/S27!@961""DBLHP&*L@H(HFXG6WLIFFD$+M39C(EXL:, M(F$4*:)P/%*3F4F!E+'!T'Y:FHX$:Z,@4C8^KME`1QEUHR#7W)SX'--18JG[ MMK(]IAEG3G2?J\RICM+,+BTRQ(RU%!;,F&FTS+Y6I\Z87I^!MC1RL#OKF;-6 M4/=X@*\HW(]QQ1O,(KH;IGXJ.S,R)FM;1N&-WRBC=#W$G"OIH_H*M'WJ"/HHS94A+BR.,%"&.#>F M@(@F*Y6$R#).C:YX9(>.$V,=UQ"T&#LC67DC%07/'MU*99-D8\W2$R<:NDJ< M8N(YN6ZF23I>K)CP5X9B'RLG:=)0.2G?AIS"E&SS@:VBS"5?0FX__2(5Y4Z5 M:GC?B#E)HGOT)*F&+I-DB`0K)+R4H="-FI+."TDA(:@I7<&!K:!^G$,-R6,? M\2P9*4A7BT,L::R[]"R)AGJ6E+",B:'(=)<+M2$LE)'YQVI#^C`DB+)F($(_ M5Z9D+@2V:>#448F$4&TH2`[K%Y<8X9BS)`HR6%(-*98)F?`98L'5(KH2O\])3XUYKR)[G&5-]51 MDM10Q*&80PF'4@YE",*Z_R?3"!5*=TP%F2JC=#W$G"OIH\R)35;-M(_27!GBPN(0 M+WEC"G#3Z"C3B%:I*5EL`AW5[U.AAJZZFDA%J0V0/=9IDIXWT=!5WA3S.G33 MR#0+WQ+%\9)93C<4$]%D.9(0?A2FF07=9Y9$0SU+JB%U%#,E>TRFVSL67#["JAESZX88TMC!5-65N7:4_DL5*<@;2Y,X'A.O&>L^/4VBH9XFU33J^,4C+)GN+;P,L>"2 M$7;MTR))SX=$DA!Y;F,BJ:B^!$)'0C?LDHKRY#F0X[N$.58!QA-A+7"\<1?P)L2CL/QS"*"TQ'>`H&ULK)S=D^(X#L#?K^K^ MAR[>!T@"X:.F>ZLAWP2XNMJ[>V9H>IJ:IND"9F;WOU\YMF)+RJ9AZO9AZ?E% MDFU95F23\/FW/PZO=S]VI_/^^';?\;K]SMWN;7M\VK]]O>_\Y_?DT[AS=[YL MWIXVK\>WW7WGS]VY\]O#/__Q^>?Q].W\LMM=[L#"V_F^\W*YO$][O?/V97?8 MG+O']]T;7'D^G@Z;"_SS]+5W?C_M-D^5TN&UY_?[8>^PV;]UM(7IZ1H;Q^?G M_787';??#[NWBS9RVKUN+M#_\\O^_8S6#MMKS!TVIV_?WS]MCX=W,/%E_[J_ M_%D9[=P=MM/\Z]OQM/GR"N/^PQMLMFB[^H#8:?W\+ERT'_WNY]GY^^[\\OQ9WK:/Y7[ MMQUX&^9)S<"7X_&;$LV?%`+EGM!.JAGXU^GN:?>\^?YZ^??Q9[;;?WVYP'0/ M841J8-.G/Z/=>0L>!3-=O^K&]O@*'8#_WQWV*C3`(YL_JL^?^Z?+RWTG"+O# M43_P0/SNR^Y\2?;*9.=N^_U\.1[^IX4\U:G:B&^,P"<:\;KCX7`0CD=@I44S M,)KP:30'W8$_'(VKYEL4!T81/HVB?UV+T)]JP/!I%+W`#KBEQ=`HPJ=1A#74 M(C\R\O!9#ZUV;(L>6*TZ")_8P?YU0YL83?C$'G9'7G\2?#`)'D2=#@(5?GJ" M_:M\XM7A`W]@;\.N-^B'*GQ:1NEAS*@_4/.Z87H8-.H/H^K$;%NC>#9OV M251+2;O&QLND-4)[>H%5ZS7:7#8/GT_'GW>0!,%#Y_>-2JG>5)G%E:K[6Z_= MOUNZL-R4E4=EYKX#O895>89\\^/!G_B?>S\@1VR-S$S*>%1BCA)J%2NS$0^KAT.@?7_<+@RHQR.KIHA<&:`>1X4$E3%VHRUD5IM=P%B6KB!.^`17A<"^'L)(*D@F0U<4VS=9'7 M0FBZ$&0A2%D3U_20+KEE+82F5RXAGH8*DGA:5PY=5=5=7O;;;[,C+&VX"S:D MX``J!%TW*"-T`C1Q)T"0R)!0%QI]CXTBKJ_C*!)A(Q4DJ[6J\J7O<;?7U]%J M(6PL!"EK+=?M(7-[+82F5ZXAXG:HL8C;&]P+12[Z5TE3_VH20+*WF7,P4]%0=DU#.6G(ZPZ8/PO1 MT$(T5%[3T)(U-&*1MG(;(M,$NYT;IDE)TVG2)(`PL/X>L]ID;H1L%1C5:NCA MV)!)-2=]-B&UN-L*F[54M)+5:MA*WM9*48NWM+(0K92U&K:R;&ME58LWMT)F M1^TM;YB>2IS.CT%D'7D3YM\Y2CD+"5%0KZW8H*%7S1$WDEB-YI%5F31%*=M4 MAL@VE;:/Y(4L(A51<(++F2T36 M_++)O#=A)C<,U)VT4>(W,IG:G%W MZGYM>+JB)S-:%_EN*F)[G[EGI-P9U6@`'W4.:YA1+354F^(?#_#%2)_=WQ)B MFHY9%;UM8_[]^/YWFW!GE^CIVID,6B.9[?W;2N=*O`H7ZP-_PH)CAE(0N[6G M?![:HD&@A42G14J*51&N"J$MO*U!A??#49U#@?#T@ M4211+%$B46K0V+TGP/?0=!>?62E<%SFQ1<>LRKBVE''5N9VOBT%H!IN<&41< MH:4<%!FI`11NSDIG&2^V4F@^D>93*^7:8A5]9J705DYL4>^H@M+US@>+3->? MQ`T:T?M_R/8!<[^6PDY%!@WM=BQ&*7W0";<.?]AG)7"",O:^DR*"2J[VL;CO M9$;*G-9YW0ES7(YF*LO42ZI&O,%+NJ0D7M*(E`R^S\8V5]_6J^V?=4F$R.YC M8X-"?7PRZON3L;B%2K44$10A;5XR7<`=,3\!S-%,U2'J)56)W>`E7;@1+YE: MCBQ_G]>2?BUE8\D@&Q2QD3*%XR<_\$-Q/HN6K%J*R.U"0RSI]LP)%AS(LA25 MHYF&6%)%H.NE7RK;?%U*$N=IQ$*,EVU&D8285@RM%V(C9(A9+(5K64=9)!-B9BM`57ZM'ZX@01I:QBB@BBI59L6(FFQ5;S.=J222NX MK;ROQ&F5:1"-*)&TK%3M+$0V-&*#Z)F=<)943!&UIZVKS.=H2T86%#9T^?U2 M[JJL,!^:O5"JU7Q.S),4 M%O`:_-=\*$OSRC`_.QX*'VI%B%8;AQJ-;=41&UMFC]ZT'`!E* M88G!,QLQ3'VGZFLW_7/?7;?]5TN5'>D8)+?_P6T%L79>POL<.@^=&$8Z(L*^1060BFVR%[`O11-I*I:W,2CG]"ME7DKF5 MPGX5TM8"$101=HS\VY`2I6Q*6%KSKB*[5:ZL%'9B36S1B52;`78[43KWFP>:*EZ;\9F-#+7G2(K-LC9/B8HI;>/@1<.^:XA11&;;S.#QK9P MS1'I@JK)4(&&;(PM#)K`!LB9.%:,E5)QB:C51RN4,F=YXU&_SU;W&D7D1F-P MVZZL$JR+7%4=R*>I94QDB M:RHWJ.UPKY!J"T3D88^0G7"6*&7;6R)J]=/*2)E>!9-^(&<3+57&R;(<\&UC M^[*LQ-ELFOUAZ_9V;A3-J9S?]>$M2.<_=@.-C+B[2A'999*@4?T%]-`;B>\C M4M1R5BDB:RC_V%`AM18&34AZ';&55$K%):)6EZV,5/N!PQIM-2Q4M7>\/N,. M]%;3S;@&?;10M2)D#/6E<=!EV]K(6L';1(S(!GMBD`GCT//[[':3HI*[2$W3 MUD[^H9T"[5BE!2*R1$>L<"E1RBHN$7VP1&L/V80GCCW6:*LR3Q?I1WOKJXJ@ M@=Q:&Z320ULFUHH0:7J"92;6`F2U&F0766(:F^B'"X9J]=-==6HD'#N90>&D M+L#R#^T4:,8'V7\4IFK MOLED^Q6#5&S5XVZXUVK%R0"/_>G$1,8*)`*[A+4*%'R($FQ+3W#CR50J+64& M3>Q[+OD5E@JT9#NP0$1F8<3R48E25G&)[;5Z:852>GR!/Y8AO";&Z13S0Q,^ MQ=<=D$%A*^98(^>`3+\,KU^N/>Q.7W?SW>OK^6Y[_*Y>=*\6MP!,^#;;@BGJ\L.D*&(.GY.251[\_ M?=3)@O<9KJC'5Z3.S(>?&X"G,!JN!..IVN_)*S%<4;LW>05V:U.U%Y-78`LU M51LD>05^[^"Q>E2!]QDZUM@O'SK<8&<6@/,;^*-R<=.%&7BXR<&K<`JO^,B. MPA,?4_4\A[P"3TY,U7,1\@H\!P$Z35=F00CNK<[[^,"#$5QIZD$,5]3YAVP' MSCO`\4U7X!`"'-]T)0NG\+I:@RTPU21?A%-XJTK*+\(IO%LE>1E.X9VU!CZ: M+IOD9^%TUL3GX*@F'H53>)-/VH]&4WC+3/(DG,*[9I*GX13>.`/>JR<"?N_B M??-UM]RONV=($_WJ_;F3_L4,_8^+>83OR_$"OW11/$O````__\#`%!+`P04``8`"````"$`==B'B<@- M```D0```&0```'AL+W=OW/W4OGC\WAN-V_WG6#FWZWLWE=[Q^VKT]WW?_\GGR8=CO' MT^KU8?6R?]W<=?_:'+N_??SG/VZ_[0]?CL^;S:D#'EZ/=]WGT^EMWNL=U\^; MW>IXLW_;O,*5Q_UAMSK!/P]/O>/;8;-Z:(QV+[VPWQ_W=JOM:]=ZF!_>XV/_ M^+A=;Z+]^NMN\WJR3@Z;E]4)^G]\WKX=R=MN_1YWN]7AR]>W#^O][@U/MP];N`,3]LYA\WC7_13,ZV'8[7V\;0+TW^WFV]'Y>^?XO/^6'K8/ MU?9U`]&&<3(C\'F__V*D^8-!8-Q3UDDS`O\Z=!XVCZNO+Z=_[[]EF^W3\PF& M>P1W9&YL_O!7M#FN(:+@YB8<&4_K_0MT`/[?V6U-:D!$5G_>=4-H>/MP>K[K M#L8WHTE_$("\\WES/"5;X[+;67\]GO:[_UE1@*ZL$U`V3N!/=#*YF8Y&P_%T M\GXG8W0"?Z*3\.J.3-`'_*E]7+@!F`W-#<"?:!<$-\-P-)DV8;A@.4-+^!,M MQX[A.^,7P+`W[9N_H)O9]1$,8!"M&Q[-X"?<#,@-_`5[\_[Q[-D$:_(U6IU6 M'V\/^V\=6`0@A8YO*[.D!/-@V.U0IMK@MKG[O=2%G#5>/ADW=UT8*,C*(\RW M/SZ&T^EM[P^8(VO4W&M-X"L6I#`3PKB-)(@E2"1()<@DR"4H)"@EJ"182E`[ MH`>A;>,+8_XKXFO*&\'$*CAMT(QJ6-83B=^0EWCR+8*5@TZ_NB M12MJTU*16)%$D5213)% M8XCJ%8Z-VG>,9-RN(`M%(D5B11)%4D4R17)%"D5*12I%EHK4+O$"!L6&%S"[ ML=V8TN?TO%U_N=]#EL*J?2;Q!["!V6W-./'C:,G(%FW-0J%(9,D0DJ2=",%T MXD^$N!71V">*I(IDBN2*%);8+GHA,:<+O==?&1+CQ`^))6Y(%(F03&UIT`]& M(AKM]38:2#AA4T6RUJHI./K!T/>:M]?):X&D&3XO-E`I>K$YDQ90>E->&+4? M!$L&L-XZ8RYVF44KHOY$EHPF[;2,+8%=S=R36#V3UH';BEB'TU9$K62JE?Q2 M*T7KX'PK7MQ,;7Q%X!JY'SE$`TA;#IW:-UA%=Q41XJHH)C1KHA<,1(&9T'6O M+;F1I:RBMC)"W%9."-L*QW[R%73]>VWY833UHSLW+^=?8,M-V)"IA_>(_`R< MB0`L6$6&$:%FSVF6O1C1*+#3]:8?SMS_1%HGY,%/?IF6K**F,T+<=.XW'058;6%IQ=6BT1VAGZG%N:,!PL"J.C>(D*<,3$AF%]. MI@]\7PFIV%>J44:(W>>$?/=B32Q(U;CW@V6*Q2N"A;6EFX,6^6,S$VO](FA5 M'"Q$G`@QJC`'Y4+(/IQ0.EG0Y''**FHI(\0MY1=;*L@`>LB#YK3DA]`4AE>$ M$.M(-X06Z0W*/#ZZQG5;6W*W0[DHT*C4J-)HJ5'M(3]^IOB\(GY&+LH!BP;.43Q0*-(HUBC1*-4HTRC7J&#D M3A6Q%9:LHJE2:;34J/:0'U)3LUX14EOB>GN815Y(%8H"A6*-$HU2C3*-R%U"(OI`I%@4*Q1HE&*:*IN^F$ M?9%L&:LH,KGV53!RHAR(#;5D%?FJV+UK*"K*):O(L/9\>8$/KSLM-')_>4#D M!EZC2*-8HT2C%)$?^$"4>QFKZ)YS[:M@Y,9/E'LEJ\A7Q>Y=0U'(+5E%AK7G MRP^\/%_\U.,0>#XJEVM$WGA@A(0J[Y%(J!X"L(KN*-'N4U:YT1&GKXQ5 MY"O7O@I"4+YS_1.(^JY=0S%!EZRB3M2>+W^(S!GB_8L2K$9J+/`4 MPOUS/JST50LQ8DV2PFY^T$P M%DM)1L[ML3VXD;]RY.2&.U2PC9/(H>A2J0TK,H0MKITZJDM+5(WM_4ZFHWY? M^*X]W_Z(RM.4'-'?]V_?>X;K/*P+]2D+D7>J#T.QM2U8Q4-J?0WXV!VC:HP/ M2P;3$&Y2G.G)$YNEA*"V_7[\,E+9ATSAS4"LA`!3Z3<9V&SF1H1U;N">L<+A>#I;DHH-*T1C6-C:&*D.+DDU;B;?^.Q6CV$\,S_,2?G2^+YSJ[<';F^` M+1*[C-KJ6Q4/,"+.]3BT"'>9D2EFU$ZOK%*T\GJ@PI>1;RK>1B('WA%1LF!*Z/,U(==%]3BIV7Q#B[:`DQ*J*D#,6A-BP)M08^F/Q2\[Q MSPB+TG#4.R?"U;Q$%E?8^Y^C*HA7+DT1-;0J>)2,H2$:PWU3"'51?1/9_FY+ MB/?BA`PY!U-2<>6?$6+#7!L6A'BH2T+LOB+$O5\28L.:T)D4-\?M2UO!N\I8 MD\BBC$4D4EP\[%FPBE/<^IIP1L2HPG/M>#0XL]63)\[`%-'(75W.)#BV-Z0R M5O0QUYX+\NQ/"E$5E-JP(L.+75JB"N\W'(=3M?75GG-_U?HU!WE8*M28XGF< MDVV!*F^J6!6\^T5C&J-JS&.:D"'G?^D)JSIQS2<,(OZ5$A_/Z7&`?V..N-+YYPW5HHE&]++=#0FTG6 MT)M)%CD3(B%#3O44T03$;4:=6?G0O3W`3X.)"EVN?1>$W,EF'3G/Z2I4N0^\ M"+F3S37T1P:"I48F&.F1N7RT-T6PW)@L@O63YM$"50Z*"/$?W%>-B7(K:UB)3*[3K0#@0^\%BT*IX7!"Y MZ6^1DY\)&;(J130!<=OBF97'^IK:'RJ&L\GPS-*CNE"@Y"1T'CT1P813%2*^4*CB!`G7DR(LRPAQ*H4$6P` MY#Y#-'5.'=JP(,3N2T+LOB+$O5\28L.:D,Y^Z)^]HLG M/0LT=!=_0IS7,2(G]1*M2A'](/M1-;5/Y<.;OER5M.<"D=-^J545(2?UM6%- MJC.I+T_3\L$OY?[E71<^]I4K$2+G34O[.:_]/'*W.3QM%IN7EV-GO?]J/M6% MERL^WK:8OB,>S3_9#XG%%7BU,X1D5U?&<*69!N(*O"8QC^$%`6T#+SW, MS2L-^@J\B3`W[QGH*_"-\Z?FW"):N8=OG\_I[\,Y?'BG_=P/YO`9F>:?AO-/ M]D,EV<`0/JX^8W`/]WWVMB=S^(I%-Q!-YW$S487_;#J'+SNT'MZ:FIMWHO05 M>)5I;EY4TE?@A1\(;/,(1;0";^%`8.UGWNTE^$;[;?6T6:X.3]O78^=E\PB) MT6^VR(/]RMO^XX0_3'_>G^#K[.8WZF?X&G\#'Q;VS:K]N-^?Z!_0J5[[??_' MOP$``/__`P!02P,$%``&``@````A`!R$&OZ5````J0```!````!X;"]C86QC M0VAA:6XN>&UL/(Y!"@(Q$`3O@G\(G[GI%Y4)18VL!]&4,2^+)&?!NZWZ^X(2IKCQ:7"9.!#`K/=;K1W MR5^"BZRZ@<5`:&T](8H/E)T,927NS:/4[%K'^D19*[E%`E'+"0_C.&'N`K#: MJVK@/(&*_0.H]$NT&O\C]@L``/__`P!02P,$%``&``@````A`*_Z+\^]`@`` M[P@``!``"`%D;V-0&UL(*($`2B@``$````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M````````````````````````G%9-3^,P$+VOM/^ARAW24K1:H30(6A`K\5&I M!8[6X$Q:"]?.VDX%_/J=)+1-J!-6O3F>>>,W\V;L1.=O*]E;H[%"JU$P..X' M/51<)T(M1L'C_/KH=]"S#E0"4BL]H@_/XYX]H:G2&Q@FT/0JA["A8.I>= MA:'E2UR!/2:S(DNJS0H<'//LW?,R(<1Q=9)@4'1UG&=X(;;77J>E=O'&44UHT1L9LASXUP M[W$_"NN?T8R#Q#$%CE.0%J-PMQ'=(!1%FX(P-H[6[FR-W&G3L^*#RG82]%[` M8D%G%*S!"%".:!5NU4>YEIEU)G[6YM4N$9V-0G*H-LMEW;>^%J?Q<%!ZT*KI M642HF)"AR7$NG$3[D$[!.`_EX:#.N611,:X(;51D%RIA5\I1O=@?5:DM=)WY M-H>Q5E9+D8##A%V"!,61S?8R_1]_-H7OCY@Y.JGH-,MTRAXR$FP;NRA]E4B# M51,RAH8$6\B#68`2'V4[,9H-=@\N-]AURATH6)1DV)02]\>]IN9A3R#S,M2U M4%0A`9+J2GV1>]G/4%*??:WG1@D_Q&G^>DG=F+"Q7M&4VC*1=E\VS0U?$H`] M@S'4N7[VLR+N4LN$;A-V]36/?HV.WVEI&]PBU`1B_/MT95FW_ M.2-;@4HJ^RFR.;Q0RWO9E)#]3+L@.TUM*2IEZT!(R^9TJ?GEZE:X)9E.B4_\ MV71BA@=@3OT8?R]]5N(`2$L).H]I*4&!\0A:B=1.K1720:T5_J.J3QLGQY2VZ%>K6/V5Q/Z`;>/);-S:B<^&2B^<:^VXAN MZ)TTL@@R7H):8++QV3<43_M3]?\2#TZ/^\,^O=JUO2C<_:G$_P```/__`P!0 M2P,$%``&``@````A``WM[8TR`0``0`(``!$`"`%D;V-0UG7U1F]\I*\+P_/ M.92+7C?))SBO6E,ADN4H`2-:J^LE&*PH\(!#R"3^!X]V!V3Y]GMW7J)6)&3>9K/4T+6!:'% M-267KR4^ML;[;`+J4>#?Q".`#=X__YQ]`0``__\#`%!+`0(M`!0`!@`(```` M(0#*#;D0WP$``!85```3``````````````````````!;0V]N=&5N=%]4>7!E M&UL4$L!`BT`%``&``@````A`+55,"/U````3`(```L````````````` M````&`0``%]R96QS+RYR96QS4$L!`BT`%``&``@````A`'WALP3F`0``]1,` M`!H`````````````````/@<``'AL+U]R96QS+W=OG&PO M=V]R:W-H965T&UL4$L!`BT`%``&``@````A`'Q+`QI%`P``!0H``!D````````````````` MF1@``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``& M``@````A`,ZC;;&8`P``<0L``!@`````````````````$BD``'AL+W=O"HL" M```Q!@``&0````````````````"E-P``>&PO=V]R:W-H965T&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`-JNYUC^*@``AID``!0````````` M````````F$(``'AL+W-H87)E9%-T&UL4$L!`BT`%``&``@````A M`)YN(-&0#0```(@```T`````````````````R&T``'AL+W-T>6QEP`` M>&PO=&AE;64O=&AE;64Q+GAM;%!+`0(M`!0`!@`(````(0!;G]R&M@(``.,& M```9`````````````````$B"``!X;"]W;W)K&UL M4$L!`BT`%``&``@````A`/;F%.7Z`@``1P@``!D`````````````````-84` M`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@` M```A`.%Z]AM!`P``5`H``!D`````````````````DHX``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`!R1,?#Q M!```?!,``!@`````````````````9:P``'AL+W=O&UL4$L!`BT`%``&``@````A M`*9Q*X\X$P``6&4``!D`````````````````<,(``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`!5G0T^"`@``^P4` M`!D`````````````````7=L``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`$6^&0&/#@``<$4``!D````````````` M````+>D``'AL+W=O&PO=V]R:W-H965T M&UL4$L!`BT`%``&``@````A M`*_Z+\^]`@``[P@``!``````````````````M08!`&1O8U!R;W!S+V%P<"YX M;6Q02P$"+0`4``8`"````"$`#>WMC3(!``!``@``$0````````````````"H J"@$`9&]C4')O<',O8V]R92YX;6Q02P4&`````"D`*0`("P``$0T!```` ` end XML 14 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } ZIP 15 0001144204-15-029365-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-15-029365-xbrl.zip M4$L#!!0````(`#"(JT84]TX82'$``$6?"``0`!P``L``00E#@``!#D!``#L77ESX[:2__]5Y3M@E>0)R8D]]S/)7/+*!'F6I[-W<[GTF^M\\INB?SC M\+N_??JW2H5\82X3U&1R04^K3EJ#65QF7)^:6N;5+\(=9N:*#2M4P&^0_ MC>I^H[9?;_P7^=_;J_\C9_:(#.8W:-B8_`@EQ=DRU^;!`,O/.=I@XS#I1]7-- MY37W]O:V5>HPJ^19&:%2<_N/J\M[J\MZM,)=Z5/72M'"7Z%]/#^77KUJ-E\K M$>:("]BL+YB%2IY:9F^;"DMX#MMN4\NOL)>^0UWJ>V)P#L]Q1987N+X8I,4F MF;75\9ZVHT343*UBF)61;JQ`"$#@M')1*A:LIPO:C&>7@82,[.S%ZF;GQY2, M`MQ]8M+/+A*F97#C4L!@=AF5A$7,=!')K>P"D)"5W>^+*?DA):-`("L=2OO# M,FTJ'Y5FHX0,UE^<5_#SQV4"U($O7H$-I):@'Q/R"3O"OE00OV-MHCK&OC_H ML\\ER7M]!_&KWG4%:\.[@5N)._'6B[1+9!OJ":W%B>?Z[,4G]\SRP0@I2P$M MA+;"BA(YH/G6,!_@+[+7\HS:0RW\'5(T+,%W6SL?MH>+QPWM3W65HJ"/A//PJDF%4]UN"-:L;*%BSNF3!-A*(;:RB M8!OO$6QC:8@]DC?NR@DT].U^AF3BE$5)IO%@[*ZN9.#O[I(DLW+6+2&9,3.U M+,G45D\RM:5*9N5"C11FOMW.8)!VRGO,56/$M\.TM&U^./%Z_"@]H\0>W,![QCUS[[*^`]Z%A_WC0@MCR MZ(7+#U;!N$MD'21GV%Z48`,A,(CB%H_8(78LK\^E*"S?GXFY./-,0ONTG=GX M2!K;6507VW--X@9$==-NN M+;/@9`28B$;RY,]-(62FDK-[!3TPH3%);L5,!0UZTEPW5&WL^(( M2K"`8^],9G4,,S,\FHU-PD?,K0;(K`"I5JL;!)`AMQH@LP*D5C,V""!#;C5` M9@;(1KF8FG8Q<\<@NYMD08;<:H!D3:/HL/:R[ MAG7XO_8:WB@KG4/\GKN&=0"^1AJN&O#7:#ZH;R:X=`V?4FOVX-TU[:VXAM-< MH)(S&,Y#PT83-5PUEM^'DPR;FZ9A>E8:."IT-4EZ#A>%+;,$<+>^#%%7WAO:"7&4IK9_TJ#+XQQH]?I320 MS_RZFER?=WX=2BQ[C9#13&"U.3M6US#L>#]PUB#(26&U^1ZL-I>_GBUUALUP MP:0\GQFMAR M^OA8U+-]LK>1:(3-AC#]/?M-&Q:>+NA`5SRR>]SETA?4YT_L[*4/6E!]](Y) M1H75A9^G[(DYGMI!&F5(0O'"M;P>N_>!8LQQZ5D4U;3:V'N5*03;8B2H[=XK M=D^#=*-!6E1+F@;IK6!/1X_BTK&T>W[=/8]+2L,J8P)6PZGX<,IM8OYW*L3X M4/.<'#)Z2-W@(T3ATJYVFAX@ZWAO$5:)&N(`=-X,(TP:-<8*"P& MZA6`?DV=P)F_89%2YW._*6B?LN%>QXD%W!:N-HJ4(9 M@;48)[<6=0%>&KX9`92&;E[0+4+P5E389@1OVNH6![I%L;H%"QRGP%=;W0)! MMPA6MV"PC6?:JN']`5?O6J MV=R''.^O^P$8?E!^;:P5FS\!(,?%B46O@QX3U/?$.!IG)BTI\/$:,QH\9:[7 MX^[K3;XEZO$V)RN-4Q.`=W&>.FA(;OX';9GS_U+," M3,/K94B$R3O6GAH/EA1YY[@;PGXP2X<`_G]^VAZO*>8*WQ_!2QL3SAW:F;N) M:NFP31W)PC92=24;B1N_51WM+`POYFZL5DK%*E,KSFKYG$N+.G\R*L[AC9R[ M[7K8=KK5L4JGMQN2][Z6&Z7#?YI9[28J3;9\I@SE'>NH#7RNCUY@[D9W2H?W M`]?O,I];Y)A[CM?AEBR3"]?:"FG):F:2C!.@5E!'W9GT*QO,34RO%;Q)-OGW&'B!)(ZGIB?Z;W2X9%E,0?-([.)JBS) M>ZKV9.,M06T8M=P/>H^>,[^Y,$#I?UZ'+:6JRM"KU^MYK@HIE!^1-X&/GA7+ MI!M6'SP:#\9N1H-FB:`A5!DCETIL9O$>F)3/I8OK\])ALV8V]VI&,Z7[5QJ/ M21W.)@3]?FA>J7-,(?JQV'V7,?\4E.AX:)=E"V@]=J"R^24&YN_OCG\`SH-( M?^!`Y'=U=/?EXGJ?&'T?_GLY(.M0MAR_*8/<% M;Y/2WSO^`1FK[N3R[.AN_]'SNV%-E?.CJXO+/_?'JCI0:?<7_W$6-G40DE%I MW=PJ4F8GXX!$18]O6JV;*U5Z1!ET=<_MX&-]"Y^W1R_&TN\!OA:B-Q(Z45(' M^]'V1$\-LL?*JT?@?)%2:)W]T:I<7)^>(>^U^I:)DGBWADJ$.KP#`>]_!Q)" M]D$I)INK'[37/_C>W#%"3OBR>%H6^?"C#?"/R4N21'X?+G>OV1MJ#?%I,'=`_+[Q6GK%\QN_##2E4\?'39A MP1+9]XP?#LCQS=WIV5WEY.;R\NCV'MJT/,>A?@ZW(_@65@2U'TK8!0#D@./JA#RN\*",D5!J9GGT M@)&$AL%&P."466J::SH2ZIN-A&U??*/]=Y2O^T91P("++<_Z7\!HE;UX+NE' MT9"(3M)1T9`].DMG&":]`Q0?*X<>MVV'+=DXY*_FR#RID52&;9J'^W]_!]." M=[I3N+X].CV]N/Y2N0L;;\3Q:N$D49T4A5DV=HS"8T!#7$/\FR#>+#P&E@CQ M@CCVY0[KXMD-[LI`X$177AJ?F"30Z=WCL[5C`U?[P`"C26F,O`U9KOF074>-=X7TV\ M5QNU3<9[01SZOCC*T&K@9;\/*XZ3P7;IUDJ\L( M=7UN\;Y:DSW\GO_F=WS2]@3QH;B+V]3\9^8\,=+S7+\K"16,6'@:+&X`LPF% M-^DUD5L$&\:=J=0=D!X=$)\)M8&%J3K5?M-.N'N$PE_(A"!6Q`AF,0YM0954 M=N&Q'>#"R[8J*%B/6H*:H(ZP0 M$I"HI:^8]?I,^`.E1O97P$-$35\>.Q3?DB6YX#6S'Z#[I:V(W=4K8N<9'S;T MBEB]%%*OB-4PZ.@5L:LR.[BX&>`LZQ\>M\)$N!VHW>80@PYCG4V>&RX">WIE MX%*G,4RS\`C0`-<`?S?`]_3'O?S=]W(';_=>VW^F0B]WS6O50A$"U>*M6ECR MDMG<_+:&NX:[AOLFNO'ECL)7*&37(Y)Y1R0%W2J0[]B[6BT\%#32-=(7@'1C MHY>4%\1]+W<4?LFD)-2R@E[@J'4I-NL+9O'1`6L;&KSILX*[M;32X"^*WESOLSG5K3!&BLWQ7_*_"9\+"K/C/=1#3?,^B,-U+ M="_9J%ZRL]&]9&4WQ824Z;T/3F+OPY%EB8`E3@O7AX+K+1!Z"\1*<*C7ONLM M$!H&>@N$G@6:S?K'L0ZT&[2IY0QK? MR\1WM:X/_L[?>2]WZ!8[[R?FVIX@?3K`C8NY.>XB?+HK`GOZ2.69CU3.;=)8 M8U5C=2ZLFLV=PBMS_?WI!PV&N<.D[[DL=Y=:A%"J".RMD9E:[J'&9AD͙ MIT:K1BO^KC4V&JL%<:H?,TBU'.YRBSIXP[T,'!_GF2433]S*[YZ-(D16>B7U MIFUI+M?RFYO3B->(_W#$-S9[GJ<@;EYO)]`+I?5"Z?P_S)5WZKE-)>J.HCM* M(865&2=7]W*[::,('676306+6@6O*HX7P:>:4<)6:[$?/6$SH19*1RTJ-O=Q MW?8!47DJ#AUX@;_?YB_,/GASP?6P?C'\90^I2?X4HY^Q+#YM![+2H;2_?Q_T M^XZZA((ZQ^%U$O==QOQ3+BW'DX%@LL5>_&/'L[X>?O>W[_Y&R*>X["C/31N/ M!&:N5(<7W#%UH,$)+H:[[U+!CJED]FWT26!8'4YH^/!PQ]J?2[>&^0!_<1UM MRS-J#[7P=XEP&Y1#+9_;#V:M=!BA86)M^[SK^TD*7(O9JA%V7X7V6=VU$@@O,!C]&(L_=X'@5:4G$E2%6.E)KK`HO==5&K-K7K&Q@OU M_SAM5N$4>Y--AA;PB0_502Y<7-6+][C<0L=2U(]VBGR@4FKU+;/PMWTL=J=. M,:DZ#5<)5PW#+*NK?*+;@4+)[E;-YH$DQQX5ZJZ?4RZ8Y7M"JF/6)4*JZSG@ M1>"%[?7QR!BL`VLC68`C/V%R7'<5EZ8/&,RT1)`AAQ@#$/KW:"`,5>J/LGU88Q_'H8AP%;Y`A:I,^@2TGZ@9`! M<(S\3B=O=#U4T/=KK4R"KB-L2!>-A6!`O6,EU-5'I73B3@=AUS8_"32 MQB6`H0#E`!^+"?RA+NRJV-P)%!U]X>$^-,07#R7#GI!;D`F-Z)9]A_LQ$]#S MNP4AF'*6@E&GO&?A?:=G=UJN5[?2X?0L2WA4N(7,'7+1.!+'WX@ MZ5/[^=@M9]I??2-5-VZ$@ZJ!.#":\WFM/G::D9=JSNREFE.\U/`^/@2&,D;0 M8-#'+K98@UYN&),F/>$.+>C^T*5"8P.M)UU:5WA!IXN],.(RY1_+X(752F5?R3!/0>!RD`QM@^!H2 M5`!2#3$7VN.TT1R%)+&I2-F$)'X`*R/[JQK$3%9BC*2TF6',DV`N*[:BZ(6A M_I2X!*B=45^U3$,7TJ9<0$;QE?D$U!2,!S2I7I/"4>3S[?B"R)`UI#_"UOH% M:1*!X9*&&(+S57`P`4H#L@-Y`1V>#WA=<;Z0?X5^()<=%A+GA9 MQQF$WAOC-I<@TR#IMA^Q&P8&6/IU'TL7[6+KU=WR3J/Y?A?;U"Y64_4NJL)R M.,O=+3"W-^-.QS3*4_S`6T-QTY@2Y*0"G&&NO`*<&AI$'>`L,L`!$-U`<86A M$$2U$$1IM,2!CQK61=`!?%`8D=IJ`!]-$61%"PHX(V`E8APH!.K`,7\8.F1% M!S/%('@EMD#Z$(A#$(Z\@6I-N<*/P..B8;^3V,.] MUW'Y_XSUE.CHL,@/4G_8ANJD`ATC^!>E#29T0[F+#!(:TV$12_H0["SA`646>WQ[-J8;^8!,.B M/^DLZ7RS%0KG6PEH=<,I!0<#CH16J65Y@:OTHF9M`7_*'9*TAJ/H0&)`HZ(: M90)"KY#&"*-@F2*K"15".86M.#("J"`,>@H126,;VT422#71BQ[`H0"U>PL" M`W3/_6B:F^/7?M+S;.9L+=;>I6343']R4>0Y?=J\9'Q6]=S'+PK\39W^[+[11 M6=H)B3OZA,2WEC8W$ZNUJCOK>$)B,]=M"X4007))7JV:/!IO9W(M.SJ+D5"N ME-<8/9^A^T@D3YZGN-$P^?;M#H43AK8*ZV,5WKU$N?'Z>9HK=G1J46Z^VT3^ M-[ZCK.S)LD7QD`7;$)CE'\]>\,L]W@<8?1`I_B$Z'WYN1SY;58IB^A=S%=K' M[5&J3_)?_.-+WH/I']:2*]U3=4\MLM(7WU,+$F09_);:#A_E^9VL:;VB`KIC8NXO;02?.&!3A M.<:$=@131R3+<%/H<+/OJ$1T;H=DB]1\])B'=WSS#3 M]F*^]O>,20)XK\=LCMN1(_R^OMTJ>RSTAD3?+;^/E=9X:UWJM(>]>B@G)SSJ M);0$/WN\3U^ MA>V=/G._=&`HR;6#0%N`NS6__E05H+<`(1`)JHB=;=E&5+XJ7Y69Q4Y1>;@L MB!BM]A]?)U3)+88C"!IMK*;;ML\GH@@2[5J-S0OT7C$QI0V%Q;=CL!6#GU:( M^=T1I-P@I<15VR8EPR&1$2GG0X$9)6TVJ#B8^"!HN4S+4,/M(N?"4,Q)*79X M;J14U5`FSYD:$,0,'^$TV6)0MLRC*F>H2%/NM;J[;@3IMUOJ03>"5"A2A0E5 M>"5%JE$_J_.\HJE'0+.=02UNL`LO":\%\K7G[A8'\,*Q/:(;GJ];M4"Q M]CQ,V*'7E)W8=K%1"V2%"RAB)=Y>]\'S2B"VR?![0>"#>%:U8376YRO M&SP2[*T)>Q.V\N^L"_"T>2U\LI-B-RP$H5R`6#G\A817!$$AX4+"!8?3NMZ5 M)(#@L,!?Z+!3O\-@6]#Q2;=TVT!22#UOC1/CU7>C%S->_6%X>7E]]Z7Y M&$"A15-:CL_2+3*L-@;M04/KPQ^]?G26PM^0_S@A095;O3YX)D)2.^5P;HO7 MK[6T0;FW.L'BWXZDNTI=3M/Q7]CZ]51#>R)>54W5ZVOS$8TG*NQ`W/]BSQR^ M!-,PR^(SA#`/`GJ0;.Z!>BE'EFZ15Z6A]I7YJ%7!TDIM2%BN?L&"VE*[X)D( M2>V4P[F\$_PUYU\Y.F9;HDG2$<< M@G@"<<2+S;)_=L@(89%GS]2Q4YN8,RL!P"7-MCGS:KO34`=R:>Y\E1D,?XL? M>#J^OV"#SNW+K4%IQ9&PY!RTF@(9$L#E'WPM5"_Q!!D20!!/("%!L;GY\ED- M-WHO)[B%TD)44NX"3`=1;5(;$-"#UA\GA+O6P@TN[PHR!H#+OYH[%N#$4Z@7 MV#%`L<<"NWMO.^#COVH&!1#"VWK5.6N-05]NR&U1[%S!#0FKCJ?H@ORV#)Z) MD-0.F*2]UNJWR^V]A<6_,GIO0:@A,+VWQ6JJ;KF]MQ"$'8C[7^P10,F]MW## M]-I$L?6JA-:T]JG/!("`7O4=_:*'[&BEI4_@RBBXU*?(S`-&KZ:=MT?$7V3V M8;OVQ6;V2^^\%7E\>'86=-*A*5A9O8T(RZT7`@I'UX!)WE=H!PH%4W/Q!.F3 M0Q!/(#YYL>GVTIMP827<2VA1A!!^PNM5+#8;6IK;5&5FP]_N56O(%4)>R=A` MY/LK'1O`\CA`BR?(V`"">`*)#8K-UY?/:KAA?#E1;KT:%O?F;KT:%B'D.""@ M5\]N7"'<0(4;7`(69`P`EW\U=RS`B:=0+[!C@&/=A'NK$^,U:L75Z"\`#C^C^(35A5S:QV&YI::GMOI;D.?^=7KO6NZ-Z!04](.OAD M[=8FX9ZXH%=HJI/15$JCJ_1/O1T/2%PBSB;$V42%NZ)RR=]6N"L*0H8%`GHU M;?H3X@U5O,$E@,7Y!&#TA'H2ZJG><41IYQLH:%?6J?R`#R?%^0;$_%%5TRB= MAMSM-]J=TNYSJC37X>]\D35<.]_H#X2D5_%\H],:],7YAM!4)Z.I&@-U(,XW M0,0EQ9YO\#&HDJE[2!KIF$AONN4CR1E)SM3#CNU*XV!.ZD;@`CYB%<4NU_Z`KU`MN/+_8PXBMB\HA, M27]#1!^CX/!AXW1"'$7`0J^B5E7,KA!'":=4,E"LO,NM3FG%3;`D';2F`NG_ MP^4??#54+_$4AA2V_W^$.YG3%2-=(@--7A")@@#XEXY6,PB`$/N*W$5=^%>) MNN&3KB>*J'5Q?W/_.`>DK*.%3F/0ZYQZ'7)%U!_(R`(N_VKN?(`33V&=84<6 MQ9XLE,]JN$F`VL3((L=1%_Y5XK"@U"*B_`(&F"02FZ3:2@YD-`"7?S5W,<") MIU`OL*.!8L\94M<9B5,&8.A5U+"*/$;=HP=QR@"46MNFM[?:8@X3?$T',H2` MR[^:^QG@Q%,8XA0AQ,\>'VLZ_W'Y.R.'^MPA(590?/?,<;RC.#XR'-\UWKF( MX-&[#;PXB/S%[&71#X6\.")$].*+FZOAXT75W>4 MX$JOI3'NW`X?OUQ3KM`'Z'^A+0V^(*V]L!'\HB$],\&W"3*&"7`V6$T+S,M[#)MI7CCU^ES^B%^#J9,7Q[ MK4V;$YDE9E*9F:%&FYB(_')&K5B(`3=F'^5V^Z=SB3_3M/29XWL?1_@',L_/ M)`-9ECO5#:H+^/?8SU/=-,.?Y^\G\T_FW#0L?R2+CY'%^^?/OML+,NG7O__M[W^3 MI']&K^,Z\]6Q**[NU7]\[,WN'`\M%IE_D2DMC_[PB$:_G#VTY6_T?TQVGIVV M^DT-/I])V*2F,>]3(!C389 M\[GF/'YA'T(Y>YG#_C*W4B'%`\715^3>N1107WI_B4;8P-Z'Q7>+4RK%T:!" M&O'2)]QZIS'"#?X8VW>Z/8OL>YZJ3E)DI=$/IYC/]9W+-C17W%034_!"A4MU MW0-!;]+PTZ-TKPW7VILV?)7;RTM]O;Z\__I$OQ]F@YX? MAW=/G^\?;UE$8D7C\]W`PI9-BVL(VD_X,G4X.7]Q39 M1OL#?=G]X^7B00YG\SMZ^1-[3:84F]1W=/Y$S=8^9PUPCB=6M MM1RLK`88RPLN!X>A[%.D]F?.5J(62<=SB:'!?H\\XS5Z=T!=YJP0MD=U-]%- M;ZP2:TY#&@DP;QQ3;1QX-\P?UXU7C-XBI3#"Q/4D[[O#W`Y$=Y[-W'B7RIG' MGJ8[CKZ$/3ATV:\>?`H&M;W2<$R5"8?!Y'[2G?,6'``I?:Y,E)9T;4L61C[; MI109A/F:3+,8NOLJ30/CG1*DQHHNB&X"8<$.C3("UXPIC&`=Q%\S_W*TE,M0 M62B;)5VW9*G<%274DI[I4[;/,:/?V:&J0E7I3^EO`EP"TM#G$/UY"13F/09> M)W^8P1`=K84@.92C`:&H9TK=%/9Y2K#!EQ6Z:*=.[22O>]<7=!L/;9/]P[Y'33+;9$/O0B=D1D'\ MG=OH%<]ZZ-[;NSQJ^J-OX^#!?SU=GE%%9V`J)NXO9TWU[%=9:7<&U#@O`$^U M?DY`RTH(=&<5Z&X"T#U-T0X'FNJ^J8[-JT#;TZ_?4V$D7!C="Y\0IFM2T[F7 M`++6ZZQ`G&+Q7.#=1>)^$KR=_J'P9J3D(`$RM:NH*Z`=`L0.\BCM!"`&[=X> M0#P0:G^(-WNPJ!F@M&,RREV-.Y2>,(H<#U-/6V/8[C4/@V\7S91X^+K[P^?. M[(^7:$K--=W,*R)WY]C&GH*EJ`D\#00^S9J'P;>+?IT$^NT-WJILIB=4DLU0 M>W)WB_"G7787_DE:?R!W.FF6-0S'I]K_09\QL[RO_E$2-;FV:C"WKY<5JEW$ M2=#7@T$W&U"$NM@W6'_!%O8PVEM;*PG:6NEV-@#;ON0!L.V@F9JDQ)5!/QML M!Q!,3=#BLJ9VY!6H\@%G%XT2E/9`Z_>S0Y.>*DFZ.8XJ>P&PBPX)RC>.#AO. M,`UBL<=C8^:34@BH!XIL8R^";.C@'R[^:&/KES./RNB9]/-!J^ZBPH8*3EJ5 MNH4C1,7`Y/'.?K&)FJ!I5[W/]64R0;(+[P3MNA\D%SR)D84@"5<7V=_ M.':0HY.@.'O*7G`,:6C-4DFZ]4`CB&O[0I]B3[>6OI::0ITD[2G+O?8J=,FK MYP'O+DHFJ%=9;FM*]T!X'Y&G8QN95SIA.2Z7FC%_XO.CO?!@*#U]$_1P4Y;5 M#B]_7`"`.\B<(+>;LIMN=U1#@1X,YF3GJ()SG13[J[E,C87RP+.+GHE M.-D#3>ON"P3`MP3:E$.`\ ML%YR_ZBW=8!^T)(LVD:PG;3TX:#N(GV2,=L(T/<%]Y)7> M\],CQW?I$^Z'CQQ'7!2VQZ@(C$BP=EI?+$[!`?\-+_Y>//]_\?@D4#]Z8QM M`2KD5(Z5#7KPFK$%451YJ4(JXR4#\&@@Q"!)#**.[]V2D*4''!X9Q("`..U/ MHPZ"?CBV-`V]H<2.DE-N^(*`7ERC\))N*J*KND(MTZDHL:7O5FZTNV(&JQ#Q MFHMX#[P,U'_R3[%A793=P+;K$]TV4%DF?6WI,6&R.OG!*?L.F7-C@%C\_$)`"B6V$O!J3WXDR"%O`MY MS\V@:^HIRSL0@UYL:/S,QLFCQB;\N@%%C(DI\)R+ MOU3LT+""9!7P@CJ?*-]_% M!F]/SLC[KA-1L%G6N3L$1Q7>N7O!19^EV6TA[D+[EQMZ*`EX4A*0+2<]!TMLG710-Q'P7&X7?()?=)3*?URB9:$J0@?D] M/*?LO(E8)?]8!4Q<\K[3^R"$6PAW/85;'9RT<`.QV\6&W:4V=T#PSLJM6:_" M,2&8FO52@YA>EJ(PL4O$+CFI7=(]Z5U2O[:.Y.:,Y1O7PFN:PJL(#QX,K@'M MXECM/FBW-%:-?VCSP;J,P&T*";F\&`0NYGV+WA#1&U()#$53@.@-$6(@>D-$ M>BR=]H]\';JN/Z)NJ4^H':1BXWIBKAD0?HK"^4+272=]9`\!/2'?105B&M[+.JG;2L M`C&JQPE2#0O;V-`M5B;A^I;'\LPN(F_8*.\*#0B>E2@Q/[5>[X9:7FY.2+R0 M^*-+O';:>1X@9E[T68@*BW]9=UY\$Y)=\RA:)=TP@^A]!2)I0.KZZ M$K)-^A=>?BRID?*478$U#MAU747JM30*]*-2\MZ8K&E*2(LK=D))5N'1M3>J5FBT"08-D34I7E MCH3N9@J!&8L%46ZYU5C\?,7,Q]*?-]M83EI,#L\R@2.&T`KUT0J9(T,MOHVI M8AUK4"8QGB+^)[]1*MO0!\5"`CN'V68?HTR'1'_&)@VYX=A>:;=2BIBETFHH1_9M44-*JPW_7MQ*67VQW<1VVVWU M6QK\84.U-?M'BO,M/$*2,Y*<:25NO*JF'A+1QT%ZJ"W-D$[@MQ/77#AKCI[8 M>UOVGB:V'A!_X$CU!2.'C!#V?%+>^`81E%1:(14;E)SBR6-5L1)[3>RULM$Z M)/JO?GF!#&'>U,K^NMJOVN`-J]3WY>VM+.0)VUJCZU2B)SL-";NQ#:VB_[+`_LM` MEXH&S+3F3VOG[+:`P[`N'30GC*"048$@=`2%C%8>P2VSB+XB%H4CLQ;XU9Z! MM4=0*)FZCT$0OKE`L%(("AD5"$)'4,AHY1'"A5WO^U1Y! MH6.$:R[8+1`$A*"0T'O"00KA*"0TX<-)X+;)\'M!X(- MX5K5A-=;G*\;/!+LK0E[$[;R[[KEGSBOA4]V4NR&A2"4T?J5PU](>$40%!(N M)%QP.*WK74D""`X+_(4.._7I>-N"CD^ZI=L&DIH;\T#J.8]<#.[:C5[,X*Z' MX>7E]=V7YF,`A19-:3D^2[?(L-H8M`<-K0]_J-?160I_0_[CA`15;O7ZX)D( M2>V4P[DM7K_6T@;ES@N&Q;\=27>5NIRFX[^P]>NIAO9$O*J:JM?7&A2O4Q9V M(.Y_L6<.7]@`S$QM&,"0`^DXI48/DLT]4"_ER-(M\JHTU+[2T,K33'!9"G]# MPG+U"Q;4E@K_8DE(:J<6?W:R/>0)S[ M8G/[48]-:>Z]R.17VLX6FV)XWVUH??6#8%[UMAXL1[Y8,6VW-)&SAZ]@0#KR M0D*#8W'SYK(8;O9<3W$)I(2HI=P&F@Z@VJ0T(Z$'KCQ/"76OA!I=W!1D# MP.5?S1T+<.(IU`OL&*#88X'=O;<=\/%?-8,"".%MO>JE5":UK[U&<"0$"O^HY^T4-VM-+2)W!E%%SJ4V3F M`:-7T\[;(^(O,ONP7?MB,_NE=]Z*/#X\.PLZZ=`4K*S>1H3EU@L!A:-KP"3O M*[0#A8*IN7B"],DAB"<0G[S8='OI3;BP$NXEM"A""#_A]2H6FPTMS6VJ,K/A M;_>J->0*(:]D;"#R_96.#6!Y'*#%$V1L`$$\@<0&Q>;KRVW.W7@V+$'(<$-"K9S>N$&Z@P@TN`0LR!H#+OYH[%N#$4Z@7V#'`L6["O=6) M\1JUXFKT%X[ON9YNF]@>@P\%RSP\@'']'\0FK*IF5KL-32VUO;?27(>_\RO7 M>E=T[\"@)R0=?+)V:Y-P3US0*S35R6@JI=%5^J?>C@X!+`XGP",'I"/0GU5.\XHK3S#12T*^M4?L"' MD^)\`V+^J*IIE$Y#[O8;[4YI]SE5FNOP=[[(&JZ=;_0'0M*K>+[1:0WZXGQ# M:*J3T52-@3H0YQL@XI)BSS?X&%3)U#TDC71,I#?=\I'DC"1GZF''=J5Q,"=U M(W`!'[&*XQ"1D!$)F>K9^5)3DI7S`\K=+WVY=^K#TD$I0W&X4DGTQ.&*L.7U M#F+$=(-33R#C`+C\J[ES`$X\A7J! M[<<7>QCQ%3%Y1*:DOR&BCU%P^+!Q.B&.(F"A5U&K*F97B*.$4RH9*%;>Y5:G MM.(F6)(.6E.!]/_A\@^^&JJ7>`I#"MO_/\*=S.F*D2Z1@28OB$1!`/Q+1ZL9 M!$"(?47NHB[\JT3=\$G7$T74NKB_N7^<`U+6T4*G,>AU3KT.N2+J#V1D`9=_ M-7<^P(FGL,ZP(XMB3Q;*9S7<)$!M8F21XZ@+_RIQ6%!J$5%^`0-,$HE-4FTE M!S(:@,N_FKL8X,13J!?8T4"QYPRIZXS$*0,P]"IJ6$4>H^[1@SAE`$JM;=/; M6VTQAPF^I@,90L#E7\W]#'#B*0QQBA#B9X^/-9W_N/*=Z+6,).PQ2G1B(O++ M&84B)!`'YJ/<;O]T+O%GFI8^^WFJFV;X M\_S]9/[)C#[]O/R1+#Y&$/_S9]]MCG5]^O')>$6F;Z'[T=.K3M`GW47FA3.9 M(MO566'2D^<8?]X'-4I#P\-OV)L]L]<\HQ_>)XO^\=>__^WO?Y.D?T9O?"!H MA`A!)O_J@T[NR9-'PP_S=Q9Y/"#"%Y(,Q_;H*Q[1Z)>SAZ%[;[?5;ZK\C34] MG$G8_.7LLTZ7,[]I_3/)MW'PX+^>+K]-$?G&7W$FF5$/C.*O"#\H#GC[A#WWMU"/Z+1H1I*=YM+P'M\K?926)Z>TF_W.MU!#(3I5%-V[=E+880H(655[G3V`].=V4S93G5L M7OU@7BUR'Y&+6)/MT#8OT1NRG.D$V5YZDG96%=$RH$V5[9=NL%M2+YT#K+OH MJB7"VLL&ZY(A8U^ZMEV?\%L@4I.QFP!:9\-I6UEH?T!VT:@7#XA"MT<&0$(R M7OC4RN\C7?UX:-1>9QLTJZME!&D7@08)!-+4_4&Z]UX1&;HN\MQ]2=1O)TB. MMD:CS;6R0+.#.GTY"9I.?T]H'HA#G1MO]F#IMD>WW]5_?,PWWQ?BN&XVU0?CC&-U_F*M_S(SW?9,CM7^31[GDW1\`=V5Q%5$A"5 MUZ0@#HD"4*;?NA^-L('FWST(6S4)VW+0704RR10IRA&!7&R00L4PR:0=DR]; M4,Y9#!.LY&!=]1X'VU48$PRHW%XW6?L`.30,?^);+&B[1%-"W\SSDO2SA=@' M^H+AQ"$>_HO_?N?+TV^J!`OOD3X+##N:^&DRX\1LVZ;*/K()J!;6V_*T=H/7LS*F]AN*R@9[Z MJ[FJ]DI&L'#@H5!+6Z+6FFQJ)T:MWQVJ/[&%O5DVZ>K&T$NA&ZBUG'8Z`@9P MB!8C9+TDHJER?8CVB-T_/Q/$''!$D.MED[-^#,DZ/.-.8^Z"B+8-`R@DBY&R M02+)E+9:-LE>DA=\V4>PGQ&9R'N+%PW8SGY]T/Y8HT8AP)5.AMTB([=E2@:Y M?50Z,-\JL^S=K[[XLT-&"%.O%3&!N[8?$,&.F4$6/"[CA"_78UF5K.#*&E\J3E-$OPFVO;1#^HP#O\@(VX+.;T MMN=9Y':**@,:`0^T?AY>Z"Z<\R8JGSKE)F_%I3Q6_I1-41FAJ'T6=^9'V57$ M2R'KR@8N@*S=9+)JVNH96L%49:@%9]F7/'41/!8BL(:M=U1 M!WG$FFE)`87V!E>'2R[^,I%2#:" M8^N?"@B?Y+5*A.W5N3R]VNL7(L%QM-B;!>Y>CG!Z-AS+_9"UE.Q06NH^"B4_ MNL!C2=%>2:JR>[Y#M$X]6!*]'?)&2=55H+"$O;:/WLJ5-"`94_1V2=7VM^>A M<+E<.32.`+A[4K4WPMZK$L\-=Z`(VDR*G]MG: M.6:-BG*ABV)!H1M#2:_/\JAW*)<%2Y$J(!:HJ5G0'Q02M>_-@BP'](FK7.90GI`=>[@,*-C54C3. M@,&MW!<<*,=KZD8$R'#25O]P3(6Z1Z4&-Z M?RAYE>Y:(_=QZ9N/@EI=2#XR@6-:F2B!Y<%:BUAQ>.=9G;F:(.<_7>H>FI?0 MEN/OJ3%]6I36G<%2)UO1%`!`[8(]"S6F%8U2NR_WCD[L8FKVUAP<,-*>]OB8 MS;-5D7Q#3C%VG$ MV1OL4YE6/=00@.2)9EC>82Y2_QH7T MY:L][?AN8^U8$6?J4M6LYE2^510?BG4#B]@`J0I2@SQ(KV@WM^)DCA/N5"6E M>0PYR(W&1_,I6?%D`9*MI2H'#4JNCI)2V0?=2C$A1NZU5-6?QU+J,#F0BW>Y M+ORI2CYE+ORGZEP>0O>=\IZJSK,*=/^";/JDQ>:=FA-L8[H$A>H-A?//]Y]_ MI"5-=5X?ZYP`03X`Q^FNI)',/5D]!.#M-Q%DIV_"3&6E)Z^.^(U=/P]@XVB; M,%RYVQETL@-[3W<=I;P]CBY]R$#-I`L+^FM5(1MK9@4JCFH)LXS[2KN7$:AK MVW`FZ&9C0'8:6G43IA,W=Q-KL6QVR&((UDV84MS<3;'=D%USE8 M@7!)=P^L@+9KW0/ABR-?TBCC3/!1F^2L4CFSSNLFV905`'/#>;K8,OWXB;*[217VIZ_9KO5 M7FKZ2P`D'[CC")NV48["+6>'>RT<"@Z4PLN"EPJ@#V=#BA,TK:\J':6[)"K9 MH"L4QSB6I9B$V5.Z/76@#?+"D>5(O^J$)^DSM)XO?T/N+%<2/K*0>[-<UH:!-).!`D.NHZ)@*(H:1!(>U"AM!3EN`BH:CL-`FFG M2J@M]<@BI*82H?4+ZF(0.+8(4=C2()!V%('?G/[ M]M9G_11U12H-7MA6.B::P$F;;I^D*3MJ*X-6/J6\M:%N.CO03^-14?#%#%<%!^71>+BJX?VG^*4ZB@E"S_8 MH#;EC^ZMHJV/2(*">=W8DD[=:WQV5?=6E@5?CL*7=-[D@$UUD]E@PXVY>E!0 MKQE?4GJ@;-:;++AR-*ZDTV)]?D7IK=P3;#F.<4GGZ`ZX<5%NY6ZE^/*2#-S+ MWL`-QV."QORFTN6984LPY^L"*^WXN7-ROY?/5+0<,*\H%]+H)OJU6#:H@[8J M^'`0'U)Y5$H[?G*=X,`!'$CE.RDK]T,+#N3+@72Z**;<6G#@0&N0QB52VC'E MY,P:\%FPD/F0J:=YPSV+R?DI;>:Z]+[Q28$/EFZSGY8IRWYWIT^V$3?%&:W" MD]=5NBQ]O_/79;+)*M$)N9%''C"Y*O-DS7<9EE*2/?IHM_V4+I5.<>FK]GE9;2F\?.IT+:=.4 MK1Y/B/,?^9YB4L^1A#BNXU8[^U7NM'.H/XFG07ED+E""8UJ&"[U,8.>(DJ%E M.0:#>/MZ>W25?TL8W<'$-'8"Q3*!@R[/)X]"QIZX83`R]# MG>/]@2BLAC.V\5\4BL5]!6Y<++2&-? MN[8_^2ZVD>M2HKY@F]-TKKLNL6M8CNN3^-NCC=/* M^IVU&_-WUI3C]G4/@FYWR[.R?IWKYB">+8>CB=!=HBFAK\E*L819**O'A,MK M98`CCC8)$T_ZJ>&@-H(@2K1+%/Q+'0*"ICJFIF6$"$%FJ,VIL>'9Z:'K(F__ MT1**DC0,1=%6QQ=E`ZQ0].(8DC!C9XXUB0,&=%S@[X;K8-#-N'N1#VM3U`5`)(.0% MI(R/20Y(Y#'"\2K*W.S8/*SPY9BJ(I1]=GBF3@3R?! M,B\N40 M"P+\:SP;L^X_9"#ZWA9_]^H'PQE'V&2+WNL>`"<[=J'_,./RIEO,``TI>PB9 M44[L=Y&1LGZ%SH;!ZW05;0/41`!R@GJG("29:5G6,_WH]"1:E;\S,3=Y&%?:;@?[*H:.7Z[N/4GOJT?]^G$N?[^^>/THR^_D93ZBAN$/?I4=G MHMN-X!<-Z8FJGI%T]E]C[UQ:>]W%S=7P\>.+X[T&;VI^'MY>W_SQ<>U5Y_QO M3]?__RI8ZCP`H_E\_\!!20_&N11^]=/]\_/]+?_VF:1;>&S_,Z2XS!'[;3D+;PY%.?M_'F:V=XK M\K`A?<*.Y8RQ0=]"E5!+>D]_'W*UKRCM=72PQ\D M*O&Z-,$&<5XPU7'-D6/XU*=K+"`S+&QC0[>:KJ>/F7'F*U)ER4^&67D\RV?J M4^3355S).SW2Z^6OK]B"TF>3L:(16+25/=>G3&RF^Z4*MX1!=&D M[COU==R6]$R_&N+&0%Q:3*>R0'1+>@G165]P['O+B[X?ZZY''$P5*HO_Z!?? M?[G^$#PQLNB;/D@C&FI(F+4$OB';\5WI_?7O'^@Z'J:OX#B-*$W9NZ>$PF%' M\CB7TXL6A7Q$$:#X+823OG*$C+G:B>!VF5ZQ)8]Z=7S,/H.?(-,W$%\"4YPI M)O3U$^2]ZC9;U*%_9:@[7)6Y$ZJD;`D3@OGH;NG%^8[H>V>V23B9L??*+`A% M=QIHO??7GYZ:%Q]:5(0DW30Q^V6#K[:#Q!(-MAQJE1BY.!T<<\88'QTAS@FR MP(*I340\WV4Z%+,3)\O27YQ`OP8PL1X#](/^=.&0:?27]W=_/-$-]S_W=Q\: M`9VDAU?F;2L!N2C7J#ML22;QQ]N7))#,F3OR[8!%%.3;IU8QJF.[6B]&=;`?`K$(4?AZ??G\ M&UNE_=.Y].G^\?+JL7EQ?W,S?&!TYVR:NF@?8`QD62Z54DIH=@+-?YXRN0I^ M7H!!(AA^OWI\OKX8WC2'-]=?*`4H03UGLO2D&3T9`AC9_!=+I^X05;P2=ZK. M)4[8\"T&8I[JN11BJ'1_2O)<@H]L^==5D\/T3:3"%H0=4C&+,3$_>^86#&(@ ME/<'<#>3MZ]>%OT>N)+R%O!>L)IQZ@6CTR%@YP`"LGC`=U/2ZF>/I-ADGC/= MML,V$2B?F67AOXL5TO1[)IW; MM7#7#E`]2;:K(-9F(-3A_L62##W]<==LMSLIXZIO_F5V^69 M7Y;F;8@X1M3I15FK52+DKUFC99F\SO%DLUHI1VF*^(BOKC$)# M>[&9>;M`ID[ M76#DGJ89>V`M!^RD@[7G1':+A-V=T@CSL1XN_7E[T%9YZGZ;56H^D\LY^,A-C(=VD5A';!IZR5&/0'C#6/8
ZPH4#)U3V_0%QB6SZWAQ"'TE\C3L47?0%_E6UY0 ML#&9$N^SPPAL4 M&&X&>E#]LFIQ+ZA8CAQB8XK8C>-*0WN,+`K/^W]=W`P_G$NWC]?!=PEZPY3J MU`]`Y+L^DUYF$GMD-685]EHL"6=)2/;Z8GC_OF9H%*]/;L:>J=^C,_;T@`*7N%7KNE8?N0`KT`,J#%UG,HYI5%O%!B M=[E[K6NK2V?'-EB92ZH;86EU.'$\;".A3N0HZAJ1W'G;B/2J4[OQ@A`OY4MIY:4CBXS)JQES./UY3"*0^, M8`^!+\_=U"70OPR'#QNP,SI;R$-;"1O4GN_)C&6L=)-QEO^^P9$DH"O36,0LH@P M1I(S[V=I+(')YXY$M#5T]U4:6<[W$$\GFA4P?T]48QTQ>,K;$:F@T+"&,3"" M#5M,L;.C).[!\$+LX`W>*PU<)BP<0(L"#O9:5FGNL&:!M9>SEH5HV9%/23A# M.N'P!5V7"<1W7QW?,MEJA$5U/+2R_QVY4SS%R-Z<_**%\#$@$3_]XWSE+V7$ M'MJV3[_SR!.F+*C[3%E*-WWSO^<(,-BI%61?NJ2D8F'90A.IW5#.&YYNC=<6VOLP?_OF>+$+=-?U)^'`0[Z=]=$H:K#1)WRR#ON^'DQ28M^PEF;0A'F+X%@A M3#0$68ZU[_/Z3#_X$PKG3S)D>*]-J'?FV9B6])49/`O3+P5`>:&B#DW`'!L) M!9,434XE?3HE#E7"RS`$\LV^]*);;,1`0%#6:>W8S-4\EUZ=[W0ATI!,"F!H M4+'-]`)W;0U$/)WN01Q`/-'_7`4AN%YLOI$,KJ)8N2K5?CSEPM[G$#SF/4E+ MC`CXM&8=_K>]:_UM&TGRWQ?8_X'GVP4R@,R0E*B'YP$X3C+(71+GG.P.]E-` MBRV;&XK4\&%;^]=?5S6;#XF69(D4FU0O9F=DB8^NKJKN>G3]*AD`Y5HZ7OK2 M68R5C,E,K:LF_P.-_>3`3D!W&*S:2&3^T;&C^PM6'8+7G+O6TH^CBYGS1.R? M=ZKVR'QIYE:D1F/^8Y!]Y+9\5F!;=05M'NTBP8=X%B1I$X:GN0T<29MHXQ2F M8_U-+QU'6IZ_6C:]!?%@.#*'.PPCQ5=E@$T<4;-D#2YGX_1L M`3@PC"(XR^;W'CK*9R=O"[:!V3]DE"F!--F;H,4&H_-+8AGSP^G!E(VL&&X M!4[A',']#B0%UI1$)SY18S2,?(^40OMM6BJ&6]`6=(Z&O.%M>PWHN55AN`V; MUMQG/%=)?"N!PZ>;9(+F_()-9[@=D6^T.K3GWWO@()^=OBT[DIG`Q;QHC`6D M76RHMKWU$%]#\E#+Z6+S9LGE>7GE4FMU'5UYN+*%?:?6U'=\?YXB@^YEJK[: M^@I'^)*QZ]IW76-8]96,?;CCV'5U9!X\]E00JAG[:.>Q#X:[C#W;8#+?Y5T2 M?7CK`%R59]^`#_#L?E$UA?DMV?4R/C*$IKQ.2>]OH-Q` MRLVZ2+]QPA_O`T(X.MEQA7VP@?`!$$Z%:PO7RPBHF/`:9-W<3K@Q;(KP.D5] MN)WP?DT[Z3`,KR)R:A#<,9(S_*2/CT9. MG>(XH>28_]J?$H9@^-$/$5B7>F#4_8JI!Y9!X'TA`9P(F$+3)SCAGS1?>GEX M9:SM:-F?4R4:K8(L[C'$NFG=$'\9Z[O3JE=)*S9HR[H=O?>#?'""Y0Q>SKGM M_0MV>._A0]PTX5MB(^?YL,T+!IKE$#ZEZ78`;S\`DW,\.`U,SN+Q(J,4A#.; M5)[>UD<_APK,\!'/&1DCU93GC#CFW[V%YU8@JX'HA-9T&L]C#`)3I0)8'2S= M^MOJE\=%(Z'*W/'=>&<1G0?^/'=_.4S.^3P/[%'E+Z&MVE%=,,"I1ZY8\<'"RK7O32)/67IVBE;U#%W#%?8/26,;Z&7=@2I?)X%9ZE[C^0. MJSAP.@ET!8_WTVOXJQ7LU4CNEOEZ`\R54SWRX``80V$K5-^1V
!>1+;4%V;'MA(8]8`=?>D"<(QSN!7#XW.;Q=3F_]=W<@,8335\!O'CY M4?I$U5)4QHGVXD$SJ%__+H`UEYV&2Q;)M+W%/F5-^[*[+N:VA97[L,^+L1X. M=C6ZIRU(@8W(6VLNF2@X$_,ZF$U M09\#M9^WKD-]>H]:Z,^O!'A6O>Q!4F9:(S/6]!ZK`.8\I!NR8E/)V59REJWY MCO?@NP^LFH6NZ"&9QA%K^&+379Z:!-.D:0P>_G8M9\YT/ZLHW?%,#IF>`J-.%#6]%NOK\6*H@8YZ,#U0!.JZJO*A(/)*8&$[:*:BMS#% MKLN*%].A<$V8(:'TE2'DY>&9B4)D:`1TGA\H30Z\&CWZ_!TLJ><_^[U"(,4Z)L=HIBC0"',8-3FZP^V>SGIJL'$Y\4ML<>OV,* MK6,!#JR0)L2,=_=+C'3"U"NO=3,4N+=%5/GAT1XUQ##PP`M7_N'-"_V6H4*%%N=:!@]T=5QIRV#A$N@' MYR?,J(1R,D&SPC3:@S-(Z<)";@%IM4(MXAWCZ;5C=I6P(FAXT3!A__" M#U+J3T?JC53J/^!_>XEG@5&!/PN*D$=TXBK#$&Z@)_QM2(('Y#=Q\`DV]>&F M8)5CV('_];*`8LUJL+X'Y%5!-:0RG)8R]%-E^(>7$VCV)2)ZL1."B'$&-A5= MZ",7P(BH(\PM)X9J74".6L%T@EV#96.2]!IS61\+UI@PT5KI$WS@8(LH!G'( M;/G$NLU;V3,`,:1+!P.KPL0K,#@-=N8N38U>%MO(;&"\`V0K9Z3#%=0JAH`- M^YD^#T?#UE\XVIK%03CBUJS4$&_#N>2VR\L5'(]/(2-A":!L*(!=SGV/\#@I M]S'#C,2J:P?&:K%#9UHY`(.LMDJAKPZ?>15J0;%$`=_/H1[YMP,`<@NA&(!: MS@P#-;$Q$C$&3Q26T:+9WL9@W$[QM=5@'$C7NTRF+J,KB*+2\;`HTB;4ET\@ M=I]0ZA+\UT)5)3SYTK-77[!64CG>A`IFGOV&&%!YZ*3-0SZ4P%PY;U4$;D(2 M,P%&:+@7A6EEW9>8J@%=WWEMZR'!U/&)!5/#")*@\.>0Z7SVQ$F*'U=?. M352]?%?BI7,P(LA+PZNK?+-"R=7,26^HKVR+L+P@W*O%W.OJ:58'H^(K%Y0' M\%K,O"7I3P:SXD-1Y/QC`F6?()S7.5@5]::26'@M?@^=2V< M[5SN"VQW$#_@653YYY<7N(5S$B'>TR8!>!K*@38+B5_@%(\D/$)@!HXTPP$' M=@["2A>[7`:M!_X(R^/9'#8[K71@&U1*1IK)XRN3G<%0LZ,2?!TG>KW=P MR/8Z`C\D5='I\Z%%9R[KQ]"YJ>_.3X;9>5<^B0;`U`*8=88/SOI0X,I=>B,_ MS)&.P0JQ)RGZJ`Z":D`<*\$2YW-2>CR+PT>O')2@`R>P*T"M-G5ZX0*&KTUG M)%I#TE\)423;!=\'LNEXI..L=CW3U$FI,9`%[;(V=ND,\7FI>G4=J$:Y9;)S M4P)5^8`(!)2K*!&LZB..[OW`B5B]?BZ+?1<[>%E!QG&2D0\V%S`[V>#N\'<\ M0^.M;%;UB;@7.?S*-3VNTF>]?2]*YG?M#[F@R;["UGD#,)3'*6GNM9SVRN7BZ MH!+JYRN--Z9!KO_Y[N;]Q^L_+A18_.D3MP9FGAU/FOY(VV(:BZ>RO$=9DS$V M3=_^]9&.CK6D66FH&>&\8AD-SNNJ^#[7IRRY$]D3".-4H"QJ5_/!F8%F1=1 MB-$KH"61$QX<^&\&?ZWHBR<%NQ\DHBH"M7VJ&%2*J9QZ@&6U2GJZD,-WM\%K M_!W6]!/D:I=HZ8Z$YH/S*T(Z.$'&=HF6[@CIA\09R@OH6VJ_G@Q3RVOP7F+@ MN&06[4-U5N=')6@Z)60VVW-6052`:4" M2@64"M@X>5(!=U7`;@;-6V&7UQLKA[[,R@P*$E($T6"_@U8R8"`#!L(.^7%H>7;X$[X4OS]"MYLN"!=;58Z!1S06'(](L&5\ M6!*(>&.Y"$=F1>L(W$O7-+0ZEI9X(OLJV%O9(I?N5NCD`H2*JTN6%RV0ETA M8B9@`18W\;4-7/A8^5&6JY?A!0G&_^-/0%N30X.>;AJG+/&"K'U'L\Z*:+*G MO.MM5?4^577;CV_A_ZF"##]X_!IN00PMQ)@Y.N-I<@;\X M:1&12DMM_5^&?;,W-G?J`<,;*"Y<:\KHM>YPX-#(EHYQ`6W4HPA;*$#?Q=5N M)T?KRS+4BN0(VXTE$;IB/R)5^>J`"4JG.LQWVX`.'MAU@/6HX%($$_IG#.%T M[!A5%",J+TH4$(S(T^_GK*?&:E>1J1]&;"XHUV,WXFM5KB\(/LFC.D#OF6([ M(O92->T>EE_'RIL:(@65"F]?'_9,H]@H0C;RK'_=K,V$N4P22LM\O`E[Q8.` M\]8?7+IW;@6">LRO!M5/KEH+P$/+6"M,LEQA_>FG_D@="-\"+V>I?T1#?7.& M:4M*:>7RFM))X%$TU]RBIK#42)R.%P*'(R6!C1)8TD2^8Q1VGD!]ONS9;D0\TF5>=-.JO^'46E_XA,^)5#]4F/<4M/SW>-G-$B]&[PW[ M1L_4]-8(1$?E7?9VJ%7,U8GXW96Z?\RI7B?N=Y9':HK/(IAM(I!W](6Z%8+Q&6I^`HIUN9:KZ`VV1E)!!D59/>LUQGF89#&]D_I^8JW M?S;#OI(EZ)5!W=2A/OE)LJ]]RB?67EFOH.KJ8"0\$[N_5];K:;[W@QEQI*_9 M@F)!`:LEJ]EOZS7Y7PW,06\\&3:VW[:9P>*K^($E8&VN@BW=L\]N[ M5XBNB6)NF M%-"N;YHRU2M3O:)F`J4S<$+,%E_=9=I7"KE8F_?10YN4^4^YE(+0?*WV9$25C\[O!ZVSIPG25X M),=/@N/OLA2>Y'@W.%YBK5WY7A18TRBVW&PZ/CHSR?..\'R+EG^@['>\T)EF M$_-/RXU/G/UM/0PK\4,.GHE)V1&NH?A'N$ZD1%8B0E4GZB7F0+[7N,CB<'1I MKQ83^^KZX_5-RBTI_E5,T2FKP]&KSBNR]1I=ZPS5'"E+8@7[Y!HZSE]IOG9G M3]?'HQZ]7W@IZ'YQ8ZVNK5@27VT$8]TC:T$#HG9Z9#N3UR'0HGI#K-C636U# M6S0NX=]`-?O->C;B,E#\%;6SAEQ9@*4WT?I->BI>L/^B+@,%'\Y[:P))Y(_(H*`'J/\NCONMRC= M&NK-LO0;/`,FH]9'W),Z*,YE<6VM%8=T!:RYE2(O1;[U'&]=)D=3QV.9R6G' MFB6-S=9Z7R((>:7>5ZUM<5[L@I]R6YSC359I!4]S;7%DB+_Y?;'+XEY:4=%P MRS2Q9%[HO4$$K`6I->W2FK;ZB'77(1FZS*ZU9-F3)G'#JUV_9XP;C8B)H"P; MVD7:U75%++Z^[`^<:FRG=^L'-@FPU5WR=B3R@O72PVO.76OIQ]'%S'DB]L]; M6^:ESP_23W8ZLOS'(/O(9^*7U^'2N_@:^=,?7^)@>F^%A"/F?R-/T1N7_O#; M7__RU[\HRB]Q>'YG68N+]Y83(*CC91B2*+ST[(^.=>NX3N20\!.QPC@@]K5W M0Z9Q$-`QT@L^^U[`_WQCA4X(]UN1XWO?R/3><_Z,2?@-QI2^5)GZ=$=ZBF[( M[->S+YK^G?X##1Z_^5K_>Y]]/E,<^]>S]]8T'T5?[.)B7MHGD?1'_'8>1,UOB^+[=$\4*PWB^@)D,E3@DMG*[5"+Z_94_ M7UC>4K$"DC37=/Y#?W4\_)7UQX3NFB@)M?3)K(OJH_7*Y#;1YFZ9?(CLZESD MJK1YYN+IPHHC/WW$I+8&FFOC.7(GGOU,P%%NU1^8PABYAQ/3)NS@"JCM;X8) M3IOVPG>WP6O\'9;T$^1JEVCICH2^)5,ROR5!B9#N$SYH.V.[1$MWA/0#-?XL MCS5-X0+Z]MC-=9IDJB"%9=4EB\MLGBO7#\%4#\%+4Q9[=LGI3/I8!/(DPFAE M,V&4`9[HD]:(0$5?Q>>*JE_4O^D_DG] M$XAI4O\ZP\K-^B>(35YOK#^UR1]\UXK@3-52>#^LG8N2"&ZF\#&%%RU*$_%K MKUME%4@%E`HH%5`J8./D207<50&[&31OA5U>;ZS\Q@E_*+.`$,6!61US,)[9.U72VS>1)C=Q9(T<3 MJ9$BD"V+%+KF?O0LIPBWH-Z1BN M9PG^$1_#\E!X/`X?2R%>KJWO+NX*S'RB:^MH$+GTWH:K,:L9)CHG2MJ3=]-NCI MIG'*$B_(VG`,K3?1QJ>L*=V)3QX: M*BP/.2;W7$XCYZ&*Z*+>BNAB?Z#JJT&F"J#`:P@G53O"RR0\N,Q[#U;">V7F M!P6P=OYW=`\GS>=4%NY#A7@VL5>V8L7R[/1J2(DD5ZV%4Q0G5*PPB5F&]0<3 M^R-U$D1.'=$PFF3DBR>?FR)[R^>*3+*/>F57_#&82^\.&[ M$SGMVV3'Y*[%JDN\&+TW[!L]4]-;(Q`=E7>)95ZKF*L3\;N)=#]I7:\3]SM8 M[=2#;XC/(IAM(I!W](6Z%4=I2A:E44\S)KUQF50-W6H3WZ2[&N?\HFU5]8KJ+HZ M&`G/Q.[OE?5ZFN_]8$8DW^5P-ST!M/AHWMMVUFL/@J M?N"!_C;7-)7NV>.3CL$(LFF>RM-0LVZDU&@]YH(KZ\GX@3 M+9.]]21[Q^(WP>G^=BZ3O>W=N46P2KN50SN7K&R?(HJUJ4H![?J6*3.\;=XT M1;#]A#?TV[$FB MQU$869[-NE8E07B\_5#85^-$8%_+)>CP<:ZCLUJNJ_@9OQ!BE60XI?>]*,;PN!DRTP]!)[ND4$2F9VB)DEN^H-F5N.YWAW MG2"P\QSM`+B$G.7X2',\E M727'N\'Q$FOMRO>BP)I&L>5FT_'1F4F>=X3G6[3\`V6_XX7.-)L8[-%[VNQO MZT%?B8UR\$Q,RHZG#<4_GG8BY;\2[:HZ42\Q!_KZL&<:AO#B<'1IKQ;O^^KZ MX_5-RBTI_E5,T2FKP]$KZBNR]1I=ZPS5'"E+8@7[Y!HZSE]IOG9G3]?'HQZ] M7W@IZ'[A9JVNK5@27VT$8]TC:T%SI79Z9#N3UR%`IGI#K-BR3FU#RSHIL5)B M4XF531;;$>0NX=]`-?O->C;B,E#\%;6SAEQ9@*4WT?I->BEO$IY;9.\MM4SJ9=[NCHI>L/^B+@,%'\Y[:P))Y(_(H*`'J/\NCONMRB=*.K-LO0; M/`,FH]9'W),Z*,YE<6VM%8=T!:RYE2(O1;[U'&]=)D=3QV.9R6G'FB6-S=9Z M7R((>:7>5ZTM?U[L@I]RRY_C359I!4]S+7]DB+_Y?;'+XEY:4=%P.SBQ9%[H MO4$$K`6I->W2FK;ZB'77(1FZS*ZU9-F3)G'#JUV_9XP;C8B)H"P;6F':U?0N M7']]V1\XU>UIL;ECOTS>RH.'\(PAL;?U[,K?S[W MO:_16H--74L:;`Z^^?0S_0<^?\O=G[$1+ M^MR%[]$_P\LG)USIR]D_4V+/82_ZQ]>W9XI-I@Z5X/#7LW/S[#=]HJ-V_?)Z MY[&O$OO5@@G#GS[',$CZQ[T5D!#N)O8'[QLE((3Q^-[QZ![DZ`YQ.'G2/WQ^ M3VD?:.9DJ`\SVE]"RH9I0`#O+R3`>XLD7X;77M6DFD46?U^0X#N^.D^Q0>E5 M!Z-26@OCS?>/S?C/Q_C-_Q('TWLKW"3/=1`YW,Y/3369&N\\[.IH-4R@U?B> MW+LOE:/M5`[[YM@\A%#D\AMZA0U#(52>09POX?X['.>;97;)%VL)7UT^6H'- MWY%;!IF6U,_]\?9Y&6GT,FV<+.25TYB?P9*+-JA\NLH9N,I5)"F3G95^J+$Y MV3;J"BBL?!WO@_&S(YTC\V5T\H7PO>4$B,U\:?\[#B,85Z9/NW3"KH90?O:N<'7WFWCJH*(&A1J@*1,@!1=>R$I7/2N7"L, M,R,YN`'/,6&8VU?VOCXT#2,3_&UO7QWM.RN`ODDA7P#V;W/?UX:B MMKEGPV`>,SJ7NPZ#]VQ/PP38-U6#N=V3+U'F]+O.K::*IV^,`1EW,$E4EQ8*V? M+^*(V,KM4J%#=E!!/7XI_3*Z)\ICTF96L5AW6<5CEIT_@_NI&%RI^IF>J M\M9Q\%,WQD_P"#*;D6FT>H="Z#KX0!T7C`*$\7?$]T'A"CT^^@^5(@'3RO,@->R9 M]`M=&^)HTSQ"3Z%3N:",H-/G+GOXXZY/'K`G#WJ#B4;_/\*;)\-^3Q^.B\]5 M6QA5VKH'K6Y6EU04N21^)=,X0(/H7<)B",I<9V06YC M2ZR):Q2^O"UQX`#>+,L?4&*)[.#L#JA04)G(YK&2Z6ENSDO,T./-]PY.--4[ MJG8MGNX2QZQ)$9_L$,^A*RI=4#LSYTV*N*[M$">B>Q;=LFJ>[USL[,.+2:IY3JRG:N?$V$%7JYF37_[K_/R][T>? M?6HT?B4L,T+?>W[.I\QUO!\7,WJ)1R_Y2/]0GO"KP`>3YCZ*%A>O7S\^/JI/ MMX&K^L'=:T/3^J_AY]=PX5ER?;1&UL550)``.L&%%5K!A1575X"P`!!"4.```$.0$``.U=;6_;-A#^ M/F#_07,_*XZ3=FN#=H7K)(.!I#&2M!LP#`4MG6.N,NF25!)OV'\?*4N)]492 MCA-3V3XE57GD/??<\8XO4MZ^OYU%WC4PCBEYU^GM['8\(`$-,;EZU_ET>>R_ M[GCO?_[^N[<_^+[W"Q!@2$#HC1?>(1+HDJ'@*\_DO=Y.;^>UIW[I^:=HX>_M M]EYYO^_N';S:/WCYZ@_O[]'I/][1Q:7G>SP$=.;YOAHGPN3K M&''PI&*$O^M,A9@?=+NJ_>V813N4777W=G?WNUG#SK+EP2W'N=8W^UG;7O>W MTY.+8`HSY&/"!2+!O93JIDJN]^;-FV[RO[(IQP<\D3^A`1*)J8QZ>;4MU+_\ MK)FO'OF]/7^_MW/+PXZT@>>]932"3`'$D$PHFR5Z=SS5\Z?S80Z`[$5,0>!@C&E$ MKW"0$-)53;O&#KM2XX?I/*"$TPB'J#`,;ZZMIJN'ZVDPQ2$(A*,UE+;M]ZD0 M]!X+0N_I,.P]%H:]37O\A9P$809$\+/)V5S-KW*P![I^79^/I_D`\>EQ1&\V MJ/A*EW=Z!R@*XBB!3?LS]*X3FQ")'CV1)GVI;_;2^?^%^GC+WW.DREKV7.$ MQA`EXWTI-LCLL@WU!C%CDBBCEG?M5I1=H;'/\GHC%F1=RE]+'.8S:=JBR^/9 M,DA]+-TGDY\P.JNV6SH@U>H;AEI[T3[FY+ M1'$JRN%P..>OZ&E.\56-W>+(@HXVE-;](*"QK!Y':('&$5BL:F;?K*UDY2JMG, M+2-PF!^5;RBQ(J?KIQB0EF2 MTXTE:[FIDT1MLCHI0[:>9+=Q#F-Y$6T+AS*-CL,-I]_K[WCECZ;Y.7"0_J:N M'AS"-40T.?"LV02SE'4@).IMO;HO9HG'X5HO13`D/&;IE6!-(5YHV@J>ZM5W MN-;+.U;3RR\N[5E#>]LKOUO(%H]]!<<%*+\PRG4[PB9!!^+#AB;K M>T8I+(?S3:ZRGS,(FHU+P-O&1+.QM6[MLZP(G&LVK)N0=@IL;?&C?+%W`C ME<7"&2:8"Z7]-:3::Y@R2KK$6]'SBJP9P3@<7M4;)68"#7)MHL\`Q>&]B8^4 MT/SD8B9.(^,`:>;\I='?8::.$6;)N68__#/FR0VBLTEZET^7T0QR#C!F],$B M@09(+N>[(;F&I<9+I!:G3/4B;>2N'HW#L9=;I3SPGML:?;G`L\TZ;0UH_V]* M-/?&[&!]!.QBBAA\0!P'JO3`42SND5;XGE%R6Y-BYC3'TO&6=V)CJ>>]F:7" M!5T3_;6SYMI].A!NEA27)]>U05LO,%R*P_L/:FPA#-7@TIR8AM+L#!"'0UC^ MU-VQTPAM+;R8J4$1FB1I)^::U%&J5:S8X70?,MC>POP9[R-\N"06VM?Q8E+NZM'XQH2 M\\V>!6=Y2-44O7*!HF*E-23I';'#](6:RN\CZ5=X:W7X+&A?%WRU@_SXP*FY M,GV65:S^J$]-'K47;S6AS:!6T_>3$YFUC*+P#8Y&L5R2;37+#7!64_S:S2F\ M_-F.IB27Q)\OSR6HU52_<9/J[-,3YY!<1ER72Z[0@7?*#&%LL3 MO`?N#%9VX@#_&]L9K`3H\!%GMGJ_I/W@6XP9K'-;NTDG#I#=W,%+.XL-`+M\ M+:'&$L>8(!(\,-0K.W&`_8V%>B7`1WE=O>8=3AH`A,F1G]J54^\NG4U6WIT_ MIBSY>39/7QC(MG2.;H$%N/I"[,9Z=H#IYMZ=?R]T`U9P^GC5]N]$;.,/!SS: M-Q'7#[BT_U-$X@D*1,RD"PTHK]W)T+1W(#B,%EZ-!0V41SE8T]G_LW1XR@RG M,35M6VKW(HRG.PO+B%\Y[*G9TM&V;JG=RT">+KVG*@QD.QRH;^(0'D>J.KT` M=HV#VN1M(==2-G20K,^HJO/LV[L_=I:8YE]02P,$%`````@`,(BK1F6P^":R M*0``$KD"`!0`'`!S>6XM,C`Q-3`S,S%?9&5F+GAM;%54"0`#K!A15:P8455U M>`L``00E#@``!#D!``#M75MSX[:2?M^J_0_>.<\>VY(=2:ED3VGL<=:UXTO9 MGF1/;6VQ:!*R>4*1"DEY[&SM?]\&=1=Q)0&BI?S@@29"&4?+\\X>OCY>'_0\'?__W?_V7G_[M\/#@%Y*0 MS"](>/#T?G#A%_YCY@>_YXOZ!RTN_$4?+[DY^3`Q`L MR7_^\%(4DQ^/CFCYMZ=X^/NT:+@AUG)']_R:*/TM^ZB[,G1?UU_ M>0A>R-@_C)*\\)-@58LVPZIW,A@,CLJ_0M$\^C$OZW])`[\H5265ZX!;@O[K M<%'LD/[J\*1SV#WY^):'2[F@3%@L/[/>P-G1[(\?0%T'!S]E:4SNR>B@E/7' MXGU"?OZ01^-)3#&6OWO)R`A^]YZ4A!QW9U_ZVT4:3,X8D MOIMFP0M\Y3<_R_RDR!OT#7%S9F?'!UC]"5TR\MO1[81N+$`Y#:=S7IMV-=TU MJ^FN];[\2-Z*:9U52*U50]*_I'$(.\O/?TQA.W%!1E$0%48`J#3<',.UG_C/ ML\YX!U-M4\DES367]]*/LE_]>$IN1Y=1`FM#Y,=7L%W.RGU=WE1^S>;MCMAF M_4?6:'/9;TCQ)OG?OYR&:??#$[K:TW:[2-F.X=M M:>MN3_C-+>7ULV`A\OS']:\LCZ914AR%T?AH7N;(C^,/4HR<0_+BC$M/QV8K^'BO1R&)`-_)*?V! M3I2GA\.0*EI)\T7KL/Y&X_*8GJ^*=KC36LMB/_M.* M;+G(97&ONR'NBN)AMBDX=+-%T_,>IS6WC[)TK*[`^8=3-?FG.P?RE7W>%;Q.J"TCK>H->W2*M@ M;AK$T>S@%)1HTN(7G[3_(N)&*KK'=RLIM,L'"PJ?BA'2K.IQF] MK[N,\L"/_T'\[',27L"XY[#!*^Z==':-$"$4-B>]-H?'9123[!P$>DXS\>#8 M*.F=V-QH6QP:511L$OKMD/"8^=3KY.%]_)3&'/5OE/%.3G=-\57YV2H?M+HL MI.-QFI0;B-(ZG-]."^HD0R45KQ&"BM[)V:Z1HPB*8-AHXSWPZXIO"(^1^,-S^*Z'?R.9%$:BC=' MS+)>;]<8X,+@,-'PQ*W+Q&S#-A/N$GXGLYU6RGM6;2$V&6%"X;#2LG5XM8U6 MYV19VK-I1&R!D0T@'#[F*Q_`.]J\WK!]Z<%W+ZU]XV'`^BRZ^>`7]GH-%UH# MDO,N/]@%O1]L]FWFO8=$?1)[^$KJO;KM>`A(XL.\J7K3L5[>^\'FBJ%TR2&@ M2<)G!0BRJXV%?%^3?$*":!214&H]Y];Q>E8MM/KW'!7M<]@2`D)VT6&:,:2W M'@:HLWSM49_"89[#!F#X1"\%@D+`VV9!K^?0REMK66/(;^7FHRD50Z.O0-0[NQG!(VA>K(K-RDU*?T+B,3/PH_O]%H`0(0;N'@E&W`%Q"J4-OK M.;1QUJ53%9>5&QE#F4^U%38K$W$5-Q1$??N%=D$F:1R#JQN"]29.`.SQ4JGEV M/<<,D:",Q,[U3=,93#IU>7V'GDES'8N;^KK^TOD/T4Q:([0?E*-OE/8 M@*LVX?4=^BC5.BQI(;-S&62$6?7#%+^2UT=PU-4B1,HI"Z&=RZ,&\V$0I%,: M4NJ_4P.GPM:.6<'K(S@/2U3/F3OY>,072TZXRJ8DK,(4T\6NX_41G(+K,B:` MQ"&MADF#N>N;ATFN?9RSSZL6]/H_(%B@M%0N`L)1M#-#P[Q;?!Y/XO2=D$\D M`?4J'5:%%0$LKH5)>Z`(@7%8=&9AT)K<6%,``F-0+;(X6#C\.#,[B"<^1BGH M9J@8,;"O*R%Q;G4;NH$V,)VGXW%4E#D2J)TX38HH>29)("9*4,OK([`&&2!. M!I%#I$._EQIG9)%F'/IZ&:11@I##HC.[QQVT16`:GX&5W5LQ2GM]!'9`B=*Y M=QM,,!R*W,6/KCS]I?>*6T6]`0+S8"URF$@XS+@S2H1A-!/FSH_"J^3:.*["H)XBD-+KQ+LU+-19%%3]."&J,? M4WJ;"B<64!Z(\JS`IYD/>`,$9A1#([0V?D[?P6!Z81ZB&ERA>H.],]+P<7*\ MNX_1Q0MM9G;?P>"ASK&S(T3=Z"%H#E'X4*E`WD17E?M[`-$B?*!S;/-(T"2" MJ"1*0FD5RE['$'6.K9X'&@81E?KG$":&M-=A1(!P%^*(ZK*'-I)HT[H*6X3; MK$0>EN:\189O95LSKP'0`8HC@,Z2J(,,65#2INBSQ#/#:?$")]H_5]M**9O; M%0$K@HU]$Q;9B)"%+;%$OLKSJ39SLTJ`$<'5:W/6UM'@BTJJB"M.>Z58$]`B MN&]MSET%$K)(I+4KCQIKH$)M0(WB`E:'2&58R&*9*CG7E)8^02VOXS)S;&/R MV'#L))XSR)ITR>/4`'@H+F0;L;4.!5O0DV:&1Y5J`!3%I6LCSBIXQ-%3[9N& M%9_,U#(-,]W:RP"^A;-J&4TF,OE*:GB=;HVNSI2+OMH;3F-R.ZI^CV?95:KG M=3JMYXE24MMFU]7`\MWXN[3Y=)RGC]+@3PT[25Q.AGSTPHHU04P#C=M-9<_ M#63XC+J3TDTSGV9T^R:V*FT4!3P.?>1J,"4&@L]>N]:E=+,0+<*S.EV'KG+- M*6*A06:EU4H5QN+"K)*!"<`NC/-#8[#$Q&3O*,RTMY^EX,BU@CYV$MZ-1 M%!`Y`RK50'0$D6TUZ5`'B.PTOQ#Z(1T5W_R,7"6%GSQ'L/R71RCIF%*J#\@1 M!,8U'&D:2(U9`ICC[XO_E&:T[+O:P..6!V$1N*DV&'$29,B\KKA`?\G2O-;Y MHJP(6!$X/#8[<:H@1.9VM1%M/LE($,WM-I.8E+I/PN&8!DW^6?Z>BU#`NZE/ M@/X0N%4VZR%F=8'-&\Q&/O+.*0(73$O3PA*?V%D,JU6W8\#I:)&?<'ZS)S+- MBHI[G3-3YX*576GK8VJ^1JQ*()W-(QK7T4BLK>I&1`7%/MA)EZX!Y[&?Y[>C MTAU0U:!KX:K$9\\CJ%<#`V9[7-=2*DEK%H8,%D]Q.E[%[&USCF] M;94%(AR?A!OIFP3!F)Q3V\2@F>9$F9)[` M7]+#MTI[?9=O'C7IWTP@=JUV\T^?0SF:D8;FK8&Y#,;7`\E>HX";"E]:#X1W M>+IOP((,$C+SG=D')#IG#D_GNJ0IPA%:Z!RGVX! M2E=G,\&0'%E8T[7_IL;!>CE`@B`3E2H'5.T`>TW\?)J1\#:Y)_3IY2AY!E5$^=*[0+R0=RJZ*D)F5]KY3XMK0 MX>Z=LJUC#6\WMJL&-8W-WR;-A/[Y#4X(42Y\QTJ_,=#)?EC51+VH MIE:0>3,U'0PKPV!.\[V\3:*L;*&-J4OZ;=`X@C1VN& ML;4$`3(0F!Z1]^T:&D7I`V9S\^]H4])(+J\SV`]O79>G/KF"S3F;X1@+:R<. M1[U>40)0_W<;K4E5BAW8=LBS5WH.N2>4VS)'8%)D-&&@'U/_T8ZL5[F/XP:^L_=]0GNZ4M]U)(G7 M/?YN5+.A4DX/=_<@$G5=NIMFP0N@7&1-J?<,TE\C>*Y[YN[HO%/!;,&V95M`_!<\.DB,(HGA;1*WF@J9W*=$^?WX)X"A/3)1`T>YVUU,_M MZ+.?T2-\#C/G3#WO[`8D,7<6OPK4V#32.`K5Z_*?]+&N2V01?FQQ;_RQ/.!+ M5A7P6C63*$?U6>=4IRMMZP=9&*#E_H`K]`]QQT`;*UA[3S&+O;M*.+G\S/$3=I\DIR.#K8=^Q(2JKX/: M6RN<@T3[DLOJ`WM[/E)J*=MV$S`/- MG+B2+"11<@VI%/:Z/6?7DTMII/X:&P6A=]BT-XF=+C@*Y(PFAMS[X`FQQ/40 MD,2'E4_BP\`L#XJS:7;1\SY@$"6AM`H%V>7_0L"O23XA032*2"B]Y>76`80X M'G84Z)_GR"2$A.R&WCAIN.[DS;*']AI]OB-(GNE3$PD<$(9/>1G')6"16P>0 M8K`V:"U\$C#(KHE_(0F(&P^30)JD)J!%<)*6D,%F4`D9 MLORT]R0GH)L7$/J"O)(XG=`.*V=16`^0(CCUU>)0`1>RN\<*3)T)$Q`A2$%8 MBRD.%F27:$LIKQ(X%),O::[$SZHTH,+@<55O*=N&@>P&YR9-TDU1YWU)8>\A MK0N(,7@7:1&G"`I;]LW5LWCA/Z=Y0>'>CA8Q2P(.A?6\/H8;*T5&V'0JX,-F M5[\JKX2II#.TB_6^ZZ&U*LMDS#HLBBIVE!S:N/*70F:N8& MW<2S%"*R:5&[+5`)@E.;YH:E'DALF=XV8*AR"E`0G-T:\#4#@"T/V4J^6;Q3 M`M/W%'K0ZLKRCF2?_#P*J(V`1BV1V6L?PBU*S3:]07?G#A$-P6++U%4)DX!1%>V#A]8>YJJQFI;55:Z:@68>"8.Z1.:N9C4WR<"J<0%'KAK* MJ4Y7VM8/,D\XR_T!EU\6OF6_40X0(3C5J@U(SEFG"@>9.]T] M7?PD.X5E&4!@TRB(;UW?0H[-A8Y*)QU2:Z4`A=6+:>6U=4NO`N6O"X[,_ZV6 M^G$M975XD*TQ-0[XS##?C7>23KAZYA6%,R@"(W>E#V^J6"R\,::BCX M="DD@AP4VAK>D-YRJ/KFEWMG&DI>%`8Y$9AXM;6\*;XY9R^YFCN=8W4U+PN# MG`B<[G35O"6^.;\L%35W=-3<6>?45L)-.L^34LVCLO)?L)F4;4_AXE?P=N@9 M7*F*AL_/&7GVBZVW5M%DO M!N!M&A\=^;R4C+*[314\,N?3A8!2U\+-@H#%:D2CLO-+5<%B(M;%1^;WV8`* M7(XP]3FQX'+)M@Z5H4;P^<[QL=@;AE$2!$5@=69U:(;=A">^,<])J7Y[ROKM M+03L(+"SZNMW0WS+;ZBM/GLBOIUBE`0!$=@*M?6[*;XQ]T6^?A<&0KE^-TMZ M@QWKORSQD27@NR1#_]+[^%YGKM7(CT,=LV@WQ[5-U M58,L!>"ZD-+M4[4P8+)J#%-WY=:D04[F.D!L"?\,L(9KXVN3/MG6V)S_YW@2 MI^^$Y&6^@(P$4$V\!@IJ@.087!0Y`X+A#2.#8MLK=.W[]-45(%RZ!1'6`:DQ M."_6(H`#QK;'Z%P")9TOY<+@[*6MY'7I+3N(KK@4ZG6[&,B&P5M16;-L^;$E MJGN8/N7DCRE-B?Y*GWZ![\G>L6'7`'A[&,,HV"<+]8`M!QY#6/F3*KPZ`!%' MN*.0`F76UD%ARU5GG#=(X6/`0E/(V8:!WT@<$)5&(/5XXQ)!8A]X;`G:SGMVK00XUMXMY!S MR'/F*Z&?+N2T:]4062-;2ZE8@?;7!>?HWUD*JEKZQ[7TU2%"NJPY,^E<^V_1 M>#J64K)1#B!A,`YO=W8V%0S).20X,[A<@_*42%@O!U`P&(\52:A*SB&AH?4D M)\''Y_3U*"313/_PP[;:X5?>%_+LQY^3(N+>_C-*@>!_#3=4+G8.:0TM):JD MS:3AGJ6VBX#(;IU-N6JL:KLJ-T?5#2T4%E6-8YENH'/9*MTUE9'J/!RET^Q3 ME.9!1)*`Y'#($E]O<2N`W`Z=2MD]EW&])9&?HV]CK@F3J$@GDIO9]3+>Z:E# M5SQ5K3)$YBC2V6%Y:3>8A<;1!2I-Z)(DNS<4U0.H-LV:>)9A#6UPB'=VT-Z2 M5&K_9)8':%8M8.IWAW("V,P)8'$8JDVP1GA_EZ";Y/3Q%$ M=`L&"IL>!@8.'6:#)[;>&2HCNF?3.V=)4ZT*&&Q:&O&L:GH*X9!J-&)#(`AW M&E2O##BL6LNDJYB>PO7)6H?)H"R:1<9IL"#9< MR/-;5+P\1,ES3&8/G\O'TCV&@5$1G2-M@"E0SNG"89K@^90 MZ^Z=L7)W+_?]WRCGG9[]M3Q0&>@Y1#JS^-1'OP*7A,KI1VQ\#A2+P\.503?' MEFM-"YSNY2Y::#^Z%XZS()I^)DVU8]33249@O:2_O*>91?,' M7^40H=$,8$3@=6MOEN"<-;0UQ&'?7?!3W31^U:2U]K+&\[X%*D40[FXY$Z(= MI7'ZX>X]:#"'^4MYKKA*[D@6I>$O69I;R5'*_QJH%8%S)^Z^R%4;ISE'V5E_F'>TFGG:Z`I!(ZK=CJ8=;5Q\N\YBW<;QF7C)&2CGL?SB*P$2@T` M>`3Y'.Q.2CJ:X'0#9YGR%YE!YO8K-H*;M+1-7],"S]>__MYFA=3/V$^.5:[+6_0V_L)KJ92./VDZ_0QA)+=`4L/K]TS=_E6_PGLI0%#:.^W9/&$AV(>4_#1/2A1&?O;^X)?W(J4-2)[:B5D'U&)S?Z]TU2-EC7,N%&-"EH-_ M349JY;L=K>6.E)O+I94!L]4E22MSDX`5#I6*^)`E\V^!4UP7&A;)M?`J@*$D M,7>W4A_M91E`@N'4H3BQ'Y1KM)0;=@7`AN!] MAV9$B9`9>YH`=6A9W[F;2MV]BQR7L<3A+,U@S0JR/P"5",$S8[#`P8'[)H)7G2?K.LY'57-UT09I[[`#) MFQ5])&G(-'F0L[D.T-PK"6A8P[74V:1/FD_9U$L+]/%D\I8F0K^_S4(@'P*G M%EZWKUJ<6=);?FGA+B.OPZ?L2RQ.1;-=#&1#X,VAKEFV_.9>6F"'SY#0S_(\ M2OSHFH11X,?GL(4AF3A.1E@)Y$9P8:BN=Q4TYAY"8+)PDXU_C:+_@'U'E#SG M5[*>SBL.LB(PR*EK7HP#VR,&M5Z'[MLTO-G2D%0$' MPH=T!Q4SEPX:<^GZS0R5F:?951*2-Q(^IM2C:#4KRV-75:H#<)MF,9O+CCH\ M;-GW99)+IT:U!@`\CI==U9FJQ_0Z7&S)^EOD&M?RV![ITN7473K"A2/RRF]8 M>FO!K>/U>PAN,'3&(N?"20P0V^,"I9@ES/!B2OX\O`I8LHISZNTTSD M,%^G.>_LV&'4;`/>ZX,5/YK0OB_\M9_X\X!T>IXP[@&_U?X7B?L[K[C7JY," M6T4BD>,[JZC7L_KR+=?K7:R9ZKF/+_L^^+NW?>_>L_H&KO))D4^J_)Y/!2$R M__BFM[<]JX^F6KES+VE0OK3M\5]"=?="6W/2BB\O^35`<`3F3]YP8-Q_IYNPA(2?_2RA-W[#()B. MIR7:>:"B<$3)*GL#NX\RR'?=.GL975Q")_?V]]?+@\#M:)DKDB8#S::SG),- M]MN&O?!%6W-^8:#,7::>A32\/3R[((C<>MRJ3($\\T)5[GW8O9_[.7TVF/Z/ MGJ1?_5@A[(-?"13C/%Y51!F;7!D>='MQF+2B`*9;MN#LW\I?BFW0+.@)1WRK MC$K>BM84.KJ=/\HN@NLTX::OM'7.N$X3\G[M9[^3`C9HZ53$K[`\;.90>$F@@C9Z8.9\GX/SAP] M9QY\M<\<5N^OM<\H'G/:DJX1H'FY3!AL\/`8&P;SL^_ MM]B/R5\_V"SI#3"DTE56LA`%LI0T5PELG6@X\DI7'6$]0(K#NBAE0XO$=7#(LM-8HQ'7)L(6GQ9RUC`7KU](0J_1 MATDX#,>@PKS(0))7,L]O3I^@H0F!03/4-G9!7DF<3LI-TZR`<+TSTSBH`X%Y M26$$5I=*DPK`EBWG+DL#0L+\$E2U2!%].UK+*BT8Y-*ZL*%`P+F>L441%+9< M..LI"LN7?.8/,>8+C^@U-RF1:46C&5`$AMR,>J8T;7S8TN>L(;C+HH#GQW1ARI=-FEKU`0T"=SXU9FH`LYQU MI_:+"POA/[_!$2[*Z9F,^VZ=G0^!?A`$U:D3;TL#EG,',;XNFTQ5JH'L5B.< M3;.GAL=@`5PVN16FNA`B!SF8A$X^A+ MY#]%,2B+&7C*+@CR(;!+:X^5"@)SN84X>?GHJU!4PM5@G439[-0*LI_PMAJR M>B`]@AQS&EL,-4#8T@N=QWZ>+T?E;58^_+OV[*K(74=2%0`CN'30F[+4,(G3 M$+7OLW-#BB]IGB^6Q=WWUAG4>;;*L;>.U02!NMXZ`U$"@JK<>^6M,Q_#2N]9 M\>J`6IQ'[XH(DU#+AH/,0V==2.F%3;6PUT.2;5"B=>%"4\&#S"G'`$>X;M(, MDH76#V>8%%$8Q5-Z!_1`@FE6'@<^OP7Q%'88].*`&D.F1;DWO1TMPB,7VX=/ M[^P&)'.IQ:^"MFV:&RW-QM85@LSOGRVN4NY26578SU@U.RK/]=8YU>E*V_I! MYAEEN3_@6E<0=PS9.N7,!TLGS5\U^]W`JA^]HG5!;6#R=NM,2,@\K.HY]0[L M^LW;)XU.U;R@\3Y,\C:.0 MID!9*@5.-C1.\3).O^6[:"SL#1RN8#6-A0.;TZ-V:-^`^S8L2^Z],A8^!"3Q MLRA5-12NEP=UV+PB;'0L'7`C5P10D!D(%P)^3?()":)11$+Y<^B\.H#0ZGVB MOKFPJG\.86)(R"R&QDG#=B>X"Y+7R/8;'QZ_YI3[]-;F)%@ MVY,\#P/8'1B1_1E.8DRT@X#^H>)N%M\4*R89X3X21?KT%0#H+K5UTR5;N$ MN@9L1W161(-)*LVC(I?RJU,=L""XKVW&ICY>MH;V(MLK["XE%TS2N@`9 MP9)N:\`RP9H+TK3(;P8'"7%\FDYU`(X@:LHBRTR\V")`JY(O'O&Y,-*VKT^,7)N`,A$M)+6!^@(SN_Z1"H"XW#JS#SW,)U,9L$) M?KR(?+E*1FDVGF4'E&_'%%L`^`A.9IH1'SK0.,PZS.I?D`R.!W=^%`KH6R_F M];L(CDY:6N=93;=!<=AQG*S_T7\CN92@C9(`!\-9Q@1'#%P$FB/Z8D M_Z(0DFK[TUZ_[^S$8@F;+%S6YF=!G387$V'P;3M=A3T/V=?I/@0&+[7TZ7VA MGOQBR-B+7^;="X5?]-Y7!HA7XAZ5!V580LO'KO.R6N<&_5L)=<4LGAND?"_IC'H M@TYU#?K*9B.@`P2>B5A["TM7R#)"LL2_C_+?+S-"%I<0-7H+JPG`C^`"#5M? MX6L*;=QYM:,_DFQ<S_N]DSJAK"EH%2=&]P\OWBP'#O&:#8?N[- MQ<'`ILG,\<7!@/N*O'V=?K\XX%J8K":*171Q,*@83S04]/WBH$T[E]6DM\8N M#O@)<%M2T?>+@W8UOE,7!XY[9UL7!TW>W^T/_A)&Q>J^2Z0/9)<&EA++84@I MBV/'S56/\+:!>:S_Z8A^ZPF.W:5F_Q]02P,$%`````@`,(BK1O6XM,C`Q-3`S,S%?;&%B+GAM;%54"0`#K!A15:P8455U>`L` M`00E#@``!#D!``#E??]OW#BRY^\'W/_`FSDL$J"=Q$EF,YG=?0^.D\P9Y\1& M[)F]A\'#0BVQ;;Y12[V2VDG/X?[WXQ=)38GB-[5$LKW`?G%L%E55_%3Q6['J MK__^;9V"!UB4*,_^]MWILQ??`9C%>8*RN[]]]\OMQY,?OP/__F___;_]]7^< MG("?80:+J(()6.[`^ZB*;HLH_KULZ,'IL]-G/P+RP^G)IVAW\O+%Z0_@MQG;MV^?T[_BIB7ZJ:3TEWD<55156KZ` MM`7YUTG3[(3\ZN3TYB]28E MC-/?W1=P-$N^MOIJR9ZCKETQ>?,C&,=RG=L_Y3145U0&\\_0NN;_-JR@=Q3=/Z9+C MSW"9SCR7A3G73D6Q7YVE;C-2>YK5KXD3+!4RT1E::$\;.[_.%Y`A&6ZO0U M^8&`[?7)B]-Z/O\>_ZKEA&/@-EKN+9.#F+JY,UAIN)9"J8,?VMHC>$Q4WP#& M7.^V(%E%Y9*ROBU/[J)HPY`"TZIL?M.'3/WK?^"9OX*$H?,T*LNKU4V5Q[^? M?4/E`&X,:)R!QX3_/H)H$Y"O`&V$?0]NYA$ZQD/0X,=2_W-Y&N;HOL`[1/Q; M5GV.UC(O,]S4J8>1<-O'1CTW[=L!TM"O7U$IFOBW/"X5S#,4B2B_P0NO; M_X8[)1:$MA[`(/(K04/=$-"6`#<-`0\2;8N`4*IZ+D2<;XL"?_1XB9WN=U&Q]1 M"HMS_-&[O%`[C5Y+#RZCSZO$8=!FH&D7@K<85++H*Q0:G@L$MT5$3H!O=NME M+BB_EJ'7QNG`]_GK#WG]=\`:^!WK05WRHZQ0Y,QK@WR]SC.Z0KVYC_`876TK MX<\EY),?TTCF)GIMG(YMG[_^ MX+9_!Z2!W]$=U"4_O`I%SFVY[O%EOO\2HV:-0QD8Z#4]I"A*U0] M-R+8CH0Q\!'_;N@<4M/>"S*&^):BH]X[UB"AS<-`B%3[0RC1J-X-4LC>U1PG M7&N/*.%YUF&$GB\$AQ!!ZW)\2%3N[H;CJKB+,O0'O6HYS[,R3U'"[N>RY!H/ M-.:4_O-J]1%E41:C*&T/V$O%1>W$_3N_.9E*+WT$\_TN0*=G@'<'@.^;7,:T MO8-]]T'<"\\"H/Y=S@SH<7AYN-UL4LI*E+Z+4A+S=G,/8?4>6WZ:EUO,_RW\ M5KW#+/RNND^TZL;]%:.=E'U[X,E!30]H!X#K`?Q&^@"T$PGF#Q;T`1;+O(WJ M"5Y>IW>P(Y`L7,N.AK$[B]WS/*2$2 MH,6\X[DVF?8.[CEOWOX%,#)`Z(*:!,T&28S-,Q\A MWX#;6X_1+LV\CT!@."R?"I$=,'(..)QY9BI)1=NS$M>_(2K`:V:36N1Z",+F M3GFN\Q)IGHK8D?L+S59+):*T)@-7_.%@0QG8'&$^<-(H;N-1\P!(V1,264-_ M(),]&]G#R?M;$;5VI?@(XWW(30RSJ$"YZ=N0;GM_N.CQ+<"C_G-XKT&&%"[% MB%S;#J%2\_!+5FY@C%8()N_S=80R%5SD-.XAH^!?!IL%X%J#WUC[$%"D&PL! M268#X<'Q7*(,7N`?C;P.U]B?R^$Y5DQ'I!F@[4(`C%3=4I\CT;4[B)R5)32Z MG.@W=`X-@5,A8)`VT*YM7>TR#?GU#]MA"/0AJQI_UW"M7]X8HU9H[PF\(M_# MF%B`YH74[&"NN!P5!W/?E?=G64+^CYRV/$0IO<>K MSJ.BV*'L[M;R=2' M7DT%:C+J/B@AZ*V-?#K$PT2#C*RDLN54MKA>.46!K)PL\-BW,VLP>MH]F.X: M?.\6]+N$N2R!2P\XFE6Z%`-!;PR,-@3^)H8XSEDDZVYB1N;P:C`M*E:UPQPB4$!:RV18;_ MB:FBS29%]"]?HR(I<8\T4A1$*[RD!GD&P8Z\P\0MEW"78]UB00"Q2RPX9C/> MQ2E<`+0":9[=$:7C)E%:Y@!E<;I-R'+Y[JZ@F75!W`C'9%K@$2(2DAZ7]6N9 MDKZ627#K!?E3UNJJ'DW\FPI+BN7&3=(=2%@H$Q8`94,=81UBF=>X<8&BE&@' M.ZP2)91__-,S#N_-)P8UAHG_8!HC'>"A3_HJ>H+_1CC(2';+5*&CI\\\9WPU M='J=;*]6'L_UWD"[*?"V&["\0'*Y^I9U8V3!=R`'JUK`#]BK"=I' M'ZG^/2I()GZN?\DAZE!#I\>F@YSVA[EN!-)]*W_GHH%Q;!"E8\SUNS8,ITX@ MXRL(QYCC#S3?[\SLFAPS&W%[48$";EA:K7)_NOQ5!(OGTTFY_^#/(W7.P\NN MTVR;Z7=?J=M(SAF$:30'JWEE)Y27.M?F:9]HL#'T%IJH8GF%LN0\S\C5 M!,QB-6R55.[#D)4R"*<*^]8LFI5O[SG,>&Y!G(9WZI$E!'6:PLIGGI!126F" M2DACF(RF.:H^JZH"+;<5V<;C>0!<1T$=*8Z6;_@\/H`31OLC^/`.W:]Q7S0H M@;*F>^`RV-I'B/,`SP-QOW6X15W"I'ZF/_L.Y3-3H*22?`_7SQ[\>*4 M1(VP'%E<30O46`^0-!#>K M8>=V'5;7CM&^!A.:>EEQ];@=6IWLR_P$9"/FO"NL0VD>;UXNWKS\8?'VQS>\ MD>#?_OCBS>+UG]_R]M+\Z8>WKQ=_?OGG'L$/IZ\6IZ]?AV5@,J@.K>;D.'5X M]I\D-(50E%Y'*+G(SJ,-PKM%CCW5)8`!L?O;`!.)A`/UE@@0*G"1@9INT:G) MY?F*X$#1R&.5$Y2!F-'YMQ9S]`DG\I;0[K+J'%8K!.Y2G^1V* M2[PLS^)G+%QQNRQ1@J*"Q"^&%ZDH1YK^0,27=7Q"64Z>7UQDV-7!4C4SBDV= M6\8`M]9'A%5.'T_D684_F9(]3M.;SSG$0#+,]0G/-E*R[1+X,A#U8:]&D,\I MX8(^^\%:O#% MR`EN(JW5D^+(*/V#A;?(9S.;"CS'U?B5S^_JY1"GJ%_Q'.X1PWDW919"(R$- M[IV4.MA&]CXJD.@;4XF$D)R!!U$_OCQ]\Q>E>"$]A#((XS%`H,OTT_QQ\`\@)9&*=)L3AY`=2X5.9)2@X4_0H8A#I>;1V9PO, MT>]*ZG1KJ4L[1KVW M7YZ?'AA!C'^%8(&OT;C?%W'DRSR>D>.,'$V*D=7:;VYS\ZFH?=$+_!HL8E504$QL+B#^G]AR0W.(:D'P8T"]W MRZ=R[(%W.\"WJUD$E$=0,TFGKH9-P/ADTUF3'^DVI[\&5[U0)X[=8";UHQBV MNIJM=-B6NZ&JM[;#5H4T;"833LCC-C"Y%;0,;TGT3`,'`1NMF!_5J#NJ?+LV M"QL=U9P;U:_-J#[L1Y5/5D9^+<0=PKTPGJ?8D(91F,X#8L[W0=*P*NB15R-L M7*$'5.U&'#"-[]SCP=,!&E$=2#%?+D[5"W:"VGCT!6AZ#V8V=:.B?`5DT^+A M*O)SQ'6H;U:>3ILUH'G MEW8*R;2/[S`MN"H`HV;/C`"F9Y.#[S/B@X6L7R"U3X_`$Y2!)$_QKJ(D=7S8 MYB"`R$P[J*K?X9GAU)<94E;*L_:YE['YB82>S6Y`$JVY,1JP)PK)Q*P$JDU+ M>+X7FBW)\*:V(378_-H.>P1J:3<-41`VTTI@:B\AO'L=*4C73I!"$-\VTL65 MB7T,@S$5J6LT0;W>-D2=B?E((>)=]"&Z&`)S[X1D-'['W2Y3! MBPJN9?4@E!1.(:/FO0^688`0"D!)/*/$8"!X?!B/PFAD7!>0)&]K@N:_P!)B M<>[/LN0]?(!I3E^/2#!B2.L4+:;R#)PB$KK]`X^&DH9LPBJPKX M#4^ZFUK"@AQD[3WA6>!;\T$&$CM.EONU7.8!WP/XT4"&?`6LV-;J/L+D9W,%KIQF1$".J-AMGXR5]BV`Q>`"E(WNUN\;?/OB%5,3`CZG"2D'1DL@+D M`A!*\!NA#0"5%J-FG)U#-F0!8)$P]CY?1TC8LALE+.&HP\%B1Z916&34(:-1 M'#?S7#&207.'QI:53W"]A(4">4)+YR@3>15*T^ZG5M;&\Q-1/<>?HFR[BN)J M6Y`WZ]"0?Y>XER"DCW$E/$:?F9/GG-L*KW*SY&JU0C'4X]6,S.E)N8$4`]>W ME(0Z148$0D'W%"+E3*20`&^#-_Y$V`YL3H,X*%\W^:KZ&A7P(JOP<""\#*=[ M1JW#-Z3W$=9A))<4?PTA21_>D++3BD"FC;$2-NT#,*91(!R(]K!%X.B9!H]) M7I"V.[,I1M'>Z=RBXEO(P=RV-9Y+7#E>K?IYCVNH^P#V=)>*V`\;XG!V=)>* MB!#-:==E"*$A]D-FO)N3C%<`,/RYR,M1$*P)PX%?(XGE60(E\WV_YDRD(.RH M@SEC&QH`G,-"JGS)N4T!8T0C:/#/*:09T;+D;$UJ3?Q!?R\50F%ITWW"?5'6 MZ;2C*F7(][T`;>\4_GS_V"RZ!K+H6LC4UOZ6:2F#=X1-G;7/J*Q+6)8D@S!7 M_''_`?\.86HC$JK&SF)!$X2+#R5%EFP>=$2>`L4E$JBBQ"79NH.)$%<-RG!X MN'Y$'![AI%%97JWH>P?MU=!08_>',T,<"RSC$/4!9O*5I7E!&`_TW19YL8[H*QT[[ M+L^3D@;YEY'WO-I:.QFP69V1'&JTO$LR8LZ3[;&8/MM?1BKP*\,Z:QADWK? MTWG*&,8?&..;>1FW,$\MY^=14>R(1;(L,%'9/+I9UJEI2YJ:-L';(/*7?)FB MNVB?+1]+2M:M-&5,A1:)+^CAS!L=]A9 M9H767B99D6>9`;1-0=W6N^U:,+]NF0_'@`W8)[-KW#5CKO23*%1CM-38LP%# M#\-<998R--$JS22<\@Y?[ZJ*5_"R807M!D'RL2-3H>:VU$6:>5 MG_&6QL;4(Q[,4>2`1@='W6_@RR>\M5AOU]J1[[5S/O9]/H4P;/;W`(*AE)KM M(T"A5H<8B+Z98:#;SCT&>GR*H?C?0L/`D&8%#,C5Z@X#'R-4T!RG[W:7*%JB M%%4[>D6BF?\U=,XQHI-#N(MO&@%VIQ7*BL%H//I(LA@,AWNWL;4)6VG.RG*[ M9E7`FJ*$[]$#2F"6?,&[:M6>;OYON]_K.=#G<'U7P[*$P-E>1>`?+W.$\U] M?[$O[-JP``@/G@L#>E!QJX>D;A=`:*`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`R8O3S0/3RY#R%(P/6PF MNP608.8(3*G>87"E9#]O-?/1#-\Z'D-3Z&N&L_RKYO">^]X"L"_.-(&RLX&; M*BJJV:XN+938:N`=O$,9/59XQQZ'SBK_ATR;YQ]D/_^<-5S)59E<34'+1 M-27OZ84+8X=R7G+[[?+#-UC$"(NB\CPC.G/O7<9(/*<':;Y3SG=9:I<%=Q(- M">)YN@&>5"A"']77C'&^7N,!9W>$)*\:K`GII2=WW0C/1YYPNE_L^2S^^YR`8)^Q! MQ7W]/(;%G+'I3KV^L[3;XW&&M3XJ>/Q[=QIZ=\ANKO'2X`S;.71 M'6S6\-<%$D_7YSD85G-P=/.`N6Z=W<X5)PE!D?TT1N.2W->(=H/B<%-.E+,\T.7D7,-?%/R45X MD_^D.AZS`"C'WUCZ609,Y:]GU;QV:CN>6\_IO8"UGYW+!1R1KVUO^WR[6TM& MCL_CVFIZ5J<[<,GKR^].PKUO?)1N=Y13F%R[WN`1PC(`1]Z+>/I MW.M`OL)SSS./@_?KX>-VWXY'1^O-_Y5NG'T<84SH7H['UW/7,IZ\NC$'1^>_ MS77K[*[[N(\Q9M.WZ4I:?F5^3-[7TN9GO`D.UJ,N]>(MK4_"O\`U2YYSOL^N M0]*+O=1Y5]?<'$\:QH-T[N\.N>4*<&S-F;O1_O6?]]$P5-HE6I&;YKJF*/?I M`.8R[SIT=YUJB^BCR$1YN$>?+$7E5.[\>.91^3)!)NHL68L/X>;HYM%Q.G<6 M=.E_'G7D_:<9!ZL9-+P=CA_?,;7'/MAQ',]9$CY<.\*Y&A]+GSTF)?AH@:=W16XF0GZ3)98ZHRK8:69 M>BNQT0VOI/]ZCX'05@@9<&%N/GM4938,M#A?H8U^\#;[!2`,\AS2[^M%$17W1CN-1&E.UJHOIL*^;A3&ID-%^XQS_B_\`FEW:=$N=K!HOR M'FU8VRUW,>AM:^U)QB+SVWEV;]'!5UW/J;[[9D4]&@NNLTN1C2L;_]1210_-$<_AK1)XRW?W59#8_:/P;^VYU)> M@JXF9>\1>62K40GB6L(TQN9?\]IBDJBEQUN*PK,B_P6O0=S'A,WFZA_#+!Q` M_//T/#ZB^3B(F.F1]S.//*+:P=@]HFH0KCV4KVNA&>80Q_=&8R8![QP]DING MT0[>P=54T-X\O&$YM*#$D5_/3/*TB'M?&Y7D))+Q[;>XO/AA;K;L&'Q$ M.RW+D?%^3448_5??81TX9O\254)F<4G.;\)&^"-WT\5%%N=K>(-76E36LV5) M4U`J_+>4PKE#E?/>MQ;6$K1-P6]-XP!>;VF&H(]7(_V[`]`57G=BB\GN/GPC MQ@-+`P@I:)R#2,5_'T9M6]`TU@+)U40U3HSSO*S:NEV4["?_]J!%5-\B#.'D MSB9^AAGF*#W+DK-DC3)$N"%O+&O^%):AI71N'WI9A"13C(+"JDO3H,ROJ1PF M4=2A\6\MAECKVXP5T-Q9SA=80JR`>\S7>_@`TWQ#YCB]W6CHG%N-3HX^PIKV M%&(<11@6D(J!94_C$O18IV'>4=VVROD3TO!I$#!7,DY^ M#0BV&K#G64C0%H$B!;<,)>[@_3G/\BXWM<$9;)T-:)U#WT0>(4*?HVEMH29[ M&LRN>HQD[-R[+U(`^VICV/5-QQ)S[@RI/3T]2_YK6U9D57:U:EY\*(Q(0^?< M@'1R#"8LI@1@3\&_=O'[]L=6G/-[*G1-*UG&UJJ M@[;V:RA6,K`_82LA+?W;@0X]XFV,"73HTNR8^$;.$=[A4%@6PJJ[ M,R*8)BDTR3+Q.B]86$)5%6BYK4CU$%#EY$553$KGY6G*5I-L"!:`[LY][JVT MLI(_^356+8OI?"SB<9J`0;D.73H.T?#ZKD)F=0XWGK#:[WYY*[K-NS9D,&>. MZ,O]QG2$O%J/%(;[,=W`3J0!>OPS(/C)D.3^C7$TT(6M[V$H]V3:IF;KVR3M MS>TV!]=1(;U*EG@S="-C-AOH!WA@.6"SRJ4;;'CV!^G7\/B752BF%PSDJ3<,*%Q MA\I]Z^@^/07KC9-?$LY7.X@5JUO0=,A=4"QHV0+:*;M89]VR0&;?>^3IU-'Z MF[9(`SCI2TVB;YZ@#"1XNHJ*DKP689G&9KM[,EG;3ZD%#@%Y2VXEL_N@SP/< MP7!8Z,&^P)U#%"I@='E3N#TMI7/GII>EC];!PBI]1^5SD6,OTH`;&K\`!.R:E^TX)V-KT4O/7I[NU'@=6=-=87A9^@IA)/KYUSR^KS*3S%J^]S?V,M M`GA1-*C9/CH4:AV=V:-YA$C?()Y*1U;>U&DN#`FW@G_LO*P$IYJ!GML1'L#Y ML]/7`:!4!Q3^`;\>)1-A];4%6%\'@-;7QH.N&W+W>#7G_=F?7\S-O?*<8E[> M_1C;:U-K&X3Y1.;VY@<+>]LW]FAP',?:D7_S0W`V-RG[?H#;QXPQ;IOS]FUHR+7A_IF6?3^;M#YDY)NT8;R,1F[S[*CS$0EP M)6V=XE;&K^1VH>PE^/,'65/&G?!KDBC8FN$--;$Z96]3B-%S8ETEO'DC,\#V M$22C_9S7213%)(O;JJPB6GRF6Y:>LW&WGS^>1+)V6ITA32QY,<`X&,@8NP`< M%[@MY<-=Q::Y,\(>IOQV&N`:^[]H=FG?D^5M'6W<[@M>R%GMN7D28"=UA^Y9 M.(Z2%N.T.WT-"\P'D'I%T%\`TEA*QLT1UJN81N=#.CG&4A33:.,6+U/[E2:6 M;*X$Y3V$=<6)J`)?[U%\SZI00%B".,I`%.-/8V`2(AIU6@+\7U@\8)BN\@*@ MLMS2GC`Z6:DYL&'OL.FW\KKH2KYWG32(+MX6Y)E6NFMJ5%#8;K.$YH2'_2KG MI*3%L9:N.,!)3U*KXF`/?03[`6VN=6[J[N5:_P+7$2+K1_(F@L0[;J/T%A9K MU2O)P/@\GAW&3./DKV)%9TLB%%UH>08C#9ZC'2[0*(`@[-&5. MNQF:WV$YGEV6>B4LK95P=G=7T-QG%UA2E)4HIFFO.-WH)A-O;/F9._R-@K^I MHF4/M/PU!=RUAS8.YX5PAF9(80_RFD_.G;YG5S+HXX/P(P[3F6'`?([6\.P; M4B8TZS1SG]*LRV4?Y^3/@/P=_$9:!/!`:$BM0KHJJ4[=#__[G"PU#`#0-/0& M@993!0A8FX!@T%6O#`A#NAU_)$[JFI*>,=_JAV*#+=T>,`_R*BPT:*56.LRD M70#!)69\4V8YYL.(*E'@HW-HI@/')`!]8PS0-]X!^L80H&\"`ZB<;\ILT`!] M8P;007!,`=!3=73T8$M?`#V5!Q9W`'H:0DRT&=^4V9`!VL>'!*##X'!9_"LE MZ>6OHZ+:W>)=31G%='OR;L?_1;,5L.G$0UDP"PG%JEJT":!M@ME*V`^:6%YK MW(CY`:9V*S+4V"O0I%N2'J""V9;(U:V"SJ3;DP_K39KO("QINI0"QIBL5`?# MJRC<1L0K>1>B7IO6X(SFOJG;!S*)&8Q#)\+<=!`F`<8Y=E+;M"(W[,;0&*#Q M!HXA_M7PX"@"!(AT/&00T0S&P2`Q0H57&&C'/;!AUH_KI`.Y!XAR*,5F3@=S M@,N!Y*AUDT`&5*99?DC5:G5XK[Q=EO"?6U+S]0'_SRW^GF83(J5P?QLKY5W8 M?;TF^1&Z"U3Y)2>4I';Q,!DG"][8Y:-H'XY\,QF0X8[?!@'A' MEM97:>A"09?49RGP%8S?,AH;0XQ->E;R,\Q@$:5X/W66K%&&2%99DC^WJ2*. M__`%EA"+>T^VY?`!IOF&<%,W4"ZMI^K0(1\\#XA[[CQ;_ZQR6\B](/ M686D=QN#K9PA>IA'H4`\:0%8$^^SLD*M#4JT.IUKN-GWI%.JV,3I0/>X$XZ% MZO'U/BO*-,D/KUR-XP^$DA56]SN4ES&"F,$23[#JHR$%@=M#(A7GPG$1;0RX MUB1S?B"SAGX,.H=(A@,P_K!W@ZI\HSGK[;9Q>]3;XT\P:?;W0`9W4)N=YS0+:A9:3>*Q\XQ$5NO.!=5T[L]U-'((6&$O(?;MO,_T5B,BG.R8#X?# M(C5=7K1[;TE[]P5H)'SK,!3`8L)(]4)U%;W>#XSMPR-T'Y6P><5-7VE0N,K< MC#FIA^@_K322<,":;I\'@Z/T[GYL!TN,O+,9J=GP)'4R-L1!84I^/6&"*N\> MR7[0;)`U[98H7Z_SK//)L^9+?T?5_0W*[E)XD9'D(;H@JI%].;YM'R>O>"5/ M^@$]/+9=`=(78)V!MK=`5ND'C7GWBO_@`9_&*7:^>HNI('DOB:HM.2Z/4C/X M'M2C/_=I+;O&I_8P3'L$G2Z#`_0$6)`ZX$.`,)M7'H'NP[H,RD=;XMO(58<- M\"GP8..XG4"\^(BR*(M1E)XE#ZC,B]T-+!Y0#'78'M67CS`_ M:WDEL8`DV\X>PK@GT'8%FKY`TUDP*#Y@R`=""P\9;WA1Z#2AU7BE+\;1G/TN,$RK,\[GP$MF-TYKD3),! MW/_I@0O,6&<@.Q@PAVWTFE0W64+_>;;9%!"[>O+++R2M67D3F>SNK+IQOZ6S MDW)X'U?W06.'V&_X;@#K!Y".`ED5C!U?8<G`#F@9D5E;+]C,]"[S(KF&! M\N3G(B]GR8.J^EIXD\`HG0TGFC/,`WXRD`=\L4\EQ[Z(-Y&`?9/\!G]UKA37 M<(4R1#[]\Q8E)-FS?V7RGJC6!TR.M/+#"!@=E*^P#R/D!D;SIJ8]#B4&M;H; M/Q5,EE[6=!YP7UICD+./$2IHZD/9$G"NKQU'P0RMSJ:OC=$L1OLS(B"?9>E5 MC[`*QCA%SN;09M?EK$4TK)5)Q64%,_(5*.E2XTE>@)PE]27G4_CWD.[IG];5 M,A*0;`MR9$J*5VP8!".\1R+%,K9I10BB;%<3U0,0\P-%*EPT7R!I@_%_8//& MGK&0?\WP#'J/-JSMDP\W5]=/C[4HAIE[G:3^A8UO=7AHF]+.83(L5_W.1'6: M:]B!^V->4\F$\]^&$$C=64WL?W%E-WS"B?&(L7,885K[G?IV8YC'SWG&ROU0 M&RMO\RI*^;^?YV7U.:_^`U9?8)S?9>@/F/"'**J(53??=Q\!ZTBOTEPM]8>E MYD4+,-9%G-CG%UWSPQ\&.UB!_:<7H+,5]V^83L$KQ/RZ1^YAI][W>9K@106[ MG[@E!:!4A]M#K=V?80_R/'A`5+=L"C3\1AN'G&V'C,!/A9#IC#I";7 M5])[W8$V[I.5$`M0D M@-$$@@>S0>D$4EN,R&BL?"[6OR+TO_!.&65WY87.%!H$*G?AX/9KH?GVR%'I-WH)S*X8Z>EO M^1E^I7]2IWTQZ\!#_A=#R8;C\Q@E8*1M-`&C7@!,SUK,%7!F&K9ZOEW@=0@Z4JP8RVU9`ZI;1=#MND) M<%WQ,4%@WYU_6!\R],,9?`X9]]'KF'V'GZ(L8O$MY.W+V9)D*HTKR2I&3^9T M#6,@11]]>Q*PIZG+YC5DGI0=A`!0>0J)]=TOH@:5-J5A\F)$Y7Q)KI!@,_.ZO::["LDY.X/^64 MF8SIR#<93$0K`(K!@RFV[("_HGI"=PD3T%;6=@WYL6OJ[N M8B=1`&>6'[%Q#$K\DW\S'0_OOO$>BFV'KYZ3_]J6%3WFNLW)\[8L1BG$_+-" ME)=YB7\_G='/\SGW+ZKGT9KP_GK_&7";@_9#@'B4N@3J$_*QI^3/P;D8H_Q" M'E19Y:!H54DB0U+\$?);\G-,M+@MV4U[WNHM"LE1S6FTPLOXV2W6=RX^U=)8 M0A!(1KRAY;`DJ5V(F=AD!PX#V5C\VYP:.V;YMZ8\A6)1,!_SXA,VQ[+*,UBG M6%'6F5)1N3^)4LHP?!:%6!34*B_`NB$"FYIJ:I"_97)D\(ZD!I&!_&C$L1QM41:G!=M*F M$_?/Q&TD%)^2,B+PI"%_2G(I[C=R=1?!'!0=).WY/5W`3822]W`%BP(F=4JTLRRY(CD2S^A@69FJ68(CV;(-U MO6W;`_V`)`K]C^.Y/B]156H-U8[<<>(%8ZFD1MC0$A-LJ`.QO0-%[$C#+$QE M64[VCP>(0S:2$2E]2W3&CF3IZH#?+V*#R@NZ2*@S^^*%PQIOO'8EN$,/,".9 M?DN(_0RJ=@L0YVF*^RJB=`'(5C0J[G#[I&;H&3A+RQSW$*?;A#R#Y#Z)F@S` MPJHDRROVIZ\(8XH69&!'QH2]*OJ69_EZYWE#:^L,NIE!QG@"G^N3LSC.MR1: M.]I)7ME8T`:PZA#E,5Q@-(2@I@QM7Z`7K)5@HY+`[Q)!`C?]:D")-<\&5&SQ M++7?:]G:D$`>AAF)4IE;$J$%''&`QJ07KY$CU8*3R!YGG46-XVLM7@6TH49]W1XO%-@5LD*74\4NJCL+!0K54ML M::UM9T<4NFBG@'[HXI#$`1Q)CX>WH2D;8]MAZMCZEO4V/XO_N44%Q#QCAU/M MR'O="F]3R2N@#6FB,&6;3MRGF+614#B`;>[9;W-0DX.&?D%?9E<+>F34=N+W MY/DP8>LG/26)/MC4A%0ZJ);.:;)=:\`*"7A'HC7$>7:2^37H>76:^33`U:^E MK,WJUURZ,*?.PZ?,P*SR(\JB+)YH]:OL+!0K54ML::UM9T>T^K530'_U.R1Q MN*M?`W@;FK(QM@](FI['$"8E47.3QO)J=4Z36-(HPX]YP=6:T:A^^MQ_P M5\-V9NT0Z]KG2>TE4J6AO'7Q4Z8=.+-"3"Z;Y]$(N8>FCX%0ML(>D"F&W.Y& M28)(/U&*_\Z"\+"?J@JTW%*55#EMAIDF:3L%C9%-R=<&3ZWZ/%\53^A^NJ4( M)O8];O,AL1RZ_0E'Y)4@L&9OJ[4+<3,^-R"6$E!%FQ)$^B#,FJ_ M_IB@-97(RP9'+6H.;34KS$41IDX_@(L/.;\I]\@G`$0>S'YA(R(1+PT<6!T1F.CVB?5\![`@LX2J69AR!59>Q&Q7$`U!= M1RA1QFCPS3S$8G2X'"B61?\,R-]]AU4H.:6&38.9R6(.U8W]@WP(!F*DA`P# M3D.-\C6\C;[!4HO87DL?`40]7@=BA4C>!=HD".SJ&.["MR(M0\#N("8&`GWD M@'"'X*OB+LK0'W4U\*S,4Y1$]8[E&@]NLT&]6M4G15':YF\J]TE>;^&WZAUF M\W>%"4S_*>)?#E:^FC70<5AP$">M4_> MV!J\?K6JB@N0T[B__E?P+QP:D%O0Y. MPCV\&99\/I=JYJ0O,*7AC2.?3:FZ">#YE%)*DV=4*-LOK^I.0GY/925OP,NM M,7C5O[(R!6N(D6V31+0%'O6H"Z^&TX-.X-Q$#(4F@S":D^`Y;H?B*"5' M8=N4K-MN8/&`8FE$5D.>H/6/3XSV" MI=UYJ'#),LN<9?SZ\A->@&X+F%QE7TA>'Y()"#?`V\2B^>>[J$0EH:?XN87Q M?8;^N86EK.:RF\_ZJ[`YCQ85%3KKSNG]Q@*T'Z!72OPG%J#M'^P_X+]^M$L< M2BN"S@Y"#_:L%H7R_DN6+XG7)?Q>9)MMU50:8$EJW^V:/G;G:526K,ZAB5'/ M]VU_ECVC/A7FO=RUYS8[0*D"JC?I#&M2PW4#M*.?C56;1G>??BRSLFH;.^', M',3FUS4P'4W14V_'Z8:_>44CK:0L;>G^7$;@=;A2QK[V+&L8PC',L)J%XQ>5 MCAT7/[HN4*S:#/&-_!0Y:C@<+&P$Z%\#J&4DX_(\S4MZ@D`QNY%SZ[QT46?D M!\L5#0R[G^7&=DU?`Y;DRI>4^WZ/R!EWEGR)*M.-O+H+K]._1CK%-,X1+T!# M#AIZ0#KP:QH'B-F*D]3M`KBEL<6D:L5@#L@P;.[7/,4+%;(7.<#J^IT$97>" MA-:6M^\A<-O3BMJ*]-"V#-O\AN%I8X`J;/HUP2^H_/UC`6'S=&N$`0YW$83Y M2:0S-3Y"#@@]:-\/AFE[AG)2>59$GN9=(2BD\OBV/A4R36Q/#\LP)K];6*Q' M3GF,-`A+ZTEC/;T1NO#L2B-5RWV*5O2>MTZU$J9!#0'.9A(3T>;.@/X.T=T] MYN$,#V9T!S]OR>'&U8IN):^V55E%65*?>\5G&5[PIEO<6F%68SMT;FRC)>^# MM>D(U#T!UA5YL$@[*P'7W0+0#NFA;=VES[KMTRLAJI70))RB!SXG8-E*G9`^ MT`,$3U#]YW*N^'Q#!S6?$C*&!%)+ER$AWWZB[Q2G M\!6CC]CWCS<_11G^.KE7(0EX5<^[#>F<'K^;R"$4&]L_^]T3T6S2+MY0FX2( MC9'JML[7AJ7:)[@!1?UU-O-#C2A:M^9$:[XD^DZ-^GJ/@=5DU=+>6=IZ*] M4]>KXKN/$-H6L,;[XFYA7(-J]<_['D/EN\WQ2(+B'Z*4A$:<5>=UF#"%K<+I MZ`B]Y'I42C*8%(BC6("(O)ZIHZ0IE7^W8S8^0\D330?GL#"+INI$<\&O6P#J MB-P'7Z@D&([#:"BX@(PPUGW6\F@7?1*!/2_[S)`G!*$8PN[H`PQIR+/5PG'> M[S^64$-!KW._!`!AKH!=H-7EZX"I5^0W\3U,MBF\6GTH*[0FOK1E_VI5>Y\V MT%EKK8=WZ792/4QZ85BNXP3:- M"G[6SE<`MOI9$?VT#_W(*6E]"=06P/5=F7T*(^G,\)-9R`1V7W^N?H%N:^(: M:D_6K)-)9;B-<3;$[FS3X(WP!"+F/D6T=B^!N:DCM0E;R@WYYE,\P[LZO$S&7VL2K<+VQ:I[[_L)V-!.H(0],#:.< MT7@]#'@G=GI1DM.+QDOE/GS[3LNP*_&C$\M$W@XK#JMJZDE^+( MS8#6?8UM`WG4Q?+:4H)YMY2@W]"DP^62%0'T?QAGC$&A?K8=`!T^SHS(U$59 MZ,0RE81+DMCM%L]I)=EPB`L+_J6?53?N'WC:22FL^R*VYJ,=+)I@R;P-EF2] MD(RC7#_^T3IF;(4'FJ,'U@N&Z51U#0O*HQE>>R0^L=GG7H-#MK3`[1D.@P+< MX$`HP*48A=%KX[VC;>\>\^8V4K=RL*1WNH*VD4O(E,R5'VXOTF_S_67S50AK MB8+[)IG?66D=\FD6M/INMV]R'>W(K\Z^1D6_@##9[+,94W:*.,.'W)XO MSJ&IX>P;M`O`?P9PWR'IEOEV];<`_9A00IT>R;'O>3R4=*:[DZ5:=\M:=W6[ MCNX6K?(6[K1G=);I0GWD?GO_&H8[O:Q?"+6UU*O[J`+K:`>6Q.UF>/CI@YJR MN00.+GWK?#ZN('^M?M&\S(G+I?`RFDZP7>F(UV$4ZL^A")>/.D MV8_(`S5FJ)Z-S11MO.G806W\!@G[JK(BP[+_X`85=(S>8S=U*ML8Z>G<;H@, MY!!+QC0T_`JAH0*4S./F9QZ)?.YS1DC$<4]F32X$H@3W,$U\[VM,S:>SG[&S M'8=O4DCJU_TM9O&%/'3E+C,5IVEZ4O?O4O32B"GT2&IA[FH_+P`E6_"7_/Y/ MV4P'2GB>8C5*[H#W(2HR_/FRF=Q,8N@5-,ZAIN)?\&AUV_UZ*[`'E]K!Z*/* M<"0@T6/W#MSC=)C`A%W!D.[)M:B3W^3];D_>!"NA-U+_[ M(L43Z44HW,+U"_8=@Z9G=J?+]4UO0XO&@CYZQ7 M-!.0-,Y(T=;]U=H`OX)'9G6V6*L`0G2TNA8NT=2*=ONH^6.:?_V,!<0_LH4N MBX(;J`ZW?YM_MBRK(HI5/O?PKKT\C#Y0&X-/ITF?"U#W"MIN:83E4,U!+KD# M^*WIW%,$W8RZN=EN-BD]58Q2/BYUA1?Q69Z=4&TADN[^)_^V/96E##U`G\Y, M''J._2W>>;1!>`A9C,D72*J6X&DQ+SYN*\QH6XM,C`Q-3`S,S%?<')E+GAM;%54"0`#K!A15:P8455U>`L``00E#@``!#D! M``#M?5MSV\B2YOM$['_0>IYM2Z)LBAVG=X*Z]2C&EAB2NGLG-C80$%"2:AH$ MV``HBV=B__MF@3>0J"M08"5AO73;=%6AOORR;IE96?_XM[=Q=/!*THPF\:\? MCCX=?C@@<9"$-'[^]?^0^H'?V7+^@='GXX^G1ZP/QQ]_.[//AX?'GTY^#^'Q[]\Z?UR\N7_'OSW MZ/O_.[B\?SCX>/#CQX]/(;20%RU\"I+QP<>/[#L1C?]Z]#-R`!V+LU\_O.3Y MY)?/GUGYM\?__?W;_?!"QG[ M'VF?B7Z%H1G_)BOK?DL#/"U$I^W4@+,'^]G%9["/[ MZ>/1\T:>W+/P`,C@X^$>:1.2./!T4'?@EGTW(KQ\R.IY$K./%;R\I>8+? M9G$AYO/J_7B3!=$SB?!B'EW%.\]EU_)2DXZ+3'PY8L[_?76_T'IK(7TA. M@T>:1,DS#0HV/K.BG^6M?8:^-NOM=S_VGPG[PBCRX\R\@Y4&FO?IRJ?I'WXT M);=/5S0&7:%^=`U:DQ:2J-%'98/-^WQ/(A+`N#SS(Z;<]R^$Y(V(5S9HH<]Y M$A0C(#Q/QA,29W6[*FC'4@]'TS1X@=;_]-/4K\6_H!E+_7M)HA"FW\N_IS`\ M+\@3#6A>LX_\IIKW\X;DWY(L&Y'T_L5/B7GO*@VT/F(>_,>(U.%:K]FV1D_M M;DM;:VDD->JLJ+'F?3U/XBR):.AOT5BCIY*F;*Z=&5O[+DCNTRA[(&_YU(^: MK*30Q0>M3R&K=G>%X*@M"$>[PW#<%H;C]N;R^@HD;Z[E M_M91%T5[+?>X]I2CUVI+JVW9[6^O[?XVFSQ4C;9X1K32?YV&K9\?F_9G_O9RU64_+#8\5*3S?M]FS[[,?UG(8AA'-[X^30E M9>'`CV=^1N&[HY1DT(.:QJ;:'UIAG)1^_@:0-L""#I(X).$2+ONF'6-M85:& MST=)L/'%B!FTDU0A7_C!DS4_?,R8(3]?-A/YCR0J&O=TJWJEI46WGPO!%-;U MC`2?GI/7SR&AGZ'O)^P/#,3)Q\.CA6W]7^&G55^VK3*[V-[I99'::; M7??38-DX_+%"Z:9O8%'B\Z38U'P,7FBTTH:G-!F;"W71E40/TS2#WB43]AN; M#),4YO=?/\`V!1`^D30EX;>Y@(0(BNX74FQ&Z).?/1:M3K./S[X_F;-*HCQ; M_K)-[^)G;S7-G$=^!B.Q6*J&;S3C<*RLXPWZIRZI5A&V2:\F'#[+QWO%46]HT.$#&YP4F51"(1/WQ?T])T#_)39 MST/R]A]D)N5OJZQW=+2O!/*0\!G\BIC!\VG*!'1%L\"/_I/XZ64<7L`:(R!1 M5-P[.MX_'J5@^%3V$5,Y5\LK&I'T'%`\)ZE\*&Z4](Z<'E&:#,0J#CYWIXBY M>TA]%D1W/QL_)I&`M8TRWA'&O8N"KRH"/E,#Q$PM)O]D/$[B8D==F`6SVVG. M0@49//GZ)ZGH'7W9/TXU80DL!8>(F5[*X@&:51PN6!%O#\G;[K^`)1<&'5V6 MAM#_D&&XBGS1T-LHXWW=/YXJ``1$N;#)F`ZG$4EI$LJWF=RR7G__B!,"$1"X M#\:7^7YYCN@*?E-97BKE/:>FM&9$-G$PPX_^E2N2GL8;=U&1&Y` M$=#8Q``#4OF\[<-KW[>W?<_!@CL/I!4EV30EFVVK7'F*:M[@Y-!G+<5/9#<#9=^.YT7O5W1FC<6#'[[3JTIJ*3#)H=*H! M9SU7;C1>OV0C3*L>`')JS-`7.M^_I@&N*R-,==/+P0@K!]FLPX?F$3?EJ)K2 MG+".+-(8BE;:]XX'KH;L_70RB8K>^%&9-L,1;-*,UW/JEK//G"!LPE0DEF:! M5Y(^)AGYYGPRX-^E=#`'K"5^^U3NRQV)6"3A>9+E66&7+'H[\F>Z@[]9PUZO M89C:#B1R5NZXSD30L&6OY]319)%8_J1@0SQ=G"K ML4SK]TUU%I57\@9?G"ZKFN*KGD)U8'5F@RR\&N]@6:QVYB;)B<:R)Z_H];XX MV\QR.[:><[5VLKIM>#VGKB(#,@3[4R.@'5MTMK-`.!A^EWX:T_AYU0>-@2>J MX@V^GKH:<]M]TAECPCH`!$4@M5S0_/&D`-69)4PK*\F[I4=@+S@Z/'&V.@8O M))Q&[(H9L)LNXAN'6486*4^TED?M1@"JTYB7%G@3+*2&(FEM*=V]2HW29$+2 M?,:\1L7E,=A'3(J0(0U54E<&>:'88[6N0KJBL'37JIGJ<$^TPR!(IR2\?&,F M#:*>3Y1U`+#3B)[6N=>4@/UK6)C,P>ZV"UB-PD>'UHQ,*SMBN1M#9F"9^_K/ M9A53X_"'GX:WA;:QZ^=+<\P?)(.NLXD)-)7M_AX2]E,IC+?X-Y(&-"MT6&?X MH^F?=^3VHIA-S>'8UW")N4.[G_7&CR_C8LI;2C'(Z2O-9S4VVG4;!WD[#4UJ M3ZUMRZBU;14BCTJ=E797?I4O1\XCEN;'-9B^OE'_D48TIR3[3GRFM>$MJ&H` MI[KY_':3Q.GRKT5Z%E9_OIDAP4M,_YYJ;']W^GT0L-/[EYH:H`B?:E]";O.5 M\`?;:H:[S'(Z9O-E*8QQ(<>E0-2+2],F04[.<]48:Y(=T&[3G"B48P%`>Y-A M4!O0.PV_M$"Y!CZWR4[TV&UXVJK9',C'J1G7'O]&@.TG2W&S%Q2G#7<2<;`P MC)6,9:,DHX4JZ<0=J*M[7_ONH@\6W1/E@.,7]+XZO2=E+%Q1-$$%4Z?2O]T' M)/93FNBF?BN7]W`XM3D4*;BL@.A"KK(0NGUOEO3Z*"P(YG!EW*MT2`(N;+E-PJ!DO9 MZ_(D]R.<47XW1#Z0Q=6\/HK@+NUE7(G%5@:[%D+S+LB$V7&RS0GG)HD#X<#4 MJ>;AR'FNI%`;BZWT=AB6X#E`Y93KG:(P7QCNIHM>V\IQYWYZ+?FS03^KU[(T MCDJZ37BGN,P:.H=B(VRV$N=A&,,EX/J'9G$E[Q2%0<2(3J5&\##:RK>'00>& M09!,V3.Z_HQ9`#6VTMP*WBD*JXF".,&<+T9D*R4?$J;958"JB.1D\^MXIRBL M)77YEH`24&YL-FMAG[T5140);__%+^B=?D6Q,!L1)H,BH&DOS5G+2SKC293, M"#DC,7FB6F8-:440%+8%V7B02J$)=,#8CH5!!XRF9=[4A<)@68MJ`1H!NWMH MWI)/V)Q2H-[(V+2PDRY`">([C*U8[DEE3T[0?'Z3)`[/DSBG\3.)`SG)DEK> M*0J+I07252`%2K"7=K!:UA295%'$ZEE0`@5&@0[L^*:Y-7?DO,<%9I4WFE/: M.T5AZ590)O0Y2%EK,%646^`P@!>BUHN%@&O^VG\"D,Z!S+R M:7@=G_L3"ON*$F[9X4M9V1N@.'/7XEX3G4`;]M)`=D=RG\9PYESDV8(CZ'0\ M+:X0+Y,HBK5!7=D;H#B-U](&370";=BQ[:RMC9W1ALX;H#"(UV);@$;`KK') MS?W9[3N-DQ1@7<G@`[OHVC]XQHW7+D]W)*` MZ-JJJ"CTQ*DU3%]:5;^E&$\7;JTN,BN-_#2?/:1^G($D6`ZDLUGY7Q176?4; M`<$Y-9#)"14=F'F:QF9\LIKM;#7Q_%PDREU:@4HXT.8">3W9P@%`_*-CE16,YN:/%Y MV7[/W0,&-1/L]'LH3#IJL8JL.E4T73BE".Y&RT\EXDH@&!36&!Y=`@>N`DLW MSAR@X)3EBN:CY?\JW-S::!:$BR*42T6_:*5MBASA">=[$I/9=S_]B^3+ZQ[2 M\XVP/.PR4'#;G"7.YEH.N@NY?AIG;>JAB,_37P)$&+IP5&J4$$:2+65P@HOD M+>K$:[T*DZ7#4>3Z7*1X(FYQ+GI_(T[XIKPU#X_R:3+!^JJL!WU$,0@M"KRZ MX&I*H0MG,3MY3H_=^X$T.5.LQE5473B+VHS#&R3A3$"R'!'"TU%5DU7^ M!$D-0.G4_U-[D&KA0N@*VLSZEL')D("DV.GO@KR2*"G22`EXU*H+R)W[#)3$ M5+DTP&;I-.0^!G*!^3K.IBG;&DLFWNVB(`GG3Z\8LBR'8NFT@R$8?5.535-< M+F]5'_>QZ[]4\TX%<$QE:B4A3QH'I6BZ-WLX7P M%+UE?-WIR6:YH12_I*WR&6LV`3!1W`:VR)GHG&0BD"X8080XSV8/\&V%242C MMG=\@N/,;$2M:,W7A-L%RXE83/!EI0U%HS:("D54IC:KADJQC;0+3\RLP"FC M%;9*@@A0W#769HM/-A>5)0-,"^GYV,/0TQSVL7%X^_1$`Z+F3Z<:P$9QE;@F MF?H0._02S1+P??*4_P#I7@-=\3.%%:\XY"C'LU9]D!J*N\@-1[D!5A06'>[8 MA[:2E)6=Z0UZ87D`BB*6M,%H5V"S9+#!N5V3^4WT*X.@<$2:MKF-WT)KR=2# M4RU^2Y.LEDH4%4%`*&(.=:DT5(021DLOVF#8`FQ<4('N!W1AY9M$9&%%&8Y9 MSH2YA44H'8G6V/H$R!Y%K$TS_;(KC<;/[0SFJAB39]8CQ]XC^\\K'9^@,%*V M-"6M$-IZLF>?/!#'[QX(H37[RY&E`\-Z:[7,=+X(4]"+FN15@MZAL/I8%'7U M<*$C@BZX"E82.8_\++M]*C+FZ,9,;MZ=NG^IM,K*X4%!$),KX.H=R-&#) MO.-L&K''.>Y)^DH#X7MBRGH`W'FFOIH"\ZO5P&-VS=:0O7^XR)9U-EN766`8_O#34#_TM.$W0%`H3$PV MZ!88&^R*J@NFJ#L&6)7+=5D&8*.(5K+,(U]9ME!WP1)50%)G1UJ7`N@H;$]; M7$@(*_>["V&BWV$#.YZ.E:1ME`/X*.*,*HSPB>/TO0OIB+[[;WK4EA>1#JV2+9[/E66)6F+(5*Z6T'H@'1:3/3E9/#4G83UCD4%%*1\[O MQ&>;U_`6=JP!'#]I_`SRH]GOXZGDQS^.JG/1%<[[,(VJO<1`TLEN.+:Z2ML1ER;"YGWJYFB:&638=%T+(F-68!<-= MT%<:DCB\\W.I#:WM;X,2H`BIM*5PEM793(R-PW<1N6U:$=D?203-L,7.A=YO M?MT[[N.8S_=/\WF"M!6SW#G=OZ/97UI^;QO`UTH#D][I/=B,0JT MWMCZ[CZ'V]IQ)1?8H\E$\4#2\9%*V5OY*-"#XJBX`RUO47X"]3;V5%B/UJLM MUMM-K%=)^D1H#@=W-J:OXQ%):1**+!*M?A0DCL.'V8K&[DI^`HVUD*D#83"- MDZQM:*-I^E_>HVFTS#Y]%(X\&W2W'DW3%_H-]RN:9CZ#7L,T]`8+?'(-J_[J M$72-)'`ZU4%87?,B]H5W>/4%TH7P'!5:I4=0KP$0&(J,`/KDUE..,MHNA`)= MCB=1,B.DV*O,P:MSQXGJ@%A0&*1-2.2K@0(BBI1R/X?G[KASGCOQRF1+7%V( MEFIZX+R=YEGNQR&-GV^FB@G-^K>`AJ[8:8];L-/*Q68IA&M26!;N:N=#P$57C+`MJC!/9I8BMQ"X%=CFI]@\A1?%5?`YRD(@66EG ME%V^D32@&9%JIW%C(,VN&%5E&EA3+DVCQA!E&VLZ"-3 MIO+;P!:*VRZXYU%-,38-2>N0TKO>WZ*X"X1;J05BLQ5I-M_@7L;[K<>+98T= MC5O7X\JW@!`4_A3<>BP0VWO4&'>H_TGH\PNL+D/`Y3^3Y;9ME%+IXXH[Z@%0 MA\/3@UKCC81I*XYL;PP60@,G]U#[$^J(2W ME(_S86'4$2`2A4,/^9ED0L6`< M[>%#[#_1$63P[ARU*TS!**CI,^V02(!="58P5HPSCX3D";["FOEM M2D/V3M"^CACQ5",292LW).OW!HC]6;S-+@0K&#%[^=R@Q0WJ-W*$(JC7!MV"Z<>NJ+J0)&44^?&-/U8E0RD7`_`X3M1VV>2K3!5X%Y*; M+%$IDYAL%@0!H#AI5DF1DU?N/<+'KHL%G?45FC]2OP^P61)0H3A%\63-.1&) M`*#(#*)DIZ_-3G\)[AC%MMZ#8NI3= M!G-:5*W`H+#AF7-3[K^MF\$VR5CKC92.[6(`"(6Q3)\0/@);EU+=YD:251,F$`5P4D&[V[#0.PD-A[=)@N+I;M"D"6_>JW)JVV"2KLH0N MRP!N%(:LW1@Z-U';NA/DGFWEPP^E4H`=A]%KDPP)8^5^V[KIXI2S[_X;'4_' M2M8VR@%^'$:O;4KXS''Z;NL.AUON8(G1XJY<#O#C,(IIY('"!*1!&I]M M"2H!R_MEU5D$]BG/'1OE`#\*ZXZ$'#Z;'!0"%IU&(\T#8J=I\`*STS+T2:8,2*S5%HC&J07)E$3.J:D^;(%& M.(W&$@-Y@%J`(X.SRW3>93V]:-`BB,FIU:JY=C0&+]`1I]?J5"I?0TF:-`F" M+OPXGT!^868NL*"P'4G;O MZVQO#9H!@>"P2+9&MF`7;"PC@=+LEWVS>=JO)K.6.J?8R1<4EM3=>$XLB4N@ MF/L58&;(".,L:T9V2L+%M.!)EDKLZ[X:T`, MBB!(W/HL%)Q`HW?\\/,.4@SO-K/P.MWGR1<4<9[MJ&?K@A.HYXXS8%NRR$1% MXR3D2VQQ^41FJM%J``2'(UZUU0G11!8")=JO>^++G`0+@R4?]DU26+C)_*"9 M/22Y'Y7_G>4IO4GR_R3Y'0F2YYC^DX3E$Z8L1F@7WP>^<-QA;U5W=RA*@>KO MUU7XDH_GW)]0$$0ALHQ=XDM?2T2%_N(F_Y:ANT3CRMDY5<5LT[/3UT-8)7_1IF&W+I@NIR%=2.ILMQ3,[C_Q,%7,OK0?B0>'':%\%%*HG M%DX7$IJO8,JE6HCQ]SAY9"OM_"FHR;38U,4!U"J$NRTHI5.V]6\#32B\'QJZ MI%#"=B6$-;5[[03(IZ!Q3EMT50<W>44JD=85T(@*.P\.^&8(E[JB0-%-G_[4^)T_'RWF5`ZS:=D>SOZZ*FS4Y`67(:^@:KPF0'8KPIF`9#DBM\9UR\-7QTA:+0R"0&'6K#%PMS!TP7X^6G9U'D_B MI[=I`3@V`P%`X8414\HDWP8;B<=5C6#[)[(46Z8R`@%+Y"Z_/&X!"%J1?1O%%(Q)*C<#YO7,8A M:FO2L0MKTMHTCIS$-NCFKPF61=4%T],PSFE(HVE.7\D]FWR+*?/R+8BF,#%=`3E, M0-.Y$MP^7?II#+-SMG2]GLWX#:C>C6COJT`-"K.795WC*W3KMY M"E55$!(*^U3K>F"B?MOBZ8)Q"OMS`CTDB8)W,>G9$E<78L9KRV+^A"Y[X"R= M%G3&3#M`]"&PB1F2P$MJW<]<7;,GM:>]#93C3L9 M#YM=`/YPA/7NZ7#@21.O2;!^IOPMV)=O)`UH1F2JW.X'0=0HS-/M*.XN9-?4 MF#F8JVE,GIE%I:,3]E62/A$*^)S.V95>>+VO*`ST^SIM"P3:]";(3S$D4&[J MO^((5]_3X<`5IZ6[,#QG5R>'PY^$O81)PB%LW/QG4NP,+V`>D+W[A*E[P#J. M&P#[/H@T)6WKXM'/=FK&.UR7'7-:"06;LM>[V(.O2 M`0J'`WU/!YBII`7#R]CYOA_AN+WW<-Q2?.;6C>;W<%Q1"`R.^[LVZ&X]'%=\ MF_<]'-=Q."Z.&[R6=,N]E?" M]P>YY0`^BO!!/9KX%',`=2&,]8[-O8I%:E4&8..(>]O%DK*%N@M/Y!60E$.W M5`J@HX@7V^)"0EBYWY9""FVF)5A:GHM']XZDK[CRBGHG.*X85T1=-=:+NX\B M<;`&.R<&])RL`**(!C#F9Z/_*%+[:A#4_V+`T+(P0$01]61,T28`%#EWU1P= M'Q_J<[0J#!!1^/E-.=H"@"-)K@Y)QR8D':\PHK"2F9.T`0!Q>,-&MWL]@Y&T M*@P841B!3$G:`H##\:Y!DLF2U"O-Z"B,)\8D;0+`X;C5V#<,!@;[AF5AP(C" MAF&\;]@$8,O]USI)IP;3W:JP-\!Q&]N8I$T``I+V\ATE[/?W3Y"\T+(+DY8M M<0GTTZEE9>GXWQA7@LF#6Q:@H;!UV2*I.N5(8`L8W"9)795K1U=U+4J#^&$Q>+0AA:QY@JX90JW?=!>`#A7FNO5EX M]](4:/=>/M#57B!E:6K8"J6\(\PY#+^?)W$16C7UHP>2MK,S;:.?H`8HW!)( MEXOV1"Z(&C*V`.,9PN1!QOH5.&&7/+@SA0.)HU...3+4'U\X8$]_LH'-,2;OAD6ZXW4D<8IZ0UP9'O5YD:*HPN!N]Q68HHMCD!_T9BDOK1,`Z'X9C&E.WX MV;63RS=VAB89_,,=L``2?($_7I!7$B638G,Q+R"=L^TT#K)#X?K6(+@ZW=L4 M@:5X9QSG*JVPB>IS\?T^#N>W^0EJ"X.EP&BG9([2)"`DS-A]Q>LLF_IQ,+\" M/D[B8I\CX599%W9%*(:]B$`^W9JP;(5#ZREK>41]2)9F8=7,;E0?1(`C?D*+T!K0;$696[6VU/7`[2P21QPA M,D"2OUA;7]J2@:W(^!:#6EF753.^3C4`C,M?HB1=#Y&MN'FGJWL[[Y(/D"2' M-5KG-2`A#D6O]X8XDG2CIB.S@L%61+G575B1*I'!6L\G$YK.S4T`^$BT^U+5 M`\BXS.GJ79<>)%N!T4YGU//(S[+5Q'&;WK$0/KWX,E55D!(*V[K9O*J'RE;8 M<(E[AR%7+TD$_<_F/L4+\D0#FC<)N[)EMMWNVDV2$XU4H/**WLE6R$1#3_+& MAT116)+2T!\DRYI::@+7L@A4)X*RIH\9#:F?SDJ6%55`EJ@.B,7I6JAD3&!3 MDN/I0C16V5SJC^&/)?.HTL6LK@R"PK$6RIE4FY)E\+H0L'4]NE4&:ZW*`&P< M[B)-@@1!!)MPNI"Y<9325]CTC2(_*'9^2DKY%4`@.#P_C?B58>M"`%@[8=,G MITZ=/W57:C6F+L2"V8F=/CG%Y0X2<\8G6X+*;=27R]CIDU,4/AL)-WPR.2BZ M$'NU>(]AY*
ZU7K>QL5OX759)E[49`<$Z]-S6G;5.`70CD*B-33N#5PB`( M%%X;4^K4"E#&YSAF2^`IR%/REL32,-S-0@`&A8U+)&:>#Z#:?\]8P9&W/A-\E- M6D4-@.ET:3>,9_?&KPA/XI_DCM4=1J` ML>'4%JA%J,B[J@]0H!+[%16UR%.XN#%Z-LU`2EEVGHP?:5SPM;J%L'Z/6^F& M-6O.^^+V*:4&ZE(?KD!YFEC&W(07WY#\6Y*MWA!V'U2\_:JQ1CBQJ(K7WS+* MNHAY,4W[B,,L*1>I:/*M(NE$@/$2U^+F@5:`L:@.B`5'Q!J'+`6M?"A=B"TN M(U,>BJN%O3X.\Z6"*3Z](CA=B!7F/YE^^19$4U@O6386%O\SG1-U^[0]Z9W- M^`THQGZ+7P5J4%A=]6>/UH71A6AH/D8M1XJJJC?`899I70],U&];/-T(LM8W MXE4M6P,<.:CUZ)*<_:N@NA!-72_0=H`C\W033CF`NA`XW33?X<"M@;;!&6(+ M0Q<"J!NN;,-Q,HUEU@TK[8.X<1U1MA2AE.I^5#4UVO:\H+#I2B6I9[`H@G;+8 MW0 MJLJ9@&0YHBZ8[9INCWLX3!XU!NX6AB[8MA8;D_AYE=Q>O3D0U@&QH+!3B`CC MTZN`8\GZA.&!6\7#!A+*%35!4BB,&0HJ^?QK8;-DI\*@!=*W*R0Z(*T'4D)Q M0[&6!F@@LV37PL!_140F4SU(`\7%QUH\"]!8,G/E2>Y'.)B='S99Y)`.M^O2 M(`\4]R1K+N#;0"Q9E=P3>Y/$R2;(A09K[-:4=4%6*(*:S$C7A&4K`0"&B;N= M[-VG./*U:_+)5P8-A(V3#PSFBA`7SXJ'3A5AG6!Y+JEK=C,#LY7C`,,4(!13G07`Z^%(X-6(>P4Z6SD2W.\!1FGR1'/%GFY="."C M.)*;K>K;_;>5-\$]?3TL=ISBR/#PFH<)#$.70T*I18.9D;MP7" M1'$Z-]SBU8-I*U4#BOF^+`)=C0`QH#BC-V![#L%6T@;WHW^-;!X6$<-R-07- M7<<%C$AZYF[7;]`:]/3SP-81K*W<$AEFA$GZ[B5JB,XJ: M7@_950DMS=`"92MEA/NY1`&WQHT\00LP">^A-=`(G*U$$1AFA3\)>VH'$$)G M_&>R\6IMZ0$>_KJ+DAY,8QE5' M2OW0>LM(7,WK;V7&V8-HQOX`UZE>*%9%*$T)S7M(XS*NK.\VLX>,)`6=51CO M(8W;`8#]`:Y3>94S`'HB--'2S]`0[/:4WF ME`Z8`I^EN,>='J*PSMG5N/8D M92EFT[WN+NU8)&07*DF<%8S+MBC<"B`5%):9]A@7;'8DTK`4^]EL_1(G#9TG MO[M*TN\@H2Q/8C+R9X7D..QKU/(&/12+UJY40%LD34-%$46'M14FB.*(L^NY M0T,H70HQO2#0YX"JUI=R,9`>"JO5KC6C*@-;[UMA4`006DI@R;P@\_^7Q'3N M3VCN1WI9!#0;\4Z/4&Q-[&YM3?%W*5*UBGV4DHE/PXL%DF6,9QS>YB\D'689 MD2Y/]1H$P:((;S=5!5V%TI=!XTA8*UL\; M]1]I5"SC4SQ=R=^5X!\?HG1DG]:TAB($\5,9,4_K<39 MI0#?I<7Z(1D&?T]I2D`:,%SR&7ME,X>=/WLPITA=(G-@:S<"`D3A*ZA+O<#! M;8B_<7`OHL.3OB2MS#C>Z3%F?W5-!3+%;^MM.[0+UQ6-_3BPM'!)&@-QHK`1 M6UFXE#AMO7_7@F<:L`2$A,4]/.97!2#D]ND\&8^3N'"V7B5I*=T_S*E+A]GE M&TD#RD\Y9:EED!Z*]))U>:\:^ZP)Q=:K>!CV0OKBM3('@0!16`;M:%5=_`(% MVL-L#`7LXO'1;5.&1%W$E4`\*(R"9DN3"H^`;F/+,`ZZ85YD_V/;^U<_8D>` M(6A_FLY`T8L(#P7SROH@-!1V&G,ET(0FT`=C$_!D_NIO[J?Y3Z$5>VAN,8`F MT`ICR^Y<*RYCMT?D^^ED$A5R\J/ES<;K^"E)QW/"-&ZR*_/E8MYI#X7YPX@SD;]G&Y:`V[VTJ\X#!!_\-Y(I MZ=TH":+`89&PP3`'F>!JYUY&MB[EPC*'P1_7YKHXY)QWU@_*:\SX39OV!CAR MIYMO$9JC%JB8A9A9-[DS;M-G/Z;_]!>6F!L_!\CE][_@1Y9$)+M]&I4ZX2*C M1KFKZY0?\WZ7^W;[M.#3C];90'2>";'1OG=Z=3(#84*Y-%'>#/0NT(SE)*$NU)Z1^?&;A'/R,%8_\?4$L#!!0````(`#"( MJT:O7GK5Q`P``.^-```0`!P``L``00E#@``!#D!``#M76UOXS82_EZ@_T&7`PZ]#XXC>]/=Y'9;Y&73 M!L@;-NEN@<.AH"7:)E8679+*QCW+WJL][\\G M'&.&!`Z]T<([1P(],!1\Y+F\Y^_[^Z\\>>'WKM&B-SCP#[U_'PR.#X?'+P[_ MX_WW[OI_WMO[!Z_G??KT:3\$#4)IV`_HS.OU9#D\F.(9\@1B$RQNT`SS.0KP MF[VI$//C?E_*\44LIEB08$1H1"X5A<4#8[QV.41.+- MWN\)BLB8X'#/`Y-C?@Q:VFE58FLBGX;[E$T@RX'?__7ZZEY!S_5')/ZXEOMI MQ*(\_[`ODT>(XSR[3`W%4J"8^;"?)BZS1@:]OUZ!XJ)28LA,8BY0'*Q`5$!G M)OI'1T=]E9IG37AO@M!\F7F,^$AES1)DQ;WH'?B]9=4=!S2)!5NLV\AQL#^A MC_TL48H-2V()8]`F=7)9:DUY(2;U,I!0DQT_!=/Z_#*E1H#$CYB+>I$TK<:: M&$'+JI=125+$7Q?A)*@7@(2:[$"`6,PQKZ5&I=38PL6<:0J!E)I20CQG.)#. M0-N^COJ(!8Q&&!`$HH>?YA&*D:!L<0'WRPJA<9S,ZI6$@O4EXCYDZD$NS$BP ME&L6R@3`K7C>:Q3'%/P-^"EU+Y_,YR0>T^P6'LCV?2P!/X"X)R]^>7=IXR24 MD>@ MRDMU>05EK_ME#=]^4U:?QC^H:Z"2@S8E*_U')I]E,/^^[-<7_[/ALQ^>RFOGM^'8N(TO` M5-/]-/G,/+XP\;C2Z-&QM]+9,;@Y@V>(3R\B^JF!P%4V,W^']OQ)E9[2V?'7 MS-\MFZ"8_*&*A^CA!HF$X6+'@H>GB!/@ZJY0/2FKFPJ;N?Y>1C2$!Q'EH`YN MBL5X"$*;&XKADT-X-K",4GJ@_=P3LMZ[3EAV;:7I9I6XE[ M2K[CH9F'"T38>Q0ET(LN2`S1!4'1)0S+F8KO,UZ:,IEY>E7F2:KSE#[9BG9COY;,"1JHV;?PC,[F..9% MPNK3C#SY!Q6>I);>J53C%?5T[%BRP8`K5]P$QAI:.L#[)S(U?RXV7:_%R M-1TUEM1,:11BQM_^GA"Q.`=+`B(*]-0FFRDJ3YH4]?SC[\.C?WFI-N^[3%\W MUK8@ZP:+*\KY'6;W4\1P2E'YH9F88;GO@+@GY3T(PSVEH6-BZTCA`8TBS*WB MA2RKF;47[:,&[[M4<]>Q-@X?UE@TY3"3=V@;2G24;1M35!C39#`35IF]T,07 M'5\;34]P.95PC@4B$7_`3R+)I_O-644B_3VE&W_8Q& M'97M1,S4;C+;T1']&:*:K$JMPIH\KYG:#69#ELQVC.Z,4;\-I;Z9TT%UYL2> M4\_O6-T9JX,VK`X:6*W.N;1@=="QNO$@9-WI&K.8&1S8#T,Z#[LCUGP+VIK\ M:67&II&WSHMNS]Q:-&N5T\QB=0:GD<4NH.8N9 MQ\K42_63_5^:-_E'#L[>X;&G=C0>R\UB;_8XF?YI%>0Y9@&%KI:*Z7$U9N;F*;'N<><,E**'`G""8]W/L>UY_=W8!'VWM M6J?02:LB-&IK%8C@R%F#H/&W-:C47W9K5MK7BGLHX:ZXQU(]`JLH$UY M?V^#(9>1%UN77]Z:;P4@%U)7&T"H;O-7+YL83^3>/#O/%3&V)B7=UY%TF_[W M6\.P=)X%"&(GQ9L/.["%5-3R=J5D`X3&(R]L6DHN(R\VZ+#F0QFL*J0LM2U/ M]>=)M$-"XYN-P9A/XMC\S:MTZ2G*SL-1@,RG4)R,N#R1!]IK&I6J`V2.X1F) M)Y<"S^2(:L]#6:XW>X(E,F95N2!,)#1\4')APK(M-3&)(KGL,<_+$Q`F(I&I M/S&:S/-""*A/1[\0]OYF!U)G(9Y33H3DOD=5S[/;%HKC*4BR(!GAR_66THQ58V4U_Q6)E7;^Q;DS8M/8 M<\?P')&EXWF'.8;8<0JM^QP_XHC.9RZ_Z2S1:VR77B(1\'Z$]^1X3`(LOTPH MD6L\&V%6\FHAG2$2/RNCS0@UIEVA$64JY'?.)@.T1L]2]YITTJW4`[6+3]QQ M*'I@9DNN49S(D6L`(%J M)W/0O"K@SQ0SYP'A!65C3.1Y0N^0P)?QG3)UZ5[!MTH7`<)?5PS<9-YGJM6? M5-2=%Z/NSJ'K;PG@-(;FJ.P:!K^]*^%J/ MRLJ$%V[:\**5$2\/W;1BA%H MWQBVZQO^T9&39A1PF;]?\#6Q+_]RU<#:=1QR0[.7<+K`MG`P00F`-.$F*3*\ M<:"G'=1][KAC(V-U-:Z6L4/T+W^"PY6F7PO*PH"7+AKPTMX`WYE702THG0.= MS2.ZP%A^0SHG#(;0E'%7##&"LS!('IJ=1+*?.VE2#;P&HURSH@'VRD!7@%<1 M::"GO_44`4LGX8S$1"(3Y!'G4\J04/_1)LO@BL&[LD/'<#BF"3LEE`<$QX$< M/0>NF&["INMG_C#: M9*Y*^/'.V./4?>&6Z+BA;'G)W$CX23MGB M'K-'&+HZ5!<;P39UE-52,'5[,I>_3T<4S'=R(IO?(W?:0GO$S_+Y[J_WU<[B M8UUE=[5SBU=T"#467<:"X2<:N](9RGCT"]X>3T;L*G(FP*XBTGEI'$)7YN#> MR#4T]@!%9Y"(F2N&-.'3F'7#9N\)^1E:'C1^?ND0,WIDNH&/ZC>WXS&6'?D> M13`RS-],KAAE@U&W(V)Y(,#Z3SPYLWJY&:#&LM(IT*[YYGIX.C!&T810.,0W[!Z$Q6H41Q.RX,3J%&"\.3 MPM::Y0JAYZR>MML*=F"<]4#`'7]FQ&9>,'P6D5A%?,LA>3[J=G[IL`FZB<2< MK;6@6D9RCNWHLX"IBQF@G2VN$?N(!=`L#]!PAB<#M#9A@V-4-6%LW-OS M%DJ9R5,<"C_C4=KDNW!RU^E6%C162Z;@)!#DT?D::`!K:^S7M>MX8_16B_%> M.;,>1H=+%R4O`Z>E-Z"Y?U@+IK[X(K062'<]?_XG7)G7?OU=C81J8ZN?G,R: MOBLK.&L0:H>*\@.<^C:W5#$G*1JY"\)?YSF4>ZV>U3(+@-*TU_WT6!EEY?\! M4$L!`AX#%`````@`,(BK1A3W3AA(<0``19\(`!``&````````0```*2!```` M`'-Y;BTR,#$U,#,S,2YX;6Q55`4``ZP8455U>`L``00E#@``!#D!``!02P$" M'@,4````"``PB*M&\QF81F4(``!-;@``%``8```````!````I(&2<0```L``00E#@``!#D!``!02P$" M'@,4````"``PB*M&9;#X)K(I```2N0(`%``8```````!````I(%%>@```L``00E#@``!#D!``!02P$" M'@,4````"``PB*M&]P^81(9```#PJ0,`%``8```````!````I(%%I````L``00E#@``!#D!``!02P$" M'@,4````"``PB*M&J1*B%;0N``#8+@,`%``8```````!````I($9Y0```L``00E#@``!#D!``!02P$" M'@,4````"``PB*M&KUYZU<0,``#OC0``$``8```````!````I($;%`$` XML 16 R25.htm IDEA: XBRL DOCUMENT v2.4.1.9

Stock Purchase Warrants (Details) (Stock Warrants [Member], USD $)
0 Months Ended 3 Months Ended 12 Months Ended

Oct. 10, 2014

Mar. 31, 2015

Dec. 31, 2014

Stock Warrants [Member]

Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]

Closing stock price $ 1.75 $ 2.19 $ 1.46

Expected dividends 0.00% 0.00% 0.00%

Expected volatility 95.00% 90.00% 90.00%

Risk free interest rate 1.39% 1.26% 1.59%

Expected life of warrant 5 years 4 years 6 months 18 days 4 years 9 months 14 days

X

- Details

Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueAssumptionsExpectedTerm

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Risk-free interest rate assumption used in valuing an instrument.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Price of a single share of a number of saleable stocks of a company.

+ References

No definition available.

+ Details

Name: us-gaap_SharePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

XML 17 R9.htm IDEA: XBRL DOCUMENT v2.4.1.9

Selected Balance Sheet Information
3 Months Ended

Mar. 31, 2015

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Supplemental Balance Sheet Disclosures [Text Block]

4. Selected Balance Sheet Information

Prepaid expenses and other current assets (in thousands):

March 31, 2015

December 31, 2014

Intrexon prepaid research and development expenses

$

1,060

$

1,067

Prepaid insurance

140

228

Prepaid expenses

374

253

Total

$

1,574

$

1,548

The anticipated Intrexon research and development expenses for the next twelve months are classified as a current asset. The Company may terminate the arrangement at any time and receive a cash refund of the remaining balance minus any amounts owed to Intrexon.

Property and equipment (in thousands):

March 31, 2015

December 31, 2014

Computer and office equipment

$

111

$

93

Software

11

11

122

104

Less accumulated depreciation

(47)

(39)

Total

$

75

$

65

Accrued expenses (in thousands):

March 31, 2015

December 31, 2014

Accrued manufacturing costs

$

74

$

247

Accrued vendor payments

225

176

Accrued milestone payments

1,000

350

Accrued clinical consulting services

1,347

525

Total

$

2,646

$

1,298

X

- Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.

+ References

No definition available.

+ Details

Name: us-gaap_SupplementalBalanceSheetDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

EXCEL 18 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\V,6,U961C-U\Y-V0T7S0R.3=?8C'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=OF%T M:6]N7V%N9%].871U#I%>&-E;%=O#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/D9A:7)?5F%L=65?;V9?1FEN86YC M:6%L7TEN#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I. M86UE/E-E;&5C=&5D7T)A;&%N8V5?4VAE971?26YF;W)M83PO>#I.86UE/@T* M("`@(#QX.E=O#I% M>&-E;%=O#I.86UE/E-T;V-K0F%S961?0V]M<&5N M#I%>&-E;%=O M#I7;W)K#I7;W)K#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O'1U/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T M4V]U#I%>&-E;%=O#I%>&-E;%=O#I.86UE/E-E;&5C=&5D M7T)A;&%N8V5?4VAE971?26YF;W)M83(\+W@Z3F%M93X-"B`@("`\>#I7;W)K M#I%>&-E;%=O#I.86UE/@T*("`@(#QX M.E=O#I%>&-E;%=O M#I.86UE/E-T;V-K0F%S961?0V]M<&5N#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE M/E-T;V-K0F%S961?0V]M<&5N#I7;W)K#I% M>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/E-T;V-K7U!U#I7;W)K#I%>&-E;%=O#I%>&-E;%=O#I.86UE/E-T;V-K M:&]L9&5R#I.86UE/@T*("`@(#QX.E=O M#I%>&-E;%=O#I.86UE/DYE=%],;W-S7W!E#PO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O6QE#I!8W1I=F53:&5E=#X-"B`@/'@Z4')O=&5C=%-T'1087)T7S8Q8S5E9&,W7SDW9#1?-#(Y-U]B M-S1F7S,W-C!D-C9B,#(R,@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]# M.B\V,6,U961C-U\Y-V0T7S0R.3=?8C'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6YT:&5T M:6,@0FEO;&]G:6-S+"!);F,N/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$"!+97D\ M+W1D/@T*("`@("`@("`\=&0@8VQA2!&:6QE3PO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^06-C96QE2!#;VUM;VX@4W1O8VLL(%-H87)E'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^,3`M43QS<&%N/CPO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^43$\'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D M>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\V,6,U961C-U\Y-V0T M7S0R.3=?8C'0O M:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$65E(&)E;F5F:71S M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,C@\2`H1&5F:6-I="DZ/"]S=')O;F<^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\6YT:&5T:6,@0FEO;&]G:6-S+"!);F,N(&%N9"!3=6)S:61I87)I M97,@17%U:71Y("A$969I8VET*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S2`H1&5F:6-I="D\+W1D/@T*("`@("`@("`\=&0@ M8VQA'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA&-E<'0@4VAA'!E;G-E M'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$3PO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6UE M;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-3`\'!E;G-E6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA M65E(&)E;F5F:71S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S M,3`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S2!A;F0@97%U:7!M96YT/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q."D\&5R8VES97,\+W1D/@T*("`@ M("`@("`\=&0@8VQA&5S/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`\'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQAF%T:6]N M+"!#;VYS;VQI9&%T:6]N(&%N9"!0'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/&1I=B!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%2 M1TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[5$585"U)3D1%3E0Z(#,T+C%P=#L@34%21TE..B`P<'0@,'!X.R!& M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E28C.#(R,3L@;W(@)B,X,C(P.U-Y M;G1H971I8R!":6]L;V=I8W,F(S@R,C$[*2!I2!I6YD3XF(S$V,#L\+V1I=CX@/'1A8FQE('-T>6QE/3-$)U=) M1%1(.B`Q,#`E.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!&3TY4.B`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`\+W1D M/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\ M+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4E.1$5.5#H@+3$Q M<'0[(%!!1$1)3D6QE/3-$)U9%4E1) M0T%,+4%,24=..B!T;W`G/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[34%2 M1TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-EGEM92D\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1% M6%0M04Q)1TXZ(&-E;G1E'!E8W1E9"!T;R!I;FET:6%T92!D=7)I;F<@ M,CQS=7`@6QE.FYO6QE/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G/B`\=&0@6QE/3-$ M)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T-,14%2.F)O M=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M24Y$14Y4.B`M,3%P=#L@4$%$1$E.1RU, M1494.B`Q,7!T.R!615)424-!3"U!3$E'3CH@=&]P)SX@/&1I=B!S='EL93TS M1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H)SY)6QE/3-$)U9%4E1)0T%, M+4%,24=..B!T;W`G/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[34%21TE. M.B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E6QE/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G/B`\ M9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/DEN=&5N9"!T M;R!I;FET:6%T92!0:&%S92`R(&-L:6YI8V%L('1R:6%L6QE/3-$)T9/3E0M4TE:13H@,3!P="<^/'-U<"!S='EL93TS1&9O M;G0M6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z M(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M M04Q)1TXZ(&-E;G1E6QE/3-$)T-,14%2.F)O=&@[0TQ% M05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T-,14%2 M.F)O=&@[0TQ%05(Z(&)O=&@G/E!E6QE/3-$)U9%4E1)0T%,+4%, M24=..B!T;W`G/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[34%21TE..B`P M<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E M6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P M.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T-, M14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ M6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M24Y$14Y4.B`M,3%P=#L@4$%$ M1$E.1RU,1494.B`Q,7!T.R!615)424-!3"U!3$E'3CH@=&]P)SX@/&1I=B!S M='EL93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H)SY296QA<'-I;F6QE M/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D M/B`\=&0@6QE/3-$)T-,14%2.F)O=&@[ M0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE M/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G/B`\=&0@6QE/3-$)U1%6%0M M04Q)1TXZ(&-E;G1E6QE/3-$)T-,14%2.F)O=&@[0TQ% M05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1% M6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M24Y$14Y4.B`M,3%P=#L@4$%$1$E.1RU,1494.B`Q M,7!T.R!615)424-!3"U!3$E'3CH@=&]P)SX@/&1I=B!S='EL93TS1"=#3$5! M4CIB;W1H.T-,14%2.B!B;W1H)SY#;V=N:71I=F4@9'ES9G5N8W1I;VX@:6X@ M35,\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E M#L@1D].5#H@,3!P="!4:6UE#L@1D].5#H@,3!P="!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!- M05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE#L@1D].5#H@,3!P="!4:6UE3XF(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!& M3TY4+49!34E,63I4:6UE#L@1D].5#H@,3!P="!4:6UE2!O=&AE65A#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E2!W:71H(%4N4RX@1T%!4"P@=VAI8V@@&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D M/CPO=&0^/"]T7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$#L@1D].5#H@,3!P="!4:6UE6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)RPG2!H87,@:6YC=7)R960@;F5G871I=F4@8V%S:"!F;&]W(&9R M;VT@;W!E2P@:6YC M;'5D:6YG('1H92!P;&%N;F5D('!R;V1U8W0@9&5V96QO<&UE;G0@969F;W)T M2!E9F9O6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$58 M5"U)3D1%3E0Z(#,T+C%P=#L@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E3Y4:&4@86-T=6%L(&%M;W5N="!O9B!F=6YD2!W:6QL(&YE960@=&\@;W!E6QE/3-$)U=)1%1(.B`Q,#`E.R!"3U)$15(M0T],3$%04T4Z M(&-O;&QA<'-E.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E6QE/3-$)U=)1%1(.B`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`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O M=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0^(#QD:78@6QE/3-$)U1%6%0M04Q)1TXZ(&IU6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/G1H92!C;W-T M2<^(#QD:78@6QE/3-$)T-,14%2 M.F)O=&@[0TQ%05(Z(&)O=&@G/CQF;VYT/B8C.#DP,3L\+V9O;G0^/"]D:78^ M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y)SX@/&1I M=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H)SYT:&4@86)I;&ET M>2!T;R!A8VAI979E(&UI;&5S=&]N97,@=6YD97(@;&EC96YS:6YG(&%R6QE/3-$)T)!0TM' M4D]53D0M0T],3U(Z('=H:71E.R!615)424-!3"U!3$E'3CH@=&]P)SX@/'1D M/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P M.SPO9&EV/B`\+W1D/B`\=&0^(#QD:78@6QE/3-$)U1%6%0M04Q)1TXZ(&IU6QE M/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/G1H92!C;W-T2!R:6=H=',[(&%N9#PO M9&EV/B`\+W1D/B`\+W1R/B`\='(@2<^(#QD:78@2!A<'!R;W9A;',N/"]D:78^(#PO=&0^(#PO='(^(#PO=&%B;&4^ M(#QD:78@#L@1D].5#H@,3!P="!4:6UE2!N M965D('1O(&]B=&%I;B!A9&1I=&EO;F%L(&9U;F1S('-O;VYE28C.#(Q-SMS('-H87)E6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$58 M5"U)3D1%3E0Z(#(W+C5P=#L@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E3Y4:&4@0V]M<&%N>2!M87D@2!M87)K M971S('=H96X@8V]N9&ET:6]N2!L M:6UI="!I=',@;W!E2!H87)M960N/"]D:78^(#PO9&EV/CQT86)L92!B;W)D M97(],T0P('-T>6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE M9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\ M+W1D/CPO='(^/"]T86)L93X\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA#L@1D].5#H@,3!P="!4:6UE M6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P M<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E M2!I;B!A;B!O2X@1F%I6QE/3-$)U=)1%1(.B`V)2<^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^ M(#QT9"!S='EL93TS1"=724142#H@-"4G/B`\9&EV/CQF;VYT/B8C,3@S.SPO M9F]N=#X\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U=)1%1(.B`Y,"4G/B`\ M9&EV/DQE=F5L(#$@:6YP=71S.B!1=6]T960@<')I8V5S("AU;F%D:G5S=&5D M*28C,38P.V9O6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#!I;CL@34%2 M1TE..B`P:6X@,'!X(#!I;B`P:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE6QE M/3-$)U=)1%1(.B`Q,#`E.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!& M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2!O6QE/3-$ M)U9%4E1)0T%,+4%,24=..B!T;W`G/B`\=&0@6QE/3-$)U=)1%1( M.B`T)2<^(#QD:78^/&9O;G0^)B,Q.#,[/"]F;VYT/CPO9&EV/B`\+W1D/B`\ M=&0@3XF(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB M;W1H.R!&3TY4+49!34E,63I4:6UE#L@1D].5#H@,3!P="!4:6UE2P@=&AE(&AI M97)A2!L979E;"!I#L@1D].5#H@ M,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@ M5&EM97,L(%-E&5D M.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO M=&0^/"]T7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879AF%T:6]N M+"!#;VYS;VQI9&%T:6]N(&%N9"!0'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$3X\:3XF(S$V,#L\+VD^ M/"]D:78^(#QD:78@3X\:3X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@)U1I;65S($YE=R!2;VUA;B#L@1D].5#H@,3!P="!4:6UE6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=. M.B!C96YT97([($9/3E0M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@ M(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXQ-#`\ M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO#L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!& M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXS-S0\+V1I=CX@ M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO#L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C M965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXR-3,\+V1I M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L M93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4 M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/ M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P M)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E' M3CH@6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)' M24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M3XF(S$V,#L\+V1I=CX@/&1I=B!S M='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE#L@1D].5#H@,3!P M="!4:6UE2!M87D@=&5R;6EN871E('1H92!A&]N+CPO9&EV M/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0G/B`F(S$V,#L\+V1I=CX@/&1I M=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE#L@1D].5#H@ M,3!P="!4:6UE6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$58 M5"U)3D1%3E0Z(#(W+C5P=#L@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$ M)TU!4D=)3CH@,&EN.R!724142#H@.#`E.R!"3U)$15(M0T],3$%04T4Z(&-O M;&QA<'-E.R!/5D521DQ/5SH@=FES:6)L92<@8V5L;'-P86-I;F<],T0P(&-E M;&QP861D:6YG/3-$,"!A;&EG;CTS1&QE9G0^(#QT6QE/3-$ M)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT M97([($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1) M3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-! M3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI M9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^,3$Q/"]D M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4 M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@] M,T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%, M24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4 M.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4 M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H M=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/ M3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO#L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXQ,3PO9&EV M/B`\+W1D/B`\=&0@6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@5$585"U!3$E'3CH@;&5F M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[ M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E' M3CH@6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@ M;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/ M54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=. M.B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4 M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@ M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L M93L@5$585"U!3$E'3CH@"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I M=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C M,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4 M64Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U3 M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0 M.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@] M,T0Q,B4^(#QD:78^-C4\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO3X\:3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M)U1I;65S($YE=R!2;VUA;B6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#(W M+C5P=#L@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E' M3CI,969T.R!415A4+4E.1$5.5#H@,&EN.R!724142#H@,3`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`Q,'!T M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W M:61T:#TS1#$R)3X@/&1I=CXQ+#`P,#PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5. M1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@ M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXS M-3`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-4 M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@ M1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO#L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXU,C4\+V1I M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L M93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4 M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/ M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P M)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E' M3CH@6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF M:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT M9#X\+W1D/CPO='(^/"]T86)L93X\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4 M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E3Y$=7)I;F<@,C`P,2P@=&AE($-O;7!A;GDF(S@R,3<[65E(&]F('1H92!#;VUP86YY(&]R(&$@2!D=7)I;F<@86YY(&]N92UY96%R('!E&-E960@/&9O;G0@&5R8VES92!P'!I M2!T:6UE+B!!6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@ M,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E3Y/;B!-87)C:"`R,"P@,C`P M-RP@=&AE($-O;7!A;GDF(S@R,3<[65E2!A;F0@:71S('-U8G-I M9&EA2!S=&]C:VAO;&1E M2!B92!G2!O;F4@96UP;&]Y964@;V8@=&AE($-O;7!A;GD@;W(@82!S=6)S:61I M87)Y(&1U6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E3X@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4 M:6UE#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[0TQ% M05(Z(&)O=&@G/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P M<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E M6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG M28C.#(Q M-SMS(#(P,3`@26YC96YT:79E(%-T;V-K(%!L86X@=&\@:6YC&5R8VES92!P2!T M:&4@8V]M<&5N&5R8VES86)L92!O=F5R('9A65A6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E65E)B,X,C$W.W,@=&5R;6EN871I;VXL M('1H92!#;VUP86YY('=I;&P@8V5A'!E;G-E(&9O65E+B!4:&5R92!I2!O=F5R('1H M92!S=&%T960@=F5S=&EN9R!P97)I;V0N/"]D:78^(#QD:78@3XF(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=# M3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE#L@1D].5#H@,3!P="!4:6UE6UE;G0@87=A"!S;VQI9#L@0D]21$52+5))1TA4 M.B`P<'@@6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G M/CPO9&EV/B`\+W1D/B`\+W1R/B`\+W1A8FQE/B`\9&EV('-T>6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#,W+C1P=#L@34%21TE..B`P<'0@,'!X M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)TU!4D=)3CH@,&EN.R!72414 M2#H@-C`E.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!/5D521DQ/5SH@ M=FES:6)L92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!A;&EG M;CTS1&QE9G0^(#QT6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E M6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO M6QE/3-$)U1%6%0M M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X M('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E' M2%0Z(#0P,"<@=VED=&@],T0Q-24@8V]L"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`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`G5&EM97,@3F5W M(%)O;6%N)RPG#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E3XF(S$V,#L\+V1I M=CX@/'1A8FQE('-T>6QE/3-$)U=)1%1(.B`Q,#`E.R!"3U)$15(M0T],3$%0 M4T4Z(&-O;&QA<'-E.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E2!A;F0@ M=&AE(')E;6%I;F1E6QE/3-$ M)U9%4E1)0T%,+4%,24=..B!T;W`G/B`\=&0^(#QD:78^)B,Q-C`[/"]D:78^ M(#PO=&0^(#QT9#X@/&1I=CX\9F]N=#XF(S@Y,#$[/"]F;VYT/CPO9&EV/B`\ M+W1D/B`\=&0^(#QD:78^86YN=6%L;'D@;W9E6QE/3-$)U9%4E1)0T%,+4%,24=..B!T M;W`G/B`\=&0^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9#X@/&1I=CX\ M9F]N=#XF(S@Y,#$[/"]F;VYT/CPO9&EV/B`\+W1D/B`\=&0^(#QD:78^;VYE M+71H:7)D(&EM;65D:6%T92!V97-T:6YG(&%N9"!R96UA:6YI;F<@86YN=6%L M;'D@;W9E65A6QE/3-$)U9%4E1)0T%,+4%,24=..B!T M;W`G/B`\=&0^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9#X@/&1I=CX\ M9F]N=#XF(S@Y,#$[/"]F;VYT/CPO9&EV/B`\+W1D/B`\=&0^(#QD:78^;VYE M('%U87)T97(@:6UM961I871E('9E65A6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@ M,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E3Y$=7)I;F<@=&AE('1H&EM871E M(&9A:7(@=F%L=64@;V8@)#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)RPG2!G6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG65E&EM871E(&9A M:7(@=F%L=64@;V8@)#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)RPG#L@1D].5#H@,3!P M="!4:6UE6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)RPG2!O9B!S=&]C M:R!O<'1I;VX@86-T:79I=&EE65A#L@1D].5#H@,3!P="!4 M:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U! M3$E'3CI,969T.R!415A4+4E.1$5.5#H@,&EN.R!724142#H@,3`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`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4 M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U19 M3$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO M6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E M"!S;VQI9#L@1D].5"U714E'2%0Z(#0P M,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T M>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@ M/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q) M1TXZ(&-E;G1E6QE/3-$)U1% M6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@ M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^)B,Q-C`[/"]D M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/ M3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P M,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S M='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO65A6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%# M2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U! M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@ M/&1I=CXW.#4L,#`P/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%, M24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T M:6UE6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W M:61T:#TS1#$P)3X@/&1I=CXR+C,V/"]D:78^(#PO=&0^(#QT9"!S='EL93TS M1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4 M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!D;W5B;&4[($9/3E0M5T5) M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^ M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@ M;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/ M54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=. M.B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L93L@1D]. M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^ M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-4 M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N M;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ M(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE M"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E, M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+ M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%, M24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]4 M5$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X M('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L M.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!& M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@ M=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`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`Q,'!T.R!615)424-!3"U!3$E'3CH@ M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXV M.#4L,#`P/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L M969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO"!D;W5B;&4[($9/3E0M5T5)1TA4 M.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\ M=&0@6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO&5R8VES960\+V1I=CX@/"]T M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T M:6UE"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U3 M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!" M04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%, M+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^ M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D]. M5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%- M24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T M:6UE6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U7 M14E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q% M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ M(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E, M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+ M1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%, M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD M:78^)#PO9&EV/B`\+W1D/B`\=&0@"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H M/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@"!D;W5B M;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P M.SPO9&EV/B`\+W1D/B`\=&0@"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H M/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO&5R M8VES86)L93PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O M=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!& M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E M969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[ M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\ M+W1D/B`\=&0@65A6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)4 M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS M1#$P)3X@/&1I=CXQ+#DS.2PP,#`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO"!D M;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[ M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@ M,W!X(&1O=6)L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=. M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE M6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$58 M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E, M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4 M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU4 M3U`Z(",P,#`P,#`@,W!X(&1O=6)L93L@1D].5"U714E'2%0Z(#0P,"<@=VED M=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$ M15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4[($9/3E0M5T5)1TA4 M.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/C@Q-RPP,#`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`Q,'!T.R!615)424-!3"U! M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@ M/&1I=CXQ+C0Y/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=. M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE M6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[ M($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L M93L@5$585"U!3$E'3CH@"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H M/3-$,3`E/B`\9&EV/C0L.36QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T M:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E, M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+ M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%, M24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L93L@ M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I M=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,W!X(&1O=6)L93L@5$585"U!3$E'3CH@"!D;W5B;&4[($9/3E0M M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\ M+W1D/B`\=&0@6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%- M24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H M/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!& M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG#L@1D].5#H@,3!P="!4:6UE M6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P M<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E M'!E M;G-E6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG3Y!F5D('-T;V-K+6)A'!E;G-E M(')E;&%T960@=&\@6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2`R,#$W+CPO M9&EV/B`\+V1I=CX\=&%B;&4@8F]R9&5R/3-$,"!S='EL93TS1"=W:61T:#HQ M,#`E.R!T86)L92UL87EO=70Z9FEX960[)R!C96QL3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\V,6,U961C-U\Y M-V0T7S0R.3=?8C'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG&5R8VES86)L92!F;W(@86X@86=G6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)RPG65A3XF(S$V,#L\+V1I=CX@/&1I M=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE3Y4:&4@=V%R2P@=&AE($-O;7!A;GD@F5D(&EN('1H92!F;VQL;W=I;F<@=&%B;&4Z/"]D:78^(#QD:78@6QE/3-$ M)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C M96YT97([($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4 M+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X M('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&-E M;G1E6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED M=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4 M+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5)) M1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q% M.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I% M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C M,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q M,B4^(#QD:78^,2XW-3PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO'!E8W1E9"!D:79I9&5N9',\+V1I=CX@/"]T9#X@/'1D('-T M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M M.R!&3TY4+5=%24=(5#H@-#`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`Q M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`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`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@ M-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXU('EE87)S/"]D:78^(#PO=&0^(#QT M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z("TV+C9P=#L@34%21TE. M.B`P<'0@,RXS<'0@,'!T(#8N-G!T.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E2`\:3XH:6X@=&AO=7-A;F1S*3PO:3XZ/"]D:78^ M(#QD:78@3XF M(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49! M34E,63I4:6UE#IA=71O M.R!724142#H@.#`E.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!/5D52 M1DQ/5SH@=FES:6)L92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$ M,"!A;&EG;CTS1&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O M;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/ M3E0M1D%-24Q9.B!T:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R M;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I M=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C M,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4 M64Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U3 M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0 M.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@] M,T0Q,B4^(#QD:78^,3`L.3`X/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4 M15A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%- M24Q9.B!T:6UE6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[5$585"U)3D1%3E0Z("TV+C9P=#L@34%21TE..B`P<'0@,RXS<'0@ M,'!T(#8N-G!T.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E3XF(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4 M+49!34E,63I4:6UE#L@1D].5#H@,3!P="!4:6UE2!I M&5R8VES92!P'!I2!R86ES92P@ M=&AE($-O;7!A;GD@:&%S('1R96%T960@=&AE;2!A2X@5V%R3XF(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5! M4CIB;W1H.R!&3TY4+49!34E,63I4:6UE#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#,W+C1P=#L@34%2 M1TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E6QE/3-$)TU!4D=)3CH@,&EN.R!724142#H@ M,3`P)3L@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@3U9%4D9,3U6QE/3-$ M)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M M04Q)1TXZ(&-E;G1E6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M M4U193$4Z(&YO&5R8VES928C,38P.U!R:6-E/"]D:78^ M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N M;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P M)R!W:61T:#TS1#$P)3X@/&1I=CXQ+C6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%- M24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!! M1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)4 M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS M1#$P)3X@/&1I=CXQ+C0W/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4 M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9 M.B!T:6UE"!S M;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!& M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[ M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D M:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P M(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4 M+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5)) M1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF M(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C M965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z M(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^-RPY-S0L-SDT/"]D:78^(#PO=&0^ M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N M;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I M=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H M=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/ M3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%# M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U! M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@ M/&1I=CXM/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L M969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q% M.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I% M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@ M-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXM/"]D:78^(#PO=&0^(#QT9"!S='EL M93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/ M3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%# M2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U! M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@ M/&1I=CXM/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L M969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q% M.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I% M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@ M-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXM/"]D:78^(#PO=&0^(#QT9"!S='EL M93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/ M3E0M1D%-24Q9.B!T:6UE"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@ M;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/ M54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=. M.B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^ M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]- M.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E, M13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T M:6UE6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@ M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@ M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P M<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($)/4D1%4BU43U`Z(",P,#`P M,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\ M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO"!S;VQI9#L@1D]. M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^ M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B M;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!! M1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)4 M24-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S M;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,2XX M,#PO9&EV/B`\+W1D/B`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`Q M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P M,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q."4^ M(#QD:78^,S$V+#4R,CPO9&EV/B`\+W1D/B`\=&0@"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF M(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C M965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E# M04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO65A6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!& M3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@ M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$ M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@ M=VED=&@],T0Q."4^(#QD:78^,3@W+#`P,#PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1) M3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-! M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$Y M)3X@/&1I=CXQ+C6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N M;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P M)R!W:61T:#TS1#$X)3X@/&1I=CXW+#`R.2PX,#@\+V1I=CX@/"]T9#X@/'1D M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5. M1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@ M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$X)3X@/&1I=CXU M,36QE M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E65A M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4 M+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D]. M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=% M24=(5#H@-#`P)R!W:61T:#TS1#$X)3X@/&1I=CXV,2PR,#<\+V1I=CX@/"]T M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E65A6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M#L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C M965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$Y)3X@/&1I=CXS+C6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-! M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$X M)3X@/&1I=CXU,"PP,#`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!6 M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T M:#TS1#$X)3X@/&1I=CXU,"PP,#`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)4 M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS M1#$X)3X@/&1I=CXM/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%, M24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T M:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-! M3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI M9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q."4^(#QD:78^-RPY-S0L M-SDT/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E' M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($)/4D1%4BU43U`Z(",P M,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@ M;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/ M54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=. M.B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4 M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@ M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L M93L@5$585"U!3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0G/CPO9&EV/B`\+V1I=CX@ M/"]D:78^/'1A8FQE(&)O&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D M:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA2`H1&5F:6-I="D\ M8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L M2!.;W1E(%M!8G-T'0^/&1I=B!S='EL93TS1"=-05)' M24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M3Y$=7)I;F<@=&AE('1H6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)RPG6QE/3-$)U=)1$]74SH@,3L@5$585"U44D%.4T9/ M4DTZ(&YO;F4[(%1%6%0M24Y$14Y4.B`P<'@[($1)4U!,05DZ(&EN;&EN92`A M:6UP;W)T86YT.R!&3TY4.B`Q,W!X("=4:6UE"<^('1H870@=V%S/&9O;G0@3L@5TE$3U=3.B`Q.R!415A4+51204Y31D]233H@;F]N93L@5$585"U) M3D1%3E0Z(#!P>#L@5TA)5$4M4U!!0T4Z(&YO'0M#L@1$E34$Q!63H@:6YL:6YE("%I;7!O#L@+7=E8FMI="UT97AT+7-T3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%\V,6,U961C-U\Y-V0T7S0R.3=?8C'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R3X\8CXF(S$V,#L\+V(^/"]D:78^(#QD:78@3Y.970@;&]S2P@86YD(&9O6QE/3-$ M)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C:6YG M/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L M93X\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@ M,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#,T+C%P=#L@34%21TE. M.B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E3X\:3Y0 M3X\:3XF(S$V,#L\+VD^/"]D:78^(#QD:78@6QE/3-$)TU!4D=)3CH@,&EN.R!72414 M2#H@.3`E.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!/5D521DQ/5SH@ M=FES:6)L92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!A;&EG M;CTS1&QE9G0^(#QT6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E M6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO M6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!& M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!! M1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)4 M24-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S M;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^,2PP M-C`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%# M2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U! M3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@ M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^,2PP-C<\+V1I M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E, M13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T M:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N M;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U3 M5%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9 M.B!T:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E, M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+ M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%, M24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!& M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T M9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O M=6)L93L@5$585"U!3$E'3CH@"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q M)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]4 M5$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!& M3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@ M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$ M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@ M=VED=&@],T0Q,B4^(#QD:78^,2PU-#@\+V1I=CX@/"]T9#X@/'1D('-T>6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D M/CPO=&0^/"]T6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D]. M5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0G/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U) M3D1%3E0Z(#(W+C5P=#L@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)TU! M4D=)3CH@,&EN.R!724142#H@.#`E.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA M<'-E.R!/5D521DQ/5SH@=FES:6)L92<@8V5L;'-P86-I;F<],T0P(&-E;&QP M861D:6YG/3-$,"!A;&EG;CTS1&QE9G0^(#QT6QE/3-$)U1% M6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&-E M;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%# M2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U! M3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@ M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^,3$Q/"]D:78^ M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-4 M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q M)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=. M.B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U M<'@[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-4 M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@ M1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO#L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!& M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXQ,3PO9&EV/B`\ M+W1D/B`\=&0@6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@ M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9% M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=" M3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@ M6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$ M.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B M;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=% M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@ M5$585"U!3$E'3CH@"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P M,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q% M.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I% M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C M,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q M,B4^(#QD:78^-C4\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO&5D.R<@8V5L;'-P M86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T'!E;G-E#L@1D].5#H@,3!P="!4 M:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'!E;G-E3X\:3XF(S$V,#L\ M+VD^/"]D:78^(#QD:78@6QE/3-$)TU!4D=)3CH@,&EN.R!724142#H@.#`E.R!"3U)$15(M0T], M3$%04T4Z(&-O;&QA<'-E.R!/5D521DQ/5SH@=FES:6)L92<@8V5L;'-P86-I M;F<],T0P(&-E;&QP861D:6YG/3-$,"!A;&EG;CTS1&QE9G0^(#QT6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%, M24=..B!C96YT97([($9/3E0M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(&-E;G1E"!S M;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[ M($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E' M2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S M='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L M.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@ M=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4 M15A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y' M+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!& M3TY4+5=%24=(5#H@-#`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`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4 M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXQ+#,T-SPO9&EV/B`\ M+W1D/B`\=&0@"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D]. M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1) M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$ M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$ M15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P M,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q% M.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I% M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C M,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q M,B4^(#QD:78^,BPV-#8\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE M+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS M1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L93X\'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/&1I=B!S M='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(#!P>"!S;VQI M9#L@0D]21$52+4Q%1E0Z(#!P>"!S;VQI9#L@5TE$5$@Z(#$P,"4[($9/3E0M M4TE:13H@,3!P=#L@0D]21$52+51/4#H@,'!X('-O;&ED.R!"3U)$15(M4DE' M2%0Z(#!P>"!S;VQI9"<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$ M,#X@/'1R/B`\=&0@3XF(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=# M3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF M(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E M;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF M(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@ M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q-"4^(#QD:78^,#PO9&EV/B`\ M+W1D/B`\=&0@3PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q% M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO'!E8W1E9"!L:69E(&]F(&]P=&EO;CPO9&EV/B`\+W1D/B`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`@ M("`@("`\=&0@8VQA3X\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB M;W1H.R!&3TY4+49!34E,63I4:6UE#L@1D].5#H@,3!P="!4:6UE6QE M/3-$)T9/3E0M1D%-24Q9.B`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`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C M96YT97([($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P M,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S M='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^ M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%, M24=..B!C96YT97([($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q) M1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q% M.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I% M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@ M-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXS+#DP.2PU.#`\+V1I=CX@/"]T9#X@ M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E' M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T M,#`G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!D;W5B;&4[($9/3E0M5T5) M1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D M/B`\=&0@6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO&5R8VES960\+V1I=CX@ M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED M.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D]. M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`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`Q,'!T M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W M:61T:#TS1#$P)3X@/&1I=CXU+#DX,2PQ,#8\+V1I=CX@/"]T9#X@/'1D('-T M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[ M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I M9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`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`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=% M24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXM/"]D:78^(#PO=&0^(#QT M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q% M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^ M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L M969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P M,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[ M($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T M:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O M=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!& M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E M969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[ M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D M:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P M(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N M;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P M)R!W:61T:#TS1#$P)3X@/&1I=CXV+#4S,2PQ,#8\+V1I=CX@/"]T9#X@/'1D M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4 M64Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U3 M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=( M5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXQ+CDW/"]D:78^(#PO=&0^(#QT M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`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`P,#`@,W!X(&1O=6)L93L@5$58 M5"U!3$E'3CH@6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L M93L@5$585"U!3$E'3CH@6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$58 M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E, M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4 M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5) M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@ M"!D M;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C M,38P.SPO9&EV/B`\+W1D/B`\=&0@"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$ M,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!& M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO"!D;W5B;&4[($9/ M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^ M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U3 M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!" M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%, M+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L M93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[ M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!& M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q% M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!D;W5B;&4[($9/3E0M5T5)1TA4 M.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT M9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$ M.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B M;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L93L@1D].5"U7 M14E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q% M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ M(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E' M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T M,#`G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X M(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C M8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T M;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L93L@1D].5"U714E' M2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1% M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%# M2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@ M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P M,#`P,"`S<'@@9&]U8FQE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P M)3X@/&1I=CXT+#DW-"PP,#`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M"!D;W5B;&4[($9/3E0M M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO M=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D M;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[ M($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE M9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\ M+W1D/CPO='(^/"]T86)L93X\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA3XF(S$V,#L\+V1I=CX@/&1I=B!S M='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE#IA=71O.R!724142#H@.3`E.R!"3U)$ M15(M0T],3$%04T4Z(&-O;&QA<'-E.R!/5D521DQ/5SH@=FES:6)L92<@8V5L M;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!A;&EG;CTS1&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E M6QE/3-$)U1%6%0M M04Q)1TXZ(&-E;G1E6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N M;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P M,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^ M(#QD:78^,BXQ.3PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO"!S M;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D]. M5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%- M24Q9.B!T:6UE6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N M;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P M)R!W:61T:#TS1#$R)3X@/&1I=CXP/"]D:78^(#PO=&0^(#QT9"!S='EL93TS M1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO3PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!& M3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@ M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4 M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXY,#PO9&EV/B`\+W1D M/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q% M.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I% M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@ M-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXY,#PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[ M(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!6 M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T M:#TS1#$R)3X@/&1I=CXY-3PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5. M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@ M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXQ M+C4Y/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!& M3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@ M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4 M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXT+C4U('EE87)S/"]D M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4 M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO65A M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO&5D.R<@8V5L;'-P86-I;F<],T0P M(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T'0^/&1I=B!S='EL93TS1"=-05)'24XZ(#!P="`P M<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z M("TV+C9P=#L@34%21TE..B`P<'0@,RXS<'0@,'!T(#8N-G!T.R!&3TY4.B`Q M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-EF5S('1H92!E6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[5$585"U)3D1%3E0Z("TV+C9P=#L@34%21TE..B`P<'0@,RXS<'0@ M,'!T(#8N-G!T.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2 M3U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E' M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I M=CXV+#6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO3PO M9&EV/B`\+W1D/B`\=&0@"!S;VQI9#L@5$585"U!3$E'3CH@;&5F M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[ M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E' M3CH@6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO'0^/&1I=B!S='EL93TS1"=- M05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE#L@1D].5#H@,3!P="!4 M:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@ M,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$58 M5"U!3$E'3CI,969T.R!415A4+4E.1$5.5#H@,&EN.R!724142#H@,3`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`Q,'!T M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P M(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD M:78^,2XY.3PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO&5R8VES960\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",P,#`P,#`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`Q M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P M)R!W:61T:#TS1#$P)3X@/&1I=CXM/"]D:78^(#PO=&0^(#QT9"!S='EL93TS M1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M M1D%-24Q9.B!T:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X M('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[ M($9/3E0M1D%-24Q9.B!T:6UE"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO"!S M;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V M,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D M:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE M6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#,T+C%P=#L@34%21TE..B`P<'0@,'!X M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[5$585"U!3$E'3CI,969T.R!415A4+4E.1$5.5#H@,&EN.R!724142#H@ M,3`P)2<^(#QT86)L92!S='EL93TS1"=-05)'24XZ(#!I;CL@5TE$5$@Z(#$P M,"4[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P6QE M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1% M6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q) M1TXZ(&-E;G1E6QE/3-$ M)U1%6%0M04Q)1TXZ(&-E;G1E&5R8VES93PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$ M)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT M97([($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/ M3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/ M3E0M4U193$4Z(&YO&5R8VES86)L93PO9&EV/B`\+W1D M/B`\=&0@6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/ M3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4 M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z M(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL M93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0 M041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M M1D%-24Q9.B!T:6UE"!S;VQI9#L@1D].5"U7 M14E'2%0Z(#0P,"<@=VED=&@],T0Q."4^(#QD:78^,S$V+#4R,CPO9&EV/B`\ M+W1D/B`\=&0@"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q M."4^(#QD:78^,BXU-R!Y96%R6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!& M3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@ M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4 M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$X)3X@/&1I=CXS+#DP,RPP,#`\+V1I M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%# M2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U! M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$X)3X@ M/&1I=CXU,36QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$Y)3X@/&1I=CXS+C,P/"]D M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4 M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2 M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E' M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$X)3X@/&1I M=CXV,2PR,#<\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-4 M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%, M24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T M:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@ M=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=" M3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ M(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@ M(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T M=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E' M2%0Z(#0P,"<@=VED=&@],T0Q.24^(#QD:78^,2XX,#PO9&EV/B`\+W1D/B`\ M=&0@6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E' M3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4 M64Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3 M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0 M.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@] M,T0Q."4^(#QD:78^-RPY-S0L-SDT/"]D:78^(#PO=&0^(#QT9"!S='EL93TS M1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E65A6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%\V,6,U961C-U\Y-V0T7S0R.3=?8C'0O:'1M;#L@8VAA'1U86PI("A54T0@ M)"D\8G(^26X@5&AO=7-A;F1S+"!U;FQE'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!-87)K970@06-C;W5N=',@6TUE;6)E3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%\V,6,U961C-U\Y-V0T7S0R.3=?8C'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2P@4&QA;G0@ M86YD($5Q=6EP;65N="P@1W)O2P@4&QA M;G0@86YD($5Q=6EP;65N="!;3&EN92!)=&5M2P@4&QA;G0@86YD M($5Q=6EP;65N="!;3&EN92!)=&5M7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'!E8W1E9"!V;VQA=&EL M:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,S$N,#`E/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^,3`@>65A M'!E8W1E9"!F;W)F96ET=7)E7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$2!3:&%R92UB87-E9"!087EM96YT($%W87)D(%M,:6YE($ET M96US73PO'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$&5R8VES960\+W1D/@T*("`@("`@("`\ M=&0@8VQA'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M&5R8VES86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$&5R8VES92!0&5R8VES92!0'0^-2!Y96%R'0^-2!Y96%R'0^-2!Y96%R7,\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%\V,6,U961C-U\Y-V0T7S0R.3=?8C'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M'1U86PI("A5 M4T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$ M=&@@8V]L65T M(%)E8V]G;FEZ960L(%-T;V-K($]P=&EO;G,\+W1D/@T*("`@("`@("`\=&0@ M8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'!E;G-E/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX,C8L,#`P/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!3:&%R92UB87-E9"!087EM96YT M($%W87)D(%M,:6YE($ET96US73PO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$2!3:&%R92UB87-E9"!087EM96YT($%W87)D+"!/ M<'1I;VYS+"!'65E(%M- M96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\6UE;G0@07=A2!3:&%R92UB87-E9"!087EM M96YT($%W87)D+"!/<'1I;VYS+"!'6UE;G0@07=A6UE;G0@07=A M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$2!3:&%R92UB87-E M9"!087EM96YT($%W87)D+"!/<'1I;VYS+"!''0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S6UE;G0@07=A2!3:&%R92UB87-E9"!087EM96YT($%W87)D+"!/<'1I;VYS+"!/=71S=&%N M9&EN9RP@3G5M8F5R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT M,C@L-C4W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$6UE;G0@07=A2!3:&%R92UB M87-E9"!087EM96YT($%W87)D+"!/<'1I;VYS+"!''0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S6UE;G0@07=A&EM=6T@6TUE;6)E'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'!E8W1E9"!V;VQA=&EL:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M;G5M<#XY-2XP,"4\'0^-2!Y96%R65A65A7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA&5R8VES92!0&5R8VES92!0 M'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA65A&5R8VES92!06UE;G0@07=A65A&5R8VES92!06UE;G0@07=A&5R8VES86)L93PO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^,2!Y96%R(#<@;6]N=&AS(#(X(&1A M>7,\&5R8VES86)L93PO=&0^#0H@("`@("`@(#QT M9"!C;&%S7,\'0^,3`@;6]N=&AS(#$W(&1A M>7,\&5R8VES86)L93PO=&0^#0H@("`@("`@ M(#QT9"!C;&%S7,\3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%\V,6,U961C-U\Y-V0T7S0R.3=?8C'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M3V-T(#(U+`T*"0DR,#$W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$6UE;G0@07=A'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA2!;3&EN92!) M=&5M'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&-L=61E9"!F3X-"CPO M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\V,6,U961C-U\Y-V0T7S0R.3=? M8C'0O:'1M;#L@ M8VAA&UL;G,Z;STS1")U&UL/@T*+2TM+2TM/5].97AT4&%R=%\V,6,U961C-U\Y-V0T ;7S0R.3=?8C XML 19 R29.htm IDEA: XBRL DOCUMENT v2.4.1.9

Stock Purchase Warrants (Details Textual) (USD $)
3 Months Ended 1 Months Ended 0 Months Ended

Mar. 31, 2015

Mar. 31, 2014

Oct. 25, 2012

Oct. 10, 2014

Dec. 31, 2014

Fair Value Adjustment of Warrants $ 4,152,000us-gaap_FairValueAdjustmentOfWarrants $ 0us-gaap_FairValueAdjustmentOfWarrants

Warrant liabilities 10,908,000syn_WarrantLiabilities 6,756,000syn_WarrantLiabilities

Class of Warrant or Right, Outstanding 316,522

Warrant [Member]

Issuance Of Warrants To Purchase Of Common Stock 635,855

Warrants Exercisable Price Per Share $ 1.60

Investment Warrants Expiration Date1 Oct. 25, 2017

Stock Warrants [Member]

Proceeds from Issuance of Common Stock 19,100,000

Sale of Stock, Number of Shares Issued in Transaction 14,059,616

Sale of Stock, Price Per Share $ 1.47

Issuance Of Warrants To Purchase Of Common Stock 0.5

Share Based Compensation Arrangement By Share Based Payment Award Warrants Exercisable Number 7,029,808

Warrants Exercisable Price Per Share $ 1.75

Fair Value Adjustment of Warrants 10,900,000

Warrant liabilities $ 4,200,000

Investment Warrants Expiration Date1 Oct. 10, 2019

X

- Definition

Expiration date of warrants held.

+ References

No definition available.

+ Details

Name: syn_InvestmentWarrantsExpirationDate1

Namespace Prefix: syn_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

Warrants issued to purchase common stock.

+ References

No definition available.

+ Details

Name: syn_IssuanceOfWarrantsToPurchaseOfCommonStock

Namespace Prefix: syn_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The number of exercisable share warrants that may be converted as of the balance sheet date.

+ References

No definition available.

+ Details

Name: syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableNumber

Namespace Prefix: syn_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

It represents value of warrant liabilities.

+ References

No definition available.

+ Details

Name: syn_WarrantLiabilities

Namespace Prefix: syn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Warrants exercisable price per share.

+ References

No definition available.

+ Details

Name: syn_WarrantsExercisablePricePerShare

Namespace Prefix: syn_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of warrants or rights outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph i

-Article 4

+ Details

Name: us-gaap_ClassOfWarrantOrRightOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Amount of expense (income) related to adjustment to fair value of warrant liability.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 480

-SubTopic 10

-Section 25

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=6939902&loc=d3e20148-110875

+ Details

Name: us-gaap_FairValueAdjustmentOfWarrants

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow from the additional capital contribution to the entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.

+ References

No definition available.

+ Details

Name: us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.

+ References

No definition available.

+ Details

Name: us-gaap_SaleOfStockPricePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=syn_StockWarrantsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 20 R28.htm IDEA: XBRL DOCUMENT v2.4.1.9

Stock Purchase Warrants (Details 3) (USD $)
3 Months Ended

Mar. 31, 2015

Exercise Price 1.60 [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Exercise Price $ 1.60

Warrants Outstanding 316,522

Warrants Exercisable 316,522

Weighted Average Remaining Contractual Life 2 years 6 months 25 days

Aggregate Intrinsic value $ 187,000

Exercise Price 1.75 [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Exercise Price $ 1.75

Warrants Outstanding 7,029.808

Warrants Exercisable 7,029,808

Weighted Average Remaining Contractual Life 4 years 6 months 11 days

Aggregate Intrinsic value 3,903,000

Exercise Price 2.22 [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Exercise Price $ 2.22

Warrants Outstanding 517,257

Warrants Exercisable 517,257

Weighted Average Remaining Contractual Life 1 year 7 months 28 days

Aggregate Intrinsic value 0

Exercise Price 3.30 [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Exercise Price $ 3.30

Warrants Outstanding 61,207

Warrants Exercisable 61,207

Weighted Average Remaining Contractual Life 1 month 28 days

Aggregate Intrinsic value 0

Exercise Price 3.75 [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Exercise Price $ 3.75

Warrants Outstanding 50,000

Warrants Exercisable 50,000

Weighted Average Remaining Contractual Life 10 months 17 days

Aggregate Intrinsic value 0

Exercise Price 1.80 [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Exercise Price $ 1.80

Warrants Outstanding 7,974,794

Warrants Exercisable 7,974,794

Weighted Average Remaining Contractual Life 4 years 2 months 16 days

Aggregate Intrinsic value $ 3,280,000

X

- Definition

The value as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the share warrants plan.

+ References

No definition available.

+ Details

Name: syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber

Namespace Prefix: syn_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Exercise price of the warrants.

+ References

No definition available.

+ Details

Name: syn_WarrantsExercisePrice

Namespace Prefix: syn_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Intrinsic value of equity-based compensation awards outstanding. Excludes stock and unit options.

+ References

No definition available.

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of equity instruments other than options outstanding, including both vested and non-vested instruments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_RangeAxis=syn_ExercisePrice14Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=syn_ExercisePrice175Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=syn_ExercisePrice180Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=syn_ExercisePrice222Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=syn_ExercisePrice330Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=syn_ExercisePrice375Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 21 R30.htm IDEA: XBRL DOCUMENT v2.4.1.9

Stockholders' Equity (Deficit) (Details Textual) (Prev Abr Llc [Member], USD $)
3 Months Ended

Mar. 31, 2015

Prev Abr Llc [Member]

Stockholders Equity [Line Items]

Stock Issued During Period, Shares, New Issues 212,843

Equity Issued in Business Combination, Fair Value Disclosure $ 350,000

X

- Details

Name: syn_StockholdersEquityLineItems

Namespace Prefix: syn_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Fair value of equity issued in a business combination.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Number of new stock issued during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 22 R31.htm IDEA: XBRL DOCUMENT v2.4.1.9

Net Loss per Share (Details Textual)
3 Months Ended

Mar. 31, 2015

Mar. 31, 2014

Equity Option [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6,531,106 4,490,497

Warrant [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 7,974,794 963,168

X

- Definition

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Antidilution

-URI http://asc.fasb.org/extlink&oid=6505113

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Diluted Earnings Per Share

-URI http://asc.fasb.org/extlink&oid=6510752

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Contingent Stock Agreement

-URI http://asc.fasb.org/extlink&oid=6508534

+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 23 R8.htm IDEA: XBRL DOCUMENT v2.4.1.9

Fair Value of Financial Instruments
3 Months Ended

Mar. 31, 2015

Fair Value Disclosures [Abstract]

Fair Value Disclosures [Text Block]

3. Fair Value of Financial Instruments

The fair value accounting standards define fair value as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is determined based upon assumptions that market participants would use in pricing an asset or liability. Fair value measurements are rated on a three-tier hierarchy as follows:

·

Level 1 inputs: Quoted prices (unadjusted) for identical assets or liabilities in active markets;

·

Level 2 inputs: Inputs, other than quoted prices included in Level 1 that are observable either directly or indirectly; and

·

Level 3 inputs: Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions.

If the inputs used to measure fair value fall in different levels of the fair value hierarchy, the hierarchy level is based upon the lowest level of input that is significant to the fair value measurement.

Cash and cash equivalents include money market accounts of $8.5 million and $13.6 million as of March 31, 2015 and December 31, 2014, respectively, that are measured using Level 1 inputs.

X

- Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13537-108611

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13433-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13504-108611

+ Details

Name: us-gaap_FairValueDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 24 R2.htm IDEA: XBRL DOCUMENT v2.4.1.9

Consolidated Balance Sheets (USD $)
In Thousands, unless otherwise specified

Mar. 31, 2015

Dec. 31, 2014

Current Assets

Cash and cash equivalents $ 12,049 $ 17,525

Prepaid expenses and other current assets 1,574 1,548

Total Current Assets 13,623us-gaap_AssetsCurrent 19,073us-gaap_AssetsCurrent

Property and equipment, net 75us-gaap_PropertyPlantAndEquipmentNet 65us-gaap_PropertyPlantAndEquipmentNet

Deposits and other assets 18syn_DepositsAndOtherAssetsNoncurrent 6syn_DepositsAndOtherAssetsNoncurrent

Total Assets 13,716us-gaap_Assets 19,144us-gaap_Assets

Current Liabilities:

Accounts payable 1,559us-gaap_AccountsPayableCurrent 996us-gaap_AccountsPayableCurrent

Accrued expenses 2,646us-gaap_AccruedLiabilitiesCurrent 1,298us-gaap_AccruedLiabilitiesCurrent

Warrant liabilities 10,908syn_WarrantLiabilities 6,756syn_WarrantLiabilities

Accrued employee benefits 228us-gaap_AccruedEmployeeBenefitsCurrent 538us-gaap_AccruedEmployeeBenefitsCurrent

Total Current Liabilities 15,341us-gaap_LiabilitiesCurrent 9,588us-gaap_LiabilitiesCurrent

Total Liabilities 15,341us-gaap_Liabilities 9,588us-gaap_Liabilities

Commitments and Contingencies

Stockholders' Equity (Deficit):

Preferred stock, $0.001 par value; 10,000,000 shares authorized, none issued and outstanding 0us-gaap_PreferredStockValue 0us-gaap_PreferredStockValue

Common stock, $0.001 par value; 100,000,000 shares authorized, 72,725,987 issued and 72,807,469 outstanding and 72,594,626 issued and 72,513,144 outstanding 73us-gaap_CommonStockValue 72us-gaap_CommonStockValue

Additional paid-in capital 111,702 110,526

Accumulated deficit (113,400) (101,042)

Total Synthetic Biologics, Inc. and Subsidiaries Equity (Deficit) (1,625)us-gaap_StockholdersEquity 9,556us-gaap_StockholdersEquity

Non-controlling interest 0us-gaap_MinorityInterest 0us-gaap_MinorityInterest

Total Stockholders' Equity (Deficit) (1,625) 9,556

Total Liabilities and Stockholders’ Equity $ 13,716 $ 19,144

X

- Definition

Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer and also includes aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet due to materiality considerations. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).

+ References

No definition available.

+ Details

Name: syn_DepositsAndOtherAssetsNoncurrent

Namespace Prefix: syn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

It represents value of warrant liabilities.

+ References

No definition available.

+ Details

Name: syn_WarrantLiabilities

Namespace Prefix: syn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765

+ Details

Name: us-gaap_AccruedEmployeeBenefitsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.30(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AdditionalPaidInCapitalCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 18

-Article 5

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.9)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 9

-Article 5

+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 25

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 7

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 17

-Article 9

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.17)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.(a),19)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19-26)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.32)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 25

-Article 7

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 32

-Article 5

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.21)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 21

-Article 5

+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 27

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 7

+ Details

Name: us-gaap_MinorityInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 8

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The cumulative amount of the reporting entity's undistributed earnings or deficit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4568447-111683

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4568740-111683

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4I

-URI http://asc.fasb.org/extlink&oid=35736750&loc=SL4590271-111686

+ Details

Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 25 R6.htm IDEA: XBRL DOCUMENT v2.4.1.9

Organization and Nature of Operations and Basis of Presentation
3 Months Ended

Mar. 31, 2015

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]

1. Organization and Nature of Operations and Basis of Presentation

Description of Business

Synthetic Biologics, Inc. (the “Company” or “Synthetic Biologics”) is a microbiome-focused, clinical-stage company developing therapeutics to protect the microbiome while targeting pathogen-specific diseases. The Company is developing an oral biologic to protect the gut microbiome (gastrointestinal (GI) microflora) from intravenous (IV) antibiotics for the prevention of C. difficile infection and an oral statin treatment to reduce the impact of methane producing organisms on irritable bowel syndrome with constipation (IBS-C). In addition, the Company is developing a monoclonal antibody combination for the treatment of Pertussis in collaboration with Intrexon Corporation (NYSE: XON), and a Phase 2 oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS.

Therapeutic Area

Product Candidate

Status

C. difficile infection prevention

SYN-004

(oral enzyme)

Initiated Phase 2a SYN-004 clinical trial during 1^st quarter 2015; Phase 2b proof-of- concept SYN-004 clinical trial is expected to initiate during 2^nd  half 2015

Irritable bowel syndrome with constipation (IBS-C)

SYN-010

(oral compound)

Intend to initiate Phase 2 clinical trials during 2^nd  quarter of 2015; Collaboration with Cedars-Sinai Medical Center

Pertussis

SYN-005

(monoclonal antibodies)

Positive preclinical research findings reported at ECCMID in April 2015; Seeking non-dilutive funding to support clinical development of SYN-005; Collaborations with Intrexon and The University of Texas at Austin

Relapsing-remitting MS

Trimesta

(oral estriol)

The lead principal investigator presented additional Phase 2 clinical outcome data, including more detailed results on improvements in cognitive and disability measures at the ACTRIMS-ECTRIMS Joint Meeting in September 2014; Partnership discussions ongoing pending data from University of California, Los Angeles (UCLA); MRI data review underway by UCLA

Cognitive dysfunction in MS

Trimesta

(oral estriol)

Patient enrollment underway in Phase 2 clinical trial

Basis of Presentation

The accompanying consolidated financial statements have been prepared pursuant to the rules and regulations of Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all of the information and notes required by U.S. Generally Accepted Accounting Principles (“GAAP”) for complete financial statements. The accompanying consolidated financial statements include all adjustments, comprised of normal recurring adjustments, considered necessary by management to fairly state our results of operations, financial position and cash flows. The operating results for the interim periods are not necessarily indicative of results that may be expected for any other interim period or for the full year. These consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2014 (“2014 Form 10-K”) as filed with the SEC. The interim results for the three months ended March 31, 2015, are not necessarily indicative of results for the full year.

The consolidated financial statements are prepared in conformity with U.S. GAAP, which requires the use of estimates, judgments and assumptions that affect the amounts of assets and liabilities at the reporting date and the amounts of revenue and expenses in the periods presented. We believe that the accounting estimates employed are appropriate and the resulting balances are reasonable; however, due to the inherent uncertainties in making estimates actual results could differ from the original estimates, requiring adjustments to these balances in future periods.

X

- Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=35735333&loc=d3e288-107754

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 915

-SubTopic 235

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38932-110933

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 272

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 26 R22.htm IDEA: XBRL DOCUMENT v2.4.1.9

Stock-Based Compensation (Details)
3 Months Ended

Mar. 31, 2015

Mar. 31, 2014

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Expected dividends 0.00% 0.00%

Expected volatility 131.00% 126.00%

Risk free interest rate 2.03% 1.57%

Expected life of warrant 10 years 5 years

Expected forfeitures 0.00% 0.00%

X

- Definition

The number of shares under options that were expected to be cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.

+ References

No definition available.

+ Details

Name: syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod

Namespace Prefix: syn_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(iii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.D.2)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section D

-Subsection 2

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

The risk-free interest rate assumption that is used in valuing an option on its own shares.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(iv)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 27 R24.htm IDEA: XBRL DOCUMENT v2.4.1.9

Stock-Based Compensation (Details Textual) (USD $)
3 Months Ended 12 Months Ended

Mar. 31, 2015

Mar. 31, 2014

Dec. 31, 2001

Dec. 31, 2007

Mar. 20, 2007

Nov. 02, 2010

Oct. 22, 2013

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options $ 4,000,000

General and Administrative Expenses and Research and Development Expense [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Allocated Share-based Compensation Expense 826,000 362,000

Employees And Consultants [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 587,500

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Fair Value 1,400,000

Employee [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 550,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Fair Value $ 817,000

2001 Stock Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number 682,449

2001 Stock Plan [Member] | Maximum [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 250,000

2007 Stock Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number 428,657 2,500,000

2007 Stock Plan [Member] | Maximum [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 250,000

2010 Stock Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number 5,420,000 3,000,000

2010 Stock Plan [Member] | Maximum [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Common Stock, Capital Shares Reserved for Future Issuance 6,000,000

2010 Stock Plan [Member] | Minimum [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Common Stock, Capital Shares Reserved for Future Issuance 3,000,000

X

- Definition

Fair value of stock (or other type of equity) granted during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP).

+ References

No definition available.

+ Details

Name: syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue

Namespace Prefix: syn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.F)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section F

+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Aggregate number of common shares reserved for future issuance.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CommonStockCapitalSharesReservedForFutureIssuance

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Unrecognized cost of unvested options awarded to employees as compensation.

+ References

No definition available.

+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Gross number of share options (or share units) granted during the period.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of options outstanding, including both vested and non-vested options.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=syn_StockPlan2001Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=syn_StockPlan2007Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=syn_StockPlan2010Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=syn_EmployeeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=syn_EmployeesAndConsultantsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 28 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 29 R7.htm IDEA: XBRL DOCUMENT v2.4.1.9

Management Plans
3 Months Ended

Mar. 31, 2015

Disclosure Management Plan [Abstract]

Disclosure Management Plan [Text Block]

2. Management’s Plan

The Company has incurred an accumulated deficit of $113.4 million through March 31, 2015. With the exception of the quarter ended June 30, 2010, the Company has incurred negative cash flow from operations since it started the business. The Company has spent, and expects to continue to spend, substantial amounts in connection with implementing its business strategy, including the planned product development efforts, clinical trials, and research and discovery efforts.

The actual amount of funds the Company will need to operate is subject to many factors, some of which are beyond the Company’s control. These factors include the following:

⋅

the progress of research activities;

⋅

the number and scope of research programs;

⋅

the progress of preclinical and clinical development activities;

⋅

the progress of the development efforts of parties with whom the Company has entered into research and development agreements;

⋅

the costs associated with additional clinical trials of product candidates;

⋅

the ability to maintain current research and development licensing arrangements and to establish new research and development and licensing arrangements;

⋅

the ability to achieve milestones under licensing arrangements;

⋅

the costs involved in prosecuting and enforcing patent claims and other intellectual property rights; and

⋅

the costs and timing of regulatory approvals.

The Company has based its estimate on assumptions that may prove to be wrong. The Company may need to obtain additional funds sooner or in greater amounts than it currently anticipates. Potential sources of financing include strategic relationships, public or private sales of the Company’s shares or debt and other sources.

The Company may seek to access the public or private equity markets when conditions are favorable due to long-term capital requirements. The Company does not have any committed sources of financing at this time, and it is uncertain whether additional funding will be available when needed on terms that will be acceptable to it, or at all. If the Company raises funds by selling additional shares of common stock or other securities convertible into common stock, the ownership interest of the existing stockholders will be diluted. If the Company is not able to obtain financing when needed, it may be unable to carry out the business plan. As a result, the Company may have to significantly limit its operations and its business, financial condition and results of operations would be materially harmed.

X

- Details

Name: syn_DisclosureManagementPlanAbstract

Namespace Prefix: syn_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure related to Management's Plan.

+ References

No definition available.

+ Details

Name: syn_DisclosureManagementPlanTextBlock

Namespace Prefix: syn_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 30 R3.htm IDEA: XBRL DOCUMENT v2.4.1.9

Consolidated Balance Sheets (Parenthetical) (USD $)

Mar. 31, 2015

Dec. 31, 2014

Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001

Preferred stock, shares authorized 10,000,000us-gaap_PreferredStockSharesAuthorized 10,000,000us-gaap_PreferredStockSharesAuthorized

Preferred stock, shares issued 0us-gaap_PreferredStockSharesIssued 0us-gaap_PreferredStockSharesIssued

Preferred stock, shares outstanding 0us-gaap_PreferredStockSharesOutstanding 0us-gaap_PreferredStockSharesOutstanding

Common stock, par value (in dollars per share) $ 0.001 $ 0.001

Common stock, shares authorized 100,000,000us-gaap_CommonStockSharesAuthorized 100,000,000us-gaap_CommonStockSharesAuthorized

Common stock, shares, issued 72,725,987us-gaap_CommonStockSharesIssued 72,594,626us-gaap_CommonStockSharesIssued

Common stock, shares outstanding 72,807,469us-gaap_CommonStockSharesOutstanding 72,513,144us-gaap_CommonStockSharesOutstanding

X

- Definition

Face amount or stated value per share of common stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of common shares permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

XML 31 R17.htm IDEA: XBRL DOCUMENT v2.4.1.9

Management's Plan (Details Textual) (USD $)
In Thousands, unless otherwise specified

Mar. 31, 2015

Dec. 31, 2014

Management's Plan [Line Items]

Accumulated deficit $ (113,400) $ (101,042)

X

- Details

Name: syn_ManagementsPlanLineItems

Namespace Prefix: syn_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The cumulative amount of the reporting entity's undistributed earnings or deficit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 32 R1.htm IDEA: XBRL DOCUMENT v2.4.1.9

Document And Entity Information
3 Months Ended

Mar. 31, 2015

May 08, 2015

Document Information [Line Items]

Entity Registrant Name Synthetic Biologics, Inc.

Entity Central Index Key 0000894158

Current Fiscal Year End Date --12-31

Entity Filer Category Accelerated Filer

Trading Symbol SYN

Entity Common Stock, Shares Outstanding 73,179,307dei_EntityCommonStockSharesOutstanding

Document Type 10-Q

Amendment Flag false

Document Period End Date Mar. 31, 2015

Document Fiscal Period Focus Q1

Document Fiscal Year Focus 2015

X

- Definition

If the value is true, then the document is an amendment to previously-filed/accepted document.

+ References

No definition available.

+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition

End date of current fiscal year in the format --MM-DD.

+ References

No definition available.

+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Details

Name: dei_DocumentInformationLineItems

Namespace Prefix: dei_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.

+ References

No definition available.

+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".

+ References

No definition available.

+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.

+ References

No definition available.

+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

XML 33 R18.htm IDEA: XBRL DOCUMENT v2.4.1.9

Fair Value of Financial Instruments (Details Textual) (Money Market Accounts [Member], USD $)
In Millions, unless otherwise specified

Mar. 31, 2015

Dec. 31, 2014

Money Market Accounts [Member]

Cash Equivalents, at Carrying Value $ 8.5 $ 13.6

X

- Definition

Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 34 R4.htm IDEA: XBRL DOCUMENT v2.4.1.9

Consolidated Statements of Operations (USD $)
In Thousands, except Share data, unless otherwise specified
3 Months Ended

Mar. 31, 2015

Mar. 31, 2014

Operating Costs and Expenses:

General and administrative $ 1,713us-gaap_GeneralAndAdministrativeExpense $ 1,122us-gaap_GeneralAndAdministrativeExpense

Research and development 6,494us-gaap_ResearchAndDevelopmentExpense 2,717us-gaap_ResearchAndDevelopmentExpense

Total Operating Costs and Expenses 8,207us-gaap_OperatingExpenses 3,839us-gaap_OperatingExpenses

Loss from Operations (8,207)us-gaap_OperatingIncomeLoss (3,839)us-gaap_OperatingIncomeLoss

Other Income (Expense):

Change in fair value of warrant liability (4,152)us-gaap_FairValueAdjustmentOfWarrants 0us-gaap_FairValueAdjustmentOfWarrants

Interest income 1us-gaap_InvestmentIncomeInterest 1us-gaap_InvestmentIncomeInterest

Total Other Income (Expense) (4,151)us-gaap_NonoperatingIncomeExpense 1us-gaap_NonoperatingIncomeExpense

Net Loss (12,358)us-gaap_ProfitLoss (3,838)us-gaap_ProfitLoss

Net Loss Attributable to Non-controlling Interest 0 0

Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries $ (12,358)us-gaap_NetIncomeLoss $ (3,838)us-gaap_NetIncomeLoss

Net Loss Per Share - Basic and Dilutive (in dollars per share) $ (0.17) $ (0.07)

Net Loss Per Share Attributable to Synthetic Biologics, Inc. and Subsidiaries (in dollars per share) $ (0.17)us-gaap_EarningsPerShareBasicAndDiluted $ (0.07)us-gaap_EarningsPerShareBasicAndDiluted

Weighted average number of shares outstanding during the period - Basic and Dilutive (in shares) 72,673,959 58,324,260

X

- Definition

The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

No definition available.

+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of expense (income) related to adjustment to fair value of warrant liability.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 480

-SubTopic 10

-Section 25

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=6939902&loc=d3e20148-110875

+ Details

Name: us-gaap_FairValueAdjustmentOfWarrants

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.

+ References

No definition available.

+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 7

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7(b))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_InvestmentIncomeInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of Net Income (Loss) attributable to noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1A

-URI http://asc.fasb.org/extlink&oid=18733093&loc=SL4573702-111684

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4J

-URI http://asc.fasb.org/extlink&oid=35736750&loc=SL4591551-111686

+ Details

Name: us-gaap_NetIncomeLossAttributableToNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 7

-Article 5

+ Details

Name: us-gaap_NonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_NonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net result for the period of deducting operating expenses from operating revenues.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4K

-URI http://asc.fasb.org/extlink&oid=35736750&loc=SL4591552-111686

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 19

-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4569616-111683

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1A

-Subparagraph (a),(c)

-URI http://asc.fasb.org/extlink&oid=18733093&loc=SL4573702-111684

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4J

-URI http://asc.fasb.org/extlink&oid=35736750&loc=SL4591551-111686

+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).

+ References

No definition available.

+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 35 R12.htm IDEA: XBRL DOCUMENT v2.4.1.9

Stockholders' Equity (Deficit)
3 Months Ended

Mar. 31, 2015

Stockholders' Equity Note [Abstract]

Stockholders' Equity Note Disclosure [Text Block]

7. Stockholders’ Equity (Deficit)

During the three months ended March 31, 2015, the Company issued 212,843 shares of common stock to Prev ABR LLC, with a fair value of $350,000, that was recorded as research and development expense, in consideration for achieving the first two milestones as set forth in the Asset Purchase Agreement dated November 28, 2012. In lieu of receiving any cash payment for achieving the first two milestones, Prev ABR LLC exercised its option to receive the milestone payments in shares of the Company’s common stock. The number of shares of common stock issued upon achievement of each milestone was based upon the average of the opening and closing prices of the Company’s stock on the date each milestone was achieved as specified in the Asset Purchase Agreement.

X

- Details

Name: us-gaap_StockholdersEquityNoteAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d),(e))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Article 4

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Preferred Stock

-URI http://asc.fasb.org/extlink&oid=6521494

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 17: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 18: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph d

-Article 4

Reference 19: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 36 R11.htm IDEA: XBRL DOCUMENT v2.4.1.9

Stock Purchase Warrants
3 Months Ended

Mar. 31, 2015

Stock Purchase Warrants [Abstract]

Stock Purchase Warrants [Text Block]

6. Stock Purchase Warrants

On October 10, 2014, the Company raised net proceeds of $19.1 million through the sale of 14,059,616 units at a price of $1.47 per unit to certain institutional investors in a registered direct offering. Each unit consisted of one share of the Company’s common stock and a warrant to purchase 0.5 shares of common stock. The warrants, exercisable for an aggregate of 7,029,808 shares of common stock, have an exercise price of $1.75 per share and a life of five years. The warrants vested immediately and expire October 10, 2019.

The warrants issued in conjunction with the registered direct offering in October 2014 include a provision, that if the Company were to enter into a certain transaction, as defined in the agreement, the warrants would be purchased from the holder at a premium. Accordingly, the Company recorded the warrants as a liability at their estimated fair value on the issuance date and changes in estimated fair value will be recorded as non-cash income or expense in the Company’s statement of operations at each subsequent period. At March 31, 2015, the fair value of the warrant liability was $10.9 million, which represented non-cash expense of $4.2 million for the three months ended March 31, 2015. In accordance with authoritative accounting guidance, the warrant was valued on the date of grant and in subsequent periods using the Black-Scholes valuation model. The assumptions used by the Company are summarized in the following table:

March 31,
2015

December 31,
2014

Issuance
Date

Closing stock price

$

2.19

$

1.46

$

1.75

Expected dividends

0

%

0

%

0

%

Expected volatility

90

%

90

%

95

%

Risk free interest rate

1.26

%

1.59

%

1.39

%

Expected life of warrant

4.55 years

4.79 years

5 years

The following table summarizes the estimated fair value of the warrant liability (in thousands):

Balance at December 31, 2014

$

6,756

Change in fair value of warrant liability

4,152

Balance at March 31, 2015

$

10,908

As of March 31, 2015, all of the warrants remained outstanding.

On October 25, 2012, the Company entered into a Common Stock Purchase Agreement with certain accredited investors. As part of this agreement, the Company issued warrants to purchase 635,855 shares of common stock to the placement agent, or its permitted assigns. The warrants have an exercise price of $1.60 and a life of five years. The warrants vested immediately and expire October 25, 2017. Since these warrants were granted as part of an equity raise, the Company has treated them as a direct offering cost. The result of the transaction has no affect to equity. Warrants outstanding as of March 31, 2015 were 316,522.

A summary of warrant activity for the Company for the three months ended March 31, 2015 and for the year ended December 31, 2014 is as follows:

Weighted Average

Number of Warrants

Exercise Price

Balance at December 31, 2013

1,632,501

$

1.99

Granted

7,029,808

$

1.75

Exercised

(232,619)

$

1.47

Forfeited

(454,896)

$

1.88

Balance at December 31, 2014

7,974,794

$

1.80

Granted

-

$

-

Exercised

-

$

-

Forfeited

-

$

-

Balance at March 31, 2015

7,974,794

$

1.80

A summary of all outstanding and exercisable warrants as of March 31, 2015 is as follows:

Weighted Average

Exercise

Warrants

Warrants

Remaining

Aggregate

Price

Outstanding

Exercisable

Contractual Life

Intrinsic Value

$

1.60

316,522

316,522

2.57 years

$

187,000

$

1.75

7,029.808

7,029,808

4.53 years

$

3,903,000

$

2.22

517,257

517,257

1.66 years

$

-

$

3.30

61,207

61,207

0.16 years

$

-

$

3.75

50,000

50,000

0.88 years

$

-

$

1.80

7,974,794

7,974,794

4.21 years

$

3,280,000

X

- Details

Name: syn_StockPurchaseWarrantsAbstract

Namespace Prefix: syn_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure related to Stock Purchase Warrants.

+ References

No definition available.

+ Details

Name: syn_StockPurchaseWarrantsTextBlock

Namespace Prefix: syn_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 37 R23.htm IDEA: XBRL DOCUMENT v2.4.1.9

Stock-Based Compensation (Details 1) (Stock Option [Member], USD $)
3 Months Ended 12 Months Ended

Mar. 31, 2015

Dec. 31, 2014

Dec. 31, 2013

Stock Option [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Options, Beginning Balance 5,981,106 3,909,580

Options, Granted 550,000 2,382,500

Options, Exercised 0 (6,583)

Options, Forfeited 0 (304,391)

Options, Ending Balance 6,531,106 5,981,106 3,909,580

Options, Exercisable 4,168,043

Weighted Average Exercise Price, Beginning Balance $ 2.01 $ 1.78

Weighted Average Exercise Price, Granted $ 1.54 $ 2.36

Weighted Average Exercise Price, Exercised $ 0 $ 0.58

Weighted Average Exercise Price, Forfeited $ 0 $ 1.93

Weighted Average Exercise Price, Ending Balance $ 1.97 $ 2.01 $ 1.78

Weighted Average Exercise Price, Exercisable $ 1.89

Weighted Average Remaining Contractual Life, Balance Outstanding 5 years 9 months 14 days 5 years 9 months 18 days 5 years 7 months 2 days

Weighted Average Remaining Contractual Life, Exercisable 4 years 11 months 23 days

Aggregate Intrinsic Value, Beginning Balance $ 685,000 $ 785,000

Aggregate Intrinsic Value, Ending Balance 2,628,000 685,000 785,000

Aggregate Intrinsic Value, Exercisable 1,939,000

Grant date fair value of options granted $ 817,000 $ 4,974,000

Weighted average grant date fair value $ 1.49 $ 2.09

X

- Definition

Fair value of stock (or other type of equity) granted during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP).

+ References

No definition available.

+ Details

Name: syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue

Namespace Prefix: syn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(3)-(4)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Weighted average price of options that were either forfeited or expired.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(3)-(4)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Net number of share options (or share units) granted during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (d)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Number of options outstanding, including both vested and non-vested options.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Weighted average price at which option holders acquired shares when converting their stock options into shares.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of share options (or share units) exercised during the current period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28,29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 38 R19.htm IDEA: XBRL DOCUMENT v2.4.1.9

Selected Balance Sheet Information (Details) (USD $)
In Thousands, unless otherwise specified

Mar. 31, 2015

Dec. 31, 2014

Other Current Assets [Line Items]

Intrexon prepaid research and development expenses $ 1,060 $ 1,067

Prepaid insurance 140us-gaap_PrepaidInsurance 228us-gaap_PrepaidInsurance

Prepaid expenses 374us-gaap_PrepaidExpenseCurrent 253us-gaap_PrepaidExpenseCurrent

Total $ 1,574us-gaap_OtherAssetsCurrent $ 1,548us-gaap_OtherAssetsCurrent

X

- Details

Name: syn_OtherCurrentAssetsLineItems

Namespace Prefix: syn_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Sum of the amounts paid in advance for research and development expenses.

+ References

No definition available.

+ Details

Name: syn_PrepaidExpensesResearchAndDevelopment

Namespace Prefix: syn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Aggregate carrying amount, as of the balance sheet date, of current assets not separately disclosed in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.8)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 8

-Article 5

+ Details

Name: us-gaap_OtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Assets

-URI http://asc.fasb.org/extlink&oid=6509628

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (g)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6787-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 340

-SubTopic 10

-Section 05

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=47804770&loc=d3e5879-108316

+ Details

Name: us-gaap_PrepaidExpenseCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Assets

-URI http://asc.fasb.org/extlink&oid=6509628

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6787-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (g)(1)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 340

-SubTopic 10

-Section 05

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=47804770&loc=d3e5865-108316

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 340

-SubTopic 10

-Section 05

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=47804770&loc=d3e5879-108316

+ Details

Name: us-gaap_PrepaidInsurance

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 39 R15.htm IDEA: XBRL DOCUMENT v2.4.1.9

Stock-Based Compensation (Tables)
3 Months Ended

Mar. 31, 2015

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Share-based Compensation Arrangement by Share-based Payment Award Options and Warrants Vested and Expected to Vest Outstanding and Exercisable [Table Text Block]

The Black-Scholes assumptions used in the three months ended March 31, 2015 and 2014 are as follows:

Three Months Ended March 31,

2015

2014

Expected dividends

0

%

0

%

Expected volatility

131

%

126

%

Risk free interest rate

2.03

%

1.57

%

Expected life of option

10 years

5 years

Expected forfeitures

0

%

0

%

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

A summary of stock option activities as of March 31, 2015, and for the year ended December 31, 2014, is as follows:

Weighted

Average

Weighted

Remaining

Aggregate

Average Exercise

Contractual

Intrinsic

Options

Price

Life

Value

Balance - December 31, 2013

3,909,580

$

1.78

5.59 years

$

785,000

Granted

2,382,500

$

2.36

Exercised

(6,583)

$

0.58

Forfeited

(304,391)

$

1.93

Balance - December 31, 2014

5,981,106

$

2.01

5.80 years

$

685,000

Granted

550,000

$

1.54

Exercised

-

$

-

Forfeited

-

$

-

Balance - March 31, 2015 - outstanding

6,531,106

$

1.97

5.79 years

$

2,628,000

Balance - March 31, 2015 - exercisable

4,168,043

$

1.89

4.98 years

$

1,939,000

Grant date fair value of options granted - March 31, 2015

$

817,000

Weighted average grant date fair value - March 31, 2015

$

1.49

Grant date fair value of options granted - December 31, 2014

$

4,974,000

Weighted average grant date fair value - December 31, 2014

$

2.09

X

- Definition

Tabular disclosure relates to share based compensation arrangement by share based payment award options and warrants vested and expected to vest outstanding and exercisable.

+ References

No definition available.

+ Details

Name: syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock

Namespace Prefix: syn_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 40 R13.htm IDEA: XBRL DOCUMENT v2.4.1.9

Net Loss per Share
3 Months Ended

Mar. 31, 2015

Earnings Per Share [Abstract]

Earnings Per Share [Text Block]

8. Net Loss per Share

Net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding. Diluted loss per share is computed by dividing net loss by the weighted average number of common shares outstanding including the effect of common share equivalents. All common equivalent shares were anti-dilutive at March 31, 2014 and 2015, as such there is no separate computation for diluted loss per share. The number of options and warrants for the purchase of common stock, that were excluded from the computations of net loss per common share for the three months ended March 31, 2015 were 6,531,106 and 7,974,794, respectively, and for the three months ended March 31, 2014 were 4,490,497 and 963,168, respectively.

X

- Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for earnings per share.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1278-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=32703322&loc=d3e4984-109258

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_EarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 41 R14.htm IDEA: XBRL DOCUMENT v2.4.1.9

Selected Balance Sheet Information (Tables)
3 Months Ended

Mar. 31, 2015

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of Other Current Assets [Table Text Block]

Prepaid expenses and other current assets (in thousands):

March 31, 2015

December 31, 2014

Intrexon prepaid research and development expenses

$

1,060

$

1,067

Prepaid insurance

140

228

Prepaid expenses

374

253

Total

$

1,574

$

1,548

Property, Plant and Equipment [Table Text Block]

Property and equipment (in thousands):

March 31, 2015

December 31, 2014

Computer and office equipment

$

111

$

93

Software

11

11

122

104

Less accumulated depreciation

(47)

(39)

Total

$

75

$

65

Accrued Expenses [Table Text Block]

Accrued expenses (in thousands):

March 31, 2015

December 31, 2014

Accrued manufacturing costs

$

74

$

247

Accrued vendor payments

225

176

Accrued milestone payments

1,000

350

Accrued clinical consulting services

1,347

525

Total

$

2,646

$

1,298

X

- Definition

Tabular disclosure of accrued expenses.

+ References

No definition available.

+ Details

Name: syn_AccruedExpensesTableTextBlock

Namespace Prefix: syn_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph b

-Article 5

+ Details

Name: us-gaap_PropertyPlantAndEquipmentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the carrying amounts of other current assets.

+ References

No definition available.

+ Details

Name: us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 42 R16.htm IDEA: XBRL DOCUMENT v2.4.1.9

Stock Purchase Warrants (Tables)
3 Months Ended

Mar. 31, 2015

Stock Purchase Warrants [Abstract]

Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]

The assumptions used by the Company are summarized in the following table:

March 31,
2015

December 31,
2014

Issuance
Date

Closing stock price

$

2.19

$

1.46

$

1.75

Expected dividends

0

%

0

%

0

%

Expected volatility

90

%

90

%

95

%

Risk free interest rate

1.26

%

1.59

%

1.39

%

Expected life of warrant

4.55 years

4.79 years

5 years

Schedule Of Estimated Fair Value Of The Warrant Liability [Table Text Block]

The following table summarizes the estimated fair value of the warrant liability (in thousands):

Balance at December 31, 2014

$

6,756

Change in fair value of warrant liability

4,152

Balance at March 31, 2015

$

10,908

Schedule Of Warrant Activity [Table Text Block]

A summary of warrant activity for the Company for the three months ended March 31, 2015 and for the year ended December 31, 2014 is as follows:

Weighted Average

Number of Warrants

Exercise Price

Balance at December 31, 2013

1,632,501

$

1.99

Granted

7,029,808

$

1.75

Exercised

(232,619)

$

1.47

Forfeited

(454,896)

$

1.88

Balance at December 31, 2014

7,974,794

$

1.80

Granted

-

$

-

Exercised

-

$

-

Forfeited

-

$

-

Balance at March 31, 2015

7,974,794

$

1.80

Schedule Of Warrant Outstanding and Exercisable [Table Text Block]

A summary of all outstanding and exercisable warrants as of March 31, 2015 is as follows:

Weighted Average

Exercise

Warrants

Warrants

Remaining

Aggregate

Price

Outstanding

Exercisable

Contractual Life

Intrinsic Value

$

1.60

316,522

316,522

2.57 years

$

187,000

$

1.75

7,029.808

7,029,808

4.53 years

$

3,903,000

$

2.22

517,257

517,257

1.66 years

$

-

$

3.30

61,207

61,207

0.16 years

$

-

$

3.75

50,000

50,000

0.88 years

$

-

$

1.80

7,974,794

7,974,794

4.21 years

$

3,280,000

X

- Definition

Tabular disclosure of estimated fair value of the warrant liability.

+ References

No definition available.

+ Details

Name: syn_ScheduleOfEstimatedFairValueOfWarrantLiabilityTableTextBlock

Namespace Prefix: syn_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of warrant activity.

+ References

No definition available.

+ Details

Name: syn_ScheduleOfWarrantActivityTableTextBlock

Namespace Prefix: syn_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure relates to warrant outstanding and exercisable.

+ References

No definition available.

+ Details

Name: syn_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock

Namespace Prefix: syn_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: syn_StockPurchaseWarrantsAbstract

Namespace Prefix: syn_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the inputs and valuation techniques used to measure fair value, and a discussion of changes in valuation techniques and related inputs, if any, applied during the period to each separate class of assets, liabilities, and financial instruments classified in shareholders' equity that are measured on a recurring and/or nonrecurring basis.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (bbb)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 43 R21.htm IDEA: XBRL DOCUMENT v2.4.1.9

Selected Balance Sheet Information (Details 2) (USD $)
In Thousands, unless otherwise specified

Mar. 31, 2015

Dec. 31, 2014

Accrued Expenses [Line Items]

Accrued manufacturing costs $ 74syn_AccruedManufacturingCosts $ 247syn_AccruedManufacturingCosts

Accrued vendor payments 225syn_AccruedVendorPayments 176syn_AccruedVendorPayments

Accrued milestone payments 1,000syn_AccruedMilestonePayable 350syn_AccruedMilestonePayable

Accrued clinical consulting services 1,347syn_AccruedClinicalConsultingServices 525syn_AccruedClinicalConsultingServices

Total $ 2,646us-gaap_AccruedLiabilitiesCurrent $ 1,298us-gaap_AccruedLiabilitiesCurrent

X

- Definition

The carrying value of accrued clinical consulting services payable as on balance sheet date.

+ References

No definition available.

+ Details

Name: syn_AccruedClinicalConsultingServices

Namespace Prefix: syn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: syn_AccruedExpensesLineItems

Namespace Prefix: syn_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The manufacturing costs incurred in the production of goods for sale.

+ References

No definition available.

+ Details

Name: syn_AccruedManufacturingCosts

Namespace Prefix: syn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The carrying value of accrued milestone payments payable as on balance sheet date.

+ References

No definition available.

+ Details

Name: syn_AccruedMilestonePayable

Namespace Prefix: syn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of obligations and payables pertaining to vendor payments.

+ References

No definition available.

+ Details

Name: syn_AccruedVendorPayments

Namespace Prefix: syn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 44 R26.htm IDEA: XBRL DOCUMENT v2.4.1.9

Stock Purchase Warrants (Details 1) (USD $)
In Thousands, unless otherwise specified
3 Months Ended

Mar. 31, 2015

Mar. 31, 2014

Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]

Beginning Balance $ 6,756syn_WarrantLiabilities

Change in fair value of warrant liabilities 4,152us-gaap_FairValueAdjustmentOfWarrants 0us-gaap_FairValueAdjustmentOfWarrants

Ending Balance $ 10,908syn_WarrantLiabilities

X

- Definition

It represents value of warrant liabilities.

+ References

No definition available.

+ Details

Name: syn_WarrantLiabilities

Namespace Prefix: syn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of expense (income) related to adjustment to fair value of warrant liability.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 480

-SubTopic 10

-Section 25

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=6939902&loc=d3e20148-110875

+ Details

Name: us-gaap_FairValueAdjustmentOfWarrants

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 45 R5.htm IDEA: XBRL DOCUMENT v2.4.1.9

Consolidated Statements of Cash Flows (USD $)
In Thousands, unless otherwise specified
3 Months Ended

Mar. 31, 2015

Mar. 31, 2014

Cash Flows From Operating Activities:

Net Loss $ (12,358)us-gaap_ProfitLoss $ (3,838)us-gaap_ProfitLoss

Adjustments to reconcile net loss to net cash used in operating activities:

Stock-based compensation 827us-gaap_ShareBasedCompensation 362us-gaap_ShareBasedCompensation

Stock issued for milestone payments 350syn_StockIssuedForMilestonePayments 0syn_StockIssuedForMilestonePayments

Change in fair value of warrant liabilities 4,152us-gaap_FairValueAdjustmentOfWarrants 0us-gaap_FairValueAdjustmentOfWarrants

Depreciation 8us-gaap_Depreciation 3us-gaap_Depreciation

Changes in operating assets and liabilities:

Prepaid expenses and other current assets (26) 259

Deposits and other assets (12) (2)

Accounts payable 563 631

Accrued liabilities 1,348 0

Accrued employee benefits (310) (885)

Net Cash Used In Operating Activities (5,458) (3,470)

Cash Flows From Investing Activities:

Purchases of property and equipment (18) (4)

Net Cash Used In Investing Activities (18) (4)

Cash Flows From Financing Activities:

Proceeds from issuance of common stock for stock option exercises 0 4

Net Cash Provided By Financing Activities 0 4

Net decrease in cash (5,476)us-gaap_CashPeriodIncreaseDecrease (3,470)us-gaap_CashPeriodIncreaseDecrease

Cash at beginning of period 17,525 14,625

Cash at end of period 12,049 11,155

Supplemental disclosures of cash flow information:

Cash paid for interest 0us-gaap_InterestPaid 0us-gaap_InterestPaid

Cash paid for taxes $ 0us-gaap_IncomeTaxesPaid $ 0us-gaap_IncomeTaxesPaid

X

- Definition

The aggregate net change during the reporting period in moneys given as security, collateral, or margin deposits. Also includes, net change in other operating assets not otherwise defined in the taxonomy.

+ References

No definition available.

+ Details

Name: syn_IncreaseDecreaseInDepositsAndOtherAssets

Namespace Prefix: syn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash inflow from the additional capital contribution to the entity for stock option and warrants exercises.

+ References

No definition available.

+ Details

Name: syn_ProceedsFromIssuanceOfCommonStockForStockOptionAndWarrantsExercises

Namespace Prefix: syn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The value of stock granted for milestone payments during the period.

+ References

No definition available.

+ Details

Name: syn_StockIssuedForMilestonePayments

Namespace Prefix: syn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of increase (decrease) in cash. Cash is the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Includes effect from exchange rate changes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450594&loc=d3e33268-110906

+ Details

Name: us-gaap_CashPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_Depreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of expense (income) related to adjustment to fair value of warrant liability.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 480

-SubTopic 10

-Section 25

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=6939902&loc=d3e20148-110875

+ Details

Name: us-gaap_FairValueAdjustmentOfWarrants

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (f)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_IncomeTaxesPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The amount of cash paid for interest during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_InterestPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4K

-URI http://asc.fasb.org/extlink&oid=35736750&loc=SL4591552-111686

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 19

-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4569616-111683

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1A

-Subparagraph (a),(c)

-URI http://asc.fasb.org/extlink&oid=18733093&loc=SL4573702-111684

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4J

-URI http://asc.fasb.org/extlink&oid=35736750&loc=SL4591551-111686

+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_SupplementalCashFlowInformationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 46 R10.htm IDEA: XBRL DOCUMENT v2.4.1.9

Stock-Based Compensation
3 Months Ended

Mar. 31, 2015

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

5. Stock-Based Compensation

Stock Incentive Plan

During 2001, the Company’s Board of Directors and stockholders adopted the 2001 Stock Incentive Plan (the “2001 Stock Plan”). The total number of shares of stock with respect to which stock options and stock appreciation rights may be granted to any one employee of the Company or a subsidiary during any one-year period under the 2001 Stock Plan shall not exceed 250,000. All awards pursuant to the 2001 Stock Plan shall terminate upon the termination of the grantee’s employment for any reason. Awards include options, restricted shares, stock appreciation rights, performance shares and cash-based awards (the “Awards”). The 2001 Stock Plan contains certain anti-dilution provisions in the event of a stock split, stock dividend or other capital adjustment, as defined in the plan. The 2001 Stock Plan provides for a Committee of the Board to grant Awards and to determine the exercise price, vesting term, expiration date and all other terms and conditions of the Awards, including acceleration of the vesting of an Award at any time. As of March 31, 2015, there were 682,449 options issued and outstanding under the 2001 Stock Plan.

On March 20, 2007, the Company’s Board of Directors approved the 2007 Stock Incentive Plan (the “2007 Stock Plan”) for the issuance of up to 2,500,000 shares of common stock to be granted through incentive stock options, nonqualified stock options, stock appreciation rights, dividend equivalent rights, restricted stock, restricted stock units and other stock-based awards to officers, other employees, directors and consultants of the Company and its subsidiaries. This plan was approved by stockholders on November 2, 2007. The exercise price of stock options under the 2007 Stock Plan is determined by the compensation committee of the Board of Directors, and may be equal to or greater than the fair market value of the Company’s common stock on the date the option is granted. The total number of shares of stock with respect to which stock options and stock appreciation rights may be granted to any one employee of the Company or a subsidiary during any one-year period under the 2007 plan shall not exceed 250,000. Options become exercisable over various periods from the date of grant, and generally expire ten years after the grant date. As of March 31, 2015, there are 428,657 options issued and outstanding under the 2007 Stock Plan.

On November 2, 2010, the Board of Directors and stockholders adopted the 2010 Stock Incentive Plan (“2010 Stock Plan”) for the issuance of up to 3,000,000 shares of common stock to be granted through incentive stock options, nonqualified stock options, stock appreciation rights, dividend equivalent rights, restricted stock, restricted stock units and other stock-based awards to officers, other employees, directors and consultants of the Company and its subsidiaries. On October 22, 2013, the stockholders approved and adopted an amendment to the Company’s 2010 Incentive Stock Plan to increase the number of shares of the Company’s common stock reserved for issuance under the Plan from 3,000,000 to 6,000,000. The exercise price of stock options under the 2010 Stock Plan is determined by the compensation committee of the Board of Directors, and may be equal to or greater than the fair market value of the Company’s common stock on the date the option is granted. Options become exercisable over various periods from the date of grant, and generally expire ten years after the grant date. As of March 31, 2015, there are 5,420,000 options issued and outstanding under the 2010 Stock Plan.

In the event of an employee’s termination, the Company will cease to recognize compensation expense for that employee. There is no deferred compensation recorded upon initial grant date, instead, the fair value of the stock-based payment is recognized ratably over the stated vesting period.

The Company has applied fair value accounting for all share based payment awards since inception. The fair value of each option or warrant granted is estimated on the date of grant using the Black-Scholes option pricing model. The Black-Scholes assumptions used in the three months ended March 31, 2015 and 2014 are as follows:

Three Months Ended March 31,

2015

2014

Expected dividends

0

%

0

%

Expected volatility

131

%

126

%

Risk free interest rate

2.03

%

1.57

%

Expected life of option

10 years

5 years

Expected forfeitures

0

%

0

%

The Company records stock-based compensation based upon the stated vested provisions in the related agreements. The vesting provisions for these agreements have various terms as follows:

⋅

immediate vesting,

⋅

half vesting immediately and the remainder over three years,

⋅

quarterly over three years,

⋅

annually over three years,

⋅

one-third immediate vesting and remaining annually over two years,

⋅

one half immediate vesting with remaining vesting over nine months,

⋅

one quarter immediate vesting with the remaining over three years,

⋅

one quarter immediate vesting with the remaining over 33 months; and

⋅

monthly over three years.



During the three months ended March 31, 2015, the Company granted 550,000 options to employees having an approximate fair value of $817,000 based upon the Black-Scholes option pricing model. During the same period in 2014, the Company granted 587,500 options to employees and consultants having an approximate fair value of $1.4 million based upon the Black-Scholes option pricing model.

A summary of stock option activities as of March 31, 2015, and for the year ended December 31, 2014, is as follows:

Weighted

Average

Weighted

Remaining

Aggregate

Average Exercise

Contractual

Intrinsic

Options

Price

Life

Value

Balance - December 31, 2013

3,909,580

$

1.78

5.59 years

$

785,000

Granted

2,382,500

$

2.36

Exercised

(6,583)

$

0.58

Forfeited

(304,391)

$

1.93

Balance - December 31, 2014

5,981,106

$

2.01

5.80 years

$

685,000

Granted

550,000

$

1.54

Exercised

-

$

-

Forfeited

-

$

-

Balance - March 31, 2015 - outstanding

6,531,106

$

1.97

5.79 years

$

2,628,000

Balance - March 31, 2015 - exercisable

4,168,043

$

1.89

4.98 years

$

1,939,000

Grant date fair value of options granted - March 31, 2015

$

817,000

Weighted average grant date fair value - March 31, 2015

$

1.49

Grant date fair value of options granted - December 31, 2014

$

4,974,000

Weighted average grant date fair value - December 31, 2014

$

2.09

Stock-based compensation expense included in general and administrative expenses and research and development expenses relating to stock options issued to employees and consultants for the three months ended March 31, 2015 and 2014 were $826,000 and $362,000, respectively

As of March 31, 2015, total unrecognized stock-based compensation expense related to stock options was $4.0 million, which is expected to be expensed through February 2017.

X

- Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 50

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 40

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 47 R27.htm IDEA: XBRL DOCUMENT v2.4.1.9

Stock Purchase Warrants (Details 2) (USD $)
3 Months Ended 12 Months Ended

Mar. 31, 2015

Dec. 31, 2014

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of Warrants, Beginning Balance 7,974,794 1,632,501

Number of Warrants, Granted 0 7,029,808

Number of Warrants, Exercised 0 (232,619)

Number of Warrants, Forfeited 0 (454,896)

Number of Warrants, Ending Balance 7,974,794 7,974,794

Weighted Average Exercise Price, Beginning Balance $ 1.8 $ 1.99

Weighted Average Exercise Price, Granted $ 0 $ 1.75

Weighted Average Exercise Price, Exercised $ 0 $ 1.47

Weighted Average Exercise Price, Forfeited $ 0 $ 1.88

Weighted Average Exercise Price, Ending Balance $ 1.8 $ 1.8

X

- Definition

Number of share warrants exercised during the period.

+ References

No definition available.

+ Details

Name: syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod

Namespace Prefix: syn_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans are exercise in period.

+ References

No definition available.

+ Details

Name: syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: syn_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(3)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(iii)(3)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(iii)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(iii)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 48 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.1.9 Html 63 152 1 false 24 0 false 4 false false R1.htm 101 - Document - Document And Entity Information Sheet http://www.syntheticbiologics.com/role/DocumentAndEntityInformation Document And Entity Information true false R2.htm 102 - Statement - Consolidated Balance Sheets Sheet http://www.syntheticbiologics.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets false false R3.htm 103 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.syntheticbiologics.com/role/ConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) false false R4.htm 104 - Statement - Consolidated Statements of Operations Sheet http://www.syntheticbiologics.com/role/ConsolidatedStatementsOfOperations Consolidated Statements of Operations false false R5.htm 105 - Statement - Consolidated Statements of Cash Flows Sheet http://www.syntheticbiologics.com/role/ConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows false false R6.htm 106 - Disclosure - Organization and Nature of Operations and Basis of Presentation Sheet http://www.syntheticbiologics.com/role/OrganizationAndNatureOfOperationsAndBasisOfPresentation Organization and Nature of Operations and Basis of Presentation false false R7.htm 107 - Disclosure - Management Plans Sheet http://www.syntheticbiologics.com/role/ManagementPlans Management Plans false false R8.htm 108 - Disclosure - Fair Value of Financial Instruments Sheet http://www.syntheticbiologics.com/role/FairValueOfFinancialInstruments Fair Value of Financial Instruments false false R9.htm 109 - Disclosure - Selected Balance Sheet Information Sheet http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformation Selected Balance Sheet Information false false R10.htm 110 - Disclosure - Stock-Based Compensation Sheet http://www.syntheticbiologics.com/role/StockbasedCompensation Stock-Based Compensation false false R11.htm 111 - Disclosure - Stock Purchase Warrants Sheet http://www.syntheticbiologics.com/role/StockPurchaseWarrants Stock Purchase Warrants false false R12.htm 112 - Statement - Stockholders' Equity (Deficit) Sheet http://www.syntheticbiologics.com/role/StockholdersEquityDeficit Stockholders' Equity (Deficit) false false R13.htm 113 - Disclosure - Net Loss per Share Sheet http://www.syntheticbiologics.com/role/NetLossPerShare Net Loss per Share false false R14.htm 114 - Disclosure - Selected Balance Sheet Information (Tables) Sheet http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationTables Selected Balance Sheet Information (Tables) false false R15.htm 115 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.syntheticbiologics.com/role/StockbasedCompensationTables Stock-Based Compensation (Tables) false false R16.htm 116 - Disclosure - Stock Purchase Warrants (Tables) Sheet http://www.syntheticbiologics.com/role/StockPurchaseWarrantsTables Stock Purchase Warrants (Tables) false false R17.htm 117 - Disclosure - Management's Plan (Details Textual) Sheet http://www.syntheticbiologics.com/role/ManagementsPlanDetailsTextual Management's Plan (Details Textual) false false R18.htm 118 - Disclosure - Fair Value of Financial Instruments (Details Textual) Sheet http://www.syntheticbiologics.com/role/FairValueOfFinancialInstrumentsDetailsTextual Fair Value of Financial Instruments (Details Textual) false false R19.htm 119 - Disclosure - Selected Balance Sheet Information (Details) Sheet http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationDetails Selected Balance Sheet Information (Details) false false R20.htm 120 - Disclosure - Selected Balance Sheet Information (Details 1) Sheet http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationDetails1 Selected Balance Sheet Information (Details 1) false false R21.htm 121 - Disclosure - Selected Balance Sheet Information (Details 2) Sheet http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationDetails2 Selected Balance Sheet Information (Details 2) false false R22.htm 122 - Disclosure - Stock-Based Compensation (Details) Sheet http://www.syntheticbiologics.com/role/StockbasedCompensationDetails Stock-Based Compensation (Details) false false R23.htm 123 - Disclosure - Stock-Based Compensation (Details 1) Sheet http://www.syntheticbiologics.com/role/StockbasedCompensationDetails1 Stock-Based Compensation (Details 1) false false R24.htm 124 - Disclosure - Stock-Based Compensation (Details Textual) Sheet http://www.syntheticbiologics.com/role/StockbasedCompensationDetailsTextual Stock-Based Compensation (Details Textual) false false R25.htm 125 - Disclosure - Stock Purchase Warrants (Details) Sheet http://www.syntheticbiologics.com/role/StockPurchaseWarrantsDetails Stock Purchase Warrants (Details) false false R26.htm 126 - Disclosure - Stock Purchase Warrants (Details 1) Sheet http://www.syntheticbiologics.com/role/StockPurchaseWarrantsDetails1 Stock Purchase Warrants (Details 1) false false R27.htm 127 - Disclosure - Stock Purchase Warrants (Details 2) Sheet http://www.syntheticbiologics.com/role/StockPurchaseWarrantsDetails2 Stock Purchase Warrants (Details 2) false false R28.htm 128 - Disclosure - Stock Purchase Warrants (Details 3) Sheet http://www.syntheticbiologics.com/role/StockPurchaseWarrantsDetails3 Stock Purchase Warrants (Details 3) false false R29.htm 129 - Disclosure - Stock Purchase Warrants (Details Textual) Sheet http://www.syntheticbiologics.com/role/StockPurchaseWarrantsDetailsTextual Stock Purchase Warrants (Details Textual) false false R30.htm 130 - Disclosure - Stockholders' Equity (Deficit) (Details Textual) Sheet http://www.syntheticbiologics.com/role/StockholdersEquityDeficitDetailsTextual Stockholders' Equity (Deficit) (Details Textual) false false R31.htm 131 - Disclosure - Net Loss per Share (Details Textual) Sheet http://www.syntheticbiologics.com/role/NetLossPerShareDetailsTextual Net Loss per Share (Details Textual) false false All Reports Book All Reports Element syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue had a mix of decimals attribute values: -5 0. Element syn_WarrantLiabilities had a mix of decimals attribute values: -5 -3. Element us-gaap_FairValueAdjustmentOfWarrants had a mix of decimals attribute values: -5 -3. Element us-gaap_FairValueAssumptionsExpectedVolatilityRate had a mix of decimals attribute values: 1 2. 'Monetary' elements on report '124 - Disclosure - Stock-Based Compensation (Details Textual)' had a mix of different decimal attribute values. 'Monetary' elements on report '129 - Disclosure - Stock Purchase Warrants (Details Textual)' had a mix of different decimal attribute values. Process Flow-Through: 102 - Statement - Consolidated Balance Sheets Process Flow-Through: Removing column 'Mar. 31, 2014' Process Flow-Through: Removing column 'Dec. 31, 2013' Process Flow-Through: 103 - Statement - Consolidated Balance Sheets (Parenthetical) Process Flow-Through: 104 - Statement - Consolidated Statements of Operations Process Flow-Through: 105 - Statement - Consolidated Statements of Cash Flows Process Flow-Through: 112 - Statement - Stockholders' Equity (Deficit) syn-20150331.xml syn-20150331.xsd syn-20150331_cal.xml syn-20150331_def.xml syn-20150331_lab.xml syn-20150331_pre.xml true true XML 49 R20.htm IDEA: XBRL DOCUMENT v2.4.1.9

Selected Balance Sheet Information (Details 1) (USD $)
In Thousands, unless otherwise specified

Mar. 31, 2015

Dec. 31, 2014

Property, Plant and Equipment [Line Items]

Property, Plant and Equipment, Gross $ 122us-gaap_PropertyPlantAndEquipmentGross $ 104us-gaap_PropertyPlantAndEquipmentGross

Less accumulated depreciation (47) (39)

Total 75us-gaap_PropertyPlantAndEquipmentNet 65us-gaap_PropertyPlantAndEquipmentNet

Computer and office equipment [Member]

Property, Plant and Equipment [Line Items]

Property, Plant and Equipment, Gross 111 93

Software [Member]

Property, Plant and Equipment [Line Items]

Property, Plant and Equipment, Gross $ 11 $ 11

X

- Definition

Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.14)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 14

-Article 5

+ Details

Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_PropertyPlantAndEquipmentGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=syn_ComputerAndOfficeEquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

Stock Purchase Warrants (Details) (Stock Warrants [Member], USD $)	0 Months Ended	3 Months Ended	12 Months Ended
	Oct. 10, 2014	Mar. 31, 2015	Dec. 31, 2014
Stock Warrants [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Closing stock price	$ 1.75	$ 2.19	$ 1.46
Expected dividends	0.00%	0.00%	0.00%
Expected volatility	95.00%	90.00%	90.00%
Risk free interest rate	1.39%	1.26%	1.59%
Expected life of warrant	5 years	4 years 6 months 18 days	4 years 9 months 14 days

Stock Purchase Warrants (Details Textual) (USD $)	3 Months Ended		1 Months Ended	0 Months Ended
Stock Purchase Warrants (Details Textual) (USD $)	Mar. 31, 2015	Mar. 31, 2014	Oct. 25, 2012	Oct. 10, 2014	Dec. 31, 2014
Fair Value Adjustment of Warrants	$ 4,152,000us-gaap_FairValueAdjustmentOfWarrants	$ 0us-gaap_FairValueAdjustmentOfWarrants
Warrant liabilities	10,908,000syn_WarrantLiabilities				6,756,000syn_WarrantLiabilities
Class of Warrant or Right, Outstanding	316,522
Warrant [Member]
Issuance Of Warrants To Purchase Of Common Stock			635,855
Warrants Exercisable Price Per Share			$ 1.60
Investment Warrants Expiration Date1			Oct. 25, 2017
Stock Warrants [Member]
Proceeds from Issuance of Common Stock				19,100,000
Sale of Stock, Number of Shares Issued in Transaction				14,059,616
Sale of Stock, Price Per Share				$ 1.47
Issuance Of Warrants To Purchase Of Common Stock				0.5
Share Based Compensation Arrangement By Share Based Payment Award Warrants Exercisable Number				7,029,808
Warrants Exercisable Price Per Share				$ 1.75
Fair Value Adjustment of Warrants	10,900,000
Warrant liabilities	$ 4,200,000
Investment Warrants Expiration Date1				Oct. 10, 2019

Stock Purchase Warrants (Details 3) (USD $)	3 Months Ended
Stock Purchase Warrants (Details 3) (USD $)	Mar. 31, 2015
Exercise Price 1.60 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 1.60
Warrants Outstanding	316,522
Warrants Exercisable	316,522
Weighted Average Remaining Contractual Life	2 years 6 months 25 days
Aggregate Intrinsic value	$ 187,000
Exercise Price 1.75 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 1.75
Warrants Outstanding	7,029.808
Warrants Exercisable	7,029,808
Weighted Average Remaining Contractual Life	4 years 6 months 11 days
Aggregate Intrinsic value	3,903,000
Exercise Price 2.22 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 2.22
Warrants Outstanding	517,257
Warrants Exercisable	517,257
Weighted Average Remaining Contractual Life	1 year 7 months 28 days
Aggregate Intrinsic value	0
Exercise Price 3.30 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 3.30
Warrants Outstanding	61,207
Warrants Exercisable	61,207
Weighted Average Remaining Contractual Life	1 month 28 days
Aggregate Intrinsic value	0
Exercise Price 3.75 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 3.75
Warrants Outstanding	50,000
Warrants Exercisable	50,000
Weighted Average Remaining Contractual Life	10 months 17 days
Aggregate Intrinsic value	0
Exercise Price 1.80 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 1.80
Warrants Outstanding	7,974,794
Warrants Exercisable	7,974,794
Weighted Average Remaining Contractual Life	4 years 2 months 16 days
Aggregate Intrinsic value	$ 3,280,000

Stockholders' Equity (Deficit) (Details Textual) (Prev Abr Llc [Member], USD $)	3 Months Ended
	Mar. 31, 2015
Prev Abr Llc [Member]
Stockholders Equity [Line Items]
Stock Issued During Period, Shares, New Issues	212,843
Equity Issued in Business Combination, Fair Value Disclosure	$ 350,000

Net Loss per Share (Details Textual)	3 Months Ended
Net Loss per Share (Details Textual)	Mar. 31, 2015	Mar. 31, 2014
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	6,531,106	4,490,497
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	7,974,794	963,168

Consolidated Balance Sheets (USD $) In Thousands, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
Current Assets
Cash and cash equivalents	$ 12,049	$ 17,525
Prepaid expenses and other current assets	1,574	1,548
Total Current Assets	13,623us-gaap_AssetsCurrent	19,073us-gaap_AssetsCurrent
Property and equipment, net	75us-gaap_PropertyPlantAndEquipmentNet	65us-gaap_PropertyPlantAndEquipmentNet
Deposits and other assets	18syn_DepositsAndOtherAssetsNoncurrent	6syn_DepositsAndOtherAssetsNoncurrent
Total Assets	13,716us-gaap_Assets	19,144us-gaap_Assets
Current Liabilities:
Accounts payable	1,559us-gaap_AccountsPayableCurrent	996us-gaap_AccountsPayableCurrent
Accrued expenses	2,646us-gaap_AccruedLiabilitiesCurrent	1,298us-gaap_AccruedLiabilitiesCurrent
Warrant liabilities	10,908syn_WarrantLiabilities	6,756syn_WarrantLiabilities
Accrued employee benefits	228us-gaap_AccruedEmployeeBenefitsCurrent	538us-gaap_AccruedEmployeeBenefitsCurrent
Total Current Liabilities	15,341us-gaap_LiabilitiesCurrent	9,588us-gaap_LiabilitiesCurrent
Total Liabilities	15,341us-gaap_Liabilities	9,588us-gaap_Liabilities
Commitments and Contingencies
Stockholders' Equity (Deficit):
Preferred stock, $0.001 par value; 10,000,000 shares authorized, none issued and outstanding	0us-gaap_PreferredStockValue	0us-gaap_PreferredStockValue
Common stock, $0.001 par value; 100,000,000 shares authorized, 72,725,987 issued and 72,807,469 outstanding and 72,594,626 issued and 72,513,144 outstanding	73us-gaap_CommonStockValue	72us-gaap_CommonStockValue
Additional paid-in capital	111,702	110,526
Accumulated deficit	(113,400)	(101,042)
Total Synthetic Biologics, Inc. and Subsidiaries Equity (Deficit)	(1,625)us-gaap_StockholdersEquity	9,556us-gaap_StockholdersEquity
Non-controlling interest	0us-gaap_MinorityInterest	0us-gaap_MinorityInterest
Total Stockholders' Equity (Deficit)	(1,625)	9,556
Total Liabilities and Stockholders’ Equity	$ 13,716	$ 19,144

Stock-Based Compensation (Details)	3 Months Ended
Stock-Based Compensation (Details)	Mar. 31, 2015	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected dividends	0.00%	0.00%
Expected volatility	131.00%	126.00%
Risk free interest rate	2.03%	1.57%
Expected life of warrant	10 years	5 years
Expected forfeitures	0.00%	0.00%

Stock-Based Compensation (Details Textual) (USD $)	3 Months Ended		12 Months Ended
Stock-Based Compensation (Details Textual) (USD $)	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2001	Dec. 31, 2007	Mar. 20, 2007	Nov. 02, 2010	Oct. 22, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options	$ 4,000,000
General and Administrative Expenses and Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	826,000	362,000
Employees And Consultants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		587,500
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Fair Value		1,400,000
Employee [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	550,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Fair Value	$ 817,000
2001 Stock Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	682,449
2001 Stock Plan [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			250,000
2007 Stock Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	428,657				2,500,000
2007 Stock Plan [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				250,000
2010 Stock Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	5,420,000					3,000,000
2010 Stock Plan [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance							6,000,000
2010 Stock Plan [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance							3,000,000

Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000us-gaap_PreferredStockSharesAuthorized	10,000,000us-gaap_PreferredStockSharesAuthorized
Preferred stock, shares issued	0us-gaap_PreferredStockSharesIssued	0us-gaap_PreferredStockSharesIssued
Preferred stock, shares outstanding	0us-gaap_PreferredStockSharesOutstanding	0us-gaap_PreferredStockSharesOutstanding
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000us-gaap_CommonStockSharesAuthorized	100,000,000us-gaap_CommonStockSharesAuthorized
Common stock, shares, issued	72,725,987us-gaap_CommonStockSharesIssued	72,594,626us-gaap_CommonStockSharesIssued
Common stock, shares outstanding	72,807,469us-gaap_CommonStockSharesOutstanding	72,513,144us-gaap_CommonStockSharesOutstanding

Management's Plan (Details Textual) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
Management's Plan [Line Items]
Accumulated deficit	$ (113,400)	$ (101,042)

Document And Entity Information	3 Months Ended
Document And Entity Information	Mar. 31, 2015	May 08, 2015
Document Information [Line Items]
Entity Registrant Name	Synthetic Biologics, Inc.
Entity Central Index Key	0000894158
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Trading Symbol	SYN
Entity Common Stock, Shares Outstanding		73,179,307dei_EntityCommonStockSharesOutstanding
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2015
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2015

Fair Value of Financial Instruments (Details Textual) (Money Market Accounts [Member], USD $) In Millions, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
Money Market Accounts [Member]
Cash Equivalents, at Carrying Value	$ 8.5	$ 13.6

Stock-Based Compensation (Details 1) (Stock Option [Member], USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options, Beginning Balance	5,981,106	3,909,580
Options, Granted	550,000	2,382,500
Options, Exercised	0	(6,583)
Options, Forfeited	0	(304,391)
Options, Ending Balance	6,531,106	5,981,106	3,909,580
Options, Exercisable	4,168,043
Weighted Average Exercise Price, Beginning Balance	$ 2.01	$ 1.78
Weighted Average Exercise Price, Granted	$ 1.54	$ 2.36
Weighted Average Exercise Price, Exercised	$ 0	$ 0.58
Weighted Average Exercise Price, Forfeited	$ 0	$ 1.93
Weighted Average Exercise Price, Ending Balance	$ 1.97	$ 2.01	$ 1.78
Weighted Average Exercise Price, Exercisable	$ 1.89
Weighted Average Remaining Contractual Life, Balance Outstanding	5 years 9 months 14 days	5 years 9 months 18 days	5 years 7 months 2 days
Weighted Average Remaining Contractual Life, Exercisable	4 years 11 months 23 days
Aggregate Intrinsic Value, Beginning Balance	$ 685,000	$ 785,000
Aggregate Intrinsic Value, Ending Balance	2,628,000	685,000	785,000
Aggregate Intrinsic Value, Exercisable	1,939,000
Grant date fair value of options granted	$ 817,000	$ 4,974,000
Weighted average grant date fair value	$ 1.49	$ 2.09

Selected Balance Sheet Information (Details) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
Other Current Assets [Line Items]
Intrexon prepaid research and development expenses	$ 1,060	$ 1,067
Prepaid insurance	140us-gaap_PrepaidInsurance	228us-gaap_PrepaidInsurance
Prepaid expenses	374us-gaap_PrepaidExpenseCurrent	253us-gaap_PrepaidExpenseCurrent
Total	$ 1,574us-gaap_OtherAssetsCurrent	$ 1,548us-gaap_OtherAssetsCurrent

Selected Balance Sheet Information (Details 2) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
Accrued Expenses [Line Items]
Accrued manufacturing costs	$ 74syn_AccruedManufacturingCosts	$ 247syn_AccruedManufacturingCosts
Accrued vendor payments	225syn_AccruedVendorPayments	176syn_AccruedVendorPayments
Accrued milestone payments	1,000syn_AccruedMilestonePayable	350syn_AccruedMilestonePayable
Accrued clinical consulting services	1,347syn_AccruedClinicalConsultingServices	525syn_AccruedClinicalConsultingServices
Total	$ 2,646us-gaap_AccruedLiabilitiesCurrent	$ 1,298us-gaap_AccruedLiabilitiesCurrent

Consolidated Statements of Cash Flows (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Cash Flows From Operating Activities:
Net Loss	$ (12,358)us-gaap_ProfitLoss	$ (3,838)us-gaap_ProfitLoss
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	827us-gaap_ShareBasedCompensation	362us-gaap_ShareBasedCompensation
Stock issued for milestone payments	350syn_StockIssuedForMilestonePayments	0syn_StockIssuedForMilestonePayments
Change in fair value of warrant liabilities	4,152us-gaap_FairValueAdjustmentOfWarrants	0us-gaap_FairValueAdjustmentOfWarrants
Depreciation	8us-gaap_Depreciation	3us-gaap_Depreciation
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(26)	259
Deposits and other assets	(12)	(2)
Accounts payable	563	631
Accrued liabilities	1,348	0
Accrued employee benefits	(310)	(885)
Net Cash Used In Operating Activities	(5,458)	(3,470)
Cash Flows From Investing Activities:
Purchases of property and equipment	(18)	(4)
Net Cash Used In Investing Activities	(18)	(4)
Cash Flows From Financing Activities:
Proceeds from issuance of common stock for stock option exercises	0	4
Net Cash Provided By Financing Activities	0	4
Net decrease in cash	(5,476)us-gaap_CashPeriodIncreaseDecrease	(3,470)us-gaap_CashPeriodIncreaseDecrease
Cash at beginning of period	17,525	14,625
Cash at end of period	12,049	11,155
Supplemental disclosures of cash flow information:
Cash paid for interest	0us-gaap_InterestPaid	0us-gaap_InterestPaid
Cash paid for taxes	$ 0us-gaap_IncomeTaxesPaid	$ 0us-gaap_IncomeTaxesPaid

Stock Purchase Warrants (Details 2) (USD $)	3 Months Ended	12 Months Ended
Stock Purchase Warrants (Details 2) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Warrants, Beginning Balance	7,974,794	1,632,501
Number of Warrants, Granted	0	7,029,808
Number of Warrants, Exercised	0	(232,619)
Number of Warrants, Forfeited	0	(454,896)
Number of Warrants, Ending Balance	7,974,794	7,974,794
Weighted Average Exercise Price, Beginning Balance	$ 1.8	$ 1.99
Weighted Average Exercise Price, Granted	$ 0	$ 1.75
Weighted Average Exercise Price, Exercised	$ 0	$ 1.47
Weighted Average Exercise Price, Forfeited	$ 0	$ 1.88
Weighted Average Exercise Price, Ending Balance	$ 1.8	$ 1.8

Selected Balance Sheet Information (Details 1) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 122us-gaap_PropertyPlantAndEquipmentGross	$ 104us-gaap_PropertyPlantAndEquipmentGross
Less accumulated depreciation	(47)	(39)
Total	75us-gaap_PropertyPlantAndEquipmentNet	65us-gaap_PropertyPlantAndEquipmentNet
Computer and office equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	111	93
Software [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 11	$ 11